{
  "metadata": {
    "company": "pfizer",
    "year": "2023",
    "region": "us",
    "report_type": "annual",
    "source_file": "pfizer_2023_annual.pdf",
    "total_pages": 168,
    "original_chars": 811433,
    "cleaned_chars": 794529,
    "reduction_percent": 2.08,
    "total_chunks": 994,
    "avg_chunk_size": 917.0
  },
  "chunks": [
    {
      "chunk_id": "pfizer_2023_chunk0000",
      "chunk_index": 0,
      "text": "UNITED STATES SECURITIES AND EXCHANGE COMMISSION\nWashington, D.C. 20549\nFORM 10-K\n(Mark One)\nANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the fiscal year ended December 31, 2023\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the transition period from to\nCommission file number 1-3619\n\n(Exact name of registrant as specified in its charter)\nDelaware\n13-5315170\n(State or other jurisdiction of incorporation or organization)\n(I.R.S. Employer Identification Number)\n66 Hudson Boulevard East, New York, New York 10001-2192\n(Address of principal executive offices) (zip code)\n(212) 733-2323\n(Registrant’s telephone number, including area code)\nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which registered\nCommon Stock, $0.05 par value\nPFE\nNew York Stock Exchange\n1.000% Notes due 2027\nPFE27\nNew York Stock Exchange",
      "char_count": 979,
      "start_char": 0,
      "end_char": 980
    },
    {
      "chunk_id": "pfizer_2023_chunk0001",
      "chunk_index": 1,
      "text": "ach class\nTrading Symbol(s)\nName of each exchange on which registered\nCommon Stock, $0.05 par value\nPFE\nNew York Stock Exchange\n1.000% Notes due 2027\nPFE27\nNew York Stock Exchange\nSecurities registered pursuant to Section 12(g) of the Act: None\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12\nmonths (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.",
      "char_count": 856,
      "start_char": 800,
      "end_char": 1657
    },
    {
      "chunk_id": "pfizer_2023_chunk0002",
      "chunk_index": 2,
      "text": "ubject to such filing requirements for the past 90 days. Yes ☒ No ☐\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of\nthis chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) Yes ☒ No ☐\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.\nSee the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\nLarge Accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐",
      "char_count": 857,
      "start_char": 1600,
      "end_char": 2458
    },
    {
      "chunk_id": "pfizer_2023_chunk0003",
      "chunk_index": 3,
      "text": "r ☐ Smaller reporting company ☐ Emerging growth company ☐\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting\nunder Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.   ☒\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of\nan error to previously issued financial statements.",
      "char_count": 891,
      "start_char": 2400,
      "end_char": 3292
    },
    {
      "chunk_id": "pfizer_2023_chunk0004",
      "chunk_index": 4,
      "text": "in the filing reflect the correction of\nan error to previously issued financial statements. ☐\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s\nexecutive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\nThe aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most\nrecently completed second fiscal quarter was approximately $207 billion. This excludes shares of common stock held by directors and executive officers.",
      "char_count": 819,
      "start_char": 3200,
      "end_char": 4020
    },
    {
      "chunk_id": "pfizer_2023_chunk0005",
      "chunk_index": 5,
      "text": "executive officers. Exclusion of shares held by\nany person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the\nregistrant, or that such person is controlled by or under common control with the registrant. The registrant has no non-voting common stock.\nThe number of shares outstanding of the registrant’s common stock as of February 15, 2024 was 5,646,778,425 shares of common stock, all of one class.\nDOCUMENTS INCORPORATED BY REFERENCE\nPortions of the Proxy Statement for the 2024 Annual Meeting of Shareholders\nPart III\n\nTABLE OF CONTENTS\n \nPage\nDefined Terms\nAvailable Information\niii\nForward-Looking Information and Factors that May Affect Future Results\n\nPART I\n\nITEM 1. BUSINESS\n\nAbout Pfizer\n\nCommercial Operations\n\nResearch and Development\n\nCollaboration and Co-Promotion Agreements\n\nInternational Operations\n\nSales and Marketing",
      "char_count": 954,
      "start_char": 4000,
      "end_char": 4955
    },
    {
      "chunk_id": "pfizer_2023_chunk0006",
      "chunk_index": 6,
      "text": "S\n\nAbout Pfizer\n\nCommercial Operations\n\nResearch and Development\n\nCollaboration and Co-Promotion Agreements\n\nInternational Operations\n\nSales and Marketing\n\nPatents and Other Intellectual Property Rights\n\nCompetition\n\nPricing Pressures and Managed Care Organizations\n\nRaw Materials\n\nGovernment Regulation and Price Constraints\n\nEnvironmental Matters\n\nOur People\n\nITEM 1A. RISK FACTORS\n\nITEM 1B. UNRESOLVED STAFF COMMENTS\nN/A\nITEM 1C. CYBERSECURITY\n\nITEM 2. PROPERTIES\n\nITEM 3. LEGAL PROCEEDINGS\n\nITEM 4. MINE SAFETY DISCLOSURES\nN/A\nINFORMATION ABOUT OUR EXECUTIVE OFFICERS\n\nPART II\n\nITEM 5. MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES\n\nITEM 6. [RESERVED]\n\nITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS\n\nITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK\n\nITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA",
      "char_count": 936,
      "start_char": 4800,
      "end_char": 5737
    },
    {
      "chunk_id": "pfizer_2023_chunk0007",
      "chunk_index": 7,
      "text": "OF OPERATIONS\n\nITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK\n\nITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA\n\nITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE\n\nITEM 9A. CONTROLS AND PROCEDURES\n\nITEM 9B. OTHER INFORMATION\n\nITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS\nN/A\nPART III\n\nITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE\n\nITEM 11. EXECUTIVE COMPENSATION\n\nITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS\n\nITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE\n\nITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES\n\nPART IV\n\nITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES\n\n15(a)(1) Financial Statements\n\n15(a)(2) Financial Statement Schedules\n\n15(a)(3) Exhibits\n\nITEM 16. FORM 10-K SUMMARY\n\nSIGNATURES\n\nN/A = Not Applicable",
      "char_count": 929,
      "start_char": 5600,
      "end_char": 6531
    },
    {
      "chunk_id": "pfizer_2023_chunk0008",
      "chunk_index": 8,
      "text": "tatements\n\n15(a)(2) Financial Statement Schedules\n\n15(a)(3) Exhibits\n\nITEM 16. FORM 10-K SUMMARY\n\nSIGNATURES\n\nN/A = Not Applicable\n\nDEFINED TERMS\nUnless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Form 10-K (defined below) refer to Pfizer Inc. and its subsidiaries. For each\nyear presented, Pfizer’s fiscal year-end for subsidiaries operating outside the U.S. is as of and for the year ended November 30 and for U.S. subsidiaries is as of and for the year\nended December 31. References to “Notes” in this Form 10-K are to the Notes to the consolidated financial statements in Item 8. Financial Statements and Supplementary Data in\nthis Form 10-K. We also have used several other terms in this Form 10-K, most of which are explained or defined below:\nForm 10-K\nThis Annual Report on Form 10-K for the fiscal year ended December 31, 2023\n2022 Form 10-K\nOur Annual Report on Form 10-K for the fiscal year ended December 31, 2022\nProxy Statement",
      "char_count": 996,
      "start_char": 6400,
      "end_char": 7397
    },
    {
      "chunk_id": "pfizer_2023_chunk0009",
      "chunk_index": 9,
      "text": "low:\nForm 10-K\nThis Annual Report on Form 10-K for the fiscal year ended December 31, 2023\n2022 Form 10-K\nOur Annual Report on Form 10-K for the fiscal year ended December 31, 2022\nProxy Statement\nProxy Statement for the 2024 Annual Meeting of Shareholders, which will be filed no later than 120 days after December 31, 2023\nABO\nAccumulated benefit obligation; represents the present value of the benefit obligation earned through the end of the year but does not factor in\nfuture compensation increases\nACIP\nAdvisory Committee on Immunization Practices\nADC\nAntibody-Drug Conjugate\nAlexion\nAlexion Pharma International Operations Limited, a subsidiary of AstraZeneca PLC\nALK\nanaplastic lymphoma kinase\nAlliance revenues\nRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us\nArena\nArena Pharmaceuticals, Inc.\nArray\nArray BioPharma Inc.\nArvinas\nArvinas, Inc.\nAstellas\nAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.",
      "char_count": 996,
      "start_char": 7200,
      "end_char": 8197
    },
    {
      "chunk_id": "pfizer_2023_chunk0010",
      "chunk_index": 10,
      "text": "or developed by other companies or us\nArena\nArena Pharmaceuticals, Inc.\nArray\nArray BioPharma Inc.\nArvinas\nArvinas, Inc.\nAstellas\nAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.\nATTR-CM\ntransthyretin amyloid cardiomyopathy\nBeam\nBeam Therapeutics Inc.\nBiohaven\nBiohaven Pharmaceutical Holding Company Limited\nBioNTech\nBioNTech SE\nBiopharma\nGlobal Biopharmaceuticals Business\nBlackstone\nBlackstone Life Sciences\nBLA\nBiologics License Application\nBMS\nBristol-Myers Squibb Company\nBOD\nBoard of Directors\nCDC\nU.S. Centers for Disease Control and Prevention\ncGMP\ncurrent Good Manufacturing Practices\nCGRP\ncalcitonin gene-related peptide\nCMS\nCenters for Medicare & Medicaid Services\nComirnaty*\nUnless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech\nCOVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula), the Pfizer-BioNTech",
      "char_count": 980,
      "start_char": 8000,
      "end_char": 8981
    },
    {
      "chunk_id": "pfizer_2023_chunk0011",
      "chunk_index": 11,
      "text": "oNTech COVID-19 Vaccine, the Pfizer-BioNTech\nCOVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula), the Pfizer-BioNTech\nCOVID-19 Vaccine (2023-2024 Formula), Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4/BA.5 and Comirnaty XBB.1.5.\nConsumer Healthcare JV\nGSK Consumer Healthcare JV\nCOVID-19\nnovel coronavirus disease of 2019\nDEA\nU.S. Drug Enforcement Agency\nDeveloped Europe\nIncludes the following markets: Western Europe, Scandinavian countries and Finland\nDeveloped Markets\nIncludes the following markets: U.S., Developed Europe and Developed Rest of World\nDeveloped Rest of World\nIncludes the following markets: Japan, Canada, South Korea, Australia and New Zealand\nEuropean Commission\nEMA\nEuropean Medicines Agency\nEmerging Markets\nIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the\nMiddle East, Africa and Turkey\nEPS",
      "char_count": 997,
      "start_char": 8800,
      "end_char": 9798
    },
    {
      "chunk_id": "pfizer_2023_chunk0012",
      "chunk_index": 12,
      "text": "merging Markets\nIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the\nMiddle East, Africa and Turkey\nEPS\nearnings per share\nESG\nEnvironmental, Social and Governance\nESOP\nemployee stock ownership plan\nEuropean Union\nEUA\nemergency use authorization\nExchange Act\nSecurities Exchange Act of 1934, as amended\nFASB\nFinancial Accounting Standards Board\nFCPA\nU.S. Foreign Corrupt Practices Act\nFDA\nU.S. Food and Drug Administration\nFFDCA\nU.S. Federal Food, Drug and Cosmetic Act\nGAAP\nGenerally Accepted Accounting Principles\n\nGBT\nGlobal Blood Therapeutics, Inc.\nGDFV\ngrant-date fair value\nGenmab\nGenmab A/S\nGPD\nGlobal Product Development organization\nGSK\nGSK plc\nHaleon\nHaleon plc\nHHS\nU.S. Department of Health and Human Services\nHIPAA\nHealth Insurance Portability and Accountability Act of 1996\nHospira\nHospira, Inc.\nIPR&D\nin-process research and development\nIRA\nInflation Reduction Act of 2022\nIRC",
      "char_count": 984,
      "start_char": 9600,
      "end_char": 10585
    },
    {
      "chunk_id": "pfizer_2023_chunk0013",
      "chunk_index": 13,
      "text": "Human Services\nHIPAA\nHealth Insurance Portability and Accountability Act of 1996\nHospira\nHospira, Inc.\nIPR&D\nin-process research and development\nIRA\nInflation Reduction Act of 2022\nIRC\nInternal Revenue Code\nIRS\nU.S. Internal Revenue Service\ninformation technology\njoint venture\nKing\nKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)\nLIBOR\nLondon Interbank Offered Rate\nLOE\nloss of exclusivity\nMCO\nmanaged care organization\nmCRC\nmetastatic colorectal cancer\nmCRPC\nmetastatic castration-resistant prostate cancer\nmCSPC\nmetastatic castration-sensitive prostate cancer\nMD&A\nManagement’s Discussion and Analysis of Financial Condition and Results of Operations\nMDL\nMulti-District Litigation\nMedivation\nMedivation LLC (formerly Medivation, Inc.)\nMeridian\nMeridian Medical Technologies, Inc.\nMoody’s\nMoody’s Investors Service\nmRNA\nmessenger ribonucleic acid\nMSA\nManufacturing Supply Agreement\nMylan\nMylan N.V.\nMylan-Japan collaboration",
      "char_count": 941,
      "start_char": 10400,
      "end_char": 11342
    },
    {
      "chunk_id": "pfizer_2023_chunk0014",
      "chunk_index": 14,
      "text": "ody’s\nMoody’s Investors Service\nmRNA\nmessenger ribonucleic acid\nMSA\nManufacturing Supply Agreement\nMylan\nMylan N.V.\nMylan-Japan collaboration\na pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020\nNAV\nnet asset value\nNDA\nnew drug application\nNimbus\nNimbusTherapeutics, LLC\nnmCRPC\nnon-metastatic castration-resistant prostate cancer\nnmCSPC\nnon-metastatic castration-sensitive prostate cancer\nNSCLC\nnon-small cell lung cancer\nNYSE\nNew York Stock Exchange\nODT\noral disintegrating tablet\nOno\nOno Pharmaceutical Co., Ltd.\nOPKO\nOPKO Health, Inc.\nORD\nOncology Research and Development\nOTC\nover-the-counter\nPaxlovid*\nan oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)\nPBM\npharmacy benefit manager\nPBO\nProjected benefit obligation; represents the present value of the benefit obligation earned through the end of the year and factors in future\ncompensation increases\nPC1\nPfizer CentreOne\nPGS\nPfizer Global Supply",
      "char_count": 997,
      "start_char": 11200,
      "end_char": 12198
    },
    {
      "chunk_id": "pfizer_2023_chunk0015",
      "chunk_index": 15,
      "text": "efit obligation; represents the present value of the benefit obligation earned through the end of the year and factors in future\ncompensation increases\nPC1\nPfizer CentreOne\nPGS\nPfizer Global Supply\nPharmacia\nPharmacia LLC (formerly Pharmacia Corporation)\nPIE\n\nPP&E\nProperty, plant and equipment\nPRAC\nPharmacovigilance Risk Assessment Committee\nPRD\nPfizer Research and Development\nPrevnar family\nIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)\nPsA\npsoriatic arthritis\nQCE\nquality consistency evaluation\nrheumatoid arthritis\n\n2023 Form 10-K\n\nRCC\nrenal cell carcinoma\nR&D\nresearch and development\nReViral\nReViral Ltd.\nROU\nright of use\nRSV\nrespiratory syncytial virus\nS&P\nStandard & Poor’s\nSeagen\nSeagen Inc. and its subsidiaries\nSEC\nU.S. Securities and Exchange Commission\nSI&A\nselling, informational and administrative\nSMPA\nSumitomo Pharma America, Inc.\nTakeda\nTakeda Pharmaceutical Company Limited\nTax Cuts and Jobs Act or TCJA",
      "char_count": 978,
      "start_char": 12000,
      "end_char": 12979
    },
    {
      "chunk_id": "pfizer_2023_chunk0016",
      "chunk_index": 16,
      "text": "d Exchange Commission\nSI&A\nselling, informational and administrative\nSMPA\nSumitomo Pharma America, Inc.\nTakeda\nTakeda Pharmaceutical Company Limited\nTax Cuts and Jobs Act or TCJA\nLegislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017\nTrillium\nTrillium Therapeutics ULC (formerly Trillium Therapeutics Inc.)\nTSAs\ntransition service arrangements\nulcerative colitis\nU.K.\nUnited Kingdom\nUpjohn Business\n\nbrands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on\nNovember 16, 2020 and combined with Mylan to create Viatris\nU.S.\nUnited States\nValneva\nValneva SE\nVBP\nvolume-based procurement\nViatris\nViatris Inc.\nViiV\nViiV Healthcare Limited\nVyndaqel family\nIncludes Vyndaqel, Vyndamax and Vynmac\nWRDM\nWorldwide Research, Development and Medical\nWTO\nWorld Trade Organization\nWyeth\nWyeth LLC (formerly Wyeth)",
      "char_count": 903,
      "start_char": 12800,
      "end_char": 13704
    },
    {
      "chunk_id": "pfizer_2023_chunk0017",
      "chunk_index": 17,
      "text": "rldwide Research, Development and Medical\nWTO\nWorld Trade Organization\nWyeth\nWyeth LLC (formerly Wyeth)\nThe Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) and certain uses of Paxlovid have not been approved or licensed by the FDA. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)\nhas been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months through 11 years of age. Paxlovid has been authorized for emergency use by the FDA\nunder an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including\nhospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the",
      "char_count": 894,
      "start_char": 13600,
      "end_char": 14495
    },
    {
      "chunk_id": "pfizer_2023_chunk0018",
      "chunk_index": 18,
      "text": "mstances exist justifying the authorization of emergency use of the medical product during the\nCOVID-19 pandemic under Section 564(b)(1) of the FFDCA, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and\nwww.cvdvaccine-us.com.\nThis Form 10-K includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical\ndata relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are\nsubject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product,\nregulatory authorities may not share our views and may require additional data or may deny approval altogether.",
      "char_count": 970,
      "start_char": 14400,
      "end_char": 15371
    },
    {
      "chunk_id": "pfizer_2023_chunk0019",
      "chunk_index": 19,
      "text": "duct candidate or a new indication for an in-line product,\nregulatory authorities may not share our views and may require additional data or may deny approval altogether.\nSome amounts in this Form 10-K may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their\nowners.\nAVAILABLE INFORMATION\nOur website is www.pfizer.com. This Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and our proxy statements, and amendments to those reports\nfiled or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are, or will be, available (free of charge) on our website, in text format and, where applicable, in interactive\ndata file format, as soon as reasonably practicable after we electronically file this material with, or furnish it to, the SEC.",
      "char_count": 862,
      "start_char": 15200,
      "end_char": 16063
    },
    {
      "chunk_id": "pfizer_2023_chunk0020",
      "chunk_index": 20,
      "text": "tronically file this material with, or furnish it to, the SEC.\nThroughout this Form 10-K, we “incorporate by reference” certain information from other documents filed or to be filed with the SEC, including our Proxy Statement. Please refer to\nthis information. This Form 10-K will be available on our website on or about February 22, 2024. Our Proxy Statement will be available on our website on or about March 14, 2024.\nOur 2023 Impact Report, which provides enhanced ESG disclosures, will be available on our website on or about March 14, 2024. We also have a Pfizer Investor Insights website,\nwhich includes articles on the company, its products and its pipeline, located at insights.pfizer.com. Information in our 2023 Impact Report and on the Pfizer Investor Insights website\nare not incorporated by reference into this Form 10-K.",
      "char_count": 835,
      "start_char": 16000,
      "end_char": 16836
    },
    {
      "chunk_id": "pfizer_2023_chunk0021",
      "chunk_index": 21,
      "text": "d by reference into this Form 10-K.\nWe may use our website as a means of disclosing material information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC.\nThese disclosures are included on our website in the “About—Investors” or “Newsroom” sections. Accordingly, investors should monitor these portions of our website, in addition to\nfollowing our press releases, SEC filings, public conference calls and webcasts, as well as our social media channels (our Facebook page, Instagram account (@Pfizerinc), YouTube\npage, LinkedIn page, and X (formerly known as Twitter) accounts (@Pfizer and @Pfizer_News)). The information contained on our website, our Facebook, Instagram, YouTube and\nLinkedIn pages or our X accounts, or any third-party website, is not incorporated by reference into this Form 10-K.",
      "char_count": 856,
      "start_char": 16800,
      "end_char": 17657
    },
    {
      "chunk_id": "pfizer_2023_chunk0022",
      "chunk_index": 22,
      "text": "e, is not incorporated by reference into this Form 10-K.\nInformation relating to corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Pfizer Policies on Business Conduct (for all\nof our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of Business Conduct and Ethics for Members of the Board of\nDirectors; information concerning our Directors; ways to\n\n2023 Form 10-K\niii\n\ncommunicate by e-mail with our Directors; information concerning our Board Committees; Committee Charters; Charter of the Lead Independent Director; and transactions in Pfizer\nsecurities by Directors and Officers are available on our website. We will provide any of the foregoing information without charge upon written request to our Corporate Secretary,",
      "char_count": 852,
      "start_char": 17600,
      "end_char": 18453
    },
    {
      "chunk_id": "pfizer_2023_chunk0023",
      "chunk_index": 23,
      "text": "rge upon written request to our Corporate Secretary,\n\nConduct affecting our Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and executive officers on our website as promptly as practicable, as may be\nrequired under applicable SEC and NYSE rules. Information relating to shareholder services, including the Computershare Investment Program, book-entry share ownership and\ndirect deposit of dividends, is also available on our website.\n\n2023 Form 10-K\n\nFORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS\nThis Form 10-K contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given\ntheir forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions.",
      "char_count": 861,
      "start_char": 18400,
      "end_char": 19262
    },
    {
      "chunk_id": "pfizer_2023_chunk0024",
      "chunk_index": 24,
      "text": "risks, uncertainties and potentially inaccurate assumptions.\nWe have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,”\n“plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning or by using future dates.\nWe include forward-looking information in our discussion of the following, among other topics:\n• our anticipated operating and financial performance, including financial guidance and projections;\n• reorganizations, business plans, strategy, goals and prospects;\n• expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches,",
      "char_count": 878,
      "start_char": 19200,
      "end_char": 20080
    },
    {
      "chunk_id": "pfizer_2023_chunk0025",
      "chunk_index": 25,
      "text": "ated regulatory submissions, data read-outs, study starts, approvals, launches,\nclinical trial results and other developing data; revenue contribution and projections; potential pricing and reimbursement; potential market dynamics, including patient demand,\nmarket size and utilization rates; and growth, performance, timing of exclusivity and potential benefits;\n• strategic reviews, capital allocation objectives, dividends and share repurchases;\n• plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities and prospects;\n• sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;\n• expectations regarding the impact of or changes to existing or new government regulations or laws;",
      "char_count": 853,
      "start_char": 20000,
      "end_char": 20854
    },
    {
      "chunk_id": "pfizer_2023_chunk0026",
      "chunk_index": 26,
      "text": "es to existing or new government regulations or laws;\n• our ability to anticipate and respond to and our expectations regarding the impact of macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other\nlarge-scale crises; and\n• manufacturing and product supply.\nIn particular, forward-looking information in this Form 10-K includes statements relating to specific future actions, performance and effects, including, among others, the expected\nbenefits of the organizational changes to our operations; our anticipated operating and financial performance; our ongoing efforts to respond to COVID-19, including our plans and\nexpectations regarding Comirnaty and Paxlovid, and any potential future vaccines or treatments, including anticipated revenue and expectations for the commercial market for\nComirnaty and Paxlovid; our expectations regarding the impact of COVID-19 on our business; expected patent terms; the expected impact of patent expiries and generic and",
      "char_count": 993,
      "start_char": 20800,
      "end_char": 21794
    },
    {
      "chunk_id": "pfizer_2023_chunk0027",
      "chunk_index": 27,
      "text": "he commercial market for\nComirnaty and Paxlovid; our expectations regarding the impact of COVID-19 on our business; expected patent terms; the expected impact of patent expiries and generic and\nbiosimilar competition; the expected pricing pressures on our products and the anticipated impact to our business; the benefits expected from our business development\ntransactions, including our December 2023 acquisition of Seagen; our anticipated liquidity position; the anticipated costs, savings and potential benefits from certain of our initiatives,\nincluding our enterprise-wide Realigning our Cost Base program, which we launched in October 2023, and our Transforming to a More Focused Company program; our expectations\nregarding the impact from the 2023 tornado on our manufacturing facility in Rocky Mount, NC; our greenhouse gas emission reduction goals; our planned capital spending; and our\ncapital allocation framework.",
      "char_count": 926,
      "start_char": 21600,
      "end_char": 22527
    },
    {
      "chunk_id": "pfizer_2023_chunk0028",
      "chunk_index": 28,
      "text": "ky Mount, NC; our greenhouse gas emission reduction goals; our planned capital spending; and our\ncapital allocation framework.\nGiven their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from\npast results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or\nincomplete, or by known or unknown risks and uncertainties, including those described in this section, in the Item 1A. Risk Factors section or in MD&A.\nTherefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form 10-K. We undertake no obligation to update forwardlooking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.",
      "char_count": 941,
      "start_char": 22400,
      "end_char": 23342
    },
    {
      "chunk_id": "pfizer_2023_chunk0029",
      "chunk_index": 29,
      "text": "rwardlooking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. You are advised, however, to consult any\nfurther disclosures we make on related subjects.\nSome of the factors that could cause actual results to differ are identified below, as well as those discussed in the Item 1A. Risk Factors section and within MD&A. We note these\nfactors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below, in the Item 1A. Risk Factors section, or\nwithin MD&A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase\nour accruals for contingencies. It is not possible to predict or identify all such factors.",
      "char_count": 869,
      "start_char": 23200,
      "end_char": 24070
    },
    {
      "chunk_id": "pfizer_2023_chunk0030",
      "chunk_index": 30,
      "text": "ngencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential\nrisks or uncertainties:\nRisks Related to Our Business, Industry and Operations, and Business Development:\n• the outcome of R&D activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or\nclinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including\nthe possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or\ninterim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process,",
      "char_count": 976,
      "start_char": 24000,
      "end_char": 24977
    },
    {
      "chunk_id": "pfizer_2023_chunk0031",
      "chunk_index": 31,
      "text": "interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process,\nin the scientific community generally, and by regulatory authorities; and whether and when additional data from our pipeline programs will be published in scientific\njournal publications, and if so, when and with what modifications and interpretations;\n• our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from\nregulators on a timely basis or at all;\n• regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters,\nincluding decisions relating to emerging developments regarding potential product impurities; uncertainties regarding the ability to obtain, and the scope of,",
      "char_count": 964,
      "start_char": 24800,
      "end_char": 25765
    },
    {
      "chunk_id": "pfizer_2023_chunk0032",
      "chunk_index": 32,
      "text": "ters,\nincluding decisions relating to emerging developments regarding potential product impurities; uncertainties regarding the ability to obtain, and the scope of,\nrecommendations by technical or advisory committees, and the timing of, and ability to obtain, pricing approvals and product launches, all of which could impact the\navailability or commercial potential of our products and product candidates;\n• claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the\noutcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential;\n\n2023 Form 10-K\n\n• the success and impact of external business development activities, such as the recent acquisition of Seagen, including the ability to identify and execute on potential",
      "char_count": 906,
      "start_char": 25600,
      "end_char": 26507
    },
    {
      "chunk_id": "pfizer_2023_chunk0033",
      "chunk_index": 33,
      "text": "ties, such as the recent acquisition of Seagen, including the ability to identify and execute on potential\nbusiness development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize\nthe anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue\nthese opportunities, which has in the past and could in the future result in increased leverage and/or a downgrade of our credit ratings and could limit our ability to obtain\nfuture financing; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain\nacquired or partnered products; significant transaction costs; and unknown liabilities;",
      "char_count": 889,
      "start_char": 26400,
      "end_char": 27290
    },
    {
      "chunk_id": "pfizer_2023_chunk0034",
      "chunk_index": 34,
      "text": "n\nacquired or partnered products; significant transaction costs; and unknown liabilities;\n• competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or\nprevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;\n• the ability to successfully market both new and existing products, including biosimilars;\n• difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or\nregulatory actions;\n• the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts\non our employees, manufacturing, supply chain, sales and marketing, R&D and clinical trials;",
      "char_count": 943,
      "start_char": 27200,
      "end_char": 28144
    },
    {
      "chunk_id": "pfizer_2023_chunk0035",
      "chunk_index": 35,
      "text": "financial condition and results, including impacts\non our employees, manufacturing, supply chain, sales and marketing, R&D and clinical trials;\n• risks and uncertainties related to our efforts to continue to develop and commercialize Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or\ncombinations, as well as challenges related to their manufacturing, supply and distribution, including, among others, the risk that as the market for COVID-19 products\ncontinues to become more endemic and seasonal, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, or may no longer\nexist, which has and may continue to lead to reduced revenues, excess inventory on-hand and/or in the channel which, for Paxlovid and Comirnaty, resulted in\nsignificant inventory write-offs in 2023 and could continue to result in inventory write-offs, or other unanticipated charges; challenges related to the transition to the",
      "char_count": 967,
      "start_char": 28000,
      "end_char": 28968
    },
    {
      "chunk_id": "pfizer_2023_chunk0036",
      "chunk_index": 36,
      "text": "nificant inventory write-offs in 2023 and could continue to result in inventory write-offs, or other unanticipated charges; challenges related to the transition to the\ncommercial market for our COVID-19 products; uncertainties related to the public’s adherence to vaccines, boosters, treatments or combinations; and risks related to\nour ability to accurately predict or achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments;\n• trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our\nproducts;\n• interest rate and foreign currency exchange rate fluctuations, including the impact of currency devaluations and monetary policy actions in countries experiencing high\ninflation or deflation rates;",
      "char_count": 861,
      "start_char": 28800,
      "end_char": 29662
    },
    {
      "chunk_id": "pfizer_2023_chunk0037",
      "chunk_index": 37,
      "text": "in countries experiencing high\ninflation or deflation rates;\n• any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;\n• the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain;\n• any significant issues related to the outsourcing of certain operational and staff functions to third parties;\n• any significant issues related to our JVs and other third-party business arrangements, including modifications related to supply agreements or other contracts with\ncustomers including governments or other payors;\n• uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact",
      "char_count": 844,
      "start_char": 29600,
      "end_char": 30446
    },
    {
      "chunk_id": "pfizer_2023_chunk0038",
      "chunk_index": 38,
      "text": "mitation, uncertainties related to the impact\non us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such\nas inflation or interest rate fluctuations, and recent and possible future changes in global financial markets;\n• the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions and/or other restrictive government\nactions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes;\n• the impact of disruptions related to climate change and natural disasters, including uncertainties related to the impact of the tornado at our manufacturing facility in\nRocky Mount, NC in 2023;",
      "char_count": 830,
      "start_char": 30400,
      "end_char": 31231
    },
    {
      "chunk_id": "pfizer_2023_chunk0039",
      "chunk_index": 39,
      "text": "ty in\nRocky Mount, NC in 2023;\n• any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action,\nincluding the ongoing conflicts between Russia and Ukraine and in the Middle East and the resulting economic or other consequences;\n• the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, including our\nongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines;\n• trade buying patterns;\n• the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;\n• the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies,",
      "char_count": 927,
      "start_char": 31200,
      "end_char": 32128
    },
    {
      "chunk_id": "pfizer_2023_chunk0040",
      "chunk_index": 40,
      "text": "ed to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies,\nand cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs,\norganizational disruption, adverse effects on employee morale, retention issues or other unintended consequences;\n• the ability to successfully achieve our climate goals and progress our environmental sustainability and other ESG priorities;\nRisks Related to Government Regulation and Legal Proceedings:\n• the impact of any U.S. healthcare reform or legislation or any significant spending reduction or cost control efforts affecting Medicare, Medicaid or other publicly funded\nor subsidized health programs, including the IRA, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;\n• U.S.",
      "char_count": 923,
      "start_char": 32000,
      "end_char": 32924
    },
    {
      "chunk_id": "pfizer_2023_chunk0041",
      "chunk_index": 41,
      "text": ", including the IRA, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;\n• U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property,\nreimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on\n\n2023 Form 10-K\n\ninteractions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive\nbiopharmaceutical markets;\n• legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing,\nintellectual property, medical regulation, environmental protections, reimbursement or access, including, in particular, continued government-mandated reductions in",
      "char_count": 912,
      "start_char": 32800,
      "end_char": 33713
    },
    {
      "chunk_id": "pfizer_2023_chunk0042",
      "chunk_index": 42,
      "text": "ntal protections, reimbursement or access, including, in particular, continued government-mandated reductions in\nprices and access restrictions for certain biopharmaceutical products to control costs in those markets;\n• legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to actual or alleged environmental\ncontamination;\n• the risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings;\n• the risk and impact of tax related litigation and investigations;\n• governmental laws and regulations affecting our operations, including, without limitation, the IRA, changes in laws and regulations or their interpretation, including,\namong others, changes in tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S.",
      "char_count": 915,
      "start_char": 33600,
      "end_char": 34516
    },
    {
      "chunk_id": "pfizer_2023_chunk0043",
      "chunk_index": 43,
      "text": "regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. generally\neffective in most jurisdictions since January 1, 2024 and potential changes to existing tax law by the current U.S. Presidential administration and Congress, including the\nproposed “Tax Relief for American Families and Workers Act of 2024”;\nRisks Related to Intellectual Property, Technology and Security:\n• any significant breakdown or interruption of our IT systems and infrastructure (including cloud services);\n• any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a\ncyber-attack or other malfeasance by, but not limited to, nation states, employees, business partners or others;\n• risks and challenges related to the use of artificial intelligence-based software;",
      "char_count": 915,
      "start_char": 34400,
      "end_char": 35317
    },
    {
      "chunk_id": "pfizer_2023_chunk0044",
      "chunk_index": 44,
      "text": "s, business partners or others;\n• risks and challenges related to the use of artificial intelligence-based software;\n• the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be\ngranted on a timely basis, if at all; and\n• risks to our products, patents and other intellectual property, such as: (i) claims of invalidity that could result in LOE; (ii) claims of patent infringement, including asserted and/or\nunasserted intellectual property claims; (iii) claims we may assert against intellectual property rights held by third parties; (iv) challenges faced by our collaboration or licensing\npartners to the validity of their patent rights; or (v) any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking",
      "char_count": 888,
      "start_char": 35200,
      "end_char": 36089
    },
    {
      "chunk_id": "pfizer_2023_chunk0045",
      "chunk_index": 45,
      "text": "by, various stakeholders or governments that could potentially result in us not seeking\nintellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid.\nPART I\nITEM 1.\nBUSINESS\nABOUT PFIZER\n\ntheir lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging\nmarkets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and\nlocal communities to support and expand access to reliable, affordable healthcare around the world. The Company was incorporated under the laws of the State of Delaware on\nJune 2, 1942.\nMost of our revenues come from the manufacture and sale of biopharmaceutical products.",
      "char_count": 927,
      "start_char": 36000,
      "end_char": 36929
    },
    {
      "chunk_id": "pfizer_2023_chunk0046",
      "chunk_index": 46,
      "text": "of the State of Delaware on\nJune 2, 1942.\nMost of our revenues come from the manufacture and sale of biopharmaceutical products. We also sell products for the detection of certain illnesses and provide end-to-end R&D\nservices to select innovative biotech companies. We believe that our medicines and vaccines provide significant value for healthcare providers and patients through improved\ntreatment of diseases and improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room visits or hospitalizations. We\nseek to enhance the value of our medicines and vaccines and actively engage in dialogues about how we can best work with patients, physicians and payors to prevent and treat\ndisease and improve outcomes. We seek to maximize patient access and evaluate our pricing arrangements and contracting methods with payors to minimize adverse impact on\nour revenues within the current legal and pricing structures.",
      "char_count": 971,
      "start_char": 36800,
      "end_char": 37772
    },
    {
      "chunk_id": "pfizer_2023_chunk0047",
      "chunk_index": 47,
      "text": "ccess and evaluate our pricing arrangements and contracting methods with payors to minimize adverse impact on\nour revenues within the current legal and pricing structures.\nWe are committed to fulfilling our purpose: Breakthroughs that change patients’ lives. Our purpose fuels everything we do and reflects both our passion for science and our\ncommitment to patients. Our core business principles are:\nTrust is Everything\nScience Will Win\nDisruption Calls for Innovation\nTime is Life\nExecution Makes the Difference.\nIn addition, Pfizer’s ESG strategy, which is integrated into our corporate strategy, focuses on six areas where we see opportunities to create a meaningful impact: product innovation;\nequitable access and pricing; product quality and safety; diversity, equity and inclusion; climate change; and business ethics.",
      "char_count": 827,
      "start_char": 37600,
      "end_char": 38428
    },
    {
      "chunk_id": "pfizer_2023_chunk0048",
      "chunk_index": 48,
      "text": "hange; and business ethics.\nWe are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also\nthrough various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities\nand transactions that have the potential to strengthen our business and our\n\n2023 Form 10-K\n\ncapabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business\ndevelopment activities that will help advance our business strategy.\nOn December 14, 2023, we completed our acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.",
      "char_count": 895,
      "start_char": 38400,
      "end_char": 39296
    },
    {
      "chunk_id": "pfizer_2023_chunk0049",
      "chunk_index": 49,
      "text": "technology company that discovers, develops and commercializes transformative cancer medicines.\nWith the addition of Seagen’s pipeline and its four in-line medicines (Padcev, Adcetris, Tukysa and Tivdak), Pfizer’s oncology portfolio spans multiple modalities, including ADCs,\nsmall molecules, bispecifics and other immunotherapies. In addition to the acquisition of Seagen, our significant recent business development activities in 2023 include, among\nothers, the September 2023 divestiture of our early-stage rare disease gene therapy portfolio to Alexion. For a further discussion of our strategy and our business development\ninitiatives, see the Overview of Our Performance, Operating Environment, Strategy and Outlook section within MD&A and Note 2.\nCOMMERCIAL OPERATIONS\nIn 2023, we managed our commercial operations through a global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative sciencebased biopharmaceutical business, and Business Inn",
      "char_count": 1000,
      "start_char": 39200,
      "end_char": 40200
    },
    {
      "chunk_id": "pfizer_2023_chunk0050",
      "chunk_index": 50,
      "text": "commercial operations through a global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative sciencebased biopharmaceutical business, and Business Innovation, an operating segment established in the first quarter of 2023 that includes PC1, our contract development and\nmanufacturing organization and a leading supplier of specialty active pharmaceutical ingredients, and Pfizer Ignite, an offering that provides strategic guidance and end-to-end R&D\nservices to select innovative biotech companies that align with our R&D focus areas. In 2023, Biopharma was the only reportable segment. The commercial structure within\nBiopharma included three broad customer groups in 2023: Primary Care, Specialty Care and Oncology.\nAt the beginning of 2024, we made changes in our commercial organization to incorporate Seagen and improve focus, speed and execution.",
      "char_count": 902,
      "start_char": 40000,
      "end_char": 40903
    },
    {
      "chunk_id": "pfizer_2023_chunk0051",
      "chunk_index": 51,
      "text": "e changes in our commercial organization to incorporate Seagen and improve focus, speed and execution. Specifically, within our Biopharma\nreportable segment we created the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division:\nDivision\nDescription\nPfizer Oncology Division\nCombines the U.S. Oncology commercial organizations, global Oncology marketing organizations and global and U.S. Oncology medical affairs from both\n\nrange of cancers including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma,\ngastrointestinal, gynecological and thoracic cancers, which includes lung cancer.\nPfizer U.S. Commercial\nDivision\nIncludes the U.S. Primary Care and U.S. Specialty Care customer groups, the Chief Marketing Office, the Global Chief Medical Affairs Office and\nGlobal Access & Value.\nU.S.",
      "char_count": 913,
      "start_char": 40800,
      "end_char": 41714
    },
    {
      "chunk_id": "pfizer_2023_chunk0052",
      "chunk_index": 52,
      "text": "tomer groups, the Chief Marketing Office, the Global Chief Medical Affairs Office and\nGlobal Access & Value.\nU.S. Primary Care includes:\nInternal medicine product portfolio of brands in cardiovascular metabolic, bone graft for spinal fusion and women’s health, as well as post-LOE\nbrands.\nMigraine product portfolio.\nVaccines product portfolio across all ages with a pipeline focus on infectious diseases with significant unmet medical need, including COVID-19.\nTreatment for COVID-19.\nProducts for detection of COVID-19 and influenza.\nU.S. Specialty Care includes:\nInflammation & immunology product portfolio of brands and biosimilars for chronic immune and inflammatory diseases.\nRare disease product portfolio of brands for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia, endocrine diseases\nand sickle cell disease.\nHospital product portfolio of sterile injectable and immunoglobulin medicines.\nPfizer International Commercial\nDivision\nIncludes the ex-U.S.",
      "char_count": 996,
      "start_char": 41600,
      "end_char": 42597
    },
    {
      "chunk_id": "pfizer_2023_chunk0053",
      "chunk_index": 53,
      "text": "hemophilia, endocrine diseases\nand sickle cell disease.\nHospital product portfolio of sterile injectable and immunoglobulin medicines.\nPfizer International Commercial\nDivision\nIncludes the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets.\nSelect products within Oncology, Primary Care and Specialty Care include:\n• Oncology: Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak\n• Primary Care:\n◦Internal medicine: Eliquis, the Premarin family and BMP2\n◦Migraine: Nurtec ODT/Vydura and Zavzpret\n◦Vaccines: Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba\n◦Treatment for COVID-19: Paxlovid\n◦Detection of COVID-19 and influenza: Lucira by Pfizer\n• Specialty Care:\n◦Inflammation & immunology: Xeljanz, Enbrel (outside the U.S.",
      "char_count": 897,
      "start_char": 42400,
      "end_char": 43298
    },
    {
      "chunk_id": "pfizer_2023_chunk0054",
      "chunk_index": 54,
      "text": "Lucira by Pfizer\n• Specialty Care:\n◦Inflammation & immunology: Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo and Velsipity\n◦Rare disease: the Vyndaqel family, Genotropin, BeneFIX, Oxbryta, Somavert and Ngenla\n◦Hospital: Sulperazon, Zavicefta, Zithromax, Medrol and Panzyga\nFor additional information on our operating segments and products, including product revenues, see Note 17, and for additional information on the key operational revenue drivers of\nour business, see the Analysis of the Consolidated Statements of Income section within MD&A. For a discussion of the risks associated with our dependence on certain of our major\nproducts, see the Item 1A. Risk Factors—Concentration section.\nRESEARCH AND DEVELOPMENT\nR&D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients’ lives as we work to translate advanced science and technologies into the medicines and\nvaccines that may be the most impactful for patients.",
      "char_count": 982,
      "start_char": 43200,
      "end_char": 44184
    },
    {
      "chunk_id": "pfizer_2023_chunk0055",
      "chunk_index": 55,
      "text": "eliver breakthroughs that change patients’ lives as we work to translate advanced science and technologies into the medicines and\nvaccines that may be the most impactful for patients. In addition to discovering and developing new products, our R&D efforts seek to add value to our existing products by\nimproving their safety, efficacy and ease of dosing and by discovering potential new indications.\n\n2023 Form 10-K\n\nOur R&D Priorities and Strategy. Our R&D priorities include:\n• delivering a pipeline of highly differentiated medicines and vaccines where we have a unique opportunity to bring the most important new therapies to patients in need;\n• advancing our capabilities that can position us for long-term R&D leadership; and\n• advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.",
      "char_count": 870,
      "start_char": 44000,
      "end_char": 44871
    },
    {
      "chunk_id": "pfizer_2023_chunk0056",
      "chunk_index": 56,
      "text": "and urgency to deliver innovation to patients as quickly as possible.\nTo that end, our R&D primarily focuses on our main therapeutic areas, which are inflammation and immunology, internal medicine, oncology, rare diseases, vaccines, and antiinfectives.\nWhile a significant portion of our R&D is internal, we also seek promising chemical and biological lead molecules and innovative technologies developed by others to incorporate into\nour discovery and development processes or projects, as well as our portfolio. We do so by entering into collaboration, alliance and license agreements with universities,\nbiotechnology companies and other firms as well as through acquisitions and investments. These collaboration, alliance and license agreements and investments allow us to share\nknowledge, risk and cost. They also enable us to access external scientific and technological expertise, as well as provide us the opportunity to advance our own products and inlicensed or acquired products.",
      "char_count": 989,
      "start_char": 44800,
      "end_char": 45791
    },
    {
      "chunk_id": "pfizer_2023_chunk0057",
      "chunk_index": 57,
      "text": "nd cost. They also enable us to access external scientific and technological expertise, as well as provide us the opportunity to advance our own products and inlicensed or acquired products. For information on certain of these collaborations, alliances and license arrangements and investments, see Note 2.\nOur R&D Operations. In 2023, we continued to strengthen our global R&D operations and pursue strategies to improve R&D productivity to achieve a sustainable pipeline that is\npositioned to deliver value in the near term and over time. Our R&D activity is conducted through various platform functions that support our global operations. Beginning in July\n2023, in consideration of planned future investments in oncology, including the December 2023 acquisition of Seagen, we reorganized our R&D platform operations.",
      "char_count": 820,
      "start_char": 45600,
      "end_char": 46421
    },
    {
      "chunk_id": "pfizer_2023_chunk0058",
      "chunk_index": 58,
      "text": "platform operations. Discovery to\nlate-phase clinical development for oncology is performed by a new end-to-end Oncology Research and Development (ORD) organization and discovery to late-phase clinical\ndevelopment for all remaining therapeutic areas is consolidated into the end-to-end Pfizer Research and Development (PRD) organization. ORD and PRD replace our former\nWRDM and GPD organizations, where, prior to July 2023, research units within WRDM were generally responsible for research and early-stage development assets and, prior to\nJuly 2023, GPD was generally responsible for the clinical development strategy and operational execution of clinical trials for both early- and late-stage clinical assets in Pfizer’s\npipeline. In 2023, Biopharma received R&D services from ORD, PRD and the predecessor WRDM and GPD organizations.",
      "char_count": 835,
      "start_char": 46400,
      "end_char": 47236
    },
    {
      "chunk_id": "pfizer_2023_chunk0059",
      "chunk_index": 59,
      "text": "ecessor WRDM and GPD organizations. These services included IPR&D projects for new\ninvestigational products and additional indications for in-line products.\nWe manage R&D operations on a total-company basis through our PRD and ORD organizations described above. Specifically, the Portfolio Management Team, currently led by our\nChairman and Chief Executive Officer and composed of other senior executives, is accountable for aligning resources across PRD and ORD, and for helping to ensure optimal\ncapital allocation across the innovative R&D portfolio. We believe that this approach also serves to maximize accountability and flexibility.\nWe do not disaggregate total R&D expense by development phase or by therapeutic area since, as described above, we do not manage all of our R&D operations by development\nphase or by therapeutic area.",
      "char_count": 839,
      "start_char": 47200,
      "end_char": 48040
    },
    {
      "chunk_id": "pfizer_2023_chunk0060",
      "chunk_index": 60,
      "text": "velopment\nphase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, we believe that any prior-period information about R&D expense by\ndevelopment phase or by therapeutic area would not necessarily be representative of future spending.\nFor additional information on our R&D operations, including R&D related costs and expenses, see the Costs and Expenses—Research and Development Expenses section within\nMD&A and Note 17.\nOur R&D Pipeline. The process of drug and biological product discovery from initiation through development and to potential regulatory approval is lengthy and can take more than\nten years. As of January 30, 2024, we had the following number of projects in various stages of R&D:\nDevelopment of a single compound is often pursued as part of multiple programs. While our product candidates may or may not receive regulatory approval, new candidates\nentering clinical development phases are the foundation for future products.",
      "char_count": 997,
      "start_char": 48000,
      "end_char": 48998
    },
    {
      "chunk_id": "pfizer_2023_chunk0061",
      "chunk_index": 61,
      "text": "ed as part of multiple programs. While our product candidates may or may not receive regulatory approval, new candidates\nentering clinical development phases are the foundation for future products. Information concerning several of our drug and vaccine candidates in development, as well as\nsupplemental filings for existing products, is set forth in the Product Developments section within MD&A. The discovery and development of drugs, vaccines and biological products\nare time consuming, costly and unpredictable. For information on the risks associated with R&D, see the Item 1A. Risk Factors—Research and Development section.\nCOLLABORATION AND CO-PROMOTION AGREEMENTS\nWe use collaboration and/or co-promotion arrangements to enhance our development, R&D, sales and distribution of certain biopharmaceutical products, which include, among\nothers, the following:",
      "char_count": 864,
      "start_char": 48800,
      "end_char": 49665
    },
    {
      "chunk_id": "pfizer_2023_chunk0062",
      "chunk_index": 62,
      "text": "maceutical products, which include, among\nothers, the following:\n• Comirnaty is an mRNA-based coronavirus vaccine to help prevent COVID-19, which is being jointly developed and commercialized with BioNTech. Pfizer and BioNTech equally\nshare the costs of development for the Comirnaty program. Comirnaty has been granted an approval or an authorization in many countries around the world in populations varying\nby country. We also share gross profits equally from commercialization of Comirnaty and are working jointly with BioNTech in our respective territories to commercialize the\nvaccine worldwide (excluding China, Hong Kong, Macau and Taiwan), subject to regulatory authorizations or approvals market by market. For discussion on Comirnaty, see the\nOverview of Our Performance, Operating Environment, Strategy and Outlook—COVID-19 section within MD&A.",
      "char_count": 856,
      "start_char": 49600,
      "end_char": 50457
    },
    {
      "chunk_id": "pfizer_2023_chunk0063",
      "chunk_index": 63,
      "text": "ment, Strategy and Outlook—COVID-19 section within MD&A.\n• Eliquis (apixaban) is part of the Novel Oral Anticoagulant market and was jointly developed and commercialized with BMS as an alternative treatment option to warfarin in\nappropriate patients. We fund between 50% and 60% of all development costs depending on the study, and profits and losses are shared equally except in certain countries\nwhere we commercialize Eliquis and pay a percentage of net sales to BMS. In\n\n2023 Form 10-K\n\ncertain smaller markets we have full commercialization rights and BMS supplies the product to us at cost plus a percentage of the net sales to end-customers.\n• Xtandi (enzalutamide) is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells that is being developed and\ncommercialized in collaboration with Astellas. We share equally in the gross profits and losses related to U.S.",
      "char_count": 935,
      "start_char": 50400,
      "end_char": 51336
    },
    {
      "chunk_id": "pfizer_2023_chunk0064",
      "chunk_index": 64,
      "text": "is being developed and\ncommercialized in collaboration with Astellas. We share equally in the gross profits and losses related to U.S. net sales and also share equally all Xtandi commercialization costs\nattributable to the U.S. market, subject to certain exceptions. In addition, we share certain development and other collaboration expenses. For international net sales we receive\nroyalties based on a tiered percentage.\n• Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer that is being\ndeveloped and commercialized with SMPA. The companies are also collaborating on Myfembree (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for heavy\nmenstrual bleeding associated with uterine fibroids in premenopausal women and the management of moderate to severe pain associated with endometriosis in premenopausal\nwomen.",
      "char_count": 937,
      "start_char": 51200,
      "end_char": 52139
    },
    {
      "chunk_id": "pfizer_2023_chunk0065",
      "chunk_index": 65,
      "text": "terine fibroids in premenopausal women and the management of moderate to severe pain associated with endometriosis in premenopausal\nwomen. The companies equally share profits and allowable expenses in the U.S. for Orgovyx, and in the U.S. and Canada for Myfembree. Pfizer does not have rights outside of\nthese markets. SMPA remains responsible for regulatory interactions and drug supply and continues to lead clinical development for the relugolix combination tablet.\n• Padcev (enfortumab vedotin-ejfv) is a first-in-class ADC that is directed to Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer, that is being\nco-developed and jointly commercialized with Astellas. In the U.S., Padcev has been approved for use with Keytruda (pembrolizumab) for adult patients with locally advanced or\nmetastatic urothelial cancer. Other approvals and indications for Padcev vary by market.",
      "char_count": 917,
      "start_char": 52000,
      "end_char": 52918
    },
    {
      "chunk_id": "pfizer_2023_chunk0066",
      "chunk_index": 66,
      "text": "nts with locally advanced or\nmetastatic urothelial cancer. Other approvals and indications for Padcev vary by market. In the U.S., the companies jointly promote, and we record net sales and are responsible\nfor all U.S. distribution activities for Padcev. The companies each bear the costs of their own sales organizations in the U.S., and equally share certain other costs associated with\ncommercializing and any profits realized in the U.S. for Padcev. Outside the U.S., we have commercialization rights in all countries in North and South America, and Astellas has\ncommercialization rights in the rest of the world. The agreement between us and Astellas provides that the companies will effectively equally share in profits realized in markets\noutside of the U.S. through: (i) a costs-incurred and profit-sharing mechanism based on product sales and costs of commercialization in certain markets and (ii) a royalty-payment",
      "char_count": 924,
      "start_char": 52800,
      "end_char": 53725
    },
    {
      "chunk_id": "pfizer_2023_chunk0067",
      "chunk_index": 67,
      "text": "profit-sharing mechanism based on product sales and costs of commercialization in certain markets and (ii) a royalty-payment\nmechanism intended to approximate an equal profit share for both parties in the remaining markets.\nIn addition, we have collaboration and/or co-promotion arrangements with respect to certain other biopharmaceutical products, including Adcetris and Tivdak as a result of our\nacquisition of Seagen.\nRevenues associated with these arrangements are included in Alliance revenues (except in certain markets where we have direct sales and except for the majority of revenues for\nComirnaty and Padcev, which are included in Product revenues). In addition, we have collaboration arrangements for the development and commercialization of certain pipeline\nproducts that are in development stage, including, among others certain of those described in the Product Developments section within MD&A. For further discussion of collaboration\nand co-promotion agreements, see the Item 1.",
      "char_count": 995,
      "start_char": 53600,
      "end_char": 54596
    },
    {
      "chunk_id": "pfizer_2023_chunk0068",
      "chunk_index": 68,
      "text": "ent stage, including, among others certain of those described in the Product Developments section within MD&A. For further discussion of collaboration\nand co-promotion agreements, see the Item 1. Business—Patents and Other Intellectual Property Rights section, the Item 1A. Risk Factors—Collaborations and Other Relationships\nwith Third Parties section and Notes 2 and 17.\nINTERNATIONAL OPERATIONS\nOur operations are conducted globally, and we supply our medicines and vaccines to approximately 200 countries and territories. Emerging markets are an important component of\nour strategy for global leadership, and our commercial structure recognizes that the demographics and rising economic power of the fastest-growing emerging markets are becoming\nmore closely aligned with the profile found within developed markets. Urbanization and the rise of the middle class in emerging markets provide potential growth opportunities for our\nproducts.\nRevenues from operations outside the U.S.",
      "char_count": 984,
      "start_char": 54400,
      "end_char": 55385
    },
    {
      "chunk_id": "pfizer_2023_chunk0069",
      "chunk_index": 69,
      "text": "developed markets. Urbanization and the rise of the middle class in emerging markets provide potential growth opportunities for our\nproducts.\nRevenues from operations outside the U.S. of $31.4 billion accounted for 54% of Total revenues in 2023. Revenues exceeded $500 million in each of 14, 24 and 21 countries\noutside the U.S. in 2023, 2022 and 2021, respectively. The decrease in the number of countries exceeding $500 million in revenues from 2022 to 2023 was primarily driven by\ndecreases in revenues related to Comirnaty and Paxlovid. As a percentage of Total revenues, our largest country outside the U.S. was Japan in 2023. For a geographic breakdown\nof Total revenues, see the Total Revenues by Geography section within MD&A and Note 17B.\nOur international operations are subject to risks inherent in carrying on business in other countries. See the Item 1A. Risk Factors—Global Operations and Item 1.",
      "char_count": 910,
      "start_char": 55200,
      "end_char": 56112
    },
    {
      "chunk_id": "pfizer_2023_chunk0070",
      "chunk_index": 70,
      "text": "nherent in carrying on business in other countries. See the Item 1A. Risk Factors—Global Operations and Item 1. Business—\nGovernment Regulation and Price Constraints sections.\nSALES AND MARKETING\nOur prescription biopharmaceutical products, with the exception of Paxlovid in 2022 and 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals,\nclinics, government agencies and pharmacies. In 2022 and 2023, we principally sold Paxlovid globally to government agencies. Our vaccines in the U.S. are primarily sold directly to\nthe federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily\nsold to government and non-government institutions. Certain of these government contracts may be renegotiated or terminated at the discretion of a government entity. Our\n\n2023 Form 10-K",
      "char_count": 925,
      "start_char": 56000,
      "end_char": 56926
    },
    {
      "chunk_id": "pfizer_2023_chunk0071",
      "chunk_index": 71,
      "text": "of these government contracts may be renegotiated or terminated at the discretion of a government entity. Our\n\n2023 Form 10-K\n\ncontracts with government and supranational organizations for the sales of Comirnaty and Paxlovid, which are binding contracts, represented a significant amount of revenues in\n2022 and 2023. Sales of Comirnaty and Paxlovid in the U.S. transitioned to commercial channels in the second half of 2023. For information on our October 2023 amended\nagreement with the U.S. government regarding Paxlovid, see Note 17C.\nWe also seek to gain access for our products on formularies, which are lists of approved medicines available to members of healthcare programs or PBMs. PBMs use various\nbenefit designs, such as tiered co-pays for formulary products, to drive utilization of products in preferred formulary positions. We may also work with payors on disease\nmanagement programs that help to develop tools and materials to educate patients and physicians on key disease areas.",
      "char_count": 996,
      "start_char": 56800,
      "end_char": 57797
    },
    {
      "chunk_id": "pfizer_2023_chunk0072",
      "chunk_index": 72,
      "text": "ucts in preferred formulary positions. We may also work with payors on disease\nmanagement programs that help to develop tools and materials to educate patients and physicians on key disease areas. For information on our significant customers, see Note\n17C.\nWe promote our products to healthcare providers and patients consistent with applicable laws. Through our marketing organizations, we explain the approved uses, benefits and\nrisks of our products to healthcare providers and patients; MCOs that provide insurance coverage, such as hospitals, integrated delivery systems, PBMs and health plans; and\nemployers and government agencies who hire MCOs to provide health benefits to their employees. In the U.S., we market directly to consumers through direct-to-consumer\nadvertising that seeks to communicate the approved uses, benefits and risks of our products while motivating people to have meaningful conversations with their doctors.",
      "char_count": 939,
      "start_char": 57600,
      "end_char": 58540
    },
    {
      "chunk_id": "pfizer_2023_chunk0073",
      "chunk_index": 73,
      "text": "municate the approved uses, benefits and risks of our products while motivating people to have meaningful conversations with their doctors. In addition,\nwe sponsor general advertising to educate the public on disease awareness, prevention and wellness, important public health issues and our patient assistance programs.\nAs part of our commitment to engaging our customers in a manner they prefer, we take an omnichannel approach, including both virtual and in person interactions, and see\ngenerally positive customer response to both approaches.\nPATENTS AND OTHER INTELLECTUAL PROPERTY RIGHTS\nPatents. We own or have co-promotion and/or license rights related to a number of patents covering pharmaceutical and other products, their uses, formulations, and product\nmanufacturing processes.\nPatents for individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection\nis obtained.",
      "char_count": 989,
      "start_char": 58400,
      "end_char": 59390
    },
    {
      "chunk_id": "pfizer_2023_chunk0074",
      "chunk_index": 74,
      "text": "or individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection\nis obtained. The scope of protection afforded by a patent can vary from country to country and depends on the patent type, the scope of its patent claims and the availability of legal\nremedies. Patent term extensions (PTE) may be available in some countries to compensate for a loss of patent term due to delay in a product’s approval due to the regulatory\nrequirements, while patent term adjustment may be available in some countries to compensate for administrative delays during prosecution of patents. One of the primary\nconsiderations in limiting our operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products, although international and U.S.\nfree trade agreements have included some global protection of intellectual property rights. See the Item 1.",
      "char_count": 994,
      "start_char": 59200,
      "end_char": 60195
    },
    {
      "chunk_id": "pfizer_2023_chunk0075",
      "chunk_index": 75,
      "text": "ive intellectual property protection for our products, although international and U.S.\nfree trade agreements have included some global protection of intellectual property rights. See the Item 1. Business—Government Regulation and Price Constraints section.\nIn various markets, a period of regulatory exclusivity may be provided for drugs or vaccines upon approval. The scope and term of such exclusivity will vary but, in general, the\nperiod will run concurrently with the term of any existing patent rights associated with the drug at the time of approval.\nBased on current sales and other factors, and considering the competition with products sold by our competitors, the patent rights we consider most significant in relation to our\nbusiness as a whole, together with the year in which the basic product patent expires, are as follows:\n\n2023 Form 10-K",
      "char_count": 855,
      "start_char": 60000,
      "end_char": 60856
    },
    {
      "chunk_id": "pfizer_2023_chunk0076",
      "chunk_index": 76,
      "text": "product patent expires, are as follows:\n\n2023 Form 10-K\n\nProduct\nU.S. Basic Product Patent Expiration\nYear\nMajor Europe Basic Product Patent\nExpiration Year\nJapan Basic Product Patent Expiration\nYear\nInlyta\n\nXeljanz\n\nPrevnar 13/Prevenar 13\n\nEliquis\n\nIbrance\n\nXtandi\n\nVyndaqel/Vyndamax/Vynmac\n2024 (2028 pending PTE)\n\n2026/2029\nAdcetris\n\nNurtec ODT/Vydura\n2030 (2034 pending PTE)\n\nBraftovi\n2030 (2031 pending PTE)\nMektovi\n\nTalzenna\n\n(2032 pending PTE)\n\nOxbryta\n\nLorbrena\n\nPadcev\n\nTukysa\n\n(2034 pending PTE)\n\nZavzpret\n\n(2034 pending PTE)\n\nVelsipity\n\n(2034 pending PTE)\n\nPrevnar 20/Apexxnar\n2033 (2035 pending PTE)\n2033 (2037 pending SPC)\n\nNgenla\n\nCibinqo\n\n(2036 pending PTE)\n\nTivdak\n\nLitfulo\n\n(2037 pending PTE)\n\n(2038 pending SPC)\n\n(2039 pending PTE)\nAbrysvo\n\n(2037 pending PTE)\n\nElrexfio\n\n(2037 pending PTE)\n\nPenbraya\n\nCOVID-19 Products\nPfizer-BioNTech COVID-19 Vaccine\n\nPaxlovid",
      "char_count": 879,
      "start_char": 60800,
      "end_char": 61680
    },
    {
      "chunk_id": "pfizer_2023_chunk0077",
      "chunk_index": 77,
      "text": "ng PTE)\n\nPenbraya\n\nCOVID-19 Products\nPfizer-BioNTech COVID-19 Vaccine\n\nPaxlovid\n\nPfizer-BioNTech COVID-19 Vaccine,\nBivalent (Original and Omicron BA.4/BA.5)/\nComirnaty Original/Omicron BA.1\nVaccine\nXBB.1.5-Adapted Monovalent COVID-19\nvaccine\nUnless otherwise indicated, the years pertain to the basic product patent expiration, including granted PTEs, supplementary protection certificates (SPC) or pediatric exclusivity periods. SPCs are\nincluded when granted in three out of five major European markets (France, Germany, Italy, Spain and the U.K.). Noted in parentheses is the projected year of expiry of the earliest pending patent term\nextension in the U.S. or Japan and/or SPC application in Europe, the term of which, if granted, may be shorter than originally requested due to a number of factors.",
      "char_count": 804,
      "start_char": 61600,
      "end_char": 62405
    },
    {
      "chunk_id": "pfizer_2023_chunk0078",
      "chunk_index": 78,
      "text": "ors. In some instances, there are laterexpiring patents relating to our products which may or may not protect our product from generic or biosimilar competition after the expiration of the basic patent.\nExpiry is provided by regulatory exclusivity in this market.\nThe Europe patent that covers the combination of the 13 serotype conjugates of Prevenar 13 was revoked following an opposition and has now been withdrawn. There are other Europe patents and\npending applications covering the formulation, various aspects of the manufacturing process, and the combination of serotype conjugates of Prevenar 13 that remain in force.\nEliquis was developed and is being commercialized in collaboration with BMS. In the U.S., we and BMS previously settled certain patent litigations with a number of generic companies permitting their\nlaunch of a generic version of Eliquis on April 1, 2028 (the settled generic companies).",
      "char_count": 914,
      "start_char": 62400,
      "end_char": 63315
    },
    {
      "chunk_id": "pfizer_2023_chunk0079",
      "chunk_index": 79,
      "text": "ompanies permitting their\nlaunch of a generic version of Eliquis on April 1, 2028 (the settled generic companies). We continued to litigate against three\n(1)\n(1)\n(1)\n(2)\n(3)\n(4)\n(5)\n(6)\n(6)\n(6)\n(7)\n(8)\n(9)\n(10)\n(9)\n(9)\n(11)\n(12)\n(12)\n(12)\n(12)\n(13)\n(12)\n(12)\n(11)\n(14)\n(15)\n(14)\n(14)\n(16)\n(11)\n(11)\n(11)\n(11)\n(11)\n(17)\n(2)\n(2)\n(2)\n(18)\n(19)\n(11)\n(18)\n(22)\n(11)\n(11)\n(11)\n(20)\n(21)(23)\n(22)\n(20)\n(22)\n(22)(23)\n(22)\n(20)\n(22)\n (22)(23)\n(22)\n(1)\n(2)\n(3)\n(4)\n\n2023 Form 10-K\n\nremaining generic companies and following the resolution of the litigation in our favor, the three generic companies are not permitted to launch their products until the 2031 expiration date of the\nformulation patent. Both the composition of matter patent expiring in November 2026 and the formulation patent expiring in 2031 may be subject to future challenges. While we cannot predict the outcome",
      "char_count": 870,
      "start_char": 63200,
      "end_char": 64071
    },
    {
      "chunk_id": "pfizer_2023_chunk0080",
      "chunk_index": 80,
      "text": "y be subject to future challenges. While we cannot predict the outcome\nof any potential future litigation, there are certain potential alternatives that might occur which could potentially permit generic launch prior to April 1, 2028: (i) if the formulation patent is held invalid or not\ninfringed in future litigation, through appeal, the settled generic companies and any successful future litigant would be permitted to launch on November 21, 2026; or (ii) if both patents are held invalid or\nnot infringed in future litigation, through appeal, the settled generic companies and any successful future litigant could launch products immediately upon such an adverse decision. Refer to Note 16A1 for\nmore information.\nOn October 31, 2023, the U.K. Supreme Court refused BMS’s permission to appeal in relation to the judgment having found the apixaban basic product patent and associated SPC invalid.",
      "char_count": 900,
      "start_char": 64000,
      "end_char": 64901
    },
    {
      "chunk_id": "pfizer_2023_chunk0081",
      "chunk_index": 81,
      "text": "relation to the judgment having found the apixaban basic product patent and associated SPC invalid. Additional\nchallenges are pending in other jurisdictions.\nXtandi is being developed and commercialized in collaboration with Astellas, which has exclusive commercialization rights for Xtandi outside the U.S. Pfizer receives tiered royalties as a percentage of\ninternational Xtandi net sales.\nInterim patent term extension requests have been granted extending the expiry from December 2023 to December 2024 and Pfizer has filed applications for patent term extension to 2028.\nVyndaqel (tafamidis meglumine) basic patent expiry in Japan is August 2026 for treatment of polyneuropathy. Vynmac (tafamidis) was approved in Japan for treatment of cardiomyopathy with regulatory\nexclusivity expiring in March 2029.\nAdcetris is being developed and commercialized in collaboration with Takeda. Pfizer has commercialization rights for Adcetris in the U.S. and its territories and in Canada.",
      "char_count": 980,
      "start_char": 64800,
      "end_char": 65782
    },
    {
      "chunk_id": "pfizer_2023_chunk0082",
      "chunk_index": 82,
      "text": "ch 2029.\nAdcetris is being developed and commercialized in collaboration with Takeda. Pfizer has commercialization rights for Adcetris in the U.S. and its territories and in Canada. Takeda has commercialization\nrights in the rest of the world and pays Pfizer a royalty based on a percentage of Takeda's net sales of Adcetris in its licensed territories, based on annual net sales tiers.\nThere are other U.S. patents covering related ADC uses, technology and manufacturing that remain in force beyond composition of matter expiry.\nProduct not yet approved or authorized in this market.\nWe have exclusive rights to Braftovi and Mektovi in the U.S., Canada and certain emerging markets. The Pierre Fabre Group has exclusive rights to commercialize both products in Europe and Ono has\nexclusive rights to commercialize both products in Japan. We receive royalties from The Pierre Fabre Group and Ono on sales of Braftovi and Mektovi in a majority of markets outside the U.S.\nMektovi U.S.",
      "char_count": 983,
      "start_char": 65600,
      "end_char": 66584
    },
    {
      "chunk_id": "pfizer_2023_chunk0083",
      "chunk_index": 83,
      "text": "commercialize both products in Japan. We receive royalties from The Pierre Fabre Group and Ono on sales of Braftovi and Mektovi in a majority of markets outside the U.S.\nMektovi U.S. expiry is provided by a method of use patent.\nPadcev is being commercialized in collaboration with Astellas. Pfizer has co-promotion rights in the U.S. Outside the U.S., Pfizer has commercialization rights in all countries in North and South America,\nand Astellas has commercialization rights in the rest of the world, including Europe, Asia, Australia and Africa.\nThere is a U.S. patent covering related ADC manufacturing that will remain in force beyond the composition of matter expiry.\nIn September 2020, Seagen and Merck began a collaboration to commercialize Tukysa. As of December 31, 2023, this collaboration ended and all commercialization rights were returned to Seagen\n(Pfizer).\nNgenla is being developed in collaboration with OPKO.\nTivdak is developed and commercialized in collaboration with Genmab.",
      "char_count": 995,
      "start_char": 66400,
      "end_char": 67397
    },
    {
      "chunk_id": "pfizer_2023_chunk0084",
      "chunk_index": 84,
      "text": "ended and all commercialization rights were returned to Seagen\n(Pfizer).\nNgenla is being developed in collaboration with OPKO.\nTivdak is developed and commercialized in collaboration with Genmab. Pfizer and Genmab have co-promotion rights in the U.S. Outside the U.S., Pfizer has commercialization rights in the rest of the\nworld except for Japan, where Genmab has commercialization rights, and certain territories where Zai Lab Limited (Zai Lab) has commercialization rights (mainland China, Hong Kong, Macau, and\nTaiwan). Pfizer and Genmab equally share all costs and profits for Tivdak in the U.S., Europe, China (including the payments from Zai Lab described below) and Japan. In markets outside the U.S. other\nthan Europe, China, and Japan, Pfizer will pay Genmab a royalty based on a percentage of aggregate net sales.",
      "char_count": 824,
      "start_char": 67200,
      "end_char": 68026
    },
    {
      "chunk_id": "pfizer_2023_chunk0085",
      "chunk_index": 85,
      "text": "e of aggregate net sales. Further, pursuant to the agreement with Zai Lab, Pfizer is entitled to receive potential\ndevelopment, regulatory and commercial milestone payments, and tiered royalties on net sales of Tivdak in the Zai Lab territories, which will be shared equally with Genmab.\nExpiry is provided by regulatory exclusivity in this market. In addition to regulatory exclusivity, there are U.S. patents covering related ADC manufacturing and technology that remain in force beyond the\nregulatory exclusivity expiry.\nProduct is being commercialized in collaboration with BioNTech.\nThe basic product patent has been granted in the U.K. and expires in 2041. In the other major markets, a patent application has been filed. If granted, a full term is expected.\nThe basic product patent application has been filed in this market.",
      "char_count": 832,
      "start_char": 68000,
      "end_char": 68833
    },
    {
      "chunk_id": "pfizer_2023_chunk0086",
      "chunk_index": 86,
      "text": "n has been filed in this market. If granted, a full term is expected in this market.\nPfizer does not have co-promotion rights for this product in Germany.\nFor information regarding profit sharing and royalty arrangements for certain of these products, see Item 1. Business—Collaboration and Co-Promotion Agreements.\nLoss of Intellectual Property Rights. The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments and the expiration of co-promotion\nand licensing rights can have a material adverse effect on our revenues. Once patent protection has expired or has been lost prior to the expiration date as a result of a legal\nchallenge, we typically lose exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell\nthem for a lower price.",
      "char_count": 883,
      "start_char": 68800,
      "end_char": 69684
    },
    {
      "chunk_id": "pfizer_2023_chunk0087",
      "chunk_index": 87,
      "text": "rally produce identical or highly similar products and sell\nthem for a lower price. The date at which generic or biosimilar competition commences may be different from the date that the patent or regulatory exclusivity expires. However,\nwhen generic or biosimilar competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short\nperiod of time. Also, if one of our product-related patents is found to be invalid by judicial, court or regulatory or administrative proceedings, generic or biosimilar products could be\nintroduced, resulting in the erosion of sales of our existing products. Additionally, we could be subject to claims that our intellectual property rights infringe third party patents.\nCertain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face",
      "char_count": 963,
      "start_char": 69600,
      "end_char": 70564
    },
    {
      "chunk_id": "pfizer_2023_chunk0088",
      "chunk_index": 88,
      "text": "oducts have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face\nincreased generic competition over the next few years. While additional patent expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from\n2024 through 2025. We anticipate a more significant impact of reduced revenues from patent expiries in 2026 through 2030 as several of our in-line products experience patentbased expirations. There is no assurance that a particular product will maintain market exclusivity for the full time period that appears in the estimates included in this Form 10-K or\nthat we assume when we provide our financial guidance. For additional information on the impact of LOEs on our revenues, see the Overview of Our Performance, Operating\nEnvironment, Strategy and Outlook—Our 2023 Performance section within MD&A.",
      "char_count": 944,
      "start_char": 70400,
      "end_char": 71345
    },
    {
      "chunk_id": "pfizer_2023_chunk0089",
      "chunk_index": 89,
      "text": "LOEs on our revenues, see the Overview of Our Performance, Operating\nEnvironment, Strategy and Outlook—Our 2023 Performance section within MD&A.\nWe continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking\nnecessary steps to help ensure appropriate patient access. See the Item 1A. Risk Factors—Competitive Products, —Intellectual Property Protection and —Third-Party Intellectual\nProperty Claims sections and Note 16A1.\nTrademarks. Our products are sold under brand-name and logo trademarks and trade dress. Registrations generally are for fixed, but renewable, terms and protection is provided in\nsome countries for as long as the mark is used while in others, for as long as it is registered. Protecting our trademarks is of material importance to us.\n(5)\n(6)\n(7)\n(8)\n(9)\n(10)\n(11)\n(12)\n(13)\n(14)\n(15)\n(16)\n(17)\n(18)\n(19)\n(20)\n(21)\n(22)\n(23)\n\n2023 Form 10-K",
      "char_count": 980,
      "start_char": 71200,
      "end_char": 72181
    },
    {
      "chunk_id": "pfizer_2023_chunk0090",
      "chunk_index": 90,
      "text": "is registered. Protecting our trademarks is of material importance to us.\n(5)\n(6)\n(7)\n(8)\n(9)\n(10)\n(11)\n(12)\n(13)\n(14)\n(15)\n(16)\n(17)\n(18)\n(19)\n(20)\n(21)\n(22)\n(23)\n\n2023 Form 10-K\n\nCOMPETITION\nOur business is conducted in intensely competitive and highly regulated markets. Many of our products face competition in the form of branded or generic drugs or biosimilars that\ntreat similar diseases or indications. The principal forms of competition include efficacy, safety, ease of use and cost. Though the means of competition vary among our products,\ndemonstrating the value of our products is a critical factor for success.\nWe compete with other companies that manufacture and sell products that treat or prevent diseases or indications similar to those treated or prevented by our major products. These\ncompetitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus and generic drug and biosimilar\nmanufacturers.",
      "char_count": 994,
      "start_char": 72000,
      "end_char": 72996
    },
    {
      "chunk_id": "pfizer_2023_chunk0091",
      "chunk_index": 91,
      "text": "These\ncompetitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus and generic drug and biosimilar\nmanufacturers. Our competitors also may devote substantial funds and resources to R&D and their successful R&D could result in erosion of the sales of our existing products and\npotential sales of our products in development, as well as product obsolescence. In addition, several of our competitors operate without large R&D expenses and make a regular\npractice of challenging our product patents before their expiration.\nTo help address competitive trends we continually emphasize innovation, which is underscored by our multi-billion-dollar investment in R&D, as well as our business development\ntransactions, both designed to result in a strong and differentiated product pipeline.",
      "char_count": 864,
      "start_char": 72800,
      "end_char": 73665
    },
    {
      "chunk_id": "pfizer_2023_chunk0092",
      "chunk_index": 92,
      "text": "igned to result in a strong and differentiated product pipeline. Our investment in research continues even after drug or vaccine approval as we seek to further\ndemonstrate the value of our products for the conditions they treat or prevent, as well as investigating potential new applications. We educate patients, physicians, payors and global\nhealth authorities on the benefits and risks of our medicines and vaccines, and seek to continually enhance the organizational effectiveness of our biopharmaceutical functions,\nincluding our efforts to effectively launch and market our products to our customers.\nOperating conditions have also shifted as a result of increased global competitive pressures, industry regulation and cost containment. We continue to evaluate, adapt and improve\nour organization and business practices in an effort to better meet customer and public needs. We believe that we have taken an industry-leading role in evolving our ethical\napproaches to U.S.",
      "char_count": 978,
      "start_char": 73600,
      "end_char": 74579
    },
    {
      "chunk_id": "pfizer_2023_chunk0093",
      "chunk_index": 93,
      "text": "on and business practices in an effort to better meet customer and public needs. We believe that we have taken an industry-leading role in evolving our ethical\napproaches to U.S. direct-to-consumer advertising, interactions with, and payments to, healthcare professionals and medical education grants. We also continue to support\nprograms to address patient affordability and access barriers, as we strive to advance fundamental health system change through our support for better healthcare solutions. For\nexample, in May 2022, we launched An Accord for a Healthier World, which aims to provide our full portfolio of patented and off-patent medicines and vaccines for which Pfizer holds\nglobal rights on a not-for-profit basis to 1.2 billion people living in 45 lower-income countries around the world.\nOur vaccines have and may continue to face competition, including from the introduction of alternative vaccines or “next-generation” vaccines prior to or after the expiration of their",
      "char_count": 987,
      "start_char": 74400,
      "end_char": 75388
    },
    {
      "chunk_id": "pfizer_2023_chunk0094",
      "chunk_index": 94,
      "text": "ld.\nOur vaccines have and may continue to face competition, including from the introduction of alternative vaccines or “next-generation” vaccines prior to or after the expiration of their\npatents, which may adversely affect our future results.\nOur biosimilars, which include biosimilars of certain inflammation & immunology and oncology biologic medicines, compete with branded products from competitors, as well as other\ngenerics and biosimilars manufacturers. We seek to maximize the opportunity to establish a “first-to-market” or early market position for our biosimilars to provide customers a lowercost alternative immediately when available and also to potentially provide us with higher levels of sales and profitability until other competitors enter the market.\nGeneric Products. Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a",
      "char_count": 937,
      "start_char": 75200,
      "end_char": 76138
    },
    {
      "chunk_id": "pfizer_2023_chunk0095",
      "chunk_index": 95,
      "text": "rmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a\ncompeting version of our product after the expiration or loss of our patent protection and often charge much less. Several competitors regularly challenge our product patents before\ntheir expiration. Generic competitors often operate without large R&D expenses, as well as without costs of conveying medical information about products to the medical community.\nIn addition, the approval process in the U.S. and in the EU exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic\nmanufacturers to rely on the safety and efficacy data of the innovator product. In China, for example, given the expansion of the QCE process and continuation of the VBP program,",
      "char_count": 860,
      "start_char": 76000,
      "end_char": 76861
    },
    {
      "chunk_id": "pfizer_2023_chunk0096",
      "chunk_index": 96,
      "text": "sion of the QCE process and continuation of the VBP program,\nwe expect to continue to face intensified competition by certain generic manufacturers in 2024 and beyond, which has and may continue to result in price cuts and volume loss of\nsome of our products. In addition, generic versions of competitors’ branded products have and may continue to compete with our products.\nCommercial and government payors typically encourage the use of generics as alternatives to brand-name drugs in their healthcare programs, including Medicaid in the U.S., and\nU.S. laws generally allow, and in some cases require, pharmacists to substitute generic drugs for brand-name drugs. In a small subset of states, prescribing physicians are able to\nexpressly prevent such substitution. Similar rules also apply in several EU member states, where national authorities typically encourage and incentivize the use of generic products.\nBiosimilars.",
      "char_count": 925,
      "start_char": 76800,
      "end_char": 77726
    },
    {
      "chunk_id": "pfizer_2023_chunk0097",
      "chunk_index": 97,
      "text": "al EU member states, where national authorities typically encourage and incentivize the use of generic products.\nBiosimilars. Certain of our biologic products, including Enbrel (we market Enbrel outside the U.S. and Canada), already face, or may face in the\nfuture, competition from biosimilars (also referred to as follow-on biologics). Biosimilars are versions of biologic medicines that have been developed and proven to be highly similar\nto the original biologic in terms of safety and efficacy and that have no clinically meaningful differences in safety, purity or potency. Biosimilars have the potential to offer high-quality,\nlower-cost alternatives to innovative biologic medicines. In the U.S., biosimilars referencing innovative biologic products are approved by the FDA under the U.S. Public Health\nService Act, whereas in the EU the EMA is responsible for evaluating the majority of applications for biosimilars through the centralized procedure.",
      "char_count": 959,
      "start_char": 77600,
      "end_char": 78560
    },
    {
      "chunk_id": "pfizer_2023_chunk0098",
      "chunk_index": 98,
      "text": "lic Health\nService Act, whereas in the EU the EMA is responsible for evaluating the majority of applications for biosimilars through the centralized procedure.\nPRICING PRESSURES AND MANAGED CARE ORGANIZATIONS\nCommercial Pricing Pressures. Pricing and access pressures in the commercial sector continue to be significant. Overall, there is increasing pressure on U.S. providers to deliver\nhealthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Many employers have adopted or make available high\ndeductible health plans, which can increase out-of-pocket costs for medicines. This trend is likely to continue. Private third-party payors, such as health plans, increasingly challenge\npharmaceutical product pricing, which could result in lower prices, lower reimbursement rates for payors and a reduction in demand for our products, including denial of coverage of\nour products, if lower cost alternatives are available.",
      "char_count": 982,
      "start_char": 78400,
      "end_char": 79383
    },
    {
      "chunk_id": "pfizer_2023_chunk0099",
      "chunk_index": 99,
      "text": "lower prices, lower reimbursement rates for payors and a reduction in demand for our products, including denial of coverage of\nour products, if lower cost alternatives are available. Payors often require significant discounts, or rebates, from our prices in exchange for more favorable formulary placement.\nPricing pressures also may occur as a result of highly competitive biopharmaceutical markets and increasing concentration of insurers and PBMs. Healthcare provider purchasers,\ndirectly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.\nLonger term, we foresee a shift in focus among payors and their PBMs away from fee-for-service reimbursement towards outcomes-based payments and risk-sharing arrangements\nthat reward providers and pharmaceutical manufacturers for cost reductions and improved patient outcomes.",
      "char_count": 912,
      "start_char": 79200,
      "end_char": 80113
    },
    {
      "chunk_id": "pfizer_2023_chunk0100",
      "chunk_index": 100,
      "text": "ements\nthat reward providers and pharmaceutical manufacturers for cost reductions and improved patient outcomes. These new payment models can, at times, lead to lower prices for, and\nrestricted access to, new medicines. At the same time, these models can also promote utilization of drugs by encouraging physicians to screen and diagnose and consider drugs as\na means of forestalling more costly medical interventions. Further, these models may also encourage payors and their PBMs to cover higher cost drugs where coverage is tied to\npatient outcomes and other quality incentives.\n\n2023 Form 10-K\n\nThe impact of large-scale healthcare disruptions, like the COVID-19 pandemic, on the pace of adoption of value-based payment models remains unclear. Both payors and providers\nmay resist adopting such models or choose to adopt such models at a slower pace if the incentives available do not outweigh the financial risk involved.",
      "char_count": 926,
      "start_char": 80000,
      "end_char": 80927
    },
    {
      "chunk_id": "pfizer_2023_chunk0101",
      "chunk_index": 101,
      "text": "odels or choose to adopt such models at a slower pace if the incentives available do not outweigh the financial risk involved. Adoption of such models, in\nparticular models that involve downside risk, may depend on revenue predictability for hospitals and other institutional providers, many of which are still struggling to recover\nfinancially following the COVID-19 pandemic. Providers in more advanced value-based payment models, such as full capitation, a fixed amount paid in advance per-patient per-unit\nof time-period, generally found their revenues remained steady during the COVID-19 pandemic, which may ultimately encourage the growth of such models. Going forward, we\nexpect continued focus on value-based payment models that support financial resiliency and advance healthcare equity by incorporating features intended to reduce disparities in\nhealthcare quality and access experienced by underrepresented and underserved populations.",
      "char_count": 946,
      "start_char": 80800,
      "end_char": 81747
    },
    {
      "chunk_id": "pfizer_2023_chunk0102",
      "chunk_index": 102,
      "text": "ncorporating features intended to reduce disparities in\nhealthcare quality and access experienced by underrepresented and underserved populations.\nWe believe medicines and vaccines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We work with law\nmakers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and help ensure access to medicines and vaccines within\nan efficient and affordable healthcare system. This includes assessing our go-to market model to help address patient affordability challenges. We have engaged with major payors\nand the U.S. government to explore opportunities to improve access and reimbursement in an effort to drive pro-patient policies. In addition, in response to the evolving U.S.",
      "char_count": 857,
      "start_char": 81600,
      "end_char": 82458
    },
    {
      "chunk_id": "pfizer_2023_chunk0103",
      "chunk_index": 103,
      "text": "t policies. In addition, in response to the evolving U.S. and\nglobal healthcare spending landscape, we work with health authorities, health technology assessment and quality measurement bodies and major U.S. payors throughout the\nproduct-development process to better understand how these entities value our compounds and products. Further, we are developing stronger support designed to demonstrate the\nnet value of the medicines and vaccines that we discover or develop, register and manufacture.\nFor information on government pricing pressures, see the Item 1. Business—Government Regulation and Price Constraints and Item 1A. Risk Factors—Pricing and Reimbursement\nsections.\nManaged Care Organizations. The evolution of managed care in the U.S. has been a major factor in the competitiveness of the healthcare marketplace. Approximately 318 million\npeople in the U.S.",
      "char_count": 871,
      "start_char": 82400,
      "end_char": 83272
    },
    {
      "chunk_id": "pfizer_2023_chunk0104",
      "chunk_index": 104,
      "text": "he healthcare marketplace. Approximately 318 million\npeople in the U.S. now have some form of health insurance coverage, and the marketing of prescription drugs and vaccines to both consumers and the entities that manage\ncoverage in the U.S. continues to grow in importance. In particular, the influence of MCOs has increased in recent years due to the growing number of patients receiving coverage\nthrough MCOs. At the same time, consolidation in the MCO industry has resulted in fewer, even larger MCOs, which enhances those MCOs’ ability to negotiate lower pricing and\nfurther increases their importance to our business. Since MCOs seek to contain and reduce healthcare expenditures, their growing influence has increased downward pressure on\ndrug prices, as well as negatively impacted revenues.\nMCOs and their PBMs typically negotiate prices with pharmaceutical providers by using formularies (which are lists of approved medicines available to MCO members), clinical",
      "char_count": 972,
      "start_char": 83200,
      "end_char": 84173
    },
    {
      "chunk_id": "pfizer_2023_chunk0105",
      "chunk_index": 105,
      "text": "MCOs and their PBMs typically negotiate prices with pharmaceutical providers by using formularies (which are lists of approved medicines available to MCO members), clinical\nprotocols (which require prior authorization for a branded product if a generic product is available or require the patient to first fail on one or more generic products before permitting\naccess to a branded medicine), long-term contracts and their ability to influence volume and market share of prescription drugs. In addition, by placing branded medicines on highertier or non-preferred status in their formularies, MCOs transfer to the patient higher patient out-of-pocket expenses. This financial disincentive is a tool for MCOs to manage drug\ncosts and channel patients to medicines preferred by the MCOs. We expect payment reforms for MCOs will continue to evolve with increased emphasis on expanded participation\nand on removing barriers to equitable healthcare.",
      "char_count": 943,
      "start_char": 84000,
      "end_char": 84944
    },
    {
      "chunk_id": "pfizer_2023_chunk0106",
      "chunk_index": 106,
      "text": "nt reforms for MCOs will continue to evolve with increased emphasis on expanded participation\nand on removing barriers to equitable healthcare.\nThe breadth of the products covered by formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for\ntreatment of particular medical problems. MCOs emphasize primary and preventive care, out-patient treatment and procedures performed at doctors’ offices and clinics as ways to\nmanage costs. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed, and drugs that can help in chronic care management and reduce\nthe need for hospitalization, professional therapy or surgery may become favored first-line treatments for certain diseases. At the same time, MCOs may seek to exclude high-cost\ndrugs from formularies in their efforts to manage and lower their costs.",
      "char_count": 915,
      "start_char": 84800,
      "end_char": 85716
    },
    {
      "chunk_id": "pfizer_2023_chunk0107",
      "chunk_index": 107,
      "text": "e time, MCOs may seek to exclude high-cost\ndrugs from formularies in their efforts to manage and lower their costs.\nExclusion of a product from a formulary or other MCO-implemented restrictions can significantly impact drug usage in the MCO patient population and beyond. Consequently,\npharmaceutical companies compete to gain access to formularies for their products, typically on the basis of unique product features, such as greater efficacy, better patient ease of\nuse, or fewer side effects, as well as the overall cost of the therapy. We continue to seek to ensure that our major products are included on MCO formularies. However, our branded\nproducts are increasingly being placed on the higher tiers or in a non-preferred status. Continuing efforts by managed care entities to contain or reduce costs of healthcare and/or\nimpose price controls may adversely affect demand for our products and our financial performance. See the Item 1A.",
      "char_count": 944,
      "start_char": 85600,
      "end_char": 86545
    },
    {
      "chunk_id": "pfizer_2023_chunk0108",
      "chunk_index": 108,
      "text": "ce costs of healthcare and/or\nimpose price controls may adversely affect demand for our products and our financial performance. See the Item 1A. Risk Factors—Managed Care Trends section.\nRAW MATERIALS\nWe procure raw materials essential to our business from numerous suppliers worldwide. In general, these materials have been available in sufficient quantities to support our\ndemand and in many cases are available from multiple suppliers. No significant impact to our operations due to the availability of raw materials is currently anticipated in 2024.\nHowever, we continue to see heightened demand in the industry for certain components and raw materials, which could potentially result in constraining available supply leading to a\npossible future impact on our business. We are continuing to monitor and implement mitigation strategies to reduce any potential risk or impact including active supplier",
      "char_count": 904,
      "start_char": 86400,
      "end_char": 87305
    },
    {
      "chunk_id": "pfizer_2023_chunk0109",
      "chunk_index": 109,
      "text": "tor and implement mitigation strategies to reduce any potential risk or impact including active supplier\nmanagement, qualification of additional suppliers and advanced purchasing to the extent possible.\nGOVERNMENT REGULATION AND PRICE CONSTRAINTS\nWe are subject to extensive regulation by government authorities in the countries in which we do business. This includes laws and regulations governing the operations of\nbiopharmaceutical companies, such as the approval, manufacturing and marketing of products, pricing (including discounts and rebates) and price reporting, interactions with\nhealthcare professionals, institutions, and referral sources, reporting of remuneration provided to healthcare providers and academic medical centers, financial assistance provided\nto patients, clinical research, data privacy and information security, among others.",
      "char_count": 855,
      "start_char": 87200,
      "end_char": 88056
    },
    {
      "chunk_id": "pfizer_2023_chunk0110",
      "chunk_index": 110,
      "text": "h, data privacy and information security, among others. These laws and regulations may require administrative guidance for implementation, and a failure\nto comply could subject us to legal and/or administrative actions. Enforcement measures may include substantial fines and/or penalties, orders to stop non-compliant activities,\ncriminal charges, warning letters, product recalls or seizures, delays in product approvals, exclusion from participation in government programs or contracts as well as limitations on\nconducting business in applicable jurisdictions, and could result in harm to our reputation and business. See Note 16A. Compliance with these laws and regulations may be costly,\nand may require significant technical expertise and capital investment to ensure compliance. While capital expenditures or operating costs for compliance with government\nregulations\n\n2023 Form 10-K",
      "char_count": 889,
      "start_char": 88000,
      "end_char": 88890
    },
    {
      "chunk_id": "pfizer_2023_chunk0111",
      "chunk_index": 111,
      "text": "xpenditures or operating costs for compliance with government\nregulations\n\n2023 Form 10-K\n\ncannot be predicted with certainty, we do not currently anticipate they will have a material effect on our capital expenditures or competitive position.\nIn the U.S.\nDrug and Biologic Regulation. The FDA, pursuant to the FFDCA, the Public Health Service Act and other federal statutes and regulations, extensively regulates pre- and postmarketing activities related to our biopharmaceutical products and devices. The regulations govern areas such as safety and efficacy, clinical trials, advertising and promotion, quality\ncontrol, manufacturing, labeling, distribution, post-marketing safety surveillance and reporting, and record keeping. Other U.S. federal agencies, including the DEA, also regulate\ncertain of our products and activities.",
      "char_count": 832,
      "start_char": 88800,
      "end_char": 89633
    },
    {
      "chunk_id": "pfizer_2023_chunk0112",
      "chunk_index": 112,
      "text": "of our products and activities.\nFor a biopharmaceutical company to market a drug or a biologic product, including vaccines, the FDA must evaluate whether the product is safe and effective for its intended use. If\nthe FDA determines that the drug or biologic is safe and effective, the FDA will approve the product’s NDA or BLA (or supplemental NDA or supplemental BLA), as appropriate.\nA drug or biologic may be subject to postmarketing commitments, which are studies or clinical trials that the product sponsor agrees to conduct, or postmarketing requirements,\nwhich are studies or clinical trials that are required as a condition of approval. In addition, we are also required to report adverse events and comply with cGMPs (the FDA\nregulations that govern all aspects of manufacturing quality for pharmaceuticals) and the Drug Supply Chain Security Act (the law that, among other things, sets forth requirements",
      "char_count": 914,
      "start_char": 89600,
      "end_char": 90516
    },
    {
      "chunk_id": "pfizer_2023_chunk0113",
      "chunk_index": 113,
      "text": "pharmaceuticals) and the Drug Supply Chain Security Act (the law that, among other things, sets forth requirements\nrelated to product tracing, product identifiers and verification for manufacturers, wholesale distributors, re-packagers and dispensers to facilitate the tracing of product through the\npharmaceutical distribution supply chain), as well as advertising and promotion regulations. See the Item 1A. Risk Factors—Development, Regulatory Approval and Marketing of\nProducts and —Post-Authorization/Approval Data sections.\nIn the context of public health emergencies, like the COVID-19 pandemic, we may apply to the FDA for an EUA which, if granted, allows for the distribution and use of our products\nduring the declared emergency, in accordance with the conditions set forth in the EUA, unless the EUA is terminated by the government.",
      "char_count": 843,
      "start_char": 90400,
      "end_char": 91245
    },
    {
      "chunk_id": "pfizer_2023_chunk0114",
      "chunk_index": 114,
      "text": "ess the EUA is terminated by the government. Although the criteria for an EUA differ from\nthe criteria for approval of an NDA or BLA, EUAs nevertheless require the development and submission of data to satisfy the relevant FDA standards, and a number of ongoing\nobligations. The FDA generally expects EUA holders to work toward submission of full applications, such as a BLA or an NDA, as soon as possible.\nBiosimilar Regulation. The FDA is responsible for approval of biosimilars. Innovator biologics, or reference products, are entitled to 12 years exclusivity. Applications for biosimilars\nmay not be submitted until four years after the date on which the reference product was first licensed and may not be approved until 12 years after the reference product was first\nlicensed.\nSales and Marketing Regulations.",
      "char_count": 815,
      "start_char": 91200,
      "end_char": 92016
    },
    {
      "chunk_id": "pfizer_2023_chunk0115",
      "chunk_index": 115,
      "text": "ng Regulations. Our marketing practices are subject to federal and state laws, such as the Anti-Kickback Statute (AKS), Civil Monetary Penalties Law and False\nClaims Act, intended to prevent fraud and abuse in the healthcare industry. The AKS prohibits soliciting, offering, receiving, or paying anything of value to generate business that may\nbe paid for, in whole or in part, by a federal healthcare program. The Civil Monetary Penalties Law covers a variety of conduct, often violations under other laws, and includes\npenalties for AKS violations as well as causing the submission of false claims. The False Claims Act generally prohibits anyone from knowingly and willingly presenting, or causing to\nbe presented, any claims for payment for goods or services, including to government payors, such as Medicare and Medicaid, that are false or fraudulent including false certifications\nof compliance with applicable law.",
      "char_count": 921,
      "start_char": 92000,
      "end_char": 92922
    },
    {
      "chunk_id": "pfizer_2023_chunk0116",
      "chunk_index": 116,
      "text": "as Medicare and Medicaid, that are false or fraudulent including false certifications\nof compliance with applicable law. The federal government and states also regulate sales and marketing activities and financial interactions between manufacturers and healthcare\nproviders, requiring disclosure to government authorities and the public of such interactions, and the adoption of compliance standards or programs. State attorneys general have\nalso taken action to regulate the marketing of prescription drugs under state consumer protection and false advertising laws.\nPricing, Reimbursement and Access Regulations. Pricing and reimbursement for our products depend in part on government regulation. Any significant efforts at the federal or state\nlevels to reform the healthcare system by changing the way healthcare is provided or funded or to expand controls on drug pricing, government reimbursement, and access to",
      "char_count": 917,
      "start_char": 92800,
      "end_char": 93719
    },
    {
      "chunk_id": "pfizer_2023_chunk0117",
      "chunk_index": 117,
      "text": "he way healthcare is provided or funded or to expand controls on drug pricing, government reimbursement, and access to\nmedicines and vaccines on public and private insurance plans could have a material impact on us.\nWe must offer discounts or rebates on purchases of pharmaceutical products under various government programs including Medicare, Medicaid, the Veterans Administration and the\n340B Drug Pricing Program (340B Program). We also must report specific prices to government agencies. The calculations necessary to determine the prices reported are complex\nand the failure to do so accurately may expose us to enforcement measures. See the discussion regarding rebates in the Product Revenue Deductions section within MD&A and\nNote 1G.\nThe drug pricing provisions of the IRA, which was signed into law in August 2022, began to be implemented in 2022 and implementation will continue over the next several years.",
      "char_count": 919,
      "start_char": 93600,
      "end_char": 94520
    },
    {
      "chunk_id": "pfizer_2023_chunk0118",
      "chunk_index": 118,
      "text": "into law in August 2022, began to be implemented in 2022 and implementation will continue over the next several years.\nThe IRA includes several provisions to lower prescription drug costs for Medicare patients and to reduce drug spending by the federal government. Among other things, the IRA\nenhances the Medicare Part D benefit by eliminating the coverage gap (“donut hole”) beginning in 2025, adds a maximum out-of-pocket cap for Medicare beneficiaries (set at $2,000\nfor 2025), and creates a new program that allows patients to pay their cost-sharing over time. The law also requires manufacturers to provide a 10% discount on branded\nprescriptions in the initial coverage phase and a 20% discount in the catastrophic phase, imposes rebates under Medicare Part B and Medicare Part D on drug price increases that\noutpace inflation, and directs HHS to set the prices of certain high-expenditure, single-source drugs and biologics covered under Medicare (known as the “Medicare Drug Price",
      "char_count": 989,
      "start_char": 94400,
      "end_char": 95391
    },
    {
      "chunk_id": "pfizer_2023_chunk0119",
      "chunk_index": 119,
      "text": "e increases that\noutpace inflation, and directs HHS to set the prices of certain high-expenditure, single-source drugs and biologics covered under Medicare (known as the “Medicare Drug Price\nNegotiation Program”). In August 2023, the Biden Administration published the first ten medicines subject to the Medicare Drug Price Negotiation Program, which included Eliquis.\nAs a selected drug, CMS will establish a “maximum fair price” for Eliquis and that price will be published by September 1, 2024. The price will be in effect in 2026. The maximum fair\nprice established by CMS is required to be offered to all Medicare beneficiaries and to covered entities participating in the 340B Program if that maximum fair price is lower than the\ndiscounted price such entities are offered under the 340B Program ceiling price calculation.",
      "char_count": 828,
      "start_char": 95200,
      "end_char": 96029
    },
    {
      "chunk_id": "pfizer_2023_chunk0120",
      "chunk_index": 120,
      "text": "m ceiling price calculation. In addition, there will be a new Medicare manufacturer discount program agreement\nexpected to be signed in March 2024 that will change our discounting obligations for all medicines in Medicare, with few exceptions, beginning in 2025. The Medicare Drug Price\nNegotiation Program is currently subject to legal challenges and therefore, the outcome of the Program remains uncertain. We continue to evaluate the impact of the IRA on our\nbusiness, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain.\nChanges to the Medicaid Drug Rebate Program or the 340B Program could have a material impact on our business. For example, certain changes finalized by CMS in a December\n2020 final rule, including which products qualify as so-called “line extension” drugs subject to increased rebate liability, may have a material impact on our business.",
      "char_count": 954,
      "start_char": 96000,
      "end_char": 96955
    },
    {
      "chunk_id": "pfizer_2023_chunk0121",
      "chunk_index": 121,
      "text": "e, including which products qualify as so-called “line extension” drugs subject to increased rebate liability, may have a material impact on our business. Additionally, in\nMay 2023, CMS proposed new rules that could, if finalized, have a material impact on our business. Those proposals include, for example, new rules regarding how manufacturers\nwould be required to aggregate discounts for purposes of determining their Medicaid Best Price. Additionally, various potential changes to the 340B Program are undergoing\n\n2023 Form 10-K\n\nreview or are the subject of current regulatory activity and/or litigation, and their status is unclear. In 2022, we implemented a policy that will help improve contract pharmacy integrity.\nThe HHS Health Resources and Services Administration (HRSA), which administers the 340B Program, has sent letters to numerous manufacturers that have also implemented",
      "char_count": 891,
      "start_char": 96800,
      "end_char": 97692
    },
    {
      "chunk_id": "pfizer_2023_chunk0122",
      "chunk_index": 122,
      "text": "ers the 340B Program, has sent letters to numerous manufacturers that have also implemented\ncontract pharmacy policies and integrity initiatives; the letters express HRSA’s view that those manufacturers’ policies are in violation of the 340B statute. HRSA also has referred\nsome of those other manufacturers to the HHS Office of Inspector General (OIG) for potential enforcement action. Pfizer has not received an enforcement letter from HRSA to date\nrelating to our 340B Program integrity initiative. Several manufacturers have challenged HRSA’s enforcement letters in federal court and litigation is ongoing in those cases. We\nbelieve that our policy is consistent with the statute. In addition, some states have enacted laws seeking to restrict manufacturer policies related to contract pharmacy transactions in\ntheir states. At least one state has begun to pursue enforcement proceedings under its law. Several stakeholders have challenged such laws in certain states.",
      "char_count": 972,
      "start_char": 97600,
      "end_char": 98573
    },
    {
      "chunk_id": "pfizer_2023_chunk0123",
      "chunk_index": 123,
      "text": "ransactions in\ntheir states. At least one state has begun to pursue enforcement proceedings under its law. Several stakeholders have challenged such laws in certain states. Other states have\nconsidered and could enact similar laws going forward, although any such laws also may be subject to legal challenges. Additional legal or legislative developments at the federal or\nstate level with respect to the 340B Program may have an adverse impact on our integrity initiative, and we may face enforcement action or penalties, depending upon such\ndevelopments. The 340B Program continues to be a subject of regulatory activity, congressional scrutiny and inquiries, litigation, and other developments, any or all of which could\naffect the scope of the program and Pfizer’s obligation to offer discounts to 340B Program covered entities under the program. See the Item 1A.",
      "char_count": 867,
      "start_char": 98400,
      "end_char": 99268
    },
    {
      "chunk_id": "pfizer_2023_chunk0124",
      "chunk_index": 124,
      "text": "o 340B Program covered entities under the program. See the Item 1A. Risk Factors—Pricing and\nReimbursement section.\nStates seek to control healthcare costs related to Medicaid and other state regulated healthcare programs. A majority of states use preferred drug lists to manage access to\npharmaceutical products under Medicaid, including some of our products. States may seek to negotiate supplemental rebate agreements that are larger than the minimum federal\nrequirement for preferred formulary access. Preferred access to our products under the Medicaid managed care programs are often determined by the managed care health plans\ncontracted by the state to administer benefits, which may also require supplemental rebates for preferred formulary access. We expect states will continue to seek cost cutting, which\nmay focus on managed care capitation payments, supplemental rebates, and/or formulary management.",
      "char_count": 914,
      "start_char": 99200,
      "end_char": 100115
    },
    {
      "chunk_id": "pfizer_2023_chunk0125",
      "chunk_index": 125,
      "text": "t cutting, which\nmay focus on managed care capitation payments, supplemental rebates, and/or formulary management.\nWe expect to see continued focus by Congress and the Biden Administration on regulating pricing and access to medicine, in addition to actions already taken, which could result in\nlegislative and regulatory changes. Government and private payors routinely seek to manage utilization and control the costs of our products. There is considerable public and\ngovernment scrutiny of pharmaceutical pricing and actions being taken at the state and federal level. Further efforts by states and the federal government to regulate prices or\npayment for pharmaceutical products, including proposed actions to facilitate drug importation, such as Florida’s drug importation program which was recently authorized by the",
      "char_count": 822,
      "start_char": 100000,
      "end_char": 100823
    },
    {
      "chunk_id": "pfizer_2023_chunk0126",
      "chunk_index": 126,
      "text": "ntly authorized by the\nFDA, limit reimbursement to lower reference prices, require deep discounts, impose financial penalties related to pricing practices, and require manufacturers to report and make\npublic price increases and sometimes a written justification for the increase, could adversely affect our business if implemented. Further, commercial payors often follow Medicare\ncoverage and reimbursement policies when setting their own payment rates. Any reduction in cost or other containment measures may similarly be adopted by commercial plans.\nPayors may continue to promote generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect\nthat consolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. See the Item 1A. Risk Factors—Managed Care\nTrends section.\nAnti-Corruption. The FCPA prohibits U.S.",
      "char_count": 957,
      "start_char": 100800,
      "end_char": 101758
    },
    {
      "chunk_id": "pfizer_2023_chunk0127",
      "chunk_index": 127,
      "text": "and PBMs will increase pricing pressures in the industry. See the Item 1A. Risk Factors—Managed Care\nTrends section.\nAnti-Corruption. The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official,\ngovernment staff member, political party or political candidate to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals\nin many countries. Other countries have enacted similar anti-corruption laws and/or regulations.\nData Privacy. The number of privacy and data security laws and regulations in the U.S. to which we are subject on the federal and state level continues to increase. We routinely\ncollect and use sensitive personal information relating to digital health. The legislative, regulatory and litigation landscape for privacy and data protection requirements is rapidly\nevolving and changing.",
      "char_count": 954,
      "start_char": 101600,
      "end_char": 102555
    },
    {
      "chunk_id": "pfizer_2023_chunk0128",
      "chunk_index": 128,
      "text": "ing to digital health. The legislative, regulatory and litigation landscape for privacy and data protection requirements is rapidly\nevolving and changing. These requirements are not universal and can conflict between jurisdictions. Compliance with those laws and regulations is made more complex by the lack\nof consistent standards, common definitions, or clear regulatory expectations. At the same time, enforcement of these laws and regulations is increasing and litigation is becoming\nmore common. Any failure or perceived failure by us to comply with applicable privacy and data protection laws and regulations, including cybersecurity breaches or incidents, could\nsubject us to significant fines and penalties, litigation, and negatively impact our reputation.\nOutside the U.S.\nNew Drug Approvals.",
      "char_count": 802,
      "start_char": 102400,
      "end_char": 103203
    },
    {
      "chunk_id": "pfizer_2023_chunk0129",
      "chunk_index": 129,
      "text": "s. In the EU, the EMA conducts the scientific evaluation, supervision and safety monitoring of our innovative medicinal products that are eligible for the\ncentralized marketing authorization procedure. Through the centralized procedure, pharmaceutical companies may submit to the EMA a single application for a marketing\nauthorization valid in all the EU and the European Economic Area (EEA) countries. The EC takes a legally binding decision based on the EMA's recommendation. For medicinal\nproducts that are not eligible for the centralized procedure, the mutual recognition procedure is based on the recognition of a pre-existing national marketing authorization by one or\nmore EU member states, and the decentralized procedure allows the submission of a marketing authorization application simultaneously in several EU member states. In the U.K.,\nthe Medicines and Healthcare Products Regulatory Agency is the sole regulatory authority.",
      "char_count": 940,
      "start_char": 103200,
      "end_char": 104141
    },
    {
      "chunk_id": "pfizer_2023_chunk0130",
      "chunk_index": 130,
      "text": "aneously in several EU member states. In the U.K.,\nthe Medicines and Healthcare Products Regulatory Agency is the sole regulatory authority. In Japan, the Pharmaceuticals and Medical Device Agency is involved in a wide range of\nregulatory activities, including clinical studies, approvals, post-marketing reviews and pharmaceutical safety. In China, the National Medical Product Administration is the primary\nregulatory authority for approving and supervising medicines. Health authorities in many middle- and lower-income countries might require marketing approval or scientific opinions\nby a recognized regulatory authority (e.g., the FDA or EMA) before they begin reviewing or approving applications. By way of example, the EMA, in cooperation with the World\nHealth Organization (WHO), can provide scientific opinions on high priority human medicines, including vaccines, for markets outside the EU.\nIn April 2023, the EC proposed to revise the EU pharmaceutical legislation.",
      "char_count": 978,
      "start_char": 104000,
      "end_char": 104979
    },
    {
      "chunk_id": "pfizer_2023_chunk0131",
      "chunk_index": 131,
      "text": "scientific opinions on high priority human medicines, including vaccines, for markets outside the EU.\nIn April 2023, the EC proposed to revise the EU pharmaceutical legislation. The proposed legislation includes a significant focus on tackling inequalities on access, affordability and\navailability of medicines across the EU. The legislative process is ongoing and when eventually completed, it is likely to be the largest reform in over 20 years to EU medicines\nregulation, with a wide range of impacts including on approval procedures, regulatory data protection and environmental protection measures.\nPharmacovigilance. In the EU, the EMA’s PRAC is responsible for reviewing and making recommendations on product safety issues. Specifically, the PRAC focuses on detecting,\nassessing and communicating the risks associated with adverse reactions of medicinal products, while considering their therapeutic effects.",
      "char_count": 916,
      "start_char": 104800,
      "end_char": 105718
    },
    {
      "chunk_id": "pfizer_2023_chunk0132",
      "chunk_index": 132,
      "text": "ating the risks associated with adverse reactions of medicinal products, while considering their therapeutic effects. It also evaluates post-authorization\nsafety studies and conducts pharmacovigilance audits. Outside developed markets, pharmacovigilance requirements vary and are generally not as extensive, but there is a trend\ntoward increasing regulation.\nPricing and Reimbursement. Certain governments, including in the different EU member states, the U.K., Japan, China, Canada and South Korea, provide healthcare at low-to-zero\ndirect cost to consumers at the point of care and have significant power to regulate pharmaceutical\n\n2023 Form 10-K\n\nprices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global financing pressures.",
      "char_count": 808,
      "start_char": 105600,
      "end_char": 106409
    },
    {
      "chunk_id": "pfizer_2023_chunk0133",
      "chunk_index": 133,
      "text": "essures. Governments globally\nmay use a variety of measures to control costs, including, among others, legislative or regulatory pricing reforms, cross country collaboration and procurement, price cuts, mandatory\nrebates, health technology assessments, forced localization as a condition of market access, “international reference pricing” (i.e., the practice of a country linking its regulated\nmedicine prices to those of other countries), QCE processes and VBP. In addition, the international patchwork of price regulation, differing economic conditions and incomplete value\nassessments across countries has led to varying access to quality medicines in many markets and some third-party trade in our products between countries. Several important\nmultilateral organizations such as the WHO scrutinize international pharmaceutical pricing through policy recommendations and sponsorship of programs, such as “The Oslo",
      "char_count": 917,
      "start_char": 106400,
      "end_char": 107318
    },
    {
      "chunk_id": "pfizer_2023_chunk0134",
      "chunk_index": 134,
      "text": "ze international pharmaceutical pricing through policy recommendations and sponsorship of programs, such as “The Oslo\nMedicines Initiative” (OMI) which aims to ensure “affordability for high-priced medicines”. The OMI concluded its work in September 2022, and the WHO/Europe Access to Novel\nMedicines Platform was established to enhance affordable and equitable access to effective, innovative and high-priced medicinal products in the region.\nIn China, pricing pressures have increased in recent years because of an overall focus on healthcare cost containment with the central government emphasizing improved health\noutcomes and decreased drug prices as key indicators of progress towards its healthcare reform. State owned hospitals and the state insurance program account for the vast\nmajority of all drug purchases.",
      "char_count": 820,
      "start_char": 107200,
      "end_char": 108021
    },
    {
      "chunk_id": "pfizer_2023_chunk0135",
      "chunk_index": 135,
      "text": "all drug purchases. For patented innovative products, drug prices have decreased dramatically as a result of adding innovative drugs (including oncology medicines,\nmedicines for children and orphan drugs) to the National Reimbursement Drug List via access-price negotiation. A centralized VBP program with a tendering process aims to contain\nhealthcare costs by driving utilization of generics that have passed QCE. This has resulted in further lowering the price of medicines, especially off-patent medicines; this trend is\nexpected to continue. China is increasing its use of Health Technology Assessment and is controlling mark-ups within the country using a two-invoice limited system, which is a\ngovernment policy that regulates the pricing of pharmaceutical products and medical devices. Pfizer, along with most off-patent originators, have mostly not been successful in the\nVBP bidding process.",
      "char_count": 901,
      "start_char": 108000,
      "end_char": 108903
    },
    {
      "chunk_id": "pfizer_2023_chunk0136",
      "chunk_index": 136,
      "text": "r, along with most off-patent originators, have mostly not been successful in the\nVBP bidding process. The government has indicated that additional post-LOE drugs (including biological products) could be subjected to VBP qualification in future rounds. Certain\nof our products, such as Sulperazon and Vfend injectables, were included as candidates in VBP rounds in 2023, and Pfizer was not successful in the bidding process for such\nproducts. While certain details of future QCE expansion have been made available, we are unable to determine the impact on our business of the various pricing measures\nunderway.\nHealthcare Provider Transparency and Disclosures. Several countries have implemented laws requiring (or industry trade associations have recommended) disclosure of transfers of\nvalue made by pharmaceutical companies to healthcare providers and/or healthcare organizations, such as academic teaching hospitals.\nIntellectual Property.",
      "char_count": 943,
      "start_char": 108800,
      "end_char": 109744
    },
    {
      "chunk_id": "pfizer_2023_chunk0137",
      "chunk_index": 137,
      "text": "y pharmaceutical companies to healthcare providers and/or healthcare organizations, such as academic teaching hospitals.\nIntellectual Property. Reliable patent protection and enforcement around the world are among the key factors we consider for continued business and R&D investment. The WTO\nAgreement on Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) requires participant countries to provide patent and other intellectual property-related protection\nfor pharmaceutical products by law, with a time-limited exemption provided for least-developed countries. While some countries have made improvements, we still face patent grant,\nenforcement and other intellectual property challenges in many countries.\nWhile the global intellectual property policy environment has generally improved following implementation of WTO-TRIPS and bilateral/multilateral trade agreements, our growth and",
      "char_count": 903,
      "start_char": 109600,
      "end_char": 110504
    },
    {
      "chunk_id": "pfizer_2023_chunk0138",
      "chunk_index": 138,
      "text": "roved following implementation of WTO-TRIPS and bilateral/multilateral trade agreements, our growth and\nability to bring new product innovation to patients depends on maintaining those standards and further progress in intellectual property protection. In certain developed international\nmarkets, governments maintain relatively effective intellectual property policies. However, in the EU, pursuant to the ongoing review of pharmaceutical intellectual property and\nregulatory incentives, proposals introduced in 2023 may reduce the basic period of regulatory data protection from eight to six years, subject to the outcome of the ongoing\nlegislative procedure. In several emerging market countries, governments have used intellectual property policies as a tool to force innovators to accept less than fair value for\nmedicines, as well as to advance industrial policy and localization goals.",
      "char_count": 892,
      "start_char": 110400,
      "end_char": 111293
    },
    {
      "chunk_id": "pfizer_2023_chunk0139",
      "chunk_index": 139,
      "text": "an fair value for\nmedicines, as well as to advance industrial policy and localization goals. Multilateral institutions continue to address the role of intellectual property in the context of the COVID-19\nresponse, as well as pandemic preparedness and access to medicine more generally.\nConsiderable political and economic pressure has weakened current intellectual property protection in some countries and has led to policies such as more restrictive standards for\nobtaining patents and more difficult procedures for patenting biopharmaceutical inventions, restrictions on patenting certain types of inventions, revocation of patents, laws or\nregulations that promote or provide broad discretion to issue a compulsory license, weak intellectual property enforcement and failure to implement effective regulatory data\nprotection.",
      "char_count": 829,
      "start_char": 111200,
      "end_char": 112030
    },
    {
      "chunk_id": "pfizer_2023_chunk0140",
      "chunk_index": 140,
      "text": "e regulatory data\nprotection. Our industry advocacy efforts focus on seeking a fair and transparent business environment for foreign manufacturers, underscoring the importance of strong intellectual\nproperty systems for all innovative industries (both domestic and foreign) and helping improve patients’ access to innovative medicines and vaccines.\nData Privacy. We are subject to extensive privacy and data protection laws and regulations around the world concerning the collection, use and sharing of personal data. We\nroutinely collect and use sensitive personal information relating to digital health. The legislative, regulatory and litigation landscape for privacy and data protection requirements is\nrapidly evolving and changing. These requirements are not universal and can conflict between jurisdictions. Compliance with those laws and regulations is made more complex by\nthe lack of consistent standards, common definitions, or clear regulatory expectations.",
      "char_count": 969,
      "start_char": 112000,
      "end_char": 112970
    },
    {
      "chunk_id": "pfizer_2023_chunk0141",
      "chunk_index": 141,
      "text": "jurisdictions. Compliance with those laws and regulations is made more complex by\nthe lack of consistent standards, common definitions, or clear regulatory expectations. At the same time, enforcement of these laws and regulations is increasing and fines and\npenalties are also increasing. Any failure or perceived failure by us to comply with applicable privacy and data protection laws and regulations, including cybersecurity breaches or\nincidents, could subject us to significant fines and penalties, litigation, and negatively impact our reputation.\nENVIRONMENTAL MATTERS\nOur operations are affected by national, state and/or local environmental laws. We have made, and intend to continue to make, the expenditures necessary for compliance with\napplicable laws. We also are cleaning up environmental contamination from past industrial activity at certain sites.",
      "char_count": 865,
      "start_char": 112800,
      "end_char": 113666
    },
    {
      "chunk_id": "pfizer_2023_chunk0142",
      "chunk_index": 142,
      "text": "tal contamination from past industrial activity at certain sites. We incurred capital and operational expenditures in 2023 for\nenvironmental compliance purposes and for the clean-up of certain past industrial activity as follows: $92 million in environment-related capital expenditures and $158 million in other\nenvironment-related expenses.\nWhile capital expenditures or operating costs for environmental compliance cannot be predicted with certainty, we do not currently anticipate they will have a material effect on our\ncapital expenditures or financial position. See also Note 16A3.\nAs a science guided organization, we take a proactive approach to our environmental sustainability initiatives. In 2022, we announced a new goal to further reduce greenhouse gas\n(GHG) emissions and achieve the Science Based Target Initiative’s voluntary Net-Zero Standard by 2040.",
      "char_count": 868,
      "start_char": 113600,
      "end_char": 114469
    },
    {
      "chunk_id": "pfizer_2023_chunk0143",
      "chunk_index": 143,
      "text": "ience Based Target Initiative’s voluntary Net-Zero Standard by 2040. As part of this goal, Pfizer aims to decrease its GHG emissions by 95%\nand its value chain emissions by 90% from 2019 levels by 2040. To support our goal, we are developing and implementing our emission reduction plan, which will include strategies\nto achieve reductions throughout our value chain including investing in new technologies and innovative climate solutions, and setting expectations for our suppliers to establish\nscience-aligned GHG emission reduction goals. Our emission reduction plan-related expenses and capital spending incurred for 2023 were not\n\n2023 Form 10-K\n\nmaterial to our consolidated financial statements. While we expect to incur incremental capital and operational expenditures to meet our goal, we do not currently anticipate they will\nhave a material effect on our financial position in the near term.",
      "char_count": 903,
      "start_char": 114400,
      "end_char": 115304
    },
    {
      "chunk_id": "pfizer_2023_chunk0144",
      "chunk_index": 144,
      "text": "o not currently anticipate they will\nhave a material effect on our financial position in the near term. Longer term uncertainties such as the likelihood of commercially available technologies make it difficult to predict the\nfinancial impact of meeting the goal, and we will continue to assess and monitor the financial impact of the emission reduction plan.\nFor a discussion of the risks associated with climate change and our environmental initiatives, see the Item 1A. Risk Factors—Climate Change and Sustainability section.\nOUR PEOPLE\nOur purpose is: Breakthroughs that change patients’ lives. These breakthroughs are delivered through the collaboration of our talented workforce. As of December 31, 2023,\nincluding Seagen colleagues, we employed approximately 88,000 people worldwide, with approximately 35,000 based in the U.S.",
      "char_count": 833,
      "start_char": 115200,
      "end_char": 116034
    },
    {
      "chunk_id": "pfizer_2023_chunk0145",
      "chunk_index": 145,
      "text": "ximately 35,000 based in the U.S. Women compose approximately 52% of our global\nworkforce, and approximately 39% of our U.S.-based employees are individuals with ethnically diverse backgrounds.\nOur continued success links directly to the commitment, engagement and performance of our employees. It is important that we not only attract and retain the best and brightest\ntalent, but also ensure they remain engaged and can thrive in an environment that is committed to helping them grow, succeed and contribute directly to achieving our purpose. At\nPfizer, prioritizing a positive colleague experience is of utmost importance, particularly during times of business transformation. We were conscious of the impact that the challenges\nand opportunities facing our business throughout the year had on colleagues. Our goal is to prioritize the health and wellness of our colleagues, creating an environment where\ncolleagues can excel in their work and advance our purpose.",
      "char_count": 967,
      "start_char": 116000,
      "end_char": 116968
    },
    {
      "chunk_id": "pfizer_2023_chunk0146",
      "chunk_index": 146,
      "text": "leagues. Our goal is to prioritize the health and wellness of our colleagues, creating an environment where\ncolleagues can excel in their work and advance our purpose. To achieve this, we strive to cultivate an inclusive and empowering work environment. This involves simplifying\nprocesses and eliminating unnecessary complexity, recognizing both performance and leadership skills, fostering career growth and internal mobility, and providing competitive\ncompensation and benefits programs that promote mental and physical well-being.\nCore Values. To fully realize Pfizer’s purpose we have established a clear set of goals regarding what we need to achieve for patients and how we will go about achieving them. The\n“how” is represented by four simple, powerful company core values – Courage, Excellence, Equity and Joy.\nEach value defines our company and our culture:\n• Courage: Breakthroughs start by challenging convention – especially in the face of uncertainty or adversity.",
      "char_count": 978,
      "start_char": 116800,
      "end_char": 117779
    },
    {
      "chunk_id": "pfizer_2023_chunk0147",
      "chunk_index": 147,
      "text": "ce, Equity and Joy.\nEach value defines our company and our culture:\n• Courage: Breakthroughs start by challenging convention – especially in the face of uncertainty or adversity. This happens when we think big, speak up and are decisive.\n• Excellence: We can only change patients’ lives when we perform at our best together. This happens when we focus on what matters, agree who does what and measure\noutcomes.\n• Equity: Every person deserves to be seen, heard and cared for. This happens when we are inclusive, act with integrity and reduce healthcare disparities.\n• Joy: We give ourselves to our work, and it also gives to us. We find joy when we take pride, recognize one another and have fun.\nDiversity, Equity and Inclusion. At Pfizer, every person deserves to be seen, heard and cared for. We embed diversity, equity and inclusion in our workplace and our purpose of\ndelivering breakthroughs that change patients’ lives.",
      "char_count": 926,
      "start_char": 117600,
      "end_char": 118527
    },
    {
      "chunk_id": "pfizer_2023_chunk0148",
      "chunk_index": 148,
      "text": "mbed diversity, equity and inclusion in our workplace and our purpose of\ndelivering breakthroughs that change patients’ lives. As we work to bring together people with different backgrounds, perspectives and experiences we take specific actions to help\nfoster an inclusive environment within Pfizer and beyond, including, among others: (i) building a more inclusive colleague experience through representation and meaningful\nconnections; (ii) advancing equitable health outcomes by evaluating our work through the lens of the communities we serve, (iii) providing resources on allyship and the science\nbehind inclusion to support all colleagues in having courageous conversations about equity, race and the avoidance of bias; (iv) working to help transform society with external\ndiversity, equity and inclusion partnerships, including deploying capital, engaging diverse suppliers and amplifying equity initiatives; and (v) working to help ensure demographics of",
      "char_count": 962,
      "start_char": 118400,
      "end_char": 119363
    },
    {
      "chunk_id": "pfizer_2023_chunk0149",
      "chunk_index": 149,
      "text": "inclusion partnerships, including deploying capital, engaging diverse suppliers and amplifying equity initiatives; and (v) working to help ensure demographics of\nclinical trials correlate to those of the countries where trials are taking place.\nColleague Engagement. To attract, develop and inspire the brightest talent, we aim to support our colleagues by engaging and partnering with them to help ensure they feel they are\npart of a community. We understand that continuously listening and responding to colleague feedback is essential to fostering a healthy work environment particularly during times of\nchange and uncertainty. We are passionate about creating safe spaces at work so our employees feel able and encouraged to provide the company with feedback. The Office of the\nOmbuds is a resource where all Pfizer colleagues at any level can come to get information and guidance to help them address and resolve work-related issues.",
      "char_count": 938,
      "start_char": 119200,
      "end_char": 120140
    },
    {
      "chunk_id": "pfizer_2023_chunk0150",
      "chunk_index": 150,
      "text": "rce where all Pfizer colleagues at any level can come to get information and guidance to help them address and resolve work-related issues. We also host\ncompany-wide safe space calls and provide various other public, private and anonymous channels for employees to share feedback without fear of retaliation.\nOur annual engagement survey, Pfizer Pulse, provides a forum for our colleagues to give structured feedback about their colleague experience. Through this survey, we measure\nand track priority areas of the overall colleague experience and equip leaders with actionable insights for discussion and follow up. Regular topics in the survey include: (i) employee\nengagement, such as colleagues’ commitment to and advocacy for Pfizer; (ii) purpose, including how colleagues’ work connects with our purpose; (iii) inclusion, such as having a",
      "char_count": 844,
      "start_char": 120000,
      "end_char": 120845
    },
    {
      "chunk_id": "pfizer_2023_chunk0151",
      "chunk_index": 151,
      "text": "r purpose; (iii) inclusion, such as having a\nclimate in which diverse perspectives are valued; (iv) empowerment, such as colleagues feeling empowered and enabled to do their best work together; and (v) growth, including the\nability for colleagues to gain new experiences that align with their individual career goals. In addition, we ask for feedback at various points in the employee lifecycle through surveys,\nfocus groups and colleague forums. The information we receive helps enable us to adapt to the real-time needs of our employees and continuously improve our ways of working.\nWhile we have already made progress in reducing bureaucracy and streamlining processes, we recognize that there is still room for improvement, particularly in the effectiveness of\nour cross-functional teams.\nThroughout 2023, we have developed and tested a new approach that aims to expedite decision-making, provide clarity in roles and responsibilities, enhance governance, redefine",
      "char_count": 968,
      "start_char": 120800,
      "end_char": 121769
    },
    {
      "chunk_id": "pfizer_2023_chunk0152",
      "chunk_index": 152,
      "text": "out 2023, we have developed and tested a new approach that aims to expedite decision-making, provide clarity in roles and responsibilities, enhance governance, redefine\nthe role of a leader, and ultimately improve overall team productivity and performance. This new way of working signifies our commitment to becoming a more dynamic organization\nthat thrives on collaboration and agility. By revolutionizing the way our teams operate, we believe we can drive better business outcomes and, most importantly, make a meaningful\ndifference in the lives of people around the world.\nPfizer also prioritizes colleague recognition to drive engagement, a sense of belonging, motivation, and productivity. Our global rewards and recognition program, Bravo, lets\ncolleagues celebrate and acknowledge each other for demonstrating Pfizer values in a way that makes an impact on the company, a colleague, a team or a patient.",
      "char_count": 911,
      "start_char": 121600,
      "end_char": 122512
    },
    {
      "chunk_id": "pfizer_2023_chunk0153",
      "chunk_index": 153,
      "text": "for demonstrating Pfizer values in a way that makes an impact on the company, a colleague, a team or a patient. In 2023, 84% of\ncolleagues were recognized, and more than 650,000 recognitions were given.\n\n2023 Form 10-K\n\nPerformance and Leadership. We understand the significance of leadership and its crucial role in promoting growth and delivering breakthrough results. We believe that each of our\ncolleagues has the potential to lead in a unique way and create a meaningful impact on a global scale. To support this belief, we have developed a new leadership profile for our\ncolleagues that aligns with our company values of courage, excellence, equity and joy.\nWe believe this renewed focus on leadership applies to all colleagues, which may help us to foster transformational thinking and executional excellence.",
      "char_count": 816,
      "start_char": 122400,
      "end_char": 123217
    },
    {
      "chunk_id": "pfizer_2023_chunk0154",
      "chunk_index": 154,
      "text": "onal excellence. By pursuing these\nleadership qualities, we believe Pfizer can help ensure that its leaders and colleagues are aligned with the company’s values, behaviors and purpose, which may help lead to better\noutcomes and a positive impact on the lives they touch.\nWe are committed to helping our colleagues reach their full potential by rewarding both their performance and leadership skills and by providing opportunities for growth and\ndevelopment. Our performance management approach—called Performance and Leadership Insights—is based on six-month semesters during which our colleagues and their\nmanagers set goals, receive feedback and meet to discuss performance. These conversations are meant to help colleagues grow and develop by evaluating performance (what the\ncolleague achieved, measured by outcomes), leadership (how they achieved it, taking into account Pfizer’s values of courage, excellence, equity and joy), and identifying areas of",
      "char_count": 957,
      "start_char": 123200,
      "end_char": 124158
    },
    {
      "chunk_id": "pfizer_2023_chunk0155",
      "chunk_index": 155,
      "text": "easured by outcomes), leadership (how they achieved it, taking into account Pfizer’s values of courage, excellence, equity and joy), and identifying areas of\ngrowth that help move colleagues towards fulfilling their career goals and their potential.\nGrowth and Development. By prioritizing the ongoing development of our employees, we not only support their individual success but also cultivate a resilient and adaptable\nworkforce that can thrive in the face of change. As we navigate the evolving landscape of our industry, we recognize that providing our employees with opportunities for learning,\nskill-building and growth is essential to their engagement, productivity, and overall job satisfaction. In 2023, we continued to maintain low voluntary turnover rates relative to the\npharmaceutical industry.\nOur view of career growth is built on aspirations and empowers individuals to boldly own their growth journey.",
      "char_count": 919,
      "start_char": 124000,
      "end_char": 124920
    },
    {
      "chunk_id": "pfizer_2023_chunk0156",
      "chunk_index": 156,
      "text": "ndustry.\nOur view of career growth is built on aspirations and empowers individuals to boldly own their growth journey. We deepened our efforts to redefine growth as a fluid process that\npromotes incremental in-role growth or mobility along horizontal, vertical or diagonal individualized pathways—what we are calling “zig-zag” growth. Our commitments to colleague\ndevelopment consist of specific actions to encourage non-linear “zig-zag” career growth paths for all colleagues, including (i) a common language around growth—along with a\nguiding framework—to help colleagues identify their next best growth experience, (ii) tools and resources to encourage growth conversations and offer transparency on the sources\nof growth available, and (iii) a variety of opportunities to grow through experiences, connections with others and learning programs, including mentoring, job rotations, experiential",
      "char_count": 898,
      "start_char": 124800,
      "end_char": 125699
    },
    {
      "chunk_id": "pfizer_2023_chunk0157",
      "chunk_index": 157,
      "text": "s, connections with others and learning programs, including mentoring, job rotations, experiential\nprojects, skill-based volunteering and personalized learning pathways that address a variety of topics, including leadership and management skills and industry- and job-specific\nlearning, as well as general business, manufacturing, finance and technology skills.\nHealth, Safety and Well-Being. Protecting the health, safety and well-being of colleagues and contingent workers, all of whom are essential to delivering our business objectives, is\nan integral part of how we operate. Our Global Environment, Health & Safety (EHS) Policy and supporting standards outline our approach to assessment, evaluation, elimination,\nand mitigation of EHS risks across our operations globally. We are committed to supporting and encouraging our colleagues’ well-being and use results from Pfizer Pulse and other",
      "char_count": 896,
      "start_char": 125600,
      "end_char": 126497
    },
    {
      "chunk_id": "pfizer_2023_chunk0158",
      "chunk_index": 158,
      "text": "upporting and encouraging our colleagues’ well-being and use results from Pfizer Pulse and other\nemployee feedback forums to inform the wellness services we offer, such as (i) a Wellness Day for every colleague, (ii) on-site health clinics for colleagues in select locations, with\naccess to certain vaccinations, where allowed by law, (iii) digital accessibility cafés that provide employees with disabilities the tools and equipment to do their jobs effectively, (iv)\nmental health resources, including a manager/team toolkit designed to facilitate conversations, actively care for coworkers, and provide local resources for employees to access\nsupport, (v) programming through Employee Assistance Program (EAP) providers, including our mental health partner THRIVE, our fitness partner Exos, and healthcare partner\nKepro, (vi) financial support, including short-term loans and natural disaster relief, and (vii) flexible work policies enabling employees to work from home and their local offices.",
      "char_count": 998,
      "start_char": 126400,
      "end_char": 127399
    },
    {
      "chunk_id": "pfizer_2023_chunk0159",
      "chunk_index": 159,
      "text": "althcare partner\nKepro, (vi) financial support, including short-term loans and natural disaster relief, and (vii) flexible work policies enabling employees to work from home and their local offices.\nPay Equity. Our commitment to pay equity for all colleagues is based in our value of Equity and our intention to continue to build a diverse, inclusive and highly motivated workforce.\nWe are committed to equitable pay practices at Pfizer for employees based on role, education, experience, performance, and location and we conduct and report publicly on pay\nequity on an annual basis.\nITEM 1A.\nRISK FACTORS\nThis section describes the material risks to our business, which should be considered carefully in addition to the other information in this report and our other filings with the SEC.\nInvestors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or\nuncertainties.",
      "char_count": 984,
      "start_char": 127200,
      "end_char": 128185
    },
    {
      "chunk_id": "pfizer_2023_chunk0160",
      "chunk_index": 160,
      "text": "should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or\nuncertainties. Additionally, our business is subject to general risks applicable to any company, such as economic conditions, geopolitical events, extreme weather and natural\ndisasters. If known or unknown risks or uncertainties materialize, our business operations, financial condition, operating results (including components of our financial results), cash\nflows, prospects, reputation or credit ratings could be adversely affected now and in the future, potentially in a material way. The following discussion of risk factors contains forwardlooking statements, as discussed in the Forward-Looking Information and Factors that May Affect Future Results section.\nRISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS:\nMANAGED CARE TRENDS",
      "char_count": 911,
      "start_char": 128000,
      "end_char": 128912
    },
    {
      "chunk_id": "pfizer_2023_chunk0161",
      "chunk_index": 161,
      "text": "May Affect Future Results section.\nRISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS:\nMANAGED CARE TRENDS\nPrivate payors, such as health plans, and other managed care entities, such as PBMs, continue to take action to manage the utilization and costs of drugs in the U.S., the single\nlargest market for biopharmaceutical products. The negotiating power of MCOs and other private third-party payors has increased due to consolidation, and they, along with state\nand federal governments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of deductibles, utilization\nmanagement tools, cost sharing or formulary placement. They may demand rebates from biopharmaceutical manufacturers for preferred placement on a drug formulary. The\ngrowing availability and use of innovative specialty pharmaceutical medicines that treat rare or life threatening conditions, typically with a relatively higher cost as compared to other",
      "char_count": 989,
      "start_char": 128800,
      "end_char": 129791
    },
    {
      "chunk_id": "pfizer_2023_chunk0162",
      "chunk_index": 162,
      "text": "The\ngrowing availability and use of innovative specialty pharmaceutical medicines that treat rare or life threatening conditions, typically with a relatively higher cost as compared to other\ntypes of pharmaceutical products, also has generated increased payor interest in development of cost-containment strategies. These initiatives have increased consumers’ interest\nin drug prices and input in medication choices, as they pay for a larger portion of their prescription costs and may cause them to favor lower-cost generic alternatives. We may fail to\nobtain or maintain timely or adequate pricing or formulary placement of our products, or fail to obtain such formulary placement at favorable pricing net of rebates.\nThird-party payors also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing and value-based pricing/contracting to improve their cost\ncontainment efforts and cost efficiency.",
      "char_count": 938,
      "start_char": 129600,
      "end_char": 130539
    },
    {
      "chunk_id": "pfizer_2023_chunk0163",
      "chunk_index": 163,
      "text": "clusion lists, indication-based pricing and value-based pricing/contracting to improve their cost\ncontainment efforts and cost efficiency. Such payors are also increasingly imposing utilization management tools requiring prior authorization for a branded product or requiring the\npatient to first fail on one or more other products before permitting access to a particular branded medicine. As the U.S. private third-party payor market consolidates further, and as\nthe IRA prices become publicly available, we may face greater pricing pressure from private third-party payors as they continue to drive more of their patients to use lower cost\nalternatives\n\n2023 Form 10-K\n\nor seek even larger rebates to control costs or offset losses from the IRA. For additional information on the IRA, see the Item 1.",
      "char_count": 803,
      "start_char": 130400,
      "end_char": 131204
    },
    {
      "chunk_id": "pfizer_2023_chunk0164",
      "chunk_index": 164,
      "text": "1. Business—Government Regulation and Price\nConstraints section.\nAlso, business arrangements in this area are subject to a high degree of government scrutiny, and available safe harbors under applicable federal and state fraud and abuse laws\nare subject to change through legislative and regulatory action, as well as evolving judicial interpretations. Our approach to these arrangements may also be informed by such\ngovernment and industry guidance.\nCOMPETITIVE PRODUCTS\nCompetitive product launches have and may erode future sales of our products, including our existing products and those currently under development, or result in product\nobsolescence. Such launches continue to occur, and potentially competitive products are in various stages of development. We cannot predict with accuracy the timing or impact of\nthe introduction of competitive products that treat or prevent diseases and conditions like those treated or prevented by our in-line products and product candidates.",
      "char_count": 986,
      "start_char": 131200,
      "end_char": 132188
    },
    {
      "chunk_id": "pfizer_2023_chunk0165",
      "chunk_index": 165,
      "text": "timing or impact of\nthe introduction of competitive products that treat or prevent diseases and conditions like those treated or prevented by our in-line products and product candidates.\nSome of our competitors may have competitive, technical or other advantages over us for the development of technologies and processes or greater experience in particular\ntherapeutic areas, and consolidation among certain pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to\ncompete with them successfully to discover, develop and market new products and for our current products to compete with new products or indications they may bring to market.\nOur products have been competing and may continue to compete, and our product candidates may compete, against products or product candidates that offer higher rebates or",
      "char_count": 873,
      "start_char": 132000,
      "end_char": 132875
    },
    {
      "chunk_id": "pfizer_2023_chunk0166",
      "chunk_index": 166,
      "text": "mpete, against products or product candidates that offer higher rebates or\ndiscounts, exclusionary contracting, lower prices, equivalent or superior efficacy, better safety profiles, easier administration, earlier market availability or other competitive features.\nIf we are unable to compete effectively, this could reduce sales, which could negatively impact our results of operations.\nIn addition, competition from manufacturers of generic drugs, including from generic versions of competitors’ branded products that lose their market exclusivity, is a major challenge\nfor our branded products. Certain of our products have experienced significant generic competition over the last few years. We anticipate a more significant impact of reduced\nrevenues from patent expiries in 2026 through 2030 as several of our in-line products experience patent-based expirations. See the Item 1. Business—Patents and Other Intellectual\nProperty Rights section.",
      "char_count": 950,
      "start_char": 132800,
      "end_char": 133751
    },
    {
      "chunk_id": "pfizer_2023_chunk0167",
      "chunk_index": 167,
      "text": "several of our in-line products experience patent-based expirations. See the Item 1. Business—Patents and Other Intellectual\nProperty Rights section. In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts\nand volume loss of some of our products.\nIn addition, our patented products may face generic or biosimilar competition before patent exclusivity expires, including from “at-risk” launch (despite pending patent infringement\nlitigation against the generic or biosimilar product) by a manufacturer of a generic or biosimilar version of one of our patented products. Generic and biosimilar manufacturers have\nfiled or could file applications with the FDA seeking approval of product candidates that they claim do not infringe our or our collaboration and licensing partners’ patents or claim that\nour or our collaboration and licensing partners’ patents are not valid.",
      "char_count": 972,
      "start_char": 133600,
      "end_char": 134574
    },
    {
      "chunk_id": "pfizer_2023_chunk0168",
      "chunk_index": 168,
      "text": "hat they claim do not infringe our or our collaboration and licensing partners’ patents or claim that\nour or our collaboration and licensing partners’ patents are not valid. We and our licensing and collaboration partners also face challenges in various jurisdictions by generic drug\nmanufacturers to patents covering products for which we have patent rights, licenses or co-promotion rights. See Note 16A1.\nWe may become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars.\nWe also commercialize biosimilar products that compete with products of others, including other biosimilar products. The entry to the market of competing biosimilars is expected to\nincrease pricing pressures on our biosimilar products.",
      "char_count": 806,
      "start_char": 134400,
      "end_char": 135207
    },
    {
      "chunk_id": "pfizer_2023_chunk0169",
      "chunk_index": 169,
      "text": "ducts. Uptake of our biosimilars may be lower due to various factors, such as anti-competitive practices, access challenges where\nour product may not receive appropriate coverage/reimbursement access or remains in a disadvantaged position relative to an innovator product, physician reluctance to prescribe\nbiosimilars for existing patients taking the reference product, or misaligned financial incentives for certain prescribers.\nFor additional information on competition our products face, see the Item 1. Business—Competition section.\nCONCENTRATION\nWe recorded direct product and/or Alliance revenues of more than $1 billion for each of nine products that collectively accounted for 64% of Total revenues in 2023. In particular,\nComirnaty accounted for 19% of Total revenues in 2023. See Notes 1 and 17.",
      "char_count": 806,
      "start_char": 135200,
      "end_char": 136007
    },
    {
      "chunk_id": "pfizer_2023_chunk0170",
      "chunk_index": 170,
      "text": "nd 17. If these products or any of our other major products were to, or continue to (if applicable), experience\nloss of patent protection (if applicable), changes in prescription or vaccination purchasing or growth rates, reduced product demand, material product liability litigation, unexpected\nside effects or safety concerns, regulatory proceedings or investigations, lower governmental and/or regulatory confidence, negative publicity affecting doctor or patient confidence,\npressure from competitive products, changes in labeling, pricing and access pressures or supply shortages or if a new, more effective product should be introduced, the adverse\nimpact on our revenues could be significant and our revenue forecasts and expectations could prove to be inaccurate and we may fail to meet these expectations. In particular,\ncertain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years.",
      "char_count": 971,
      "start_char": 136000,
      "end_char": 136972
    },
    {
      "chunk_id": "pfizer_2023_chunk0171",
      "chunk_index": 171,
      "text": "expectations. In particular,\ncertain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. We anticipate a more significant impact of\nreduced revenues from patent expiries in 2026 through 2030 as several of our in-line products experience patent-based expirations. In addition, patents covering a number of our\nbest-selling products are, or have been, the subject of pending legal challenges. For additional information on our patents, see the Item 1. Business—Patents and Other Intellectual\nProperty Rights section. For Comirnaty and Paxlovid, while we believe that these products have the potential to provide ongoing revenue streams for Pfizer for the foreseeable\nfuture, revenues of these products following the COVID-19 pandemic have decreased substantially, and our current expectations for total COVID-19 product revenues in 2024 are\nlower than the total 2023 revenues from COVID-19 products.",
      "char_count": 979,
      "start_char": 136800,
      "end_char": 137781
    },
    {
      "chunk_id": "pfizer_2023_chunk0172",
      "chunk_index": 172,
      "text": "ID-19 pandemic have decreased substantially, and our current expectations for total COVID-19 product revenues in 2024 are\nlower than the total 2023 revenues from COVID-19 products. For information on risks associated with Comirnaty and Paxlovid, see the COVID-19 section below.\nIn addition, certain of our customers account for a significant portion of our revenues. If one of our significant customers should encounter financial or other difficulties, it might\ndecrease the amount of business such customer does with us and/or we might be unable to timely collect all the amounts that such customer owes us or at all, which could\nnegatively impact our results of operations. In addition, we expect that consolidation and integration of pharmacy chains and wholesalers will increase competitive and pricing\npressures on pharmaceutical manufacturers, including us.",
      "char_count": 863,
      "start_char": 137600,
      "end_char": 138464
    },
    {
      "chunk_id": "pfizer_2023_chunk0173",
      "chunk_index": 173,
      "text": "ricing\npressures on pharmaceutical manufacturers, including us. See Note 17C for a discussion of our significant customers.\nRESEARCH AND DEVELOPMENT\nThe discovery and development of new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our business. Our\nproduct lines must be replenished over time to offset revenue losses when products lose exclusivity or market share or to respond to healthcare and innovation trends, as well as to\nprovide for earnings growth, primarily through internal R&D or through collaborations, acquisitions, JVs, licensing or other arrangements. Growth depends in large part on our ability\nto identify and develop\n\n2023 Form 10-K\n\nnew products or new indications for existing products that address unmet medical needs and receive reimbursement from payors. However, balancing current growth, investment for\nfuture growth and the delivery of shareholder return remains a major challenge.",
      "char_count": 987,
      "start_char": 138400,
      "end_char": 139388
    },
    {
      "chunk_id": "pfizer_2023_chunk0174",
      "chunk_index": 174,
      "text": "nmet medical needs and receive reimbursement from payors. However, balancing current growth, investment for\nfuture growth and the delivery of shareholder return remains a major challenge. The costs of product development continue to be high and are growing, as are regulatory\nrequirements in many therapeutic areas, which may affect the complexity of drug trials, and the number of candidates we are able to fund as well as the sustainability of the R&D\nportfolio. Decisions made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketing strategy and payor reimbursement\npossibilities if the candidate receives regulatory approval. We try to plan clinical trials prudently and to reasonably anticipate and address challenges, but there is no assurance that\nan optimal balance between trial conduct, speed and desired outcome will be achieved.",
      "char_count": 895,
      "start_char": 139200,
      "end_char": 140096
    },
    {
      "chunk_id": "pfizer_2023_chunk0175",
      "chunk_index": 175,
      "text": "ance that\nan optimal balance between trial conduct, speed and desired outcome will be achieved.\nAdditionally, our product candidates can fail at any stage of the R&D process, and may not receive regulatory approval even after many years of R&D. We may fail to correctly\nidentify compounds or indications for which our science is promising or allocate R&D investment resources efficiently, and failure to invest in the right technology platforms,\ntherapeutic areas, product classes, geographic markets and/or licensing opportunities could adversely impact the productivity of our pipeline. Further, even if we identify areas with\nthe greatest commercial potential, the scientific approach may not succeed despite the significant investment required for R&D, and the product may not be as competitive as\nexpected because of the highly dynamic regulatory and market environments and the hurdles in terms of access, coverage and reimbursement.",
      "char_count": 939,
      "start_char": 140000,
      "end_char": 140940
    },
    {
      "chunk_id": "pfizer_2023_chunk0176",
      "chunk_index": 176,
      "text": "s\nexpected because of the highly dynamic regulatory and market environments and the hurdles in terms of access, coverage and reimbursement. For example, certain of our gene\ntherapy product candidates are based on a novel technology with only a handful of gene therapies approved to date, which make it difficult to predict the time and cost of\ndevelopment and the ability to obtain regulatory approval.\nGLOBAL OPERATIONS\nWe operate on a global scale and could be affected by currency and interest rate fluctuations; capital and exchange controls; local and global economic conditions including inflation,\nrecession, volatility and/or lack of liquidity in capital markets; expropriation and other restrictive government actions; changes in intellectual property; legal protections and remedies;\ntrade regulations; tax laws and regulations; and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as",
      "char_count": 973,
      "start_char": 140800,
      "end_char": 141774
    },
    {
      "chunk_id": "pfizer_2023_chunk0177",
      "chunk_index": 177,
      "text": "regulations; tax laws and regulations; and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as\nwell as impacts of political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and their economic consequences,\ngeopolitical instability, terrorist activity, unstable governments and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or\ndisruptions related to climate change.\nSome emerging market countries may be particularly vulnerable to periods of financial, economic or political instability or significant currency fluctuations or may have limited\nresources for healthcare spending. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and any growth rates in these markets\nmay not be sustainable.",
      "char_count": 954,
      "start_char": 141600,
      "end_char": 142555
    },
    {
      "chunk_id": "pfizer_2023_chunk0178",
      "chunk_index": 178,
      "text": "of these and other factors, our strategy to grow in emerging markets may not be successful, and any growth rates in these markets\nmay not be sustainable. Additionally, local economic conditions may adversely affect the ability of payors, as well as our distributors, customers, suppliers and service providers, to\npay for our products, or otherwise to buy necessary inventory or raw materials, and to perform their obligations under agreements with us.\nGovernment financing and economic pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria\n(e.g., through health technology assessments) or other means of cost control. For additional information on government pricing pressures, see the Item 1. Business—Government\nRegulation and Price Constraints section.\nWe continue to monitor the global trade environment and potential trade conflicts and impediments that could impact our business.",
      "char_count": 972,
      "start_char": 142400,
      "end_char": 143374
    },
    {
      "chunk_id": "pfizer_2023_chunk0179",
      "chunk_index": 179,
      "text": "t\nRegulation and Price Constraints section.\nWe continue to monitor the global trade environment and potential trade conflicts and impediments that could impact our business. If trade restrictions or tariffs reduce global\neconomic activity, potential impacts could include declining sales; increased costs; volatility in foreign exchange rates; a decline in the value of our financial assets and pension plan\ninvestments; required increases of our pension funding obligations; increased government cost control efforts; delays or failures in the performance of customers, suppliers and\nother third parties on whom we may depend for the performance of our business; and the risk that our allowance for doubtful accounts may not be adequate.\nWe operate in many countries and transact in many different currencies. Changes in the value of those currencies relative to the U.S.",
      "char_count": 872,
      "start_char": 143200,
      "end_char": 144073
    },
    {
      "chunk_id": "pfizer_2023_chunk0180",
      "chunk_index": 180,
      "text": "urrencies. Changes in the value of those currencies relative to the U.S. dollar, or high inflation or deflation in those\ncountries, can impact our revenues, costs and expenses and our financial guidance. Significant portions of our revenues, costs and expenses, as well as our substantial international\nnet assets, are exposed to exchange rate changes. 54% of our total 2023 revenues were derived from international operations, including 24% from Europe and 20% from Japan,\nChina and the rest of the Asia Pacific region. Future changes in exchange rates or economic conditions and the impact they may have on our results of operations, financial\ncondition or business are difficult to predict. For additional information about our exposure to foreign currency risk, see the Analysis of Financial Condition, Liquidity, Capital\nResources and Market Risk section within MD&A.",
      "char_count": 872,
      "start_char": 144000,
      "end_char": 144873
    },
    {
      "chunk_id": "pfizer_2023_chunk0181",
      "chunk_index": 181,
      "text": "ition, Liquidity, Capital\nResources and Market Risk section within MD&A.\nIn addition, our borrowing, pension benefit and postretirement benefit obligations and interest-bearing investments are subject to risk from changes in interest and exchange rates.\nThe risks related to interest-bearing investments and borrowings and the measures we have taken to help contain them are discussed in the Analysis of Financial Condition,\nLiquidity, Capital Resources and Market Risk section within MD&A and Note 7E. For additional details on critical accounting estimates and assumptions for our benefit plans, see the\nSignificant Accounting Policies and Application of Critical Accounting Estimates and Assumptions—Benefit Plans section within MD&A and Note 11.\nPRODUCT MANUFACTURING, SALES AND MARKETING RISKS\nWe could encounter difficulties, delays or inefficiencies in our supply chain, product manufacturing and distribution networks, as well as sales or marketing, due to regulatory actions,",
      "char_count": 984,
      "start_char": 144800,
      "end_char": 145785
    },
    {
      "chunk_id": "pfizer_2023_chunk0182",
      "chunk_index": 182,
      "text": "e could encounter difficulties, delays or inefficiencies in our supply chain, product manufacturing and distribution networks, as well as sales or marketing, due to regulatory actions,\nshut-downs, work stoppages or strikes, approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely\non, reputational harm, the impact to our facilities due to health pandemics or natural or man-made disasters, including as a result of climate change, product liability or unanticipated\ncosts. Examples of such difficulties or delays include the inability to increase or maintain production capacity commensurate with demand; challenges related to component materials\nto maintain supply and/or appropriate quality standards throughout our supply network and/or comply with applicable regulations; inability to supply certain products due to voluntary",
      "char_count": 924,
      "start_char": 145600,
      "end_char": 146525
    },
    {
      "chunk_id": "pfizer_2023_chunk0183",
      "chunk_index": 183,
      "text": "roughout our supply network and/or comply with applicable regulations; inability to supply certain products due to voluntary\nproduct recalls; and supply chain disruptions at our facilities or at a supplier or vendor. In addition, we engage contract manufacturers, and, from time to time, our contract\nmanufacturers may face difficulties or are unable to manufacture our products at the necessary quantity or quality levels.\nRegulatory agencies periodically inspect our manufacturing facilities, as well as third-party facilities that we rely on, to evaluate compliance with cGMP or other applicable\nrequirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of\nproduct, injunctions, debarment, product recalls, delays or denials of product approvals, import bans or denials of import certifications.\nIn 2021, Pfizer recalled all lots of Chantix in the U.S.",
      "char_count": 971,
      "start_char": 146400,
      "end_char": 147372
    },
    {
      "chunk_id": "pfizer_2023_chunk0184",
      "chunk_index": 184,
      "text": "barment, product recalls, delays or denials of product approvals, import bans or denials of import certifications.\nIn 2021, Pfizer recalled all lots of Chantix in the U.S. due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the FDA interim acceptable intake limit. Regulatory\nauthorities outside the U.S. have issued updated guidance on nitrosamine acceptable intake levels. With this recently issued guidance, which included an updated intake level for Nnitroso-varenicline, we expect to make regulatory submissions in 2024 to potentially enable Chantix to return to market outside the U.S., and our related discussions with FDA are\nongoing.\n\n2023 Form 10-K\n\nOur manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. While manufacturing has resumed, the supply of medicines impacted by the tornado is\nexpected to be affected through 2024.",
      "char_count": 887,
      "start_char": 147200,
      "end_char": 148088
    },
    {
      "chunk_id": "pfizer_2023_chunk0185",
      "chunk_index": 185,
      "text": "he supply of medicines impacted by the tornado is\nexpected to be affected through 2024. See the Overview of Our Performance, Operating Environment, Strategy and Outlook—Our Operating Environment section within MD&A.\nCOLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES\nWe depend on third-party collaborators, service providers, and others in the research, development, manufacturing and commercialization of our products and product candidates\nand also enter into JVs and other business development transactions. To achieve expected longer-term benefits, we may make substantial upfront payments as part of these\ntransactions, which may negatively impact our earnings or cash flows. We rely heavily on these parties for multiple aspects of our drug development, manufacturing and\ncommercialization activities, but we do not control many aspects of those activities.",
      "char_count": 870,
      "start_char": 148000,
      "end_char": 148871
    },
    {
      "chunk_id": "pfizer_2023_chunk0186",
      "chunk_index": 186,
      "text": "on activities, but we do not control many aspects of those activities. We also outsource certain services, including activities related to transaction processing,\naccounting, IT, manufacturing, clinical trial recruitment and execution, clinical lab services, non-clinical research, safety services, integrated facilities management and other areas.\nFailure by one or more of the third-party collaborators, service providers and others to complete activities on schedule or in accordance with our expectations or to meet their\ncontractual or other obligations to us; failure of one or more of these parties to comply with applicable laws or regulations; disruptions in one or more of these parties’ businesses,\nincluding unexpected demand for or shortage of raw materials or components, cyber-attacks on supplier systems, labor disputes or shortage and inclement weather, as well as",
      "char_count": 881,
      "start_char": 148800,
      "end_char": 149682
    },
    {
      "chunk_id": "pfizer_2023_chunk0187",
      "chunk_index": 187,
      "text": "on supplier systems, labor disputes or shortage and inclement weather, as well as\nnatural or man-made disasters or pandemics; or any disruption in the relationships between us and these parties have or could delay or prevent the development, approval,\nmanufacturing or commercialization of our products and product candidates, expose us to suboptimal quality of service delivery or deliverables, result in repercussions such as\nmissed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry\nstandards or subject us to reputational harm, all with potential negative implications for our product pipeline and business. Further, our Alliance revenues will be adversely affected\nby the termination or expiration of collaboration and co-promotion agreements that we have entered into and that we may enter into from time to time.\nCOUNTERFEIT PRODUCTS",
      "char_count": 956,
      "start_char": 149600,
      "end_char": 150557
    },
    {
      "chunk_id": "pfizer_2023_chunk0188",
      "chunk_index": 188,
      "text": "tion or expiration of collaboration and co-promotion agreements that we have entered into and that we may enter into from time to time.\nCOUNTERFEIT PRODUCTS\nOur reputation, in-line and pipeline portfolios render our medicines and vaccines prime targets for counterfeiters. Counterfeits pose a significant risk to patient health and safety\nbecause of the conditions under which they are manufactured—often in unregulated, unlicensed, uninspected, and unsanitary sites—as well as the lack of regulation of their\ncontents. Failure to mitigate this threat could adversely impact Pfizer’s patients, potentially causing them harm. This situation, in turn, may result in the loss of patient confidence in\nthe Pfizer name and in the integrity of our medicines and vaccines, and potentially impact our business through lost sales, product recalls, and possible litigation.\nThe prevalence of counterfeit medicines is an industry-wide issue due to a variety of factors, including the adoption of e-commerce.",
      "char_count": 996,
      "start_char": 150400,
      "end_char": 151397
    },
    {
      "chunk_id": "pfizer_2023_chunk0189",
      "chunk_index": 189,
      "text": "s through lost sales, product recalls, and possible litigation.\nThe prevalence of counterfeit medicines is an industry-wide issue due to a variety of factors, including the adoption of e-commerce. The increased adoption during the COVID-19\npandemic further exposed consumers to fake prescription treatments via the internet as access to traditional brick and mortar pharmacies or authorized full-service internet\npharmacies that offer authentic treatments may have been hindered. The internet exposes patients to greater risk as it is a preferred vehicle for dangerous counterfeit offers and\nscams that target unsuspecting consumers. Traffic to these generally deceptive pharmacy sites is largely driven by misplaced trust in sophisticated internet retailers and social media\noffers coupled with the convenience e-commerce affords consumers.",
      "char_count": 841,
      "start_char": 151200,
      "end_char": 152042
    },
    {
      "chunk_id": "pfizer_2023_chunk0190",
      "chunk_index": 190,
      "text": "convenience e-commerce affords consumers. Counterfeiters generally target any medicine or vaccine boasting strong demand and we have observed\nheightened counterfeit and fraud attempts to our internal medicine portfolio, as well as products utilized in the treatment of COVID-19.\nWe consistently invest in an enterprise-wide strategy to aggressively combat counterfeit threats by educating patients and healthcare providers about the risks, investing in\ninnovative technologies to detect and disrupt sophisticated internet offers and scams, proactively monitoring and interdicting supply with the help of law enforcement, and advising\nlegislators and regulators. However, our efforts and those of others may not be entirely successful, and the presence of counterfeit medicines may continue to increase.\nRISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS:\nPRICING AND REIMBURSEMENT\nU.S.",
      "char_count": 895,
      "start_char": 152000,
      "end_char": 152896
    },
    {
      "chunk_id": "pfizer_2023_chunk0191",
      "chunk_index": 191,
      "text": "e.\nRISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS:\nPRICING AND REIMBURSEMENT\nU.S. and international governmental regulations that mandate price controls or limitations on patient access to our products, create coverage criteria or establish prices paid by\ngovernment entities or programs for our products impact our business, and our future results could be adversely affected by changes in such regulations or policies. In addition to\nthe recent expansion of price controls in the U.S. in the IRA, the adoption of restrictive coverage policies and price controls in new jurisdictions, more restrictive controls in existing\njurisdictions or the failure to obtain or maintain timely or adequate coverage and pricing could also adversely impact revenue. We expect pricing pressures and other cost\ncontainment measures for drugs and vaccines will continue globally.",
      "char_count": 876,
      "start_char": 152800,
      "end_char": 153677
    },
    {
      "chunk_id": "pfizer_2023_chunk0192",
      "chunk_index": 192,
      "text": "her cost\ncontainment measures for drugs and vaccines will continue globally.\nIn the U.S., pharmaceutical product pricing is subject to government and public scrutiny and calls for reform, and many of our products are subject to increasing pricing pressures as\na result. We expect to see continued focus by the U.S. Congress and the Biden Administration on regulating pricing and access to medicine. For example, in August 2022, the drug\npricing provisions of the IRA were signed into law, which, among other things, require manufacturers of certain drugs, including Pfizer, to engage in price negotiations with Medicare\nwhich will permit the CMS to set a maximum fair price for selected drugs, impose rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace\ninflation, and replace the Part D coverage gap discount program with a new discounting program.",
      "char_count": 887,
      "start_char": 153600,
      "end_char": 154488
    },
    {
      "chunk_id": "pfizer_2023_chunk0193",
      "chunk_index": 193,
      "text": "n, and replace the Part D coverage gap discount program with a new discounting program. The drug pricing provisions of the IRA began to be implemented in 2022 and\nimplementation efforts are expected to continue over the next several years. In August 2023, the Biden Administration unveiled the first round of medicines subject to the Medicare\nDrug Pricing Negotiation Program, which included Eliquis. CMS will establish a maximum fair price for Eliquis that will be in effect in 2026. That maximum fair price will be required to\nbe offered to all Medicare beneficiaries and to covered entities participating in the 340B Program if lower than the 340B price. Health plans may also require rebates in addition to\nthe maximum fair price for preferred placement on a Medicare plan formulary. The Medicare Drug Price Negotiation Program is currently subject to legal challenges and therefore,\nthe outcome of the 340B Program remains uncertain.",
      "char_count": 938,
      "start_char": 154400,
      "end_char": 155339
    },
    {
      "chunk_id": "pfizer_2023_chunk0194",
      "chunk_index": 194,
      "text": "Drug Price Negotiation Program is currently subject to legal challenges and therefore,\nthe outcome of the 340B Program remains uncertain. We continue to evaluate the impact of the IRA on our business, operations, financial condition and results as the full effect of\nthe IRA on our business and the pharmaceutical industry remains uncertain.\nPayors may promote generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect that\nconsolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. Some states have implemented, and others are\nconsidering, patient access constraints or cost cutting under state regulated programs including the Medicaid program. State legislatures also have continued to focus on addressing\ndrug costs, generally by increasing price transparency or attempting to limit drug price increases for state regulated insurance.",
      "char_count": 990,
      "start_char": 155200,
      "end_char": 156192
    },
    {
      "chunk_id": "pfizer_2023_chunk0195",
      "chunk_index": 195,
      "text": "State legislatures also have continued to focus on addressing\ndrug costs, generally by increasing price transparency or attempting to limit drug price increases for state regulated insurance. Measures to regulate prices or payment for\npharmaceutical\n\n2023 Form 10-K\n\nproducts, including legislation on drug importation, such as Florida’s drug importation program which was recently approved by the FDA, could adversely affect our business. For\nadditional information on U.S. pricing and reimbursement, see the Item 1. Business—Government Regulation and Price Constraints section.\nWe encounter similar regulatory and legislative issues in most other countries in which we operate. In certain markets, such as in EU member states, the U.K., Japan, China,\nCanada and South Korea, governments have significant power as large single payors to regulate prices, access criteria, or impose other means of cost control, particularly as a\nresult of recent global financing pressures.",
      "char_count": 973,
      "start_char": 156000,
      "end_char": 156974
    },
    {
      "chunk_id": "pfizer_2023_chunk0196",
      "chunk_index": 196,
      "text": "icant power as large single payors to regulate prices, access criteria, or impose other means of cost control, particularly as a\nresult of recent global financing pressures. For example, the QCE and VBP tender process in China has resulted in significant price cuts for off-patent medicines. Additionally, in the\nEU, the EC proposed the largest reform to drug pricing and access in 20 years, which if enacted would change regulatory exclusivity for our products. For additional information\nregarding these government initiatives, see the Item 1. Business—Government Regulation and Price Constraints section. We anticipate that these and similar initiatives will continue\nto increase pricing and access pressures globally. In addition, in many countries, with respect to our vaccines, we participate in a tender process for selection in national\nimmunization programs.",
      "char_count": 867,
      "start_char": 156800,
      "end_char": 157668
    },
    {
      "chunk_id": "pfizer_2023_chunk0197",
      "chunk_index": 197,
      "text": "n a tender process for selection in national\nimmunization programs. Failure to secure participation in national immunization programs or to obtain acceptable pricing in the tender process could adversely affect our business.\nPricing pressures have been, and we anticipate will continue to be, amplified by COVID-19 induced budget deficits and focus on pricing for COVID-19 treatments and vaccines.\nU.S. HEALTHCARE REGULATION\nThe U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. Any significant additional efforts at the U.S. federal or state levels to reform the\nhealthcare system by changing the way healthcare is provided or funded could have a material impact on us. For additional information on U.S. healthcare regulation, see the Item\n1. Business––Government Regulation and Price Constraints section.\nOther U.S.",
      "char_count": 862,
      "start_char": 157600,
      "end_char": 158463
    },
    {
      "chunk_id": "pfizer_2023_chunk0198",
      "chunk_index": 198,
      "text": "overnment Regulation and Price Constraints section.\nOther U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budget control actions, changes\nin patent laws, the importation of prescription drugs to the U.S. at prices that are regulated by foreign governments, revisions to reimbursement of biopharmaceuticals under\ngovernment programs that could reference international prices or require new discounts, limitations on interactions with healthcare professionals and other industry stakeholders, or\nthe use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences\namong pharmaceutical products and restricts access to innovative medicines.\nAny additional reduction of U.S.",
      "char_count": 875,
      "start_char": 158400,
      "end_char": 159276
    },
    {
      "chunk_id": "pfizer_2023_chunk0199",
      "chunk_index": 199,
      "text": "restricts access to innovative medicines.\nAny additional reduction of U.S. federal spending on entitlement programs beyond the IRA, including Medicare and Medicaid, may affect payment for our products or services\nprovided using our products. Any other significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may\nbe implemented could have an adverse impact on our results of operations. The IRA will be implemented largely through government guidance and as its effect on Medicare and\ncommercial markets evolve, we will continue to evaluate the potential impacts to our business.\nWe expect additional cost containment measures at both the federal and state levels as efforts to reduce drug costs continue. Further, commercial payors often follow Medicare\ncoverage policy and payment limitations when setting their own payment rates.",
      "char_count": 913,
      "start_char": 159200,
      "end_char": 160115
    },
    {
      "chunk_id": "pfizer_2023_chunk0200",
      "chunk_index": 200,
      "text": "mercial payors often follow Medicare\ncoverage policy and payment limitations when setting their own payment rates. Any reduction in cost or other containment measures may similarly be adopted by commercial plans.\nCoverage policies and reimbursement rates for commercial plans may change at any time. Even if favorable coverage and reimbursement status is attained for one or more\nproducts, less favorable coverage policies and reimbursement rates may be implemented in the future.\nDEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS\nThe discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. The outcome is inherently uncertain and involves a high\ndegree of risk due to the following factors, among others:\n• The process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years and have high costs.",
      "char_count": 929,
      "start_char": 160000,
      "end_char": 160930
    },
    {
      "chunk_id": "pfizer_2023_chunk0201",
      "chunk_index": 201,
      "text": "iscovery to design and adequate implementation of clinical trials to regulatory approval can take many years and have high costs.\n• We may have difficulties recruiting and enrolling patients for clinical trials on a consistent basis.\n• Product candidates can and do fail at any stage of the process, including as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new pre-clinical or clinical\ndata and further analyses of existing pre-clinical or clinical data, including results that may not support further clinical development of the product candidate or indication.\n• We may need to amend our clinical trial protocols or conduct additional clinical trials under certain circumstances, for example, to further assess appropriate dosage or collect\nadditional safety data.\n• We may not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates,",
      "char_count": 988,
      "start_char": 160800,
      "end_char": 161789
    },
    {
      "chunk_id": "pfizer_2023_chunk0202",
      "chunk_index": 202,
      "text": "ata.\n• We may not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates,\nregulatory approval dates and/or launch dates.\n• We may not be able to successfully address all the comments received from regulatory authorities such as the FDA and the EMA, or be able to obtain approval for new products\nand indications from regulators.\nRegulatory approvals of our products depend on myriad factors, including regulatory determinations as to the product’s safety and efficacy. In the context of public health\nemergencies like the COVID-19 pandemic, regulators evaluate various factors and criteria to potentially allow for marketing authorization on an emergency or conditional basis.\nAdditionally, clinical trial and other product data are subject to differing interpretations and assessments by regulatory authorities.",
      "char_count": 927,
      "start_char": 161600,
      "end_char": 162528
    },
    {
      "chunk_id": "pfizer_2023_chunk0203",
      "chunk_index": 203,
      "text": "ally, clinical trial and other product data are subject to differing interpretations and assessments by regulatory authorities. As a result of regulatory interpretations and\nassessments or other developments that may occur during the review process, or even after a product is authorized or approved for marketing, a product’s commercial potential\ncould be adversely affected by potential emerging concerns or regulatory decisions regarding or impacting the scope of indicated patient populations, labeling or marketing,\nmanufacturing processes, safety issues and/or other matters, including decisions relating to emerging developments regarding potential product impurities. Also, certain of our\nproducts have received and may in the future receive approvals under accelerated approval pathways where continued approval may be contingent upon confirmatory studies\ndemonstrating the anticipated clinical benefit and/or safety profile.",
      "char_count": 934,
      "start_char": 162400,
      "end_char": 163335
    },
    {
      "chunk_id": "pfizer_2023_chunk0204",
      "chunk_index": 204,
      "text": "e continued approval may be contingent upon confirmatory studies\ndemonstrating the anticipated clinical benefit and/or safety profile.\nWe may not be able to receive or maintain favorable recommendations by technical or advisory committees, such as the ACIP or an FDA Advisory Committee, which may impact the\navailability or commercial potential of our products and product candidates. Further, claims and concerns that may arise regarding the safety and/or efficacy of in-line products and\nproduct candidates can negatively impact current or future product sales, as applicable, and potentially lead to product recalls or withdrawals, including regulator-directed risk\nevaluations and assessments, and/or consumer fraud, product liability and other litigation and claims. Regulatory requirements may also result in a more challenging, expensive and\nlengthy regulatory approval process than anticipated due to requests for, among other things, additional or more extensive clinical trials prior",
      "char_count": 993,
      "start_char": 163200,
      "end_char": 164194
    },
    {
      "chunk_id": "pfizer_2023_chunk0205",
      "chunk_index": 205,
      "text": "also result in a more challenging, expensive and\nlengthy regulatory approval process than anticipated due to requests for, among other things, additional or more extensive clinical trials prior\n\n2023 Form 10-K\n\nto granting approval, or increased post-approval requirements. For these and other reasons discussed in this Risk Factors section, we may not obtain the approvals we expect within\nthe timeframe we anticipate, or at all.\nPOST-AUTHORIZATION/APPROVAL DATA\nAs a condition to granting marketing authorization or approval of a product, the FDA may require, or the sponsor may voluntarily agree to undertake, post-marketing commitments\nsuch as additional clinical trials or other studies. The results generated in these trials have in the past impacted certain of our products and could impact our products in the future,",
      "char_count": 825,
      "start_char": 164000,
      "end_char": 164826
    },
    {
      "chunk_id": "pfizer_2023_chunk0206",
      "chunk_index": 206,
      "text": "r products in the future,\nsuch as by resulting in the loss of marketing approval, changes in labeling, and/or new or increased concerns about safety and/or efficacy, including newly discovered adverse\nevents. Regulatory agencies in countries outside the U.S. often have similar regulations and may impose comparable requirements, although there are differences between the U.S.,\nthe EU and other international regulatory requirements, which may contribute to inconsistency or uncertainty in the marketability of our products across different jurisdictions. Postmarketing studies and clinical trials, whether conducted by us or by others, whether mandated by regulatory agencies or conducted voluntarily, and other emerging data about\nproducts, such as adverse event reports, may also adversely affect the availability or commercial potential of our products.",
      "char_count": 858,
      "start_char": 164800,
      "end_char": 165659
    },
    {
      "chunk_id": "pfizer_2023_chunk0207",
      "chunk_index": 207,
      "text": "the availability or commercial potential of our products. Further, if safety or efficacy concerns are raised about a\nproduct in the same class as one of our products, those concerns could implicate the entire class; and this, in turn, could have an adverse impact on the availability or commercial\nviability of our product(s) as well as other products in the class. The potential regulatory and commercial implications of post-marketing study results typically cannot immediately be\ndetermined.\nThe terms of our EUA for Comirnaty require that we conduct post-observational studies to evaluate the association between the Pfizer-BioNTech COVID-19 Vaccine (Original\nmonovalent), Pfizer-BioNTech COVID-19 Vaccine, Bivalent, and the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), and a pre-specified list of adverse events of special\ninterest, including myocarditis and pericarditis, along with deaths and hospitalizations, and severe COVID-19.",
      "char_count": 947,
      "start_char": 165600,
      "end_char": 166549
    },
    {
      "chunk_id": "pfizer_2023_chunk0208",
      "chunk_index": 208,
      "text": "ied list of adverse events of special\ninterest, including myocarditis and pericarditis, along with deaths and hospitalizations, and severe COVID-19. The required study populations include individuals specified in our\nSeptember 2023 authorization letter (reissued) as well as populations of interest, such as healthcare workers, pregnant women, immunocompromised individuals and\nsubpopulations with specific comorbidities. Additionally, in relation to the FDA approval for Comirnaty, we are required to complete certain postmarketing study requirements and\ncommitments through 2024 and beyond. In the FDA’s revision to the EUA for Paxlovid, the FDA removed the post-authorization requirements as they were addressed as a postmarketing commitment associated with the approval of the Paxlovid NDA. The terms of our Paxlovid EUA had previously required monitoring of a genomic database(s) for the",
      "char_count": 892,
      "start_char": 166400,
      "end_char": 167293
    },
    {
      "chunk_id": "pfizer_2023_chunk0209",
      "chunk_index": 209,
      "text": "erms of our Paxlovid EUA had previously required monitoring of a genomic database(s) for the\nemergence of global viral variants of SARS-CoV-2 and providing reports to the FDA on a monthly basis summarizing any findings. Also, the FDA required Pfizer to assess the activity\nof the authorized Paxlovid against any global SARS-CoV-2 variant(s) of interest and complete certain other analyses and studies as identified in our October 2022 EUA.\nLEGAL MATTERS\nWe are and may be involved in various legal proceedings, including patent litigation, product liability and other product-related litigation, including personal injury, consumer, off-label\npromotion, securities, antitrust and breach of contract claims, commercial and other asserted and unasserted matters, environmental, government and tax investigations,\nemployment, tax litigation and other legal proceedings that arise from time to time in the ordinary course of our business.",
      "char_count": 934,
      "start_char": 167200,
      "end_char": 168135
    },
    {
      "chunk_id": "pfizer_2023_chunk0210",
      "chunk_index": 210,
      "text": "tigations,\nemployment, tax litigation and other legal proceedings that arise from time to time in the ordinary course of our business. Litigation is inherently unpredictable, and excessive\nverdicts do occur. Although we believe that our claims and defenses in matters in which we are a defendant are substantial, we have in the past and could in the future incur\njudgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of\noperations.\nClaims against our patents include challenges to the coverage and/or validity of our patents on various products or processes. There can be no assurance as to the outcome of\nthese matters, and a loss in any of these cases could result in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and\ncould materially affect future results of operations.",
      "char_count": 968,
      "start_char": 168000,
      "end_char": 168969
    },
    {
      "chunk_id": "pfizer_2023_chunk0211",
      "chunk_index": 211,
      "text": "of patent protection for the product at issue, which could lead to a significant loss of sales of that product and\ncould materially affect future results of operations.\nWe are also involved in government investigations that arise in the ordinary course of our business. There continues to be a significant volume of government investigations and\nlitigation against companies operating in our industry, both in the U.S. and around the world. Government investigations and actions have and could result in substantial criminal and\ncivil fines and/or criminal charges, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements and other\ndisciplinary actions, as well as reputational harm, including as a result of increased public interest in the matter.",
      "char_count": 824,
      "start_char": 168800,
      "end_char": 169625
    },
    {
      "chunk_id": "pfizer_2023_chunk0212",
      "chunk_index": 212,
      "text": "interest in the matter. In addition, in a qui tam lawsuit in which the government declines to\nintervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.\nOur sales and marketing activities, the pricing of our products and other aspects of our business are subject to extensive regulation under the FFDCA, the Medicaid Drug Rebate\nProgram, the FCPA and other federal and state statutes, including those discussed elsewhere in this Form 10-K, as well as the Anti-Kickback Statute, anti-bribery laws, the False\nClaims Act, and similar laws in international jurisdictions. In addition to the potential for changes to relevant laws, the compliance and enforcement landscape is informed by\ngovernment litigation, settlement precedent, advisory opinions, and special fraud alerts. Our approach to certain practices may evolve over time in light of these types of\ndevelopments.\nRequirements or industry standards in the U.S.",
      "char_count": 980,
      "start_char": 169600,
      "end_char": 170582
    },
    {
      "chunk_id": "pfizer_2023_chunk0213",
      "chunk_index": 213,
      "text": "ry opinions, and special fraud alerts. Our approach to certain practices may evolve over time in light of these types of\ndevelopments.\nRequirements or industry standards in the U.S. and certain jurisdictions abroad require pharmaceutical manufacturers to track and disclose financial interactions with healthcare\nprofessionals and healthcare providers and can increase government and public scrutiny of such financial interactions. If an interaction is found to be improper, government\nenforcement actions and penalties could result. Like many companies in our industry, we have from time-to-time received, and may receive in the future, inquiries and subpoenas\nand other types of information demands from government authorities. In addition, we have been subject to claims and other actions related to our business activities, brought by\ngovernmental authorities, as well as consumers and private payors.",
      "char_count": 905,
      "start_char": 170400,
      "end_char": 171306
    },
    {
      "chunk_id": "pfizer_2023_chunk0214",
      "chunk_index": 214,
      "text": "to our business activities, brought by\ngovernmental authorities, as well as consumers and private payors. In some instances, we have incurred significant expense, civil payments, fines and other adverse consequences\nas a result of these claims, actions and inquiries. Such claims, actions and inquiries may relate to alleged non-compliance with laws and regulations associated with the\ndissemination of product (approved and unapproved) information, potentially resulting in government enforcement action and reputational damage. This risk may be heightened by\ndigital marketing, including social media, mobile applications and blogger outreach.\nIn connection with the resolution of a U.S. government investigation concerning independent copay assistance organizations that provide financial assistance to Medicare patients,\nin 2018, we entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the HHS (OIG), which expired in May 2023.",
      "char_count": 973,
      "start_char": 171200,
      "end_char": 172174
    },
    {
      "chunk_id": "pfizer_2023_chunk0215",
      "chunk_index": 215,
      "text": "ce to Medicare patients,\nin 2018, we entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the HHS (OIG), which expired in May 2023. Pfizer submitted its final\nannual report and is awaiting a response from the OIG.\nWe and certain of our subsidiaries are also subject to numerous contingencies arising in the ordinary course of business relating to legal claims and proceedings, including\nenvironmental contingencies. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and\ncan rely heavily on estimates and assumptions. While we have accrued for\n\n2023 Form 10-K\n\nworldwide legal liabilities, no guarantee exists that additional costs will not be incurred or additional payments will not be required beyond the amounts accrued.\nFor additional information, including information regarding certain legal proceedings in which we are involved in, see Note 16A.",
      "char_count": 987,
      "start_char": 172000,
      "end_char": 172988
    },
    {
      "chunk_id": "pfizer_2023_chunk0216",
      "chunk_index": 216,
      "text": "payments will not be required beyond the amounts accrued.\nFor additional information, including information regarding certain legal proceedings in which we are involved in, see Note 16A.\nRISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY:\nINTELLECTUAL PROPERTY PROTECTION\nOur success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of intellectual property, including\npatent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and\nproprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from launching generic or biosimilar versions\nof our branded products, from using our proprietary technologies or from marketing products that are very similar or identical to ours.",
      "char_count": 971,
      "start_char": 172800,
      "end_char": 173773
    },
    {
      "chunk_id": "pfizer_2023_chunk0217",
      "chunk_index": 217,
      "text": "ching generic or biosimilar versions\nof our branded products, from using our proprietary technologies or from marketing products that are very similar or identical to ours. Our currently pending or future patent\napplications may not result in issued patents or be granted on a timely basis. Similarly, any term extensions that we seek may not be granted on a timely basis, if at all, and any term\nadjustments related to patent office delays in obtaining a patent may be reduced or eliminated entirely due to risks associated with changes in law relating to patent terms. In\naddition, our issued patents may not contain claims sufficiently broad to protect us against claims regarding validity, enforceability, scope and effective term made by parties with\nsimilar technologies or products or provide us with any competitive advantage, including exclusivity in a particular product area.",
      "char_count": 886,
      "start_char": 173600,
      "end_char": 174487
    },
    {
      "chunk_id": "pfizer_2023_chunk0218",
      "chunk_index": 218,
      "text": "us with any competitive advantage, including exclusivity in a particular product area.\nFurther, legal or regulatory action by various stakeholders or governments could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or\nbeing restricted from enforcing intellectual property related to our products. The WTO continues to address the role of intellectual property in the context of the COVID-19 response.\nThis includes the June 2022 Ministerial Decision on the Agreement on Trade-Related Aspects of Intellectual Property Rights, which seeks to make it easier for certain WTO members\nto issue a compulsory license on COVID-19 vaccines, and discussions continue on whether to expand that decision to COVID-19 therapeutics and diagnostics.\nThe scope of our patent claims also may vary between countries, as individual countries have distinct patent laws, and our ability to enforce our patents depends on the laws of each",
      "char_count": 968,
      "start_char": 174400,
      "end_char": 175369
    },
    {
      "chunk_id": "pfizer_2023_chunk0219",
      "chunk_index": 219,
      "text": "our patent claims also may vary between countries, as individual countries have distinct patent laws, and our ability to enforce our patents depends on the laws of each\ncountry, its enforcement practices, and the extent to which certain countries engage in policies or practices that weaken a country’s intellectual property framework (e.g., laws or\nregulations that promote or provide broad discretion to issue a compulsory license). In countries that provide some form of regulatory exclusivity, mechanisms exist permitting some\nform of challenge to our patents by competitors or generic drug marketers prior to or immediately following the expiration of such regulatory exclusivity, and generic companies are\nemploying aggressive strategies, such as “at-risk” launches that challenge our patent rights.",
      "char_count": 805,
      "start_char": 175200,
      "end_char": 176006
    },
    {
      "chunk_id": "pfizer_2023_chunk0220",
      "chunk_index": 220,
      "text": "ghts. Most of the suits involve claims by generic drug manufacturers that patents covering our\nproducts, uses, processes or dosage forms are invalid and/or do not cover the product of the generic or biosimilar drug manufacturer. Independent actions have been filed alleging\nthat our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. Such claims may also be\nbrought as counterclaims to actions we bring to enforce our patents. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug\nmanufacturers, payors, governments or other parties are seeking damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as inter\npartes review, post-grant review, re-examination or opposition proceedings, before the U.S.",
      "char_count": 903,
      "start_char": 176000,
      "end_char": 176904
    },
    {
      "chunk_id": "pfizer_2023_chunk0221",
      "chunk_index": 221,
      "text": "ch as inter\npartes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts\nrelating to our intellectual property or the intellectual property rights of others. Also, if one of our patents or a competitors’ patents is found to be invalid in such proceedings, generic\nor biosimilar products could be introduced into the market resulting in the erosion of sales of our existing products. For additional information, including information regarding certain\nlegal proceedings in which we are involved, see Note 16A1. Further, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties\ngrant us rights to intellectual property, our operating results and financial condition could be adversely affected.",
      "char_count": 866,
      "start_char": 176800,
      "end_char": 177667
    },
    {
      "chunk_id": "pfizer_2023_chunk0222",
      "chunk_index": 222,
      "text": "ating results and financial condition could be adversely affected.\nWe currently hold trademark registrations and have trademark applications pending in many jurisdictions, any of which may be the subject of a governmental or third-party objection,\nwhich could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors\nincreases and, as a result, our business could be adversely affected if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that\ninfringe, dilute or otherwise violate our rights. We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees,\nconsultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their relationship with us.",
      "char_count": 955,
      "start_char": 177600,
      "end_char": 178556
    },
    {
      "chunk_id": "pfizer_2023_chunk0223",
      "chunk_index": 223,
      "text": "her advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their relationship with us. Despite\nthese efforts and precautions, we may be unable to prevent a third-party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without\nauthorization, and legal remedies may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop\nsubstantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.\nTHIRD-PARTY INTELLECTUAL PROPERTY CLAIMS\nA properly functioning intellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights of other companies, but the\npatent granting process is imperfect.",
      "char_count": 924,
      "start_char": 178400,
      "end_char": 179325
    },
    {
      "chunk_id": "pfizer_2023_chunk0224",
      "chunk_index": 224,
      "text": "itted to respecting the valid intellectual property rights of other companies, but the\npatent granting process is imperfect. Accordingly, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by others that we believe\nwere improperly granted, including challenges through negotiation and litigation, and such challenges may not always be successful.\nPart of our business depends upon identifying biosimilar opportunities and launching products to take advantage of those opportunities, which may involve litigation, associated\ncosts and time delays, and may ultimately not be successful. These opportunities may arise in situations where patent protection of equivalent branded products has expired or been\ndeclared invalid, or where products do not infringe the patents of others.",
      "char_count": 833,
      "start_char": 179200,
      "end_char": 180034
    },
    {
      "chunk_id": "pfizer_2023_chunk0225",
      "chunk_index": 225,
      "text": "t infringe the patents of others. In some circumstances we may take action, such as litigation, asserting that our products do not infringe\npatents of existing products or that those patents are invalid or unenforceable in order to achieve a “first-to-market” or early market position for our products.\nThird parties may claim that our products infringe one or more patents owned or controlled by them. Claims of intellectual property infringement can be costly and time-consuming to\nresolve, may delay or prevent product launches, and may result in significant royalty payments or damages or potential licensing agreements. For example, our R&D in a therapeutic\narea may not be first and another company or entity may have obtained relevant patents before us. We are involved in patent-related disputes with third parties over our attempts to\nmarket pharmaceutical products, including related to Abrysvo, Comirnaty and Paxlovid.",
      "char_count": 929,
      "start_char": 180000,
      "end_char": 180930
    },
    {
      "chunk_id": "pfizer_2023_chunk0226",
      "chunk_index": 226,
      "text": "tes with third parties over our attempts to\nmarket pharmaceutical products, including related to Abrysvo, Comirnaty and Paxlovid. As we expand our mRNA portfolio, patent-related disputes may increase. Once we have final\nregulatory approval of the related products, we may decide to commercially market these products even though associated legal proceedings (including any appeals) have not been\nresolved (i.e., “at-risk” launch). If one of our marketed products (or a product of our\n\n2023 Form 10-K\n\ncollaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant\ndamages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is\nfound to have willfully infringed valid patent rights of a third party.\nINFORMATION TECHNOLOGY AND SECURITY",
      "char_count": 969,
      "start_char": 180800,
      "end_char": 181770
    },
    {
      "chunk_id": "pfizer_2023_chunk0227",
      "chunk_index": 227,
      "text": "ced as much as three-fold if we or one of our subsidiaries is\nfound to have willfully infringed valid patent rights of a third party.\nINFORMATION TECHNOLOGY AND SECURITY\nSignificant disruptions of IT systems or breaches of information security could adversely affect our business. We extensively rely upon sophisticated IT systems (including cloud\nservices) to operate our business. We produce, collect, process, store and transmit large amounts of confidential information (including personal information and intellectual\nproperty), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality, integrity and availability of such confidential information. We\ndevelop and operate digital systems to engage patients, healthcare providers, governments, payors and supply chain partners to conduct business and deliver medicines, digital\ndiagnostics, clinical trials and digital therapies.",
      "char_count": 929,
      "start_char": 181600,
      "end_char": 182530
    },
    {
      "chunk_id": "pfizer_2023_chunk0228",
      "chunk_index": 228,
      "text": "and supply chain partners to conduct business and deliver medicines, digital\ndiagnostics, clinical trials and digital therapies. Such systems include mobile applications, wearable devices, internet websites and other digital technologies that may be targets of\nattack. We have outsourced significant elements of our operations, including significant elements of our IT infrastructure and, as a result, we manage relationships with many thirdparty providers who may or could have access to our confidential information. We rely on technology developed, supplied and/or maintained by third-parties that may make us\nvulnerable to “supply chain” style cyber-attacks. Further, technology and security vulnerabilities of acquisitions, business partners or third-party providers may not be identified during\ndue diligence or soon enough to mitigate exploitation.",
      "char_count": 855,
      "start_char": 182400,
      "end_char": 183257
    },
    {
      "chunk_id": "pfizer_2023_chunk0229",
      "chunk_index": 229,
      "text": "g\ndue diligence or soon enough to mitigate exploitation. The size and complexity of our IT and information security systems, and those of our third-party providers (and the large\namounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional\nactions by, but not limited to, our employees, contingent workers, service providers, business partners, customers or malicious attackers. As a global pharmaceutical company, our\nsystems and assets are the target of frequent cyber-attacks. Such cyber-attacks are of ever-increasing levels of sophistication, including the use of adversarial artificial intelligence\ntechniques, and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage, extortion, property destruction and personal",
      "char_count": 906,
      "start_char": 183200,
      "end_char": 184107
    },
    {
      "chunk_id": "pfizer_2023_chunk0230",
      "chunk_index": 230,
      "text": "motives (including, but not limited to, industrial espionage, extortion, property destruction and personal\ninformation theft) and expertise, including, but not limited to, organized criminal groups, “hacktivists,” nation states, employees, business partners and others. Due to the nature of\nsome of these attacks, there is a risk that they may remain undetected for a period of time. While we have invested in the protection of data and IT and develop and maintain\nsystems and controls, our efforts, like those of other similar companies, have not always and may not in the future prevent service interruptions, extortion, theft of confidential,\npersonal or proprietary information, compromise of data integrity or unauthorized information disclosure. Any technology service interruption or breach of our systems could\nadversely affect our business operations and/or result in the loss of personal data, confidential information or intellectual property.",
      "char_count": 954,
      "start_char": 184000,
      "end_char": 184955
    },
    {
      "chunk_id": "pfizer_2023_chunk0231",
      "chunk_index": 231,
      "text": "our systems could\nadversely affect our business operations and/or result in the loss of personal data, confidential information or intellectual property. Such incidents could require disclosure to\ngovernment authorities and/or regulators and could require notification to impacted individuals and any incident could result in financial, legal, business and reputational harm to us.\nWe maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or\nbreach of our systems.\nArtificial intelligence-based software is increasingly being used in the biopharmaceutical and global healthcare industries. As with many developing technologies, artificial\nintelligence-based software presents risks and challenges.",
      "char_count": 825,
      "start_char": 184800,
      "end_char": 185627
    },
    {
      "chunk_id": "pfizer_2023_chunk0232",
      "chunk_index": 232,
      "text": "ents risks and challenges. For example, algorithms may be flawed; data sets may be insufficient, of poor quality, or contain biased information; and\ninappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. If the analyses that artificial intelligence-based applications assist in\nproducing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Furthermore, use of artificial intelligencebased software may lead to the release of confidential information which may impact our ability to realize the benefits of our intellectual property.\nGENERAL RISKS\nBUSINESS DEVELOPMENT ACTIVITIES AND STRATEGIC GOALS\nWe have established significant growth goals, which we plan to achieve, in part, by not only advancing our own product pipelines and maximizing the value of our existing products,",
      "char_count": 914,
      "start_char": 185600,
      "end_char": 186515
    },
    {
      "chunk_id": "pfizer_2023_chunk0233",
      "chunk_index": 233,
      "text": "hieve, in part, by not only advancing our own product pipelines and maximizing the value of our existing products,\nbut also through various forms of business development activities, which can include alliances, licenses, JVs, collaborations, equity- or debt-based investments, dispositions,\ndivestments, mergers and acquisitions. Our recent acquisition of Seagen is part of that growth plan. We view our business development activity as an enabler of our strategies and\nseek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. The success of our business\ndevelopment activities is dependent on the availability and accurate evaluation of appropriate opportunities, competition from others that are seeking similar opportunities and our",
      "char_count": 818,
      "start_char": 186400,
      "end_char": 187219
    },
    {
      "chunk_id": "pfizer_2023_chunk0234",
      "chunk_index": 234,
      "text": "ortunities and our\nability to successfully identify, structure and execute transactions, including the ability to satisfy closing conditions in the anticipated timeframes or at all, and our ability to\nsuccessfully integrate acquired businesses and develop and commercialize acquired products. Pursuing, executing and consummating these transactions may require substantial\ninvestment, which may require us to obtain additional equity or debt financing, which has in the past and could in the future result in increased leverage and/or a downgrade of our\ncredit ratings and could limit our ability to obtain future financing. We have incurred substantial indebtedness to fund our recent acquisition of Seagen. We financed a portion of the\ntransaction with the proceeds from the $31 billion of long-term debt issued in May 2023, plus $8 billion in additional short-term indebtedness issued prior to the acquisition.",
      "char_count": 913,
      "start_char": 187200,
      "end_char": 188114
    },
    {
      "chunk_id": "pfizer_2023_chunk0235",
      "chunk_index": 235,
      "text": "m debt issued in May 2023, plus $8 billion in additional short-term indebtedness issued prior to the acquisition. The\namount of debt that we have incurred could have significant consequences including, among other things, reducing our operating or financial flexibility, requiring a portion of our cash\nflow from operations to make interest payments and reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow our business. To the\nextent we incur additional indebtedness or interest rates increase, these risks could increase further.\nThe success of our business development transactions, including our recent acquisition of Seagen, depends on our ability to realize the anticipated benefits of these transactions\nand is subject to numerous risks and uncertainties, many of which are outside of our control.",
      "char_count": 854,
      "start_char": 188000,
      "end_char": 188855
    },
    {
      "chunk_id": "pfizer_2023_chunk0236",
      "chunk_index": 236,
      "text": "certainties, many of which are outside of our control. Unsuccessful clinical trials, regulatory hurdles and commercialization challenges,\namong other factors, may adversely impact revenue and income contribution from business development transactions, including from acquired products and businesses. We may\nfail to generate expected revenue growth for our existing products, product pipeline and contribution from these transactions or from acquired products or businesses or we may fail\nto achieve anticipated cost savings, such as those expected with respect to Seagen, within expected time frames or at all, which may impact our ability to meet our growth\nobjectives. In certain transactions, we may agree to provide certain transition services for an extended period of time, which may divert our focus and resources that would otherwise\nbe invested into maintaining or growing our business.",
      "char_count": 896,
      "start_char": 188800,
      "end_char": 189697
    },
    {
      "chunk_id": "pfizer_2023_chunk0237",
      "chunk_index": 237,
      "text": "r focus and resources that would otherwise\nbe invested into maintaining or growing our business. Similarly, the accretive impact anticipated from certain transactions may not be realized or may be delayed. Integration of\nacquired products or businesses may result in the loss of key employees, the disruption of ongoing business, including third-party relationships, or inconsistencies in standards,\ncontrols, procedures and policies. Further, while we seek to mitigate risks and liabilities through, among other things, due diligence, we may be exposed to risks and liabilities as a\nresult of business development transactions. There is no assurance that we will be able to acquire attractive businesses or enter into strategic business relationships on favorable\nterms ahead of our competitors, or that such acquisitions or strategic business development relationships will be accretive to earnings or improve our competitive position.\n\n2023 Form 10-K",
      "char_count": 953,
      "start_char": 189600,
      "end_char": 190554
    },
    {
      "chunk_id": "pfizer_2023_chunk0238",
      "chunk_index": 238,
      "text": "that such acquisitions or strategic business development relationships will be accretive to earnings or improve our competitive position.\n\n2023 Form 10-K\n\nWhere we invest in or otherwise obtain debt or equity securities of third parties in connection with business development transactions, such as our ownership interest in Haleon, we\nmay be unable to direct or influence the management, operational decisions and policies of such companies and the value of the acquired securities will fluctuate and may lose\nvalue. Any future distribution or sale of such securities will be subject to prevailing market conditions and other factors, including the size of our ownership stake, at the time of such\ndistribution or sale and there is no assurance as to the price that such securities will ultimately be sold or that such securities will be sold at all.\nPANDEMICS",
      "char_count": 861,
      "start_char": 190400,
      "end_char": 191262
    },
    {
      "chunk_id": "pfizer_2023_chunk0239",
      "chunk_index": 239,
      "text": "e sold or that such securities will be sold at all.\nPANDEMICS\nPandemics, such as the COVID-19 pandemic, have impacted and may in the future impact our business, operations and financial condition and results. Related risks and challenges\nfor our business include, among others: uncertainty regarding the severity and duration of a pandemic; impacts to business operations; decreased demand for certain of our\nproducts; increased costs of doing business; manufacturing disruptions and delays; supply chain disruptions and shortages, including challenges related to reliance on third-party\nsuppliers resulting in reduced availability of materials or components used in the development, manufacturing, distribution or administration of our products; evolving macroeconomic\nfactors and conditions, including general economic uncertainty, unemployment rates and recessionary pressures; changes in labor markets, including challenges related to our",
      "char_count": 942,
      "start_char": 191200,
      "end_char": 192143
    },
    {
      "chunk_id": "pfizer_2023_chunk0240",
      "chunk_index": 240,
      "text": "ing general economic uncertainty, unemployment rates and recessionary pressures; changes in labor markets, including challenges related to our\nhuman capital and talent development; unknown consequences on our business performance and initiatives stemming from the substantial investment of time and other resources\nto any potential pandemic response; increased difficulty and uncertainty regarding predicting or estimating future performance; pace of post-pandemic recovery, disruption and\nvolatility within the financial or credit markets; and our financial performance in general.\nCOVID-19\nThe extent to which COVID-19 impacts our business going forward will depend on many factors, and we have made certain assumptions regarding COVID-19 for purposes of our\noperational planning and financial projections, including assumptions regarding the global macroeconomic impact of COVID-19, as well as the demand, revenues, supply, contracts,",
      "char_count": 937,
      "start_char": 192000,
      "end_char": 192938
    },
    {
      "chunk_id": "pfizer_2023_chunk0241",
      "chunk_index": 241,
      "text": "ections, including assumptions regarding the global macroeconomic impact of COVID-19, as well as the demand, revenues, supply, contracts,\nmarket share and commercial markets for our current or future COVID-19 products, which remain dynamic. Despite careful tracking and planning, we are unable to accurately\npredict the extent of the impact of COVID-19 or our COVID-19 products on our business, operations and financial condition and results due to the uncertainty of future\ndevelopments. COVID-19 or our COVID-19 products may also affect our business, operations or financial condition and results in a manner that is not presently known to us or that\nwe currently do not consider as presenting significant risks.\nWe also face risks and uncertainties related to our efforts to develop and commercialize our COVID-19 products, as well as challenges related to their manufacturing, supply and\ndistribution, including, among others:",
      "char_count": 930,
      "start_char": 192800,
      "end_char": 193731
    },
    {
      "chunk_id": "pfizer_2023_chunk0242",
      "chunk_index": 242,
      "text": "ize our COVID-19 products, as well as challenges related to their manufacturing, supply and\ndistribution, including, among others:\n• the risk that as the market for COVID-19 products becomes more endemic and seasonal, demand for any of our COVID-19 products has and may continue to be reduced or not\nmeet expectations, or may no longer exist, which has and may continue to lead to reduced revenues, excess inventory on-hand and/or in the channel which, for Paxlovid and\nComirnaty, has resulted in significant inventory write-offs in 2023 and could continue to result in inventory write-offs or other unanticipated charges;\n• challenges related to the transition to the commercial market for our COVID-19 products;\n• uncertainties related to the public’s demand for vaccines, boosters and COVID-19 treatments;\n• risks related to our ability to accurately forecast and achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments;",
      "char_count": 980,
      "start_char": 193600,
      "end_char": 194581
    },
    {
      "chunk_id": "pfizer_2023_chunk0243",
      "chunk_index": 243,
      "text": "atments;\n• risks related to our ability to accurately forecast and achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments;\n• uncertainties inherent in R&D, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates,\nregulatory approval dates and/or launch dates, as well as risks associated with pre-clinical and clinical data (including Phase 1/2/3 or Phase 4 data for Comirnaty or any vaccine\ncandidate in the BNT162 program or Paxlovid or any future COVID-19 treatment) in any of our studies in pediatrics, adolescents or adults or real world evidence, including the\npossibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of\npre-clinical, clinical or safety data, including by audit or inspection;",
      "char_count": 977,
      "start_char": 194400,
      "end_char": 195378
    },
    {
      "chunk_id": "pfizer_2023_chunk0244",
      "chunk_index": 244,
      "text": "alyses of existing pre-clinical, clinical or safety data or further information regarding the quality of\npre-clinical, clinical or safety data, including by audit or inspection;\n• the ability to produce comparable clinical or other results for Comirnaty, any vaccine candidate or other vaccines that may result from the BNT162 program, Paxlovid or any future\nCOVID-19 treatment or any other COVID-19 program, including the rate of effectiveness and/or efficacy, safety and tolerability profile observed to date, in additional analyses of\nthe Phase 3 trial for any such products and additional studies, in real-world data studies or in larger, more diverse populations following commercialization;\n• the ability of Comirnaty or any future vaccine to prevent, or Paxlovid or any future COVID-19 treatment to be effective against, COVID-19 caused by emerging virus variants;",
      "char_count": 871,
      "start_char": 195200,
      "end_char": 196072
    },
    {
      "chunk_id": "pfizer_2023_chunk0245",
      "chunk_index": 245,
      "text": "nt to be effective against, COVID-19 caused by emerging virus variants;\n• the risk that use of Comirnaty or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of\nwhich may be serious;\n• the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific\ncommunity generally, and by regulatory authorities;\n• whether and when additional data from the BNT162 program, Paxlovid or other COVID-19 programs will be published in scientific journal publications and, if so, when and with\nwhat modifications and interpretations;\n• whether regulatory authorities will be satisfied with the design of and results from existing or future pre-clinical and clinical studies;",
      "char_count": 864,
      "start_char": 196000,
      "end_char": 196865
    },
    {
      "chunk_id": "pfizer_2023_chunk0246",
      "chunk_index": 246,
      "text": "sults from existing or future pre-clinical and clinical studies;\n• whether and when submissions to request emergency use or conditional marketing authorizations for Comirnaty or any future vaccines in additional populations, for a potential\nbooster dose for Comirnaty, or any potential future vaccine or vaccine candidates (including potential future annual boosters or re-vaccinations), and/or biologics license and/or\nEUA applications or amendments to any such applications may be filed in particular jurisdictions for Comirnaty or any other potential vaccine or vaccine candidates, and if\nobtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate;\n• whether and when submissions to request emergency use or conditional marketing authorizations for Paxlovid or any future COVID-19 treatment and/or any drug applications",
      "char_count": 854,
      "start_char": 196800,
      "end_char": 197655
    },
    {
      "chunk_id": "pfizer_2023_chunk0247",
      "chunk_index": 247,
      "text": "future COVID-19 treatment and/or any drug applications\nand/or EUA applications or amendments to any such applications for any indication for Paxlovid or any future COVID-19 treatment may be filed in particular jurisdictions, and if\nobtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate;\n• whether and when any application that may be pending or filed for Comirnaty, any vaccine candidate or other vaccines that may result from the BNT162 program, Paxlovid or any\nfuture COVID-19 treatment or any other COVID-19 program may be approved by particular regulatory\n\n2023 Form 10-K\n\nauthorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s or drug’s benefits outweigh its known risks and determination of the\nvaccine’s or drug’s efficacy and, if approved, whether it will be commercially successful;",
      "char_count": 884,
      "start_char": 197600,
      "end_char": 198485
    },
    {
      "chunk_id": "pfizer_2023_chunk0248",
      "chunk_index": 248,
      "text": "e’s or drug’s efficacy and, if approved, whether it will be commercially successful;\n• decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential\nof any vaccine or drug, including the authorization or approval of products or therapies developed by other companies;\n• disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including our relationship with BioNTech;\n• the risk that other companies may produce competitive products that may be superior in terms of efficacy, safety, affordability, convenience, or a number of other competitive\nfactors;\n• risks related to the availability or cost of raw materials to manufacture or test any such products;",
      "char_count": 842,
      "start_char": 198400,
      "end_char": 199243
    },
    {
      "chunk_id": "pfizer_2023_chunk0249",
      "chunk_index": 249,
      "text": "to manufacture or test any such products;\n• challenges related to our vaccine’s formulation and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by\nus;\n• challenges and risks related to medication errors such as prescribing or dispensing the wrong strength, improper dosing and self-administration errors;\n• the risk that we may not be able to successfully develop other vaccine formulations, booster doses or potential future vaccines, potential combination respiratory vaccines or next\ngeneration COVID-19 treatments;\n• the risk that we may not be able to recoup costs associated with our R&D and manufacturing efforts;\n• risks associated with any changes in the way we approach or provide research funding for the BNT162 program, Paxlovid or any other COVID-19 program;\n• challenges and risks associated with the pace of our development programs;",
      "char_count": 928,
      "start_char": 199200,
      "end_char": 200130
    },
    {
      "chunk_id": "pfizer_2023_chunk0250",
      "chunk_index": 250,
      "text": "162 program, Paxlovid or any other COVID-19 program;\n• challenges and risks associated with the pace of our development programs;\n• the risk that we may not be able to maintain manufacturing capacity or access to logistics or supply channels commensurate with global demand for our COVID-19 products,\nwhich would negatively impact our ability to supply our COVID-19 products within the projected time periods;\n• whether and when additional supply or purchase agreements will be reached or existing agreements will be modified;\n• uncertainties regarding the ability to obtain recommendations from vaccine or treatment advisory or technical committees and other public health authorities and uncertainties\nregarding the commercial impact of any such recommendations;\n• pricing and access challenges for such products;\n• challenges related to public confidence in, or awareness of Comirnaty, Paxlovid or any future COVID-19 product candidates, including challenges driven by misinformation or",
      "char_count": 989,
      "start_char": 200000,
      "end_char": 200990
    },
    {
      "chunk_id": "pfizer_2023_chunk0251",
      "chunk_index": 251,
      "text": "such products;\n• challenges related to public confidence in, or awareness of Comirnaty, Paxlovid or any future COVID-19 product candidates, including challenges driven by misinformation or\ndisinformation, access, concerns about clinical data integrity, or prescriber and pharmacy education;\n• trade restrictions; and\n• the risk that we may owe third-party royalties or other adverse outcomes from existing litigation related to Comirnaty and Paxlovid, or have additional other claims asserted related\nto Comirnaty or Paxlovid.\nCertain of these risks and uncertainties also apply to our COVID-19 and influenza diagnostic tests.\nCLIMATE CHANGE AND SUSTAINABILITY\n\nin increased energy prices; customer preference for low or no-carbon products; stakeholder pressure to decarbonize assets; or new legal or regulatory requirements that result in\nnew or expanded carbon pricing, taxes, restrictions on greenhouse gas emissions, and increased greenhouse gas disclosure and transparency.",
      "char_count": 978,
      "start_char": 200800,
      "end_char": 201780
    },
    {
      "chunk_id": "pfizer_2023_chunk0252",
      "chunk_index": 252,
      "text": "r regulatory requirements that result in\nnew or expanded carbon pricing, taxes, restrictions on greenhouse gas emissions, and increased greenhouse gas disclosure and transparency. These risks could increase operating\ncosts, including the cost of our electricity and energy use, or otherwise increase compliance costs. Physical risks to our operations include water stress and drought; flooding and\nstorm surge; wildfires; extreme temperatures and storms, which could impact pharmaceutical production, increase costs, or disrupt supply chains of medicines for patients. For\nexample, our manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. While manufacturing has resumed, the supply of medicines impacted by the\ntornado is expected to be affected through 2024. For additional details on the impact of the tornado in Rocky Mount, NC, see the Overview of Our Performance, Operating\nEnvironment, Strategy and Outlook—Our Operating Environment section within MD&A.",
      "char_count": 988,
      "start_char": 201600,
      "end_char": 202589
    },
    {
      "chunk_id": "pfizer_2023_chunk0253",
      "chunk_index": 253,
      "text": "nal details on the impact of the tornado in Rocky Mount, NC, see the Overview of Our Performance, Operating\nEnvironment, Strategy and Outlook—Our Operating Environment section within MD&A. Our supply chain is subject to these same transitional and physical risks and would likely\npass along any increased costs to us.\nIn June 2022, Pfizer established our fourth consecutive greenhouse gas reduction goal with new near- and long-term targets to achieve the Science Based Target Initiative’s\nvoluntary Net-Zero Standard by 2040. While we are working to develop and implement emission reduction plans to achieve our voluntary climate goals, various factors, including the\nlong time horizons and commercial availability of new technologies to enable the emission reductions, in the time and scale needed, may present inherent risk in our ability to meet\nthese goals.",
      "char_count": 862,
      "start_char": 202400,
      "end_char": 203263
    },
    {
      "chunk_id": "pfizer_2023_chunk0254",
      "chunk_index": 254,
      "text": "may present inherent risk in our ability to meet\nthese goals. Additionally, success may depend on the actions of governments and third parties and may require, among other things, significant capital investment; R&D; and\ngovernment policies and incentives to foster innovation and reduce costs of technologies that may not currently exist or be available at scale.\nGovernmental authorities, non-governmental organizations, customers, investors, employees, and other stakeholders are increasingly sensitive to ESG matters, such as equitable\naccess to medicines and vaccines, product quality and safety, diversity, equity and inclusion, environmental stewardship, support for local communities, value chain environmental\nand social due diligence, corporate governance and transparency, and addressing human capital factors in our operations.",
      "char_count": 839,
      "start_char": 203200,
      "end_char": 204041
    },
    {
      "chunk_id": "pfizer_2023_chunk0255",
      "chunk_index": 255,
      "text": "human capital factors in our operations. In addition, governments and the public expect\ncompanies like us to report on our business practices with respect to human rights, responsible sourcing and environmental impact, as well as the actions of our third-party\ncontractors and suppliers around the world. This focus on ESG matters may lead to new expectations or requirements that could result in increased costs associated with research,\ndevelopment, manufacture, or distribution of our products. Our ability to compete could also be affected by changing customer preferences and requirements, such as growing\ndemand for companies to establish validated Net Zero targets or offer more sustainable products. While we strive to improve our ESG performance and meet our voluntary goals, if\nwe do not meet, or are perceived not to meet, our goals or other stakeholder expectations in key ESG areas, we risk negative stakeholder reaction, including from proxy advisory",
      "char_count": 964,
      "start_char": 204000,
      "end_char": 204965
    },
    {
      "chunk_id": "pfizer_2023_chunk0256",
      "chunk_index": 256,
      "text": "et, or are perceived not to meet, our goals or other stakeholder expectations in key ESG areas, we risk negative stakeholder reaction, including from proxy advisory\nservices, as well as damage to our brand and reputation, reduced demand for our products or other negative impacts on our business and operations. While we monitor a broad\nrange of ESG matters, we cannot be certain that we will manage such matters successfully, or that we will successfully meet the expectations of investors, employees, consumers,\ngovernments and other stakeholders.\n\n2023 Form 10-K\n\nMARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS\nChanges in the fair value of certain equity investments that are recognized in net income may result in increased volatility of our income. See Note 4 and the Analysis of Financial\nCondition, Liquidity, Capital Resources and Market Risk section within MD&A.",
      "char_count": 880,
      "start_char": 204800,
      "end_char": 205681
    },
    {
      "chunk_id": "pfizer_2023_chunk0257",
      "chunk_index": 257,
      "text": "ial\nCondition, Liquidity, Capital Resources and Market Risk section within MD&A.\nOur pension benefit obligations and postretirement benefit obligations are subject to volatility from changes in the fair value of equity investments and other investment risk in the\nassets funding these plans, as well as changes in the appropriate discount rate. See the Significant Accounting Policies and Application of Critical Accounting Estimates and\nAssumptions—Benefit Plans section within MD&A and Note 11.\nCOST AND EXPENSE CONTROL AND NONORDINARY EVENTS\nGrowth in costs and expenses, changes in product and geographic mix and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product withdrawals,\nrecalls and other unusual events that could result from evolving business strategies, evaluation of asset realization and organizational restructuring could adversely affect future\nresults.",
      "char_count": 911,
      "start_char": 205600,
      "end_char": 206512
    },
    {
      "chunk_id": "pfizer_2023_chunk0258",
      "chunk_index": 258,
      "text": "tegies, evaluation of asset realization and organizational restructuring could adversely affect future\nresults. Such risks and uncertainties include, in particular, our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including our enterprise-wide\ncost realignment program, other corporate strategic initiatives and any acquisitions, divestitures or other initiatives, as well as potential disruption of ongoing business, such as\npotential impacts on our ability to deliver on our pipeline as planned. Additionally, as a result of these initiatives, we may experience a loss of continuity, loss of accumulated\nknowledge or intellectual property and/or inefficiency, adverse effects on employee morale, loss of key employees and/or other retention issues during transitional periods.\nReorganizations and restructurings can require a significant amount of time and focus, which may divert attention from operating and growing our business.",
      "char_count": 982,
      "start_char": 206400,
      "end_char": 207383
    },
    {
      "chunk_id": "pfizer_2023_chunk0259",
      "chunk_index": 259,
      "text": "uring transitional periods.\nReorganizations and restructurings can require a significant amount of time and focus, which may divert attention from operating and growing our business. If we fail to achieve\nsome or all of the expected benefits of restructuring, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash\nflows.\nINTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS\nOur consolidated balance sheet contains significant amounts of intangible assets, including IPR&D and goodwill. For IPR&D assets, the risk of failure is significant, and there can be\nno certainty that these assets ultimately will yield successful products. Our ability to realize value on these significant investments is often contingent upon, among other things,\nregulatory approvals and market acceptance.",
      "char_count": 864,
      "start_char": 207200,
      "end_char": 208065
    },
    {
      "chunk_id": "pfizer_2023_chunk0260",
      "chunk_index": 260,
      "text": "among other things,\nregulatory approvals and market acceptance. As such, IPR&D assets may become impaired and/or be written off in the future if the associated R&D effort is abandoned or is\ncurtailed. See Note 4 for a discussion of recent impairments of IPR&D assets. For goodwill, all reporting units can confront events and circumstances that can lead to a goodwill\nimpairment charge such as, among other things, unanticipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in the\nbusiness climate and/or a failure to replace the contributions of products that lose exclusivity. Our other intangible assets, including developed technology rights and brands, face\nsimilar risks for impairment. Our equity-method investments may also be subject to impairment charges that may result from the occurrence of unexpected adverse events or",
      "char_count": 897,
      "start_char": 208000,
      "end_char": 208899
    },
    {
      "chunk_id": "pfizer_2023_chunk0261",
      "chunk_index": 261,
      "text": "subject to impairment charges that may result from the occurrence of unexpected adverse events or\nmanagement decisions that impact our estimates of expected cash flows to be generated from these investments. We may recognize impairment charges as a result of a weak\neconomic environment, events related to particular customers or asset types, challenging market conditions or decisions by management. Any such impairment charge of our\nintangible assets, goodwill and equity-method investments may be significant. For additional details, see the Significant Accounting Policies and Application of Critical Accounting\nEstimates and Assumptions—Asset Impairments section within MD&A.\nCHANGES IN LAWS AND ACCOUNTING STANDARDS\nOur future results could be adversely affected by changes in laws and regulations or their interpretation, including, among others, changes in accounting standards, tax laws and\nregulations internationally and in the U.S.",
      "char_count": 943,
      "start_char": 208800,
      "end_char": 209745
    },
    {
      "chunk_id": "pfizer_2023_chunk0262",
      "chunk_index": 262,
      "text": "ions or their interpretation, including, among others, changes in accounting standards, tax laws and\nregulations internationally and in the U.S. (including, among other things, the IRA, changes in laws and regulations or their interpretation, including, among others, the adoption of\nglobal minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024 and potential changes to existing tax law by the current U.S.\nPresidential administration and Congress, including the proposed “Tax Relief for American Families and Workers Act of 2024”), competition laws, privacy laws and environmental\nlaws in the U.S. and other countries. For additional information on changes in tax laws or rates or accounting standards, see the Provision/(Benefit) for Taxes on Income and New\nAccounting Standards sections within MD&A and Note 1B.\nITEM 1C.\nCYBERSECURITY\nManaging cybersecurity risk is a crucial part of our overall strategy for safely operating our business.",
      "char_count": 999,
      "start_char": 209600,
      "end_char": 210600
    },
    {
      "chunk_id": "pfizer_2023_chunk0263",
      "chunk_index": 263,
      "text": "n Income and New\nAccounting Standards sections within MD&A and Note 1B.\nITEM 1C.\nCYBERSECURITY\nManaging cybersecurity risk is a crucial part of our overall strategy for safely operating our business. We incorporate cybersecurity practices into our Enterprise Risk Management\n(ERM) approach, which is subject to oversight by our BOD. Our cybersecurity policies and practices are aligned with relevant industry standards.\nConsistent with our overall ERM program and practices, our cybersecurity program includes:\n• Vigilance: We maintain a global cybersecurity operation that endeavors to detect, prevent, contain, and respond to cybersecurity threats and incidents in a prompt and effective\nmanner with the goal of minimizing business disruptions.\n• External Collaboration: We collaborate with public and private entities, including intelligence and law enforcement agencies, industry groups and third-party service providers to\nidentify, assess and mitigate cybersecurity risks.",
      "char_count": 978,
      "start_char": 210400,
      "end_char": 211379
    },
    {
      "chunk_id": "pfizer_2023_chunk0264",
      "chunk_index": 264,
      "text": "and private entities, including intelligence and law enforcement agencies, industry groups and third-party service providers to\nidentify, assess and mitigate cybersecurity risks.\n• Systems Safeguards: We deploy technical safeguards that are designed to protect our information systems, products, operations and sensitive information from cybersecurity\nthreats. These include firewalls, intrusion prevention and detection systems, disaster recovery capabilities, malware and ransomware prevention, access controls and data\nprotection. We continuously conduct vulnerability assessments to identify new risks and periodically test the efficacy of our safeguards through both internal and external\npenetration tests.\n• Education: We provide periodic training for all personnel regarding cybersecurity threats, with such training appropriate to the roles, responsibilities and access of the relevant\nCompany personnel.",
      "char_count": 913,
      "start_char": 211200,
      "end_char": 212114
    },
    {
      "chunk_id": "pfizer_2023_chunk0265",
      "chunk_index": 265,
      "text": "eats, with such training appropriate to the roles, responsibilities and access of the relevant\nCompany personnel. Our policies require all workers to report any real or suspected cybersecurity events.\n• Supplier Ecosystem Management: We extend our cybersecurity management control expectations to our supply chain ecosystem, as applicable. This includes identifying\ncybersecurity risks presented by third parties.\n• Incident Response Planning: We have established, and maintain and periodically test, incident response plans that direct our response to cybersecurity events and incidents.\nSuch plans include the protocol by which material incidents would be communicated to executive management, our BOD, external regulators and shareholders.\n• Enterprise-Wide Coordination: We engage experts from across the Company to identify emerging risks and respond to cybersecurity threats.",
      "char_count": 881,
      "start_char": 212000,
      "end_char": 212882
    },
    {
      "chunk_id": "pfizer_2023_chunk0266",
      "chunk_index": 266,
      "text": "ross the Company to identify emerging risks and respond to cybersecurity threats. This cross-functional approach\nincludes personnel from our R&D, manufacturing, commercial, technology, legal, compliance, internal audit and other business functions.\n\n2023 Form 10-K\n\n• Governance: Our BOD’s oversight of cybersecurity risk management is led by the Audit Committee, which oversees our ERM program. Cybersecurity threats, risks and mitigation\nare periodically reviewed by the Audit Committee and such reviews include both internal and independent assessment of risks, controls and effectiveness.\nOur risk assessment efforts have indicated that we are a target for theft of intellectual property, financial resources, personal information, and trade secrets from a wide range of\nactors including nation states, organized crime, malicious insiders and activists.",
      "char_count": 857,
      "start_char": 212800,
      "end_char": 213658
    },
    {
      "chunk_id": "pfizer_2023_chunk0267",
      "chunk_index": 267,
      "text": "tates, organized crime, malicious insiders and activists. The impacts of attacks, abuse and misuse of Pfizer’s systems and information include, without\nlimitation, loss of assets, operational disruption and damage to Pfizer’s reputation.\nA key element of managing cybersecurity risk is the ongoing assessment and testing of our processes and practices through auditing, assessments, drills and other exercises\nfocused on evaluating the sufficiency and effectiveness of our risk mitigation. We regularly engage third parties to perform assessments of our cybersecurity measures, including\ninformation security maturity assessments and independent reviews of our information security control environment and operating effectiveness. Certain results of such assessments\nand reviews are reported to the Audit Committee and the BOD, as appropriate, and we make adjustments to our cybersecurity processes and practices as necessary based on the",
      "char_count": 938,
      "start_char": 213600,
      "end_char": 214539
    },
    {
      "chunk_id": "pfizer_2023_chunk0268",
      "chunk_index": 268,
      "text": "udit Committee and the BOD, as appropriate, and we make adjustments to our cybersecurity processes and practices as necessary based on the\ninformation provided by the third-party assessments and reviews.\nThe Audit Committee oversees cybersecurity risk management, including the policies, processes and practices that management implements to prevent, detect and address risks\nfrom cybersecurity threats. The Audit Committee receives regular briefings on cybersecurity risks and risk management practices, including, for example, recent developments in the\nexternal cybersecurity threat landscape, evolving standards, vulnerability assessments, third-party and independent reviews, technological trends and considerations arising from\nour supplier ecosystem. The Audit Committee may also promptly receive information regarding any material cybersecurity incident that may occur, including any ongoing updates\nregarding the same.",
      "char_count": 927,
      "start_char": 214400,
      "end_char": 215328
    },
    {
      "chunk_id": "pfizer_2023_chunk0269",
      "chunk_index": 269,
      "text": "ive information regarding any material cybersecurity incident that may occur, including any ongoing updates\nregarding the same. The Audit Committee periodically discusses our approach to cybersecurity risk management with our Chief Information Security Officer (CISO).\nOur CISO is a member of our management team who is principally responsible for overseeing our cybersecurity risk management program, in partnership with other business\nleaders across the Company. The CISO works in coordination with other members of the management team, including, among others, the Chief Digital Officer, the Chief Financial\nOfficer, the Chief Compliance and Risk Officer and the General Counsel and their designees. We believe our business leaders have the appropriate expertise, background and\ndepth of experience to manage risks arising from cybersecurity threats.",
      "char_count": 853,
      "start_char": 215200,
      "end_char": 216054
    },
    {
      "chunk_id": "pfizer_2023_chunk0270",
      "chunk_index": 270,
      "text": "e to manage risks arising from cybersecurity threats.\nOur CISO, along with leaders from our privacy and corporate compliance functions, collaborate to implement a program designed to manage our exposure to cybersecurity risks and\nto promptly respond to cybersecurity incidents. Prompt response to incidents is delivered by multi-disciplinary teams in accordance with our incident response plan. Through ongoing\ncommunications with these teams during incidents, the CISO monitors the triage, mitigation and remediation of cybersecurity incidents, and reports such incidents to executive\nmanagement, the Audit Committee and other Pfizer colleagues in accordance with our cybersecurity policies and procedures, as is appropriate.\nAs of the date of this Form 10-K, we are not aware of any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the Company, including our\nbusiness strategy, results of operations, or financial condition at this time.",
      "char_count": 990,
      "start_char": 216000,
      "end_char": 216991
    },
    {
      "chunk_id": "pfizer_2023_chunk0271",
      "chunk_index": 271,
      "text": "ncidents that have materially affected or are reasonably likely to materially affect the Company, including our\nbusiness strategy, results of operations, or financial condition at this time. For further discussion of the risks associated with cybersecurity incidents, see the Item 1A. Risk Factors—\nInformation Technology and Security section in this Form 10-K.\nITEM 2.\nPROPERTIES\nWe own and lease space globally for sales and marketing, customer service, regulatory compliance, R&D, manufacturing and distribution and corporate enabling functions. In many\nlocations, our business and operations are co-located to achieve synergy and operational efficiencies. Our global headquarters are located in New York City. We continue to advance\nour global workplace strategy to provide workplaces that enable collaboration and foster innovation.",
      "char_count": 837,
      "start_char": 216800,
      "end_char": 217638
    },
    {
      "chunk_id": "pfizer_2023_chunk0272",
      "chunk_index": 272,
      "text": "collaboration and foster innovation. As of December 31, 2023, we had 284 owned and leased properties (including\nproperties acquired in the Seagen acquisition), amounting to approximately 38 million square feet. The recent Seagen acquisition has increased our real estate portfolio by 14 sites\ntotaling 1 million square feet.\nAs of December 31, 2023, of the 284 properties, PGS had responsibility for 37 plants around the world, which manufacture products for our commercial divisions, including in\nBelgium, Germany, India, Ireland, Italy, Japan, Singapore and the U.S. The leadership team for PGS is primarily located in New York City. PGS also operates multiple distribution\nfacilities around the world.\nIn general, we believe that our properties, including the principal properties described above, are well-maintained, adequate and suitable for their current requirements and for our\noperations in the foreseeable future.",
      "char_count": 924,
      "start_char": 217600,
      "end_char": 218526
    },
    {
      "chunk_id": "pfizer_2023_chunk0273",
      "chunk_index": 273,
      "text": ", are well-maintained, adequate and suitable for their current requirements and for our\noperations in the foreseeable future. See Note 9 for amounts invested in land, buildings and equipment.\nITEM 3.\nLEGAL PROCEEDINGS\nCertain legal proceedings in which we are involved are discussed in Note 16A.\n\n2023 Form 10-K\n\nINFORMATION ABOUT OUR EXECUTIVE OFFICERS\nThe executive officers of the Company are set forth in this table. Each holds the office or offices indicated until his or her successor is chosen and qualified at the regular meeting of\nthe BOD to be held on the date of the 2024 Annual Meeting of Shareholders, or until his or her earlier death, resignation or removal. Each of the executive officers is a member of\nthe Pfizer Executive Leadership Team.\nName\nAge\nPosition\nAlbert Bourla\n\nChairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018\nuntil December 2018.",
      "char_count": 943,
      "start_char": 218400,
      "end_char": 219344
    },
    {
      "chunk_id": "pfizer_2023_chunk0274",
      "chunk_index": 274,
      "text": "of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018\nuntil December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global\nInnovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June\n2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Our Director\nsince February 2018.\nChris Boshoff\n\nChief Oncology Officer, Executive Vice President since December 2023. Chief Oncology Research and Development Officer and\nExecutive Vice President from July 2023 until December 2023. Senior Vice President, Oncology, from 2017 until 2023.\nDavid M. Denton\n\nChief Financial Officer, Executive Vice President since May 2022.",
      "char_count": 857,
      "start_char": 219200,
      "end_char": 220059
    },
    {
      "chunk_id": "pfizer_2023_chunk0275",
      "chunk_index": 275,
      "text": "inancial Officer, Executive Vice President since May 2022. Executive Vice President, Chief Financial Officer, Lowe’s Companies,\nInc., from November 2018 until April 2022; Executive Vice President and Chief Financial Officer, CVS Health Corporation (a diversified\nhealth solutions company), from January 2010 until November 2018. Director of Tapestry, Inc. from 2014 to 2023. Director of Haleon plc.\nAlexandre de Germay\n\nChief International Commercial Officer, Executive Vice President since December 2023. Chief Executive Officer, Laboratoires Majorelle (a\nspecialty pharma company based in France dedicated to women’s health and urology) from 2021 until January 2024 (assisting with\ntransition matters after December 15, 2023). From 2020 until 2021 was Senior Vice President; Global Franchise Head of Cardiology,\nTransplant and Established Products, and from 2016 until 2020 was Head of Mature Markets General Medicines of Sanofi. Regional\nPresident of Asia-Pacific of Pfizer Inc.",
      "char_count": 981,
      "start_char": 220000,
      "end_char": 220982
    },
    {
      "chunk_id": "pfizer_2023_chunk0276",
      "chunk_index": 276,
      "text": "f Cardiology,\nTransplant and Established Products, and from 2016 until 2020 was Head of Mature Markets General Medicines of Sanofi. Regional\nPresident of Asia-Pacific of Pfizer Inc. from 2013 until 2016.\nMikael Dolsten\n\nChief Scientific Officer, President, Pfizer Research and Development since July 2023. Chief Scientific Officer and President, Worldwide\nResearch, Development and Medical from January 2019 until July 2023. President of Worldwide Research and Development from\nDecember 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until\nDecember 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until\nMay 2010. Director of Agilent Technologies, Inc, and Vimian Group AB.\nLidia Fonseca",
      "char_count": 814,
      "start_char": 220800,
      "end_char": 221615
    },
    {
      "chunk_id": "pfizer_2023_chunk0277",
      "chunk_index": 277,
      "text": "Lidia Fonseca\n\nChief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer and Senior Vice President of\nQuest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of Laboratory Corporation of America Holdings from 2008 until\nMarch 2013. Director of Tegna, Inc. from 2014 to 2023. Director of Medtronic plc.\nRady A. Johnson\n\nChief Compliance, Quality and Risk Officer, Executive Vice President since January 2019. Executive Vice President, Chief Compliance\nand Risk Officer from December 2013 until December 2018. Senior Vice President and Associate General Counsel from October 2006\nuntil December 2013.\nDouglas M. Lankler\n\nGeneral Counsel, Executive Vice President since December 2013. Corporate Secretary from January 2014 until February 2014.\nExecutive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013.\nAamir Malik",
      "char_count": 919,
      "start_char": 221600,
      "end_char": 222521
    },
    {
      "chunk_id": "pfizer_2023_chunk0278",
      "chunk_index": 278,
      "text": "ry 2014.\nExecutive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013.\nAamir Malik\n\nChief U.S. Commercial Officer, Executive Vice President since December 2023. Chief Business Innovation Officer, Executive Vice\nPresident from August 2021 until December 2023. Various U.S. geographic leadership roles with McKinsey & Company from 2019 to\n2021; previously co-led McKinsey & Company’s Global Pharmaceuticals & Medical Products practice from 2015 to 2018.\nMichael McDermott\n\nChief Global Supply Officer, Executive Vice President since January 2022. President of Pfizer Global Supply from 2018 until 2021. Vice\nPresident of Pfizer Global Supply from 2014 until 2018. Vice President of the Biotechnology Unit from 2012 until 2014.\nPayal Sahni\n\nChief People Experience Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice\nPresident from June 2020 to December 2021.",
      "char_count": 942,
      "start_char": 222400,
      "end_char": 223343
    },
    {
      "chunk_id": "pfizer_2023_chunk0279",
      "chunk_index": 279,
      "text": "Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice\nPresident from June 2020 to December 2021. From May 2016 until June 2020 served as Senior Vice President of Human Resources for\nmultiple operating units. Vice President of Human Resources, Vaccines, Oncology & Consumer from 2015 until 2016. Ms. Sahni has\nserved in a number of positions in the Human Resources organization with increasing responsibility since joining Pfizer in 1997.\nSally Susman\n\nChief Corporate Affairs Officer, Executive Vice President since January 2019. Executive Vice President, Corporate Affairs (formerly Policy,\nExternal Affairs and Communications) from December 2010 until December 2018. Senior Vice President, Policy, External Affairs and\nCommunications from December 2009 until December 2010.\n\n2023 Form 10-K",
      "char_count": 837,
      "start_char": 223200,
      "end_char": 224038
    },
    {
      "chunk_id": "pfizer_2023_chunk0280",
      "chunk_index": 280,
      "text": "until December 2010.\n\n2023 Form 10-K\n\nPART II\nITEM 5.\nMARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES\nOF EQUITY SECURITIES\nThe principal market for our common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol “PFE”. As of February 15, 2024, there were 123,387\nholders of record of our common stock.\nThe following summarizes purchases of our common stock during the fourth quarter of 2023 :\nPeriod\nTotal Number\nof Shares\nPurchased\nAverage Price\nPaid per\n Share\nTotal Number of\nShares Purchased as\nPart of Publicly\n Announced Plan\nApproximate Value of\nShares\nthat May Yet Be\nPurchased\n Under the Plan\nOctober 2 through October 29, 2023\n12,222\n32.93 \n3,292,882,444 \nOctober 30 through November 30, 2023\n25,825\n29.95 \n3,292,882,444 \nDecember 1 through December 31, 2023\n14,449\n28.58 \n3,292,882,444 \nTotal\n52,496 \n30.26 \nSee Note 12.",
      "char_count": 901,
      "start_char": 224000,
      "end_char": 224903
    },
    {
      "chunk_id": "pfizer_2023_chunk0281",
      "chunk_index": 281,
      "text": "4 \nDecember 1 through December 31, 2023\n14,449\n28.58 \n3,292,882,444 \nTotal\n52,496 \n30.26 \nSee Note 12.\nRepresents (i) 49,685 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii)\nthe open market purchase by the trustee of 2,811 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of\nperformance share awards.\nPEER GROUP PERFORMANCE GRAPH\nThe following graph assumes a $100 investment on December 31, 2018, and reinvestment of all dividends, in each of the Company’s Common Stock, a composite peer group of the\nmajor U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc,",
      "char_count": 894,
      "start_char": 224800,
      "end_char": 225695
    },
    {
      "chunk_id": "pfizer_2023_chunk0282",
      "chunk_index": 282,
      "text": "c., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc,\nJohnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Roche Holding AG and Sanofi SA, the S&P 500 Index and the NYSE Arca Pharmaceutical Index (DRG index).\nFive Year Performance\n\nPFIZER \n$100.0\n$93.1\n$96.3\n$160.5\n$143.8\n$84.5\nPEER GROUP\n$100.0\n$122.0\n$128.7\n$154.4\n$179.9\n$207.8\nS&P 500 \n$100.0\n$131.5\n$155.6\n$200.3\n$164.0\n$207.0\nDRG Index\n$100.0\n$118.4\n$128.7\n$158.8\n$171.1\n$184.3\nITEM 6.\n[RESERVED]\n(a)\n(b)\n(b)\n(a)\n(a)\n(b)\n\n2023 Form 10-K\n\nITEM 7.\nMANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS\nGENERAL\nThe following MD&A is intended to assist the reader in understanding our financial condition and results of operations, including an evaluation of the amounts and certainty of cash",
      "char_count": 830,
      "start_char": 225600,
      "end_char": 226431
    },
    {
      "chunk_id": "pfizer_2023_chunk0283",
      "chunk_index": 283,
      "text": "amounts and certainty of cash\nflows from operations and from outside sources, and is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related notes\nin Item 8. Financial Statements and Supplementary Data in this Form 10-K. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 that are not included\nin this Form 10-K can be found within MD&A in our 2022 Form 10-K.\nOVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK\nFinancial Highlights––The following is a summary of certain financial performance metrics (in billions, except per share data):\n2023 Total Revenues––$58.5 billion\n2023 Net Cash Flow from Operations––$8.7 billion\nA decrease of 42% compared to 2022\nA decrease of 70% compared to 2022\n2023 Reported Diluted EPS––$0.37\n2023 Adjusted Diluted EPS (Non-GAAP)––$1.84*\nA decrease of 93% compared to 2022\nA decrease of 72% compared to 2022",
      "char_count": 949,
      "start_char": 226400,
      "end_char": 227351
    },
    {
      "chunk_id": "pfizer_2023_chunk0284",
      "chunk_index": 284,
      "text": "22\n2023 Reported Diluted EPS––$0.37\n2023 Adjusted Diluted EPS (Non-GAAP)––$1.84*\nA decrease of 93% compared to 2022\nA decrease of 72% compared to 2022\nFor additional information regarding Adjusted diluted EPS (which is a non-GAAP financial measure), including reconciliations of certain GAAP Reported to non-GAAP Adjusted information, see the NonGAAP Financial Measure: Adjusted Income section within MD&A.\nReferences to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of\nour business, they are not within our control and since they can mask positive or negative trends in the business, we believe presenting operational variances excluding these\nforeign exchange changes provides useful information to evaluate our results.\nOur Business and Strategy––Pfizer Inc. is a research-based, global biopharmaceutical company.",
      "char_count": 929,
      "start_char": 227200,
      "end_char": 228130
    },
    {
      "chunk_id": "pfizer_2023_chunk0285",
      "chunk_index": 285,
      "text": "nformation to evaluate our results.\nOur Business and Strategy––Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that\nextend and significantly improve their lives. See the Item 1. Business––About Pfizer section. As a science-driven global biopharmaceutical company, we remain focused on\nadvancing our pipeline, supporting our marketed brands and deploying capital responsibly, with a focus on initiatives that can help contribute to our long-term revenue and future\ngrowth. Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for\nhealthcare providers and patients and continuously evaluate how we can best collaborate with patients, physicians and payors to support and expand patient access to reliable,\naffordable healthcare around the world.",
      "char_count": 936,
      "start_char": 228000,
      "end_char": 228937
    },
    {
      "chunk_id": "pfizer_2023_chunk0286",
      "chunk_index": 286,
      "text": "llaborate with patients, physicians and payors to support and expand patient access to reliable,\naffordable healthcare around the world. In addition, we continually seek to expand and broaden our product portfolio offerings through prioritized development of our pipeline and\nbusiness development opportunities targeted at critical unmet patient needs. As a result, our commercial organizational structure and R&D operations are critical to the successful\nexecution of our business strategy. Our ability to fulfill our purpose, Breakthroughs that change patients’ lives, remains a core focus and underscores our commitment to addressing\nthe needs of society to help sustain long-term value creation for all stakeholders. Our 2024 key priorities are:\n• Achieve world-class oncology leadership\n• Deliver next wave of pipeline innovation\n• Maximize performance of our new products\n• Expand margins by realigning our cost base\n• Allocate capital to enhance shareholder value\n\n2023 Form 10-K",
      "char_count": 986,
      "start_char": 228800,
      "end_char": 229787
    },
    {
      "chunk_id": "pfizer_2023_chunk0287",
      "chunk_index": 287,
      "text": "r next wave of pipeline innovation\n• Maximize performance of our new products\n• Expand margins by realigning our cost base\n• Allocate capital to enhance shareholder value\n\n2023 Form 10-K\n\nIn 2023, we managed our commercial operations through a global structure consisting of two operating segments: Biopharma and Business Innovation. Biopharma was the only\nreportable segment. See Note 1A and the Item 1. Business––Commercial Operations section.\nIn December 2023, we completed our acquisition of Seagen. At the beginning of 2024, we made changes in our commercial organization that went into effect on January 1, 2024 to\nincorporate Seagen and improve focus, speed and execution. Specifically, within our Biopharma reportable segment we created:\n• the Pfizer Oncology Division, which brings together U.S.",
      "char_count": 804,
      "start_char": 229600,
      "end_char": 230405
    },
    {
      "chunk_id": "pfizer_2023_chunk0288",
      "chunk_index": 288,
      "text": "U.S. oncology commercial operations from both Pfizer and Seagen and is led by the Chief Oncology Officer, Executive Vice\nPresident, who also leads Pfizer’s newly combined global oncology R&D operations;\n• the Pfizer U.S. Commercial Division, which focuses on the commercialization of non-oncology products in the U.S. and is led by the Chief U.S. Commercial Officer, Executive Vice\nPresident; and\n• the Pfizer International Commercial Division, which focuses on the commercialization of Pfizer’s entire product portfolio outside the U.S. and is led by the Chief International\nCommercial Officer, Executive Vice President.\nIn the fourth quarter of 2022, we began taking steps through our Transforming to a More Focused Company restructuring program to optimize our end-to-end R&D operations to\nreduce costs and cycle times as well as to further prioritize our internal R&D portfolio in areas where our capabilities are differentiated while increasing external innovation efforts to",
      "char_count": 980,
      "start_char": 230400,
      "end_char": 231381
    },
    {
      "chunk_id": "pfizer_2023_chunk0289",
      "chunk_index": 289,
      "text": "costs and cycle times as well as to further prioritize our internal R&D portfolio in areas where our capabilities are differentiated while increasing external innovation efforts to\nleverage an expanding and productive biotech sector. Beginning in July 2023, in consideration of planned future investments in oncology, including the acquisition of Seagen on\nDecember 14, 2023, we reorganized our R&D platform operations. See Note 17A. In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost\nrealignment program that aims to realign our costs with our longer-term revenue expectations. See Note 3. For a description of savings related to these programs, see the Costs and\nExpenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives section within MD&A.\nR&D: We believe we have a strong pipeline and are well-positioned for future growth.",
      "char_count": 936,
      "start_char": 231200,
      "end_char": 232137
    },
    {
      "chunk_id": "pfizer_2023_chunk0290",
      "chunk_index": 290,
      "text": "ction/Productivity Initiatives section within MD&A.\nR&D: We believe we have a strong pipeline and are well-positioned for future growth. R&D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients’ lives\nas we work to translate advanced science and technologies into the medicines and vaccines that may be the most impactful for patients. Innovation, drug discovery and\ndevelopment are critical to our success. In addition to discovering and developing new products, our R&D efforts seek to add value to our existing products by improving their\neffectiveness and ease of dosing and by discovering potential new indications. See the Item 1. Business—Research and Development section for our R&D priorities and strategy.\nWe seek to leverage a strong pipeline, organize around expected operational growth drivers and capitalize on trends creating long-term growth opportunities, including:",
      "char_count": 918,
      "start_char": 232000,
      "end_char": 232919
    },
    {
      "chunk_id": "pfizer_2023_chunk0291",
      "chunk_index": 291,
      "text": "round expected operational growth drivers and capitalize on trends creating long-term growth opportunities, including:\n• an aging global population that is generating increased demand for innovative medicines and vaccines that address patients’ unmet needs; and\n• advances in both biological science and platform technologies that are enhancing the delivery of breakthrough new medicines and vaccines.\nOur Business Development Initiatives––We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and\nmaximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies\nand seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities.",
      "char_count": 886,
      "start_char": 232800,
      "end_char": 233687
    },
    {
      "chunk_id": "pfizer_2023_chunk0292",
      "chunk_index": 292,
      "text": "transactions that have the potential to strengthen our business and our capabilities. We assess our business, assets and\nscientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our\nbusiness strategy. For a discussion of recent significant business development activities, see Note 2.\nOur 2023 Performance\nTotal Revenues––Total revenues decreased $41.8 billion, or 42%, to $58.5 billion in 2023 from $100.3 billion in 2022, reflecting an operational decrease of $40.8 billion, or 41%, as\nwell as an unfavorable impact of foreign exchange of $1.0 billion, or 1%. The operational decrease was primarily driven by significant declines in revenues from Comirnaty and\nPaxlovid, including a $3.5 billion non-cash revenue reversal for Paxlovid recorded in the fourth quarter of 2023.",
      "char_count": 895,
      "start_char": 233600,
      "end_char": 234497
    },
    {
      "chunk_id": "pfizer_2023_chunk0293",
      "chunk_index": 293,
      "text": "ng a $3.5 billion non-cash revenue reversal for Paxlovid recorded in the fourth quarter of 2023. Excluding contributions from Comirnaty and Paxlovid, Total revenues\nincreased 7% operationally, reflecting an increase in revenues from Nurtec ODT/Vydura and Oxbryta; revenues from Abrysvo, primarily driven by the launch of the older adult\nindication in the U.S.; as well as continued growth from the Vyndaqel family and Eliquis; partially offset by a decline in Ibrance.\nThe following chart outlines the components of the net change in Total revenues:\nSee the Total Revenues by Geography and Total Revenues––Selected Product Discussion sections within MD&A for more information, including a discussion of key drivers of our\nrevenue performance. See also The Global Economic Environment––COVID-19 section below for information about our COVID-19 products. For information regarding the primary\nindications or class of certain products, see Note 17C.\n\n2023 Form 10-K",
      "char_count": 962,
      "start_char": 234400,
      "end_char": 235363
    },
    {
      "chunk_id": "pfizer_2023_chunk0294",
      "chunk_index": 294,
      "text": "n below for information about our COVID-19 products. For information regarding the primary\nindications or class of certain products, see Note 17C.\n\n2023 Form 10-K\n\nWhile royalty income through December 31, 2023 has been recorded in Other Income/(Deductions)—net, we will begin reporting such royalty income in Total revenues beginning in\n2024 and will restate prior periods for consistency with our 2024 presentation. Additionally, we will no longer record royalties from U.S. sales of Bavencio, as we have irrevocably\nchosen to donate the right to such royalties to the American Association for Cancer Research.\nIncome from Continuing Operations Before Provision/(Benefit) for Taxes on Income––The decrease in Income from continuing operations before provision/(benefit) for taxes on\nincome of $33.7 billion, to $1.1 billion in 2023 from $34.7 billion in 2022, was primarily attributable to (i) lower revenues, (ii) higher intangible asset impairment charges, and (iii)",
      "char_count": 970,
      "start_char": 235200,
      "end_char": 236171
    },
    {
      "chunk_id": "pfizer_2023_chunk0295",
      "chunk_index": 295,
      "text": "billion, to $1.1 billion in 2023 from $34.7 billion in 2022, was primarily attributable to (i) lower revenues, (ii) higher intangible asset impairment charges, and (iii)\nincreases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by\n(iv) a decrease in Cost of sales and (v) net gains on equity securities in 2023 versus net losses on equity securities in 2022.\nSee the Analysis of the Consolidated Statements of Income section within MD&A and Note 4. For information on our tax provision and effective tax rate, see the Provision/(Benefit)\nfor Taxes on Income section within MD&A and Note 5.\nOur Operating Environment––We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed\nbelow. See also the Item 1. Business––Government Regulation and Price Constraints and Item 1A.",
      "char_count": 978,
      "start_char": 236000,
      "end_char": 236980
    },
    {
      "chunk_id": "pfizer_2023_chunk0296",
      "chunk_index": 296,
      "text": "certain industry-specific challenges. These include, among others, the topics listed\nbelow. See also the Item 1. Business––Government Regulation and Price Constraints and Item 1A. Risk Factors sections.\nRegulatory Environment––Pipeline Productivity––Our product lines must be replenished over time to offset revenue losses when products lose exclusivity or market share or to\nrespond to healthcare and innovation trends, as well as to provide for earnings growth, primarily through internal R&D or through collaborations, acquisitions, JVs, licensing or other\narrangements. As a result, we devote considerable resources to our R&D activities which, while essential to our growth, incorporate a high degree of risk and cost, including whether\na particular product candidate or new indication for an in-line product will achieve the desired clinical endpoint or safety profile, will be approved by regulators or will be successful\ncommercially.",
      "char_count": 942,
      "start_char": 236800,
      "end_char": 237743
    },
    {
      "chunk_id": "pfizer_2023_chunk0297",
      "chunk_index": 297,
      "text": "-line product will achieve the desired clinical endpoint or safety profile, will be approved by regulators or will be successful\ncommercially. Clinical trials are conducted to determine, among other things, whether an investigational drug, vaccine or device is safe and effective for a particular patient\npopulation. After a product has been approved or authorized and launched, we continue to monitor its safety as long as it is available to patients, including conducting postmarketing\ntrials, voluntarily or pursuant to a regulatory request. For the entire life of the product, we collect safety data and report safety information to the FDA and other regulators. Regulatory\nauthorities evaluate potential safety concerns and take any regulatory action deemed necessary and appropriate. Such action(s) may include: updating a product’s labeling,\nrestricting its use, communicating new safety information or, in rare cases, seeking to suspend or remove a product from the market.",
      "char_count": 981,
      "start_char": 237600,
      "end_char": 238582
    },
    {
      "chunk_id": "pfizer_2023_chunk0298",
      "chunk_index": 298,
      "text": "n(s) may include: updating a product’s labeling,\nrestricting its use, communicating new safety information or, in rare cases, seeking to suspend or remove a product from the market.\nIntellectual Property Rights and Collaboration/Licensing Rights––The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments, and\nthe expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of\nregulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent\nexpiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from 2024 through 2025.",
      "char_count": 848,
      "start_char": 238400,
      "end_char": 239249
    },
    {
      "chunk_id": "pfizer_2023_chunk0299",
      "chunk_index": 299,
      "text": "s due to patent expiries from 2024 through 2025. We anticipate a more significant impact of reduced\nrevenues from patent expiries in 2026 through 2030 as several of our in-line products experience patent-based expirations. We continue to vigorously defend our patent rights\nagainst infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient\naccess.\nFor additional information on patent rights we consider most significant to our business as a whole, see the Item 1. Business––Patents and Other Intellectual Property Rights\nsection. For a discussion of recent developments with respect to patent litigation, see Note 16A1.\nRegulatory Environment/Pricing and Access––Government and Other Payor Group Pressures––The pricing of medicines and vaccines by pharmaceutical manufacturers and the",
      "char_count": 900,
      "start_char": 239200,
      "end_char": 240101
    },
    {
      "chunk_id": "pfizer_2023_chunk0300",
      "chunk_index": 300,
      "text": "Payor Group Pressures––The pricing of medicines and vaccines by pharmaceutical manufacturers and the\ncost of healthcare, which includes medicines, vaccines, medical services and hospital services, continues to be important to payors, governments, patients, and other stakeholders.\nFederal and state governments and private third-party payors in the U.S. continue to take action to manage the utilization and cost of drugs, including increasingly employing\nformularies to control costs and encourage utilization of certain drugs, including through the use of deductibles, utilization management tools, cost sharing or formulary placement.\nWe consider a number of factors impacting the pricing of our medicines and vaccines. Within the U.S., we often engage with patients, doctors and healthcare plans. We also often\nprovide significant discounts from the list price to insurers, including PBMs and MCOs. The price that patients pay in the U.S.",
      "char_count": 942,
      "start_char": 240000,
      "end_char": 240943
    },
    {
      "chunk_id": "pfizer_2023_chunk0301",
      "chunk_index": 301,
      "text": "We also often\nprovide significant discounts from the list price to insurers, including PBMs and MCOs. The price that patients pay in the U.S. for prescribed medicines and vaccines is ultimately set\nby healthcare providers and insurers. Governments globally, as well as private third-party payors in the U.S., may use a variety of measures to control costs, including, among\nothers, legislative or regulatory pricing reforms, drug formularies (including tiering and utilization management tools), cross country collaboration and procurement, price cuts,\nmandatory rebates, health technology assessments, forced localization as a condition of market access, “international reference pricing” (i.e., the practice of a country linking its\nregulated medicine prices to those of other countries), QCE processes and VBP. We anticipate that these and similar initiatives will continue to increase pricing and access\npressures globally.",
      "char_count": 927,
      "start_char": 240800,
      "end_char": 241729
    },
    {
      "chunk_id": "pfizer_2023_chunk0302",
      "chunk_index": 302,
      "text": "esses and VBP. We anticipate that these and similar initiatives will continue to increase pricing and access\npressures globally. In the U.S., we expect to see continued focus by Congress and the Biden Administration on regulating pricing. The drug pricing provisions of the IRA, which was\nsigned into law in August 2022, began to be implemented in 2022 and implementation efforts will continue over the next several years. In August 2023, the Biden Administration\nunveiled the first ten medicines subject to the “Medicare Drug Price Negotiation Program,” which requires manufacturers of select drugs to engage in a process with the federal\ngovernment to set new Medicare prices which would go into effect in 2026. Among the first ten medicines subject to the Program included Eliquis. We continue to evaluate the\nimpact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain.",
      "char_count": 991,
      "start_char": 241600,
      "end_char": 242592
    },
    {
      "chunk_id": "pfizer_2023_chunk0303",
      "chunk_index": 303,
      "text": "evaluate the\nimpact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. In\naddition, changes to the Medicaid Drug Rebate program or the 340B Program, including legal or legislative developments at the federal or state level with respect to the 340B\nprogram, could have a material impact on our business. See the Item 1. Business––Pricing Pressures and Managed Care Organizations and ––Government Regulation and Price\nConstraints and the Item 1A. Risk Factors––Pricing and Reimbursement sections.\nImpact of the July 2023 Tornado in Rocky Mount, North Carolina (NC)––Our manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. The facility is a key\nproducer of sterile injectables and is responsible for manufacturing nearly 25 percent of all our sterile injectables—including anesthesia, analgesia, and micronutrients—which is",
      "char_count": 970,
      "start_char": 242400,
      "end_char": 243371
    },
    {
      "chunk_id": "pfizer_2023_chunk0304",
      "chunk_index": 304,
      "text": "of sterile injectables and is responsible for manufacturing nearly 25 percent of all our sterile injectables—including anesthesia, analgesia, and micronutrients—which is\nnearly eight percent of all the sterile injectables used in U.S. hospitals. While manufacturing has resumed, the supply of medicines impacted by the tornado is expected to be\naffected through 2024.\nIn 2023, we recorded $286 million to Cost of sales for inventory losses, overhead costs related to the period in which the facility could not operate, and incremental costs resulting\nfrom the tornado damage. Losses incurred in 2023 were partially offset by insurance recoveries received in the fourth quarter of 2023. We may record additional losses and/or costs\nand/or insurance recoveries in future periods, but we are unable to predict them with certainty at this time.\n\n2023 Form 10-K",
      "char_count": 856,
      "start_char": 243200,
      "end_char": 244058
    },
    {
      "chunk_id": "pfizer_2023_chunk0305",
      "chunk_index": 305,
      "text": "predict them with certainty at this time.\n\n2023 Form 10-K\n\nProduct Supply––We periodically encounter supply delays, disruptions and shortages, including due to voluntary product recalls and natural or man-made disasters. In 2021, Pfizer\nrecalled all lots of Chantix in the U.S. due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the FDA interim acceptable intake limit. Regulatory authorities outside\nthe U.S. have issued updated guidance on nitrosamine acceptable intake levels. With this recently issued guidance, which included an updated intake level for N-nitroso-varenicline,\nwe expect to make regulatory submissions in 2024 to potentially enable Chantix to return to market outside the U.S., and our related discussions with FDA are ongoing.\nExcept for the tornado in Rocky Mount, NC discussed above, we have not seen a significant disruption of our supply chain in 2023 and through the date of filing of this Form 10-K,",
      "char_count": 949,
      "start_char": 244000,
      "end_char": 244950
    },
    {
      "chunk_id": "pfizer_2023_chunk0306",
      "chunk_index": 306,
      "text": "ky Mount, NC discussed above, we have not seen a significant disruption of our supply chain in 2023 and through the date of filing of this Form 10-K,\nand all of our manufacturing sites globally have continued to operate at or near normal levels; however, we continue to see heightened demand in the industry for certain\ncomponents and raw materials, which could potentially result in constraining available supply leading to a possible future impact on our business. We continue to monitor and\nimplement mitigation strategies in an effort to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing\nto the extent possible. For information on risks related to product manufacturing, see the Item 1A. Risk Factors––Product Manufacturing, Sales and Marketing Risks section.",
      "char_count": 849,
      "start_char": 244800,
      "end_char": 245650
    },
    {
      "chunk_id": "pfizer_2023_chunk0307",
      "chunk_index": 307,
      "text": "Manufacturing, Sales and Marketing Risks section.\nThe Global Economic Environment––In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are\nexposed to economic cycles. Certain factors in the global economic environment that may impact our global operations include, among other things, currency and interest rate\nfluctuations, capital and exchange controls, local and global economic conditions including inflation, recession, volatility and/or lack of liquidity in capital markets, expropriation and\nother restrictive government actions, changes in intellectual property, legal protections and remedies, trade regulations, tax laws and regulations and procedures and actions\naffecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the",
      "char_count": 942,
      "start_char": 245600,
      "end_char": 246543
    },
    {
      "chunk_id": "pfizer_2023_chunk0308",
      "chunk_index": 308,
      "text": "marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the\nongoing conflicts between Russia and Ukraine and in the Middle East and their economic consequences, geopolitical instability, terrorist activity, unstable governments and legal\nsystems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change. Government pressures can lead to\nnegative pricing pressure in various markets where governments take an active role in setting prices, access criteria or other means of cost control. For additional information on\nrisks related to our global operations, see the Item 1A. Risk Factors—Global Operations section.\nCOVID-19––In response to COVID-19, we developed Paxlovid and collaborated with BioNTech to jointly develop Comirnaty, including an Omicron XBB.1.5-adapted monovalent\nvaccine.",
      "char_count": 949,
      "start_char": 246400,
      "end_char": 247351
    },
    {
      "chunk_id": "pfizer_2023_chunk0309",
      "chunk_index": 309,
      "text": "COVID-19, we developed Paxlovid and collaborated with BioNTech to jointly develop Comirnaty, including an Omicron XBB.1.5-adapted monovalent\nvaccine. As part of our strategy for COVID-19, we are continuing to make significant investments in breakthrough science and global manufacturing. This includes continuing to\nevaluate Comirnaty and Paxlovid, including against new variants of concern, developing variant adapted vaccine candidates and developing potential combination respiratory\nvaccines and potential next generation vaccines and therapies. We are also evaluating Paxlovid for additional populations. See the Product Developments section within MD&A.\nIn 2023, we principally sold Comirnaty globally under government contracts. In September 2023, Comirnaty transitioned to traditional commercial market sales in the U.S., triggered",
      "char_count": 839,
      "start_char": 247200,
      "end_char": 248041
    },
    {
      "chunk_id": "pfizer_2023_chunk0310",
      "chunk_index": 310,
      "text": "cial market sales in the U.S., triggered\nby the expiration of current contracts and the COVID-19 vaccines from Pfizer and BioNTech purchased through them becoming either depleted or not used following the introduction\nof a new variant vaccine. Internationally, sales of Comirnaty in international developed markets were generally under government contracts in 2023, and in emerging markets, under\na combination of private channels and government contracts; in both cases, we expect to start transitioning to commercial markets in 2024. Due to the commercial market transition\nas well as the anticipated seasonal nature of COVID vaccination, we expect more than 80% of our 2024 global revenues for Comirnaty to be recorded in the second half of the year.\nIn 2023, we principally sold Paxlovid globally to government agencies.",
      "char_count": 824,
      "start_char": 248000,
      "end_char": 248825
    },
    {
      "chunk_id": "pfizer_2023_chunk0311",
      "chunk_index": 311,
      "text": "to government agencies. Internationally, for Paxlovid, we are continuing the transition to commercial markets and are expecting most\nrevenue for Paxlovid to be generated through commercial channels in 2024. On October 13, 2023, we announced an amended agreement with the U.S. government, which\nfacilitated the transition of Paxlovid to traditional commercial markets in November 2023, with minimal uptake of NDA-labeled commercial product before January 1, 2024. See Note\n17C.\nFor information on risks associated with our COVID-19 products, including certain assumptions made for purposes of our operational planning and financial projections and the\nuncertainty of future developments, as well as COVID-19 intellectual property disputes, see the Item 1A. Risk Factors—COVID-19, —Intellectual Property Protection and ––ThirdParty Intellectual Property Claims sections and Note 16A1.",
      "char_count": 882,
      "start_char": 248800,
      "end_char": 249684
    },
    {
      "chunk_id": "pfizer_2023_chunk0312",
      "chunk_index": 312,
      "text": "ty Protection and ––ThirdParty Intellectual Property Claims sections and Note 16A1.\nIsrael/Hamas Conflict––Our local operations have been impacted by the armed conflict between Israel and Hamas that began on October 7, 2023. For the years ended December\n31, 2023 and 2022, the business of our Israeli subsidiary represented less than 1% of our consolidated revenues and assets. We are closely monitoring developments in this\nconflict, including evaluating potential impacts to our business, customers, suppliers, employees, and operations in Israel and elsewhere in the Middle East that may impact global\noperations. At this time, longer term impacts to the Company are uncertain and subject to change.\nRussia/Ukraine Conflict––Our local operations have been impacted by the armed conflict between Russia and Ukraine.",
      "char_count": 817,
      "start_char": 249600,
      "end_char": 250418
    },
    {
      "chunk_id": "pfizer_2023_chunk0313",
      "chunk_index": 313,
      "text": "ssia and Ukraine. For the years ended December 31, 2023 and 2022, the\nbusiness of our Russia and Ukraine subsidiaries represented less than 1% of our consolidated revenues and assets, and while we are monitoring the effects of the conflict between\nRussia and Ukraine, the situation continues to evolve and the long-term implications, including the broader economic consequences of the conflict, are difficult to predict at this time.\nWhile as of now, we do not anticipate any significant negative impacts on our global operations from this conflict, continued regional instability, geopolitical shifts, potential additional\nsanctions and other restrictive measures against Russia, neighboring countries or allies of Russia, any retaliatory measures taken by Russia, neighboring countries or allies of\nRussia, and actions by our customers or suppliers, including financial institutions, in response to such measures could adversely affect the global macroeconomic environment, our",
      "char_count": 979,
      "start_char": 250400,
      "end_char": 251380
    },
    {
      "chunk_id": "pfizer_2023_chunk0314",
      "chunk_index": 314,
      "text": "Russia, and actions by our customers or suppliers, including financial institutions, in response to such measures could adversely affect the global macroeconomic environment, our\noperations, currency exchange rates and financial markets, which could in turn adversely impact our business and results of operations.\nSIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS\nFollowing is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. Also, see Note 1C.\nFor a description of our significant accounting policies, see Note 1. Of these policies, the following are considered critical to an understanding of our consolidated financial\nstatements as they require the application of the most subjective and the most complex judgments: Acquisitions (Note 1D); Fair Value (Note 1E); Revenues (Note 1G); Asset",
      "char_count": 908,
      "start_char": 251200,
      "end_char": 252110
    },
    {
      "chunk_id": "pfizer_2023_chunk0315",
      "chunk_index": 315,
      "text": "ctive and the most complex judgments: Acquisitions (Note 1D); Fair Value (Note 1E); Revenues (Note 1G); Asset\nImpairments (Note 1M); Tax Assets and Liabilities and Income Tax Contingencies (Note 1Q); Pension and Postretirement Benefit Plans (Note 1R); and Legal and Environmental\nContingencies (Note 1S).\nFor a discussion of recently adopted accounting standards, see Note 1B.\n\n2023 Form 10-K\n\nAcquisitions\nWe account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be\nrecognized at their estimated fair value as of the acquisition date. To estimate fair value, we utilize an exit price approach from the perspective of a market participant. For further\ndetail on acquisition accounting, see Note 1D. For further detail on the techniques and methodologies that we use to estimate fair value, see Note 1E.",
      "char_count": 910,
      "start_char": 252000,
      "end_char": 252911
    },
    {
      "chunk_id": "pfizer_2023_chunk0316",
      "chunk_index": 316,
      "text": "te 1D. For further detail on the techniques and methodologies that we use to estimate fair value, see Note 1E. Historically, intangible assets\nhave been the most significant fair values within our business combinations. We utilize an income approach to estimate the acquisition date fair value of each identifiable intangible\nasset. Some of the more significant estimates and assumptions inherent in this approach include the amount and timing of projected net cash flows, the discount rate, the tax rate,\nand, for IPR&D assets, the probability of technical and regulatory success (PTRS). All of these judgments and estimates can materially impact our results of operations. For further\ninformation on our process to estimate the fair value of intangible assets, see Asset Impairments below.\nWe estimate the fair value of acquired inventory, including finished goods and work in process, by determining the estimated selling price when completed, less an estimate of costs",
      "char_count": 972,
      "start_char": 252800,
      "end_char": 253773
    },
    {
      "chunk_id": "pfizer_2023_chunk0317",
      "chunk_index": 317,
      "text": "ate the fair value of acquired inventory, including finished goods and work in process, by determining the estimated selling price when completed, less an estimate of costs\nto be incurred to complete and sell the inventory, and an estimate of a reasonable profit allowance for those manufacturing and selling efforts. The fair value of inventory is\nrecognized in our results of operations as the inventory is sold. Some of the more significant estimates and assumptions inherent in the estimate of the fair value of inventory include\nstage of completion, costs to complete, costs to dispose and selling price.\nWe estimate the fair value of acquired PP&E using a combination of the cost and market approaches. Some of the more significant estimates and assumptions inherent in these\napproaches are the values of asset replacement costs, comparable assets and estimated remaining economic lives of the assets.",
      "char_count": 907,
      "start_char": 253600,
      "end_char": 254508
    },
    {
      "chunk_id": "pfizer_2023_chunk0318",
      "chunk_index": 318,
      "text": "values of asset replacement costs, comparable assets and estimated remaining economic lives of the assets.\nFor the provisional amounts recognized for the Seagen assets acquired and liabilities assumed as of the acquisition date, see Note 2A. The estimated values are not yet finalized\nand are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses. We expect to\nfinalize the amounts of assets acquired and liabilities assumed as soon as possible but no later than one year from the acquisition date.\nRevenues\nOur gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable\nconsideration represents chargebacks, rebates, sales allowances and sales returns.",
      "char_count": 864,
      "start_char": 254400,
      "end_char": 255266
    },
    {
      "chunk_id": "pfizer_2023_chunk0319",
      "chunk_index": 319,
      "text": "resents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and\njudgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual\nresults or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a\nsignificant impact on year-over-year individual product revenue growth trends. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate\nestimates of our future experience, our results could be materially affected. The potential of our estimates to vary (sensitivity) differs by program, product, type of customer and\ngeographic location. However, estimates associated with U.S.",
      "char_count": 933,
      "start_char": 255200,
      "end_char": 256134
    },
    {
      "chunk_id": "pfizer_2023_chunk0320",
      "chunk_index": 320,
      "text": "to vary (sensitivity) differs by program, product, type of customer and\ngeographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material adjustment because of the\nextensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this lag, our recording of\nadjustments to reflect actual amounts can incorporate revisions of several prior quarters. Rebate accruals are product specific and, therefore for any period, are impacted by the mix\nof products sold as well as the forecasted channel mix for each individual product. For further information, see the Product Revenue Deductions section within MD&A and Note 1G.\nAsset Impairments\nWe review all of our long-lived assets for impairment indicators throughout the year.",
      "char_count": 888,
      "start_char": 256000,
      "end_char": 256890
    },
    {
      "chunk_id": "pfizer_2023_chunk0321",
      "chunk_index": 321,
      "text": "nts\nWe review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually\nand for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the\nfair value is less than the carrying value of these assets. Our impairment review processes are described in Note 1M.\nExamples of events or circumstances that may be indicative of impairment include:\n• A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely\nresult in generic competition earlier than expected.\n• A significant adverse change in the extent or manner in which an asset is used such as a restriction imposed by the FDA or other regulatory authorities that could affect our ability",
      "char_count": 992,
      "start_char": 256800,
      "end_char": 257793
    },
    {
      "chunk_id": "pfizer_2023_chunk0322",
      "chunk_index": 322,
      "text": "xpected.\n• A significant adverse change in the extent or manner in which an asset is used such as a restriction imposed by the FDA or other regulatory authorities that could affect our ability\nto manufacture or sell a product.\n• An expectation of losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement program that results in an\ninability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor’s product that impacts projected revenue growth, as well\nas the lack of acceptance of a product by patients, physicians and payors. For IPR&D projects, this could result from, among other things, a change in outlook based on clinical\ntrial data, a delay in the projected launch date or additional expenditures to commercialize the product.",
      "char_count": 869,
      "start_char": 257600,
      "end_char": 258470
    },
    {
      "chunk_id": "pfizer_2023_chunk0323",
      "chunk_index": 323,
      "text": "launch date or additional expenditures to commercialize the product.\nIdentifiable Intangible Assets––We use an income approach, specifically the discounted cash flow method to determine the fair value of intangible assets, other than goodwill. We\nstart with a forecast of all the expected net cash flows associated with the asset, which incorporates the consideration of a terminal value for indefinite-lived assets, and then we\napply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions that impact our fair value estimates include:\nthe amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of\ntechnological advancements and risk associated with IPR&D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks",
      "char_count": 961,
      "start_char": 258400,
      "end_char": 259363
    },
    {
      "chunk_id": "pfizer_2023_chunk0324",
      "chunk_index": 324,
      "text": "vancements and risk associated with IPR&D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks\ninherent in the projected cash flows; and the tax rate, which seeks to incorporate the jurisdictional mix of the projected cash flows.\nWhile all intangible assets other than goodwill can face events and circumstances that can lead to impairment, those that are most at risk of impairment include IPR&D assets\n(approximately $23.2 billion as of December 31, 2023) and newly acquired or recently impaired indefinite-lived brand assets. IPR&D assets are high-risk assets, given the uncertain\nnature of R&D. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently\nmeasured at the lower of fair value or carrying value at the end of each reporting period.",
      "char_count": 919,
      "start_char": 259200,
      "end_char": 260120
    },
    {
      "chunk_id": "pfizer_2023_chunk0325",
      "chunk_index": 325,
      "text": "ue and are then subsequently\nmeasured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after acquisition or impairment, even small declines in the outlook for\nthese assets can negatively impact our ability to recover the carrying value and can result in an impairment charge.\n\n2023 Form 10-K\n\nGoodwill––Our goodwill impairment review work as of December 31, 2023 concluded that none of our goodwill was impaired and we do not believe the risk of impairment is\nsignificant at this time, as the fair value of each of our reporting units is significantly higher than their respective net book values.\nIn our review, we first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors\nthat we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events.",
      "char_count": 995,
      "start_char": 260000,
      "end_char": 260996
    },
    {
      "chunk_id": "pfizer_2023_chunk0326",
      "chunk_index": 326,
      "text": "han its carrying amount. Qualitative factors\nthat we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more\nlikely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.\nWhen we are required to determine the fair value of a reporting unit, we typically use the income approach. The income approach is a forward-looking approach to estimating fair\nvalue and relies primarily on internal forecasts. Within the income approach, we use the discounted cash flow method. We start with a forecast of all the expected net cash flows for\nthe reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount.",
      "char_count": 893,
      "start_char": 260800,
      "end_char": 261694
    },
    {
      "chunk_id": "pfizer_2023_chunk0327",
      "chunk_index": 327,
      "text": "hen we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the\nmore significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of\ntechnological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the\nvarious risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.\nFor all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent\ngoodwill impairment testing. For a list of these factors, see the Forward-Looking Information and Factors That May Affect Future Results and the Item 1A.",
      "char_count": 949,
      "start_char": 261600,
      "end_char": 262550
    },
    {
      "chunk_id": "pfizer_2023_chunk0328",
      "chunk_index": 328,
      "text": "will impairment testing. For a list of these factors, see the Forward-Looking Information and Factors That May Affect Future Results and the Item 1A. Risk Factors sections.\nBenefit Plans\nFor a description of our different benefit plans, see Note 11.\nOur assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in\ndetermining the costs of our benefit plans can materially impact our results of operations.\nThe following provides (i) at the end of each year, the expected annual rate of return on plan assets for the following year, (ii) the actual annual rate of return on plan assets\nachieved in each year, and (iii) the weighted-average discount rate used to measure the benefit obligations at the end of each year for our U.S. pension plans and our\ninternational pension plans :",
      "char_count": 885,
      "start_char": 262400,
      "end_char": 263286
    },
    {
      "chunk_id": "pfizer_2023_chunk0329",
      "chunk_index": 329,
      "text": "the end of each year for our U.S. pension plans and our\ninternational pension plans :\n\nU.S. Pension Plans\nExpected annual rate of return on plan assets\n8.0 %\n7.5 %\n6.3 %\nActual annual rate of return on plan assets\n10.4 \n(22.4)\n9.2 \nDiscount rate used to measure the plan obligations\n5.4 \n5.4 \n2.9 \nInternational Pension Plans\nExpected annual rate of return on plan assets\n5.1 \n4.5 \n3.1 \nActual annual rate of return on plan assets\n(4.6)\n(26.0)\n11.4 \nDiscount rate used to measure the plan obligations\n4.4 \n3.8 \n1.6 \nFor detailed assumptions associated with our benefit plans, see Note 11B.\nExpected Annual Rate of Return on Plan Assets––The assumptions for the expected annual rate of return on all of our plan assets reflect our actual historical return experience and\nour long-term assessment of forward-looking return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our\ntargeted asset allocation in our respective plans.",
      "char_count": 997,
      "start_char": 263200,
      "end_char": 264198
    },
    {
      "chunk_id": "pfizer_2023_chunk0330",
      "chunk_index": 330,
      "text": "rward-looking return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our\ntargeted asset allocation in our respective plans.\nThe expected annual rate of return on plan assets for our U.S. plans and international plans is applied to the fair value of plan assets at each year-end and the resulting amount is\nreflected in our net periodic benefit costs in the following year. Differences between the actual rate of return on plan assets and the expected annual rate of return on plan assets are\nimmediately recognized through earnings upon remeasurement.\nThe following illustrates the sensitivity of net periodic benefit costs to a 50 basis point decline in our assumption for the expected annual rate of return on plan assets, holding all\nother assumptions constant (in millions, pre-tax):\nAssumption\nChange\nIncrease in 2024\nNet Periodic\nBenefit Costs\nExpected annual rate of return on plan assets\n50 basis point decline\n$84",
      "char_count": 996,
      "start_char": 264000,
      "end_char": 264997
    },
    {
      "chunk_id": "pfizer_2023_chunk0331",
      "chunk_index": 331,
      "text": "olding all\nother assumptions constant (in millions, pre-tax):\nAssumption\nChange\nIncrease in 2024\nNet Periodic\nBenefit Costs\nExpected annual rate of return on plan assets\n50 basis point decline\n$84\nThe estimate excludes any potential mark-to-market adjustments.\nThe actual return on plan assets resulted in a net gain on our plan assets of approximately $835 million during 2023.\nDiscount Rate Used to Measure Plan Obligations––The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at\nleast annually and evaluated and modified, as required, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better, that reflect\nthe rates at which the pension benefits could be effectively settled.",
      "char_count": 807,
      "start_char": 264800,
      "end_char": 265608
    },
    {
      "chunk_id": "pfizer_2023_chunk0332",
      "chunk_index": 332,
      "text": "ettled. The discount rate used to measure the plan obligations for our significant international plans is determined at least\nannually by reference to investment grade corporate bonds, rated AA/Aa or better, including, when there is sufficient data, a yield-curve approach. These discount rate\ndeterminations are made in consideration of local requirements. The measurement of plan obligations at the end of the year will affect (i) the actuarial (gains)/losses recognized in\nour net periodic benefit cost for that year and (ii) the amount of service cost and interest cost reflected in our net periodic benefit costs in the following year.\n(a)\n(a)\n(a)\n(a)\n\n2023 Form 10-K\n\nThe following illustrates the sensitivity of net periodic benefit costs and benefit obligations to a 10 basis point decline in our assumption for the discount rate, holding all other\nassumptions constant (in millions, pre-tax):\nAssumption\nChange\nDecrease in 2024 Net\nPeriodic Benefit Costs\nIncrease to 2023",
      "char_count": 980,
      "start_char": 265600,
      "end_char": 266581
    },
    {
      "chunk_id": "pfizer_2023_chunk0333",
      "chunk_index": 333,
      "text": "our assumption for the discount rate, holding all other\nassumptions constant (in millions, pre-tax):\nAssumption\nChange\nDecrease in 2024 Net\nPeriodic Benefit Costs\nIncrease to 2023\nBenefit Obligations\nDiscount rate\n10 basis point decline\n$210\nThe change in the discount rates used in measuring our plan obligations as of December 31, 2023 resulted in a decrease in the measurement of our aggregate plan obligations by\napproximately $616 million.\nIncome Tax Assets and Liabilities\nIncome tax assets and liabilities include income tax valuation allowances and accruals for uncertain tax positions. See Notes 1Q and 5, as well as the Analysis of Financial\nCondition, Liquidity, Capital Resources and Market Risk section within MD&A.\nContingencies\nWe and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and\nindemnifications.",
      "char_count": 931,
      "start_char": 266400,
      "end_char": 267333
    },
    {
      "chunk_id": "pfizer_2023_chunk0334",
      "chunk_index": 334,
      "text": "us contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and\nindemnifications. See Notes 1Q, 1S, 5D and 16.\nANALYSIS OF THE CONSOLIDATED STATEMENTS OF INCOME\nTotal Revenues by Geography\nThe following presents worldwide Total revenues by geography:\n \nYear Ended December 31,\n% Change\n \nWorldwide\nU.S.\nInternational\nWorldwide\nU.S.\nInternational\n(MILLIONS)\n\n23/22\n22/21\n23/22\n22/21\n23/22\n22/21\nOperating segments:\nBiopharma\n57,186 \n$ 98,988 \n$ 79,557 \n$ 26,698 \n$ 42,083 \n$ 29,221 \n$ 30,488 \n$ 56,905 \n$ 50,336 \n(42)\n\n(37)\n\n(46)\n\nBusiness Innovation\n1,310 \n1,342 \n1,731 \n\n1,206 \n(2)\n(22)\n(26)\n(3)\n(21)\nTotal revenues\n58,496 \n$ 100,330 \n$ 81,288 \n$ 27,088 \n$ 42,473 \n$ 29,746 \n$ 31,408 \n$ 57,857 \n$ 51,542 \n(42)\n\n(36)\n\n(46)\n\n2023 v. 2022\nThe following provides an analysis of the worldwide change in Total revenues by geographic areas from 2022 to 2023:\n(MILLIONS)\nWorldwide\nU.S.\nInternational\nOperational growth/(decline):",
      "char_count": 973,
      "start_char": 267200,
      "end_char": 268174
    },
    {
      "chunk_id": "pfizer_2023_chunk0335",
      "chunk_index": 335,
      "text": "g provides an analysis of the worldwide change in Total revenues by geographic areas from 2022 to 2023:\n(MILLIONS)\nWorldwide\nU.S.\nInternational\nOperational growth/(decline):\nWorldwide declines from Comirnaty\n(26,423)\n(6,370)\n(20,053)\nWorldwide declines from Paxlovid\n(17,506)\n(11,803)\n(5,703)\nWorldwide growth from the Vyndaqel family, Eliquis, the Prevnar family and Inlyta, partially offset by worldwide\ndeclines from Ibrance, Xeljanz and Xtandi\n1,016 \n1,018 \n(2)\nIncrease in revenues from Nurtec ODT/Vydura and Oxbryta, which were acquired in the fourth quarter of 2022\n\nRevenues from Abrysvo, primarily driven by launch of the older adult indication in the U.S. in July 2023\n\nRevenues from legacy Seagen products subsequent to the acquisition on December 14, 2023\n\nOther operational factors, net\n\n(185)",
      "char_count": 806,
      "start_char": 268000,
      "end_char": 268807
    },
    {
      "chunk_id": "pfizer_2023_chunk0336",
      "chunk_index": 336,
      "text": "(185)\n\nOperational growth/(decline), net\n(40,812)\n(15,385)\n(25,428)\nUnfavorable impact of foreign exchange\n(1,022)\n(1,022)\nTotal revenues increase/(decrease)\n(41,834)\n(15,385)\n(26,449)\nEmerging markets revenues decreased $8.1 billion, or 40%, in 2023 to $12.0 billion from $20.1 billion in 2022, reflecting an operational decrease of $7.4 billion, or 37%, and an\nunfavorable impact from foreign exchange of 3%. The operational decrease in emerging markets revenues was primarily driven by declines from Comirnaty and Paxlovid, partially\noffset by growth from Lorbrena, Zavicefta and Eliquis.\nSee the Total Revenues––Selected Product Discussion section within MD&A for additional analysis.\nProduct Revenue Deductions––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the\nrevenues are recognized.",
      "char_count": 879,
      "start_char": 268800,
      "end_char": 269681
    },
    {
      "chunk_id": "pfizer_2023_chunk0337",
      "chunk_index": 337,
      "text": "are estimated and recorded in the same period that the\nrevenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these\nproduct revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been\nmaterial to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual\nproduct revenue growth trends.\n\n2023 Form 10-K\n\nThe following presents information about product revenue deductions:\n \nYear Ended December 31,\n(MILLIONS)\n\nMedicare rebates\n\n\n\nMedicaid and related state program rebates\n1,655",
      "char_count": 806,
      "start_char": 269600,
      "end_char": 270409
    },
    {
      "chunk_id": "pfizer_2023_chunk0338",
      "chunk_index": 338,
      "text": "s\n1,655 \n\n1,214 \nPerformance-based contract rebates\n5,159 \n3,575 \n3,253 \nChargebacks\n9,828 \n7,560 \n6,122 \nSales allowances\n6,790 \n5,460 \n4,809 \nSales returns and cash discounts\n5,619 \n1,290 \n1,054 \nTotal\n30,048 \n19,697 \n17,178 \nThe increase in sales returns and cash discounts in 2023 was primarily due to the revenue reversal of $3.5 billion in the fourth quarter of 2023, related to the expected return of an estimated 6.5 million\ntreatment courses of EUA-labeled U.S. government Paxlovid inventory (see Note 17C).\nProduct revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.\nFor information on our accruals for product revenue deductions, including the balance sheet classification of these accruals, see Note 1G.\n(a)\n(a) \n\n2023 Form 10-K\n\nTotal Revenues—Selected Product Discussion\nBiopharma\nRevenue\n(MILLIONS)\nYear Ended Dec. 31,\n% Change\nProduct\nGlobal\nRevenues\nRegion",
      "char_count": 962,
      "start_char": 270400,
      "end_char": 271363
    },
    {
      "chunk_id": "pfizer_2023_chunk0339",
      "chunk_index": 339,
      "text": "1G.\n(a)\n(a) \n\n2023 Form 10-K\n\nTotal Revenues—Selected Product Discussion\nBiopharma\nRevenue\n(MILLIONS)\nYear Ended Dec. 31,\n% Change\nProduct\nGlobal\nRevenues\nRegion\n\nTotal\nOper.\nOperational Results Commentary\nComirnaty\n$11,220\nDown 70%\n(operationally)\nU.S.\n2,404 \n8,775 \n(73)\nDeclines largely driven by lower contracted deliveries and demand in\ninternational markets and lower U.S. government contracted deliveries, due to\ntransition to new variant vaccines in most markets and the transition to traditional\nU.S. commercial market sales which began in September 2023.\nInt’l.\n8,816 \n29,032 \n(70)\n(69)\nWorldwide\n11,220 \n37,806 \n(70)\n(70)\nEliquis\n$6,747\nUp 5%\n(operationally)\nU.S.\n4,228 \n3,822 \n\nGrowth driven primarily by continued oral anti-coagulant adoption and market\nshare gains in the non-valvular atrial fibrillation indication in the U.S.",
      "char_count": 841,
      "start_char": 271200,
      "end_char": 272043
    },
    {
      "chunk_id": "pfizer_2023_chunk0340",
      "chunk_index": 340,
      "text": "atrial fibrillation indication in the U.S. and certain\nmarkets in Europe, partially offset by declines due to LOE and generic\ncompetition in certain international markets.\nInt’l.\n2,519 \n2,658 \n(5)\n(3)\nWorldwide\n6,747 \n6,480 \n\nPrevnar family\n$6,440\nUp 3%\n(operationally)\nU.S.\n4,204 \n4,032 \n\nGrowth primarily driven by the adult indications in the U.S. due to strong patient\ndemand for Prevnar 20 for the eligible adult population, partially offset by the\nPrevnar pediatric indication in the U.S. driven by lower market share due to\ncompetitor entry.\nInt’l.\n2,236 \n2,305 \n(3)\nWorldwide\n6,440 \n6,337 \n\nIbrance\n$4,753\nDown 6%\n \n(operationally)\nU.S.\n3,151 \n3,370 \n(6)\nDeclines primarily driven by lower demand globally due to competitive pressure,\nlower clinical trial purchases internationally, and planned price decreases in\ncertain international developed markets.\nInt’l.\n1,602 \n1,751 \n(8)\n(6)\nWorldwide\n4,753 \n5,120 \n(7)\n(6)\nVyndaqel family\n$3,321\nUp 36%\n(operationally)\nU.S.\n1,863 \n1,245",
      "char_count": 987,
      "start_char": 272000,
      "end_char": 272989
    },
    {
      "chunk_id": "pfizer_2023_chunk0341",
      "chunk_index": 341,
      "text": "ed price decreases in\ncertain international developed markets.\nInt’l.\n1,602 \n1,751 \n(8)\n(6)\nWorldwide\n4,753 \n5,120 \n(7)\n(6)\nVyndaqel family\n$3,321\nUp 36%\n(operationally)\nU.S.\n1,863 \n1,245 \n\nGrowth largely driven by continued strong uptake of the ATTR-CM indication,\nprimarily in the U.S. and developed Europe, partially offset by a planned price\ndecrease that went into effect in Japan in the second quarter of 2022.\nInt’l.\n1,458 \n1,202 \n\nWorldwide\n3,321 \n2,447 \n\nXeljanz\n$1,703\nDown 4%\n(operationally)\nU.S.\n1,154 \n1,129 \n\nDecline driven primarily by decreased prescription volumes globally resulting\nfrom ongoing shifts in prescribing patterns related to label changes, partially\noffset by higher net price in the U.S. due to favorable changes in channel mix.\nInt’l.\n\n(18)\n(15)\nWorldwide\n1,703 \n1,796 \n(5)\n(4)\nPaxlovid\n$1,279\nDown 92%\n(operationally)\nU.S.\n(1,289)\n10,514 \nDeclines primarily driven by:\na non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of",
      "char_count": 980,
      "start_char": 272800,
      "end_char": 273781
    },
    {
      "chunk_id": "pfizer_2023_chunk0342",
      "chunk_index": 342,
      "text": "6 \n(5)\n(4)\nPaxlovid\n$1,279\nDown 92%\n(operationally)\nU.S.\n(1,289)\n10,514 \nDeclines primarily driven by:\na non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of\n2023, of which a portion was associated with sales recorded in 2022, related\nto the expected return of an estimated 6.5 million treatment courses of EUAlabeled U.S. government inventory (see Note 17C); and\nlower contractual deliveries in most international markets,\npartially offset by:\nstrong demand in China under the temporary National Reimbursement Drug\nList (which ended on April 1, 2023) due to surge in COVID-19 infection during\nthe first quarter of 2023; and\nfourth quarter sales under traditional commercial markets following transition,\nprimarily in the U.S.\nInt’l.\n2,568 \n8,419 \n(69)\n(68)\nWorldwide\n1,279 \n18,933 \n(93)\n(92)\nXtandi\n$1,191\nDown 1%\n(operationally)\nU.S.\n1,191 \n1,198 \n(1)\nDecline driven by lower net price mainly due to unfavorable changes in channel\nmix, partially offset by higher demand.",
      "char_count": 995,
      "start_char": 273600,
      "end_char": 274596
    },
    {
      "chunk_id": "pfizer_2023_chunk0343",
      "chunk_index": 343,
      "text": ",933 \n(93)\n(92)\nXtandi\n$1,191\nDown 1%\n(operationally)\nU.S.\n1,191 \n1,198 \n(1)\nDecline driven by lower net price mainly due to unfavorable changes in channel\nmix, partially offset by higher demand.\nInt’l.\nWorldwide\n1,191 \n1,198 \n(1)\n(1)\nInlyta\n$1,036\nUp 5%\n(operationally)\nU.S.\n\n\nGrowth primarily reflects continued growth in emerging markets and the U.S.\ndriven by the adoption of combinations of certain immune checkpoint inhibitors\nand Inlyta for the first-line treatment of patients with advanced RCC, partially\noffset by lower volumes and lower net price in certain European markets.\nInt’l.\n\nWorldwide\n1,036 \n1,003 \n\nNurtec\nODT/Vydura\n$928\nU.S.\n\n\nGrowth primarily driven by timing of the acquisition of Biohaven (fourth quarter of\n2022) as well as strong patient demand in the U.S. See Note 2A.\nInt’l.\n\nWorldwide\n\n\n(a)\n\n2023 Form 10-K\n\nBusiness Innovation\nRevenue\n(MILLIONS)\nYear Ended Dec. 31,\n% Change\nOperating\nSegment\nGlobal\nRevenues\nRegion",
      "char_count": 947,
      "start_char": 274400,
      "end_char": 275348
    },
    {
      "chunk_id": "pfizer_2023_chunk0344",
      "chunk_index": 344,
      "text": "t’l.\n\nWorldwide\n\n\n(a)\n\n2023 Form 10-K\n\nBusiness Innovation\nRevenue\n(MILLIONS)\nYear Ended Dec. 31,\n% Change\nOperating\nSegment\nGlobal\nRevenues\nRegion\n\nTotal\nOper.\nOperational Results Commentary\nBusiness\nInnovation\n$1,310\nDown 2%\n(operationally)\nU.S.\n\n\nDecline primarily driven by a reduction in Comirnaty supply to BioNTech and\nlower revenues from our active pharmaceutical ingredient sales operation,\npartially offset by higher manufacturing activities performed on behalf of\ncustomers as well as an increase in R&D services to select innovative biotech\ncompanies under our Pfizer Ignite operations.\nInt’l.\n\n(3)\n(3)\nWorldwide\n1,310 \n1,342 \n(2)\n(2)\nComirnaty includes direct sales and Alliance revenues related to sales of the Pfizer-BioNTech COVID-19 vaccine, which are recorded within our Primary Care customer group.",
      "char_count": 817,
      "start_char": 275200,
      "end_char": 276018
    },
    {
      "chunk_id": "pfizer_2023_chunk0345",
      "chunk_index": 345,
      "text": "e customer group. It does not include revenues\nfor certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in PC1, which is part of the Business Innovation operating segment. See Note 17C.\nIndicates calculation not meaningful.\nSee the Item 1. Business—Patents and Other Intellectual Property Rights section for information regarding the expiration of various patent rights, Note 16 for a discussion of recent\ndevelopments concerning patent and product litigation relating to certain of the products discussed above and Note 17C for the primary indications or class of the selected products\ndiscussed above.\nCosts and Expenses\nCosts and expenses follow:\nYear Ended December 31,\n% Change\n(MILLIONS)\n\n23/22\n22/21\nCost of sales\n24,954 \n34,344 \n30,821 \n(27)\n\nPercentage of Total revenues\n42.7 %\n34.2 %\n37.9 %\nSelling, informational and administrative expenses\n14,771 \n13,677 \n12,703 \n\nResearch and development expenses\n10,679 \n11,428 \n10,360 \n(7)",
      "char_count": 988,
      "start_char": 276000,
      "end_char": 276989
    },
    {
      "chunk_id": "pfizer_2023_chunk0346",
      "chunk_index": 346,
      "text": "Percentage of Total revenues\n42.7 %\n34.2 %\n37.9 %\nSelling, informational and administrative expenses\n14,771 \n13,677 \n12,703 \n\nResearch and development expenses\n10,679 \n11,428 \n10,360 \n(7)\n\nAcquired in-process research and development expenses\n\n3,469 \n(80)\n(73)\nAmortization of intangible assets\n4,733 \n3,609 \n3,700 \n\n(2)\nRestructuring charges and certain acquisition-related\ncosts\n2,943 \n1,375 \n\n\nOther (income)/deductions—net\n(835)\n\n(4,878)\nIndicates calculation not meaningful.\nBeginning in 2024, we will include royalty income in Total revenues and will restate prior periods for consistency with our 2024 presentation.\n2023 v. 2022\nCost of Sales\nCost of sales decreased $9.4 billion, primarily due to:\n• a reduction of $14.2 billion due to lower sales of Comirnaty; and\n• a reduction of $1.5 billion due to lower sales of Paxlovid,\npartially offset by:\n• non-cash charges of $6.2 billion for inventory write-offs and related charges ($5.0 billion for Paxlovid and $1.2 billion for Comirnaty).",
      "char_count": 996,
      "start_char": 276800,
      "end_char": 277798
    },
    {
      "chunk_id": "pfizer_2023_chunk0347",
      "chunk_index": 347,
      "text": "lion due to lower sales of Paxlovid,\npartially offset by:\n• non-cash charges of $6.2 billion for inventory write-offs and related charges ($5.0 billion for Paxlovid and $1.2 billion for Comirnaty).\nThe increase in Cost of sales as a percentage of Total revenues was mainly driven by the non-cash charge of $6.2 billion discussed above, and unfavorable changes in sales mix,\nprimarily due to lower sales of Paxlovid and Comirnaty, which includes the unfavorable impact of the $3.5 billion non-cash Paxlovid revenue reversal.\nSelling, Informational and Administrative Expenses\nSelling, informational and administrative expenses increased $1.1 billion, mostly due to:\n• an increase of $1.1 billion in marketing and promotional expenses for recently acquired and launched products;\n• an increase of $280 million for the expected Paxlovid commercial launch;\n• an increase of $210 million in our liability to be paid to participants of our supplemental savings plan; and",
      "char_count": 964,
      "start_char": 277600,
      "end_char": 278565
    },
    {
      "chunk_id": "pfizer_2023_chunk0348",
      "chunk_index": 348,
      "text": "million for the expected Paxlovid commercial launch;\n• an increase of $210 million in our liability to be paid to participants of our supplemental savings plan; and\n• an increase of $170 million in marketing and promotional expenses for rare disease products,\npartially offset by:\n• a decrease of $690 million due to a lower provision for U.S. healthcare reform fees related to Comirnaty and Paxlovid.\nResearch and Development Expenses\nResearch and development expenses decreased $749 million, primarily due to:\n• lower spending of $870 million mainly for lower compensation-related expenses, and ongoing vaccine and hospital programs, as well as\n• a decrease of $260 million in the value of the portfolio performance share grants reflecting the decrease in the price of Pfizer’s common stock,\n(a)\n(a)\n(a)\n\n2023 Form 10-K",
      "char_count": 821,
      "start_char": 278400,
      "end_char": 279222
    },
    {
      "chunk_id": "pfizer_2023_chunk0349",
      "chunk_index": 349,
      "text": ")\n(a)\n\n2023 Form 10-K\n\npartially offset by:\n• increased investments of $345 million, mainly to develop certain acquired assets, as well as activities to support upcoming product launches.\nAcquired In-Process Research and Development Expenses\nAcquired in-process research and development expenses decreased $758 million primarily reflecting the non-recurrence of:\n• an upfront payment of $426 million related to the closing of the acquisition of ReViral Ltd. in 2022;\n• an upfront payment to Biohaven and a premium paid on our equity investment in Biohaven totaling $263 million in 2022; and\n• a $76 million premium paid on our equity investment in BioNTech to develop a potential mRNA vaccine against shingles, both recorded in 2022.\nSee Notes 2A and 2E.\nAmortization of Intangible Assets\nAmortization of intangible assets increased $1.1 billion, primarily as a result of 2023 reflecting a full year of amortization of intangible assets from our acquisitions of Biohaven and",
      "char_count": 974,
      "start_char": 279200,
      "end_char": 280175
    },
    {
      "chunk_id": "pfizer_2023_chunk0350",
      "chunk_index": 350,
      "text": "n of intangible assets increased $1.1 billion, primarily as a result of 2023 reflecting a full year of amortization of intangible assets from our acquisitions of Biohaven and\nGBT, higher amortization of intangible assets related to Prevnar, as well as reclassifications of IPR&D to developed technology rights, partially offset by fully amortized assets. See\nNotes 2A and 10A.\nRestructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives\nTransforming to a More Focused Company Program––In connection with restructuring our corporate enabling functions, we achieved gross cost savings of $1.0 billion, or net cost\nsavings, excluding merit and inflation growth and certain real estate cost increases, of $700 million, in the two year period from 2021 through 2022. In connection with transforming\nour commercial go-to market strategy, we expect net cost savings of $1.4 billion, to be achieved primarily from 2022 through 2024.",
      "char_count": 975,
      "start_char": 280000,
      "end_char": 280976
    },
    {
      "chunk_id": "pfizer_2023_chunk0351",
      "chunk_index": 351,
      "text": "hrough 2022. In connection with transforming\nour commercial go-to market strategy, we expect net cost savings of $1.4 billion, to be achieved primarily from 2022 through 2024. In connection with manufacturing network\noptimization, we achieved net cost savings of $550 million. In connection with optimizing our end-to-end R&D operations, we expect net cost savings of $2.3 billion to be achieved\nprimarily from 2023 through 2025.\nRealigning our Cost Base Program––This program is expected to deliver net cost savings of at least $4 billion, to be achieved primarily from 2023 through 2024.\nCertain qualifying costs for these programs were recorded in 2023, 2022 and 2021, and are reflected as Certain Significant Items and excluded from our non-GAAP measure of\nAdjusted Income. See the Non-GAAP Financial Measure: Adjusted Income section within MD&A.\nIn connection with our acquisition of Seagen, we are focusing our efforts on achieving an appropriate cost structure for the combined company.",
      "char_count": 993,
      "start_char": 280800,
      "end_char": 281794
    },
    {
      "chunk_id": "pfizer_2023_chunk0352",
      "chunk_index": 352,
      "text": "cial Measure: Adjusted Income section within MD&A.\nIn connection with our acquisition of Seagen, we are focusing our efforts on achieving an appropriate cost structure for the combined company. We expect to generate approximately\n$1 billion of annual cost synergies, to be achieved by 2026.\nFor a description of our programs, as well as the anticipated and actual costs, see Note 3A, The program savings discussed above may be rounded and represent approximations.\nIn addition to these programs, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the\nexpiration of collaborative arrangements for various products.\nOther (Income)/Deductions––Net\nThe favorable period-over-period change of $1.1 billion was primarily driven by net gains on equity securities in 2023 versus net losses recognized on equity securities in 2022 and",
      "char_count": 920,
      "start_char": 281600,
      "end_char": 282521
    },
    {
      "chunk_id": "pfizer_2023_chunk0353",
      "chunk_index": 353,
      "text": "primarily driven by net gains on equity securities in 2023 versus net losses recognized on equity securities in 2022 and\nlower net interest expense, partially offset by higher intangible asset impairment charges. See\nNote 4.\nUpjohn Separation Costs\nSince inception through December 31, 2023, we have incurred substantially all costs of approximately $700 million in connection with separating Upjohn, including costs and\nexpenses related to separation of legal entities and transaction costs.\nProvision/(Benefit) for Taxes on Income\n \nYear Ended December 31,\n% Change\n(MILLIONS)\n\n23/22\n22/21\nProvision/(benefit) for taxes on income\n(1,115)\n3,328 \n1,852 \n\nEffective tax rate on continuing operations\n(105.4)%\n9.6 %\n7.6 %\nIndicates calculation not meaningful.\nFor information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted\nour tax provisions, see Note 5.",
      "char_count": 969,
      "start_char": 282400,
      "end_char": 283370
    },
    {
      "chunk_id": "pfizer_2023_chunk0354",
      "chunk_index": 354,
      "text": "te and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted\nour tax provisions, see Note 5.\nChanges in Tax Laws––Many countries outside the U.S. have enacted legislation for global minimum taxation resulting from the Organization for Economic Co-operation and\nDevelopment’s (OECD) Base Erosion and Profit Shifting “Pillar 2” project. The EU has approved a directive requiring member states to incorporate the OECD provisions into their\nrespective domestic laws, and other countries outside the EU are also enacting the provisions into their domestic law. The provisions are generally effective for Pfizer in 2024,\nthough significant details and guidance around the provisions are still pending. Income tax expense could be adversely affected as the legislation becomes effective in countries in\nwhich we do business, and such impact could be material to our results of operations.",
      "char_count": 958,
      "start_char": 283200,
      "end_char": 284159
    },
    {
      "chunk_id": "pfizer_2023_chunk0355",
      "chunk_index": 355,
      "text": "adversely affected as the legislation becomes effective in countries in\nwhich we do business, and such impact could be material to our results of operations. We continue to monitor pending OECD guidance and legislation enactment and\nimplementation by individual countries.\nDiscontinued Operations\nFor information about our discontinued operations, see Note 2B.\n\n2023 Form 10-K\n\nPRODUCT DEVELOPMENTS\nA comprehensive update of Pfizer’s development pipeline was published as of January 30, 2024 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an\noverview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase\n1 and all candidates from Phase 2 through registration.\nThis section provides information as of the date of this filing about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory",
      "char_count": 987,
      "start_char": 284000,
      "end_char": 284989
    },
    {
      "chunk_id": "pfizer_2023_chunk0356",
      "chunk_index": 356,
      "text": "ion.\nThis section provides information as of the date of this filing about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory\nauthorities in the EU and Japan.\nThe tables below include filing and approval milestones for products that have occurred in the last twelve months and generally do not include approvals that may have occurred\nprior to that time. The tables include filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).\nCOVID-19 Vaccine Products\nBeginning with the original monovalent Pfizer-BioNTech COVID-19 Vaccine, initially authorized for emergency use, to Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula),\napproved by the FDA for individuals 12 years and older and the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) authorized by the FDA for emergency use for individuals 6",
      "char_count": 920,
      "start_char": 284800,
      "end_char": 285721
    },
    {
      "chunk_id": "pfizer_2023_chunk0357",
      "chunk_index": 357,
      "text": "r and the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) authorized by the FDA for emergency use for individuals 6\nmonths through 11 years of age, efforts to stay current with circulating COVID-19 strains have resulted in the rapid development of targeted, adapted vaccines for licensure in the\nU.S., Europe, Japan and other markets. The adapted vaccines have included two bivalent formulations (Original and Omicron BA.1, not authorized in the U.S., and Original and\nOmicron BA.4/BA.5). As updated COVID-19 vaccines are formulated to more closely target currently circulating vaccines, prior vaccine formulations are generally no longer utilized\nin a majority of the markets.\nThe 2023-2024 Formula includes a monovalent (single) component that corresponds to the Omicron sub-variant XBB.1.5 of severe acute respiratory syndrome coronavirus 2\n(SARS-CoV-2).",
      "char_count": 862,
      "start_char": 285600,
      "end_char": 286463
    },
    {
      "chunk_id": "pfizer_2023_chunk0358",
      "chunk_index": 358,
      "text": "severe acute respiratory syndrome coronavirus 2\n(SARS-CoV-2). The table below summarizes the approval of the 2023-2024 Formula in the markets indicated:\nPRODUCT\nINDICATION\nREGULATORY STATUS\nU.S.\nJAPAN\nComirnaty\n(COVID-19 Vaccine,\nmRNA, 2023-2024 Formula)\nActive immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months\nthrough 4 years of age\nAuthorized\nSeptember\n\nApproved\nAugust\n\nApproved\nSeptember\n\nActive immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 5 through\n11 years of age\nAuthorized\nSeptember\n\nApproved\nAugust\n\nApproved\nSeptember\n\nActive immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of\nage and older\nApproved\nSeptember\n\nApproved\nAugust\n\nApproved\nSeptember\n\nIn September 2023, Pfizer and BioNTech announced the FDA approved a regulatory application for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 12 years of age and older\n(Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula)).",
      "char_count": 995,
      "start_char": 286400,
      "end_char": 287397
    },
    {
      "chunk_id": "pfizer_2023_chunk0359",
      "chunk_index": 359,
      "text": "A approved a regulatory application for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 12 years of age and older\n(Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula)). The FDA also granted EUA for the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 months through 11 years of\nage (Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)).\n(a)\n(a)\n\n2023 Form 10-K\n\nOther Products\nPRODUCT\nINDICATION OR PROPOSED INDICATION\nAPPROVED/FILED*\nU.S.\nJAPAN\nNgenla\n(somatrogon)\nPediatric growth hormone deficiency\nApproved\nJune\n\nApproved\nFebruary\n\nApproved\nJanuary\n\nPrevnar 20/Apexxnar\n(Vaccine)\nActive immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus\npneumoniae (adults)\nApproved\nJune\n\nApproved\nFebruary\n\nFiled\nSeptember\n\nActive immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus\npneumoniae (pediatric)\nApproved\nApril\n\nFiled\nNovember\n\nFiled\nMarch",
      "char_count": 971,
      "start_char": 287200,
      "end_char": 288172
    },
    {
      "chunk_id": "pfizer_2023_chunk0360",
      "chunk_index": 360,
      "text": "ber\n\nActive immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus\npneumoniae (pediatric)\nApproved\nApril\n\nFiled\nNovember\n\nFiled\nMarch\n\nTicoVac\n(Vaccine)\nActive immunization to prevent tick-borne encephalitis disease\nApproved\nAugust\n\nFiled\nMarch\n\nPaxlovid (nirmatrelvir and\nritonavir)\nCOVID-19 in high-risk adults\nApproved\nMay\n\nApproved\nFebruary\n\nApproved\nJuly\n\nNurtec ODT/Vydura\n(rimegepant)\nAcute treatment of migraine with or without aura (adults)\nApproved\nFebruary\n\nApproved\nApril\n\nPrevention of episodic migraine (adults)\nApproved\nMay\n\nApproved\nApril\n\nLitfulo/Ritfulo\n(ritlecitinib)\nAlopecia areata\nApproved\nJune\n\nApproved\nSeptember\n\nApproved\nJune\n\nZavzpret (zavegepant)\n(intranasal)\nAcute treatment of migraine with or without aura (adults)\nApproved\nMarch\n\nPenbraya (PF-06886992)\n(Vaccine)\nActive immunization to prevent serogroups ABCWY meningococcal infections (adolescent and young adults)\nApproved\nOctober\n\nFiled\nJune",
      "char_count": 964,
      "start_char": 288000,
      "end_char": 288965
    },
    {
      "chunk_id": "pfizer_2023_chunk0361",
      "chunk_index": 361,
      "text": "Penbraya (PF-06886992)\n(Vaccine)\nActive immunization to prevent serogroups ABCWY meningococcal infections (adolescent and young adults)\nApproved\nOctober\n\nFiled\nJune\n\nAbrysvo\n(Vaccine)\nActive immunization to prevent RSV infection (maternal)\nApproved\nAugust\n\nApproved\nAugust\n\nApproved\nJanuary\n\nActive immunization to prevent RSV infection (older adults)\nApproved\nMay\n\nApproved\nAugust\n\nFiled\nMay\n\nVelsipity (etrasimod)\nUlcerative colitis (moderately to severely active)\nApproved\nOctober\n\nApproved\nFebruary\n\nBraftovi (encorafenib) and Mektovi\n(binimetinib)\nBRAF\n-mutant metastatic non-small cell lung cancer\nApproved\nOctober\n\nFiled\nOctober\n\nElrexfio (elranatamab)\nMultiple myeloma triple-class relapsed/refractory\nApproved\nAugust\n\nApproved\nDecember\n\nFiled\nJune\n\nTalzenna (talazoparib)\nCombination with Xtandi (enzalutamide) for adult patients with homologous recombination repair (HRR) genemutated mCRPC\nApproved\nJune\n\nApproved\nJanuary\n\nApproved\nJanuary",
      "char_count": 949,
      "start_char": 288800,
      "end_char": 289750
    },
    {
      "chunk_id": "pfizer_2023_chunk0362",
      "chunk_index": 362,
      "text": "andi (enzalutamide) for adult patients with homologous recombination repair (HRR) genemutated mCRPC\nApproved\nJune\n\nApproved\nJanuary\n\nApproved\nJanuary\n\nTreatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer who have been treated\nwith cancer chemotherapy\nApproved\nOctober\n\nApproved\nJune\n\nApproved\nJanuary\n\nfidanacogene elaparvovec (PF06838435)\nHemophilia B (adults)\nFiled\nJune\n\nFiled\nMay\n\nXtandi (enzalutamide)\nnmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR)\nApproved\nNovember\n\nFiled\nSeptember\n\nmarstacimab (PF-06741086)\nHemophilia A and B\nFiled\nDecember\n\nFiled\nOctober\n\naztreonam-avibactam\n(PF-06947387)\nTreatment of infections caused by Gram-negative bacteria with limited or no treatment options\nFiled\nSeptember\n\nPadcev (enfortumab vedotin-ejfv)\nIn combination with Keytruda (pembrolizumab) for locally advanced or metastatic urothelial cancer (adults)\nApproved\nDecember\n\nFiled\nJanuary\n\nFiled\nJanuary",
      "char_count": 962,
      "start_char": 289600,
      "end_char": 290563
    },
    {
      "chunk_id": "pfizer_2023_chunk0363",
      "chunk_index": 363,
      "text": "n-ejfv)\nIn combination with Keytruda (pembrolizumab) for locally advanced or metastatic urothelial cancer (adults)\nApproved\nDecember\n\nFiled\nJanuary\n\nFiled\nJanuary\n\nTivdak (tisotumab vedotin-tftv)\nRecurrent or metastatic cervical cancer with disease progression on or after first-line therapy\nFiled\nJanuary\n\nFiled\nFebruary\n\nTukysa (tucatinib)\nIn combination with trastuzumab for HER2-positive metastatic colorectal cancer that has progressed following\ntreatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy\nApproved\nJanuary\n\n(a)\n(b)\nV600E\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(i)\n(j)\n(k)\n\n2023 Form 10-K\n\nFor the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission.\nBeing developed in collaboration with OPKO.\nPreviously authorized under EUA in the U.S. (December 2021) and approved by the FDA in high-risk adults (May 2023).",
      "char_count": 944,
      "start_char": 290400,
      "end_char": 291345
    },
    {
      "chunk_id": "pfizer_2023_chunk0364",
      "chunk_index": 364,
      "text": "in collaboration with OPKO.\nPreviously authorized under EUA in the U.S. (December 2021) and approved by the FDA in high-risk adults (May 2023). Remains under EUA for children (12-18 years of age; >88lbs) in the U.S.\nPierre Fabre is the Marketing Authorization Holder for Braftovi (encorafenib) and Mektovi (binimetinib) in the EU.\nListed indication applies to U.S. only. EU indication (all comers): mCRPC in whom chemotherapy is not clinically indicated; Japan indication: BRCA gene-mutated mCRPC.\nBeing developed in collaboration with Spark Therapeutics, Inc.\nBeing developed in collaboration with Astellas.\nBeing developed in collaboration with AbbVie. AbbVie has the exclusive commercialization rights to this investigative therapy in the U.S. and Canada; Pfizer leads the joint development program and has\ncommercialization rights in all other countries.\nBeing developed in collaboration with Astellas.\nKeytruda is a registered trademark of Merck Sharp & Dohme Corp.",
      "char_count": 970,
      "start_char": 291200,
      "end_char": 292172
    },
    {
      "chunk_id": "pfizer_2023_chunk0365",
      "chunk_index": 365,
      "text": "am and has\ncommercialization rights in all other countries.\nBeing developed in collaboration with Astellas.\nKeytruda is a registered trademark of Merck Sharp & Dohme Corp.\nBeing developed in collaboration with Genmab.\nJanuary 2024 filing date refers to application for conversion from accelerated to full approval.\nThe following provides information about additional indications and new drug candidates in late-stage development:\nPRODUCT/CANDIDATE\nPROPOSED DISEASE AREA\nLATE-STAGE\nCLINICAL PROGRAMS\nFOR ADDITIONAL USES\nAND DOSAGE FORMS\nFOR IN-LINE AND INREGISTRATION\nPRODUCTS\nIbrance (palbociclib)\nER+/HER2+ metastatic breast cancer\nTalzenna (talazoparib)\nCombination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC\nNgenla (somatrogon)\nAdult growth hormone deficiency\nBraftovi (encorafenib) and Erbitux®\n(cetuximab)\nFirst-line BRAF\n-mutant mCRC\nPaxlovid (nirmatrelvir; ritonavir)\nCOVID-19 in high-risk children (6-11 years of age; >88lbs)\nLitfulo (ritlecitinib)\nVitiligo",
      "char_count": 987,
      "start_char": 292000,
      "end_char": 292988
    },
    {
      "chunk_id": "pfizer_2023_chunk0366",
      "chunk_index": 366,
      "text": "afenib) and Erbitux®\n(cetuximab)\nFirst-line BRAF\n-mutant mCRC\nPaxlovid (nirmatrelvir; ritonavir)\nCOVID-19 in high-risk children (6-11 years of age; >88lbs)\nLitfulo (ritlecitinib)\nVitiligo\nElrexfio (elranatamab)\nMultiple myeloma double-class exposed\nNewly diagnosed multiple myeloma post-transplant maintenance\nNewly diagnosed multiple myeloma transplant-ineligible\nOxbryta (voxelotor)\nSickle cell disease (pediatric)\nEliquis (apixaban)\nVenous thromboembolism (pediatric)\nAbrysvo (vaccine)\nActive immunization to prevent RSV infection in adults (18-59)\nPadcev (enfortumab vedotin)\nCisplatin-ineligible/decline muscle-invasive bladder cancer\nCisplatin-eligible muscle-invasive bladder cancer\nTukysa (tucatinib)\nHER2+ adjuvant breast cancer\n2nd line/3rd line HER2+ metastatic breast cancer\n1st line HER2+ metastatic colorectal cancer \nNEW DRUG\nCANDIDATES IN LATESTAGE DEVELOPMENT\ngiroctocogene fitelparvovec\n(PF-07055480)\nHemophilia A\nPF-06425090 (Vaccine)",
      "char_count": 953,
      "start_char": 292800,
      "end_char": 293754
    },
    {
      "chunk_id": "pfizer_2023_chunk0367",
      "chunk_index": 367,
      "text": "+ metastatic colorectal cancer \nNEW DRUG\nCANDIDATES IN LATESTAGE DEVELOPMENT\ngiroctocogene fitelparvovec\n(PF-07055480)\nHemophilia A\nPF-06425090 (Vaccine)\nImmunization to prevent primary clostridioides difficile infection\nsasanlimab (PF-06801591)\nCombination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer\nfordadistrogene movaparvovec (PF06939926)\nDuchenne muscular dystrophy (ambulatory)\nVLA15 (PF-07307405) vaccine\nImmunization to prevent Lyme disease\nPF-07252220 (quadrivalent mRNA-based\nvaccine)\nImmunization to prevent influenza\nVepdegestrant (PF-07850327)\nBreast cancer metastatic - 2 line ER+/HER2inclacumab (PF-07940370)\nSickle cell disease\nIbrance + vepdegestrant\nER+/HER2- metastatic breast cancer\nDazukibart (PF-06823859)\nDermatomyositis, polymyositis\nDisitamab vedotin\n1st line HER2 (≥IHC1+) metastatic urothelial cancer\nPF-07926307 (COVID/flu combo vaccine) Immunization to prevent COVID infection and influenza\nsisunatovir (PF-07923568)",
      "char_count": 971,
      "start_char": 293600,
      "end_char": 294572
    },
    {
      "chunk_id": "pfizer_2023_chunk0368",
      "chunk_index": 368,
      "text": "n\n1st line HER2 (≥IHC1+) metastatic urothelial cancer\nPF-07926307 (COVID/flu combo vaccine) Immunization to prevent COVID infection and influenza\nsisunatovir (PF-07923568)\nRespiratory syncytial virus infection (adults)\nNote: Braftovi/Mektovi/Keytruda previously listed as a late-stage clinical candidate is no longer considered registrational and has been removed.\nNote: Zavzpret oral for the prevention of chronic migraine previously listed as a late-stage clinical candidate has been removed.\nBeing developed in collaboration with The Alliance Foundation Trials, LLC.\nBeing developed in collaboration with OPKO.\nErbitux is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono.\nBeing developed in collaboration with BMS.\nBeing developed in collaboration with Astellas.\nBeing developed in collaboration with Sangamo Therapeutics, Inc.\nBeing developed in collaboration with Valneva.",
      "char_count": 996,
      "start_char": 294400,
      "end_char": 295397
    },
    {
      "chunk_id": "pfizer_2023_chunk0369",
      "chunk_index": 369,
      "text": "developed in collaboration with BMS.\nBeing developed in collaboration with Astellas.\nBeing developed in collaboration with Sangamo Therapeutics, Inc.\nBeing developed in collaboration with Valneva.\nVepdegestrant is being developed in collaboration with Arvinas.\nBeing developed in collaboration with RemeGen Co., Ltd.\nBeing developed in collaboration with BioNTech.\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(i)\n(j)\n(k)\n(a)\n(b)\n(c)\nV600E\n(d)\n(e)\n(f)\n(g)\n(h)\n(h)\n(i)\n(j)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(i)\n(j)\n\n2023 Form 10-K\n\nFor additional information about our R&D organization, see Note 17 and the Item 1. Business—Research and Development section. For additional information regarding certain\ncollaboration arrangements, see Item 1. Business—Collaboration and Co-Promotion Agreements.\nNON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME\nAdjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP Reported performance\nmeasures.",
      "char_count": 993,
      "start_char": 295200,
      "end_char": 296194
    },
    {
      "chunk_id": "pfizer_2023_chunk0370",
      "chunk_index": 370,
      "text": "ASURE: ADJUSTED INCOME\nAdjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP Reported performance\nmeasures. As such, we believe that investors’ understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted\nincome and Adjusted diluted EPS to present the results of our major operations––the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical\nproducts worldwide––prior to considering certain income statement elements as follows:\nMeasure\nDefinition\nRelevance of Metrics to Our Business\nPerformance\nAdjusted income\nNet income attributable to Pfizer Inc. common shareholders\nbefore the impact of amortization of intangible assets, certain acquisition-related\nitems, discontinued operations and certain significant items\n• Provides investors useful information to:\n◦evaluate the normal recurring",
      "char_count": 982,
      "start_char": 296000,
      "end_char": 296983
    },
    {
      "chunk_id": "pfizer_2023_chunk0371",
      "chunk_index": 371,
      "text": "intangible assets, certain acquisition-related\nitems, discontinued operations and certain significant items\n• Provides investors useful information to:\n◦evaluate the normal recurring\noperational activities, and their\ncomponents, on a comparable yearover-year basis\n◦assist in modeling expected future\nperformance on a normalized basis\n• Provides investors insight into the way\nwe manage our budgeting and\nforecasting, how we evaluate and\nmanage our recurring operations and\nhow we reward and compensate our\nsenior management\nAdjusted cost of sales, Adjusted selling,\ninformational and administrative expenses,\nAdjusted research and development expenses\nand Adjusted other (income)/deductions––net\nCost of sales, Selling, informational and administrative expenses, Research and\ndevelopment expenses and Other (income)/deductions––net\n, each before the\nimpact of amortization of intangible assets, certain acquisition-related items,",
      "char_count": 930,
      "start_char": 296800,
      "end_char": 297731
    },
    {
      "chunk_id": "pfizer_2023_chunk0372",
      "chunk_index": 372,
      "text": "d Other (income)/deductions––net\n, each before the\nimpact of amortization of intangible assets, certain acquisition-related items,\ndiscontinued operations and certain significant items, which are components of the\nAdjusted income measure\nAdjusted diluted EPS\nEPS attributable to Pfizer Inc. common shareholders––diluted before the impact\nof amortization of intangible assets, certain acquisition-related items, discontinued\noperations and certain significant items\nMost directly comparable GAAP measure.\nThe short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part versus three budgeted metrics, one\nof which is Adjusted diluted EPS (as defined for annual incentive compensation purposes), which is derived from Adjusted income and accounts for 40% of the bonus pool funding tied to financial\nperformance.",
      "char_count": 911,
      "start_char": 297600,
      "end_char": 298512
    },
    {
      "chunk_id": "pfizer_2023_chunk0373",
      "chunk_index": 373,
      "text": "h is derived from Adjusted income and accounts for 40% of the bonus pool funding tied to financial\nperformance. Additionally, the payout for performance share awards is determined in part by Adjusted net income, which is derived from Adjusted income. Beginning in the first quarter of 2022, we no\nlonger exclude any expenses for acquired IPR&D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for annual incentive compensation\npurposes. The bonus pool funding, which is largely based on financial performance, is adjusted by our R&D pipeline performance, as measured by four metrics, and performance against certain of our\nESG metrics, and may be further modified by our Compensation Committee’s assessment of other factors.\nAdjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are\nlimited in their usefulness to investors.",
      "char_count": 996,
      "start_char": 298400,
      "end_char": 299397
    },
    {
      "chunk_id": "pfizer_2023_chunk0374",
      "chunk_index": 374,
      "text": "ncome and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are\nlimited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are\npresented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without\nincluding all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their\nmost directly comparable GAAP measures of Net income attributable to Pfizer Inc. common shareholders, components of Net income attributable to Pfizer Inc. common\nshareholders and EPS attributable to Pfizer Inc.",
      "char_count": 903,
      "start_char": 299200,
      "end_char": 300104
    },
    {
      "chunk_id": "pfizer_2023_chunk0375",
      "chunk_index": 375,
      "text": "nents of Net income attributable to Pfizer Inc. common\nshareholders and EPS attributable to Pfizer Inc. common shareholders—diluted, respectively.\nWe also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these\nmeasures. We also use other tools designed to achieve the highest levels of performance. For example, our R&D organization has productivity targets, upon which its effectiveness\nis measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts\nunder certain of our incentive compensation plans.\nAdjusted Income and Adjusted Diluted EPS\nAmortization of Intangible Assets—Adjusted income excludes all amortization of intangible assets.",
      "char_count": 864,
      "start_char": 300000,
      "end_char": 300865
    },
    {
      "chunk_id": "pfizer_2023_chunk0376",
      "chunk_index": 376,
      "text": "—Adjusted income excludes all amortization of intangible assets.\nAcquisition-Related Items––Adjusted income excludes certain acquisition-related items, which are composed of transaction, integration, restructuring charges and additional\ndepreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as\na result of an acquisition. We have made no adjustments for resulting synergies.\nThe significant costs incurred in connection with a business combination result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of\nacquiring a fully integrated set of activities. For this reason, we believe that such costs incurred can be viewed differently in the context of an acquisition from those costs incurred in\nother, more normal, business contexts.",
      "char_count": 903,
      "start_char": 300800,
      "end_char": 301704
    },
    {
      "chunk_id": "pfizer_2023_chunk0377",
      "chunk_index": 377,
      "text": "ly in the context of an acquisition from those costs incurred in\nother, more normal, business contexts. The integration and restructuring costs for a business combination may occur over several years, with the more significant impacts typically\nending within three years of the relevant transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring\nand integration activities can be lengthy.\nAcquisition-related items may include purchase accounting impacts such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair\nvalue, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value\nchanges for contingent consideration.\n(a)\n(b)\n (a)\n(a)\n(a)\n(b)\n\n2023 Form 10-K",
      "char_count": 906,
      "start_char": 301600,
      "end_char": 302507
    },
    {
      "chunk_id": "pfizer_2023_chunk0378",
      "chunk_index": 378,
      "text": "ed debt, and the fair value\nchanges for contingent consideration.\n(a)\n(b)\n (a)\n(a)\n(a)\n(b)\n\n2023 Form 10-K\n\nDiscontinued Operations––Adjusted income excludes the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe\nthat this presentation is meaningful to investors because, while we review our product portfolio for strategic fit with our operations, we do not build or run our business with the intent\nto discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in\nrespect of the restated periods, but are presented for consistency across all periods.\nCertain Significant Items––Adjusted income excludes certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and\nqualitative basis.",
      "char_count": 926,
      "start_char": 302400,
      "end_char": 303327
    },
    {
      "chunk_id": "pfizer_2023_chunk0379",
      "chunk_index": 379,
      "text": "t items representing substantive and/or unusual items that are evaluated individually on a quantitative and\nqualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future\nperiods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs\nbased on reorganizations of the business, cost productivity or in response to LOE or economic conditions. Legal charges to resolve litigation are also related to specific cases, which\nare facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the\ndate of acquisition, or legal matters related to divested products or businesses.",
      "char_count": 906,
      "start_char": 303200,
      "end_char": 304107
    },
    {
      "chunk_id": "pfizer_2023_chunk0380",
      "chunk_index": 380,
      "text": "ble or unresolved at the\ndate of acquisition, or legal matters related to divested products or businesses. Gains and losses on equity securities and pension and postretirement actuarial remeasurement gains\nand losses have a very high degree of inherent market volatility, which we do not control and cannot predict with any level of certainty, and we do not believe including these gains\nand losses assists investors in understanding our business or is reflective of our core operations and business. Unusual items represent items that are not part of our ongoing\nbusiness; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or\nitems that relate to products we no longer sell. See the Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items below for a non-inclusive list of\ncertain significant items.",
      "char_count": 951,
      "start_char": 304000,
      "end_char": 304952
    },
    {
      "chunk_id": "pfizer_2023_chunk0381",
      "chunk_index": 381,
      "text": "the Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items below for a non-inclusive list of\ncertain significant items.\nReconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items\nYear Ended December 31, 2023\nData presented will not (in all cases) aggregate to totals.\nMILLIONS, EXCEPT PER SHARE DATA\nCost of sales\nSelling, informational and\nadministrative expenses\nOther\n(income)/deductions––\nnet\nNet income attributable to\n\nshareholders\nEarnings per\ncommon share\nattributable to Pfizer\nInc. common\nshareholders––\ndiluted\nGAAP Reported\n24,954 \n14,771 \n(835)\n2,119 \n0.37 \nAmortization of intangible assets\n4,733 \nAcquisition-related items\n(629)\n(11)\n(28)\n1,874 \nDiscontinued operations\n(11)\nCertain significant items:\nRestructuring charges/(credits) and implementation\ncosts and additional depreciation—asset\nrestructuring\n(98)\n(290)\n2,227 \nCertain asset impairments\n(3,024)\n3,024 \n(Gains)/losses on equity securities\n1,588 \n(1,588)",
      "char_count": 989,
      "start_char": 304800,
      "end_char": 305791
    },
    {
      "chunk_id": "pfizer_2023_chunk0382",
      "chunk_index": 382,
      "text": "redits) and implementation\ncosts and additional depreciation—asset\nrestructuring\n(98)\n(290)\n2,227 \nCertain asset impairments\n(3,024)\n3,024 \n(Gains)/losses on equity securities\n1,588 \n(1,588)\nActuarial valuation and other pension and\npostretirement plan (gains)/losses\n\n(265)\nOther\n(238)\n(24)\n(246)\n\nIncome tax provision—Non-GAAP items\n(2,131)\nNon-GAAP Adjusted\n23,988 \n14,446 \n(2,281)\n10,501 \n1.84 \nYear Ended December 31, 2022\nData presented will not (in all cases) aggregate to totals.\nMILLIONS, EXCEPT PER SHARE DATA\nCost of sales\nSelling, informational and\nadministrative expenses\nOther\n(income)/deductions––\nnet\nNet income attributable to\n\nshareholders\nEarnings per\ncommon share\nattributable to Pfizer\nInc. common\nshareholders––\ndiluted\nGAAP Reported\n34,344 \n13,677 \n\n31,372 \n5.47 \nAmortization of intangible assets\n3,609 \nAcquisition-related items\n(119)\n(7)\n(74)",
      "char_count": 868,
      "start_char": 305600,
      "end_char": 306469
    },
    {
      "chunk_id": "pfizer_2023_chunk0383",
      "chunk_index": 383,
      "text": "of intangible assets\n3,609 \nAcquisition-related items\n(119)\n(7)\n(74)\n\nDiscontinued operations\n(21)\nCertain significant items:\nRestructuring charges/(credits) and implementation\ncosts and additional depreciation—asset\nrestructuring\n(88)\n(562)\n1,396 \nCertain asset impairments\n(421)\n\n(Gains)/losses on equity securities\n(1,270)\n1,270 \nActuarial valuation and other pension and\npostretirement plan (gains)/losses\n\n(230)\nOther\n(40)\n(59)\n(636)\n\nIncome tax provision—Non-GAAP items\n(1,683)\nNon-GAAP Adjusted\n34,096 \n13,049 \n(1,954)\n37,717 \n6.58 \n(a)\n(a)\n(a)\n(a), (b), (c)\n(d)\n(e)\n(f)\n(f)\n(g)\n(h)\n(a)\n(a)\n(a)\n(a), (b), (c)\n(d)\n(e)\n(f)\n(f)\n(h)\n\n2023 Form 10-K\n\nYear Ended December 31, 2021\nData presented will not (in all cases) aggregate to totals.\nMILLIONS, EXCEPT PER SHARE DATA\nCost of sales\nSelling, informational and\nadministrative expenses\nOther\n(income)/deductions––\nnet\nNet income attributable to",
      "char_count": 897,
      "start_char": 306400,
      "end_char": 307298
    },
    {
      "chunk_id": "pfizer_2023_chunk0384",
      "chunk_index": 384,
      "text": "ormational and\nadministrative expenses\nOther\n(income)/deductions––\nnet\nNet income attributable to\n\nshareholders\nEarnings per\ncommon share\nattributable to Pfizer\nInc. common\nshareholders––\ndiluted\nGAAP Reported\n30,821 \n12,703 \n(4,878)\n21,979 \n3.85 \nAmortization of intangible assets\n(38)\n(2)\n3,746 \nAcquisition-related items\n\n(3)\n(114)\n\nDiscontinued operations\n\nCertain significant items:\nRestructuring charges/(credits) and implementation\ncosts and additional depreciation—asset\nrestructuring\n(108)\n(450)\n1,309 \nCertain asset impairments\n(86)\n\n(Gains)/losses on equity securities\n1,338 \n(1,338)\nActuarial valuation and other pension and\npostretirement plan (gains)/losses\n1,601 \n(1,601)\nOther\n(52)\n(141)\n(334)\n\nIncome tax provision—Non-GAAP items\n(2,250)\nNon-GAAP Adjusted\n30,685 \n12,071 \n(2,475)\n23,196 \n4.06 \nItems that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax.",
      "char_count": 894,
      "start_char": 307200,
      "end_char": 308095
    },
    {
      "chunk_id": "pfizer_2023_chunk0385",
      "chunk_index": 385,
      "text": "196 \n4.06 \nItems that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP Reported income from continuing operations were: (105.4)% in 2023, 9.6% in\n2022 and 7.6% in 2021. See Note 5. Our effective tax rates for non-GAAP Adjusted income were: 9.0% in 2023, 11.7% in 2022 and 14.5% in 2021.\nIncludes reconciling amounts for Research and development expenses that are not material to our non-GAAP consolidated results of operations.\nFor 2023, the total acquisition-related items of $1.9 billion include reconciling amounts for Restructuring charges and certain acquisition-related costs of $1.2 billion, mainly composed of $785 million of\nintegration costs and other charges, $190 million of transaction costs and $125 million of employee termination-related charges.",
      "char_count": 819,
      "start_char": 308000,
      "end_char": 308820
    },
    {
      "chunk_id": "pfizer_2023_chunk0386",
      "chunk_index": 386,
      "text": "on-related charges. For 2022, the total acquisition-related items of $832 million included\nreconciling amounts for Restructuring charges and certain acquisition-related costs of $631 million, composed of $348 million of integration costs and other charges, $144 million of transaction costs and\n$138 million of employee termination-related charges. See Note 3.\nSee Note 2B.\nIncludes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions. See Note 3.\nSee Note 4.\nFor 2023, the total of $238 million mainly includes $286 million in inventory losses, overhead costs related to the period in which the facility could not operate, and incremental costs resulting from tornado\ndamage to our manufacturing facility in Rocky Mount, NC, partially offset by insurance recoveries.",
      "char_count": 874,
      "start_char": 308800,
      "end_char": 309675
    },
    {
      "chunk_id": "pfizer_2023_chunk0387",
      "chunk_index": 387,
      "text": "ing facility in Rocky Mount, NC, partially offset by insurance recoveries.\nFor 2023, the total of $246 million includes charges of (i) $474 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued\nand/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters, and (ii) $127 million mostly related to our equity-method accounting pro-rata share of intangible asset\namortization and impairments, costs of separating from GSK and restructuring costs recorded by Haleon, partially offset by: (i) a $222 million gain on the divestiture of our early-stage rare disease gene\ntherapy portfolio to Alexion, and (ii) dividend income of $211 million related to our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2)\ninhibitor program subsidiary.",
      "char_count": 931,
      "start_char": 309600,
      "end_char": 310532
    },
    {
      "chunk_id": "pfizer_2023_chunk0388",
      "chunk_index": 388,
      "text": "s resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2)\ninhibitor program subsidiary. For 2022, the total of $636 million included charges of (i) $307 million mostly representing our equity-method accounting pro rata share of restructuring charges and costs of\nseparating from GSK recorded by Haleon/the Consumer Healthcare JV, and adjustments to our equity-method basis differences which are also related to the separation of Haleon/the Consumer\nHealthcare JV from GSK, and (ii) $230 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.\nFor 2021, the total of $334 million included charges of (i) $185 million mostly representing our equity-method accounting pro rata share of restructuring charges and costs of separating from GSK recorded",
      "char_count": 903,
      "start_char": 310400,
      "end_char": 311304
    },
    {
      "chunk_id": "pfizer_2023_chunk0389",
      "chunk_index": 389,
      "text": "ity-method accounting pro rata share of restructuring charges and costs of separating from GSK recorded\nby the Consumer Healthcare JV, and (ii) $162 million for certain legal matters, primarily for certain product liability expenses related to products discontinued and/or divested by Pfizer, and to a lesser\nextent, legal obligations related to pre-acquisition matters.\nFor 2021, the total of $141 million primarily included costs for consulting, legal, tax and advisory services associated with a non-recurring internal reorganization of legal entities.\n(a)\n(a)\n(a)\n(a), (b)\n(d)\n(e)\n(f)\n(i)\n(h)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(i)\n\n2023 Form 10-K\n\nANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS\nFor a discussion of the drivers of change for 2022 versus 2021 as well as cash flows from discontinued operations in 2021, see the Analysis of the Consolidated Statements of Cash\nFlows section within MD&A in our 2022 Form 10-K.\nCash Flows from Continuing Operations\n \nYear Ended December 31,",
      "char_count": 995,
      "start_char": 311200,
      "end_char": 312196
    },
    {
      "chunk_id": "pfizer_2023_chunk0390",
      "chunk_index": 390,
      "text": "tinued operations in 2021, see the Analysis of the Consolidated Statements of Cash\nFlows section within MD&A in our 2022 Form 10-K.\nCash Flows from Continuing Operations\n \nYear Ended December 31,\n(MILLIONS)\n\nDrivers of change 2023 v. 2022\nCash provided by/(used in):\nOperating activities from continuing\noperations\n8,700 \n29,267 \n32,922 \nThe change was driven primarily by a decrease in net income adjusted for non-cash items and the\ntiming of receipts and payments in the ordinary course of business, partially offset by net changes\nin inventory greater than one year (see Note 8A).\nInvesting activities from continuing\noperations\n(32,278)\n(15,783)\n(22,534)\nThe change was driven mainly by $43.4 billion cash paid in 2023 for the acquisition of Seagen, net\nof cash acquired, compared with $23.0 billion cash paid in 2022 for acquisitions (Biohaven,\n$11.5 billion, Arena, $6.2 billion and GBT, $5.2 billion), net of cash acquired (see Note 2A), as well",
      "char_count": 952,
      "start_char": 312000,
      "end_char": 312953
    },
    {
      "chunk_id": "pfizer_2023_chunk0391",
      "chunk_index": 391,
      "text": "ion cash paid in 2022 for acquisitions (Biohaven,\n$11.5 billion, Arena, $6.2 billion and GBT, $5.2 billion), net of cash acquired (see Note 2A), as well\nas a $4.0 billion dividend received from the Consumer Healthcare JV in 2022 that was allocated to\ninvesting activities (see Note 2C), partially offset by a $5.5 billion increase in net redemptions of\nshort-term investments in 2023 and a $1.7 billion decrease in purchases of long-term investments.\nFinancing activities from continuing\noperations\n26,066 \n(14,834)\n(9,816)\nThe change was driven mostly by $30.8 billion of proceeds from the issuance of long-term debt in\nMay of 2023 and a $7.9 billion increase in net proceeds from the issuance of short-term\nborrowings.\nANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK\nOur historically robust operating cash flow, which we expect to continue over time, is a key strength of our liquidity and capital resources and our primary funding source.",
      "char_count": 971,
      "start_char": 312800,
      "end_char": 313772
    },
    {
      "chunk_id": "pfizer_2023_chunk0392",
      "chunk_index": 392,
      "text": "ur historically robust operating cash flow, which we expect to continue over time, is a key strength of our liquidity and capital resources and our primary funding source. We believe\nas a result of this, together with our financial assets, access to capital markets, revolving credit agreements, and available lines of credit, we have and will maintain the ability to meet\nour liquidity needs to support ongoing operations, our capital allocation objectives, and our contractual and other obligations for the foreseeable future.\nWe focus efforts to optimize operating cash flows through achieving working capital efficiencies that target accounts receivable, inventories, accounts payable, and other working\ncapital. Excess cash from operating cash flows is invested in money market funds and available-for-sale debt securities which consist of primarily high-quality, highly liquid, welldiversified debt securities.",
      "char_count": 916,
      "start_char": 313600,
      "end_char": 314517
    },
    {
      "chunk_id": "pfizer_2023_chunk0393",
      "chunk_index": 393,
      "text": "le-for-sale debt securities which consist of primarily high-quality, highly liquid, welldiversified debt securities. We have taken, and will continue to take, a conservative approach to our financial investments and monitoring of our liquidity position in response to\nmarket changes. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of\nour commercial paper and other short-term borrowings.\nAdditionally, we may obtain funding through short-term or long-term sources from our access to the capital markets, banking relationships and relationships with other financial\nintermediaries to meet our liquidity needs.\nDiverse sources of funds:\nRelated disclosure presented in this Form 10-K\nInternal sources:\n• Operating cash flows\nConsolidated Statements of Cash Flows – Operating Activities and the Analysis of the Consolidated\nStatements of Cash Flows section within MD&A",
      "char_count": 979,
      "start_char": 314400,
      "end_char": 315380
    },
    {
      "chunk_id": "pfizer_2023_chunk0394",
      "chunk_index": 394,
      "text": "rnal sources:\n• Operating cash flows\nConsolidated Statements of Cash Flows – Operating Activities and the Analysis of the Consolidated\nStatements of Cash Flows section within MD&A\n• Cash and cash equivalents\nConsolidated Balance Sheets\n• Money market funds\nNote 7A\n• Available-for-sale debt securities\nNote 7A, 7B\n• Equity investments\nNote 7A, 7B\nExternal sources:\nShort-term funding:\n• Commercial paper\nNote 7C\n• Revolving credit facilities\nNote 7C\n• Lines of credit\nNote 7C\nLong-term funding:\n• Long-term debt\nNote 7D\n• Equity\nConsolidated Statements of Equity and Note 12\nFor additional information about the sources and uses of our funds and capital resources for the years ended December 31, 2023 and 2022, see the Analysis of the Consolidated\nStatements of Cash Flows section within MD&A.\nFinancing for Seagen Acquisition––As part of the financing for our acquisition of Seagen, we issued $31 billion of long-term debt in May 2023 and $8 billion of commercial paper",
      "char_count": 971,
      "start_char": 315200,
      "end_char": 316172
    },
    {
      "chunk_id": "pfizer_2023_chunk0395",
      "chunk_index": 395,
      "text": "cing for Seagen Acquisition––As part of the financing for our acquisition of Seagen, we issued $31 billion of long-term debt in May 2023 and $8 billion of commercial paper\nin the fourth quarter of 2023. The net proceeds from long-term debt were invested in short-term investments in a combination of money market funds and available-for-sale debt\nsecurities until the completion of the acquisition.\n\n2023 Form 10-K\n\nCredit Ratings––The cost and availability of financing are influenced by credit ratings, and an increase or decrease in our credit rating could have a beneficial or adverse effect on\nfinancing. Our long-term debt is rated high-quality by both S&P and Moody’s. In March 2023, following the announcement of the proposed acquisition of Seagen, Moody’s changed\nits outlook on our long-term debt to Negative; S&P downgraded our short-term rating from A-1+ to A-1. In October 2023, following the announcement of the amended Paxlovid\nsupply agreement with the U.S.",
      "char_count": 973,
      "start_char": 316000,
      "end_char": 316974
    },
    {
      "chunk_id": "pfizer_2023_chunk0396",
      "chunk_index": 396,
      "text": "m debt to Negative; S&P downgraded our short-term rating from A-1+ to A-1. In October 2023, following the announcement of the amended Paxlovid\nsupply agreement with the U.S. government and updated 2023 guidance, S&P changed its outlook on our long-term debt to Negative. In December 2023, following the release of\n2024 guidance (i) Moody’s downgraded our long-term rating from A1 to A2 and changed its outlook on our long-term debt to Stable and (ii) S&P downgraded our long-term rating\nfrom A+ to A and changed its outlook on our long-term debt to Stable.\nAs of the date of the filing of this Form 10-K, the following ratings have been assigned to our commercial paper and senior unsecured long-term debt:\nNAME OF RATING AGENCY\nPfizer Short-Term Rating\nPfizer Long-Term Rating\nOutlook/Watch\nMoody’s\nP-1\nStable Outlook\nS&P\nA-1\nStable Outlook",
      "char_count": 841,
      "start_char": 316800,
      "end_char": 317642
    },
    {
      "chunk_id": "pfizer_2023_chunk0397",
      "chunk_index": 397,
      "text": "P-1\nStable Outlook\nS&P\nA-1\nStable Outlook\nThese ratings are not a recommendation to buy, sell or hold securities and the ratings are subject to revision or withdrawal at any time by the rating organization. Each rating should\nbe evaluated independently of any other rating.\nCapital Allocation Framework––Our capital allocation framework is primarily devised to enhance shareholder value and is based on three core pillars: growing our dividend,\nreinvesting in the business and making share repurchases after de-levering our balance sheet. See the Overview of Our Performance, Operating Environment, Strategy and Outlook\n—Our Business and Strategy section within MD&A.\nOur current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our business. Our dividends are not restricted by debt\ncovenants.",
      "char_count": 860,
      "start_char": 317600,
      "end_char": 318461
    },
    {
      "chunk_id": "pfizer_2023_chunk0398",
      "chunk_index": 398,
      "text": "usiness. Our dividends are not restricted by debt\ncovenants. While the dividend level remains a decision of Pfizer’s BOD and will continue to be evaluated in the context of future business performance, we currently believe that we\ncan support future annual dividend increases, barring significant unforeseen events. On December 14, 2023, our BOD declared a first-quarter dividend of $0.42 per share, payable\non March 1, 2024, to shareholders of record at the close of business on January 26, 2024. The first-quarter 2024 cash dividend will be our 341st consecutive quarterly dividend.\nAs of December 31, 2023, our remaining share-purchase authorization was approximately $3.3 billion.\nOff-Balance Sheet Arrangements, Contractual, and Other Obligations––In the ordinary course of business, (i) we enter into off-balance sheet arrangements that may result in",
      "char_count": 856,
      "start_char": 318400,
      "end_char": 319257
    },
    {
      "chunk_id": "pfizer_2023_chunk0399",
      "chunk_index": 399,
      "text": "r into off-balance sheet arrangements that may result in\ncontractual and other obligations and (ii) in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities\nthat may arise in connection with the transaction or that are related to events and activities. For more information on guarantees and indemnifications, see Note 16B.\nAdditionally, certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions,\nco-promotion or other rights in specified countries with respect to certain of our products. Furthermore, collaboration, licensing or other R&D arrangements may give rise to potential\nmilestone payments. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization",
      "char_count": 951,
      "start_char": 319200,
      "end_char": 320152
    },
    {
      "chunk_id": "pfizer_2023_chunk0400",
      "chunk_index": 400,
      "text": "Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization\nmilestones, which may span several years and which may never occur.\nOur significant contractual and other obligations as of December 31, 2023 consisted of:\n• Long-term debt, including current portion (see Note 7D) and related interest payments;\n• Estimated cash payments related to the TCJA repatriation estimated tax liability (see Note 5). Estimated future payments related to the TCJA repatriation tax liability that will occur\nafter December 31, 2023 total $6.0 billion, of which an estimated $1.5 billion is to be paid in the next twelve months and an estimated $4.5 billion is to be paid in periods thereafter.\nOur obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards;",
      "char_count": 932,
      "start_char": 320000,
      "end_char": 320934
    },
    {
      "chunk_id": "pfizer_2023_chunk0401",
      "chunk_index": 401,
      "text": "esult of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards;\n• Certain commitments totaling $5.2 billion, of which an estimated $1.3 billion is to be paid in the next twelve months, and $3.9 billion in periods thereafter (see Note 16C);\n• Purchases of PP&E (see Note 9). In 2024, we expect to spend approximately $3.7 billion on PP&E; and\n• Future minimum rental commitments under non-cancelable operating leases (see Note 15).\nGlobal Economic Conditions––Venezuela, Argentina and Turkey operations function in a hyperinflationary economy. The impact to Pfizer is not considered material. See the Item\n1A. Risk Factors––Global Operations section.\nMarket Risk––We are subject to foreign exchange risk, interest rate risk, and equity price risk. The objective of our financial risk management program is to minimize the impact of\nforeign exchange rate and interest rate movements on our earnings.",
      "char_count": 967,
      "start_char": 320800,
      "end_char": 321768
    },
    {
      "chunk_id": "pfizer_2023_chunk0402",
      "chunk_index": 402,
      "text": "uity price risk. The objective of our financial risk management program is to minimize the impact of\nforeign exchange rate and interest rate movements on our earnings. We address such exposures through a combination of operational means and financial instruments. For more\ninformation on how we manage our foreign exchange and interest rate risks, see Notes 1F and 7E, as well as the Item 1A. Risk Factors—Global Operations section for key\ncurrencies in which we operate. Our sensitivity analyses of such risks are discussed below.\nForeign Exchange Risk—The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this\nanalysis, holding all other assumptions constant and assuming that a change in one currency’s rate relative to the U.S. dollar would not have any effect on another currency’s rates\nrelative to the U.S.",
      "char_count": 906,
      "start_char": 321600,
      "end_char": 322507
    },
    {
      "chunk_id": "pfizer_2023_chunk0403",
      "chunk_index": 403,
      "text": "ate relative to the U.S. dollar would not have any effect on another currency’s rates\nrelative to the U.S. dollar, if the dollar were to move against all other currencies by 10%, as of December 31, 2023, the expected impact on our net income would not be significant.\nInterest Rate Risk—The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this analysis, holding all\nother assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point change in interest\nrates as of December 31, 2023, the expected impact on our net income would not be significant.\nEquity Price Risk––We hold long-term investments in equity securities with readily determinable fair values in life science companies as a result of certain business development\ntransactions (see Note 7B).",
      "char_count": 939,
      "start_char": 322400,
      "end_char": 323340
    },
    {
      "chunk_id": "pfizer_2023_chunk0404",
      "chunk_index": 404,
      "text": "ies with readily determinable fair values in life science companies as a result of certain business development\ntransactions (see Note 7B). While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to\nchanges in the fair value of equity investments. From time to time, we will sell\n\n2023 Form 10-K\n\nsuch equity securities based on our business considerations, which may include limiting our price risk. Our equity securities with readily determinable fair values are analyzed at\nyear-end to determine their sensitivity to equity price rate changes. In this sensitivity analysis, the expected impact on our net income would not be significant.\nNEW ACCOUNTING STANDARDS\nRecently Adopted Accounting Standards\nSee Note 1B.\nRecently Issued Accounting Standards, Not Adopted as of December 31, 2023\nStandard/Description\nEffective Date\nEffect on the Financial\nStatements",
      "char_count": 953,
      "start_char": 323200,
      "end_char": 324154
    },
    {
      "chunk_id": "pfizer_2023_chunk0405",
      "chunk_index": 405,
      "text": "Note 1B.\nRecently Issued Accounting Standards, Not Adopted as of December 31, 2023\nStandard/Description\nEffective Date\nEffect on the Financial\nStatements\nIn June 2022, the FASB issued final guidance to clarify that a contractual restriction on the sale of an\nequity security is not considered part of the unit of account of the equity security and, therefore, is not\nconsidered when measuring fair value. Recognizing a contractual sale restriction as a separate unit of\naccount is not permitted.\nJanuary 1, 2024, with early adoption\npermitted.\nThe new guidance is consistent\nwith our current policy, and it will\nnot have an impact on our\nconsolidated financial statements.\nIn November 2023, the FASB issued final guidance to improve transparency of segment disclosures.\nThe final guidance requires the disclosure of significant segment expenses that are regularly provided to\nthe chief operating decision maker and included within each reported measure of segment profit or loss,",
      "char_count": 979,
      "start_char": 324000,
      "end_char": 324980
    },
    {
      "chunk_id": "pfizer_2023_chunk0406",
      "chunk_index": 406,
      "text": "e disclosure of significant segment expenses that are regularly provided to\nthe chief operating decision maker and included within each reported measure of segment profit or loss,\nother segment items by reportable segment and a description of its composition, and requires all current\nannual disclosures be provided in interim periods.\nJanuary 1, 2024 for annual reports\nand January 1, 2025 for interim\nreports. Early adoption is permitted.\nThis new guidance will result in\nincreased disclosures in the notes\nto our financial statements.\nIn December 2023, the FASB issued final guidance to improve income tax disclosures. The final\nguidance requires enhanced disclosures primarily related to existing rate reconciliation and income\ntaxes paid information.\nJanuary 1, 2025, with early adoption\npermitted.\nThis new guidance will result in\nincreased disclosures in the notes\nto our financial statements.\nITEM 7A.\nQUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK",
      "char_count": 968,
      "start_char": 324800,
      "end_char": 325769
    },
    {
      "chunk_id": "pfizer_2023_chunk0407",
      "chunk_index": 407,
      "text": "ed.\nThis new guidance will result in\nincreased disclosures in the notes\nto our financial statements.\nITEM 7A.\nQUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK\nThe information required by this Item is incorporated by reference to the discussion in the Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk section within\nMD&A.\n\n2023 Form 10-K\n\nITEM 8.\nFINANCIAL STATEMENTS AND SUPPLEMENTARY DATA\nReport of Independent Registered Public Accounting Firm\nTo the Board of Directors and Shareholders\n\nOpinion on the Consolidated Financial Statements\nWe have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies (the Company) as of December 31, 2023 and 2022, the related\nconsolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes\n(collectively, the consolidated financial statements).",
      "char_count": 967,
      "start_char": 325600,
      "end_char": 326568
    },
    {
      "chunk_id": "pfizer_2023_chunk0408",
      "chunk_index": 408,
      "text": "ty, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes\n(collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the\nCompany as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2023, in\nconformity with U.S. generally accepted accounting principles.\nWe also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over\nfinancial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations",
      "char_count": 868,
      "start_char": 326400,
      "end_char": 327269
    },
    {
      "chunk_id": "pfizer_2023_chunk0409",
      "chunk_index": 409,
      "text": "Framework (2013) issued by the Committee of Sponsoring Organizations\nof the Treadway Commission, and our report dated February 22, 2024 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial\nreporting.\nBasis for Opinion\nThese consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial\nstatements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance\nwith the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.\nWe conducted our audits in accordance with the standards of the PCAOB.",
      "char_count": 809,
      "start_char": 327200,
      "end_char": 328010
    },
    {
      "chunk_id": "pfizer_2023_chunk0410",
      "chunk_index": 410,
      "text": "he PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about\nwhether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of\nmaterial misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included\nexamining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting\nprinciples used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our\naudits provide a reasonable basis for our opinion.\nCritical Audit Matters",
      "char_count": 870,
      "start_char": 328000,
      "end_char": 328871
    },
    {
      "chunk_id": "pfizer_2023_chunk0411",
      "chunk_index": 411,
      "text": "its provide a reasonable basis for our opinion.\nCritical Audit Matters\nThe critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to\nbe communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially\nchallenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken\nas a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to\nwhich they relate.\nEvaluation of the U.S.",
      "char_count": 816,
      "start_char": 328800,
      "end_char": 329617
    },
    {
      "chunk_id": "pfizer_2023_chunk0412",
      "chunk_index": 412,
      "text": "tion of the U.S. Medicare, Medicaid, and performance-based contract rebates accrual\nAs discussed in Note 1G to the consolidated financial statements, the Company records estimated deductions for Medicare, Medicaid, and performance-based contract rebates\n(collectively, U.S. rebates) as a reduction to gross product revenues. The accrual for U.S. rebates is recorded in the same period that the corresponding revenues are recognized.\nThe length of time between when a sale is made and when the U.S. rebate is paid by the Company can be as long as one year, which increases the need for significant\nmanagement judgment and knowledge of market conditions and practices in estimating the accrual.\nWe identified the evaluation of the U.S. rebates accrual as a critical audit matter because the evaluation of the product-specific experience ratio assumption involved especially\nchallenging auditor judgment.",
      "char_count": 901,
      "start_char": 329600,
      "end_char": 330502
    },
    {
      "chunk_id": "pfizer_2023_chunk0413",
      "chunk_index": 413,
      "text": "of the product-specific experience ratio assumption involved especially\nchallenging auditor judgment. The product-specific experience ratio assumption relates to estimating which of the Company’s revenue transactions will ultimately be subject to a\nrelated rebate.\nThe following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal\ncontrols over the Company’s U.S. rebates accrual process related to the development of the product-specific experience ratio assumptions. We estimated the U.S. rebates accrual\nusing internal information and historical data and compared the result to the Company’s estimated U.S. rebates accrual. We evaluated the Company’s ability to accurately estimate\nthe accrual for U.S.",
      "char_count": 815,
      "start_char": 330400,
      "end_char": 331216
    },
    {
      "chunk_id": "pfizer_2023_chunk0414",
      "chunk_index": 414,
      "text": "ccrual for U.S. rebates by comparing historically recorded accruals to the actual amount that was ultimately paid by the Company.\nEvaluation of gross unrecognized tax benefits\nAs discussed in Notes 5D and 1Q, the Company’s tax positions are subject to audit by local taxing authorities in each respective tax jurisdiction, and the resolution of such audits\nmay span multiple years. Since tax law is complex and often subject to varied interpretations and judgments, it is uncertain whether some of the Company’s tax positions will be\nsustained upon audit. As of December 31, 2023, the Company has recorded gross unrecognized tax benefits, excluding associated interest, of $4.8 billion.\nWe identified the evaluation of certain of the Company’s gross unrecognized tax benefits as a critical audit matter because a high degree of audit effort, including specialized skills",
      "char_count": 870,
      "start_char": 331200,
      "end_char": 332071
    },
    {
      "chunk_id": "pfizer_2023_chunk0415",
      "chunk_index": 415,
      "text": "er because a high degree of audit effort, including specialized skills\nand knowledge, and complex auditor judgment was required in evaluating the Company’s interpretation of tax law and its estimate of the ultimate resolution of its tax positions.\nThe following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of an internal control\nover the Company’s liability for unrecognized tax position process related to (1) interpretation of tax law, (2) evaluation of which of the Company’s tax positions may not be sustained\nupon audit, and (3) estimation and recording of the gross\n\n2023 Form 10-K\n\nReport of Independent Registered Public Accounting Firm\nunrecognized tax benefits. We involved tax and valuation professionals with specialized skills and knowledge who assisted in evaluating the Company’s interpretation of tax laws,",
      "char_count": 920,
      "start_char": 332000,
      "end_char": 332921
    },
    {
      "chunk_id": "pfizer_2023_chunk0416",
      "chunk_index": 416,
      "text": "professionals with specialized skills and knowledge who assisted in evaluating the Company’s interpretation of tax laws,\nincluding the assessment of transfer pricing practices in accordance with applicable tax laws and regulations. We inspected settlements with applicable taxing authorities, including\nassessing the expiration of statutes of limitations. We tested the calculation of the liability for uncertain tax positions, including an evaluation of the Company’s assessment of the\ntechnical merits of tax positions and estimates of the amount of tax benefits expected to be sustained.\nEvaluation of product liability and other product-related litigation\nAs discussed in Notes 1S and 16 to the consolidated financial statements, the Company is involved in product liability and other product-related litigation, which can include personal\ninjury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others.",
      "char_count": 949,
      "start_char": 332800,
      "end_char": 333750
    },
    {
      "chunk_id": "pfizer_2023_chunk0417",
      "chunk_index": 417,
      "text": "ated litigation, which can include personal\ninjury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others. Certain of these pending product and other product-related legal proceedings\ncould result in losses that could be substantial. The accrued liability and/or disclosure for the pending product liability and other product-related legal proceedings requires a complex\nseries of judgments by the Company about future events, which involves a number of uncertainties.\nWe identified the evaluation of product liability and other product-related litigation as a critical audit matter. Challenging auditor judgment was required to evaluate the Company’s\njudgments about future events and uncertainties.\nThe following are the primary procedures we performed to address this critical audit matter.",
      "char_count": 836,
      "start_char": 333600,
      "end_char": 334437
    },
    {
      "chunk_id": "pfizer_2023_chunk0418",
      "chunk_index": 418,
      "text": "address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal\ncontrols over the Company’s product liability and other product-related litigation processes, including controls related to (1) the evaluation of information from external and internal\nlegal counsel, (2) forward-looking expectations, and (3) new legal proceedings, or other legal proceedings not currently reserved or disclosed. We read letters received directly from\nthe Company’s external and internal legal counsel that described the Company’s probable or reasonably possible legal contingency to pending product liability and other productrelated legal proceedings. We inspected the Company’s minutes from meetings of the Audit Committee, which included the status of key litigation matters.",
      "char_count": 814,
      "start_char": 334400,
      "end_char": 335216
    },
    {
      "chunk_id": "pfizer_2023_chunk0419",
      "chunk_index": 419,
      "text": "gation matters. We evaluated the\nCompany’s ability to estimate its monetary exposure to pending product and other product-related legal proceedings by comparing historically recorded liabilities to actual monetary\namounts incurred upon resolution of prior legal matters. We analyzed relevant publicly available information about the Company, its competitors, and the industry.\nEvaluation of the fair value measurement of the developed technology rights and in-process research and development intangible assets acquired in the Seagen business\ncombination\nAs discussed in Note 2A to the consolidated financial statements, on December 14, 2023, the Company acquired Seagen Inc. and its subsidiaries (Seagen). The total fair value of\nconsideration transferred was $44.2 billion. Of that, the Company provisionally recorded $7.5 billion of developed technology rights with an estimated weighted-average life of\napproximately 18 years and $20.8 billion of in-process research and development (IPR&D).",
      "char_count": 995,
      "start_char": 335200,
      "end_char": 336196
    },
    {
      "chunk_id": "pfizer_2023_chunk0420",
      "chunk_index": 420,
      "text": "visionally recorded $7.5 billion of developed technology rights with an estimated weighted-average life of\napproximately 18 years and $20.8 billion of in-process research and development (IPR&D).\nWe identified the evaluation of the fair value measurement of the acquired developed technology rights and IPR&D as a critical audit matter. A high degree of subjective auditor\njudgment was required to evaluate certain key assumptions used to estimate the acquisition-date fair value of the acquired developed technology rights and IPR&D. Specifically, the\nkey assumptions for certain IPR&D assets, including revenue growth rates, probability of technical and regulatory success (PTRS) rates, and the discount rate, and the key\nassumptions for certain developed technology rights, including revenue growth rates and the discount rate, represented subjective determinations of future market and economic\nconditions.",
      "char_count": 910,
      "start_char": 336000,
      "end_char": 336911
    },
    {
      "chunk_id": "pfizer_2023_chunk0421",
      "chunk_index": 421,
      "text": "h rates and the discount rate, represented subjective determinations of future market and economic\nconditions. Changes to those assumptions could have had a significant effect on the determination of the fair value measurements.\nThe following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal\ncontrols related to the Company’s acquisition-date valuation process, including controls related to the development of the key assumptions for certain IPR&D assets and developed\ntechnology rights. We performed sensitivity analyses over the key assumptions for certain IPR&D assets and developed technology rights to assess the impact of changes in those\nkey assumptions on the Company’s determination of the fair value of the IPR&D and developed technology rights, respectively.",
      "char_count": 883,
      "start_char": 336800,
      "end_char": 337684
    },
    {
      "chunk_id": "pfizer_2023_chunk0422",
      "chunk_index": 422,
      "text": "ation of the fair value of the IPR&D and developed technology rights, respectively. We evaluated the reasonableness of the Company’s\nforecasted revenue growth rates by comparing them to historical results for comparable products and peer companies, analyst expectations, and industry related third-party data.\nFurther, we evaluated the PTRS rates for certain IPR&D assets by considering the phase of development of the clinical projects and the Company's history of obtaining regulatory\napproval and comparing them to PTRS rates derived from analyst reports and other industry related third-party data. We evaluated the data sources used by management in\ndetermining the key assumptions for certain IPR&D assets and developed technology rights by comparing to industry standards and evidence obtained in other areas of the audit.",
      "char_count": 829,
      "start_char": 337600,
      "end_char": 338430
    },
    {
      "chunk_id": "pfizer_2023_chunk0423",
      "chunk_index": 423,
      "text": "in other areas of the audit. In\naddition, we involved valuation professionals with specialized skills and knowledge, who assisted in:\n(1) evaluating the discount rates used by the Company for certain IPR&D and developed technology rights by comparing them against discount rate ranges that were independently\ndeveloped using publicly available market data for comparable entities\n(2) testing the source information underlying the determination of the discount rates.\nWe have not been able to determine the specific year that we or our predecessor firms began serving as the Company’s auditor, however, we are aware that we or our predecessor\nfirms have served as the Company’s auditor since at least 1942.\nNew York, New York\nFebruary 22, 2024\n\n2023 Form 10-K\n\nConsolidated Statements of Income\n\n \nYear Ended December 31,\n(MILLIONS, EXCEPT PER SHARE DATA)",
      "char_count": 854,
      "start_char": 338400,
      "end_char": 339256
    },
    {
      "chunk_id": "pfizer_2023_chunk0424",
      "chunk_index": 424,
      "text": "ar Ended December 31,\n(MILLIONS, EXCEPT PER SHARE DATA)\n\nRevenues:\nProduct revenues\n50,914 \n91,793 \n73,636 \nAlliance revenues\n7,582 \n8,537 \n7,652 \nTotal revenues\n58,496 \n100,330 \n81,288 \nCosts and expenses:\n \n \nCost of sales\n24,954 \n34,344 \n30,821 \nSelling, informational and administrative expenses\n14,771 \n13,677 \n12,703 \nResearch and development expenses\n10,679 \n11,428 \n10,360 \nAcquired in-process research and development expenses\n\n3,469 \nAmortization of intangible assets\n4,733 \n3,609 \n3,700 \nRestructuring charges and certain acquisition-related costs\n2,943 \n1,375 \n\nOther (income)/deductions––net\n(835)\n\n(4,878)\nIncome from continuing operations before provision/(benefit) for taxes on income\n1,058 \n34,729 \n24,311 \nProvision/(benefit) for taxes on income\n(1,115)\n3,328 \n1,852 \nIncome from continuing operations\n2,172 \n31,401 \n22,459 \nDiscontinued operations––net of tax\n(15)",
      "char_count": 883,
      "start_char": 339200,
      "end_char": 340084
    },
    {
      "chunk_id": "pfizer_2023_chunk0425",
      "chunk_index": 425,
      "text": "ntinuing operations\n2,172 \n31,401 \n22,459 \nDiscontinued operations––net of tax\n(15)\n\n(434)\nNet income before allocation to noncontrolling interests\n2,158 \n31,407 \n22,025 \nLess: Net income attributable to noncontrolling interests\n\nNet income attributable to Pfizer Inc. common shareholders\n2,119 \n31,372 \n21,979 \nEarnings per common share––basic:\n \n \n \nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n0.38 \n5.59 \n4.00 \nDiscontinued operations––net of tax\n(0.08)\nNet income attributable to Pfizer Inc. common shareholders\n0.38 \n5.59 \n3.92 \nEarnings per common share––diluted:\n \n \nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n0.37 \n5.47 \n3.93 \nDiscontinued operations––net of tax\n(0.08)\nNet income attributable to Pfizer Inc. common shareholders\n0.37 \n5.47 \n3.85 \nWeighted-average shares––basic\n5,643 \n5,608 \n5,601 \nWeighted-average shares––diluted\n5,709 \n5,733 \n5,708 \nSee Note 1G.\nExclusive of amortization of intangible assets.",
      "char_count": 998,
      "start_char": 340000,
      "end_char": 340999
    },
    {
      "chunk_id": "pfizer_2023_chunk0426",
      "chunk_index": 426,
      "text": "shareholders\n0.37 \n5.47 \n3.85 \nWeighted-average shares––basic\n5,643 \n5,608 \n5,601 \nWeighted-average shares––diluted\n5,709 \n5,733 \n5,708 \nSee Note 1G.\nExclusive of amortization of intangible assets.\nSee Notes 8A and 17A.\nSee Accompanying Notes.\n(a)\n(a)\n(b), (c)\n(b)\n(b)\n(a)\n(b)\n(c)\n\n2023 Form 10-K\n\nConsolidated Statements of Comprehensive Income\n\nYear Ended December 31,\n(MILLIONS)\n\nNet income before allocation to noncontrolling interests\n2,158 \n31,407 \n22,025 \nForeign currency translation adjustments, net\n\n(2,328)\n(682)\nUnrealized holding gains/(losses) on derivative financial instruments, net\n\n1,444 \n\nReclassification adjustments for (gains)/losses included in net income\n(413)\n(2,062)\n\n(618)\n\nUnrealized holding gains/(losses) on available-for-sale securities, net\n(121)\n(1,306)\n(355)\nReclassification adjustments for (gains)/losses included in net income\n(141)\n1,809 \n(30)\n(261)\n\n(384)\nBenefit plans: prior service (costs)/credits and other, net\n(25)\n(24)",
      "char_count": 964,
      "start_char": 340800,
      "end_char": 341766
    },
    {
      "chunk_id": "pfizer_2023_chunk0427",
      "chunk_index": 427,
      "text": "sification adjustments for (gains)/losses included in net income\n(141)\n1,809 \n(30)\n(261)\n\n(384)\nBenefit plans: prior service (costs)/credits and other, net\n(25)\n(24)\n\nReclassification adjustments related to amortization of prior service costs and other, net\n(117)\n(129)\n(154)\nReclassification adjustments related to curtailments of prior service costs and other, net\n(15)\n(12)\n(75)\n \n(157)\n(166)\n(113)\nOther comprehensive income/(loss), before tax\n\n(2,609)\n(519)\nTax provision/(benefit) on other comprehensive income/(loss)\n(85)\n(187)\n\nOther comprehensive income/(loss) before allocation to noncontrolling interests\n\n(2,422)\n(589)\n \n \n \nComprehensive income/(loss) before allocation to noncontrolling interests\n2,488 \n28,985 \n21,435 \nLess: Comprehensive income/(loss) attributable to noncontrolling interests",
      "char_count": 808,
      "start_char": 341600,
      "end_char": 342409
    },
    {
      "chunk_id": "pfizer_2023_chunk0428",
      "chunk_index": 428,
      "text": "nterests\n\nComprehensive income/(loss) attributable to Pfizer Inc.\n2,462 \n28,965 \n21,393 \nReclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.\nReclassified into Other (income)/deductions—net.\nSee Accompanying Notes.\n(a)\n(b)\n(a)\n(b)\n\n2023 Form 10-K\n\nConsolidated Balance Sheets\n\nAs of December 31,\n(MILLIONS, EXCEPT PER SHARE DATA)\n\nAssets\nCash and cash equivalents\n2,853 \n\nShort-term investments\n9,837 \n22,316 \nTrade accounts receivable, less allowance for doubtful accounts: 2023—$470; 2022—$449\n11,177 \n10,952 \nInventories\n10,189 \n8,981 \nCurrent tax assets\n3,978 \n3,577 \nOther current assets\n5,299 \n5,017 \nTotal current assets\n43,333 \n51,259 \nEquity-method investments\n11,637 \n11,033 \nLong-term investments\n3,731 \n4,036 \nProperty, plant and equipment\n18,940 \n16,274 \nIdentifiable intangible assets\n64,900 \n43,370 \nGoodwill\n67,783 \n51,375 \nNoncurrent deferred tax assets and other noncurrent tax assets\n3,706 \n6,693 \nOther noncurrent assets\n12,471 \n13,163 \nTotal assets",
      "char_count": 996,
      "start_char": 342400,
      "end_char": 343397
    },
    {
      "chunk_id": "pfizer_2023_chunk0429",
      "chunk_index": 429,
      "text": "ifiable intangible assets\n64,900 \n43,370 \nGoodwill\n67,783 \n51,375 \nNoncurrent deferred tax assets and other noncurrent tax assets\n3,706 \n6,693 \nOther noncurrent assets\n12,471 \n13,163 \nTotal assets\n226,501 \n197,205 \nLiabilities and Equity\n \n \nShort-term borrowings, including current portion of long-term debt: 2023—$2,254; 2022—$2,560\n10,350 \n2,945 \nTrade accounts payable\n6,710 \n6,809 \nDividends payable\n2,372 \n2,303 \nIncome taxes payable\n2,349 \n1,587 \nAccrued compensation and related items\n2,776 \n3,407 \nDeferred revenues\n2,700 \n2,520 \nOther current liabilities\n20,537 \n22,568 \nTotal current liabilities\n47,794 \n42,138 \nLong-term debt\n61,538 \n32,884 \nPension and postretirement benefit obligations\n2,167 \n2,250 \nNoncurrent deferred tax liabilities\n\n1,023 \nOther taxes payable\n8,534 \n9,812 \nOther noncurrent liabilities\n16,539 \n13,180 \nTotal liabilities\n137,213 \n101,288 \nCommitments and Contingencies",
      "char_count": 903,
      "start_char": 343200,
      "end_char": 344104
    },
    {
      "chunk_id": "pfizer_2023_chunk0430",
      "chunk_index": 430,
      "text": "oncurrent liabilities\n16,539 \n13,180 \nTotal liabilities\n137,213 \n101,288 \nCommitments and Contingencies\nPreferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding as of December 31, 2023\nand December 31, 2022\nCommon stock, $0.05 par value; 12,000 shares authorized; issued: 2023—9,562; 2022—9,519\n\nAdditional paid-in capital\n92,631 \n91,802 \nTreasury stock, shares at cost: 2023—3,916; 2022—3,903\n(114,487)\n(113,969)\nRetained earnings\n118,353 \n125,656 \nAccumulated other comprehensive loss\n(7,961)\n(8,304)\nTotal Pfizer Inc. shareholders’ equity\n89,014 \n95,661 \nEquity attributable to noncontrolling interests\n\nTotal equity\n89,288 \n95,916 \nTotal liabilities and equity\n226,501 \n197,205 \nSee Accompanying Notes.\n\n2023 Form 10-K\n\nConsolidated Statements of Equity",
      "char_count": 802,
      "start_char": 344000,
      "end_char": 344803
    },
    {
      "chunk_id": "pfizer_2023_chunk0431",
      "chunk_index": 431,
      "text": "ty\n\n \nCommon Stock\n \nTreasury Stock\n \n \n \n(MILLIONS, EXCEPT PER SHARE DATA)\nShares\nPar Value\nAdd’l\nPaid-In\nCapital\nShares\nCost\nRetained\nEarnings\nAccum.\nOther\nComp. Loss\nShare -\nholders’\nEquity\nNoncontrolling\nInterests\nTotal\nEquity\nBalance, January 1, 2021\n9,407 \n\n88,674 \n(3,840)\n(110,988)\n90,392 \n(5,310)\n63,238 \n\n63,473 \nNet income\n21,979 \n21,979 \n\n22,025 \nOther comprehensive income/(loss), net of tax\n(587)\n(587)\n(3)\n(589)\nCash dividends declared, per share: $1.57\nCommon stock\n(8,816)\n(8,816)\n(8,816)\nNoncontrolling interests\n(8)\n(8)\nShare-based payment transactions\n\n1,917 \n(11)\n(373)\n(77)\n1,470 \n1,470 \nOther\n(85)\n(85)\n(7)\n(92)\nBalance, December 31, 2021\n9,471 \n\n90,591 \n(3,851)\n(111,361)\n103,394 \n(5,897)\n77,201 \n\n77,462 \nNet income\n31,372 \n31,372 \n\n31,407 \nOther comprehensive income/(loss), net of tax\n(2,407)\n(2,407)\n(15)\n(2,422)\nCash dividends declared, per share: $1.61\nCommon stock\n(9,037)\n(9,037)\n(9,037)\nNoncontrolling interests\n(13)\n(13)\nShare-based payment transactions",
      "char_count": 987,
      "start_char": 344800,
      "end_char": 345788
    },
    {
      "chunk_id": "pfizer_2023_chunk0432",
      "chunk_index": 432,
      "text": "net of tax\n(2,407)\n(2,407)\n(15)\n(2,422)\nCash dividends declared, per share: $1.61\nCommon stock\n(9,037)\n(9,037)\n(9,037)\nNoncontrolling interests\n(13)\n(13)\nShare-based payment transactions\n\n1,192 \n(13)\n(608)\n(73)\n\nPurchases of common stock\n(39)\n(2,000)\n(2,000)\n(2,000)\nOther\n\n\n(13)\n\nBalance, December 31, 2022\n9,519 \n\n91,802 \n(3,903)\n(113,969)\n125,656 \n(8,304)\n95,661 \n\n95,916 \nNet income\n2,119 \n2,119 \n\n2,158 \nOther comprehensive income/(loss), net of tax\n\n(12)\n\nCash dividends declared, per share: $1.65\nCommon stock\n(9,316)\n(9,316)\n(9,316)\nNoncontrolling interests\n(8)\n(8)\nShare-based payment transactions\n\n(12)\n(518)\n(106)\n\nOther\nBalance, December 31, 2023\n9,562 \n\n92,631 \n(3,916)\n(114,487)\n118,353 \n(7,961)\n89,014 \n\n89,288 \nSee Accompanying Notes.\n\n2023 Form 10-K\n\nConsolidated Statements of Cash Flows\n\n \nYear Ended December 31,\n(MILLIONS)\n\nOperating Activities\n \n \nNet income before allocation to noncontrolling interests\n2,158 \n31,407 \n22,025 \nDiscontinued operations—net of tax\n(15)",
      "char_count": 989,
      "start_char": 345600,
      "end_char": 346591
    },
    {
      "chunk_id": "pfizer_2023_chunk0433",
      "chunk_index": 433,
      "text": "Flows\n\n \nYear Ended December 31,\n(MILLIONS)\n\nOperating Activities\n \n \nNet income before allocation to noncontrolling interests\n2,158 \n31,407 \n22,025 \nDiscontinued operations—net of tax\n(15)\n\n(434)\nNet income from continuing operations before allocation to noncontrolling interests\n2,172 \n31,401 \n22,459 \nAdjustments to reconcile net income before allocation to noncontrolling interests to net cash\n provided by/(used in) operating activities:\n \n \nDepreciation and amortization\n6,290 \n5,064 \n5,191 \nAsset write-offs and impairments\n3,408 \n\nDeferred taxes\n(3,442)\n(3,764)\n(4,293)\nShare-based compensation expense\n\n1,182 \nBenefit plan contributions in excess of expense/income\n(787)\n(1,158)\n(3,123)\nInventory write-offs and related charges associated with COVID-19 products\n6,199 \n1,183 \nOther adjustments, net\n(3,492)\n\n(1,573)\nOther changes in assets and liabilities, net of acquisitions and divestitures:\nTrade accounts receivable",
      "char_count": 929,
      "start_char": 346400,
      "end_char": 347331
    },
    {
      "chunk_id": "pfizer_2023_chunk0434",
      "chunk_index": 434,
      "text": "nts, net\n(3,492)\n\n(1,573)\nOther changes in assets and liabilities, net of acquisitions and divestitures:\nTrade accounts receivable\n\n(3,811)\nInventories\n(1,169)\n(591)\n(1,125)\nOther assets\n(663)\n(4,506)\n(1,057)\nTrade accounts payable\n(300)\n1,191 \n1,242 \nOther liabilities\n\n(1,449)\n18,721 \nOther tax accounts, net\n(982)\n(545)\n(1,166)\nNet cash provided by/(used in) operating activities from continuing operations\n8,700 \n29,267 \n32,922 \nNet cash provided by/(used in) operating activities from discontinued operations\n(343)\nNet cash provided by/(used in) operating activities\n8,700 \n29,267 \n32,580 \nInvesting Activities\n \n \nPurchases of property, plant and equipment\n(3,907)\n(3,236)\n(2,711)\nPurchases of short-term investments\n(30,974)\n(36,384)\n(38,457)\nProceeds from redemptions/sales of short-term investments\n39,264 \n44,821 \n27,447 \nNet (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less\n5,174 \n(483)\n(8,088)",
      "char_count": 978,
      "start_char": 347200,
      "end_char": 348179
    },
    {
      "chunk_id": "pfizer_2023_chunk0435",
      "chunk_index": 435,
      "text": "stments\n39,264 \n44,821 \n27,447 \nNet (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less\n5,174 \n(483)\n(8,088)\nPurchases of long-term investments\n(204)\n(1,913)\n(1,068)\nProceeds from redemptions/sales of long-term investments\n1,979 \n\nAcquisitions of businesses, net of cash acquired\n(43,430)\n(22,997)\nDividend received from the Consumer Healthcare JV\n3,960 \nOther investing activities, net\n(179)\n(192)\n(305)\nNet cash provided by/(used in) investing activities from continuing operations\n(32,278)\n(15,783)\n(22,534)\nNet cash provided by/(used in) investing activities from discontinued operations\n(12)\nNet cash provided by/(used in) investing activities\n(32,278)\n(15,783)\n(22,546)\nFinancing Activities\n \n \nProceeds from short-term borrowings\n4,525 \n3,891 \nPayments on short-term borrowings\n(3)\n(3,887)\nNet (payments on)/proceeds from short-term borrowings with original maturities of three months or less\n3,161 \n(222)\n(96)",
      "char_count": 987,
      "start_char": 348000,
      "end_char": 348988
    },
    {
      "chunk_id": "pfizer_2023_chunk0436",
      "chunk_index": 436,
      "text": "owings\n4,525 \n3,891 \nPayments on short-term borrowings\n(3)\n(3,887)\nNet (payments on)/proceeds from short-term borrowings with original maturities of three months or less\n3,161 \n(222)\n(96)\nProceeds from issuances of long-term debt\n30,831 \n\nPayments on long-term debt\n(2,569)\n(3,298)\n(2,004)\nPurchases of common stock\n(2,000)\nCash dividends paid\n(9,247)\n(8,983)\n(8,729)\nOther financing activities, net\n(631)\n(335)\n\nNet cash provided by/(used in) financing activities\n26,066 \n(14,834)\n(9,816)\nEffect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents\n(40)\n(165)\n(59)\nNet increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents\n2,448 \n(1,515)\n\nCash and cash equivalents and restricted cash and cash equivalents, at beginning of period\n\n1,983 \n1,825 \nCash and cash equivalents and restricted cash and cash equivalents, at end of period\n2,917 \n\n1,983 \n- Continued -\n(a)\n(a)\n(b)\n(c)\n(d)\n\n2023 Form 10-K",
      "char_count": 973,
      "start_char": 348800,
      "end_char": 349774
    },
    {
      "chunk_id": "pfizer_2023_chunk0437",
      "chunk_index": 437,
      "text": "f period\n\n1,983 \n1,825 \nCash and cash equivalents and restricted cash and cash equivalents, at end of period\n2,917 \n\n1,983 \n- Continued -\n(a)\n(a)\n(b)\n(c)\n(d)\n\n2023 Form 10-K\n\nConsolidated Statements of Cash Flows\n\nYear Ended December 31,\n\nSupplemental Cash Flow Information\n \n \nCash paid/(received) during the period for:\nIncome taxes\n3,147 \n7,867 \n7,427 \nInterest paid\n2,215 \n1,442 \n1,467 \nInterest rate hedges\n\n(2)\nNon-cash transaction:\nRight-of-use assets obtained in exchange for lease liabilities\n\n\n1,943 \nSee Notes 8A and 17A.\nSee Note 8A.\nSee Note 17C.\nSee Note 2C.\nSee Accompanying Notes.\n(a)\n(b)\n(c)\n(d)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nNote 1. Basis of Presentation and Significant Accounting Policies\nA. Basis of Presentation\nThe consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP.",
      "char_count": 913,
      "start_char": 349600,
      "end_char": 350514
    },
    {
      "chunk_id": "pfizer_2023_chunk0438",
      "chunk_index": 438,
      "text": "ts include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP. The decision of whether or\nnot to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically,\nwe do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November\n30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. All significant transactions among our\nsubsidiaries have been eliminated.\nIn 2023, we managed our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only\nreportable segment. See Note 17.\nOn December 14, 2023, we completed the acquisition of Seagen.",
      "char_count": 990,
      "start_char": 350400,
      "end_char": 351391
    },
    {
      "chunk_id": "pfizer_2023_chunk0439",
      "chunk_index": 439,
      "text": "egments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only\nreportable segment. See Note 17.\nOn December 14, 2023, we completed the acquisition of Seagen. On December 31, 2021, we completed the sale of our Meridian subsidiary, the manufacturer of EpiPen and other\nauto-injector products. In addition, other acquisitions and business development activities completed in 2023, 2022 and 2021 impacted financial results in the periods presented. See\nNote 2.\nWe have made certain reclassification adjustments to conform prior-period amounts to the current presentation. Certain amounts in the consolidated financial statements and\nassociated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.\nB. New Accounting Standards Adopted in 2023\nOn January 1, 2023, we adopted a new accounting standard for supplier finance programs which requires increased disclosures in the notes to our financial statements.",
      "char_count": 979,
      "start_char": 351200,
      "end_char": 352180
    },
    {
      "chunk_id": "pfizer_2023_chunk0440",
      "chunk_index": 440,
      "text": "opted in 2023\nOn January 1, 2023, we adopted a new accounting standard for supplier finance programs which requires increased disclosures in the notes to our financial statements. See Note\n8C.\nIn the second quarter of 2023, we adopted new accounting standards on reference rate reform that provide temporary optional expedients and exceptions to the guidance for\ncontracts, hedging relationships, and other transactions that reference LIBOR or another reference rate that were discontinued after June 30, 2023. We applied certain of the\noptional expedients related to hedge accounting relationships. The main purpose of the expedients is to allow hedge accounting to continue uninterrupted and make it easier to\napply the requirements to maintain hedge accounting during the transition period through December 31, 2024.\nC. Estimates and Assumptions\nIn preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures.",
      "char_count": 976,
      "start_char": 352000,
      "end_char": 352977
    },
    {
      "chunk_id": "pfizer_2023_chunk0441",
      "chunk_index": 441,
      "text": "December 31, 2024.\nC. Estimates and Assumptions\nIn preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all\nelements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues, determining the\ncost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as\ndetermining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the\nreported amounts of liabilities, all of which also impact the consolidated statements of income.",
      "char_count": 849,
      "start_char": 352800,
      "end_char": 353651
    },
    {
      "chunk_id": "pfizer_2023_chunk0442",
      "chunk_index": 442,
      "text": "also impact the consolidated statements of income. Certain estimates of fair value and amounts recorded in connection with acquisitions,\nrevenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans,\ncontingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on\nestimates and assumptions.\nOur estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and\nassumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our",
      "char_count": 863,
      "start_char": 353600,
      "end_char": 354464
    },
    {
      "chunk_id": "pfizer_2023_chunk0443",
      "chunk_index": 443,
      "text": "ents and their effects cannot be determined with precision, our\nestimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and\nassumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition,\nlitigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates\nand assumptions when facts and circumstances indicate the need for change.\nD. Acquisitions\nOur consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions.",
      "char_count": 809,
      "start_char": 354400,
      "end_char": 355210
    },
    {
      "chunk_id": "pfizer_2023_chunk0444",
      "chunk_index": 444,
      "text": "isitions. We account for acquired businesses using the\nacquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the\nacquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration\ntransferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no\ngoodwill is recognized and acquired IPR&D is expensed in Acquired in-process research and development expenses.\nContingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally\nestimated by using a probability-weighted discounted cash flow approach. See Note 16D.",
      "char_count": 955,
      "start_char": 355200,
      "end_char": 356156
    },
    {
      "chunk_id": "pfizer_2023_chunk0445",
      "chunk_index": 445,
      "text": "ed at fair value as of the acquisition date. Fair value is generally\nestimated by using a probability-weighted discounted cash flow approach. See Note 16D. Any liability resulting from contingent consideration is remeasured to fair value at each\nreporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net.\nE. Fair Value\nWe measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach,\nwhich requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit\nprice is considered from the perspective of market participants,\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 896,
      "start_char": 356000,
      "end_char": 356897
    },
    {
      "chunk_id": "pfizer_2023_chunk0446",
      "chunk_index": 446,
      "text": "perspective of market participants,\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nconsidering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.\nWhen estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:\n• Income approach, which is based on the present value of a future stream of net cash flows.\n• Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.\n• Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.\nOur fair value methodologies depend on the following types of inputs:\n• Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).",
      "char_count": 970,
      "start_char": 356800,
      "end_char": 357772
    },
    {
      "chunk_id": "pfizer_2023_chunk0447",
      "chunk_index": 447,
      "text": "obsolescence.\nOur fair value methodologies depend on the following types of inputs:\n• Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).\n• Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted\nprices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2\ninputs).\n• Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).\nThe following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:\n• Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield\ncurves.",
      "char_count": 941,
      "start_char": 357600,
      "end_char": 358542
    },
    {
      "chunk_id": "pfizer_2023_chunk0448",
      "chunk_index": 448,
      "text": "ty matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield\ncurves.\n• Equity securities with readily determinable fair values—quoted market prices and observable NAV prices.\n• Derivative assets and liabilities—third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use\nmarket-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our\nderivative financial instruments was not significant.\n• Money market funds—observable NAV prices.\nWe periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness.",
      "char_count": 816,
      "start_char": 358400,
      "end_char": 359217
    },
    {
      "chunk_id": "pfizer_2023_chunk0449",
      "chunk_index": 449,
      "text": "reasonableness. Our procedures can include, for example, referencing other thirdparty pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial\ninstruments.\nF. Foreign Currency Translation\nFor most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S.\ndollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that\narise from changing translation rates are recorded in Other comprehensive income/(loss). The effects of converting non-functional currency monetary assets and liabilities into the\nfunctional currency are recorded in Other (income)/deductions––net.",
      "char_count": 905,
      "start_char": 359200,
      "end_char": 360107
    },
    {
      "chunk_id": "pfizer_2023_chunk0450",
      "chunk_index": 450,
      "text": "netary assets and liabilities into the\nfunctional currency are recorded in Other (income)/deductions––net. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance\nsheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.\nG. Revenues and Trade Accounts Receivable\nRevenue Recognition––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control\nbased on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party\nsubcontractors’ locations under a bill-and-hold arrangement.",
      "char_count": 823,
      "start_char": 360000,
      "end_char": 360824
    },
    {
      "chunk_id": "pfizer_2023_chunk0451",
      "chunk_index": 451,
      "text": "l-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the\nproduct and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for\nphysical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In bill-and-hold arrangements which are part of the U.S.\nGovernment Strategic National Stockpile, we recognize revenue for the product sale when the product is initially placed into the Stockpile and we provide a rotation service to\nmaintain an agreed upon level of shelf life for product in the stockpile. In determining when the customer obtains control of the product, we consider certain indicators, including",
      "char_count": 851,
      "start_char": 360800,
      "end_char": 361652
    },
    {
      "chunk_id": "pfizer_2023_chunk0452",
      "chunk_index": 452,
      "text": "product, we consider certain indicators, including\nwhether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether\ncustomer acceptance has been received.\nIn the fourth quarter of 2023, we began reporting Product revenues and Alliance revenues as separate line items in our consolidated statements of income. Prior-period amounts\nhave been reclassified to conform to the current presentation.\nOur Sales Contracts––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in\nthe U.S. Sales are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns may occur due to LOE, product recalls or a changing\ncompetitive environment.",
      "char_count": 874,
      "start_char": 361600,
      "end_char": 362476
    },
    {
      "chunk_id": "pfizer_2023_chunk0453",
      "chunk_index": 453,
      "text": "ay occur due to LOE, product recalls or a changing\ncompetitive environment.\nDeductions from Revenues––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues\nare recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations\nand, as such, knowledge and judgment is required when estimating the impact of these product revenue deductions on gross sales for a reporting period.\nProvisions for pharmaceutical sales returns––Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and\npractices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between\nshipment and return or lag time; and any other factors that could",
      "char_count": 998,
      "start_char": 362400,
      "end_char": 363399
    },
    {
      "chunk_id": "pfizer_2023_chunk0454",
      "chunk_index": 454,
      "text": "sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between\nshipment and return or lag time; and any other factors that could\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nimpact the estimate of future returns, such as LOE, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded\nthe sales price in the form of a credit.\nWe record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our\nsales incentives based on our historical experience with similar incentives programs to predict customer behavior.\nThe following outlines our common sales arrangements:",
      "char_count": 828,
      "start_char": 363200,
      "end_char": 364030
    },
    {
      "chunk_id": "pfizer_2023_chunk0455",
      "chunk_index": 455,
      "text": "ur common sales arrangements:\n• Customers––Our prescription biopharmaceutical products, with the exception of Paxlovid in 2022 and 2023, are sold principally to wholesalers, but we also sell directly to retailers,\nhospitals, clinics, government agencies and pharmacies. In 2022 and 2023, we principally sold Paxlovid globally to government agencies. Our vaccines in the U.S. are primarily\nsold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the\nU.S. are primarily sold to government and non-government institutions. Prescription pharmaceutical products that ultimately are used by patients are generally covered under\ngovernmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable\ndirectly to those programs.",
      "char_count": 934,
      "start_char": 364000,
      "end_char": 364935
    },
    {
      "chunk_id": "pfizer_2023_chunk0456",
      "chunk_index": 456,
      "text": "programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable\ndirectly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g.,\npatented or unpatented).\nSpecifically:\n• In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with\nthe federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and\nperformance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the\nexperience ratio to the respective period’s sales to determine the rebate accrual and related expense.",
      "char_count": 927,
      "start_char": 364800,
      "end_char": 365728
    },
    {
      "chunk_id": "pfizer_2023_chunk0457",
      "chunk_index": 457,
      "text": "or periods. We apply the\nexperience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical\ntrends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the\n“doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap.\nWe evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also\nconsider current contract terms, such as changes in formulary status and rebate rates.",
      "char_count": 826,
      "start_char": 365600,
      "end_char": 366427
    },
    {
      "chunk_id": "pfizer_2023_chunk0458",
      "chunk_index": 458,
      "text": "y status and rebate rates.\n• Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each\nperiod, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical\nspending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We\nobtain third-party information that helps us to monitor the adequacy of these accruals.\n• Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely\napproximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.",
      "char_count": 951,
      "start_char": 366400,
      "end_char": 367352
    },
    {
      "chunk_id": "pfizer_2023_chunk0459",
      "chunk_index": 459,
      "text": "hird parties) closely\napproximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.\nWe recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2023, for each of ten products in 2022 and for each of nine products in\n2021. In the aggregate, these direct product sales and/or Alliance revenues represented 64%, 82% and 75% of our Total revenues in 2023, 2022 and 2021, respectively. See Note\n17C. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling\nprices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or\nexpiration of intellectual property rights.",
      "char_count": 910,
      "start_char": 367200,
      "end_char": 368111
    },
    {
      "chunk_id": "pfizer_2023_chunk0460",
      "chunk_index": 460,
      "text": "g the period in which individual markets begin to near the loss or\nexpiration of intellectual property rights.\nOur accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are\nas follows:\n \nAs of December 31,\n(MILLIONS)\n\nReserve against Trade accounts receivable, less allowance for doubtful accounts\n1,770 \n1,200 \nOther current liabilities:\nAccrued rebates\n5,546 \n4,479 \nOther accruals\n\nOther noncurrent liabilities\n\nTotal accrued rebates and other sales-related accruals\n9,014 \n6,722 \nTaxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Product revenues.\nTrade Accounts Receivable—Trade accounts receivable are stated at their net realizable value.",
      "char_count": 822,
      "start_char": 368000,
      "end_char": 368823
    },
    {
      "chunk_id": "pfizer_2023_chunk0461",
      "chunk_index": 461,
      "text": "net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of\nthe receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected\ncredit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk\nversus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.\nIn determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory\nand legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors.",
      "char_count": 914,
      "start_char": 368800,
      "end_char": 369716
    },
    {
      "chunk_id": "pfizer_2023_chunk0462",
      "chunk_index": 462,
      "text": "l environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly\nbasis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are\nconsidered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\non a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit\nrisk, specific allowances for these known troubled accounts are recorded.",
      "char_count": 819,
      "start_char": 369600,
      "end_char": 370420
    },
    {
      "chunk_id": "pfizer_2023_chunk0463",
      "chunk_index": 463,
      "text": "ounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including\nlitigation, where appropriate) have been exhausted.\nDuring 2023 and 2022, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.\nH. Collaborative Arrangements\nPayments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms),\nthe nature of the payments and applicable accounting guidance. Under co-commercialization agreements, we record the amounts received for our share of gross profits from our\ncollaboration partners as Alliance revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits.",
      "char_count": 904,
      "start_char": 370400,
      "end_char": 371305
    },
    {
      "chunk_id": "pfizer_2023_chunk0464",
      "chunk_index": 464,
      "text": "tion partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues\nare recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and\nmarketing these products including reimbursements to or from our collaboration partners for these costs are included in Selling, informational and administrative expenses. In\ncollaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners.\nIn collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all\nroyalty payments to collaboration partners as Cost of sales.",
      "char_count": 899,
      "start_char": 371200,
      "end_char": 372100
    },
    {
      "chunk_id": "pfizer_2023_chunk0465",
      "chunk_index": 465,
      "text": "f net sales or profits earned, and all\nroyalty payments to collaboration partners as Cost of sales. Royalty payments received from collaboration partners are included in Other (income)/deductions—net.\nReimbursements to or from our collaboration partners for development costs are typically recorded in Research and development expenses. Upfront payments and pre-approval\nmilestone payments due from us to our collaboration partners in development stage collaborations are recorded as Acquired in-process research and development expenses.\nMilestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in Identifiable intangible assets—developed\ntechnology rights. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in Other (income)/deductions—net over the",
      "char_count": 880,
      "start_char": 372000,
      "end_char": 372881
    },
    {
      "chunk_id": "pfizer_2023_chunk0466",
      "chunk_index": 466,
      "text": "boration partners by us are recognized in Other (income)/deductions—net over the\ndevelopment period for the products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval\nmilestone payments earned by us may be recognized in Other (income)/deductions—net immediately when earned or over other periods depending upon the nature of our\nperformance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in\nthe transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than\nthe milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.\nI.",
      "char_count": 900,
      "start_char": 372800,
      "end_char": 373701
    },
    {
      "chunk_id": "pfizer_2023_chunk0467",
      "chunk_index": 467,
      "text": "ain circumstances when recognition of the income would not be probable of a significant reversal.\nI. Cost of Sales and Inventories\nInventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We\nregularly review our inventories for impairment and reserves are established when necessary. Inventories that are not expected to be sold within 12 months are classified as Other\nnoncurrent assets. See Note 8A.\nJ. Selling, Informational and Administrative Expenses\nSelling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising,\nshipping and handling, digital and legal defense. Advertising expenses totaled approximately $3.7 billion in 2023, $2.8 billion in 2022 and $2.0 billion in 2021.",
      "char_count": 910,
      "start_char": 373600,
      "end_char": 374511
    },
    {
      "chunk_id": "pfizer_2023_chunk0468",
      "chunk_index": 468,
      "text": "dvertising expenses totaled approximately $3.7 billion in 2023, $2.8 billion in 2022 and $2.0 billion in 2021. Production costs are\nexpensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.\nK. Research and Development Expenses\nR&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as R&D activities performed in connection with certain licensing\narrangements.\nL. Acquired In-Process Research and Development Expenses\nBefore a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing and collaboration arrangements as expense.\nUpfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved.",
      "char_count": 857,
      "start_char": 374400,
      "end_char": 375258
    },
    {
      "chunk_id": "pfizer_2023_chunk0469",
      "chunk_index": 469,
      "text": "e recorded when the specific milestone has been achieved. Once a compound receives regulatory\napproval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we\ntypically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. Acquired in-process research and\ndevelopment expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity\nsecurities and (b) asset acquisitions of acquired IPR&D.\nM. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets\nLong-lived assets include:\n• Property, plant and equipment, less accumulated depreciation—These assets are recorded at cost, including any significant improvements after purchase, less accumulated\ndepreciation.",
      "char_count": 975,
      "start_char": 375200,
      "end_char": 376176
    },
    {
      "chunk_id": "pfizer_2023_chunk0470",
      "chunk_index": 470,
      "text": "ty, plant and equipment, less accumulated depreciation—These assets are recorded at cost, including any significant improvements after purchase, less accumulated\ndepreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the\nindividual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.\n• Identifiable intangible assets, less accumulated amortization—These assets are recorded at fair value at acquisition. Intangible assets with finite lives are amortized on a straightline basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 893,
      "start_char": 376000,
      "end_char": 376894
    },
    {
      "chunk_id": "pfizer_2023_chunk0471",
      "chunk_index": 471,
      "text": "a useful life can be determined.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\n• Goodwill—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.\nAmortization of finite-lived acquired intangible assets is included in Amortization of intangible assets.\nWe review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and\nfor all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less\nthan the carrying value of these assets.\nSpecifically:\n• For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are",
      "char_count": 972,
      "start_char": 376800,
      "end_char": 377774
    },
    {
      "chunk_id": "pfizer_2023_chunk0472",
      "chunk_index": 472,
      "text": "nite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are\npresent, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying\namount is greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful\nlives of the assets and modify them, as appropriate.\n• For indefinite-lived intangible assets, such as brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the\nexcess of book value over fair value.",
      "char_count": 801,
      "start_char": 377600,
      "end_char": 378402
    },
    {
      "chunk_id": "pfizer_2023_chunk0473",
      "chunk_index": 473,
      "text": ". In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as\nindefinite-lived is appropriate.\n• For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over\nthe implied fair value.\nN. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives\nWe incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction\nand productivity initiatives.\n• In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for",
      "char_count": 891,
      "start_char": 378400,
      "end_char": 379292
    },
    {
      "chunk_id": "pfizer_2023_chunk0474",
      "chunk_index": 474,
      "text": "g the transactions, integrating the acquired operations (which may include expenditures for\nconsulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that\nwill not continue in the combined company); and\n• In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and\nthe expansion of shared services, including the development of global systems.\nIncluded in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an\nacquired company. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational",
      "char_count": 947,
      "start_char": 379200,
      "end_char": 380148
    },
    {
      "chunk_id": "pfizer_2023_chunk0475",
      "chunk_index": 475,
      "text": "action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational\nand administrative expenses and/or Research and development expenses, as appropriate. Employee termination costs are generally recorded when the actions are probable and\nestimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Transaction costs, such as\nbanking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred.\nOur business and platform functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as our corporate enabling functions.\nO. Cash Equivalents and Statement of Cash Flows",
      "char_count": 840,
      "start_char": 380000,
      "end_char": 380841
    },
    {
      "chunk_id": "pfizer_2023_chunk0476",
      "chunk_index": 476,
      "text": "Equivalents and Statement of Cash Flows\nCash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items\nmeeting this definition are part of a larger investment pool, we classify them as Short-term investments.\nCash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the\nitems being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for\nfinancial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.\nP.",
      "char_count": 824,
      "start_char": 380800,
      "end_char": 381626
    },
    {
      "chunk_id": "pfizer_2023_chunk0477",
      "chunk_index": 477,
      "text": "and accounting nature.\nP. Investments and Derivative Financial Instruments\nThe classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our\ninvestments are primarily comprised of the following:\n• Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.\n• Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.\n• Held-to-maturity debt securities, which are carried at amortized cost.\n• Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus",
      "char_count": 881,
      "start_char": 381600,
      "end_char": 382482
    },
    {
      "chunk_id": "pfizer_2023_chunk0478",
      "chunk_index": 478,
      "text": "significant influence are measured at cost minus any impairment and plus or minus\nadjustments resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.\n• For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the\nequity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in Other (income)/deductions—net. The excess of the cost of\nthe investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee,\nwith any remaining\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 835,
      "start_char": 382400,
      "end_char": 383236
    },
    {
      "chunk_id": "pfizer_2023_chunk0479",
      "chunk_index": 479,
      "text": "o Consolidated Financial Statements\n\nexcess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent\nconsideration.\nRealized gains or losses on sales of investments are determined by using the specific identification cost method.\nWe regularly evaluate all of our financial assets for impairment. For investments in debt and equity, if and when a decline in fair value is determined, an impairment charge is\nrecorded and a new cost basis in the investment is established. For equity-method investments, an impairment charge is recorded only if and when a decline in fair value is\ndetermined to be other-than-temporary.\nDerivative financial instruments are carried at fair value in certain balance sheet categories (see Note 7A), with changes in fair value reported in net income or, for certain qualifying\nhedging relationships, in Other comprehensive income/(loss) (see Note 7E).\nQ.",
      "char_count": 992,
      "start_char": 383200,
      "end_char": 384193
    },
    {
      "chunk_id": "pfizer_2023_chunk0480",
      "chunk_index": 480,
      "text": "lance sheet categories (see Note 7A), with changes in fair value reported in net income or, for certain qualifying\nhedging relationships, in Other comprehensive income/(loss) (see Note 7E).\nQ. Tax Assets and Liabilities and Income Tax Contingencies\nTax Assets and Liabilities––Current tax assets primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the\nconsolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing\nauthorities or reductions to future tax obligations.\nDeferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using\nenacted tax rates and laws.",
      "char_count": 865,
      "start_char": 384000,
      "end_char": 384866
    },
    {
      "chunk_id": "pfizer_2023_chunk0481",
      "chunk_index": 481,
      "text": "bases of assets and liabilities using\nenacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable\nincome that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for\nvaluation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax\njurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.\nThe TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No.",
      "char_count": 836,
      "start_char": 384800,
      "end_char": 385637
    },
    {
      "chunk_id": "pfizer_2023_chunk0482",
      "chunk_index": 482,
      "text": ". The FASB Staff Q&A, Topic 740, No. 5,\nAccounting for Global Intangible Low-Taxed Income, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis\ndifferences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected\nto recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.\nOther non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax\njurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to\nas the competent authority process.",
      "char_count": 928,
      "start_char": 385600,
      "end_char": 386529
    },
    {
      "chunk_id": "pfizer_2023_chunk0483",
      "chunk_index": 483,
      "text": "g authorities, as required by tax treaties to minimize double taxation, commonly referred to\nas the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax\njurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.\nOther taxes payable as of December 31, 2023 and 2022 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected\npayment over eight years through 2026. See Note 5D for uncertain tax positions and Note 5A for the repatriation tax liability and other estimates and assumptions in connection with\nthe TCJA.\nIncome Tax Contingencies––We account for income tax contingencies using a benefit recognition model.",
      "char_count": 840,
      "start_char": 386400,
      "end_char": 387241
    },
    {
      "chunk_id": "pfizer_2023_chunk0484",
      "chunk_index": 484,
      "text": "ncies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained\nupon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than\n50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.\nWe regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that\nsufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an\naudit resulting in a favorable settlement of that tax year with the appropriate agency.",
      "char_count": 927,
      "start_char": 387200,
      "end_char": 388128
    },
    {
      "chunk_id": "pfizer_2023_chunk0485",
      "chunk_index": 485,
      "text": "or (iii) if there is a completion of an\naudit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash\nwithin the next 12 months. Interest and penalties, if any, are recorded in Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related\ntax liability.\nOur assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax\nbenefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the\nstatutes of limitations expire, as we treat these events as discrete items in the period of resolution.\nR.",
      "char_count": 878,
      "start_char": 388000,
      "end_char": 388879
    },
    {
      "chunk_id": "pfizer_2023_chunk0486",
      "chunk_index": 486,
      "text": "re, as we treat these events as discrete items in the period of resolution.\nR. Pension and Postretirement Benefit Plans\nThe majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental\n(non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their\neligible dependents. Net periodic pension and postretirement benefit costs other than the service costs are recognized in Other (income)/deductions—net. We immediately recognize\nactuarial gains and losses arising from the remeasurement of our pension and postretirement plans (mark-to-market accounting). Each time a pension or postretirement plan is\nremeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions––net.",
      "char_count": 945,
      "start_char": 388800,
      "end_char": 389746
    },
    {
      "chunk_id": "pfizer_2023_chunk0487",
      "chunk_index": 487,
      "text": "sion or postretirement plan is\nremeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions––net. We recognize the overfunded or underfunded status of each of\nour defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as\nprovided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of\nreturn on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels.\nFor our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which",
      "char_count": 923,
      "start_char": 389600,
      "end_char": 390524
    },
    {
      "chunk_id": "pfizer_2023_chunk0488",
      "chunk_index": 488,
      "text": "ion may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which\nthose costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nS. Legal and Environmental Contingencies\nWe and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other productrelated litigation, commercial and other asserted or unasserted matters, environmental claims and proceedings, government investigations and guarantees and indemnifications. In\nassessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record",
      "char_count": 882,
      "start_char": 390400,
      "end_char": 391283
    },
    {
      "chunk_id": "pfizer_2023_chunk0489",
      "chunk_index": 489,
      "text": "t the Company, or unasserted claims that are probable of being asserted, we record\naccruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better\nestimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other\namount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.\nT. Share-Based Payments\nOur compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are\ngenerally amortized on a straight-line basis or on an accelerated attribution approach over the vesting terms with the related costs recorded in Cost of sales, Selling, informational",
      "char_count": 956,
      "start_char": 391200,
      "end_char": 392157
    },
    {
      "chunk_id": "pfizer_2023_chunk0490",
      "chunk_index": 490,
      "text": "traight-line basis or on an accelerated attribution approach over the vesting terms with the related costs recorded in Cost of sales, Selling, informational\nand administrative expenses and/or Research and development expenses, as appropriate.\nNote 2. Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development\nArrangement\nA. Acquisitions\nSeagen––On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer\nmedicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). In addition, in connection with the\nacquisition $476 million in post-closing compensation expense for Seagen employee incentive awards was recorded in Restructuring charges and certain acquisition-related costs\n(see Note 3).",
      "char_count": 957,
      "start_char": 392000,
      "end_char": 392958
    },
    {
      "chunk_id": "pfizer_2023_chunk0491",
      "chunk_index": 491,
      "text": "t-closing compensation expense for Seagen employee incentive awards was recorded in Restructuring charges and certain acquisition-related costs\n(see Note 3). The combination of local Pfizer and Seagen entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory\nsteps.\nSeagen’s principal business was the development, manufacture, marketing and distribution of targeted cancer therapeutics, primarily using antibody-drug conjugate technology.\nSeagen’s portfolio includes four approved medicines as well as a pipeline of product candidates. Clinical development programs are ongoing for each of these approved medicines\nfor potential new or expanded indications and for several product candidates. We believe our acquisition of Seagen will strengthen our oncology capabilities by allowing us to",
      "char_count": 860,
      "start_char": 392800,
      "end_char": 393661
    },
    {
      "chunk_id": "pfizer_2023_chunk0492",
      "chunk_index": 492,
      "text": "will strengthen our oncology capabilities by allowing us to\ncombine Seagen’s antibody-drug conjugate technology with the resources and scale of the Pfizer enterprise and to advance more potential breakthroughs to patients with cancer.\nThe following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date. The estimated values are not yet finalized\n(see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses. We\nexpect to finalize these amounts as soon as possible but no later than one year from the acquisition date.\n(MILLIONS)\nAmounts Recognized\nas of Acquisition Date\n(Provisional)\nWorking capital, excluding inventories\n\nInventories\n4,195 \nProperty, plant and equipment",
      "char_count": 853,
      "start_char": 393600,
      "end_char": 394455
    },
    {
      "chunk_id": "pfizer_2023_chunk0493",
      "chunk_index": 493,
      "text": "ries\n\nInventories\n4,195 \nProperty, plant and equipment\n\nIdentifiable intangible assets, excluding in-process research and development\n7,970 \nIn-process research and development\n20,800 \nOther noncurrent assets\n\nNet income tax accounts\n(6,123)\nOther noncurrent liabilities\n(167)\nTotal identifiable net assets\n28,108 \nGoodwill\n16,126 \nNet assets acquired/total consideration transferred\n44,234 \nIncludes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities.\nComprised of $1.0 billion current inventories and $3.1 billion noncurrent inventories.\nComprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.\nAs of the acquisition date, included primarily in Noncurrent deferred tax liabilities.\nThe following items are subject to change:",
      "char_count": 901,
      "start_char": 394400,
      "end_char": 395302
    },
    {
      "chunk_id": "pfizer_2023_chunk0494",
      "chunk_index": 494,
      "text": "included primarily in Noncurrent deferred tax liabilities.\nThe following items are subject to change:\n• Amounts for certain balances included in working capital (excluding inventories), and certain legal contingencies, pending receipt of certain information that could affect provisional\namounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.\n• Amounts for identifiable intangible assets, inventories, contractual commitments, PP&E, and operating lease ROU assets and liabilities, pending finalization of valuation efforts,\nthe completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain PP&E assets.\n(a)\n(b)\n(c)\n(d)\n(a)\n(b)\n(c)\n(d)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 843,
      "start_char": 395200,
      "end_char": 396044
    },
    {
      "chunk_id": "pfizer_2023_chunk0495",
      "chunk_index": 495,
      "text": "Notes to Consolidated Financial Statements\n\n• Amounts for income tax assets, receivables and liabilities, pending the filing of Seagen’s pre-acquisition tax returns and the receipt of information, including but not limited to that\nfrom taxing authorities, which may change certain estimates and assumptions used.\nAs of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $597 million.\nIn the ordinary course of business, Seagen may incur liabilities for environmental, legal and tax matters, as well as guarantees and indemnifications. These matters may include\ncontingencies. Except as specifically excluded by the relevant accounting standard, contingencies are required to be measured at fair value as of the acquisition date if the\nacquisition-date fair value of the asset or liability arising from a contingency can be determined.",
      "char_count": 925,
      "start_char": 396000,
      "end_char": 396927
    },
    {
      "chunk_id": "pfizer_2023_chunk0496",
      "chunk_index": 496,
      "text": "he acquisition date if the\nacquisition-date fair value of the asset or liability arising from a contingency can be determined. If the acquisition-date fair value of the asset or liability cannot be determined, the\nasset or liability would be recognized at the acquisition date if both of the following criteria are met: (i) it is probable that an asset existed or that a liability had been incurred at the\nacquisition date, and (ii) the amount of the asset or liability can be reasonably estimated.\n• Environmental Matters—In the ordinary course of business, Seagen may incur liabilities for environmental matters such as remediation work, asset retirement obligations and\nenvironmental guarantees and indemnifications.\n• Legal Matters—Seagen is involved in various legal proceedings, including patent, intellectual property, and product liability matters of a nature considered normal to its business.",
      "char_count": 902,
      "start_char": 396800,
      "end_char": 397703
    },
    {
      "chunk_id": "pfizer_2023_chunk0497",
      "chunk_index": 497,
      "text": "t, intellectual property, and product liability matters of a nature considered normal to its business.\nThe contingencies arising from legal matters are not significant to our consolidated financial statements.\n• Tax Matters—In the ordinary course of business, Seagen incurs liabilities for income taxes. Income taxes are exceptions to both the recognition and fair value measurement\nprinciples associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model\npreviously used by Seagen (see Note 1Q). Net liabilities for income taxes as of the acquisition date were $6.1 billion, including $56 million for uncertain tax positions. The net tax\nliability includes $7.5 billion for the tax impact of fair value adjustments, partially offset by $1.4 billion for deferred tax assets on which Seagen had recognized a valuation\nallowance.",
      "char_count": 921,
      "start_char": 397600,
      "end_char": 398522
    },
    {
      "chunk_id": "pfizer_2023_chunk0498",
      "chunk_index": 498,
      "text": "justments, partially offset by $1.4 billion for deferred tax assets on which Seagen had recognized a valuation\nallowance.\nGoodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired\nthat could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of Seagen includes the following:\n• the expected specific synergies and other benefits that we believe will result from combining the operations of Seagen with the operations of Pfizer;\n• any intangible assets that do not qualify for separate recognition, as well as future, as yet unidentified projects and products; and\n• the value of the going-concern element of Seagen’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the\nnet assets separately).",
      "char_count": 962,
      "start_char": 398400,
      "end_char": 399363
    },
    {
      "chunk_id": "pfizer_2023_chunk0499",
      "chunk_index": 499,
      "text": "Seagen’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the\nnet assets separately).\nGoodwill is not amortized and is not deductible for tax purposes. All of the goodwill related to the acquisition of Seagen is related to our Biopharma segment (see Note 10).\nActual and Pro Forma Impact of Acquisition—The following table presents information for Seagen’s operations that are included in Pfizer’s consolidated statements of income\nbeginning from the acquisition date, December 14, 2023, through Pfizer’s year-end in 2023:\n(MILLIONS)\nDecember 31,\n\nRevenues\n\nNet loss attributable to Pfizer Inc. common shareholders\n(746)\nIncludes restructuring, integration and acquisition-related costs ($614 million pre-tax) and purchase accounting charges related to (i) the preliminary fair value adjustment for acquisition-date inventory",
      "char_count": 902,
      "start_char": 399200,
      "end_char": 400103
    },
    {
      "chunk_id": "pfizer_2023_chunk0500",
      "chunk_index": 500,
      "text": "accounting charges related to (i) the preliminary fair value adjustment for acquisition-date inventory\nestimated to have been sold ($109 million pre-tax); (ii) amortization expense related to the preliminary fair value of identifiable intangible assets acquired from Seagen ($25 million pre-tax); as well as (iii)\ndepreciation expense related to the preliminary fair value adjustment of fixed assets acquired from Seagen ($2 million pre-tax).\nThe following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:\nUnaudited Supplemental Pro Forma Consolidated Results\nYear Ended December 31,\n(MILLIONS, EXCEPT PER SHARE DATA)\n\nRevenues\n60,632 \n102,127 \nNet income/(loss) attributable to Pfizer Inc. common shareholders\n(1,474)\n27,938 \nDiluted earnings/(loss) per share attributable to Pfizer Inc.",
      "char_count": 874,
      "start_char": 400000,
      "end_char": 400875
    },
    {
      "chunk_id": "pfizer_2023_chunk0501",
      "chunk_index": 501,
      "text": "474)\n27,938 \nDiluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders\n(0.26)\n4.87 \nThe unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company’s results of operations would have been had the acquisition\noccurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the\nacquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors.\nThe unaudited supplemental pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired\nand the liabilities assumed from Seagen. The historical U.S.",
      "char_count": 863,
      "start_char": 400800,
      "end_char": 401664
    },
    {
      "chunk_id": "pfizer_2023_chunk0502",
      "chunk_index": 502,
      "text": "ed\nand the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments:\n• Additional amortization expense (approximately $503 million in 2023 and $526 million in 2022) related to the preliminary estimate of the fair value of identifiable intangible assets\nacquired.\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\n• Additional expense related to the preliminary estimate of the fair value adjustment to acquisition-date inventory estimated to have been sold (approximately $796 million in 2023\nand $887 million in 2022).\n• Additional interest expense (approximately $984 million in 2023 and $2.0 billion in 2022) related to the estimated debt issued by Pfizer and the commercial paper borrowings to\npartially finance the acquisition.",
      "char_count": 857,
      "start_char": 401600,
      "end_char": 402458
    },
    {
      "chunk_id": "pfizer_2023_chunk0503",
      "chunk_index": 503,
      "text": "al paper borrowings to\npartially finance the acquisition.\n• Elimination of interest income (approximately $1.2 billion in 2023 and $267 million in 2022) related to the debt issuance proceeds that were invested prior to the acquisition date\nand associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially fund the acquisition.\n• Adjustment to move Seagen royalty income received from collaboration partners (approximately $203 million in 2023 and $165 million in 2022) from total revenues to other\n(income)/deductions, which is consistent with Pfizer’s presentation in 2023.\nThe above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.\nThe acquisition of Seagen had no impact on Pfizer’s weighted-average shares as no shares were issued.",
      "char_count": 916,
      "start_char": 402400,
      "end_char": 403317
    },
    {
      "chunk_id": "pfizer_2023_chunk0504",
      "chunk_index": 504,
      "text": "a adjustments.\nThe acquisition of Seagen had no impact on Pfizer’s weighted-average shares as no shares were issued.\nGBT––On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved\npatient communities, starting with sickle cell disease, for $68.50 per share in cash. The total fair value of the consideration transferred was $5.7 billion ($5.2 billion, net of cash\nacquired). In addition, $136 million in payments to GBT employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing\ncompensation expense and recorded in Restructuring charges and certain acquisition-related costs (see Note 3).\nThe final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023.",
      "char_count": 872,
      "start_char": 403200,
      "end_char": 404073
    },
    {
      "chunk_id": "pfizer_2023_chunk0505",
      "chunk_index": 505,
      "text": "o the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we\nrecorded: (i) $4.4 billion in Identifiable intangible assets, consisting of $3.0 billion of IPR&D and $1.4 billion of developed technology rights with a useful life of six years, (ii) $1.1\nbillion of Goodwill, (iii) $644 million of inventories to be sold over approximately three years, (iv) $516 million of net deferred tax liabilities and (v) $331 million of assumed long-term\ndebt that was paid in full in the fourth quarter of 2022.\nBiohaven––On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and\nprevention of episodic migraine in adults. The transaction included the acquisition of Biohaven’s CGRP programs, including rimegepant, zavegepant and a portfolio of five pre-clinical\nCGRP assets.",
      "char_count": 923,
      "start_char": 404000,
      "end_char": 404924
    },
    {
      "chunk_id": "pfizer_2023_chunk0506",
      "chunk_index": 506,
      "text": "acquisition of Biohaven’s CGRP programs, including rimegepant, zavegepant and a portfolio of five pre-clinical\nCGRP assets. Under the terms of the agreement, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of\napproximately $11.5 billion, plus repayment of third-party debt of $863 million and redemption of Biohaven’s redeemable preferred stock for $495 million. Effective immediately prior\nto the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.’s shares to Biohaven shareholders. Biohaven Ltd.\nbecame a new publicly traded company that retained Biohaven’s non-CGRP development stage pipeline compounds. Pfizer, a Biohaven shareholder, received a pro rata portion of\nBiohaven Ltd.’s shares in the distribution and owns approximately 1.3% of Biohaven Ltd.",
      "char_count": 899,
      "start_char": 404800,
      "end_char": 405700
    },
    {
      "chunk_id": "pfizer_2023_chunk0507",
      "chunk_index": 507,
      "text": "portion of\nBiohaven Ltd.’s shares in the distribution and owns approximately 1.3% of Biohaven Ltd. as of December 31, 2023.\nThis acquisition follows on the November 2021 collaboration for the commercialization of rimegepant and zavegepant outside the U.S., in connection with which Pfizer acquired\n2.6% of Biohaven’s common stock (see Note 2E). Biohaven Ltd. also has the right to receive tiered royalties from Pfizer on any annual net sales of rimegepant and zavegepant in\nthe U.S. in excess of $5.25 billion. This contingent consideration was determined to have no fair value as of the acquisition date. Pfizer also acquired Biohaven’s commitments for\npayment of high single digit to mid-teen percentage tiered royalties on world-wide net sales excluding China and low to high single digit royalties on net sales in China of rimegepant",
      "char_count": 837,
      "start_char": 405600,
      "end_char": 406439
    },
    {
      "chunk_id": "pfizer_2023_chunk0508",
      "chunk_index": 508,
      "text": "es on net sales in China of rimegepant\nand zavegepant as well as certain regulatory approval and commercial milestone payments associated with rimegepant and zavegepant of up to $1.1 billion under pre-existing thirdparty license and other agreements. These milestone amounts have been reduced by $608 million since the acquisition due to payments made and renegotiation of certain of the\napplicable agreements.\nThe total fair value of the consideration transferred was $11.8 billion, which includes the fair value of Pfizer’s previous investment in Biohaven on the acquisition date of\napproximately $300 million. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this\nbusiness combination, we recorded: (i) $12.1 billion in Identifiable intangible assets, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450",
      "char_count": 951,
      "start_char": 406400,
      "end_char": 407352
    },
    {
      "chunk_id": "pfizer_2023_chunk0509",
      "chunk_index": 509,
      "text": "(i) $12.1 billion in Identifiable intangible assets, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450\nmillion of IPR&D, (ii) $823 million of Goodwill, (iii) $813 million of inventories to be sold over approximately two years, (iv) $398 million of trade accounts receivable, (v) $1.4 billion of\nassumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $544 million of net deferred tax liabilities and (vii) $526 million of Other current liabilities.\nArena––On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology, for $100\nper share in cash. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired).",
      "char_count": 824,
      "start_char": 407200,
      "end_char": 408025
    },
    {
      "chunk_id": "pfizer_2023_chunk0510",
      "chunk_index": 510,
      "text": ", net of cash acquired). In addition, $138 million in payments to Arena employees\nfor the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in Restructuring charges and certain\nacquisition-related costs (see Note 3).\nThe final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2023. In connection with this business combination, we\nrecorded: (i) $5.5 billion in Identifiable intangible assets, consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived licensing agreements and other, (ii) $1.0 billion of\nGoodwill and (iii) $490 million of net deferred tax liabilities.\nReViral––On June 9, 2022, we acquired ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral",
      "char_count": 899,
      "start_char": 408000,
      "end_char": 408900
    },
    {
      "chunk_id": "pfizer_2023_chunk0511",
      "chunk_index": 511,
      "text": "ge biopharmaceutical company focused on discovering, developing and commercializing novel antiviral\ntherapeutics that target respiratory syncytial virus, for a total consideration of up to $536 million, including upfront payments of $436 million upon closing (including a base payment\nof $425 million plus working capital adjustments) and an additional $100 million contingent upon a future development milestone for a secondary pipeline asset. It was subsequently\ndetermined the applicable milestone was not achieved.\nWe accounted for the transaction as an asset acquisition since the lead asset, sisunatovir, represented substantially all of the fair value of the gross assets acquired. At the\nacquisition date, we recorded a $426 million charge representing an acquired IPR&D asset with no alternative\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 864,
      "start_char": 408800,
      "end_char": 409665
    },
    {
      "chunk_id": "pfizer_2023_chunk0512",
      "chunk_index": 512,
      "text": "tive\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nuse in Acquired in-process research and development expenses, which is presented as a cash outflow from operating activities. Other assets acquired and liabilities assumed were\nnot significant.\nTrillium––On November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno-oncology company\ndeveloping therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for $18.50 per share in cash, for total consideration of $2.0 billion, net of\ncash acquired. As a result, Trillium became our wholly owned subsidiary. We previously held a 2% ownership investment in Trillium. Trillium’s lead program, TTI-622, is an\ninvestigational fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.",
      "char_count": 935,
      "start_char": 409600,
      "end_char": 410536
    },
    {
      "chunk_id": "pfizer_2023_chunk0513",
      "chunk_index": 513,
      "text": "fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.\nWe accounted for the transaction as an asset acquisition since the lead asset, TTI-622, represented substantially all of the fair value of the gross assets acquired, which exclude\ncash acquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Acquired in-process research and\ndevelopment expenses, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded\n$256 million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $81 million.\nPro forma information for the aforementioned acquisitions (except for Seagen) has not been presented because these acquisitions were not material to our consolidated financial\nstatements.\nB.",
      "char_count": 992,
      "start_char": 410400,
      "end_char": 411393
    },
    {
      "chunk_id": "pfizer_2023_chunk0514",
      "chunk_index": 514,
      "text": ".\nPro forma information for the aforementioned acquisitions (except for Seagen) has not been presented because these acquisitions were not material to our consolidated financial\nstatements.\nB. Divestitures\nDivestiture of Early-Stage Rare Disease Gene Therapy Portfolio––On September 19, 2023, we completed an agreement with Alexion, under which Alexion purchased and licensed\nthe assets of our early-stage rare disease gene therapy portfolio. This agreement is consistent with our previously announced strategy to pivot from viral capsid-based gene therapy\napproaches to harnessing new platform technologies that we believe can have a transformative impact on patients, such as mRNA or in vivo gene editing. Under the terms of the\nagreement, Alexion will pay us total consideration of up to $1 billion, consisting of an upfront payment of $300 million which was paid at closing and future contingent milestone\npayments, plus tiered royalties based on annual net sales of the assets.",
      "char_count": 982,
      "start_char": 411200,
      "end_char": 412183
    },
    {
      "chunk_id": "pfizer_2023_chunk0515",
      "chunk_index": 515,
      "text": "n, consisting of an upfront payment of $300 million which was paid at closing and future contingent milestone\npayments, plus tiered royalties based on annual net sales of the assets. In connection with the closing of the transaction, Pfizer recognized a $222 million pre-tax gain in Other\n(income)/deductions––net (see Note 4).\nDiscontinued Operations\nMeridian––On December 31, 2021, we completed the sale of our Meridian subsidiary for approximately $51 million in cash and recognized a loss of approximately $167 million, net\nof tax, in Discontinued operations––net of tax. In connection with the sale, Pfizer and the purchaser of Meridian entered into various agreements to provide a framework for our\nrelationship after the sale, including interim TSAs and an MSA. Services under the TSAs are completed as of December 31, 2023. The MSA is for a term of three years post sale\nwith a two year extension period.",
      "char_count": 912,
      "start_char": 412000,
      "end_char": 412913
    },
    {
      "chunk_id": "pfizer_2023_chunk0516",
      "chunk_index": 516,
      "text": "pleted as of December 31, 2023. The MSA is for a term of three years post sale\nwith a two year extension period. Amounts recorded under the interim TSAs and MSA in 2023 and 2022 were not material to our operations. No amounts were recorded under these\narrangements in 2021.\nUpjohn Separation and Combination with Mylan––In connection with the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, Pfizer and Viatris\nentered into various agreements, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters\nagreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates\nthat we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other\nparty.",
      "char_count": 975,
      "start_char": 412800,
      "end_char": 413776
    },
    {
      "chunk_id": "pfizer_2023_chunk0517",
      "chunk_index": 517,
      "text": "performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other\nparty. The terms of the MSAs range in initial duration from four to seven years post-separation. Services under the TSAs were largely completed as of December 31, 2023. Amounts\nrecorded under the above agreements in 2023, 2022 and 2021 were not material to our operations. Net amounts due to Viatris under the above agreements were $33 million as of\nDecember 31, 2023 and $94 million as of December 31, 2022. The cash flows associated with the above agreements are included in Net cash provided by operating activities from\ncontinuing operations, except for a $277 million payment to Viatris made in 2021 pursuant to terms of the separation agreement, which is reported in Other financing activities, net.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 934,
      "start_char": 413600,
      "end_char": 414535
    },
    {
      "chunk_id": "pfizer_2023_chunk0518",
      "chunk_index": 518,
      "text": "eparation agreement, which is reported in Other financing activities, net.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nComponents of Discontinued operations––net of tax:\nYear Ended December 31,\n(MILLIONS)\n\nTotal revenues\n\nCosts and expenses:\nCost of sales\n\nSelling, informational and administrative expenses\n\nResearch and development expenses\n\nAcquired in-process research and development expenses\nAmortization of intangible assets\n\nRestructuring charges and certain acquisition-related costs\n\nOther (income)/deductions––net\n(11)\n(20)\n\nPre-tax income/(loss) from discontinued operations\n\n(375)\nProvision/(benefit) for taxes on income\n\n(107)\nIncome/(loss) from discontinued operations––net of tax\n(15)\n(1)\n(268)\nPre-tax gain/(loss) on sale of discontinued operations\n\n(211)\nProvision/(benefit) for taxes on income\n\n(44)\nGain/(loss) on sale of discontinued operations––net of tax\n\n(167)\nDiscontinued operations––net of tax\n(15)",
      "char_count": 942,
      "start_char": 414400,
      "end_char": 415343
    },
    {
      "chunk_id": "pfizer_2023_chunk0519",
      "chunk_index": 519,
      "text": "(benefit) for taxes on income\n\n(44)\nGain/(loss) on sale of discontinued operations––net of tax\n\n(167)\nDiscontinued operations––net of tax\n(15)\n\n(434)\nIn 2023 and 2022, Discontinued operations—net of tax relates to post-close adjustments. In 2021, Discontinued operations—net of tax primarily includes (i) the operations of Meridian prior to its sale on\nDecember 31, 2021 recognized in Income/(loss) from discontinued operations—net of tax, which includes a pre-tax expense to resolve an MDL relating to EpiPen against the Company in the U.S. District\nCourt for the District of Kansas for $345 million; and (ii) the after tax loss of $167 million related to the sale of Meridian recognized in Gain/(loss) on sale of discontinued operations––net of tax. To a much\nlesser extent, Discontinued operations—net of tax in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-close adjustments directly",
      "char_count": 963,
      "start_char": 415200,
      "end_char": 416164
    },
    {
      "chunk_id": "pfizer_2023_chunk0520",
      "chunk_index": 520,
      "text": "—net of tax in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-close adjustments directly\nrelated to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations—net of tax.\nC. Equity-Method Investments\nHaleon/Consumer Healthcare JV––On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company\nlisted on the London Stock Exchange that holds the joint historical consumer healthcare business of GSK and Pfizer following the demerger. We continue to own 32% of Haleon as\nof December 31, 2023.\nThe carrying value of our investment in Haleon as of December 31, 2023 and December 31, 2022 was $11.5 billion and $10.8 billion, respectively, and is reported in Equity-method\ninvestments.",
      "char_count": 947,
      "start_char": 416000,
      "end_char": 416948
    },
    {
      "chunk_id": "pfizer_2023_chunk0521",
      "chunk_index": 521,
      "text": "leon as of December 31, 2023 and December 31, 2022 was $11.5 billion and $10.8 billion, respectively, and is reported in Equity-method\ninvestments. The fair value of our investment in Haleon as of December 31, 2023, based on quoted market prices of Haleon stock, was $12.1 billion. Haleon/the Consumer\nHealthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of\nforeign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The increase in the value of our investment from December 31,\n2022 to December 31, 2023 is primarily due to our share of Haleon’s earnings of $489 million as well as $280 million in pre-tax foreign currency translation adjustments (see Note 6),\npartially offset by $153 million in dividends.",
      "char_count": 887,
      "start_char": 416800,
      "end_char": 417688
    },
    {
      "chunk_id": "pfizer_2023_chunk0522",
      "chunk_index": 522,
      "text": "cy translation adjustments (see Note 6),\npartially offset by $153 million in dividends. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other\n(income)/deductions––net. Our total share of Haleon’s earnings generated in the fourth quarter of 2022 and the first nine months of 2023, which we recorded in our operating results\nin 2023, was $489 million. Our total share of Haleon/the Consumer Healthcare JV’s earnings generated in the fourth quarter of 2021 and the first nine months of 2022, which we\nrecorded in our operating results in 2022, was $536 million. Our total share of the JV’s earnings generated in the fourth quarter of 2020 and the first nine months of 2021, which we\nrecorded in our operating results in 2021, was $495 million.",
      "char_count": 808,
      "start_char": 417600,
      "end_char": 418409
    },
    {
      "chunk_id": "pfizer_2023_chunk0523",
      "chunk_index": 523,
      "text": "million. As part of the initial accounting for our investment in the Consumer Healthcare JV in 2019, we determined that the\ndifference between the initial fair value of our investment less our underlying equity in the carrying value of the net assets of the JV resulted in an initial excess basis difference of\n$4.8 billion. We allocated the difference primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities, and equity-method\ngoodwill. We recognize amortization of these basis differences in Other (income)/deductions––net. Amortization of basis differences on inventory and related deferred tax liabilities\nwas completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives\nof the underlying assets, which range from 8 to 20 years.",
      "char_count": 921,
      "start_char": 418400,
      "end_char": 419322
    },
    {
      "chunk_id": "pfizer_2023_chunk0524",
      "chunk_index": 524,
      "text": "ted deferred tax liabilities are being amortized over the lives\nof the underlying assets, which range from 8 to 20 years. In 2022, our equity-method income included in Other (income)/ deductions––net also included charges of $100 million,\nprimarily for adjustments to our equity-method basis differences related to the separation of Haleon/the Consumer Healthcare JV from GSK. The total amortization and adjustment of\nbasis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of Haleon/the Consumer\nHealthcare JV was not material to our results of operations in 2023 and 2021. See Note 4.\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nSummarized financial information for our equity-method investee, Haleon/the Consumer Healthcare JV, as of September 30, 2023, the most recent period available, and as of",
      "char_count": 924,
      "start_char": 419200,
      "end_char": 420125
    },
    {
      "chunk_id": "pfizer_2023_chunk0525",
      "chunk_index": 525,
      "text": "ty-method investee, Haleon/the Consumer Healthcare JV, as of September 30, 2023, the most recent period available, and as of\nSeptember 30, 2022 and for the periods ending September 30, 2023, 2022, and 2021 is as follows:\n(MILLIONS)\nSeptember 30, 2023\nSeptember 30, 2022\nCurrent assets\n5,876 \n5,932 \nNoncurrent assets\n36,954 \n35,204 \nTotal assets\n42,830 \n41,137 \nCurrent liabilities\n6,117 \n5,235 \nNoncurrent liabilities\n15,744 \n17,220 \nTotal liabilities\n21,862 \n22,455 \nEquity attributable to shareholders\n20,719 \n18,455 \nEquity attributable to noncontrolling interests\n\nTotal net equity\n20,968 \n18,682 \nFor the Twelve Months Ending\n(MILLIONS)\nSeptember 30, 2023\nSeptember 30, 2022\nSeptember 30, 2021\nNet sales\n13,921 \n13,566 \n12,836 \nCost of sales\n(5,580)\n(5,081)\n(4,755)\nGross profit\n8,341 \n8,486 \n8,081 \nIncome from continuing operations\n1,606 \n1,745 \n1,614 \nNet income\n1,606 \n1,745 \n1,614 \nIncome attributable to shareholders\n1,528 \n1,675 \n1,547",
      "char_count": 948,
      "start_char": 420000,
      "end_char": 420950
    },
    {
      "chunk_id": "pfizer_2023_chunk0526",
      "chunk_index": 526,
      "text": ",081 \nIncome from continuing operations\n1,606 \n1,745 \n1,614 \nNet income\n1,606 \n1,745 \n1,614 \nIncome attributable to shareholders\n1,528 \n1,675 \n1,547 \nIn connection with GSK’s previously announced planned demerger of at least 80% of GSK’s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer\nHealthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, €2.35 billion in eurodenominated senior notes of various maturities and £700 million in U.K. pound-denominated senior notes of various maturities (collectively, the “notes”). The notes were guaranteed\nby GSK generally up to and excluding the date of the demerger (the “Guarantee Assumption Date”). We agreed to indemnify GSK for 32% (representing our pro rata equity interest\nin the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes.",
      "char_count": 946,
      "start_char": 420800,
      "end_char": 421747
    },
    {
      "chunk_id": "pfizer_2023_chunk0527",
      "chunk_index": 527,
      "text": "32% (representing our pro rata equity interest\nin the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we nor any\nof our subsidiaries were an issuer or guarantor of any of the notes.\nFollowing its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds\nreceived from the notes on a pro rata equity ownership basis, for which we received a loan of £2.9 billion ($3.7 billion as of the end of our second quarter of 2022), at an interest rate\nof 1.365% per annum payable semi-annually in arrears. In conjunction with the demerger, we received £3.5 billion ($4.2 billion) in dividends from the JV in July 2022, of which",
      "char_count": 827,
      "start_char": 421600,
      "end_char": 422428
    },
    {
      "chunk_id": "pfizer_2023_chunk0528",
      "chunk_index": 528,
      "text": "e JV in July 2022, of which\n$4.0 billion related to a one-time pre-separation dividend, which decreased the carrying value of our investment and are included in Net cash provided by/(used in) investing\nactivities. Simultaneous with the receipt of the dividends, we repaid the £2.9 billion loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata\nloan from the JV. In conjunction with these transactions, our indemnification of GSK’s guarantee discussed above was terminated.\nInvestment in ViiV––In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We\nown approximately 11.7% of ViiV, and prior to 2016 we accounted for our investment under the equity method due to the significant influence that we have over the operations of ViiV\nthrough our board representation and minority veto rights.",
      "char_count": 926,
      "start_char": 422400,
      "end_char": 423327
    },
    {
      "chunk_id": "pfizer_2023_chunk0529",
      "chunk_index": 529,
      "text": "the significant influence that we have over the operations of ViiV\nthrough our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our\ninvestment was reduced to zero due to the recognition of cumulative equity-method losses and dividends, and therefore we no longer record our proportionate share of ViiV’s net\nincome (loss) in our results of operations. Since 2016, we have recognized dividends from ViiV as income in Other (income)/deductions––net when earned, including dividends of\n$265 million in 2023, $314 million in 2022 and $166 million in 2021 (see Note 4).\nSummarized financial information for our equity-method investee, ViiV, as of December 31, 2023 and 2022 and for the years ending December 31, 2023, 2022, and 2021 is as\nfollows:\nAs of December 31,\n(MILLIONS)",
      "char_count": 877,
      "start_char": 423200,
      "end_char": 424079
    },
    {
      "chunk_id": "pfizer_2023_chunk0530",
      "chunk_index": 530,
      "text": "December 31, 2023, 2022, and 2021 is as\nfollows:\nAs of December 31,\n(MILLIONS)\n\nCurrent assets\n4,237 \n4,043 \nNoncurrent assets\n3,009 \n3,014 \nTotal assets\n7,245 \n7,057 \nCurrent liabilities\n4,085 \n3,780 \nNoncurrent liabilities\n5,998 \n5,996 \nTotal liabilities\n10,083 \n9,777 \nTotal net equity/(deficit) attributable to shareholders\n(2,838)\n(2,720)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nYear Ended December 31,\n(MILLIONS)\n\nNet sales\n7,845 \n6,955 \n6,380 \nCost of sales\n(1,060)\n(819)\n(682)\nGross profit\n6,785 \n6,135 \n5,698 \nIncome from continuing operations\n3,090 \n3,108 \n2,040 \nNet income\n3,090 \n3,108 \n2,040 \nIncome attributable to shareholders\n3,090 \n3,108 \n2,040 \nD. Licensing Arrangement\nAgreement with Valneva––In June 2022, we entered into an Equity Subscription Agreement, under which we invested €90.5 million ($95 million) in Valneva to further support our",
      "char_count": 882,
      "start_char": 424000,
      "end_char": 424883
    },
    {
      "chunk_id": "pfizer_2023_chunk0531",
      "chunk_index": 531,
      "text": "er which we invested €90.5 million ($95 million) in Valneva to further support our\narrangement to co-develop and commercialize Lyme disease vaccine candidate, VLA15, which we originally entered into with Valneva in 2020. In addition, we updated the terms of\nour existing co-development and commercialization agreement for VLA15. Valneva will now fund 40% of the remaining shared development costs, and we will pay Valneva tiered\nroyalties ranging from 14% to 22%, compared to royalties starting at 19% in the initial agreement. In addition, the royalties will be complemented by up to $100 million in milestones\npayable to Valneva based on cumulative sales. Other early commercialization milestones are unchanged. As of December 31, 2023, we held a 6.9% equity stake of Valneva.\nE. Collaborative Arrangements\nWe enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval.",
      "char_count": 981,
      "start_char": 424800,
      "end_char": 425782
    },
    {
      "chunk_id": "pfizer_2023_chunk0532",
      "chunk_index": 532,
      "text": "ngements\nWe enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval.\nCollaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we\nand our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative\narrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to\nco-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product or vaccine.",
      "char_count": 851,
      "start_char": 425600,
      "end_char": 426452
    },
    {
      "chunk_id": "pfizer_2023_chunk0533",
      "chunk_index": 533,
      "text": "ring and/or distributing a drug product or vaccine.\nCollaboration with Biohaven––In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its\nsubsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Under the terms of the\nagreement, Biohaven would lead R&D globally and we would have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on\nJanuary 4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263 million for the upfront\npayment and premium paid on our equity investment in Acquired in-process research and development expenses.",
      "char_count": 854,
      "start_char": 426400,
      "end_char": 427255
    },
    {
      "chunk_id": "pfizer_2023_chunk0534",
      "chunk_index": 534,
      "text": "Acquired in-process research and development expenses. In October 2022, we acquired all outstanding common shares of\nBiohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion. See Note 2A. This acquisition represented a settlement of the preexisting relationship, and we determined that no gain or loss was required to be recognized.\nCollaborations with BioNTech––On December 30, 2021, we entered into a research, development and commercialization agreement to develop a potential first mRNA-based\nvaccine for the prevention of shingles (herpes zoster virus) based on BioNTech’s proprietary mRNA technology and our antigen technology. Under the terms of the agreement, we\nagreed to pay BioNTech $225 million, including an upfront cash payment of $75 million and an equity investment of $150 million. BioNTech is eligible to receive future regulatory and\nsales milestone payments of up to $200 million.",
      "char_count": 952,
      "start_char": 427200,
      "end_char": 428153
    },
    {
      "chunk_id": "pfizer_2023_chunk0535",
      "chunk_index": 535,
      "text": "million and an equity investment of $150 million. BioNTech is eligible to receive future regulatory and\nsales milestone payments of up to $200 million. In return, BioNTech agreed to pay us $25 million for our proprietary antigen technology. The net upfront payment to BioNTech was\nrecorded to Acquired in-process research and development expenses in our fourth quarter of 2021. We and BioNTech share development costs. We will have commercialization\nrights to the potential vaccine worldwide, excluding Germany, Turkey and certain developing countries where BioNTech will have commercialization rights. We and BioNTech will\nshare gross profits from commercialization of any product. As of December 31, 2023, we held an equity stake of 2.7% of BioNTech.\nOn April 9, 2020, we signed a global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection, which resulted\nin the development of Comirnaty.",
      "char_count": 956,
      "start_char": 428000,
      "end_char": 428958
    },
    {
      "chunk_id": "pfizer_2023_chunk0536",
      "chunk_index": 536,
      "text": "with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection, which resulted\nin the development of Comirnaty. On January 29, 2021, we and BioNTech signed an amended version of the April 2020 agreement. Under the January 2021 agreement, BioNTech\npaid us their 50 percent share of prior development costs in a lump sum payment during the first quarter of 2021. Further R&D costs are being shared equally. We have\ncommercialization rights to the vaccine worldwide, excluding Germany and Turkey where BioNTech markets and distributes the vaccine under the agreement with us, and excluding\nChina, Hong Kong, Macau and Taiwan, which are subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. We recognize\nrevenues and cost of sales on a gross basis in markets where we are commercializing the vaccine and we record our share of gross profits related to sales of the vaccine by",
      "char_count": 967,
      "start_char": 428800,
      "end_char": 429769
    },
    {
      "chunk_id": "pfizer_2023_chunk0537",
      "chunk_index": 537,
      "text": "enues and cost of sales on a gross basis in markets where we are commercializing the vaccine and we record our share of gross profits related to sales of the vaccine by\nBioNTech in Germany and Turkey in Alliance revenues.\nCollaboration with Beam––On December 24, 2021, we entered into a multi-year research collaboration with Beam to utilize Beam’s in vivo base editing programs, which use mRNA\nand lipid nanoparticles, for three targets for rare genetic diseases of the liver, muscle and central nervous system. Under the terms of the agreement, Beam conducts all research\nactivities through development candidate selection for three undisclosed targets, which are not included in Beam’s existing programs, and we may opt in to obtain exclusive licenses\nto each development candidate. Beam has a right to opt in, at the end of phase 1/2 studies, upon the payment by Beam of an option exercise fee, to a global co-development and",
      "char_count": 929,
      "start_char": 429600,
      "end_char": 430530
    },
    {
      "chunk_id": "pfizer_2023_chunk0538",
      "chunk_index": 538,
      "text": "ht to opt in, at the end of phase 1/2 studies, upon the payment by Beam of an option exercise fee, to a global co-development and\nco-commercialization agreement with respect to one program licensed under the collaboration pursuant to which we and Beam would share net profits as well as development and\ncommercialization costs in a 65%/35% ratio (Pfizer/Beam). Upon entering into the agreement, we recorded $300 million in Acquired in-process research and development expenses\nin the fourth quarter of 2021 for an upfront payment due to Beam, and if we exercise our opt in to licenses for all three targets, Beam will be eligible for up to an additional $1.05\nbillion in development, regulatory and commercial milestone payments for a potential total deal consideration of up to $1.35 billion. Beam is also eligible to receive royalties on global\nnet sales for each licensed program.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 943,
      "start_char": 430400,
      "end_char": 431344
    },
    {
      "chunk_id": "pfizer_2023_chunk0539",
      "chunk_index": 539,
      "text": "s also eligible to receive royalties on global\nnet sales for each licensed program.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nCollaboration with Arvinas––On July 21, 2021, we entered into a global collaboration with Arvinas to develop and commercialize ARV-471, an investigational oral PROTAC\n(PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. In connection with the\nagreement, we made an upfront cash payment of $650 million to Arvinas and we made a $350 million equity investment in the common stock of Arvinas. We recognized $706 million\nfor the upfront payment and a premium paid on our equity investment in Acquired in-process research and development expenses in our third quarter of 2021. Arvinas is also eligible\nto receive up to $400 million in approval milestones and up to $1 billion in commercial milestones.",
      "char_count": 933,
      "start_char": 431200,
      "end_char": 432134
    },
    {
      "chunk_id": "pfizer_2023_chunk0540",
      "chunk_index": 540,
      "text": "of 2021. Arvinas is also eligible\nto receive up to $400 million in approval milestones and up to $1 billion in commercial milestones. The companies equally share worldwide development costs, commercialization\nexpenses and profits. As of December 31, 2023, we held a 5.1% equity stake of Arvinas.\nSummarized Financial Information for Collaborative Arrangements\nThe following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:\nYear Ended December 31,\n(MILLIONS)\n\nProduct revenues\n\n\n\nAlliance revenues\n7,582 \n8,537 \n7,652 \nTotal revenues from collaborative arrangements\n7,795 \n8,974 \n8,241 \nCost of sales\n(4,277)\n(15,589)\n(16,169)\nSelling, informational and administrative expenses\n(267)\n(196)\n(175)\nResearch and development expenses\n\nAcquired in-process research and development expenses\n(13)\n(339)\n(1,056)\nOther income/(deductions)—net",
      "char_count": 897,
      "start_char": 432000,
      "end_char": 432898
    },
    {
      "chunk_id": "pfizer_2023_chunk0541",
      "chunk_index": 541,
      "text": "red in-process research and development expenses\n(13)\n(339)\n(1,056)\nOther income/(deductions)—net\n\nRepresents sales to our partners of products manufactured by us.\nSubstantially all relates to amounts earned from our partners under co-promotion agreements. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset\nby an increase in Alliance revenues from Eliquis. The increase in 2022 was primarily driven by increases in Alliance revenues from Eliquis, Comirnaty and Bavencio.\nPrimarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for\ninventory purchased from our partners. The decreases in 2023 and in 2022 primarily relate to Comirnaty.\nRepresents net reimbursements to our partners for selling, informational and administrative expenses incurred.",
      "char_count": 950,
      "start_char": 432800,
      "end_char": 433751
    },
    {
      "chunk_id": "pfizer_2023_chunk0542",
      "chunk_index": 542,
      "text": "in 2022 primarily relate to Comirnaty.\nRepresents net reimbursements to our partners for selling, informational and administrative expenses incurred.\nRepresents net reimbursements from our partners for research and development expenses incurred.\nPrimarily relates to upfront payments to our partners as well as premiums paid on our equity investments in the common stock of our partners.\nPrimarily relates to royalties from our collaboration partners.\nThe amounts outlined in the above table do not include transactions with third parties other than our collaboration partners, or other costs for the products under the collaborative\narrangements.\nF. Research and Development Arrangement\nResearch and Development Funding Arrangement with Blackstone––In April 2023, we entered into an arrangement with Blackstone under which we will receive up to a total of $550\nmillion in 2023 through 2026 to co-fund our quarterly development costs for specified treatments.",
      "char_count": 959,
      "start_char": 433600,
      "end_char": 434561
    },
    {
      "chunk_id": "pfizer_2023_chunk0543",
      "chunk_index": 543,
      "text": "h Blackstone under which we will receive up to a total of $550\nmillion in 2023 through 2026 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development\nfunding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an\nattribution model over the period of the related expenses. The reduction to Research and development expenses in 2023 was $175 million. If successful, upon regulatory approval in\nthe U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments\nof up to $468 million contingent upon the successful results of the clinical trials.",
      "char_count": 861,
      "start_char": 434400,
      "end_char": 435262
    },
    {
      "chunk_id": "pfizer_2023_chunk0544",
      "chunk_index": 544,
      "text": "ontingent upon the successful results of the clinical trials. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to\nAmortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Following potential regulatory approval, Blackstone will be\neligible to receive a combination of fixed milestone payments of up to $550 million in total based on achievement of certain levels of cumulative applicable net sales, as well as\nroyalties based on a mid-to-high single digit percentage of the applicable net sales. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to\nAmortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product, and royalties on net sales will be recorded as Cost of\nsales when incurred.\nNote 3.",
      "char_count": 910,
      "start_char": 435200,
      "end_char": 436111
    },
    {
      "chunk_id": "pfizer_2023_chunk0545",
      "chunk_index": 545,
      "text": "rcial life of the product, and royalties on net sales will be recorded as Cost of\nsales when incurred.\nNote 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives\nA. Restructuring Programs\nTransforming to a More Focused Company Program––In 2019, we announced that we would be incurring costs associated with our Transforming to a More Focused Company\nProgram, a multi-year effort to ensure our cost base aligned appropriately with our operating structure following Pfizer’s transformation into a more focused, innovative sciencebased global biopharmaceutical business. This program included activities to (i) restructure our corporate enabling functions to appropriately support our operating structure; (ii)\ntransform our commercial go-to-market model; and (iii) optimize our manufacturing network and R&D operations.",
      "char_count": 877,
      "start_char": 436000,
      "end_char": 436878
    },
    {
      "chunk_id": "pfizer_2023_chunk0546",
      "chunk_index": 546,
      "text": "arket model; and (iii) optimize our manufacturing network and R&D operations. The costs to restructure our corporate enabling functions, and to\noptimize our R&D operations and reduce cycle times, as well as to further prioritize our internal R&D portfolio, primarily included severance and implementation costs. The costs to\noptimize our manufacturing network largely included severance, implementation costs, product transfer costs, site exit costs, and accelerated depreciation. From the start of this\nprogram in the fourth quarter of 2019 through December 31, 2023, we incurred costs of $4.0 billion, of which $1.5 billion ($1.0 billion of restructuring charges) was associated with\nour Biopharma segment and have substantially completed this program.\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 870,
      "start_char": 436800,
      "end_char": 437671
    },
    {
      "chunk_id": "pfizer_2023_chunk0547",
      "chunk_index": 547,
      "text": "e)\n(f)\n(g)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nRealigning our Cost Base Program––In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our\ncosts with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue through 2024 and to total approximately $3.0 billion, primarily\nrepresenting cash expenditures for severance and implementation costs, of which $1.1 billion is associated with our Biopharma segment.\nIn 2023, we incurred costs under this program of $1.7 billion, of which $674 million (including $665 million of restructuring charges) is associated with our Biopharma segment.\nB. Key Activities\nThe following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:\nYear Ended December 31,\n(MILLIONS)\n\nRestructuring charges/(credits):\nEmployee terminations\n1,622 \n\n\nAsset impairments",
      "char_count": 979,
      "start_char": 437600,
      "end_char": 438580
    },
    {
      "chunk_id": "pfizer_2023_chunk0548",
      "chunk_index": 548,
      "text": "for acquisitions and cost-reduction/productivity initiatives:\nYear Ended December 31,\n(MILLIONS)\n\nRestructuring charges/(credits):\nEmployee terminations\n1,622 \n\n\nAsset impairments\n\nExit costs/(credits)\n\nRestructuring charges/(credits)\n1,968 \n\nTransaction costs\n\nIntegration costs and other\n\nRestructuring charges and certain acquisition-related costs\n2,943 \n1,375 \n\nNet periodic benefit costs/(credits) recorded in Other (income)/deductions––net\n(7)\n(9)\n(63)\nAdditional depreciation––asset restructuring recorded in our consolidated statements of income as follows :\nCost of sales\n\nSelling, informational and administrative expenses\n\nTotal additional depreciation––asset restructuring\n\nImplementation costs recorded in our consolidated statements of income as follows :\nCost of sales\n\nSelling, informational and administrative expenses\n\nResearch and development expenses\n\nTotal implementation costs",
      "char_count": 898,
      "start_char": 438400,
      "end_char": 439299
    },
    {
      "chunk_id": "pfizer_2023_chunk0549",
      "chunk_index": 549,
      "text": "ational and administrative expenses\n\nResearch and development expenses\n\nTotal implementation costs\n\nTotal costs associated with acquisitions and cost-reduction/productivity initiatives\n3,426 \n2,018 \n1,298 \nPrimarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: $672 million for 2023 (including charges of $665 million for Realigning our Cost Base Program and credits\nof $20 million for Transforming to a More Focused Company program), $354 million for 2022 (including charges of $291 million for Transforming to a More Focused Company program) and $610 million for\n2021 (including charges of $612 million for Transforming to a More Focused Company program).\nRepresents external costs for banking, legal, accounting and other similar services.\nRepresents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying\ncosts.",
      "char_count": 993,
      "start_char": 439200,
      "end_char": 440194
    },
    {
      "chunk_id": "pfizer_2023_chunk0550",
      "chunk_index": 550,
      "text": "nal, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying\ncosts. 2023 costs mostly relate to our acquisition of Seagen, including $476 million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of\n2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our\nacquisitions of Arena and GBT, including $138 million in payments to Arena employees in the first quarter of 2022 and $136 million in payments to GBT employees in the fourth quarter of 2022 for the fair\nvalue of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See Note 2A.",
      "char_count": 915,
      "start_char": 440000,
      "end_char": 440916
    },
    {
      "chunk_id": "pfizer_2023_chunk0551",
      "chunk_index": 551,
      "text": "eviously unvested long-term incentive awards that was recognized as post-closing compensation expense. See Note 2A. 2021 costs primarily related to our acquisition of Trillium.\nRepresents the impact of changes in the estimated useful lives of assets involved in restructuring actions.\nRepresents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.\nThe following summarizes the components and changes in restructuring accruals:\n(MILLIONS)\nEmployee\nTermination\nCosts\nAsset\nImpairment\nCharges\nExit Costs\nAccrual\nBalance, January 1, 2022\n1,014 \n\n1,071 \nProvision\n\nUtilization and other\n(594)\n(52)\n(103)\n(750)\nBalance, December 31, 2022\n1,196 \n\n1,204 \nProvision\n1,622 \n\n1,968 \nUtilization and other\n(840)\n(227)\n(116)\n(1,184)\nBalance, December 31, 2023\n1,978",
      "char_count": 830,
      "start_char": 440800,
      "end_char": 441632
    },
    {
      "chunk_id": "pfizer_2023_chunk0552",
      "chunk_index": 552,
      "text": "lance, December 31, 2023\n1,978 \n\n1,988 \nOther activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.\nIncluded in Other current liabilities ($991 million) and Other noncurrent liabilities ($213 million).\nIncluded in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).\n(a)\n(b)\n(c)\n \n(d)\n(e)\n(a)\n(b)\n(c)\n(d)\n(e)\n(a)\n(b)\n(a)\n(c)\n(a)\n(b)\n(c)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nNote 4. Other (Income)/Deductions—Net\nComponents of Other (income)/deductions––net include:\nYear Ended December 31,\n(MILLIONS)\n\nInterest income\n(1,624)\n(251)\n(36)\nInterest expense\n2,209 \n1,238 \n1,291 \nNet interest expense\n\n1,255 \nRoyalty-related income\n(1,058)\n(845)\n(857)\nNet (gains)/losses recognized during the period on equity securities\n(1,590)\n1,273 \n(1,344)\nIncome from collaborations, out-licensing arrangements and sales of compound/product rights\n(154)\n(188)\n(396)",
      "char_count": 982,
      "start_char": 441600,
      "end_char": 442583
    },
    {
      "chunk_id": "pfizer_2023_chunk0553",
      "chunk_index": 553,
      "text": "recognized during the period on equity securities\n(1,590)\n1,273 \n(1,344)\nIncome from collaborations, out-licensing arrangements and sales of compound/product rights\n(154)\n(188)\n(396)\nNet periodic benefit costs/(credits) other than service costs\n(610)\n(849)\n(2,547)\nCertain legal matters, net\n\nCertain asset impairments\n3,024 \n\nHaleon/Consumer Healthcare JV equity method (income)/loss\n(505)\n(436)\n(471)\nOther, net\n(1,002)\n(378)\n(786)\nOther (income)/deductions––net\n(835)\n\n(4,878)\nCapitalized interest totaled $160 million in 2023, $124 million in 2022 and $108 million in 2021.\nThe decrease in net interest expense in 2023 reflects higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023 as part of the financing for\nour acquisition of Seagen, which was more than offset by higher interest income on the investment of the net proceeds from the debt issuance.",
      "char_count": 924,
      "start_char": 442400,
      "end_char": 443325
    },
    {
      "chunk_id": "pfizer_2023_chunk0554",
      "chunk_index": 554,
      "text": "f Seagen, which was more than offset by higher interest income on the investment of the net proceeds from the debt issuance.\n2023 net gains primarily include, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in\nCerevel Therapeutics Holdings, Inc (Cerevel), partially offset by unrealized losses of $292 million related to our investment in BioNTech. 2022 net losses included, among other things, unrealized losses of\n$986 million related to investments in BioNTech, Allogene Therapeutics, Inc. and Arvinas. 2021 net gains included, among other things, unrealized gains of $1.6 billion related to investments in BioNTech\nand Cerevel.\n2021 included, among other things, $188 million of net collaboration income from BioNTech related to Comirnaty.",
      "char_count": 863,
      "start_char": 443200,
      "end_char": 444064
    },
    {
      "chunk_id": "pfizer_2023_chunk0555",
      "chunk_index": 555,
      "text": "of net collaboration income from BioNTech related to Comirnaty.\n2023 primarily includes certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. 2022 primarily\nincluded certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer. 2021 primarily included certain product liability expenses related to products\ndiscontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters.\n2023 primarily represents intangible asset impairment charges of $3.0 billion, of which $2.9 billion is associated with our Biopharma segment ($2.8 billion recorded in the fourth quarter), including: $1.4\nbillion for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, $964 million for Prevnar 13 developed technology rights ($834",
      "char_count": 995,
      "start_char": 444000,
      "end_char": 444996
    },
    {
      "chunk_id": "pfizer_2023_chunk0556",
      "chunk_index": 556,
      "text": "for etrasimod (Velsipity) IPR&D, based on a change in development plans for additional indications and overall revenue expectations, $964 million for Prevnar 13 developed technology rights ($834\nmillion for pediatric and $130 million for adult), due to updated commercial forecasts mainly reflecting a transition to higher serotype coverage, and $486 million for various other IPR&D assets and\ndeveloped technology rights, due to updated commercial forecasts mainly reflecting competitive pressures and/or prioritization decisions. 2023 also includes $128 million associated with Other business\nactivities, related to IPR&D and developed technology rights for acquired software assets and reflects unfavorable pivotal trial results and updated commercial forecasts. 2022 represented intangible asset\nimpairment charges associated with our Biopharma segment of: $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene",
      "char_count": 990,
      "start_char": 444800,
      "end_char": 445792
    },
    {
      "chunk_id": "pfizer_2023_chunk0557",
      "chunk_index": 557,
      "text": "impairment charges associated with our Biopharma segment of: $200 million for an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene\nencoding the lamin A/C protein that resulted from the Phase 3 trial reaching futility at a pre-planned interim analysis and $171 million for developed technology rights due to updated commercial forecasts\nmainly reflecting competitive pressures. 2022 also included intangible asset impairment charges of $50 million associated with PC1, related to finite-lived licensing agreements and reflected updated\ncontract manufacturing forecasts reflecting changes to market dynamics.\nSee Note 2C.\n2023 includes, among other things, (i) dividend income of $265 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral,",
      "char_count": 879,
      "start_char": 445600,
      "end_char": 446481
    },
    {
      "chunk_id": "pfizer_2023_chunk0558",
      "chunk_index": 558,
      "text": "m our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral,\nselective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. 2022 included,\namong other things, (i) dividend income of $314 million from our investment in ViiV, (ii) income net of costs associated with TSAs of $142 million and (iii) charges of $77 million, reflecting the change in the\nfair value of contingent consideration. 2021 included, among other things, (i) income net of costs associated with TSAs of $288 million, (ii) dividend income of $166 million from our investment in ViiV and\n(iii) charges of $142 million, reflecting the change in the fair value of contingent consideration.\nAdditional information about the intangible assets that were impaired during 2023 follows:\nYear Ended\nFair Value\nDecember 31, 2023\n(MILLIONS)\nAmount\nLevel 1\nLevel 2\nLevel 3\nImpairment",
      "char_count": 985,
      "start_char": 446400,
      "end_char": 447386
    },
    {
      "chunk_id": "pfizer_2023_chunk0559",
      "chunk_index": 559,
      "text": ".\nAdditional information about the intangible assets that were impaired during 2023 follows:\nYear Ended\nFair Value\nDecember 31, 2023\n(MILLIONS)\nAmount\nLevel 1\nLevel 2\nLevel 3\nImpairment\nIntangible assets––IPR&D\n3,860 \n3,860 \n1,704 \nIntangible assets––Developed technology rights\n1,942 \n1,942 \n1,184 \nIntangible assets––Licensing agreements and other\n\nTotal\n5,802 \n5,802 \n3,008 \nThe fair value amounts are presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.\nReflects intangible assets written down to fair value in 2023. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted\ncash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount.",
      "char_count": 914,
      "start_char": 447200,
      "end_char": 448115
    },
    {
      "chunk_id": "pfizer_2023_chunk0560",
      "chunk_index": 560,
      "text": "cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more\nsignificant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory\nforces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected\ncash flows.\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(a)\n(b)\n(b)\n(b)\n(a)\n(b)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nNote 5. Tax Matters\nA. Taxes on Income from Continuing Operations\nComponents of Income from continuing operations before provision/(benefit) for taxes on income include:\n \nYear Ended December 31,\n(MILLIONS)",
      "char_count": 910,
      "start_char": 448000,
      "end_char": 448911
    },
    {
      "chunk_id": "pfizer_2023_chunk0561",
      "chunk_index": 561,
      "text": "inuing operations before provision/(benefit) for taxes on income include:\n \nYear Ended December 31,\n(MILLIONS)\n\nUnited States\n(4,411)\n5,032 \n6,064 \nInternational\n5,469 \n29,697 \n18,247 \nIncome from continuing operations before provision/(benefit) for taxes on income\n1,058 \n34,729 \n24,311 \n2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset\nimpairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset\nby a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.\n2022 v.",
      "char_count": 814,
      "start_char": 448800,
      "end_char": 449615
    },
    {
      "chunk_id": "pfizer_2023_chunk0562",
      "chunk_index": 562,
      "text": "2022.\n2022 v. 2021––The decrease in domestic income is primarily related to net losses on equity securities in 2022 versus net gains on equity securities in 2021, lower net periodic benefit credits and higher\nrestructuring charges and certain acquisition-related costs, partially offset by Paxlovid income and lower acquired IPR&D expenses. The increase in international income is primarily related to Paxlovid and\nComirnaty income partially offset by lower net periodic benefit credits.\nComponents of Provision/(benefit) for taxes on income based on the location of the taxing authorities include:\n \nYear Ended December 31,\n(MILLIONS)\n\nUnited States\nCurrent income taxes:\nFederal\n1,321 \n2,744 \n3,342 \nState and local\n(135)\n(20)\n\nDeferred income taxes:\nFederal\n(2,606)\n(3,271)\n(3,850)\nState and local\n(184)\n(310)\n(491)\nTotal U.S. tax provision/(benefit)\n(1,605)\n(857)\n(964)\nInternational\nCurrent income taxes\n1,142 \n4,368 \n2,769 \nDeferred income taxes\n(652)\n(183)",
      "char_count": 963,
      "start_char": 449600,
      "end_char": 450565
    },
    {
      "chunk_id": "pfizer_2023_chunk0563",
      "chunk_index": 563,
      "text": "l\n(184)\n(310)\n(491)\nTotal U.S. tax provision/(benefit)\n(1,605)\n(857)\n(964)\nInternational\nCurrent income taxes\n1,142 \n4,368 \n2,769 \nDeferred income taxes\n(652)\n(183)\n\nTotal international tax provision/(benefit)\n\n4,185 \n2,816 \nProvision/(benefit) for taxes on income\n(1,115)\n3,328 \n1,852 \nThe changes in Provision/(benefit) for taxes on income impacting the effective tax rate year-over-year are summarized below:\n2023 v. 2022\nThe tax benefit of $1.1 billion for 2023 compared to the tax provision of $3.3 billion for 2022 was primarily a result of changes in the jurisdictional mix of earnings and the resolution of\nuncertain tax positions in various markets. The 2023 pre-tax income included a greater percentage of expenses taxed at higher rates as compared to the 2022 pre-tax income,\nresulting in a 2023 tax benefit compared to the 2022 tax provision. These expenses included amortization expense, acquisition-related costs, restructuring charges and intangible\nasset impairment charges.",
      "char_count": 990,
      "start_char": 450400,
      "end_char": 451391
    },
    {
      "chunk_id": "pfizer_2023_chunk0564",
      "chunk_index": 564,
      "text": "a 2023 tax benefit compared to the 2022 tax provision. These expenses included amortization expense, acquisition-related costs, restructuring charges and intangible\nasset impairment charges. The tax benefit for 2023 and the tax provision for 2022 included tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning\nmultiple tax years. The tax provision for 2022 also included the closing of U.S. IRS audits covering five tax years.\n2022 v. 2021\nThe higher effective tax rate in 2022 was mainly the result of:\n• the non-recurrence of certain initiatives executed in 2021 associated with our investment in the Consumer Healthcare JV with GSK based on estimates and assumptions that we\nbelieve to be reasonable,\npartially offset by:\n• tax benefits in 2022 related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years that included the closing of U.S.",
      "char_count": 919,
      "start_char": 451200,
      "end_char": 452120
    },
    {
      "chunk_id": "pfizer_2023_chunk0565",
      "chunk_index": 565,
      "text": "obal income tax resolutions in multiple tax jurisdictions spanning multiple tax years that included the closing of U.S. IRS audits covering five tax\nyears.\nIn all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision/(benefit) for taxes on income (see\nNote 2A).\nWe elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign\nearnings over eight years through 2026. The fifth annual installment of this liability was paid by its April 18, 2023 due date. The sixth annual installment is due April 15, 2024 and is\nreported in current Income taxes payable as of December 31, 2023. The remaining liability is reported in noncurrent Other taxes payable.",
      "char_count": 863,
      "start_char": 452000,
      "end_char": 452864
    },
    {
      "chunk_id": "pfizer_2023_chunk0566",
      "chunk_index": 566,
      "text": "aining liability is reported in noncurrent Other taxes payable. Our obligations may vary as a result of\nchanges in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.\n(a), (b)\n(a)\n(b)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nB. Tax Rate Reconciliation\nThe reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows:\n \nYear Ended December 31,\n\nU.S. statutory income tax rate\n21.0 %\n21.0 %\n21.0 %\nTaxation of non-U.S. operations\n(21.1)\n(5.0)\n(4.3)\nTax settlements and resolution of certain tax positions\n(40.3)\n(3.0)\n(0.4)\nForeign-Derived Intangible Income deduction\n(33.1)\n(1.9)\n(0.6)\nState & local taxes\n(22.4)\n(0.5)\nCharitable contributions\n(7.3)\n(0.5)\n(0.6)\nCertain Consumer Healthcare JV initiatives\n(6.0)\nU.S.",
      "char_count": 861,
      "start_char": 452800,
      "end_char": 453662
    },
    {
      "chunk_id": "pfizer_2023_chunk0567",
      "chunk_index": 567,
      "text": ")\n(0.6)\nCertain Consumer Healthcare JV initiatives\n(6.0)\nU.S. R&D tax credit\n(15.8)\n(0.6)\n(0.5)\nInterest\n13.5 \n0.2 \n0.4 \nAll other, net\n0.2 \n(0.6)\n(0.7)\nEffective tax rate for income from continuing operations\n(105.4)%\n9.6 %\n7.6 %\nThe higher rate percentages for the 2023 reconciling items are significantly impacted by the lower domestic and international Income from continuing operations before provision/(benefit) for taxes on\nincome (see Note 5A).\nFor taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our\ninternational operations, changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions,” as well as changes in valuation\nallowances.",
      "char_count": 861,
      "start_char": 453600,
      "end_char": 454462
    },
    {
      "chunk_id": "pfizer_2023_chunk0568",
      "chunk_index": 568,
      "text": "n tax positions,” as well as changes in valuation\nallowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location\nof non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year\nand generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes\nin uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an\nincrease or decrease to our effective tax rate.",
      "char_count": 936,
      "start_char": 454400,
      "end_char": 455337
    },
    {
      "chunk_id": "pfizer_2023_chunk0569",
      "chunk_index": 569,
      "text": "sitions” is a component of our effective tax rate each year that can result in either an\nincrease or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can\nvary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments\nand gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing\nauthorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income.",
      "char_count": 811,
      "start_char": 455200,
      "end_char": 456012
    },
    {
      "chunk_id": "pfizer_2023_chunk0570",
      "chunk_index": 570,
      "text": "on income.\nIn all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other\nincentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2053. Under such grant, we are\npartially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2048 on income from manufacturing and other operations.\nSee Note 5A.\nThe higher rate benefit from the Foreign-Derived Intangible Income deduction in 2022 is mainly the result of the TCJA requirement to capitalize R&D costs for tax years beginning after December 31,\n2021.\nIncludes the impact of U.S.",
      "char_count": 847,
      "start_char": 456000,
      "end_char": 456849
    },
    {
      "chunk_id": "pfizer_2023_chunk0571",
      "chunk_index": 571,
      "text": "r December 31,\n2021.\nIncludes the impact of U.S. state and local taxes and changes in the state valuation allowances including those related to the acquisition of Seagen.\nIncludes changes in interest related to our uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”.\nAll other, net is primarily due to routine business operations.\n(a), (b)\n(c)\n(d)\n(e)\n(c)\n(f)\n(g)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nC. Deferred Taxes\nComponents of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:\n2023 Deferred Tax*\n2022 Deferred Tax*\n(MILLIONS)\nAssets\n(Liabilities)\nAssets\n(Liabilities)\nPrepaid/deferred items\n2,658 \n(654)\n1,673 \n(533)\nAccrued/deferred royalties\n1,655 \n2,127 \nDeferred revenues\n\nInventories\n1,210 \n(1,060)\n\n(262)\nIntangible assets\n1,526 \n(11,605)\n1,445 \n(6,288)\nProperty, plant and equipment\n\n(2,039)",
      "char_count": 967,
      "start_char": 456800,
      "end_char": 457768
    },
    {
      "chunk_id": "pfizer_2023_chunk0572",
      "chunk_index": 572,
      "text": "ed royalties\n1,655 \n2,127 \nDeferred revenues\n\nInventories\n1,210 \n(1,060)\n\n(262)\nIntangible assets\n1,526 \n(11,605)\n1,445 \n(6,288)\nProperty, plant and equipment\n\n(2,039)\n\n(1,845)\nEmployee benefits\n1,085 \n(287)\n1,314 \n(276)\nRestructurings and other charges\n\nLegal and product liability reserves\n\nResearch and development\n6,275 \n4,137 \nNet operating loss/tax credit carryforwards\n2,708 \n2,224 \nUnremitted earnings\n(60)\n(51)\nState and local tax adjustments\n\nInvestments\n\n(395)\n\n(208)\nAll other\n\n(72)\n\n(56)\n19,037 \n(16,172)\n14,806 \n(9,519)\nValuation allowances\n(1,738)\n(1,541)\nTotal deferred taxes\n17,299 \n(16,172)\n13,265 \n(9,519)\nNet deferred tax asset/(liability)\n1,128 \n3,746 \nThe deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories.",
      "char_count": 805,
      "start_char": 457600,
      "end_char": 458406
    },
    {
      "chunk_id": "pfizer_2023_chunk0573",
      "chunk_index": 573,
      "text": "ries. See Note 1Q.\nThe increase in net deferred tax assets in 2023 is primarily related to temporary differences associated with the timing of cash tax payments made and accruals recorded in the ordinary course of\nbusiness.\nThe increase in deferred tax assets in 2023 is primarily related to temporary differences associated with the non-cash revenue reversal for Paxlovid recorded in the fourth quarter of 2023. See Note\n17C.\nThe decrease in net deferred tax assets in 2023 is primarily due to the acquisition of inventories related to Seagen, partially offset by the temporary differences associated with the non-cash charges for\ninventory write-offs for Paxlovid and Comirnaty.\nThe increase in net deferred tax liabilities in 2023 is primarily due to the acquisition of intangible assets related to Seagen, partially offset by the amortization of intangible assets and certain impairment\ncharges.",
      "char_count": 899,
      "start_char": 458400,
      "end_char": 459300
    },
    {
      "chunk_id": "pfizer_2023_chunk0574",
      "chunk_index": 574,
      "text": "o Seagen, partially offset by the amortization of intangible assets and certain impairment\ncharges.\nThe decrease in net deferred tax assets in 2023 is primarily due to changes in pension and postretirement benefit obligations, as well as the performance of plan assets reported in the period. See Note\n11.\nThe increase in deferred tax assets in 2023 is primarily related to the acquisition of capitalized R&D costs related to Seagen and the TCJA requirement to capitalize R&D costs for tax years beginning\nafter December 31, 2021.\nThe increase in deferred tax assets in 2023 is primarily due to the acquisition of net operating loss carryforwards and credit carryforwards related to Seagen. See Note 2A.\nThe amounts in 2023 and 2022 are reduced for unrecognized tax benefits of $1.3 billion and $1.2 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax",
      "char_count": 901,
      "start_char": 459200,
      "end_char": 460102
    },
    {
      "chunk_id": "pfizer_2023_chunk0575",
      "chunk_index": 575,
      "text": "billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax\ncredit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.\nThe increase in net deferred tax liabilities in 2023 is primarily due to the impact of foreign currency translation adjustments related to our equity-method investment in Haleon/the Consumer Healthcare\nJV. See Note 2C.\nIn 2023, Noncurrent deferred tax assets and other noncurrent tax assets ($1.8 billion), and Noncurrent deferred tax liabilities ($0.6 billion). In 2022, Noncurrent deferred tax assets and other noncurrent\ntax assets ($4.8 billion), and Noncurrent deferred tax liabilities ($1.0 billion).\nExcludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S.",
      "char_count": 924,
      "start_char": 460000,
      "end_char": 460925
    },
    {
      "chunk_id": "pfizer_2023_chunk0576",
      "chunk_index": 576,
      "text": "ludes indefinite- and definite-lived deferred tax assets for certain non-U.S. tax losses and interest carryforwards and U.S. state general business credits, totaling $11.1 billion, given that management\nhas determined based on applicable accounting rules that it is remote that these tax attributes will be utilized.\nWe have carryforwards, primarily related to net operating and capital losses, general business credits, foreign tax credits and charitable contributions, which are available to reduce\nfuture U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2024 to 2043. Certain of our U.S. net\noperating losses and general business credits are subject to limitations under IRC Section 382.\nAs of December 31, 2023, we have not made a U.S. tax provision on $49.0 billion of unremitted earnings of our international subsidiaries.",
      "char_count": 918,
      "start_char": 460800,
      "end_char": 461719
    },
    {
      "chunk_id": "pfizer_2023_chunk0577",
      "chunk_index": 577,
      "text": "2023, we have not made a U.S. tax provision on $49.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be\nindefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2023 is not practicable. The amount of indefinitely\nreinvested earnings is based on estimates and assumptions and subject to management evaluation, and is subject to change in the normal course of business based on operational\ncash flow, completion of local statutory financial statements and the finalization of tax returns and audits, among other things. Accordingly, we regularly update our earnings and\nprofits analysis for such events.\nD. Tax Contingencies\nFor a description of our accounting policies associated with accounting for income tax contingencies, see Note 1Q.\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g), (h)\n(i)\n(j), (k)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(i)\n(j)\n(k)\n\n2023 Form 10-K",
      "char_count": 963,
      "start_char": 461600,
      "end_char": 462564
    },
    {
      "chunk_id": "pfizer_2023_chunk0578",
      "chunk_index": 578,
      "text": "ith accounting for income tax contingencies, see Note 1Q.\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g), (h)\n(i)\n(j), (k)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n(i)\n(j)\n(k)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nUncertain Tax Positions\nAs tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2023, we had\n$3.1 billion and as of December 31, 2022, we had $2.9 billion in net unrecognized tax benefits, excluding associated interest.\n• Tax assets for uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in\nanother tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation,\ncommonly referred to as the competent authority process.",
      "char_count": 953,
      "start_char": 462400,
      "end_char": 463354
    },
    {
      "chunk_id": "pfizer_2023_chunk0579",
      "chunk_index": 579,
      "text": "ative efforts among taxing authorities, as required by tax treaties to minimize double taxation,\ncommonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment\nof taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2023, we had $1.7 billion in assets\nassociated with uncertain tax positions. These amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ($1.6 billion) and Other taxes payable\n($45 million). As of December 31, 2022, we had $1.5 billion in assets associated with uncertain tax positions. These amounts were included in Noncurrent deferred tax assets and\nother noncurrent tax assets ($1.5 billion) and Other taxes payable ($45 million).\n• Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.",
      "char_count": 993,
      "start_char": 463200,
      "end_char": 464194
    },
    {
      "chunk_id": "pfizer_2023_chunk0580",
      "chunk_index": 580,
      "text": "er noncurrent tax assets ($1.5 billion) and Other taxes payable ($45 million).\n• Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.\nThe reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:\n(MILLIONS)\n\nBalance, beginning\n(4,494)\n(6,068)\n(5,595)\nAcquisitions\n(46)\n(52)\nIncreases based on tax positions taken during a prior period\n(158)\n(67)\n(111)\nDecreases based on tax positions taken during a prior period\n\n1,339 \n\nDecreases based on settlements for a prior period\n\nIncreases based on tax positions taken during the current period\n(515)\n(701)\n(550)\nImpact of foreign exchange\n(44)\n\nOther, net\n\nBalance, ending\n(4,802)\n(4,494)\n(6,068)\nPrimarily included in Provision/(benefit) for taxes on income.\nPrimarily related to effectively settling certain issues with the U.S. and foreign tax authorities.",
      "char_count": 900,
      "start_char": 464000,
      "end_char": 464901
    },
    {
      "chunk_id": "pfizer_2023_chunk0581",
      "chunk_index": 581,
      "text": "Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See Note 5A.\nPrimarily related to cash payments and reductions of tax attributes.\nPrimarily related to decreases as a result of a lapse of applicable statutes of limitations.\nIn 2023, included in Income taxes payable ($94 million), Other current assets ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.3 billion), Noncurrent deferred tax liabilities\n($4 million) and Other taxes payable ($3.4 billion). In 2022, included in Income taxes payable ($40 million), Other current assets ($3 million), Noncurrent deferred tax assets and other noncurrent tax\nassets ($1.2 billion), Noncurrent deferred tax liabilities ($5 million) and Other taxes payable ($3.2 billion).\n• Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in Provision/(benefit) for taxes on income.",
      "char_count": 977,
      "start_char": 464800,
      "end_char": 465779
    },
    {
      "chunk_id": "pfizer_2023_chunk0582",
      "chunk_index": 582,
      "text": "terest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in Provision/(benefit) for taxes on income. In\n2023, we recorded a net increase in interest of $64 million. In 2022, we recorded a net decrease in interest of $17 million. In 2021, we recorded a net increase in interest of $108\nmillion. Gross accrued interest totaled $605 million as of December 31, 2023 (reflecting a decrease of $11 million as a result of cash payments) and gross accrued interest totaled\n$552 million as of December 31, 2022 (reflecting a decrease of $31 million as a result of cash payments). In 2023 and 2022, these amounts were substantially all included in\nOther taxes payable. Accrued penalties are not significant. See also Note 5A.\nStatus of Tax Matters and Potential Impact on Accruals for Uncertain Tax Positions\nThe U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS.",
      "char_count": 965,
      "start_char": 465600,
      "end_char": 466566
    },
    {
      "chunk_id": "pfizer_2023_chunk0583",
      "chunk_index": 583,
      "text": "of Tax Matters and Potential Impact on Accruals for Uncertain Tax Positions\nThe U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2023 are open\nbut not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in\ncertain major international tax jurisdictions such as Canada (2017-2023), Europe (2012-2023, primarily in Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (20132023, primarily in Australia, China, Japan and Singapore) and Latin America (1998-2023, primarily in Brazil).\nAny settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions.",
      "char_count": 853,
      "start_char": 466400,
      "end_char": 467255
    },
    {
      "chunk_id": "pfizer_2023_chunk0584",
      "chunk_index": 584,
      "text": "a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next\n12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $100 million, as a result of settlements with taxing authorities or the expiration\nof the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax\nbenefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of\nsettlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can",
      "char_count": 842,
      "start_char": 467200,
      "end_char": 468043
    },
    {
      "chunk_id": "pfizer_2023_chunk0585",
      "chunk_index": 585,
      "text": "s with the relevant taxing authorities can\ninclude formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and\nsuch changes could be significant.\n(a)\n(a), (b)\n(b), (c)\n(a)\n(a), (d)\n(e)\n(a)\n(b)\n(c)\n(d)\n(e)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nE. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)\nComponents of the Tax provision/(benefit) on other comprehensive income/(loss) include:\n \nYear Ended December 31,\n(MILLIONS)\n\nForeign currency translation adjustments, net\n(33)\n(126)\n\nUnrealized holding gains/(losses) on derivative financial instruments, net\n\nReclassification adjustments for (gains)/losses included in net income\n(93)\n(270)\n\n(87)\n\nUnrealized holding gains/(losses) on available-for-sale securities, net\n(15)\n(164)\n(44)\nReclassification adjustments for (gains)/losses included in net income\n(18)\n\n(4)\n \n(33)",
      "char_count": 970,
      "start_char": 468000,
      "end_char": 468971
    },
    {
      "chunk_id": "pfizer_2023_chunk0586",
      "chunk_index": 586,
      "text": "lized holding gains/(losses) on available-for-sale securities, net\n(15)\n(164)\n(44)\nReclassification adjustments for (gains)/losses included in net income\n(18)\n\n(4)\n \n(33)\n\n(48)\nBenefit plans: prior service (costs)/credits and other, net\n(5)\n(5)\n\nReclassification adjustments related to amortization of prior service costs and other, net\n(28)\n(29)\n(47)\nReclassification adjustments related to curtailments of prior service costs and other, net\n(4)\n(3)\n(18)\n \n(37)\n(37)\n(38)\nTax provision/(benefit) on other comprehensive income/(loss)\n(85)\n(187)\n\nTaxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.\nNote 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests\nThe following summarizes the changes, net of tax, in Accumulated other comprehensive loss:\nNet Unrealized Gains/(Losses)\nBenefit Plans\n(MILLIONS)\nForeign Currency\nTranslation\nAdjustments\nDerivative Financial",
      "char_count": 999,
      "start_char": 468800,
      "end_char": 469800
    },
    {
      "chunk_id": "pfizer_2023_chunk0587",
      "chunk_index": 587,
      "text": "owing summarizes the changes, net of tax, in Accumulated other comprehensive loss:\nNet Unrealized Gains/(Losses)\nBenefit Plans\n(MILLIONS)\nForeign Currency\nTranslation\nAdjustments\nDerivative Financial\nInstruments\nAvailable-For-Sale\nSecurities\nPrior Service\n(Costs)/Credits and\nOther\nAccumulated Other\nComprehensive\nIncome/(Loss)\nBalance, January 1, 2021\n(5,450)\n(428)\n\n\n(5,310)\nOther comprehensive income/(loss)\n(722)\n\n(336)\n(75)\n(587)\nBalance, December 31, 2021\n(6,172)\n\n(220)\n\n(5,897)\nOther comprehensive income/(loss)\n(2,188)\n(531)\n\n(129)\n(2,407)\nBalance, December 31, 2022\n(8,360)\n(412)\n\n(8,304)\nOther comprehensive income/(loss)\n\n(229)\n(120)\n\nBalance, December 31, 2023\n(7,863)\n(217)\n(9)\n\n(7,961)\nAmounts do not include foreign currency translation adjustments attributable to noncontrolling interests.\nForeign currency translation adjustments include net losses in 2023, 2022 and 2021 related to the impact of our net investment hedging program and our equity-method investment in Haleon/the",
      "char_count": 996,
      "start_char": 469600,
      "end_char": 470597
    },
    {
      "chunk_id": "pfizer_2023_chunk0588",
      "chunk_index": 588,
      "text": "rests.\nForeign currency translation adjustments include net losses in 2023, 2022 and 2021 related to the impact of our net investment hedging program and our equity-method investment in Haleon/the\nConsumer Healthcare JV (see Note 2C).\n(a)\n(a)\n(a)\n(b)\n(b)\n(b)\n(a)\n(b)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nNote 7. Financial Instruments\nA. Fair Value Measurements\nFinancial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:\nAs of December 31, 2023\nAs of December 31, 2022\n(MILLIONS)\nTotal\nLevel 1\nLevel 2\nTotal\nLevel 1\nLevel 2\nFinancial assets:\nShort-term investments\nEquity securities with readily determinable fair values:\nMoney market funds\n5,124 \n5,124 \n1,588 \n1,588 \nAvailable-for-sale debt securities:\nGovernment and agency—non-U.S.\n\n15,915 \n15,915 \nGovernment and agency—U.S.\n2,601 \n2,601 \n1,313 \n1,313 \nCorporate and other",
      "char_count": 919,
      "start_char": 470400,
      "end_char": 471320
    },
    {
      "chunk_id": "pfizer_2023_chunk0589",
      "chunk_index": 589,
      "text": "ernment and agency—non-U.S.\n\n15,915 \n15,915 \nGovernment and agency—U.S.\n2,601 \n2,601 \n1,313 \n1,313 \nCorporate and other\n\n1,514 \n1,514 \n4,400 \n4,400 \n18,743 \n18,743 \nTotal short-term investments\n9,524 \n9,524 \n20,331 \n20,331 \nOther current assets\nDerivative assets:\nForeign exchange contracts\n\nTotal other current assets\n\nLong-term investments\nEquity securities with readily determinable fair values\n2,779 \n2,772 \n\n2,836 \n2,823 \n\nAvailable-for-sale debt securities:\nGovernment and agency—non-U.S.\n\nCorporate and other\n\nTotal long-term investments\n2,929 \n2,772 \n\n3,188 \n2,823 \n\nOther noncurrent assets\nDerivative assets:\nInterest rate contracts\n\nForeign exchange contracts\n\nTotal derivative assets\n\nInsurance contracts\n\nTotal other noncurrent assets\n1,191 \n1,191 \n1,028 \n1,028 \nTotal assets\n13,943 \n2,772 \n11,170 \n25,261 \n2,823 \n22,439 \nFinancial liabilities:\nOther current liabilities\nDerivative liabilities:\nInterest rate contracts\n\n\n\n\nForeign exchange contracts\n\nTotal other current liabilities",
      "char_count": 994,
      "start_char": 471200,
      "end_char": 472195
    },
    {
      "chunk_id": "pfizer_2023_chunk0590",
      "chunk_index": 590,
      "text": "2 \n11,170 \n25,261 \n2,823 \n22,439 \nFinancial liabilities:\nOther current liabilities\nDerivative liabilities:\nInterest rate contracts\n\n\n\n\nForeign exchange contracts\n\nTotal other current liabilities\n\nOther noncurrent liabilities\nDerivative liabilities:\nInterest rate contracts\n\nForeign exchange contracts\n\nTotal other noncurrent liabilities\n1,000 \n1,000 \n1,185 \n1,185 \nTotal liabilities\n1,420 \n1,420 \n1,889 \n1,889 \nLong-term equity securities of $130 million as of December 31, 2023 and $143 million as of December 31, 2022 were held in restricted trusts for U.S. non-qualified employee benefit plans.\nIncludes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair\nvalue, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).",
      "char_count": 898,
      "start_char": 472000,
      "end_char": 472899
    },
    {
      "chunk_id": "pfizer_2023_chunk0591",
      "chunk_index": 591,
      "text": "t fair\nvalue, with changes in fair value recognized in Other (income)/deductions—net (see Note 4).\nFinancial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis––The carrying value of Long-term debt, excluding the current portion was $62 billion as of\nDecember 31, 2023 and $33 billion as of December 31, 2022. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $61 billion as of December\n31, 2023 and $30 billion as of December 31, 2022.\nThe differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings\nnot measured at fair value on a recurring basis were not significant as of December 31, 2023 and 2022. The fair value measurements of our held-to-maturity debt securities and\nshort-term borrowings are based on Level 2 inputs.",
      "char_count": 901,
      "start_char": 472800,
      "end_char": 473702
    },
    {
      "chunk_id": "pfizer_2023_chunk0592",
      "chunk_index": 592,
      "text": "ements of our held-to-maturity debt securities and\nshort-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.\n(a)\n(b)\n(a)\n(b)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nB. Investments\nTotal Short-Term, Long-Term and Equity-Method Investments\nThe following summarizes our investments by classification type:\nAs of December 31,\n(MILLIONS)\n\nShort-term investments\nEquity securities with readily determinable fair values\n5,124 \n1,588 \nAvailable-for-sale debt securities\n4,400 \n18,743 \nHeld-to-maturity debt securities\n\n1,985 \nTotal Short-term investments\n9,837 \n22,316 \nLong-term investments\nEquity securities with readily determinable fair values\n2,779 \n2,836 \nAvailable-for-sale debt securities\n\nHeld-to-maturity debt securities\n\nPrivate equity securities at cost",
      "char_count": 887,
      "start_char": 473600,
      "end_char": 474488
    },
    {
      "chunk_id": "pfizer_2023_chunk0593",
      "chunk_index": 593,
      "text": "le debt securities\n\nHeld-to-maturity debt securities\n\nPrivate equity securities at cost\n\nTotal Long-term investments\n3,731 \n4,036 \nEquity-method investments\n11,637 \n11,033 \nTotal long-term investments and equity-method investments\n15,368 \n15,069 \nHeld-to-maturity cash equivalents\n\n\nRepresent money market funds primarily invested in U.S. Treasury and government debt.\nRepresent investments in the life sciences sector.\nDebt Securities\nOur investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:\nAs of December 31, 2023\nAs of December 31, 2022\nGross Unrealized\nMaturities (in Years)\nGross Unrealized\n(MILLIONS)\nAmortized Cost\nGains\nLosses\nFair Value\nWithin 1\nOver 1\nto 5\nOver 5\nAmortized\nCost\nGains\nLosses\nFair Value\nAvailable-for-sale debt securities\nGovernment and agency––non-U.S.\n\n\n(14)\n\n\n\n15,946 \n\n(48)\n16,195 \nGovernment and agency––U.S.\n2,601 \n2,601 \n2,601 \n1,313 \n1,313 \nCorporate and other\n1,006",
      "char_count": 987,
      "start_char": 474400,
      "end_char": 475389
    },
    {
      "chunk_id": "pfizer_2023_chunk0594",
      "chunk_index": 594,
      "text": "Available-for-sale debt securities\nGovernment and agency––non-U.S.\n\n\n(14)\n\n\n\n15,946 \n\n(48)\n16,195 \nGovernment and agency––U.S.\n2,601 \n2,601 \n2,601 \n1,313 \n1,313 \nCorporate and other\n1,006 \n\n(2)\n1,007 \n\n1,584 \n\n(4)\n1,586 \nHeld-to-maturity debt securities\nTime deposits and other\n\n1,171 \n1,171 \nGovernment and agency––non-U.S.\n\n1,542 \n1,542 \nTotal debt securities\n5,126 \n\n(16)\n5,115 \n4,919 \n\n\n21,556 \n\n(53)\n21,807 \nAny expected credit losses to these portfolios would be immaterial to our financial statements.\nEquity Securities\nThe following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:\nYear Ended December 31,\n(MILLIONS)\n\nNet (gains)/losses recognized during the period on equity securities\n(1,590)\n1,273 \n(1,344)\nLess: Net (gains)/losses recognized during the period on equity securities sold during\nthe period\n(1,754)\n(126)\n(80)",
      "char_count": 954,
      "start_char": 475200,
      "end_char": 476155
    },
    {
      "chunk_id": "pfizer_2023_chunk0595",
      "chunk_index": 595,
      "text": "ity securities\n(1,590)\n1,273 \n(1,344)\nLess: Net (gains)/losses recognized during the period on equity securities sold during\nthe period\n(1,754)\n(126)\n(80)\nNet unrealized (gains)/losses during the reporting period on equity securities still held\nat the reporting date\n\n1,400 \n(1,264)\nReported in Other (income)/deductions––net. See Note 4.\nIncluded in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2023, there were cumulative impairments and\ndownward adjustments of $259 million and upward adjustments of $213 million. Impairments, downward and upward adjustments were not material to our operations in 2023, 2022 and 2021.\n(a)\n(b)\n(b)\n(a)\n(b)\n(a)\n(b)\n(a)\n(b)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nC. Short-Term Borrowings\nShort-term borrowings include:\nAs of December 31,\n(MILLIONS)",
      "char_count": 900,
      "start_char": 476000,
      "end_char": 476901
    },
    {
      "chunk_id": "pfizer_2023_chunk0596",
      "chunk_index": 596,
      "text": "al Statements\n\nC. Short-Term Borrowings\nShort-term borrowings include:\nAs of December 31,\n(MILLIONS)\n\nCommercial paper, principal amount\n7,965 \nCurrent portion of long-term debt, principal amount\n2,250 \n2,550 \nOther short-term borrowings, principal amount\n\nTotal short-term borrowings, principal amount\n10,467 \n2,935 \nNet fair value adjustments related to hedging and purchase accounting\n\nNet unamortized discounts, premiums and debt issuance costs\n(121)\n(1)\nTotal Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted\n10,350 \n2,945 \nIssued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see Note 2A). The weighted-average effective interest rate on commercial paper outstanding was approximately\n5.37% as of December 31, 2023.\nPrimarily includes cash collateral. See Note 7F.\nAs of December 31, 2023, we had access to a total of $15 billion in committed U.S.",
      "char_count": 956,
      "start_char": 476800,
      "end_char": 477757
    },
    {
      "chunk_id": "pfizer_2023_chunk0597",
      "chunk_index": 597,
      "text": "as of December 31, 2023.\nPrimarily includes cash collateral. See Note 7F.\nAs of December 31, 2023, we had access to a total of $15 billion in committed U.S. revolving credit facilities, consisting of an $8 billion facility maturing in October 2024 and a $7\nbillion facility maturing in October 2028, which may be used for general corporate purposes including to support our global commercial paper borrowings. In addition to the U.S.\nrevolving credit facilities, our lenders have provided us an additional $305 million in lines of credit, of which $274 million expire within one year. Essentially all lines of credit were\nunused as of December 31, 2023.\nD. Long-Term Debt\nThe following outlines our senior unsecured long-term debt* and the weighted-average stated interest rate by maturity:\nAs of December 31,\n(MILLIONS)\n\nNotes due 2024 (3.9% for 2022)\n2,250 \nNotes due 2025 (3.9% for 2023 and 0.8% for 2022)\n3,750",
      "char_count": 914,
      "start_char": 477600,
      "end_char": 478516
    },
    {
      "chunk_id": "pfizer_2023_chunk0598",
      "chunk_index": 598,
      "text": "ember 31,\n(MILLIONS)\n\nNotes due 2024 (3.9% for 2022)\n2,250 \nNotes due 2025 (3.9% for 2023 and 0.8% for 2022)\n3,750 \n\nNotes due 2026 (3.7% for 2023 and 2.9% for 2022)\n6,000 \n3,000 \nNotes due 2027 (2.1% for 2023 and 2022)\n1,029 \n1,000 \nNotes due 2028 (4.6% for 2023 and 4.8% for 2022)\n5,660 \n1,660 \nNotes due 2029 (3.5% for 2023 and 2022)\n1,750 \n1,750 \nNotes due 2030-2034 (4.1% for 2023 and 2.9% for 2022)\n12,000 \n4,000 \nNotes due 2035-2039 (5.8% for 2023 and 2022)\n8,048 \n8,017 \nNotes due 2040-2044 (4.1% for 2023 and 3.6% for 2022)\n7,995 \n4,903 \nNotes due 2045-2049 (4.1% for 2023 and 2022)\n3,500 \n3,500 \nNotes due 2050-2063 (5.0% for 2023 and 2.7% for 2022)\n11,250 \n1,250 \nTotal long-term debt, principal amount\n60,982 \n32,080 \nNet fair value adjustments related to hedging and purchase accounting\n1,039 \n\nNet unamortized discounts, premiums and debt issuance costs\n(483)\n(175)\nOther long-term debt",
      "char_count": 900,
      "start_char": 478400,
      "end_char": 479301
    },
    {
      "chunk_id": "pfizer_2023_chunk0599",
      "chunk_index": 599,
      "text": "1,039 \n\nNet unamortized discounts, premiums and debt issuance costs\n(483)\n(175)\nOther long-term debt\n\nTotal long-term debt, carried at historical proceeds, as adjusted\n61,538 \n32,884 \nCurrent portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2023 and 3.7% for\n2022))\n2,254 \n2,560 \nOur long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.\nReclassified to the current portion of long-term debt.\nIssuances\nIn May 2023, we issued, through our wholly-owned finance subsidiary, PIE, the following senior unsecured notes as part of the financing for our acquisition of Seagen\n(MILLIONS)\nPrincipal\nInterest Rate\nMaturity Date\nDecember 31, 2023\n4.65%\nMay 19, 2025\n3,000 \n4.45%\nMay 19, 2026\n3,000 \n4.45%\nMay 19, 2028\n4,000 \n4.65%\nMay 19, 2030\n3,000 \n4.75%\nMay 19, 2033\n5,000 \n5.11%\nMay 19, 2043\n3,000 \n5.30%\nMay 19, 2053\n6,000 \n5.34%\nMay 19, 2063\n4,000 \nTotal long-term debt issued in 2023",
      "char_count": 997,
      "start_char": 479200,
      "end_char": 480198
    },
    {
      "chunk_id": "pfizer_2023_chunk0600",
      "chunk_index": 600,
      "text": ",000 \n4.45%\nMay 19, 2028\n4,000 \n4.65%\nMay 19, 2030\n3,000 \n4.75%\nMay 19, 2033\n5,000 \n5.11%\nMay 19, 2043\n3,000 \n5.30%\nMay 19, 2053\n6,000 \n5.34%\nMay 19, 2063\n4,000 \nTotal long-term debt issued in 2023\n31,000 \n(a)\n(b)\n(a)\n(b)\n(a)\n(a)\n(a), (b)\n(c)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nThe notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PIE was formed to finance a portion of the consideration for the acquisition of Seagen and has no assets or\noperations, and will have no assets or operations, other than as related to the issuance, administration and repayment of the notes and any other debt securities that it may issue in the future.\nThe notes may be redeemed by us at any time, in whole, or in part, at a make-whole redemption price plus accrued and unpaid interest.\nThe weighted average effective interest rate for the notes at issuance was 4.93%.",
      "char_count": 916,
      "start_char": 480000,
      "end_char": 480917
    },
    {
      "chunk_id": "pfizer_2023_chunk0601",
      "chunk_index": 601,
      "text": "plus accrued and unpaid interest.\nThe weighted average effective interest rate for the notes at issuance was 4.93%.\nIn August 2021, we completed a public offering of $1.0 billion principal amount of senior unsecured notes due 2031 at an effective interest rate of 1.79%.\nE. Derivative Financial Instruments and Hedging Activities\nForeign Exchange Risk––A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign\nexchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These\nfinancial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S.",
      "char_count": 850,
      "start_char": 480800,
      "end_char": 481652
    },
    {
      "chunk_id": "pfizer_2023_chunk0602",
      "chunk_index": 602,
      "text": "ncy, or against the impact of translation into U.S. dollars of certain\nforeign exchange-denominated transactions.\nThe derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Canadian dollar, and Chinese renminbi, and include a portion of our\nforecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments\nof our foreign business entities.\nChanges in fair value are reported in earnings or in Other comprehensive income/(loss), depending on the nature and purpose of the financial instrument (hedge or offset\nrelationship). For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an\namortization approach in earnings.",
      "char_count": 869,
      "start_char": 481600,
      "end_char": 482470
    },
    {
      "chunk_id": "pfizer_2023_chunk0603",
      "chunk_index": 603,
      "text": "ize the excluded amount through an\namortization approach in earnings. The hedge relationships are as follows:\n• Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value\nof the hedged item. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.\n• Generally, we record in Other comprehensive income/(loss) gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts\ninto earnings in the same period or periods during which the hedged transaction affects earnings.\n• We record in Other comprehensive income/(loss)––Foreign currency translation adjustments, net the foreign exchange gains and losses related to foreign exchange-denominated",
      "char_count": 857,
      "start_char": 482400,
      "end_char": 483258
    },
    {
      "chunk_id": "pfizer_2023_chunk0604",
      "chunk_index": 604,
      "text": "gains and losses related to foreign exchange-denominated\ndebt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial\nliquidation of our net investments.\n• For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses immediately into earnings along with the earnings impact of the items\nthey generally offset. These contracts take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement.\nInterest Rate Risk––Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding\ndebt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with",
      "char_count": 979,
      "start_char": 483200,
      "end_char": 484181
    },
    {
      "chunk_id": "pfizer_2023_chunk0605",
      "chunk_index": 605,
      "text": "or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with\nfixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.\nWe recognize the change in fair value on interest rate contracts that are designated as fair value hedges in earnings, as well as the offsetting earnings impact of the hedged risk\nattributable to the hedged item.\nThe following summarizes the fair value of the derivative financial instruments and notional amounts:\n(MILLIONS)\nAs of December 31, 2023\nAs of December 31, 2022\nFair Value\nFair Value\nNotional\nAsset\nLiability\nNotional\nAsset\nLiability\nDerivatives designated as hedging instruments:\nForeign exchange contracts\n18,750 \n\n\n26,603 \n\n1,196 \nInterest rate contracts\n6,750 \n\n2,250 \n\n1,206",
      "char_count": 939,
      "start_char": 484000,
      "end_char": 484942
    },
    {
      "chunk_id": "pfizer_2023_chunk0606",
      "chunk_index": 606,
      "text": "atives designated as hedging instruments:\nForeign exchange contracts\n18,750 \n\n\n26,603 \n\n1,196 \nInterest rate contracts\n6,750 \n\n2,250 \n\n1,206 \n\n1,527 \nDerivatives not designated as hedging instruments:\nForeign exchange contracts\n25,609 \n\n29,814 \n\nTotal\n\n1,420 \n1,078 \n1,889 \nThe notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of December 31, 2023 and $4.4 billion as of December 31, 2022.\n(a)\n(b)\n(c)\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nThe following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:\n \nGains/(Losses)\nRecognized in OID\nGains/(Losses)\nRecognized in OCI\nGains/(Losses)\nReclassified from\nOCI into OID and COS\nYear Ended December 31,\n(MILLIONS)\n\nDerivative Financial Instruments in Cash Flow Hedge\nRelationships:\n \n \n \n \n \n \nInterest rate contracts\n\n\nForeign exchange contracts",
      "char_count": 993,
      "start_char": 484800,
      "end_char": 485794
    },
    {
      "chunk_id": "pfizer_2023_chunk0607",
      "chunk_index": 607,
      "text": "from\nOCI into OID and COS\nYear Ended December 31,\n(MILLIONS)\n\nDerivative Financial Instruments in Cash Flow Hedge\nRelationships:\n \n \n \n \n \n \nInterest rate contracts\n\n\nForeign exchange contracts\n\n1,296 \n\n1,916 \nAmount excluded from effectiveness testing and amortized\ninto earnings\n\nDerivative Financial Instruments in Fair Value Hedge\nRelationships:\nInterest rate contracts\n\n(337)\nHedged item\n(196)\n\nDerivative Financial Instruments in Net Investment Hedge\nRelationships:\nForeign exchange contracts\n(393)\n\nAmount excluded from effectiveness testing and amortized\ninto earnings\n\nNon-Derivative Financial Instruments in Net Investment\nHedge Relationships :\nForeign currency short-term borrowings\n\nForeign currency long-term debt\n(29)\n\nDerivative Financial Instruments Not Designated as Hedges:\nForeign exchange contracts\n\n(1,153)\n\n(1,153)\n\n2,409",
      "char_count": 843,
      "start_char": 485600,
      "end_char": 486445
    },
    {
      "chunk_id": "pfizer_2023_chunk0608",
      "chunk_index": 608,
      "text": "exchange contracts\n\n(1,153)\n\n(1,153)\n\n2,409 \n\n2,190 \nOID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income. COS = Cost of Sales, included in Cost of sales in the consolidated\nstatements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income.\nThe amounts reclassified from OCI into COS were a net gain of $253 million in 2023 and a net gain of $375 million in 2022. The remaining amounts were reclassified from OCI into OID. Based on yearend foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $11 million within the next 12 months into income. The maximum length of time over which we are hedging\nour exposure to the variability in future foreign exchange cash flows is approximately 19 years and relates to foreign currency debt.\nThe amounts reclassified from OCI were reclassified into OID.",
      "char_count": 960,
      "start_char": 486400,
      "end_char": 487361
    },
    {
      "chunk_id": "pfizer_2023_chunk0609",
      "chunk_index": 609,
      "text": "future foreign exchange cash flows is approximately 19 years and relates to foreign currency debt.\nThe amounts reclassified from OCI were reclassified into OID.\nLong-term debt includes foreign currency borrowings which are used as net investment hedges; the related carrying values as of December 31, 2023 and December 31, 2022 were $824 million and $795\nmillion, respectively.\nThe following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:\nAs of December 31, 2023\nAs of December 31, 2022\nCumulative Amount of Fair\nValue Hedging Adjustment\nIncrease/(Decrease) to\nCarrying Amount\nCumulative Amount of Fair\nValue Hedging Adjustment\nIncrease/(Decrease) to\nCarrying Amount\n(MILLIONS)\nCarrying Amount of\nHedged\nAssets/Liabilities\nActive\nHedging\nRelationships\nDiscontinued\nHedging\nRelationships\nCarrying Amount of\nHedged\nAssets/Liabilities\nActive Hedging\nRelationships\nDiscontinued\nHedging\nRelationships\nShort-term borrowings, including current\nportion of long-term debt",
      "char_count": 999,
      "start_char": 487200,
      "end_char": 488200
    },
    {
      "chunk_id": "pfizer_2023_chunk0610",
      "chunk_index": 610,
      "text": "d\nHedging\nRelationships\nCarrying Amount of\nHedged\nAssets/Liabilities\nActive Hedging\nRelationships\nDiscontinued\nHedging\nRelationships\nShort-term borrowings, including current\nportion of long-term debt\n\n\nLong-term debt\n7,196 \n(131)\n\n2,235 \n(321)\n1,042 \nCarrying amounts exclude the cumulative amount of fair value hedging adjustments.\nF. Credit Risk\nOn an ongoing basis, we monitor and review the credit risk of our customers, financial institutions and exposures in our investment portfolio.\nWith respect to our trade accounts receivable, we monitor the creditworthiness of our customers to which we grant credit in the normal course of business. In general, there is no\nrequirement for collateral from customers. For additional information on our trade accounts receivable and allowance for credit losses, see Note 1G. A significant portion of our trade\naccounts receivable balances are due from wholesalers and governments.",
      "char_count": 924,
      "start_char": 488000,
      "end_char": 488925
    },
    {
      "chunk_id": "pfizer_2023_chunk0611",
      "chunk_index": 611,
      "text": "sses, see Note 1G. A significant portion of our trade\naccounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see Note 17C.\n(a)\n(a)\n(a)\n(b)\n(c)\n(c)\n(d)\n(a)\n(b)\n(c)\n(d)\n(a)\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nWith respect to our investments, we monitor concentrations of credit risk associated with government, government agency, and corporate issuers of securities. Investments are\nplaced in instruments that are investment grade and are primarily short in duration. Exposure limits are established to limit a concentration with any single credit counterparty. As of\nDecember 31, 2023, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by\nthe U.S.",
      "char_count": 888,
      "start_char": 488800,
      "end_char": 489689
    },
    {
      "chunk_id": "pfizer_2023_chunk0612",
      "chunk_index": 612,
      "text": "government money market funds, as well as sovereign debt instruments issued by\nthe U.S.\nWith respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative\nfinancial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions\nrequiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As\nof December 31, 2023, the aggregate fair value of these derivative financial instruments that are in a net payable position was $768 million, for which we have posted collateral of\n$771 million with a corresponding amount reported in Short-term investments.",
      "char_count": 891,
      "start_char": 489600,
      "end_char": 490493
    },
    {
      "chunk_id": "pfizer_2023_chunk0613",
      "chunk_index": 613,
      "text": "d collateral of\n$771 million with a corresponding amount reported in Short-term investments. As of December 31, 2023, the aggregate fair value of our derivative financial instruments that are in a\nnet receivable position was $225 million, for which we have received collateral of $221 million with a corresponding amount reported in Short-term borrowings, including current\nportion of long-term debt.\nNote 8. Other Financial Information\nA. Inventories\nThe following summarizes the components of Inventories:\nAs of December 31,\n(MILLIONS)\n\nFinished goods\n3,495 \n2,603 \nWork-in-process\n5,688 \n5,519 \nRaw materials and supplies\n1,007 \n\nInventories\n10,189 \n8,981 \nNoncurrent inventories not included above\n4,568 \n5,827 \nThe increase from December 31, 2022 of $1.2 billion reflects an increase of approximately $1.0 billion representing acquired Seagen inventory, inclusive of the fair value step-up (see Note 2A), and",
      "char_count": 913,
      "start_char": 490400,
      "end_char": 491314
    },
    {
      "chunk_id": "pfizer_2023_chunk0614",
      "chunk_index": 614,
      "text": "ately $1.0 billion representing acquired Seagen inventory, inclusive of the fair value step-up (see Note 2A), and\nincreases for certain products due to new product launches, supply recovery and changes in net market demand. These increases were offset to a large extent by $1.0 billion in inventory write-offs for\nPaxlovid and Comirnaty.\nIncluded in Other noncurrent assets. The decrease from December 31, 2022 of $1.3 billion is primarily driven by inventory write-offs for Paxlovid of $4.2 billion and, to a lesser extent, inventory write-offs\nfor Comirnaty of $0.7 billion, offset to a large extent by an increase of approximately $3.1 billion representing acquired Seagen inventory, inclusive of the fair value step-up (see Note 2A). The charges and\ncorresponding inventory write-offs were based on our analysis of Paxlovid and Comirnaty inventory levels as of December 31, 2023 in relation to our commercial outlook for both products.",
      "char_count": 939,
      "start_char": 491200,
      "end_char": 492140
    },
    {
      "chunk_id": "pfizer_2023_chunk0615",
      "chunk_index": 615,
      "text": "on our analysis of Paxlovid and Comirnaty inventory levels as of December 31, 2023 in relation to our commercial outlook for both products. Based on\ncurrent estimates and assumptions, there are no recoverability issues for these amounts.\nB. Other Current Liabilities\nOther current liabilities includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $2.0 billion as of December 31, 2023 and\n$5.2 billion as of December 31, 2022.\nC. Supplier Finance Program Obligation\nWe maintain voluntary supply chain finance agreements with several participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell\ntheir accounts receivable with Pfizer to these financial institutions. Our suppliers negotiate their financing agreements directly with the respective financial institutions and we are not\na party to these agreements.",
      "char_count": 925,
      "start_char": 492000,
      "end_char": 492926
    },
    {
      "chunk_id": "pfizer_2023_chunk0616",
      "chunk_index": 616,
      "text": "te their financing agreements directly with the respective financial institutions and we are not\na party to these agreements. We have no economic interest in our suppliers’ decision to participate and we pay the financial institutions the stated amount of confirmed invoices on\nthe original maturity dates, which is generally within 90 to 120 days of the invoice date. The agreements with the financial institutions do not require Pfizer to provide assets pledged\nas security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in such financing arrangements are recorded\nwithin trade payables in our consolidated balance sheet. As of December 31, 2023 and December 31, 2022, respectively, $791 million and $849 million of our trade payables to\nsuppliers who participate in these financing arrangements were outstanding.\nNote 9.",
      "char_count": 898,
      "start_char": 492800,
      "end_char": 493699
    },
    {
      "chunk_id": "pfizer_2023_chunk0617",
      "chunk_index": 617,
      "text": "de payables to\nsuppliers who participate in these financing arrangements were outstanding.\nNote 9. Property, Plant and Equipment\nThe following summarizes the components of Property, plant and equipment:\n \nUseful Lives\nAs of December 31,\n(MILLIONS)\n(Years) \n\nLand\n\n\nBuildings\n33-50\n9,046 \n8,832 \nMachinery and equipment\n8-20\n14,263 \n12,881 \nFurniture, fixtures and other\n3-12.5\n5,399 \n4,491 \nConstruction in progress\n5,925 \n4,875 \n34,985 \n31,448 \nLess: Accumulated depreciation\n16,045 \n15,174 \nProperty, plant and equipment\n18,940 \n16,274 \n(a)\n(b)\n(a)\n(b)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nThe following provides long-lived assets by geographic area:\n \nAs of December 31,\n(MILLIONS)\n\nUnited States\n10,674 \n9,179 \nDeveloped Europe\n6,221 \n5,389 \nDeveloped Rest of World\n\nEmerging Markets\n1,756 \n1,413 \nProperty, plant and equipment\n18,940 \n16,274 \nNote 10. Identifiable Intangible Assets and Goodwill\nA.",
      "char_count": 927,
      "start_char": 493600,
      "end_char": 494528
    },
    {
      "chunk_id": "pfizer_2023_chunk0618",
      "chunk_index": 618,
      "text": "ing Markets\n1,756 \n1,413 \nProperty, plant and equipment\n18,940 \n16,274 \nNote 10. Identifiable Intangible Assets and Goodwill\nA. Identifiable Intangible Assets\nThe following summarizes the components of Identifiable intangible assets:\n \nAs of December 31, 2023\nAs of December 31, 2022\n(MILLIONS)\nGross\nCarrying\nAmount\nAccumulated\nAmortization\nIdentifiable\nIntangible\nAssets, less\nAccumulated\nAmortization\nGross\nCarrying\nAmount\nAccumulated\nAmortization\nIdentifiable\nIntangible\nAssets, less\nAccumulated\nAmortization\nFinite-lived intangible assets\nDeveloped technology rights\n99,267 \n(60,493)\n38,773 \n85,604 \n(56,307)\n29,297 \nBrands\n\n(877)\n\n(844)\n\nLicensing agreements and other\n2,756 \n(1,458)\n1,297 \n2,237 \n(1,397)\n\n102,944 \n(62,828)\n40,116 \n88,763 \n(58,548)\n30,215 \nIndefinite-lived intangible assets\nBrands\n\nIPR&D\n23,193 \n23,193 \n11,357 \n11,357 \nLicensing agreements and other",
      "char_count": 875,
      "start_char": 494400,
      "end_char": 495276
    },
    {
      "chunk_id": "pfizer_2023_chunk0619",
      "chunk_index": 619,
      "text": "rands\n\nIPR&D\n23,193 \n23,193 \n11,357 \n11,357 \nLicensing agreements and other\n\n24,784 \n24,784 \n13,155 \n13,155 \nIdentifiable intangible assets\n127,728 \n(62,828)\n64,900 \n101,919 \n(58,548)\n43,370 \nThe increase in the gross carrying amount primarily includes, among other things: (i) $7.5 billion for the acquisition of Seagen (see Note 2A); (ii) the transfer of IPR&D to developed technology rights of\n$3.6 billion for etrasimod (Velsipity), $2.1 billion for Padcev, $1.1 billion for Braftovi/Mektovi, and $450 million as a result of the approval in the U.S. for Zavzpret nasal spray; and (iii) $495 million of\ncapitalized milestones as a result of the approval in the U.S. for Zavzpret nasal spray, partially offset by (iv) impairments of $964 million for Prevnar 13 (see Note 4).\nThe increase in the gross carrying amount primarily reflects $450 million for the acquisition of Seagen (see Note 2A).",
      "char_count": 895,
      "start_char": 495200,
      "end_char": 496096
    },
    {
      "chunk_id": "pfizer_2023_chunk0620",
      "chunk_index": 620,
      "text": "ss carrying amount primarily reflects $450 million for the acquisition of Seagen (see Note 2A).\nThe increase in the gross carrying amount mainly reflects $20.8 billion for the acquisition of Seagen (see Note 2A), partially offset by the transfer from IPR&D to developed technology rights as mentioned\nin note (a) above, and impairments of $1.4 billion for etrasimod (Velsipity).\nThe increase is primarily due to $28.8 billion for the acquisition of Seagen (see Note 2A) and the $495 million of capitalized milestones described in note (a) above, partially offset by amortization expense\nof $4.7 billion and impairments of $3.0 billion (see Note 4).\nDeveloped Technology Rights––Developed technology rights represent the cost for developed technology acquired from third parties and can include the right to develop, use,\nmarket, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been",
      "char_count": 994,
      "start_char": 496000,
      "end_char": 496995
    },
    {
      "chunk_id": "pfizer_2023_chunk0621",
      "chunk_index": 621,
      "text": "ght to develop, use,\nmarket, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been\ncompleted. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing our commercialized products. The\nsignificant components of developed technology rights are the following: Nurtec ODT/Vydura, Adcetris, Xtandi, etrasimod (Velsipity), Padcev, Braftovi/Mektovi, Prevnar 13 family and\nOxbryta. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain prescription pharmaceutical products.\nBrands––Brands represent the cost for tradenames and know-how, as the products themselves do not receive patent protection.",
      "char_count": 836,
      "start_char": 496800,
      "end_char": 497637
    },
    {
      "chunk_id": "pfizer_2023_chunk0622",
      "chunk_index": 622,
      "text": "es do not receive patent protection. Indefinite-lived brands include Medrol and DepoMedrol, while finite-lived brands include Zavedos and Depo-Provera.\nIPR&D––IPR&D assets represent the acquisition date fair value (less impairments) of R&D assets acquired through business combinations that have not yet received regulatory\napproval in a major market which could include both new investigational products and additional indications for in-line products. The significant components of IPR&D are SGN-B6A,\nDisitamab vedotin, GBT601, Tukysa, Padcev and talazoparib. IPR&D assets are required to be classified as indefinite-lived assets until the successful completion or the\nabandonment of the associated R&D effort. Accordingly, during the development period after the date of acquisition, these assets are not amortized until approval is obtained in a\nmajor market, typically either the U.S.",
      "char_count": 889,
      "start_char": 497600,
      "end_char": 498490
    },
    {
      "chunk_id": "pfizer_2023_chunk0623",
      "chunk_index": 623,
      "text": "are not amortized until approval is obtained in a\nmajor market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine\nthe useful life of the asset, reclassify it out of IPR&D and begin amortization. If the associated R&D effort is abandoned, the related IPR&D assets will be written-off, and we will\nrecord an impairment charge. IPR&D assets are high-risk assets, given the uncertain nature of R&D. Accordingly, IPR&D assets may become impaired and/or be written-off in the\nfuture.\nLicensing Agreements––Licensing agreements for developed technology and for technology in development primarily relate to out-licensing arrangements acquired from third\nparties, including the Array, Arena and Seagen acquisitions.",
      "char_count": 826,
      "start_char": 498400,
      "end_char": 499227
    },
    {
      "chunk_id": "pfizer_2023_chunk0624",
      "chunk_index": 624,
      "text": "a and Seagen acquisitions. These assets represent the cost for the license, where we acquired the right to future royalties and/or milestones upon\ndevelopment or commercialization by the licensing partners. A\n(a)\n(b)\n(c)\n(d)\n(a)\n(b)\n(c)\n(d)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nsignificant component of the licensing arrangements are for out-licensing arrangements with a number of partners. Accordingly, during the development period after the date of\nacquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine\nthe useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization.",
      "char_count": 806,
      "start_char": 499200,
      "end_char": 500007
    },
    {
      "chunk_id": "pfizer_2023_chunk0625",
      "chunk_index": 625,
      "text": "ation. If the development effort is abandoned, the\nrelated licensing asset will be written-off, and we will record an impairment charge.\nAmortization––The weighted-average life for each of our total finite-lived intangible assets is approximately 11 years, and for the largest component, developed technology rights, is\napproximately 11 years.\nThe following provides the expected annual amortization expense:\n(MILLIONS)\n\nAmortization expense\n5,079 \n4,763 \n4,639 \n4,054 \n3,702 \nB. Goodwill\nThe following summarizes the changes in the carrying amount of Goodwill:\n(MILLIONS)\nTotal\nBalance, January 1, 2022\n49,208 \nAdditions\n2,917 \nImpact of foreign exchange\n(750)\nBalance, December 31, 2022\n51,375 \nAdditions\n16,117 \nImpact of foreign exchange and other\n\nBalance, December 31, 2023\n67,783 \nOur goodwill balance continues to be assigned within the Biopharma reportable segment.",
      "char_count": 874,
      "start_char": 500000,
      "end_char": 500875
    },
    {
      "chunk_id": "pfizer_2023_chunk0626",
      "chunk_index": 626,
      "text": "balance continues to be assigned within the Biopharma reportable segment.\nAdditions in 2022 relate to our acquisitions of GBT, Arena and Biohaven, and in 2023 primarily related to our acquisition of Seagen. See Note 2A.\nNote 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans\nThe majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we\nsponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the\nIRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in\nfavor of highly compensated employees with regard to coverage, benefits and contributions.",
      "char_count": 937,
      "start_char": 500800,
      "end_char": 501739
    },
    {
      "chunk_id": "pfizer_2023_chunk0627",
      "chunk_index": 627,
      "text": "mployees with restrictions on discriminating in\nfavor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In\naddition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans.\nA. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)\nThe following summarizes the components of net periodic benefit cost/(credit) and the changes in Other comprehensive income/(loss) for our benefit plans:\nPension Plans\n Postretirement Plans\nU.S.\nInternational\nYear Ended December 31,\n(MILLIONS)\n\nService cost\n\n\n\n\n\n\nInterest cost\n\nExpected return on plan assets\n(778)\n(862)\n(1,052)\n(304)\n(296)\n(327)\n(44)\n(47)\n(39)\nAmortization of prior service cost/(credit)\n\n(2)\n(1)\n(1)\n(119)\n(130)\n(151)\nActuarial (gains)/losses\n(410)\n\n(684)\n\n(11)\n(690)",
      "char_count": 941,
      "start_char": 501600,
      "end_char": 502542
    },
    {
      "chunk_id": "pfizer_2023_chunk0628",
      "chunk_index": 628,
      "text": ")\n(44)\n(47)\n(39)\nAmortization of prior service cost/(credit)\n\n(2)\n(1)\n(1)\n(119)\n(130)\n(151)\nActuarial (gains)/losses\n(410)\n\n(684)\n\n(11)\n(690)\n\n(440)\n(167)\nCurtailments\n(2)\n(11)\n(4)\n(12)\n(18)\n(82)\nSpecial termination benefits\n\nNet periodic benefit cost/(credit) reported in income\n(592)\n(84)\n(1,265)\n\n(45)\n(746)\n(90)\n(578)\n(372)\nCost/(credit) reported in Other comprehensive\nincome/(loss)\n(2)\n(2)\n\n(1)\n\nCost/(credit) recognized in Comprehensive income\n(594)\n(86)\n(1,264)\n\n(46)\n(742)\n\n(410)\n(265)\nReflects: (i) actuarial remeasurement net gains in 2023, primarily due to favorable asset performance in the U.S. and increases in discount rates for the international plans, partially offset by unfavorable\nasset performance for certain international plans, (ii) actuarial remeasurement net gains in 2022, primarily due to increases in discount rates, partially offset by unfavorable plan asset performance, and (iii)",
      "char_count": 912,
      "start_char": 502400,
      "end_char": 503313
    },
    {
      "chunk_id": "pfizer_2023_chunk0629",
      "chunk_index": 629,
      "text": "primarily due to increases in discount rates, partially offset by unfavorable plan asset performance, and (iii)\nactuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates.\n(a)\n(b)\n(b)\n(a)\n(b)\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nThe components of net periodic benefit cost/(credit) other than the service cost component are primarily included in Other (income)/deductions––net (see Note 4).\nB. Actuarial Assumptions\nPension Plans\nPostretirement Plans\nU.S.\nInternational\nYear Ended December 31,\n(PERCENTAGES)\n\nWeighted-average assumptions used to\ndetermine net periodic benefit cost:\nDiscount rate:\nPension plans/postretirement plans\n5.4 %\n2.9 %\n2.6 %\n5.5 %\n2.9 %\n2.5 %\nInterest cost\n3.8 %\n1.5 %\n1.2 %\nService cost\n3.6 %\n1.7 %\n1.4 %\nExpected return on plan assets\n7.5 %\n6.3 %\n6.8 %\n4.5 %\n3.1 %\n3.4 %\n7.5 %\n6.3 %\n6.8 %\nRate of compensation increase\n3.0 %\n2.8 %\n2.9 %\nWeighted-average assumptions used to",
      "char_count": 995,
      "start_char": 503200,
      "end_char": 504197
    },
    {
      "chunk_id": "pfizer_2023_chunk0630",
      "chunk_index": 630,
      "text": "ice cost\n3.6 %\n1.7 %\n1.4 %\nExpected return on plan assets\n7.5 %\n6.3 %\n6.8 %\n4.5 %\n3.1 %\n3.4 %\n7.5 %\n6.3 %\n6.8 %\nRate of compensation increase\n3.0 %\n2.8 %\n2.9 %\nWeighted-average assumptions used to\ndetermine benefit obligations at fiscal year-end:\nDiscount rate\n5.4 %\n5.4 %\n2.9 %\n4.4 %\n3.8 %\n1.6 %\n5.4 %\n5.5 %\n2.9 %\nRate of compensation increase\n3.2 %\n3.0 %\n2.8 %\nThe rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.\nAll of the assumptions are reviewed at least annually. We revise these assumptions based on an annual evaluation of long-term trends as well as market conditions that may have\nan impact on the cost of providing retirement benefits.\nThe weighted-average discount rate for our U.S.",
      "char_count": 808,
      "start_char": 504000,
      "end_char": 504809
    },
    {
      "chunk_id": "pfizer_2023_chunk0631",
      "chunk_index": 631,
      "text": "our U.S. defined benefit plans is set with reference to the prevailing market rate of a portfolio of high-quality fixed income investments, rated\nAA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against\ninvestment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local\nrequirements. Overall, the yield curves used to measure the benefit obligations at year-end 2023 resulted in broadly unchanged discount rates for the U.S. pension and\npostretirement plans and higher discount rates for the international pension plans as compared to the prior year.\nThe following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:\nAs of December 31,",
      "char_count": 912,
      "start_char": 504800,
      "end_char": 505713
    },
    {
      "chunk_id": "pfizer_2023_chunk0632",
      "chunk_index": 632,
      "text": "rovides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:\nAs of December 31,\n\nHealthcare cost trend rate assumed for next year\n7.9 %\n6.4 %\nRate to which the cost trend rate is assumed to decline\n4.0 %\n4.0 %\nYear that the rate reaches the ultimate trend rate\n\n(a)\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nC. Obligations and Funded Status\nThe following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, (ii) the funded status recognized in our\nconsolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:\n \nPension Plans\n Postretirement Plans\n \nU.S.\nInternational\nYear Ended December 31,\n(MILLIONS)\n\nChange in benefit obligation\nBenefit obligation, beginning\n11,420 \n17,150 \n7,497 \n11,657 \n\n\nService cost\n\nInterest cost\n\nEmployee contributions\n\nPlan amendments",
      "char_count": 967,
      "start_char": 505600,
      "end_char": 506568
    },
    {
      "chunk_id": "pfizer_2023_chunk0633",
      "chunk_index": 633,
      "text": "IONS)\n\nChange in benefit obligation\nBenefit obligation, beginning\n11,420 \n17,150 \n7,497 \n11,657 \n\n\nService cost\n\nInterest cost\n\nEmployee contributions\n\nPlan amendments\n\nChanges in actuarial assumptions and other\n(127)\n(4,187)\n(518)\n(2,931)\n\n(593)\nForeign exchange impact\n(1)\n\n(1,065)\n(1)\n(5)\nUpjohn spin-off\n\nAcquisitions/divestitures, net\n\n(50)\nCurtailments and special termination benefits\n\n(10)\n(3)\n(3)\nSettlements\n(675)\n(1,698)\n(56)\n(64)\n(39)\nBenefits paid\n(457)\n(457)\n(334)\n(359)\n(137)\n(101)\nBenefit obligation, ending\n10,756 \n11,420 \n7,292 \n7,497 \n\nChange in plan assets\nFair value of plan assets, beginning\n10,871 \n16,346 \n6,865 \n10,729 \n\nActual return on plan assets\n1,061 \n(3,550)\n(316)\n(2,624)\n\n(106)\nCompany contributions\n\n(15)\n\nEmployee contributions\n\nForeign exchange impact\n\n(1,037)\nUpjohn spin-off\n\nAcquisitions/divestitures, net",
      "char_count": 844,
      "start_char": 506400,
      "end_char": 507245
    },
    {
      "chunk_id": "pfizer_2023_chunk0634",
      "chunk_index": 634,
      "text": "ohn spin-off\n\nAcquisitions/divestitures, net\n\nSettlements\n(675)\n(1,698)\n(56)\n(64)\n(39)\nBenefits paid\n(457)\n(457)\n(334)\n(359)\n(137)\n(101)\nFair value of plan assets, ending\n10,935 \n10,871 \n6,552 \n6,865 \n\nFunded status\n\n(549)\n(740)\n(632)\n\n\nAmounts recorded in our consolidated balance sheet:\nNoncurrent assets\n1,010 \n\n\n\n\n\nCurrent liabilities\n(94)\n(110)\n(28)\n(27)\n(6)\n(6)\nNoncurrent liabilities\n(738)\n(785)\n(1,355)\n(1,388)\n(74)\n(78)\nFunded status\n\n(549)\n(740)\n(632)\n\n\nPre-tax components of cumulative amounts recognized in Accumulated\nother comprehensive loss:\nPrior service (costs)/credits\n(2)\n(4)\n(65)\n(34)\n\n\nInformation related to the funded status of pension plans with an ABO in\nexcess of plan assets :\nFair value of plan assets\n\n\n\nABO\n\n1,834 \n1,600 \nInformation related to the funded status of pension plans with a PBO in\nexcess of plan assets :\nFair value of plan assets\n\n\n1,081 \nPBO",
      "char_count": 886,
      "start_char": 507200,
      "end_char": 508087
    },
    {
      "chunk_id": "pfizer_2023_chunk0635",
      "chunk_index": 635,
      "text": "ion plans with a PBO in\nexcess of plan assets :\nFair value of plan assets\n\n\n1,081 \nPBO\n\n2,347 \n2,496 \nFor the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the\ninternational pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $7.0 billion in 2023 and $7.2 billion in 2022. For the postretirement plans, the benefit\nobligation is the ABO.\nFor 2023, primarily includes actuarial gains resulting from increases in discount rates for the international pension plans. For 2022, primarily includes actuarial gains resulting from increases in discount\nrates, offset by increases in inflation assumptions for the international plan.\nAs a result of a group annuity contract entered into between Pfizer and a third-party insurance company in July 2022, the third party insurance company assumed future benefit obligations and",
      "char_count": 995,
      "start_char": 508000,
      "end_char": 508996
    },
    {
      "chunk_id": "pfizer_2023_chunk0636",
      "chunk_index": 636,
      "text": "lan.\nAs a result of a group annuity contract entered into between Pfizer and a third-party insurance company in July 2022, the third party insurance company assumed future benefit obligations and\nresponsibility for the annuity payments of certain retirees in the Pfizer Consolidated Pension Plan. Benefit obligations of $586 million and plan assets of $588 million were associated with this contract. In\nFebruary 2024, regulatory approval was received for this contract.\nOur main U.S. qualified plan, U.S. postretirement plan and many of our larger funded international plans were overfunded as of December 31, 2023.\n(a)\n(b)\n(c)\n(a)\n(c)\n(d)\n(d)\n(a)\n(b)\n(c)\n(d)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nD. Plan Assets\nThe following provides the components of plan assets:\nAs of December 31, 2023\nAs of December 31, 2022\n \n \nFair Value\nFair Value\n(MILLIONS EXCEPT TARGET\nALLOCATION PERCENTAGE)\nTarget Allocation\nPercentage\nTotal\nLevel 1\nLevel",
      "char_count": 960,
      "start_char": 508800,
      "end_char": 509761
    },
    {
      "chunk_id": "pfizer_2023_chunk0637",
      "chunk_index": 637,
      "text": "ember 31, 2023\nAs of December 31, 2022\n \n \nFair Value\nFair Value\n(MILLIONS EXCEPT TARGET\nALLOCATION PERCENTAGE)\nTarget Allocation\nPercentage\nTotal\nLevel 1\nLevel\n\nLevel 3\nAssets\nMeasured at\nNAV\nTotal\nLevel 1\nLevel\n\nLevel 3\nAssets\nMeasured at\nNAV\nU.S. pension plans\nCash and cash equivalents\n0-10%\n\n\n\n\n\n\nEquity securities:\n10-40%\nGlobal equity securities\n1,537 \n1,537 \n\n1,555 \n1,553 \n\nEquity commingled funds\n\nFixed income securities:\n45-80%\nCorporate debt securities\n3,668 \n\n3,667 \n3,512 \n\n3,507 \nGovernment and agency\nobligations\n1,971 \n1,971 \n1,772 \n1,772 \nFixed income commingled funds\n\nOther investments:\n5-35%\nPartnership investments\n2,449 \n2,449 \n2,152 \n2,152 \nInsurance contracts\n\nOther commingled funds\n\n\n\nTotal\n100 %\n10,935 \n1,585 \n6,410 \n\n2,939 \n10,871 \n1,607 \n6,355 \n\n2,908 \nInternational pension plans\nCash and cash equivalents\n0-10%\n\n\n\n\n\n\nEquity securities:\n10-20%\nEquity commingled funds\n\nFixed income securities:\n45-70%\nCorporate debt securities\n\nGovernment and agency\nobligations",
      "char_count": 994,
      "start_char": 509600,
      "end_char": 510595
    },
    {
      "chunk_id": "pfizer_2023_chunk0638",
      "chunk_index": 638,
      "text": "ension plans\nCash and cash equivalents\n0-10%\n\n\n\n\n\n\nEquity securities:\n10-20%\nEquity commingled funds\n\nFixed income securities:\n45-70%\nCorporate debt securities\n\nGovernment and agency\nobligations\n\nFixed income commingled funds\n1,852 \n\n2,053 \n1,045 \n1,008 \nOther investments:\n15-35%\nPartnership investments\n\nInsurance contracts\n1,151 \n\n1,096 \n1,197 \n\n1,143 \nOther\n1,039 \n\n1,122 \n\nTotal\n100 %\n6,552 \n\n3,295 \n1,340 \n1,796 \n6,865 \n\n3,498 \n1,455 \n1,853 \nU.S. postretirement plans\nCash and cash equivalents\n0-5%\n\n\n\n\n\n\nInsurance contracts\n95-100%\n\nTotal\n100 %\n\n\n\n\n\n\nCertain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit\nreconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.\nGovernment and agency obligations are inclusive of repurchase agreements.",
      "char_count": 935,
      "start_char": 510400,
      "end_char": 511336
    },
    {
      "chunk_id": "pfizer_2023_chunk0639",
      "chunk_index": 639,
      "text": "amounts presented for the total pension benefits plan assets.\nGovernment and agency obligations are inclusive of repurchase agreements.\nMainly includes investments in private equity, private debt and real estate.\nMostly includes investments in hedge funds and real estate.\nReflects postretirement plan assets, which support our U.S. retiree medical plans.\nThe following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:\nInternational Pension Plans\nYear Ended December 31,\n(MILLIONS)\n\nFair value, beginning\n1,455 \n1,677 \nActual return on plan assets:\nAssets held, ending\n(96)\n(177)\nAssets sold during the period\n(3)\n\nPurchases, sales, and settlements, net\n(155)\n(129)\nTransfer into/(out of) Level 3\n\nExchange rate changes\n\n(161)\nFair value, ending\n1,340 \n1,455 \n(a)\n(a)\n(b)\n(c)\n(d)\n(b)\n(c)\n(d)\n(e)\n(a)\n(b)\n(c)\n(d)\n(e)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 944,
      "start_char": 511200,
      "end_char": 512145
    },
    {
      "chunk_id": "pfizer_2023_chunk0640",
      "chunk_index": 640,
      "text": "value, ending\n1,340 \n1,455 \n(a)\n(a)\n(b)\n(c)\n(d)\n(b)\n(c)\n(d)\n(e)\n(a)\n(b)\n(c)\n(d)\n(e)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nThe following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:\n• Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include shortterm investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.\n• Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded.\nLevel 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived\nfrom the quoted prices in active markets of the underlying securities.",
      "char_count": 968,
      "start_char": 512000,
      "end_char": 512970
    },
    {
      "chunk_id": "pfizer_2023_chunk0641",
      "chunk_index": 641,
      "text": "a readily determinable fair value based on quoted prices on an exchange or a published NAV derived\nfrom the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are\ntypically valued using their last available price.\n• Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are\ntraded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2\ninvestments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted\nprices of securities with similar characteristics.",
      "char_count": 903,
      "start_char": 512800,
      "end_char": 513704
    },
    {
      "chunk_id": "pfizer_2023_chunk0642",
      "chunk_index": 642,
      "text": "valued using bid evaluation pricing models or quoted\nprices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or\nbrokers, which use proprietary pricing models that incorporate unobservable inputs.\n• Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded.\nLevel 2 investments may include insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Level 3 investments may\ninclude securities or insurance contracts that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that\nincorporate unobservable inputs.\nEquity securities, Fixed income securities and Other investments may each be combined into commingled funds.",
      "char_count": 984,
      "start_char": 513600,
      "end_char": 514585
    },
    {
      "chunk_id": "pfizer_2023_chunk0643",
      "chunk_index": 643,
      "text": "which use proprietary pricing models that\nincorporate unobservable inputs.\nEquity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund\nbased on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged\nreporting of up to three months.\nCertain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.\nGlobal plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs\nand cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets.",
      "char_count": 955,
      "start_char": 514400,
      "end_char": 515357
    },
    {
      "chunk_id": "pfizer_2023_chunk0644",
      "chunk_index": 644,
      "text": "iodic benefit costs\nand cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are\ndeveloped based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio\nmanagement, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly\nand our asset allocations may vary from the target allocations.\nE. Cash Flows\nIt is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local\ntax laws.\nThe following provides the expected future cash flow information related to our benefit plans:\n \nPension Plans\nPostretirement Plans\n(MILLIONS)\nU.S.\nInternational",
      "char_count": 980,
      "start_char": 515200,
      "end_char": 516181
    },
    {
      "chunk_id": "pfizer_2023_chunk0645",
      "chunk_index": 645,
      "text": "nd local\ntax laws.\nThe following provides the expected future cash flow information related to our benefit plans:\n \nPension Plans\nPostretirement Plans\n(MILLIONS)\nU.S.\nInternational\nExpected employer contributions:\n\n\n\n\nExpected benefit payments:\n\n1,009 \n\n\n2029–2033\n4,004 \n2,073 \n\nThe above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for\nthe calculation of the benefit obligation.\nF. Defined Contribution Plans\nWe have defined contribution plans in the U.S. and other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and\nbonuses to the plans, and we match, in cash, a portion of the employee contributions. We also offer a Retirement Savings Contribution which is an annual non-contributory employer\ncontribution in the U.S. and Puerto Rico.",
      "char_count": 939,
      "start_char": 516000,
      "end_char": 516940
    },
    {
      "chunk_id": "pfizer_2023_chunk0646",
      "chunk_index": 646,
      "text": "ons. We also offer a Retirement Savings Contribution which is an annual non-contributory employer\ncontribution in the U.S. and Puerto Rico. We recorded charges related to the employer contributions to global defined contribution plans of $843 million in 2023, $770 million in 2022\nand $732 million in 2021.\nNote 12. Equity\nA. Common Stock Purchases\nWe purchase our common stock through privately negotiated transactions or in the open market as circumstances and prices warrant. Purchased shares under a share-purchase\nplan, which is authorized by our BOD, are available for general corporate purposes. In December\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\n2018, the BOD authorized a $10 billion share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019.\nIn the first quarter of 2022, we purchased 39 million shares of our common stock at a cost of $2 billion under our publicly announced share-purchase plan.",
      "char_count": 992,
      "start_char": 516800,
      "end_char": 517793
    },
    {
      "chunk_id": "pfizer_2023_chunk0647",
      "chunk_index": 647,
      "text": "reunder in the first quarter of 2019.\nIn the first quarter of 2022, we purchased 39 million shares of our common stock at a cost of $2 billion under our publicly announced share-purchase plan. Our remaining sharepurchase authorization was approximately $3.3 billion as of December 31, 2023.\nB. Employee Stock Ownership Plans\nWe have one ESOP that holds common stock of the Company (Common ESOP). As of December 31, 2023, all shares of common stock held by the Common ESOP have been\nallocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $20 million for 2023 and $19 million for each of 2022\nand 2021.\nNote 13. Share-Based Payments\nOur compensation programs can include share-based payment awards with value that is determined by reference to the fair value of our shares and that provide for the grant of\nshares or options to acquire shares or similar arrangements.",
      "char_count": 932,
      "start_char": 517600,
      "end_char": 518533
    },
    {
      "chunk_id": "pfizer_2023_chunk0648",
      "chunk_index": 648,
      "text": "rence to the fair value of our shares and that provide for the grant of\nshares or options to acquire shares or similar arrangements. Our share-based awards are designed based on competitive survey data or industry peer groups used for\ncompensation purposes, and are allocated between different long-term incentive awards, generally in the form of Total Shareholder Return Units (TSRUs), Restricted Stock Units\n(RSUs), Portfolio Performance Shares (PPSs), Performance Share Awards (PSAs), Breakthrough Performance Awards (BPAs) and stock options, as determined by the\nCompensation Committee of our BOD. No BPAs were granted in 2023 and no BPAs were outstanding as of December 31, 2023.\nThe 2019 Stock Plan (2019 Plan) provides for 400 million shares to be authorized for grants. The number of stock options, TSRUs, RSUs, or performance-based awards that may be\ngranted to any one individual during any 36-month period is limited to 20 million shares.",
      "char_count": 949,
      "start_char": 518400,
      "end_char": 519350
    },
    {
      "chunk_id": "pfizer_2023_chunk0649",
      "chunk_index": 649,
      "text": "tions, TSRUs, RSUs, or performance-based awards that may be\ngranted to any one individual during any 36-month period is limited to 20 million shares. RSUs count as three shares, and PPSs, PSAs and BPAs count as three shares times the\nmaximum potential payout, while TSRUs and stock options count as one share, toward the maximum shares available under the 2019 Plan. As of December 31, 2023, 248 million\nshares were available for award, including 68 million shares that we assumed from the remaining shares available from the stock plan of Seagen which can be issued to legacy\nemployees of Seagen and newly hired employees after the date of acquisition once such shares are registered on Form S-8. Although not required to do so, we have used\nauthorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 922,
      "start_char": 519200,
      "end_char": 520123
    },
    {
      "chunk_id": "pfizer_2023_chunk0650",
      "chunk_index": 650,
      "text": "reasury stock to satisfy our obligations under these programs.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nA summary of the awards and valuation details:\nAwarded to\nTerms\nValuation\nRecognition and Presentation\nTotal Shareholder Return Units (TSRUs)\nSenior and other key\nmanagement and\nselect employees\nEntitle the holder to receive shares of our common stock with a value equal to the\ndifference between the defined settlement price and the grant price, plus the dividend\nequivalents accumulated during the five or seven-year term, if and to the extent the total\nvalue is positive.\nSettlement price is the average closing price of our common stock during the 20 trading\ndays ending on the fifth or seventh anniversary of the grant, as applicable; the grant\nprice is the closing price of our common stock on the date of the grant.\nAutomatically settle on the fifth or seventh anniversary of the grant but vest on the third\nanniversary of the grant.",
      "char_count": 964,
      "start_char": 520000,
      "end_char": 520965
    },
    {
      "chunk_id": "pfizer_2023_chunk0651",
      "chunk_index": 651,
      "text": "of our common stock on the date of the grant.\nAutomatically settle on the fifth or seventh anniversary of the grant but vest on the third\nanniversary of the grant.\nRetirement-eligible holders can convert their TSRUs, when vested, into Profit Units\n(PTUs) with a conversion ratio based on a calculation used to determine the shares at\nTSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and\nthe PTUs and DEUs will be settled in our common stock on the TSRUs’ original\nsettlement date and will be subject to the terms and conditions of the original grant\nincluding forfeiture provisions.\nAs of the grant date\nusing a Monte\nCarlo simulation\nmodel\nAmortized on a straight-line basis over the vesting term into Cost of\nsales, Selling, informational and administrative expenses, and/or\nResearch and development expenses, as appropriate.\nRestricted Stock Units (RSUs)\nSelect employees\nEntitle the holder to receive a specified number of shares of our common stock,",
      "char_count": 986,
      "start_char": 520800,
      "end_char": 521788
    },
    {
      "chunk_id": "pfizer_2023_chunk0652",
      "chunk_index": 652,
      "text": "s, and/or\nResearch and development expenses, as appropriate.\nRestricted Stock Units (RSUs)\nSelect employees\nEntitle the holder to receive a specified number of shares of our common stock,\nincluding dividend equivalents that are reinvested into additional RSUs.\nFor RSUs granted before 2022, generally in all instances, the units vest on the third\nanniversary of the grant date assuming continuous service from the grant date.\nBeginning in 2022, generally in all instances, the units vest and distribute one-third per\nyear for three years on each of the three annual anniversaries from the date of grant\nassuming continuous service from the grant date.\nAs of the grant date\nusing the closing\nprice of our\ncommon stock\nAmortized on a straight-line basis for RSUs granted before 2022, and\non an accelerated attribution approach for RSUs granted beginning\nin 2022, over the vesting term into Cost of sales, Selling,\ninformational and administrative expenses, and/or Research and",
      "char_count": 974,
      "start_char": 521600,
      "end_char": 522575
    },
    {
      "chunk_id": "pfizer_2023_chunk0653",
      "chunk_index": 653,
      "text": "ted attribution approach for RSUs granted beginning\nin 2022, over the vesting term into Cost of sales, Selling,\ninformational and administrative expenses, and/or Research and\ndevelopment expenses, as appropriate.\nPortfolio Performance Shares (PPSs)\nSelect employees\nEntitle the holder to receive, at the end of the performance period, shares of our\ncommon stock, if any, including shares resulting from dividend equivalents earned on\nsuch shares.\nFor PPSs granted, the awards vest on the third anniversary of the grant assuming\ncontinuous service from the grant date and the number of shares paid, if any, depends\non the achievement of predetermined goals related to Pfizer’s long-term product\nportfolio during a three or five-year performance period from the year of the grant date,\nas applicable.\nThe number of shares that may be earned ranges from 0% to 200% of the initial award\ndepending on goal achievement over the performance period.\nAs of the grant date\nusing the intrinsic",
      "char_count": 982,
      "start_char": 522400,
      "end_char": 523383
    },
    {
      "chunk_id": "pfizer_2023_chunk0654",
      "chunk_index": 654,
      "text": "he number of shares that may be earned ranges from 0% to 200% of the initial award\ndepending on goal achievement over the performance period.\nAs of the grant date\nusing the intrinsic\nvalue method using\nthe closing price of\nour common stock\nAmortized on a straight-line basis over the vesting term into Cost of\nsales, Selling, informational and administrative expenses and/or\nResearch and development expenses, as appropriate, and adjusted\neach reporting period, as necessary, to reflect changes in the price of\nour common stock, the number of shares that are probable of being\nearned, and management’s assessment of the probability that the\nspecified performance criteria will be achieved.\nPerformance Share Awards (PSAs)\nSenior and other key\nmanagement\nEntitle the holder to receive, at the end of the performance period, shares of our\ncommon stock (retirees) earned, if any, or an equal value in cash (active colleagues),",
      "char_count": 923,
      "start_char": 523200,
      "end_char": 524124
    },
    {
      "chunk_id": "pfizer_2023_chunk0655",
      "chunk_index": 655,
      "text": "he performance period, shares of our\ncommon stock (retirees) earned, if any, or an equal value in cash (active colleagues),\nincluding dividend equivalents on shares earned, dependent upon the achievement of\npredetermined goals related to two measures:\na. Adjusted net income over three one-year periods; and\nb. TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the\nthree-year performance period.\nPSAs vest on the third anniversary of the grant assuming continuous service from the\ngrant date.\nThe award that may be earned ranges from 0% to 200% of the target award depending\non goal achievement over the performance period.\nAs of the grant date\nusing the intrinsic\nvalue method using\nthe closing price of\nour common stock\nAmortized on a straight-line basis over the vesting term into Cost of\nsales, Selling, informational and administrative expenses, and/or\nResearch and development expenses, as appropriate, and adjusted",
      "char_count": 942,
      "start_char": 524000,
      "end_char": 524943
    },
    {
      "chunk_id": "pfizer_2023_chunk0656",
      "chunk_index": 656,
      "text": "into Cost of\nsales, Selling, informational and administrative expenses, and/or\nResearch and development expenses, as appropriate, and adjusted\neach reporting period, as necessary, to reflect changes in the price of\nour common stock, the number of shares that are probable of being\nearned and management’s assessment of the probability that the\nspecified performance criteria will be achieved.\nBreakthrough Performance Awards (BPAs)\nSelect employees\nidentified as\ninstrumental in\ndelivering medicines\nto patients (excluding\nexecutive officers)\nEntitle the holder to receive, at the end of the performance period, shares of our\ncommon stock, if any, including shares resulting from dividend equivalents earned on\nsuch shares.\nFor BPAs granted, the awards, if earned/vested, are settled at the end of the\nperformance period, but no earlier than the one-year anniversary of the date of grant\nand dependent upon the achievement of the respective predetermined performance",
      "char_count": 966,
      "start_char": 524800,
      "end_char": 525767
    },
    {
      "chunk_id": "pfizer_2023_chunk0657",
      "chunk_index": 657,
      "text": "e\nperformance period, but no earlier than the one-year anniversary of the date of grant\nand dependent upon the achievement of the respective predetermined performance\ngoals related to advancing Pfizer’s product pipeline during the performance period.\nThe number of shares that may be earned ranges from 0% to 600% of the target award\ndepending on the level and timing of goal achievement over the performance period.\nAs of the grant date\nusing the intrinsic\nvalue method using\nthe closing price of\nour common stock\nAmortized on a straight-line basis over the probable vesting term into\nCost of sales, Selling, informational and administrative expenses,\nand/or Research and development expenses, as appropriate, and\nadjusted each reporting period, as necessary, to reflect changes in\nthe price of our common stock, the number of shares that are\nprobable of being earned and management’s assessment of the\nprobability that the specified performance criteria will be achieved",
      "char_count": 972,
      "start_char": 525600,
      "end_char": 526573
    },
    {
      "chunk_id": "pfizer_2023_chunk0658",
      "chunk_index": 658,
      "text": "common stock, the number of shares that are\nprobable of being earned and management’s assessment of the\nprobability that the specified performance criteria will be achieved\nand/or management’s assessment of the probable vesting term.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nAwarded to\nTerms\nValuation\nRecognition and Presentation\nStock Options\nSelect employees\nEntitle the holder to purchase a specified number of shares of our common stock at a\nprice per share equal to the closing market price of our common stock on the date of\ngrant, for a period of time when vested.\nSince 2016, only a limited set of non-U.S. employees received stock option grants. No\nstock options were awarded to senior and other key management in any period\npresented.\nStock options vest on the third anniversary of the grant assuming continuous service\nfrom the grant date and have a contractual term of 10 years.\nAs of the grant date\nusing the BlackScholes-Merton\noption-pricing\nmodel",
      "char_count": 983,
      "start_char": 526400,
      "end_char": 527384
    },
    {
      "chunk_id": "pfizer_2023_chunk0659",
      "chunk_index": 659,
      "text": "niversary of the grant assuming continuous service\nfrom the grant date and have a contractual term of 10 years.\nAs of the grant date\nusing the BlackScholes-Merton\noption-pricing\nmodel\nAmortized on a straight-line basis over the vesting term into Cost of\nsales, Selling, informational and administrative expenses, and/or\nResearch and development expenses, as appropriate.\nThe following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:\n(MILLIONS, EXCEPT FAIR VALUE OF\nSHARES VESTED PER TSRU AND\nSTOCK OPTION)\nTSRUs\nRSUs\nPPSs\nPSAs\nStock Options\nYear Ended December 31,\n\nTotal fair value of shares vested\n$10.71\n$11.72\n$7.26\n$505\n$345\n$304\n$116\n$145\n$181\n$58\n$57\n$33\n$7.88\n$9.44\n$4.86\nTotal intrinsic value of options exercised\nor share units converted\n$755\n$1,131\n$594\n$250\n$280\n$228\n$102\n$247\n$584\nCash received upon exercise\n$181\n$260\n$795\nTax benefits realized from exercise\n$20\n$46\n$106\nCompensation cost\nrecognized/(reduced), pre-tax\n$244\n$255\n$259\n$437\n$402\n$281\n$(138)",
      "char_count": 999,
      "start_char": 527200,
      "end_char": 528200
    },
    {
      "chunk_id": "pfizer_2023_chunk0660",
      "chunk_index": 660,
      "text": "80\n$228\n$102\n$247\n$584\nCash received upon exercise\n$181\n$260\n$795\nTax benefits realized from exercise\n$20\n$46\n$106\nCompensation cost\nrecognized/(reduced), pre-tax\n$244\n$255\n$259\n$437\n$402\n$281\n$(138)\n$144\n$535\n$(5)\n$73\n$76\nTotal compensation cost related to\nnonvested awards not yet recognized,\npre-tax\n$192\n$179\n$187\n$212\n$266\n$271\n$81\n$135\n$175\n$22\n$38\n$54\nWeighted-average period over which\ncost is expected to be recognized\n(years)\n1.7\n1.7\n1.6\n1.8\n1.7\n1.8\n1.8\n1.7\n1.8\n1.8\n1.8\n1.8\n1.7\n1.7\n1.6\nWeighted-average GDFV per TSRUs and stock options.\nTotal share-based payment expense was $525 million, $872 million and $1.2 billion in 2023, 2022 and 2021, respectively. Tax benefit for share-based compensation expense was\n$93 million, $160 million and $227 million in 2023, 2022 and 2021, respectively.\nThe table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all",
      "char_count": 984,
      "start_char": 528000,
      "end_char": 528985
    },
    {
      "chunk_id": "pfizer_2023_chunk0661",
      "chunk_index": 661,
      "text": "The table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all\nyears presented and is recorded in Restructuring charges and certain acquisition-related costs (see Note 3). Amounts capitalized as part of inventory cost were not significant for any\nperiod presented.\nSummary of the weighted-average assumptions used in the valuation of TSRUs and stock options:\nTSRUs\nStock Options\nYear Ended December 31,\n\nExpected dividend yield (based on a constant dividend yield during the\nexpected term)\n3.80 %\n3.42 %\n4.51 %\n3.80 %\n3.42 %\n4.51 %\nRisk-free interest rate (based on interpolated yield on U.S. Treasury zerocoupon issues)\n4.08 %\n1.87 %\n0.93 %\n4.03 %\n1.93 %\n1.27 %\nExpected stock price volatility (based on implied volatility, after\nconsideration of historical volatility)\n23.23 %\n29.20 %\n26.53 %\n23.23 %\n29.21 %\n26.54 %",
      "char_count": 939,
      "start_char": 528800,
      "end_char": 529741
    },
    {
      "chunk_id": "pfizer_2023_chunk0662",
      "chunk_index": 662,
      "text": "price volatility (based on implied volatility, after\nconsideration of historical volatility)\n23.23 %\n29.20 %\n26.53 %\n23.23 %\n29.21 %\n26.54 %\nTSRUs contractual/stock options expected term, years (based on\nhistorical exercise and post-vesting termination patterns for stock options)\n5.15\n5.17\n5.15\n6.50\n6.50\n6.75\nSummary of all TSRU, RSU, PPS and PSA activity during 2023 (with the shares granted representing the maximum award that could be achieved for PPSs and PSAs):\nTSRUs\nRSUs\nPPSs\nPSAs\nTSRUs \nPer TSRU, Weighted\nAverage\nShares \n Weighted Avg.\nGDFV per share\nShares \nWeighted Avg.\nIntrinsic Value\nper share\nShares \nWeighted Avg.\nIntrinsic Value\nper share\n(Thousands)\nGDFV\nGrant Price\n(Thousands)\n(Thousands)\n(Thousands)\nNonvested, December 31, 2022\n101,693\n7.58 \n35.26 \n27,826\n38.26 \n22,322\n51.24 \n5,018\n51.24 \nGranted\n26,631\n10.71 \n42.29 \n10,007\n42.11 \n8,751\n42.30 \n1,623\n42.30 \nVested\n(48,277)\n6.08 \n31.38 \n(12,330)\n37.15 \n(7,736)\n40.78 \n(1,428)\n40.74 \nReinvested dividend equivalents\n1,195",
      "char_count": 995,
      "start_char": 529600,
      "end_char": 530597
    },
    {
      "chunk_id": "pfizer_2023_chunk0663",
      "chunk_index": 663,
      "text": "5,018\n51.24 \nGranted\n26,631\n10.71 \n42.29 \n10,007\n42.11 \n8,751\n42.30 \n1,623\n42.30 \nVested\n(48,277)\n6.08 \n31.38 \n(12,330)\n37.15 \n(7,736)\n40.78 \n(1,428)\n40.74 \nReinvested dividend equivalents\n1,195 \n36.07 \nForfeited\n(2,374)\n9.99 \n40.86 \n(855)\n41.25 \n(1,112)\n36.09 \n(479)\n38.47 \nNonvested, December 31, 2023\n77,673\n9.67 \n39.92 \n25,844\n40.08 \n22,225\n28.79 \n4,734\n28.79 \nVested and non-vested shares outstanding, but not paid as of December 31, 2023 were 35.8 million.\n(a)\n(a)\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nSummary of TSRU and PTU information as of December 31, 2023\nTSRUs\n(Thousands)\nPTUs\n(Thousands)\nWeighted-Average\nGrant Price\nPer TSRU\nWeighted-Average\nRemaining\nContractual Term\n(Years)\nAggregate Intrinsic\nValue (Millions)\nTSRUs Outstanding\n163,572 \n36.83 \n2.0\n\nTSRUs Vested\n85,899 \n34.05 \n0.8\n\nTSRUs Expected to vest\n75,276 \n39.82 \n3.2\nOutstanding PTUs converted from TSRUs exercised\n1,060 \n0.6",
      "char_count": 934,
      "start_char": 530400,
      "end_char": 531336
    },
    {
      "chunk_id": "pfizer_2023_chunk0664",
      "chunk_index": 664,
      "text": "TSRUs Vested\n85,899 \n34.05 \n0.8\n\nTSRUs Expected to vest\n75,276 \n39.82 \n3.2\nOutstanding PTUs converted from TSRUs exercised\n1,060 \n0.6\n\nIn 2023, we settled 38,957,175 TSRUs with a weighted-average grant price of $29.80 per unit.\nIn 2023, 1,827,019 TSRUs with a weighted-average grant price of $31.73 per unit were converted into 679,742 PTUs.\nMarket price of our underlying common stock less exercise price.\nThe number of TSRUs expected to vest takes into account an estimate of expected forfeitures.\nSummary of all stock option activity during 2023:\nShares\n(Thousands)\nWeighted-Average\nExercise Price\nPer Share\nWeighted-Average\nRemaining Contractual\nTerm\n(Years)\nAggregate\nIntrinsic Value\n(Millions)\nOutstanding, December 31, 2022\n35,280 \n31.47 \nGranted\n\n42.30 \nExercised\n(6,709)\n27.47 \nForfeited\n(36)\n39.37 \nExpired\n(718)\n31.25 \n \n \nOutstanding, December 31, 2023\n28,452 \n32.66 \n1.7\nVested and expected to vest, December 31, 2023\n28,385 \n32.63 \n1.7\nExercisable, December 31, 2023\n26,667 \n32.19",
      "char_count": 994,
      "start_char": 531200,
      "end_char": 532198
    },
    {
      "chunk_id": "pfizer_2023_chunk0665",
      "chunk_index": 665,
      "text": "36)\n39.37 \nExpired\n(718)\n31.25 \n \n \nOutstanding, December 31, 2023\n28,452 \n32.66 \n1.7\nVested and expected to vest, December 31, 2023\n28,385 \n32.63 \n1.7\nExercisable, December 31, 2023\n26,667 \n32.19 \n1.3\nMarket price of our underlying common stock less exercise price.\nThe number of options expected to vest takes into account an estimate of expected forfeitures.\nNote 14. Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders\nThe following presents the detailed calculation of EPS:\n \nYear Ended December 31,\n(IN MILLIONS)\n\nEPS Numerator\n \n \nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n2,134 \n31,366 \n22,414 \nDiscontinued operations––net of tax\n(15)\n\n(434)\nNet income attributable to Pfizer Inc. common shareholders\n2,119 \n31,372 \n21,979 \nEPS Denominator\n \n \nWeighted-average number of common shares outstanding––Basic\n5,643 \n5,608 \n5,601 \nCommon-share equivalents",
      "char_count": 920,
      "start_char": 532000,
      "end_char": 532921
    },
    {
      "chunk_id": "pfizer_2023_chunk0666",
      "chunk_index": 666,
      "text": "enominator\n \n \nWeighted-average number of common shares outstanding––Basic\n5,643 \n5,608 \n5,601 \nCommon-share equivalents\n\nWeighted-average number of common shares outstanding––Diluted\n5,709 \n5,733 \n5,708 \nAnti-dilutive common stock equivalents\n\nThese common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an antidilutive effect.\nNote 15. Leases\nWe lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend\nleases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may\nnegotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised.",
      "char_count": 975,
      "start_char": 532800,
      "end_char": 533776
    },
    {
      "chunk_id": "pfizer_2023_chunk0667",
      "chunk_index": 667,
      "text": "tion of lease terms. We may\nnegotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are\ngenerally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and\nother non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments\namounted to $444 million in 2023, $536 million in 2022 and $381 million in 2021. We elected the practical expedient to not separate non-lease components from lease components\nin calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.\nWe determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date.",
      "char_count": 980,
      "start_char": 533600,
      "end_char": 534581
    },
    {
      "chunk_id": "pfizer_2023_chunk0668",
      "chunk_index": 668,
      "text": "all underlying asset classes.\nWe determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our\nright to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and\nliabilities are recognized at commencement date\n(a), (b)\n(c)\n(d)\n(a)\n(b)\n(c)\n(d)\n(a)\n(b)\n(a)\n(b)\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nbased on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on\nthe information available at commencement date in determining the present value of future payments.\nFor operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:\nAs of December 31,\n(MILLIONS)\nBalance Sheet Classification",
      "char_count": 982,
      "start_char": 534400,
      "end_char": 535383
    },
    {
      "chunk_id": "pfizer_2023_chunk0669",
      "chunk_index": 669,
      "text": "value of future payments.\nFor operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:\nAs of December 31,\n(MILLIONS)\nBalance Sheet Classification\n\nROU assets\nOther noncurrent assets\n2,924 \n3,002 \nLease liabilities (short-term)\nOther current liabilities\n\nLease liabilities (long-term)\nOther noncurrent liabilities\n2,626 \n2,597 \nComponents of total lease cost includes:\nYear Ended December 31,\n(MILLIONS)\n\nOperating lease cost\n\n\n\nVariable lease cost\n\nSublease income\n(24)\n(32)\n(41)\nTotal lease cost\n1,283 \n1,218 \n\nOther supplemental information follows:\nAs of December 31,\n(MILLIONS)\n\nOperating leases\nWeighted-Average Remaining Contractual Lease Term (Years)\n10.8\n\nWeighted-Average Discount Rate\n3.8 %\n3.0 %\nYear Ended December 31,\n(MILLIONS)\n\nCash paid for amounts included in the measurement of lease liabilities:\nOperating cash flows from operating leases\n\n\n\n(Gains)/losses on sale and leaseback transactions, net\n(49)",
      "char_count": 956,
      "start_char": 535200,
      "end_char": 536158
    },
    {
      "chunk_id": "pfizer_2023_chunk0670",
      "chunk_index": 670,
      "text": "s included in the measurement of lease liabilities:\nOperating cash flows from operating leases\n\n\n\n(Gains)/losses on sale and leaseback transactions, net\n(49)\n\nThe following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance\nsheet as of December 31, 2023:\n(MILLIONS)\nPeriod\nOperating Lease Liabilities\nNext one year\n\n1-2 years\n\n2-3 years\n\n3-4 years\n\n4-5 years\n\nThereafter\n1,743 \nTotal undiscounted lease payments\n3,824 \nLess: Imputed interest\n\nPresent value of minimum lease payments\n3,153 \nLess: Current portion\n\nNoncurrent portion\n2,626 \nReflects lease payments due within 12 months subsequent to the balance sheet date.\nNote 16. Contingencies and Certain Commitments\nWe and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and\nindemnifications.",
      "char_count": 975,
      "start_char": 536000,
      "end_char": 536976
    },
    {
      "chunk_id": "pfizer_2023_chunk0671",
      "chunk_index": 671,
      "text": "n of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and\nindemnifications. The following outlines our legal contingencies, guarantees and indemnifications. For a discussion of our tax contingencies, see Note 5D.\nA. Legal Proceedings\nOur legal contingencies include, but are not limited to, the following:\n• Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in\nloss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these\nactions.\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 847,
      "start_char": 536800,
      "end_char": 537648
    },
    {
      "chunk_id": "pfizer_2023_chunk0672",
      "chunk_index": 672,
      "text": "0-K\n\nNotes to Consolidated Financial Statements\n\n• Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and\nbreach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific\nevidence and findings, actual, provable injury and other matters.\n• Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing\nclaims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.\n• Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S.",
      "char_count": 941,
      "start_char": 537600,
      "end_char": 538542
    },
    {
      "chunk_id": "pfizer_2023_chunk0673",
      "chunk_index": 673,
      "text": "which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in\nother jurisdictions.\nCertain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or\ncriminal charges.\nWe believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not\nbelieve that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations\nregarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or\npaid.\nWe have accrued for losses that are both probable and reasonably estimable.",
      "char_count": 993,
      "start_char": 538400,
      "end_char": 539395
    },
    {
      "chunk_id": "pfizer_2023_chunk0674",
      "chunk_index": 674,
      "text": "erse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or\npaid.\nWe have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore,\ndetermining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of\namounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have\nbeen deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to\nchange those estimates and assumptions.",
      "char_count": 844,
      "start_char": 539200,
      "end_char": 540045
    },
    {
      "chunk_id": "pfizer_2023_chunk0675",
      "chunk_index": 675,
      "text": "s to\nchange those estimates and assumptions.\nAmounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates\nand assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual\ngovernmental monetary sanctions.\nThe principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and\nqualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of\nthe strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the",
      "char_count": 977,
      "start_char": 540000,
      "end_char": 540978
    },
    {
      "chunk_id": "pfizer_2023_chunk0676",
      "chunk_index": 676,
      "text": "ngth of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the\njurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies\nhave had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s\njudgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of\npublic interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product\nprotected by the patent(s) at issue.",
      "char_count": 943,
      "start_char": 540800,
      "end_char": 541744
    },
    {
      "chunk_id": "pfizer_2023_chunk0677",
      "chunk_index": 677,
      "text": "in which we are the plaintiff, we consider, among other things, the financial significance of the product\nprotected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts\naccrued is remote.\nA1. Legal Proceedings––Patent Litigation\nWe are involved in suits relating to our patents (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights), including but not limited to, those\ndiscussed below. We face claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or copromotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer.",
      "char_count": 865,
      "start_char": 541600,
      "end_char": 542467
    },
    {
      "chunk_id": "pfizer_2023_chunk0678",
      "chunk_index": 678,
      "text": "and/or do not cover the product of the generic drug manufacturer. Also,\ncounterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute\nunfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our\ncollaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights\nin non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In May 2023, the\nCourt of Appeal dismissed BMS’s appeal and in October 2023, the Supreme Court refused BMS’s permission to appeal. Additional challenges are pending in other jurisdictions.",
      "char_count": 988,
      "start_char": 542400,
      "end_char": 543390
    },
    {
      "chunk_id": "pfizer_2023_chunk0679",
      "chunk_index": 679,
      "text": "In May 2023, the\nCourt of Appeal dismissed BMS’s appeal and in October 2023, the Supreme Court refused BMS’s permission to appeal. Additional challenges are pending in other jurisdictions. Also,\nin July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty\ninfringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or\nBioNTech in other jurisdictions in the future. Adverse decisions in these matters could have a material adverse effect on our results of operations. We are also party to patent\ndamages suits in various jurisdictions pursuant to which generic drug manufacturers, payors, governments or other parties are seeking damages from us for allegedly causing delay\nof generic entry.",
      "char_count": 921,
      "start_char": 543200,
      "end_char": 544123
    },
    {
      "chunk_id": "pfizer_2023_chunk0680",
      "chunk_index": 680,
      "text": "ufacturers, payors, governments or other parties are seeking damages from us for allegedly causing delay\nof generic entry.\nWe also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark\nOffice, the European Patent Office, or other foreign counterparts, as well as court proceedings relating to our intellectual property or the intellectual property rights of others,\nincluding challenges to such rights initiated by us. Also, if one of our patents (or one of our collaboration/licensing partner’s patents) is found to be invalid by such proceedings,\ngeneric or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our\npneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S.",
      "char_count": 954,
      "start_char": 544000,
      "end_char": 544955
    },
    {
      "chunk_id": "pfizer_2023_chunk0681",
      "chunk_index": 681,
      "text": "le, several of the patents in our\npneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office, as well as outside the U.S.\nThe invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than\nanticipated. In the event that any of the patents are found valid and infringed, a competitor’s vaccine, if approved, might be prohibited from entering the market or a competitor might\nbe required to pay us a royalty.\nWe are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our\ncommercial or other activities. If one of our marketed products (or a product of our collaboration/\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 949,
      "start_char": 544800,
      "end_char": 545750
    },
    {
      "chunk_id": "pfizer_2023_chunk0682",
      "chunk_index": 682,
      "text": "or other activities. If one of our marketed products (or a product of our collaboration/\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nlicensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or\nroyalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to\nhave willfully infringed valid patent rights of a third party.\nActions In Which We Are The Plaintiff\nXeljanz (tofacitinib)\nBeginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications (ANDAs) with the FDA\nseeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms.",
      "char_count": 973,
      "start_char": 545600,
      "end_char": 546575
    },
    {
      "chunk_id": "pfizer_2023_chunk0683",
      "chunk_index": 683,
      "text": "seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To\ndate, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as\ndescribed below.\nIn October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering\nextended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release\ntablets. In November 2022, we filed an additional patent-infringement action against Sinotherapeutics relating to its challenge of our extended release formulation and method of",
      "char_count": 905,
      "start_char": 546400,
      "end_char": 547307
    },
    {
      "chunk_id": "pfizer_2023_chunk0684",
      "chunk_index": 684,
      "text": "ction against Sinotherapeutics relating to its challenge of our extended release formulation and method of\ntreatment patents in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets.\nIn June 2023, we brought a patent-infringement action against Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. (collectively Aurobindo) asserting the infringement and\nvalidity of our basic compound patent, in connection with Aurobindo’s ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In December\n2023, we reached a settlement agreement with Aurobindo on terms not material to the Company.\nIbrance (palbociclib)\nBeginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets.",
      "char_count": 864,
      "start_char": 547200,
      "end_char": 548065
    },
    {
      "chunk_id": "pfizer_2023_chunk0685",
      "chunk_index": 685,
      "text": "seeking approval to market generic versions of Ibrance tablets. We have\nsettled with one of these generic companies on terms not material to us, and have dismissed the patent infringement actions against all other generic companies except for the\naction against Synthon Pharmaceuticals Inc. and its affiliated entities (collectively, Synthon), in which we have asserted the infringement and validity of the composition of matter\npatent, expiring in 2027. In December 2023, we reached a settlement agreement with Synthon on terms not material to the Company.\nMektovi (binimetinib)\nBeginning in August 2022, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies\nassert the invalidity and non-infringement of two method of use patents expiring in 2030, a method of use patent expiring in 2031, two method of use patents expiring in 2033, and a\nproduct by process patent expiring in 2033.",
      "char_count": 977,
      "start_char": 548000,
      "end_char": 548979
    },
    {
      "chunk_id": "pfizer_2023_chunk0686",
      "chunk_index": 686,
      "text": "two method of use patents expiring in 2030, a method of use patent expiring in 2031, two method of use patents expiring in 2033, and a\nproduct by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against the generic filers in the U.S. District Court for the District\nof Delaware, asserting the validity and infringement of all six patents.\nIn August 2022 we received notice from Teva Pharmaceuticals, Inc. (Teva) that it had filed an ANDA seeking approval to market a generic version of Mektovi. Teva asserts the\ninvalidity and non-infringement of two method of use patents expiring in 2033 and a product by process patent expiring in 2033. In June 2023, we brought a patent infringement\naction against Teva in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the three patents.\nVyndaqel-Vyndamax(tafamidis/tafamidis meglumine)",
      "char_count": 926,
      "start_char": 548800,
      "end_char": 549727
    },
    {
      "chunk_id": "pfizer_2023_chunk0687",
      "chunk_index": 687,
      "text": "ct of Delaware, asserting the validity and infringement of the three patents.\nVyndaqel-Vyndamax(tafamidis/tafamidis meglumine)\nBeginning in June 2023, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of tafamidis capsules (61 mg) or\ntafamidis meglumine capsules (20 mg), challenging some or all of the patents listed in the FDA’s Orange Book for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine).\nScripps Research Institute (Scripps) owns the composition of matter patent and the method of treatment patents covering the products, and Pfizer is the exclusive licensee. Pfizer\nseparately owns the crystalline form patent. Beginning in August 2023, we and Scripps brought patent infringement actions against the generic filers in the U.S. District Court for the\nDistrict of Delaware, asserting the validity and infringement of the patents in suit.",
      "char_count": 923,
      "start_char": 549600,
      "end_char": 550524
    },
    {
      "chunk_id": "pfizer_2023_chunk0688",
      "chunk_index": 688,
      "text": "rs in the U.S. District Court for the\nDistrict of Delaware, asserting the validity and infringement of the patents in suit. Pfizer is the sole plaintiff in actions that assert only the infringement and validity of the crystalline\nform patent.\nActions in Which We are the Defendant\nComirnaty\nIn March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia & Upjohn Company\nLLC, our wholly owned subsidiary, alleging that Comirnaty infringes a U.S. patent issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a\nsecond complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia & Upjohn Company LLC, BioNTech and BioNTech Manufacturing GmbH, alleging\nthat Comirnaty infringes a U.S. patent issued in July 2022, and seeking unspecified monetary damages. In May 2023, Alnylam filed a separate complaint in the U.S.",
      "char_count": 978,
      "start_char": 550400,
      "end_char": 551379
    },
    {
      "chunk_id": "pfizer_2023_chunk0689",
      "chunk_index": 689,
      "text": "g GmbH, alleging\nthat Comirnaty infringes a U.S. patent issued in July 2022, and seeking unspecified monetary damages. In May 2023, Alnylam filed a separate complaint in the U.S. District Court for\nthe District of Delaware against Pfizer and Pharmacia & Upjohn Company LLC alleging that Comirnaty infringes four additional U.S. patents issued on various dates in 2023 and\nseeking unspecified monetary damages.\nIn August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District\nCourt for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement\noccurring after March 7, 2022.\nIn August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies,",
      "char_count": 963,
      "start_char": 551200,
      "end_char": 552164
    },
    {
      "chunk_id": "pfizer_2023_chunk0690",
      "chunk_index": 690,
      "text": "022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies,\nalleging that Comirnaty infringes two European patents. The German infringement action was stayed in December 2023 pending further action from the European Patent Office on\nthe patents at issue. In September 2022, ModernaTX filed patent infringement actions in the U.K. and in the Netherlands against Pfizer and certain subsidiary companies, as well as\nBioNTech and certain subsidiary companies, on the same two European patents. In its complaints, ModernaTX stated that it is seeking damages for alleged infringement occurring\nafter March 7, 2022. In the U.K., Pfizer and BioNTech brought an action against ModernaTX seeking to revoke these two European patents, which was consolidated with the\nSeptember 2022 action filed by ModernaTX. In November 2023, one of the European patents was revoked by the European Patent Office.",
      "char_count": 990,
      "start_char": 552000,
      "end_char": 552991
    },
    {
      "chunk_id": "pfizer_2023_chunk0691",
      "chunk_index": 691,
      "text": "these two European patents, which was consolidated with the\nSeptember 2022 action filed by ModernaTX. In November 2023, one of the European patents was revoked by the European Patent Office. In December 2023, the other European\npatent was declared invalid by a court in the\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nNetherlands (the invalidity decision is limited to the Netherlands). ModernaTX has also filed additional patent infringement actions against Pfizer and BioNTech in certain other exU.S. jurisdictions.\nIn April 2023, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against\nPfizer and BioNTech alleging that Comirnaty and its manufacture infringe five U.S. patents, and seeking unspecified monetary damages.\nPaxlovid\nIn June 2022, Enanta Pharmaceuticals, Inc. filed a complaint in the U.S.",
      "char_count": 927,
      "start_char": 552800,
      "end_char": 553728
    },
    {
      "chunk_id": "pfizer_2023_chunk0692",
      "chunk_index": 692,
      "text": "ts, and seeking unspecified monetary damages.\nPaxlovid\nIn June 2022, Enanta Pharmaceuticals, Inc. filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid,\nnirmatrelvir, infringes a U.S. patent issued in June 2022, and seeking unspecified monetary damages.\nAbrysvo\nIn August 2023, GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC (collectively, GSK Group) filed a complaint in the U.S. District Court for the District of Delaware against\nPfizer alleging that the active ingredient in Abrysvo infringes four U.S. patents. The complaint seeks unspecified monetary damages and a permanent injunction against sales of\nAbrysvo for use in adults over 60 years of age. In November 2023, GSK Group amended its complaint to assert infringement of two additional patents. In addition, we have\nchallenged certain of GSK’s RSV vaccine patents in certain ex-U.S.",
      "char_count": 938,
      "start_char": 553600,
      "end_char": 554539
    },
    {
      "chunk_id": "pfizer_2023_chunk0693",
      "chunk_index": 693,
      "text": "to assert infringement of two additional patents. In addition, we have\nchallenged certain of GSK’s RSV vaccine patents in certain ex-U.S. jurisdictions, including the U.K., the Netherlands and Belgium, and GSK has asserted that Abrysvo infringes\nthese patents.\nMatters Involving Pfizer and its Collaboration/Licensing Partners\nComirnaty\nIn July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts\nseeking a judgment of non-infringement for three U.S. patents relating to Comirnaty. In May 2023, the case was transferred to the U.S. District Court for the Eastern District of\nVirginia. Also in May 2023, CureVac asserted that Comirnaty infringes the three patents that were the subject of our declaratory judgment complaint, and in May and July 2023,\nCureVac asserted that Comirnaty infringes a number of additional U.S.",
      "char_count": 938,
      "start_char": 554400,
      "end_char": 555340
    },
    {
      "chunk_id": "pfizer_2023_chunk0694",
      "chunk_index": 694,
      "text": "ject of our declaratory judgment complaint, and in May and July 2023,\nCureVac asserted that Comirnaty infringes a number of additional U.S. patents.\nIn the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims.\nA2. Legal Proceedings––Product Litigation\nWe are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages\nand other relief on various grounds for alleged personal injury and economic loss.\nAsbestos\nBetween 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety\nclothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and\nother claims.",
      "char_count": 986,
      "start_char": 555200,
      "end_char": 556187
    },
    {
      "chunk_id": "pfizer_2023_chunk0695",
      "chunk_index": 695,
      "text": "g. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and\nother claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to\nexplore various means of resolving, these claims.\nNumerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged\npersonal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.\nThere also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by\nPfizer or its subsidiaries.\nEffexor",
      "char_count": 966,
      "start_char": 556000,
      "end_char": 556967
    },
    {
      "chunk_id": "pfizer_2023_chunk0696",
      "chunk_index": 696,
      "text": "ding in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by\nPfizer or its subsidiaries.\nEffexor\nBeginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other\ndefendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons\nin the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants\nfrom June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S.",
      "char_count": 898,
      "start_char": 556800,
      "end_char": 557699
    },
    {
      "chunk_id": "pfizer_2023_chunk0697",
      "chunk_index": 697,
      "text": "The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S.\nand its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth\nfraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement\nagreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative\nclass in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have\nbeen consolidated in the U.S.",
      "char_count": 865,
      "start_char": 557600,
      "end_char": 558467
    },
    {
      "chunk_id": "pfizer_2023_chunk0698",
      "chunk_index": 698,
      "text": "14, 2008. All of these actions have\nbeen consolidated in the U.S. District Court for the District of New Jersey.\nIn 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff\nclaims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payor plaintiffs, which\nplaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the\nclaims to the District Court.\nLipitor\nBeginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions,\nRanbaxy Laboratories Limited (Ranbaxy) and certain Ranbaxy affiliates.",
      "char_count": 964,
      "start_char": 558400,
      "end_char": 559366
    },
    {
      "chunk_id": "pfizer_2023_chunk0699",
      "chunk_index": 699,
      "text": "courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions,\nRanbaxy Laboratories Limited (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes\nconsisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any\nof the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in\nviolation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 827,
      "start_char": 559200,
      "end_char": 560029
    },
    {
      "chunk_id": "pfizer_2023_chunk0700",
      "chunk_index": 700,
      "text": "lidated Financial Statements\n\n2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in\nvarious markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among\nother things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition,\nindividual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar\nto the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a MDL in the\nU.S.",
      "char_count": 956,
      "start_char": 560000,
      "end_char": 560957
    },
    {
      "chunk_id": "pfizer_2023_chunk0701",
      "chunk_index": 701,
      "text": "he relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a MDL in the\nU.S. District Court for the District of New Jersey.\nIn September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with\nprejudice the claims of all other MDL plaintiffs. All plaintiffs appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit.\nIn addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In\n2017, the Court of Appeals reversed the District Court’s decisions and remanded the claims to the District Court.",
      "char_count": 863,
      "start_char": 560800,
      "end_char": 561664
    },
    {
      "chunk_id": "pfizer_2023_chunk0702",
      "chunk_index": 702,
      "text": "ourt’s decisions and remanded the claims to the District Court.\nAlso, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the\nState of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.\nEpiPen (Direct Purchaser)\nIn February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its current and former affiliates King and Meridian, and various Mylan entities,\non behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that",
      "char_count": 821,
      "start_char": 561600,
      "end_char": 562422
    },
    {
      "chunk_id": "pfizer_2023_chunk0703",
      "chunk_index": 703,
      "text": "generally allege that\nPfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen\nin violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants’ motion to\ndismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint. In August 2022, the District Court granted Pfizer’s motion to\ndismiss the complaint, and plaintiffs appealed to the U.S. Court of Appeals for the Tenth Circuit. In October 2023, the parties reached an agreement to settle the litigation on terms\nnot material to Pfizer. The settlement is subject to court approval.\nDocetaxel\n• Personal Injury Actions",
      "char_count": 848,
      "start_char": 562400,
      "end_char": 563249
    },
    {
      "chunk_id": "pfizer_2023_chunk0704",
      "chunk_index": 704,
      "text": "rt approval.\nDocetaxel\n• Personal Injury Actions\nA number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair\nloss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive\ndamages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.\nIn 2016, the federal cases were transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases\nwere transferred for coordinated pre-trial proceedings to a MDL in the U.S.",
      "char_count": 816,
      "start_char": 563200,
      "end_char": 564017
    },
    {
      "chunk_id": "pfizer_2023_chunk0705",
      "chunk_index": 705,
      "text": "MDL in the U.S. District Court for the Eastern District of Louisiana.\n• Mississippi Attorney General Government Action\nIn 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including\nPfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The\naction seeks civil penalties and injunctive relief.\nZantac\nA number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of\ndeveloping cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or\nsold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product.",
      "char_count": 991,
      "start_char": 564000,
      "end_char": 564993
    },
    {
      "chunk_id": "pfizer_2023_chunk0706",
      "chunk_index": 706,
      "text": "t majority of these cases also name other defendants that have historically manufactured and/or\nsold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to\nJohnson & Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson & Johnson in connection with the sale. Plaintiffs in these cases seek compensatory\nand punitive damages.\nIn February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for the Southern District of Florida (the Federal MDL\nCourt). Plaintiffs in the MDL filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among",
      "char_count": 832,
      "start_char": 564800,
      "end_char": 565633
    },
    {
      "chunk_id": "pfizer_2023_chunk0707",
      "chunk_index": 707,
      "text": "action complaint alleging, among\nother things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13\nstates. In December 2022, the Federal MDL Court granted defendants’ Daubert motions to exclude plaintiffs’ expert testimony and motion for summary judgment on general\ncausation, which has resulted in the dismissal of all complaints in the litigation. Plaintiffs have appealed the Federal MDL Court’s rulings.\nIn addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal\ninjury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately",
      "char_count": 872,
      "start_char": 565600,
      "end_char": 566473
    },
    {
      "chunk_id": "pfizer_2023_chunk0708",
      "chunk_index": 708,
      "text": "ate of New Mexico and the Mayor and City Council of Baltimore separately\nfiled civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of\nZantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal\ninjury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts. The large majority of the state\ncourt cases have been filed in the Superior Court of Delaware in New Castle County.\nMany of these Zantac-related cases have been outstanding for a number of years and could take many more years to resolve. From time to time, Pfizer has explored and will\ncontinue to explore opportunistic settlements of these matters.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 997,
      "start_char": 566400,
      "end_char": 567398
    },
    {
      "chunk_id": "pfizer_2023_chunk0709",
      "chunk_index": 709,
      "text": "ny more years to resolve. From time to time, Pfizer has explored and will\ncontinue to explore opportunistic settlements of these matters.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nChantix\nBeginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer’s voluntary recall of Chantix due to the\npresence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines\nsold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. In December 2022, the\nfederal actions were transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for the Southern District of New York. Similar putative class actions have\nbeen filed in Canada and Israel, where the product brand is Champix.\nA3.",
      "char_count": 996,
      "start_char": 567200,
      "end_char": 568197
    },
    {
      "chunk_id": "pfizer_2023_chunk0710",
      "chunk_index": 710,
      "text": "proceedings to a MDL in the U.S. District Court for the Southern District of New York. Similar putative class actions have\nbeen filed in Canada and Israel, where the product brand is Champix.\nA3. Legal Proceedings––Commercial and Other Matters\nMonsanto-Related Matters\nIn 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun\noff the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly\ncreated subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003\nand is a wholly owned subsidiary of Pfizer.",
      "char_count": 834,
      "start_char": 568000,
      "end_char": 568836
    },
    {
      "chunk_id": "pfizer_2023_chunk0711",
      "chunk_index": 711,
      "text": "wholly owned subsidiary of Pfizer.\nIn connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural\nbusiness. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has\nbeen indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.\nIn connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its\nreorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites\nthat Solutia has owned or operated.",
      "char_count": 920,
      "start_char": 568800,
      "end_char": 569722
    },
    {
      "chunk_id": "pfizer_2023_chunk0712",
      "chunk_index": 712,
      "text": "ions relating to Former Monsanto’s chemical businesses are primarily limited to sites\nthat Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any\nliabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s\nassumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in\nwhich Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia\nand/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been",
      "char_count": 963,
      "start_char": 569600,
      "end_char": 570564
    },
    {
      "chunk_id": "pfizer_2023_chunk0713",
      "chunk_index": 713,
      "text": "nsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been\nindemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.\nEnvironmental Matters\nIn 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as Wyeth Holdings Corporation\nand American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of\nadministrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency, the New Jersey Department of\nEnvironmental Protection and/or federal and state natural resource trustees to perform remedial design, removal and remedial actions, and related environmental remediation",
      "char_count": 994,
      "start_char": 570400,
      "end_char": 571395
    },
    {
      "chunk_id": "pfizer_2023_chunk0714",
      "chunk_index": 714,
      "text": "w Jersey Department of\nEnvironmental Protection and/or federal and state natural resource trustees to perform remedial design, removal and remedial actions, and related environmental remediation\nactivities, and to resolve alleged damages to natural resources, at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.\nWe are also party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other\nstate, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.\nContracts with Iraqi Ministry of Health\nIn 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical\nand medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S.",
      "char_count": 992,
      "start_char": 571200,
      "end_char": 572193
    },
    {
      "chunk_id": "pfizer_2023_chunk0715",
      "chunk_index": 715,
      "text": "for the District of Columbia against a number of pharmaceutical\nand medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the\ndefendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and\nseeks monetary relief. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of plaintiffs’ claims. In January 2022, the Court of Appeals reversed\nthe District Court’s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals’ decision. In February 2023, the Court of Appeals denied defendants’\nen banc petitions.\nAllergan Complaint for Indemnity",
      "char_count": 840,
      "start_char": 572000,
      "end_char": 572842
    },
    {
      "chunk_id": "pfizer_2023_chunk0716",
      "chunk_index": 716,
      "text": "titions.\nAllergan Complaint for Indemnity\nIn 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims\nfor indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without\nprejudice in January 2021.\nViatris Securities Litigation\nIn October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received\nViatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and\ncertain of each company’s current and former officers, directors and employees are named as defendants.",
      "char_count": 908,
      "start_char": 572800,
      "end_char": 573709
    },
    {
      "chunk_id": "pfizer_2023_chunk0717",
      "chunk_index": 717,
      "text": "and\ncertain of each company’s current and former officers, directors and employees are named as defendants. An amended complaint was filed in January 2023, and alleges that the\ndefendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus\nissued in connection with the Transactions, as well as related communications. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief. In November\n2023, the parties reached an agreement to settle the litigation on terms not material to Pfizer. The settlement is subject to court approval.\nBreach of Contract – Comirnaty\nIn 2023, Pfizer and BioNTech Manufacturing GmbH initiated separate formal proceedings against the Republic of Poland, the Republic of Romania and Hungary in Belgium’s Court\nof First Instance of Brussels.",
      "char_count": 913,
      "start_char": 573600,
      "end_char": 574515
    },
    {
      "chunk_id": "pfizer_2023_chunk0718",
      "chunk_index": 718,
      "text": "inst the Republic of Poland, the Republic of Romania and Hungary in Belgium’s Court\nof First Instance of Brussels. Pfizer and BioNTech are seeking an order from the Court holding those countries to their commitments for COVID-19 vaccine orders, which were\nplaced as part of their contracts signed in 2021.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nA4. Legal Proceedings––Government Investigations\nWe are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges,\nsubstantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as\nreputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business.",
      "char_count": 935,
      "start_char": 574400,
      "end_char": 575336
    },
    {
      "chunk_id": "pfizer_2023_chunk0719",
      "chunk_index": 719,
      "text": "public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters\noften involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests\nor additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and\npenalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.\nGreenstone Investigations\n• U.S. Department of Justice Antitrust Division Investigation\nSince July 2017, the U.S. Department of Justice’s Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing\nbroader antitrust investigation of the generic pharmaceutical industry.",
      "char_count": 960,
      "start_char": 575200,
      "end_char": 576162
    },
    {
      "chunk_id": "pfizer_2023_chunk0720",
      "chunk_index": 720,
      "text": "igating our former Greenstone generics business. We believe this is related to an ongoing\nbroader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation.\n• State Attorneys General and Multi-District Generics Antitrust Litigation\nIn April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more\nthan 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been\nconsolidated with a MDL in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust\nlaws and state consumer protection laws.",
      "char_count": 876,
      "start_char": 576000,
      "end_char": 576877
    },
    {
      "chunk_id": "pfizer_2023_chunk0721",
      "chunk_index": 721,
      "text": "tion of federal and state antitrust\nlaws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer,\nmaking similar allegations, but concerning a new set of drugs. This complaint was transferred to the MDL in July 2020. The MDL also includes civil complaints filed by private\nplaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State\nAttorneys General.\nSubpoena & Civil Investigative Demand relating to Tris Pharma/Quillivant XR\nIn October 2018, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug\nmanufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR.",
      "char_count": 945,
      "start_char": 576800,
      "end_char": 577746
    },
    {
      "chunk_id": "pfizer_2023_chunk0722",
      "chunk_index": 722,
      "text": "ng to our relationship with another drug\nmanufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We responded to that subpoena in full and have had no communication with\nthe SDNY in connection with the subpoena since June 2019. Additionally, in September 2020, we received a Civil Investigative Demand (CID) from the Texas Attorney General’s\noffice seeking records of a similar nature to those requested by the SDNY. We produced records in response to this request. In November 2023, the investigation culminated in a qui\ntam litigation brought by the State of Texas. The investigation is now closed.\nGovernment Inquiries relating to Meridian Medical Technologies\nIn February 2019, we received a CID from the U.S. Attorney’s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture\nof auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena issued by the U.S.",
      "char_count": 996,
      "start_char": 577600,
      "end_char": 578597
    },
    {
      "chunk_id": "pfizer_2023_chunk0723",
      "chunk_index": 723,
      "text": "ID seeks records and information related to alleged quality issues involving the manufacture\nof auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Eastern District of Missouri, in coordination with the\nDepartment of Justice’s Consumer Protection Branch, seeking similar records and information. We have produced records in response to these and subsequent requests.\nU.S. Department of Justice/SEC Inquiry relating to Russian Operations\nIn June 2019, we received an informal request from the U.S. Department of Justice’s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in\nRussia. In September 2019, we received a similar request from the SEC’s FCPA Unit. We have produced records pursuant to these requests.\nDocetaxel––Mississippi Attorney General Government Investigation",
      "char_count": 886,
      "start_char": 578400,
      "end_char": 579287
    },
    {
      "chunk_id": "pfizer_2023_chunk0724",
      "chunk_index": 724,
      "text": "nt to these requests.\nDocetaxel––Mississippi Attorney General Government Investigation\nSee Legal Proceedings––Product Litigation––Docetaxel––Mississippi Attorney General Government Action above for information regarding a government investigation related to\nDocetaxel marketing practices.\nU.S. Department of Justice Inquiries relating to India Operations\nIn March 2020, we received an informal request from the U.S. Department of Justice’s Consumer Protection Branch seeking documents relating to our manufacturing operations in\nIndia, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney’s Office for the SDNY regarding a civil\ninvestigation concerning operations at our facilities in India. We are producing records pursuant to these requests.\nU.S. Department of Justice/SEC Inquiry relating to China Operations\nIn June 2020, we received an informal request from the U.S.",
      "char_count": 959,
      "start_char": 579200,
      "end_char": 580160
    },
    {
      "chunk_id": "pfizer_2023_chunk0725",
      "chunk_index": 725,
      "text": "rds pursuant to these requests.\nU.S. Department of Justice/SEC Inquiry relating to China Operations\nIn June 2020, we received an informal request from the U.S. Department of Justice’s FCPA Unit seeking documents relating to our operations in China. In August 2020, we received\na similar request from the SEC’s FCPA Unit. We have produced records pursuant to these requests.\nZantac––State of New Mexico and Mayor and City Council of Baltimore Civil Actions\nSee Legal Proceedings––Product Litigation––Zantac above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of\nBaltimore alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions.\nGovernment Inquiries relating to Biohaven\nIn June 2022, the U.S. Department of Justice's Commercial Litigation Branch and the U.S.",
      "char_count": 907,
      "start_char": 580000,
      "end_char": 580908
    },
    {
      "chunk_id": "pfizer_2023_chunk0726",
      "chunk_index": 726,
      "text": "lating to Biohaven\nIn June 2022, the U.S. Department of Justice's Commercial Litigation Branch and the U.S. Attorney’s Office for the Western District of New York issued a CID relating to Biohaven.\nThe CID seeks records and information related to, among other things, engagements with healthcare professionals and co-pay coupons cards. In March 2023, the California\nDepartment of Insurance issued a subpoena seeking records similar to those requested by the CID. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We\nare producing records in response to these requests.\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nU.S. Department of Justice Inquiry relating to Mexico Operations\nIn March 2023, we received an informal request from the U.S. Department of Justice’s FCPA Unit seeking documents relating to our operations in Mexico.",
      "char_count": 867,
      "start_char": 580800,
      "end_char": 581668
    },
    {
      "chunk_id": "pfizer_2023_chunk0727",
      "chunk_index": 727,
      "text": "s FCPA Unit seeking documents relating to our operations in Mexico. We are producing records\npursuant to this request.\nGovernment Inquiries relating to Xeljanz\nIn April 2023, we received a HIPAA subpoena issued by the U.S. Attorney’s Office for the Western District of Virginia, in coordination with the Department of Justice’s Commercial\nLitigation Branch, seeking records and information related to programs Pfizer sponsored in retail pharmacies relating to Xeljanz. We are producing records pursuant to this request.\nB. Guarantees and Indemnifications\nIn the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities\nthat may arise in connection with the transaction or that are related to events and activities prior to or following a transaction.",
      "char_count": 868,
      "start_char": 581600,
      "end_char": 582469
    },
    {
      "chunk_id": "pfizer_2023_chunk0728",
      "chunk_index": 728,
      "text": "elated to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim\npursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations.\nHistorically, we have not paid significant amounts under these provisions and, as of December 31, 2023, the estimated fair value of these indemnification obligations is not material\nto Pfizer. See Note 2C for a description of the March 2022 indemnity provided by Pfizer to GSK in connection with the issuance of notes by the Consumer Healthcare JV. In\nconjunction with the completion of GSK’s demerger transactions in July 2022, GSK’s guarantee and our related indemnification of GSK’s guarantee were terminated.\nIn addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us.",
      "char_count": 955,
      "start_char": 582400,
      "end_char": 583356
    },
    {
      "chunk_id": "pfizer_2023_chunk0729",
      "chunk_index": 729,
      "text": "terminated.\nIn addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, our global agreement with\nBioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection, includes certain indemnity provisions pursuant to which each of\nBioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.\nSee Note 7D for information on Pfizer Inc.’s guarantee of the debt issued by PIE in May 2023.\nWe have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See Note 7D.\nC. Certain Commitments\nAs of December 31, 2023, we had commitments totaling $5.2 billion that are legally binding and enforceable.",
      "char_count": 883,
      "start_char": 583200,
      "end_char": 584085
    },
    {
      "chunk_id": "pfizer_2023_chunk0730",
      "chunk_index": 730,
      "text": ", we had commitments totaling $5.2 billion that are legally binding and enforceable. These commitments include payments relating to potential milestone\npayments deemed reasonably likely to occur, and purchase obligations for goods and services.\nSee Note 5A for information on the TCJA repatriation tax liability.\nD. Contingent Consideration for Acquisitions\nWe may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See Note 1D. The estimated fair value\nof contingent consideration as of December 31, 2023 is $692 million, of which $179 million is recorded in Other current liabilities and $512 million in Other noncurrent liabilities, and\nas of December 31, 2022 was $645 million, of which $42 million was recorded in Other current liabilities and $603 million in Other noncurrent liabilities.",
      "char_count": 875,
      "start_char": 584000,
      "end_char": 584876
    },
    {
      "chunk_id": "pfizer_2023_chunk0731",
      "chunk_index": 731,
      "text": "Other current liabilities and $603 million in Other noncurrent liabilities. The increase in the\ncontingent consideration balance from December 31, 2022 is primarily due to fair value adjustments, partially offset by payments made upon the achievement of certain sales-based\nmilestones.\nE. Insurance\nOur insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure\nvaries accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and\navailability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially",
      "char_count": 846,
      "start_char": 584800,
      "end_char": 585647
    },
    {
      "chunk_id": "pfizer_2023_chunk0732",
      "chunk_index": 732,
      "text": "are not covered by insurance or substantially\nexceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the\namounts are paid and/or accrued.\nNote 17. Segment, Geographic and Other Revenue Information\nA. Segment Information\nWe regularly review our operating segments and the approach used by management to evaluate performance and allocate resources. In 2023, we managed our commercial\noperations through two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and Business Innovation, an\noperating segment established in the first quarter of 2023 that includes PC1, our contract development and manufacturing organization and a leading supplier of specialty active",
      "char_count": 850,
      "start_char": 585600,
      "end_char": 586452
    },
    {
      "chunk_id": "pfizer_2023_chunk0733",
      "chunk_index": 733,
      "text": "nization and a leading supplier of specialty active\npharmaceutical ingredients, and Pfizer Ignite, an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with\n\nmarket, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products\nand global corporate enabling functions. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the\nrevenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Beginning in July 2023, in consideration of planned\nfuture investments in oncology, including the December 2023 acquisition of Seagen, we reorganized our R&D platform operations.",
      "char_count": 883,
      "start_char": 586400,
      "end_char": 587284
    },
    {
      "chunk_id": "pfizer_2023_chunk0734",
      "chunk_index": 734,
      "text": "he December 2023 acquisition of Seagen, we reorganized our R&D platform operations. Discovery to late-phase clinical development for\noncology is performed by a new end-to-end ORD organization and discovery to late-phase clinical development for all remaining therapeutic areas is consolidated into the end-toend PRD organization. ORD and PRD replace our former WRDM and GPD organizations, where, prior to July 2023, research units within WRDM were generally responsible for\nresearch and early-stage development assets and, prior to July 2023, GPD was generally responsible for the clinical development strategy and operational execution of clinical trials\nfor both early- and late-stage clinical assets in Pfizer’s pipeline. In 2023, Biopharma received R&D services from\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 830,
      "start_char": 587200,
      "end_char": 588031
    },
    {
      "chunk_id": "pfizer_2023_chunk0735",
      "chunk_index": 735,
      "text": "solidated Financial Statements\n\nORD, PRD and the predecessor WRDM and GPD organizations. These services included IPR&D projects for new investigational products and additional indications for in-line\nproducts.\nOther Business Activities––Other business activities include the operating results of Business Innovation as well as certain pre-tax costs not allocated to our operating segment\nresults, such as costs associated with:\n• ORD––the R&D expenses managed by our ORD organization, which is responsible for discovery to late-phase clinical development for oncology research projects for our global\nBiopharma portfolio along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&D spending may include upfront and milestone\npayments for intellectual property rights for oncology projects.",
      "char_count": 841,
      "start_char": 588000,
      "end_char": 588842
    },
    {
      "chunk_id": "pfizer_2023_chunk0736",
      "chunk_index": 736,
      "text": "al property rights for oncology projects.\n• PRD––the R&D expenses managed by our PRD organization, which is responsible for discovery to late-phase clinical development research projects for all therapeutic areas\nother than oncology for our global Biopharma portfolio, along with facilitating regulatory submissions and interactions with regulatory agencies for these projects. R&D spending\nmay include upfront and milestone payments for intellectual property rights related to non-oncology projects. The PRD organization also has responsibility for certain sciencebased and other platform-services organizations, which provide end-to-end technical expertise and other services to both ORD and PRD R&D projects, as well as the Worldwide\nMedical and Safety group, which helps ensure that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payors and health authorities––with",
      "char_count": 911,
      "start_char": 588800,
      "end_char": 589712
    },
    {
      "chunk_id": "pfizer_2023_chunk0737",
      "chunk_index": 737,
      "text": "es all stakeholders––including patients, healthcare providers, pharmacists, payors and health authorities––with\ncomplete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s\nmedicines.\n• Corporate and other unallocated––the costs associated with (i) corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources,\nworldwide public affairs, compliance and worldwide procurement, among others) and other corporate costs, including, but not limited to, all strategy, business development and\nportfolio management capabilities and certain compensation, as well as interest income and expense, and gains and losses on investments; (ii) overhead costs primarily\nassociated with our manufacturing operations (which include manufacturing variances associated with production) that are not directly assessed to an operating segment, as",
      "char_count": 981,
      "start_char": 589600,
      "end_char": 590582
    },
    {
      "chunk_id": "pfizer_2023_chunk0738",
      "chunk_index": 738,
      "text": "primarily\nassociated with our manufacturing operations (which include manufacturing variances associated with production) that are not directly assessed to an operating segment, as\nbusiness unit (segment) management does not manage these costs; and (iii) our share of earnings from Haleon/the Consumer Healthcare JV.\nReconciling Items––The following items, transactions and events are not allocated to our operating segment results: (i) all amortization of intangible assets; (ii) acquisition-related\nitems, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company, and which may also include purchase\naccounting impacts, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the",
      "char_count": 838,
      "start_char": 590400,
      "end_char": 591240
    },
    {
      "chunk_id": "pfizer_2023_chunk0739",
      "chunk_index": 739,
      "text": "fair value, depreciation related to the\nincrease/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration;\nand (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that,\neither as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such certain significant items can include, but are not\nlimited to, pension and postretirement actuarial remeasurement gains and losses, non-acquisition-related restructuring costs, net gains and losses on investments in equity\nsecurities, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.",
      "char_count": 938,
      "start_char": 591200,
      "end_char": 592139
    },
    {
      "chunk_id": "pfizer_2023_chunk0740",
      "chunk_index": 740,
      "text": "egal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.\nSegment Assets––We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating\ndecision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were\n$227 billion as of December 31, 2023 and $197 billion as of December 31, 2022.\nSelected Income Statement Information\nThe following table provides selected income statement information by reportable segment:\n \nTotal Revenues\nEarnings\nDepreciation and Amortization\nYear Ended December 31,\nYear Ended December 31,\nYear Ended December 31,\n(MILLIONS)\n\nReportable Segment:\nBiopharma\n57,186 \n98,988 \n79,557 \n30,632 \n57,148 \n40,647 \n\n\n\nOther business activities\n1,310 \n1,342 \n1,731 \n(19,050)\n(14,370)\n(13,455)",
      "char_count": 987,
      "start_char": 592000,
      "end_char": 592988
    },
    {
      "chunk_id": "pfizer_2023_chunk0741",
      "chunk_index": 741,
      "text": "r Ended December 31,\n(MILLIONS)\n\nReportable Segment:\nBiopharma\n57,186 \n98,988 \n79,557 \n30,632 \n57,148 \n40,647 \n\n\n\nOther business activities\n1,310 \n1,342 \n1,731 \n(19,050)\n(14,370)\n(13,455)\n\nReconciling Items:\nAmortization of intangible assets\n(4,733)\n(3,609)\n(3,746)\n4,733 \n3,609 \n3,746 \nAcquisition-related items\n(1,874)\n(832)\n(139)\n(11)\n(20)\n(21)\nCertain significant items\n(3,917)\n(3,608)\n1,003 \n\n58,496 \n100,330 \n81,288 \n1,058 \n34,729 \n24,311 \n6,290 \n5,064 \n5,191 \nEarnings = Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s revenues and earnings in 2023 reflect a non-cash revenue reversal of $3.5 billion (see Note\n17C). Biopharma’s earnings also include dividend income from our investment in ViiV of $265 million in 2023, $314 million in 2022 and $166 million in 2021.\nCertain production facilities are shared.",
      "char_count": 861,
      "start_char": 592800,
      "end_char": 593662
    },
    {
      "chunk_id": "pfizer_2023_chunk0742",
      "chunk_index": 742,
      "text": "66 million in 2021.\nCertain production facilities are shared. Depreciation is allocated based on estimates of physical production.\nOther business activities include revenues and costs associated with Business Innovation and costs that we do not allocate to our operating segments, per above, including acquired IPR&D expenses in\nthe periods presented (see Notes 2A and 2E). In 2023, earnings include approximately $6.2 billion of inventory write-offs and related charges to Cost of sales mainly due to lower-than-expected demand\nfor our COVID-19 products. In 2022, earnings included COVID-19-related charges of approximately $1.7 billion to Cost of sales, composed of (i) inventory write-offs of approximately $1.2 billion related to\nCOVID-19 products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for\nPaxlovid.",
      "char_count": 943,
      "start_char": 593600,
      "end_char": 594544
    },
    {
      "chunk_id": "pfizer_2023_chunk0743",
      "chunk_index": 743,
      "text": "pproved shelf-lives prior to being used and (ii) charges of approximately $0.5 billion, primarily related to excess raw materials for\nPaxlovid.\nCertain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in 2023 include, among other items: (i) intangible asset impairment charges of $3.0\nbillion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs\n(a)\n(a)\n(b)\n(c)\n(d)\n(a)\n(b)\n(c)\n(d)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nand additional depreciation—asset restructuring of $2.2 billion ($290 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring\ncharges and certain acquisition-related costs), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net.",
      "char_count": 928,
      "start_char": 594400,
      "end_char": 595329
    },
    {
      "chunk_id": "pfizer_2023_chunk0744",
      "chunk_index": 744,
      "text": "ted costs), partially offset by (iii) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net. Earnings in 2022 included, among other\nitems: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.4 billion ($562 million recorded in Selling, informational and administrative\nexpenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs) and (ii) net losses on equity securities of $1.3 billion recorded in Other\n(income)/deductions––net. Earnings in 2021 included, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in Other (income)/deductions––net\nand (ii) net gains on equity securities of $1.3 billion recorded in Other (income)/deductions––net, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation",
      "char_count": 973,
      "start_char": 595200,
      "end_char": 596174
    },
    {
      "chunk_id": "pfizer_2023_chunk0745",
      "chunk_index": 745,
      "text": "es of $1.3 billion recorded in Other (income)/deductions––net, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation\n—asset restructuring of $1.3 billion ($450 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain\nacquisition-related costs). See Notes 3 and 4.\nB. Geographic Information\nThe following summarizes revenues by geographic area:\n \nYear Ended December 31,\n(MILLIONS)\n\nUnited States\n27,088 \n42,473 \n29,746 \nDeveloped Europe\n11,650 \n21,982 \n18,336 \nDeveloped Rest of World\n7,761 \n15,778 \n12,506 \nEmerging Markets\n11,996 \n20,097 \n20,701 \nTotal revenues\n58,496 \n100,330 \n81,288 \nRevenues exceeded $500 million in each of 14, 24 and 21 countries outside the U.S. in 2023, 2022 and 2021, respectively. The U.S. is the only country to contribute more than 10%\nof total revenue in 2023, 2022 and 2021.",
      "char_count": 959,
      "start_char": 596000,
      "end_char": 596960
    },
    {
      "chunk_id": "pfizer_2023_chunk0746",
      "chunk_index": 746,
      "text": "ntries outside the U.S. in 2023, 2022 and 2021, respectively. The U.S. is the only country to contribute more than 10%\nof total revenue in 2023, 2022 and 2021. As a percentage of revenues, our largest country outside the U.S. was Japan, which contributed 6% of total revenue in 2023, 8% of total\nrevenue in 2022 and 9% of total revenue in 2021.\nC. Other Revenue Information\nSignificant Customers\nWe and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty with multiple developed and emerging nations around the\nworld and are continuing to deliver doses of Comirnaty under such agreements. This includes supply agreements entered into in November 2020 and February and May 2021 with\nthe EC for Comirnaty on behalf of the different EU member states and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is\nresponsible for payment pursuant to terms of the supply agreements negotiated by the EC.",
      "char_count": 995,
      "start_char": 596800,
      "end_char": 597796
    },
    {
      "chunk_id": "pfizer_2023_chunk0747",
      "chunk_index": 747,
      "text": "tes and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is\nresponsible for payment pursuant to terms of the supply agreements negotiated by the EC. In May 2023, we and BioNTech amended our contract with the EC to deliver COVID-19\nvaccines to the EU. The amended agreement includes rephasing of delivery of doses annually through 2026 and an aggregate volume reduction, providing additional flexibility for\nthose EU member states who agreed to the amended agreement. The EC will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment\nwith the original agreement.\nIn 2022 and 2023, we had entered into agreements to supply pre-specified treatment courses of Paxlovid with government and government sponsored customers in multiple\ndeveloped and emerging nations around the world, which represented most Paxlovid revenues in 2022 and 2023, while commercialization began in some markets in 2023.",
      "char_count": 981,
      "start_char": 597600,
      "end_char": 598582
    },
    {
      "chunk_id": "pfizer_2023_chunk0748",
      "chunk_index": 748,
      "text": "tomers in multiple\ndeveloped and emerging nations around the world, which represented most Paxlovid revenues in 2022 and 2023, while commercialization began in some markets in 2023. In\nOctober 2023, we announced an amended agreement with the U.S. government, which facilitated the transition of Paxlovid to traditional commercial markets starting in November\n2023, with prices negotiated with commercial payors and a copay assistance program for eligible privately insured patients, as the U.S. government began to discontinue the\ndistribution of EUA-labeled Paxlovid. We ensured commercial readiness by providing NDA-labeled commercial supply by the end of 2023. However, EUA-labeled Paxlovid remained\navailable free-of-charge to all eligible patients until the end of 2023, and therefore, there was only minimal uptake of NDA-labeled commercial product before January 1, 2024.",
      "char_count": 878,
      "start_char": 598400,
      "end_char": 599279
    },
    {
      "chunk_id": "pfizer_2023_chunk0749",
      "chunk_index": 749,
      "text": "only minimal uptake of NDA-labeled commercial product before January 1, 2024. In\nconnection with this agreement, we recorded a non-cash revenue reversal of $3.5 billion in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022,\nrelated to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory. We will convert these treatment courses previously\npurchased by the U.S. government to a volume-based credit, based on the actual number of treatment courses that are returned by the U.S. government, which will support\ncontinued access to Paxlovid through a U.S. government patient assistance program operated by Pfizer. Therefore, we expect the patient assistance program will provide an\nestimated 6.5 million treatment courses of FDA-approved, NDA-labeled Paxlovid free of charge to all eligible uninsured, Medicare and Medicaid patients through 2024, and to",
      "char_count": 942,
      "start_char": 599200,
      "end_char": 600144
    },
    {
      "chunk_id": "pfizer_2023_chunk0750",
      "chunk_index": 750,
      "text": "ent courses of FDA-approved, NDA-labeled Paxlovid free of charge to all eligible uninsured, Medicare and Medicaid patients through 2024, and to\neligible uninsured and underinsured patients through 2028. We also agreed to create, in 2024, a U.S. Strategic National Stockpile of 1.0 million treatment courses to enable future\npandemic preparedness through 2028, which will be managed and supplied by Pfizer at no cost to the U.S. government or taxpayers. While we will recognize revenue as the\nestimated 7.5 million treatment courses are delivered, there is no remaining cash consideration for these treatment courses.\nThe following summarizes revenue, as a percentage of Total revenues, for our three largest U.S. wholesaler customers and the U.S. government, which was concentrated in our\nBiopharma operating segment:\n \nYear Ended December 31,",
      "char_count": 843,
      "start_char": 600000,
      "end_char": 600844
    },
    {
      "chunk_id": "pfizer_2023_chunk0751",
      "chunk_index": 751,
      "text": "perating segment:\n \nYear Ended December 31,\n\nMcKesson, Inc.\n17 %\n8 %\n9 %\nCencora, Inc. (formerly AmerisourceBergen Corporation)\n12 %\n5 %\n7 %\nCardinal Health, Inc.\n10 %\n4 %\n5 %\nU.S. government\n23 %\n13 %\n The decrease in revenues from the U.S. government as a percentage of Total revenues for 2023 compared to 2022 was primarily due to the transition of Comirnaty and Paxlovid to commercial market\nsales in the second half of 2023 as well as the revenue reversal for Paxlovid in the fourth quarter of 2023.\n(a)\n(a)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nCollectively, our three largest U.S. wholesaler customers represented 44% and 32% of total trade accounts receivable as of December 31, 2023 and December 31, 2022,\nrespectively. Accounts receivable from the U.S. government as of December 31, 2023 and December 31, 2022 were not material to our consolidated financial statements.\nSignificant Revenues by Product",
      "char_count": 934,
      "start_char": 600800,
      "end_char": 601735
    },
    {
      "chunk_id": "pfizer_2023_chunk0752",
      "chunk_index": 752,
      "text": "of December 31, 2023 and December 31, 2022 were not material to our consolidated financial statements.\nSignificant Revenues by Product\nThe following provides detailed revenue information for several of our major products:\n(MILLIONS)\nYear Ended December 31,\nPRODUCT\nPRIMARY INDICATION OR CLASS\n\nTOTAL REVENUES\n58,496 \n100,330 \n81,288 \nGLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)\n57,186 \n98,988 \n79,557 \nPrimary Care\n30,589 \n73,023 \n52,029 \nComirnaty direct sales and alliance\nrevenues\nActive immunization to prevent COVID-19\n11,220 \n37,806 \n36,781 \nEliquis alliance revenues and direct sales\nNonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism\n6,747 \n6,480 \n5,970 \nPrevnar family\nActive immunization to prevent pneumonia, invasive disease and otitis media caused by\nStreptococcus pneumoniae\n6,440 \n6,337 \n5,272 \nPaxlovid\nCOVID-19 in certain high-risk patients\n1,279 \n18,933 \n\nNurtec ODT/Vydura\nAcute treatment of migraine and prevention of episodic migraine",
      "char_count": 981,
      "start_char": 601600,
      "end_char": 602582
    },
    {
      "chunk_id": "pfizer_2023_chunk0753",
      "chunk_index": 753,
      "text": "cus pneumoniae\n6,440 \n6,337 \n5,272 \nPaxlovid\nCOVID-19 in certain high-risk patients\n1,279 \n18,933 \n\nNurtec ODT/Vydura\nAcute treatment of migraine and prevention of episodic migraine\n\nAbrysvo\nActive immunization to prevent RSV infection\n\nPremarin family\nSymptoms of menopause\n\nBMP2\nBone graft for spinal fusion\n\nFSME-IMMUN/TicoVac\nActive immunization to prevent tick-borne encephalitis disease\n\nNimenrix\nActive immunization against invasive meningococcal ACWY disease\n\nTrumenba\nActive immunization to prevent invasive disease caused by Neisseria meningitidis group B\n\nAll other Primary Care\nVarious\n1,777 \n1,932 \n2,604 \nSpecialty Care\n14,970 \n13,833 \n15,194 \nVyndaqel family\nATTR-CM and polyneuropathy\n3,321 \n2,447 \n2,015 \nXeljanz\nRA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis\n1,703 \n1,796 \n2,455 \nEnbrel (Outside the U.S.",
      "char_count": 870,
      "start_char": 602400,
      "end_char": 603271
    },
    {
      "chunk_id": "pfizer_2023_chunk0754",
      "chunk_index": 754,
      "text": ", ankylosing spondylitis\n1,703 \n1,796 \n2,455 \nEnbrel (Outside the U.S. and Canada)\nRA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing\nspondylitis and nonradiographic axial spondyloarthritis\n\n1,003 \n1,185 \nSulperazon\nBacterial infections\n\nIg Portfolio\nVarious\n\nGenotropin\nReplacement of human growth hormone\n\nZavicefta\nBacterial infections\n\nInflectra\nCrohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with\nmethotrexate, ankylosing spondylitis, PsA and plaque psoriasis\n\nBeneFIX\nHemophilia B\n\nZithromax\nBacterial infections\n\nMedrol\nAnti-inflammatory glucocorticoid\n\nOxbryta\nSickle cell disease\n\nSomavert\nAcromegaly\n\nFragmin\nTreatment/prevention of venous thromboembolism\n\nReFacto AF/Xyntha\nHemophilia A\n\nCresemba\nFungal infections\n\nVfend\nFungal infections\n\nBicillin\nBacterial infections\n\nCibinqo\nAtopic dermatitis",
      "char_count": 887,
      "start_char": 603200,
      "end_char": 604088
    },
    {
      "chunk_id": "pfizer_2023_chunk0755",
      "chunk_index": 755,
      "text": "ions\n\nVfend\nFungal infections\n\nBicillin\nBacterial infections\n\nCibinqo\nAtopic dermatitis\n\nAll other Anti-infectives\nVarious\n1,092 \n1,171 \n1,572 \nAll other Specialty Care\nVarious\n2,244 \n2,350 \n2,830 \nOncology\n11,627 \n12,132 \n12,333 \nIbrance\nHR-positive/HER2-negative metastatic breast cancer\n4,753 \n5,120 \n5,437 \nXtandi alliance revenues\nmCRPC, nmCRPC, mCSPC, nmCSPC\n1,191 \n1,198 \n1,185 \nInlyta\nAdvanced RCC\n1,036 \n1,003 \n1,002 \nBosulif\nPhiladelphia chromosome–positive chronic myelogenous leukemia\n\nLorbrena\nALK-positive metastatic NSCLC\n\nZirabev\nTreatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent\nglioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer\n\n(a)\n(b)\n(c)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\n(MILLIONS)\nYear Ended December 31,\nPRODUCT\nPRIMARY INDICATION OR CLASS",
      "char_count": 868,
      "start_char": 604000,
      "end_char": 604869
    },
    {
      "chunk_id": "pfizer_2023_chunk0756",
      "chunk_index": 756,
      "text": "ILLIONS)\nYear Ended December 31,\nPRODUCT\nPRIMARY INDICATION OR CLASS\n\nRuxience\nNon-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis\n(Wegener’s Granulomatosis) and microscopic polyangiitis\n\nXalkori\nALK-positive and Proto-Oncogene 1, Receptor Tyrosine Kinase-positive advanced NSCLC\n\nRetacrit\nAnemia\n\nAromasin\nPost-menopausal early and advanced breast cancer\n\nBesponsa\nRelapsed or refractory B-cell acute lymphoblastic leukemia\n\nBraftovi\nIn combination with Mektovi for metastatic melanoma in patients with a BRAF\nmutation and\nfor metastatic NSCLC in patients with a BRAF\nmutation; and\nIn combination with Erbitux (cetuximab) for the treatment of BRAF\n-mutant mCRC after\nprior therapy\n\nBavencio alliance revenues\nLocally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma;\nimmunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC",
      "char_count": 918,
      "start_char": 604800,
      "end_char": 605719
    },
    {
      "chunk_id": "pfizer_2023_chunk0757",
      "chunk_index": 757,
      "text": "tastatic Merkel cell carcinoma;\nimmunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC\n\nSutent\nAdvanced and/or metastatic RCC, adjuvant RCC, refractory gastrointestinal stromal tumors\n(after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic\nneuroendocrine tumor\n\nMektovi\nIn combination with Braftovi for metastatic melanoma in patients with a BRAF\n mutation and\nfor metastatic NSCLC in patients with a BRAF\nmutation\n\nTrazimera\nHER2-positive breast cancer and metastatic stomach cancers\n\nPadcev\nLocally advanced or metastatic urothelial cancer\n\nAdcetris\nHodgkin lymphoma and certain T-cell lymphomas\n\nTukysa\nUnresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive\nunresectable or metastatic colorectal cancer\n\nTivdak\nRecurrent or metastatic cervical cancer\n\nAll other Oncology\nVarious\n\nBUSINESS INNOVATION\n1,310 \n1,342 \n1,731 \nPfizer CentreOne\nVarious\n1,265 \n1,335 \n1,731 \nPfizer Ignite\nVarious",
      "char_count": 990,
      "start_char": 605600,
      "end_char": 606591
    },
    {
      "chunk_id": "pfizer_2023_chunk0758",
      "chunk_index": 758,
      "text": "ncer\n\nTivdak\nRecurrent or metastatic cervical cancer\n\nAll other Oncology\nVarious\n\nBUSINESS INNOVATION\n1,310 \n1,342 \n1,731 \nPfizer CentreOne\nVarious\n1,265 \n1,335 \n1,731 \nPfizer Ignite\nVarious\n\nTotal Alliance revenues included above\n7,582 \n8,537 \n7,652 \nExcludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. See\nfootnote (h) below.\nIncludes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5\nmillion treatment courses of EUA-labeled U.S. government inventory.\nImmunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.\nErbitux is a registered trademark of ImClone LLC.",
      "char_count": 877,
      "start_char": 606400,
      "end_char": 607278
    },
    {
      "chunk_id": "pfizer_2023_chunk0759",
      "chunk_index": 759,
      "text": "zyga, Octagam and Cutaquig.\nErbitux is a registered trademark of ImClone LLC.\nIn March 2023, it was announced that our alliance with Merck KGaA to co-develop and co-commercialize Bavencio (avelumab) would terminate. Effective June 30, 2023, Merck KGaA took full control of\nthe global commercialization of Bavencio. Beginning in the third quarter of 2023, the related profit share was replaced by a 15% royalty to Pfizer on net sales of Bavencio, which was recorded in Other\n(income)/deductions––net. We and Merck KGaA continue to operationalize our respective ongoing clinical trials for Bavencio; and Merck KGaA controls all future R&D activities. Bavencio is a registered\ntrademark of Merck KGaA.\nRepresents revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023. See Note 2A.\nSee Note 17A above for information about Business Innovation.",
      "char_count": 873,
      "start_char": 607200,
      "end_char": 608074
    },
    {
      "chunk_id": "pfizer_2023_chunk0760",
      "chunk_index": 760,
      "text": "ee Note 2A.\nSee Note 17A above for information about Business Innovation. Prior-period financial information has been revised to reflect the current period presentation.\nPC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($33 million for 2023, $188 million for 2022, and\n$320 million for 2021), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer\nbusinesses/partnerships.\nRemaining Performance Obligations––Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply\nComirnaty and Paxlovid to our customers totaled approximately $6 billion and $3.4 billion, respectively, as of December 31, 2023, which includes amounts received in advance and",
      "char_count": 930,
      "start_char": 608000,
      "end_char": 608931
    },
    {
      "chunk_id": "pfizer_2023_chunk0761",
      "chunk_index": 761,
      "text": "d approximately $6 billion and $3.4 billion, respectively, as of December 31, 2023, which includes amounts received in advance and\ndeferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of these amounts, current contract terms provide for expected\ndelivery of product with contracted revenue from 2024 through 2028, the timing of which may be renegotiated. Remaining performance obligations are based on foreign exchange\nrates as of the end of our fiscal fourth quarter of 2023 and exclude arrangements with an original expected contract duration of less than one year. Remaining performance\nobligations associated with contracts for other products and services were not significant as of December 31, 2023 or 2022.\nDeferred Revenues––Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers for supply\nof Paxlovid and Comirnaty.",
      "char_count": 973,
      "start_char": 608800,
      "end_char": 609774
    },
    {
      "chunk_id": "pfizer_2023_chunk0762",
      "chunk_index": 762,
      "text": "deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers for supply\nof Paxlovid and Comirnaty.\nThe deferred revenues related to Paxlovid totaled $3.4 billion as of December 31, 2023, with $1.5 billion and $1.9 billion recorded in current liabilities and noncurrent liabilities,\nrespectively, while deferred revenues related to Paxlovid were not material as of December 31, 2022. The increase in Paxlovid deferred revenues during 2023 was primarily driven\nby the reversal of Paxlovid revenues and conversion of previously purchased EUA-labeled Paxlovid treatment courses into a volume-based credit under our October 2023 amended\nagreement with the U.S. government.\nV600E/K \nV600E \n(d)\nV600E\n(e)\nV600E/K\nV600E \n(f)\n(f)\n(f)\n(f)\n(g)\n(h)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements",
      "char_count": 903,
      "start_char": 609600,
      "end_char": 610504
    },
    {
      "chunk_id": "pfizer_2023_chunk0763",
      "chunk_index": 763,
      "text": "(f)\n(g)\n(h)\n(a)\n(b)\n(c)\n(d)\n(e)\n(f)\n(g)\n(h)\n\n2023 Form 10-K\n\nNotes to Consolidated Financial Statements\n\nThe deferred revenues related to Comirnaty totaled $1.7 billion as of December 31, 2023, with $1.1 billion and $552 million recorded in current liabilities and noncurrent liabilities,\nrespectively. The deferred revenues related to Comirnaty totaled $2.5 billion as of December 31, 2022, with $2.4 billion and $77 million recorded in current liabilities and noncurrent\nliabilities, respectively. The decrease in Comirnaty deferred revenues during 2023 was primarily the result of amounts recognized in Product revenues as we delivered the products\nto our customers, partially offset by additional advance payments received as we entered into amended contracts, as well as the impact of foreign exchange.",
      "char_count": 807,
      "start_char": 610400,
      "end_char": 611208
    },
    {
      "chunk_id": "pfizer_2023_chunk0764",
      "chunk_index": 764,
      "text": "change. During 2023, we\nrecognized revenue of approximately $2.2 billion that was included in the balance of Comirnaty deferred revenues as of December 31, 2022.\nThe Paxlovid and Comirnaty deferred revenues as of December 31, 2023 will be recognized in Product revenues proportionately as we transfer control of the products to our\ncustomers and satisfy our performance obligations under the contracts, with the amounts included in current liabilities expected to be recognized in Product revenues within the next\n12 months, and the amounts included in noncurrent liabilities expected to be recognized in Product revenues from December 2024 (which falls in our international first quarter of\n2025) through 2028. Deferred revenues associated with contracts for other products were not significant as of December 31, 2023 or 2022.\nITEM 9.\nCHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE\nNone.\nITEM 9A.\nCONTROLS AND PROCEDURES\nDisclosure Controls and Procedures",
      "char_count": 995,
      "start_char": 611200,
      "end_char": 612196
    },
    {
      "chunk_id": "pfizer_2023_chunk0765",
      "chunk_index": 765,
      "text": "f December 31, 2023 or 2022.\nITEM 9.\nCHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE\nNone.\nITEM 9A.\nCONTROLS AND PROCEDURES\nDisclosure Controls and Procedures\nAs of the end of the period covered by this Form 10-K, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal\nfinancial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the\nExchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting\nthem in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.\nChanges in Internal Controls\nOn December 14, 2023, we acquired Seagen.",
      "char_count": 929,
      "start_char": 612000,
      "end_char": 612930
    },
    {
      "chunk_id": "pfizer_2023_chunk0766",
      "chunk_index": 766,
      "text": "o be disclosed in our periodic reports filed with the SEC.\nChanges in Internal Controls\nOn December 14, 2023, we acquired Seagen. Other than the addition of Seagen’s operations to our internal control over financial reporting and any related changes in control to\nintegrate Seagen into Pfizer, there has not been any change in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f)\nunder the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.\n\n2023 Form 10-K\n\nReport of Independent Registered Public Accounting Firm\nTo the Board of Directors and Shareholders\n\nOpinion on Internal Control Over Financial Reporting\nWe have audited Pfizer Inc. and Subsidiary Companies’ (the Company) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal",
      "char_count": 944,
      "start_char": 612800,
      "end_char": 613745
    },
    {
      "chunk_id": "pfizer_2023_chunk0767",
      "chunk_index": 767,
      "text": "Subsidiary Companies’ (the Company) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal\nControl—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material\nrespects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework (2013) issued by the\nCommittee of Sponsoring Organizations of the Treadway Commission.\nWe also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the\nCompany as of December 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the threeyear period ended December 31, 2023, and the related notes (collectively, the consolidated financial s",
      "char_count": 1000,
      "start_char": 613600,
      "end_char": 614600
    },
    {
      "chunk_id": "pfizer_2023_chunk0768",
      "chunk_index": 768,
      "text": "tements of income, comprehensive income, equity, and cash flows for each of the years in the threeyear period ended December 31, 2023, and the related notes (collectively, the consolidated financial statements), and our report dated February 22, 2024 expressed an\nunqualified opinion on those consolidated financial statements.\nThe scope of management’s assessment of the effectiveness of internal control over financial reporting includes all of the Company’s consolidated operations except for the\noperations of Seagen Inc. and its subsidiaries (Seagen), which the Company acquired on December 14, 2023. Seagen’s operations represent 0.2% of the Company’s\nconsolidated revenues for the year ended December 31, 2023, and assets associated with Seagen’s operations represent 22% of the Company’s consolidated total assets, as of\nDecember 31, 2023.",
      "char_count": 847,
      "start_char": 614400,
      "end_char": 615248
    },
    {
      "chunk_id": "pfizer_2023_chunk0769",
      "chunk_index": 769,
      "text": "olidated total assets, as of\nDecember 31, 2023. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Seagen.\nBasis for Opinion\nThe Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over\nfinancial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s\ninternal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the\nCompany in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.\nWe conducted our audit in accordance with the standards of the PCAOB.",
      "char_count": 980,
      "start_char": 615200,
      "end_char": 616181
    },
    {
      "chunk_id": "pfizer_2023_chunk0770",
      "chunk_index": 770,
      "text": "urities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.\nWe conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether\neffective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of\ninternal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control\nbased on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a\nreasonable basis for our opinion.\nDefinition and Limitations of Internal Control Over Financial Reporting",
      "char_count": 929,
      "start_char": 616000,
      "end_char": 616930
    },
    {
      "chunk_id": "pfizer_2023_chunk0771",
      "chunk_index": 771,
      "text": "at our audit provides a\nreasonable basis for our opinion.\nDefinition and Limitations of Internal Control Over Financial Reporting\nA company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of\nfinancial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies\nand procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;\n(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting",
      "char_count": 847,
      "start_char": 616800,
      "end_char": 617648
    },
    {
      "chunk_id": "pfizer_2023_chunk0772",
      "chunk_index": 772,
      "text": "n accordance with generally accepted accounting\nprinciples, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide\nreasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the\nfinancial statements.\nBecause of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future\nperiods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may\ndeteriorate.\nNew York, New York\nFebruary 22, 2024\n\n2023 Form 10-K",
      "char_count": 841,
      "start_char": 617600,
      "end_char": 618442
    },
    {
      "chunk_id": "pfizer_2023_chunk0773",
      "chunk_index": 773,
      "text": "ew York\nFebruary 22, 2024\n\n2023 Form 10-K\n\nManagement’s Report on Internal Control Over Financial Reporting\nManagement’s Report\nWe prepared and are responsible for the financial statements that appear in this Form 10-K. These financial statements are in conformity with accounting principles generally\naccepted in the United States of America and, therefore, include amounts based on informed judgments and estimates. We also accept responsibility for the preparation of other\nfinancial information that is included in this document.\nReport on Internal Control Over Financial Reporting\nThe management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under\nthe Securities Exchange Act of 1934.",
      "char_count": 801,
      "start_char": 618400,
      "end_char": 619202
    },
    {
      "chunk_id": "pfizer_2023_chunk0774",
      "chunk_index": 774,
      "text": ". The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial\nreporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. The\nCompany’s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and\nfairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of\nfinancial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with",
      "char_count": 847,
      "start_char": 619200,
      "end_char": 620048
    },
    {
      "chunk_id": "pfizer_2023_chunk0775",
      "chunk_index": 775,
      "text": "Company are being made only in accordance with\nauthorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or\ndisposition of the Company’s assets that could have a material effect on the financial statements.\nBecause of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future\nperiods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may\ndeteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023. In making this assessment, management\nused the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013).",
      "char_count": 995,
      "start_char": 620000,
      "end_char": 620997
    },
    {
      "chunk_id": "pfizer_2023_chunk0776",
      "chunk_index": 776,
      "text": "31, 2023. In making this assessment, management\nused the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013). Based on our assessment\nand those criteria, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2023.\nThe scope of management’s assessment of the effectiveness of internal control over financial reporting includes all of the Company’s consolidated operations except for the\noperations of Seagen Inc. and its subsidiaries (Seagen), which the Company acquired on December 14, 2023. Seagen’s operations represent 0.2% of the Company’s consolidated\nrevenues for the year ended December 31, 2023, and assets associated with Seagen’s operations represent 22% of the Company’s consolidated total assets, as of December 31,\n2023.",
      "char_count": 885,
      "start_char": 620800,
      "end_char": 621686
    },
    {
      "chunk_id": "pfizer_2023_chunk0777",
      "chunk_index": 777,
      "text": "ns represent 22% of the Company’s consolidated total assets, as of December 31,\n2023.\nThe Company’s independent auditors have issued their auditors’ report on the Company’s internal control over financial reporting. That report appears above in this Form 10-K.\nAlbert Bourla\n \nChairman and Chief Executive Officer\n \nDavid M. Denton\nJennifer B. Damico\nPrincipal Financial Officer\nPrincipal Accounting Officer\nFebruary 22, 2024\n\n2023 Form 10-K\n\nITEM 9B.\nOTHER INFORMATION\nDuring the three months ended December 31, 2023, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading\narrangement,” as each term is defined in Item 408 of Regulation S-K.\nPART III\nITEM 10.\nDIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE\nInformation about our Directors is incorporated by reference from the discussion under the heading Item 1—Election of Directors in our Proxy Statement.",
      "char_count": 932,
      "start_char": 621600,
      "end_char": 622533
    },
    {
      "chunk_id": "pfizer_2023_chunk0778",
      "chunk_index": 778,
      "text": "ur Directors is incorporated by reference from the discussion under the heading Item 1—Election of Directors in our Proxy Statement. Information about the Pfizer\nPolicies on Business Conduct governing our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, and the Code of Business\nConduct and Ethics for Members of the Board of Directors, is incorporated by reference from the discussions under the headings Governance Overview—Pfizer Policies on\nBusiness Conduct and —Code of Conduct for Directors in our Proxy Statement. Information regarding the procedures by which our shareholders may recommend nominees to our\nBoard of Directors is incorporated by reference from the discussion under the headings Item 1—Election of Directors—Criteria for Board Membership and Annual Meeting\nInformation—Submitting Proxy Proposals and Director Nominations for the 2025 Annual Meeting in our Proxy Statement.",
      "char_count": 953,
      "start_char": 622400,
      "end_char": 623354
    },
    {
      "chunk_id": "pfizer_2023_chunk0779",
      "chunk_index": 779,
      "text": "r Board Membership and Annual Meeting\nInformation—Submitting Proxy Proposals and Director Nominations for the 2025 Annual Meeting in our Proxy Statement. Information about our Audit Committee, including the\nmembers of the Committee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the heading Governance Overview—Board and\nCommittee Information—Board Committees—The Audit Committee in our Proxy Statement. The balance of the information required by this item is contained in the discussion\nentitled Information about Our Executive Officers in this Form 10-K.\nITEM 11.\nEXECUTIVE COMPENSATION\nInformation about Director and executive compensation is incorporated by reference from the discussion under the headings Non-Employee Director Compensation; Executive\nCompensation; and Governance Overview—Board and Committee Information—Board Committees—The Compensation Committee—Compensation Committee Interlocks and",
      "char_count": 960,
      "start_char": 623200,
      "end_char": 624161
    },
    {
      "chunk_id": "pfizer_2023_chunk0780",
      "chunk_index": 780,
      "text": "xecutive\nCompensation; and Governance Overview—Board and Committee Information—Board Committees—The Compensation Committee—Compensation Committee Interlocks and\nInsider Participation in our Proxy Statement.\nITEM 12.\nSECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER\nMATTERS\nInformation required by this item is incorporated by reference from the discussion under the headings Executive Compensation—Compensation Tables—Equity Compensation Plan\nInformation and Securities Ownership in our Proxy Statement.\nITEM 13.\nCERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE\nInformation about certain relationships and transactions with related parties is incorporated by reference from the discussion under the headings Governance Overview—Other\nGovernance Practices and Policies—Related Person Transactions and Indemnification and —Transactions with Related Persons in our Proxy Statement.",
      "char_count": 941,
      "start_char": 624000,
      "end_char": 624942
    },
    {
      "chunk_id": "pfizer_2023_chunk0781",
      "chunk_index": 781,
      "text": "ernance Practices and Policies—Related Person Transactions and Indemnification and —Transactions with Related Persons in our Proxy Statement. Information about director\nindependence is incorporated by reference from the discussion under the heading Item 1—Election of Directors—Director Independence in our Proxy Statement.\nITEM 14.\nPRINCIPAL ACCOUNTING FEES AND SERVICES\nOur independent registered public accounting firm is KPMG LLP, New York, NY, Auditor Firm ID: 185. Information about the fees for professional services rendered by our\nindependent registered public accounting firm in 2023 and 2022 is incorporated by reference from the discussion under the heading Item 2—Ratification of Selection of Independent\nRegistered Public Accounting Firm—Audit and Non-Audit Fees in our Proxy Statement. Our Audit Committee’s policy on pre-approval of audit and permissible non-audit services of",
      "char_count": 892,
      "start_char": 624800,
      "end_char": 625693
    },
    {
      "chunk_id": "pfizer_2023_chunk0782",
      "chunk_index": 782,
      "text": "Our Audit Committee’s policy on pre-approval of audit and permissible non-audit services of\nour independent registered public accounting firm is incorporated by reference from the discussion under the heading Item 2—Ratification of Selection of Independent Registered\nPublic Accounting Firm—Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services in our Proxy Statement.\nPART IV\nITEM 15.\nEXHIBITS, FINANCIAL STATEMENT SCHEDULES\n15(a)(1) Financial Statements. The following consolidated financial statements, related notes and report of independent registered public accounting firm are set forth in Item 8.\nFinancial Statements and Supplementary Data in this Form 10-K:\nReport of Independent Registered Public Accounting Firm on the Consolidated Financial Statements\nConsolidated Statements of Income\nConsolidated Statements of Comprehensive Income\nConsolidated Balance Sheets\nConsolidated Statements of Equity\nConsolidated Statements of Cash Flows",
      "char_count": 975,
      "start_char": 625600,
      "end_char": 626577
    },
    {
      "chunk_id": "pfizer_2023_chunk0783",
      "chunk_index": 783,
      "text": "lidated Statements of Income\nConsolidated Statements of Comprehensive Income\nConsolidated Balance Sheets\nConsolidated Statements of Equity\nConsolidated Statements of Cash Flows\nNotes to Consolidated Financial Statements\n15(a)(2) Financial Statement Schedules. Schedules are omitted because they are not required or because the information is provided elsewhere in the financial statements. The\nfinancial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.\n\n2023 Form 10-K\n\n15(a)(3) Exhibits. These exhibits are available upon request. Requests should be directed to our Corporate Secretary, Pfizer Inc., 66 Hudson Boulevard East, New York, New York\n10001-2192. The exhibit numbers preceded by an asterisk (*) indicate exhibits filed with this Form 10-K. All other exhibit numbers indicate exhibits filed by incorporation by\nreference.",
      "char_count": 926,
      "start_char": 626400,
      "end_char": 627327
    },
    {
      "chunk_id": "pfizer_2023_chunk0784",
      "chunk_index": 784,
      "text": "indicate exhibits filed with this Form 10-K. All other exhibit numbers indicate exhibits filed by incorporation by\nreference. Exhibit numbers 10.1 through 10.50 are management contracts or compensatory plans or arrangements.\n2.1\nStock and Asset Purchase Agreement, dated December 19, 2018, by and among us, GlaxoSmithKline plc and GlaxoSmithKline Consumer Healthcare Holdings Limited is\nincorporated by reference from our 2018 Annual Report on Form 10-K. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish\nto the SEC upon request any omitted schedule or exhibit to the Stock and Asset Purchase Agreement.)\n2.2\nAgreement and Plan of Merger, by and among Pfizer Inc., Aris Merger Sub, Inc. and Seagen Inc., dated as of March 12, 2023 is incorporated by reference from our Current\nReport on Form 8-K filed on March 13, 2023.\n3.1",
      "char_count": 876,
      "start_char": 627200,
      "end_char": 628078
    },
    {
      "chunk_id": "pfizer_2023_chunk0785",
      "chunk_index": 785,
      "text": "by reference from our Current\nReport on Form 8-K filed on March 13, 2023.\n3.1\nOur Restated Certificate of Incorporation dated December 14, 2020, is incorporated by reference from our Current Report on Form 8-K filed on December 14, 2020.\n3.2\nOur By-laws, as amended on December 9, 2022, are incorporated by reference from our Current Report on Form 8-K filed on\nDecember 13, 2022.\n4.1\nIndenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is incorporated by reference from our Current Report on Form 8-K filed on January 30,\n2001.\n4.2\nFirst Supplemental Indenture, dated as of March 24, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan\nChase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Quarterly Report on Form\n10-Q for the period ended June 28, 2009.\n4.3",
      "char_count": 934,
      "start_char": 628000,
      "end_char": 628935
    },
    {
      "chunk_id": "pfizer_2023_chunk0786",
      "chunk_index": 786,
      "text": "ed as of January 30, 2001, is incorporated by reference from our Quarterly Report on Form\n10-Q for the period ended June 28, 2009.\n4.3\nSecond Supplemental Indenture, dated as of June 2, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan\nChase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K\nfiled on June 3, 2009.\n4.4\nThird Supplemental Indenture, dated as of June 3, 2013, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan\nChase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K\nfiled on June 3, 2013.\n4.5\nFourth Supplemental Indenture, dated as of May 15, 2014, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A.",
      "char_count": 983,
      "start_char": 628800,
      "end_char": 629784
    },
    {
      "chunk_id": "pfizer_2023_chunk0787",
      "chunk_index": 787,
      "text": "port on Form 8-K\nfiled on June 3, 2013.\n4.5\nFourth Supplemental Indenture, dated as of May 15, 2014, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan\nChase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K\nfiled on May 15, 2014.\n4.6\nFifth Supplemental Indenture, dated as of October 5, 2015, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan\nChase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K\nfiled on October 6, 2015.\n4.7\nSixth Supplemental Indenture, dated as of June 3, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase\nBank, N.A.",
      "char_count": 928,
      "start_char": 629600,
      "end_char": 630529
    },
    {
      "chunk_id": "pfizer_2023_chunk0788",
      "chunk_index": 788,
      "text": "June 3, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase\nBank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is\nincorporated by reference from our Current Report on Form 8-K filed on June 3, 2016.\n4.8\nSeventh Supplemental Indenture, dated as of November 21, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan\nChase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is\nincorporated by reference from our Current Report on Form 8-K filed on November 21, 2016.\n4.9\nEighth Supplemental Indenture, dated as of March 17, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank,\nN.A.",
      "char_count": 955,
      "start_char": 630400,
      "end_char": 631357
    },
    {
      "chunk_id": "pfizer_2023_chunk0789",
      "chunk_index": 789,
      "text": "lemental Indenture, dated as of March 17, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank,\nN.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (successor to the Chase Manhattan Bank (National Association)))), as trustee, and The Bank of\nNew York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on\nMarch 17, 2017.\n4.10\nNinth Supplemental Indenture, dated as of March 6, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank,\nN.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as\npaying agent and calculation agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on March 6, 2017.\n4.11",
      "char_count": 996,
      "start_char": 631200,
      "end_char": 632197
    },
    {
      "chunk_id": "pfizer_2023_chunk0790",
      "chunk_index": 790,
      "text": "llon, London Branch, as\npaying agent and calculation agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on March 6, 2017.\n4.11\nTenth Supplemental Indenture, dated as of December 19, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase\nBank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as\npaying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on December 19, 2017.\n4.12\nIndenture, dated as of April 10, 1992, between Wyeth (formerly American Home Products Corporation) and The Bank of New York Mellon (as successor to JPMorgan Chase\nBank, N.A.), as trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3, filed on January 18, 1995.\n4.13",
      "char_count": 974,
      "start_char": 632000,
      "end_char": 632975
    },
    {
      "chunk_id": "pfizer_2023_chunk0791",
      "chunk_index": 791,
      "text": "Mellon (as successor to JPMorgan Chase\nBank, N.A.), as trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3, filed on January 18, 1995.\n4.13\nSupplemental Indenture, dated as of October 13, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is\nincorporated by reference from Wyeth’s Registration Statement on Form S-3, filed on January 18, 1995.\n4.14\nFifth Supplemental Indenture, dated as of December 16, 2003, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee,\nis incorporated by reference from Wyeth’s 2003 Annual Report on Form 10-K.\n4.15\nSixth Supplemental Indenture, dated as of November 14, 2005, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee,\nis incorporated by reference from Wyeth’s Current Report on Form 8-K filed on November 15, 2005.\n\n2023 Form 10-K",
      "char_count": 961,
      "start_char": 632800,
      "end_char": 633763
    },
    {
      "chunk_id": "pfizer_2023_chunk0792",
      "chunk_index": 792,
      "text": "cessor to JPMorgan Chase Bank, N.A.), as trustee,\nis incorporated by reference from Wyeth’s Current Report on Form 8-K filed on November 15, 2005.\n\n2023 Form 10-K\n\n4.16\nSeventh Supplemental Indenture, dated as of March 27, 2007, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee,\nis incorporated by reference from Wyeth’s Current Report on Form 8-K filed on March 28, 2007.\n4.17\nEighth Supplemental Indenture, dated as of October 30, 2009, between Wyeth, us and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, formerly The\nChase Manhattan Bank), as trustee, to Indenture dated as of April 10, 1992 (as amended on October 13, 1992), is incorporated by reference from our Current Report on Form\n8-K filed on November 3, 2009.\n4.18\nIndenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed\non September 7, 2018.\n4.19",
      "char_count": 994,
      "start_char": 633600,
      "end_char": 634595
    },
    {
      "chunk_id": "pfizer_2023_chunk0793",
      "chunk_index": 793,
      "text": "ndenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed\non September 7, 2018.\n4.19\nFirst Supplemental Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report\non Form 8-K filed on September 7, 2018.\n4.20\nSecond Supplemental Indenture, dated as of March 11, 2019, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report\non Form 8-K filed on March 11, 2019.\n4.21\nThird Supplemental Indenture, dated as of March 27, 2020, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report\non Form 8-K filed on March 27, 2020.\n4.22\nFourth Supplemental Indenture, dated as of May 28, 2020, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on",
      "char_count": 997,
      "start_char": 634400,
      "end_char": 635398
    },
    {
      "chunk_id": "pfizer_2023_chunk0794",
      "chunk_index": 794,
      "text": "iled on March 27, 2020.\n4.22\nFourth Supplemental Indenture, dated as of May 28, 2020, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on\nForm 8-K filed on May 28, 2020.\n4.23\nFifth Supplemental Indenture, dated as of August 18, 2021 between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on\nForm 8-K filed on August 18, 2021.\n4.24\nIndenture, dated as of May 19, 2023, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and The Bank of New York Mellon, as trustee, is incorporated by reference\nfrom our Current Report on Form 8-K filed on May 19, 2023.\n4.25\nFirst Supplemental Indenture, dated as of May 19, 2023, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and The Bank of New York Mellon, as trustee, is\nincorporated by reference from our Current Report on Form 8-K filed on May 19, 2023.\n*4.26\nDescription of Pfizer’s Securities.\n4.27",
      "char_count": 973,
      "start_char": 635200,
      "end_char": 636174
    },
    {
      "chunk_id": "pfizer_2023_chunk0795",
      "chunk_index": 795,
      "text": "e Bank of New York Mellon, as trustee, is\nincorporated by reference from our Current Report on Form 8-K filed on May 19, 2023.\n*4.26\nDescription of Pfizer’s Securities.\n4.27\nExcept as set forth in Exhibits 4.1-4.26 above, the instruments defining the rights of holders of long-term debt securities of the Company and its subsidiaries have been\nomitted. We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.\n10.1\n2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001 Annual Meeting of Shareholders.\n10.2\n\n10.3\nAmendment No. 1 to Pfizer 2004 Stock Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n10.4\n\n10.5\nAmendment No. 1 to Pfizer Inc.",
      "char_count": 805,
      "start_char": 636000,
      "end_char": 636806
    },
    {
      "chunk_id": "pfizer_2023_chunk0796",
      "chunk_index": 796,
      "text": "Inc. 2014 Stock Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n10.6\nForm of Acknowledgment and Consent and Summary of Key Terms for Grants of RSUs, TSRUs, PPSs and PSAs is incorporated by reference from our Quarterly Report on\nForm 10-Q for the period ended April 2, 2023.\n10.7\nForm of Executive Grant Letter is incorporated by reference from our 2015 Annual Report on Form 10-K.\n10.8\n\n10.9\nAmendment No. 1 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2018 Annual\nReport on Form 10-K.\n10.10\nAmendment No. 2 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2020 Annual\nReport on Form 10-K.\n10.11\nAmendment No.",
      "char_count": 813,
      "start_char": 636800,
      "end_char": 637615
    },
    {
      "chunk_id": "pfizer_2023_chunk0797",
      "chunk_index": 797,
      "text": "Amendment No. 3 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2022 Annual\nReport on Form 10-K.\n*10.12\nAmendment No. 4 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees.\n10.13\n\n10.14\nAmendment No. 1 to the Pfizer Supplemental Savings Plan (Amended and Restated as of January 1, 2016), is incorporated by reference from our Quarterly Report on Form\n10-Q for the period ended October 1, 2017.\n10.15\nAmendment No. 2 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2017 Annual Report on Form 10-K.\n10.16\nAmendment No. 3 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 30, 2018.\n10.17\nAmendment No. 4 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.\n10.18\nAmendment No.",
      "char_count": 982,
      "start_char": 637600,
      "end_char": 638584
    },
    {
      "chunk_id": "pfizer_2023_chunk0798",
      "chunk_index": 798,
      "text": "riod ended September 30, 2018.\n10.17\nAmendment No. 4 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.\n10.18\nAmendment No. 5 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.\n10.19\nAmendment No. 6 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 30, 2019.\n10.20\nAmendment No. 7 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2019 Annual Report on Form 10-K.\n\n2023 Form 10-K\n\n10.21\nAmendment No. 8 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n10.22\nAmendment No. 9 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n10.23\nAmendment No.",
      "char_count": 898,
      "start_char": 638400,
      "end_char": 639299
    },
    {
      "chunk_id": "pfizer_2023_chunk0799",
      "chunk_index": 799,
      "text": "gs Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n10.23\nAmendment No. 10 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2022 Annual Report on Form 10-K.\n10.24\nAmended and Restated Pfizer Inc. Global Performance Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1, 2023.\n10.25\nAmended and Restated Deferred Compensation Plan is incorporated by reference from our 2012 Annual Report on Form 10-K.\n10.26\nAmendment to Amended and Restated Deferred Compensation Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on Form 10-K.\n10.27\nAmendment No. 2 to Amended and Restated Deferred Compensation Plan, dated April 27, 2016, is incorporated by reference from our Quarterly Report on Form 10-Q for the\nperiod ended July 3, 2016.\n10.28\nAmendment No.",
      "char_count": 885,
      "start_char": 639200,
      "end_char": 640086
    },
    {
      "chunk_id": "pfizer_2023_chunk0800",
      "chunk_index": 800,
      "text": "Quarterly Report on Form 10-Q for the\nperiod ended July 3, 2016.\n10.28\nAmendment No. 3 to Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n*10.29\nAmendment No. 4 to Amended and Restated Deferred Compensation Plan.\n10.30\nWyeth 2005 (409A) Deferred Compensation Plan (frozen as of January 2012), together with certain Amendments, is incorporated by reference from our 2013 Annual Report\non Form 10-K.\n10.31\nAmendment No. 2 to Wyeth 2005 (409A) Deferred Compensation Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n10.32\nAmended and Restated Wyeth Supplemental Employee Savings Plan (effective as of January 1, 2005 and frozen as of January 2012), together with all material Amendments\nis incorporated by reference from our 2011 Annual Report on Form 10-K.\n10.33",
      "char_count": 857,
      "start_char": 640000,
      "end_char": 640859
    },
    {
      "chunk_id": "pfizer_2023_chunk0801",
      "chunk_index": 801,
      "text": "reference from our 2011 Annual Report on Form 10-K.\n10.33\nAmendment to Amended and Restated Wyeth Supplemental Employee Savings Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on\nForm 10-K.\n10.34\nThe form of Indemnification Agreement with each of our non-employee Directors is incorporated by reference from our 1996 Annual Report on Form 10-K.\n10.35\nThe form of Indemnification Agreement with each of the Named Executive Officers identified in our Proxy Statement for the 2023 Annual Meeting of Shareholders is\nincorporated by reference from our 1997 Annual Report on Form 10-K.\n10.36\nLetter to Frank A. D’Amelio regarding replacement pension benefit dated August 22, 2007 is incorporated by reference from our Current\nReport on Form 8-K filed on August 22, 2007.\n10.37",
      "char_count": 806,
      "start_char": 640800,
      "end_char": 641608
    },
    {
      "chunk_id": "pfizer_2023_chunk0802",
      "chunk_index": 802,
      "text": ".\n10.37\n\n10.38\nAmendment No. 1 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.\n10.39\nAmendment No. 2 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2019 Annual Report on Form 10-K.\n10.40\nAmendment No. 3 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.\n10.41\nAmendment No. 4 to the Pfizer Inc. Executive Severance Plan is incorporate by reference from our 2022 Annual Report on Form 10-K.\n10.42\nAnnual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference from our 2008 Annual Report on Form\n10-K.\n10.43\nNonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from our 2022 Annual Report on Form 10-K.\n10.44",
      "char_count": 909,
      "start_char": 641600,
      "end_char": 642510
    },
    {
      "chunk_id": "pfizer_2023_chunk0803",
      "chunk_index": 803,
      "text": "-Employee Directors, as amended, is incorporated by reference from our 2022 Annual Report on Form 10-K.\n10.44\nForm of Special Award Letter Agreement is incorporated by reference from our Current Report on Form 8-K filed on October 28, 2009.\n10.45\nOffer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2011.\n10.46\nForm of Special Performance-Based Incentive Award Letter is incorporated by reference from our 2017 Annual Report on\nForm 10-K.\n10.47\nForm of Special Performance-Based Incentive Grant Letter is incorporated by reference from our 2017 Annual Report on\nForm 10-K.\n10.48\n\n10.49\nTime Sharing Agreement, dated July 9, 2020, between Pfizer Inc. and Albert Bourla is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended\nJune 28, 2020.\n10.50",
      "char_count": 879,
      "start_char": 642400,
      "end_char": 643280
    },
    {
      "chunk_id": "pfizer_2023_chunk0804",
      "chunk_index": 804,
      "text": "rom our Quarterly Report on Form 10-Q for the period ended\nJune 28, 2020.\n10.50\n\n*21\nSubsidiaries of the Company.\n*22\nSubsidiary Issuers of Guaranteed Securities.\n*23\nConsent of Independent Registered Public Accounting Firm.\n*24\nPower of Attorney (included as part of signature page).\n*31.1\nCertification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n2023 Form 10-K\n\n*31.2\nCertification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n*32.1\nCertification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n*32.2\nCertification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n*97",
      "char_count": 839,
      "start_char": 643200,
      "end_char": 644040
    },
    {
      "chunk_id": "pfizer_2023_chunk0805",
      "chunk_index": 805,
      "text": "of the Sarbanes-Oxley Act of 2002.\n*97\n\nExhibit 101:\n*101.INS\nXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n*101.SCH\nInline XBRL Taxonomy Extension Schema\n*101.CAL\nInline XBRL Taxonomy Extension Calculation Linkbase\n*101.LAB\nInline XBRL Taxonomy Extension Label Linkbase\n*101.PRE\nInline XBRL Taxonomy Extension Presentation Linkbase\n*101.DEF\nInline XBRL Taxonomy Extension Definition Document\n\nCover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline\nXBRL document.\nITEM 16.\nFORM 10-K SUMMARY\nNone.\n\n2023 Form 10-K\n\nSIGNATURES\nUnder the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.",
      "char_count": 928,
      "start_char": 644000,
      "end_char": 644930
    },
    {
      "chunk_id": "pfizer_2023_chunk0806",
      "chunk_index": 806,
      "text": "of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.\n\nDated: February 22, 2024\nBy:\n/S/ MARGARET M. MADDEN\nMargaret M. Madden\nSenior Vice President and Corporate Secretary\nChief Governance Counsel\nWe, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful\nattorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed\nwith the Securities and Exchange Commission.\nUnder the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date\nindicated.\nSignature\nTitle\nDate\n/S/ ALBERT BOURLA\nAlbert Bourla\nChairman, Chief Executive Officer and Director\n(Principal Executive Officer)",
      "char_count": 988,
      "start_char": 644800,
      "end_char": 645790
    },
    {
      "chunk_id": "pfizer_2023_chunk0807",
      "chunk_index": 807,
      "text": "Registrant and in the capacities and on the date\nindicated.\nSignature\nTitle\nDate\n/S/ ALBERT BOURLA\nAlbert Bourla\nChairman, Chief Executive Officer and Director\n(Principal Executive Officer)\nFebruary 20, 2024\n/S/ DAVID M. DENTON\nDavid M. Denton\nChief Financial Officer, Executive Vice President\n(Principal Financial Officer)\nFebruary 20, 2024\n/S/ JENNIFER B. DAMICO\nJennifer B. Damico\nSenior Vice President and Controller\n(Principal Accounting Officer)\nFebruary 20, 2024\n/S/ RONALD E. BLAYLOCK\nRonald E. Blaylock\nDirector\nFebruary 21, 2024\n/S/ SUSAN DESMOND-HELLMANN\nSusan Desmond-Hellmann\nDirector\nFebruary 21, 2024\n/S/ JOSEPH J. ECHEVARRIA\nJoseph J. Echevarria\nDirector\nFebruary 20, 2024\n/S/ SCOTT GOTTLIEB\nScott Gottlieb\nDirector\nFebruary 21, 2024\n/S/ HELEN H. HOBBS\nHelen H. Hobbs\nDirector\nFebruary 20, 2024\n/S/ SUSAN HOCKFIELD\nSusan Hockfield\nDirector\nFebruary 20, 2024\n/S/ DAN R. LITTMAN\nDan R.",
      "char_count": 899,
      "start_char": 645600,
      "end_char": 646500
    },
    {
      "chunk_id": "pfizer_2023_chunk0808",
      "chunk_index": 808,
      "text": "y 20, 2024\n/S/ SUSAN HOCKFIELD\nSusan Hockfield\nDirector\nFebruary 20, 2024\n/S/ DAN R. LITTMAN\nDan R. Littman\nDirector\nFebruary 20, 2024\n/S/ SHANTANU NARAYEN\nShantanu Narayen\nDirector\nFebruary 20, 2024\n/S/ SUZANNE NORA JOHNSON\nSuzanne Nora Johnson\nDirector\nFebruary 20, 2024\n/S/ JAMES QUINCEY\nJames Quincey\nDirector\nFebruary 21, 2024\n/S/ JAMES C. SMITH\nJames C. Smith\nDirector\nFebruary 20, 2024\n\n2023 Form 10-K\n\nEXHIBIT 4.26\nDESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934\nAs of February 22, 2024, Pfizer Inc. has common stock and its 1.000% Notes due 2027 (the “notes”) registered under Section 12 of the Securities Exchange Act of 1934, as\namended. The following descriptions of our common stock and the notes are summaries and do not purport to be complete.",
      "char_count": 826,
      "start_char": 646400,
      "end_char": 647227
    },
    {
      "chunk_id": "pfizer_2023_chunk0809",
      "chunk_index": 809,
      "text": "ot purport to be complete. The description of our common stock is subject to and\nqualified in its entirety by reference to our restated certificate of incorporation (the “Certificate of Incorporation”), and our bylaws, as amended (the “Bylaws”), and the description of\nthe notes is subject to and qualified in its entirety by reference to the base indenture (as defined below) and the ninth supplemental indenture (as defined below), each of which are\nincorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.25 is a part. We encourage you to read the Certificate of Incorporation, the Bylaws,\nthe applicable provisions of the Delaware General Corporation Law (the “DGCL”), the base indenture and the ninth supplemental indenture for additional information. References in\nthis section to “Pfizer,” “we,” “us” and “our” are to Pfizer Inc., unless otherwise stated or the context so requires.\nDESCRIPTION OF CAPITAL STOCK\nCommon Stock",
      "char_count": 973,
      "start_char": 647200,
      "end_char": 648174
    },
    {
      "chunk_id": "pfizer_2023_chunk0810",
      "chunk_index": 810,
      "text": "eferences in\nthis section to “Pfizer,” “we,” “us” and “our” are to Pfizer Inc., unless otherwise stated or the context so requires.\nDESCRIPTION OF CAPITAL STOCK\nCommon Stock\nUnder the Certificate of Incorporation, we are authorized to issue up to 12 billion shares of common stock, par value $0.05 per share. The common stock is not redeemable, does\nnot have any conversion rights and is not subject to call. Holders of shares of common stock have no preemptive rights to maintain their percentage of ownership in future offerings\nor sales of our stock. Holders of shares of common stock have one vote per share in all elections of Directors and on all other matters submitted to a vote of our stockholders. The\nholders of common stock are entitled to receive dividends, if any, as and when may be declared from time to time by our Board of Directors, out of funds legally available therefor.",
      "char_count": 892,
      "start_char": 648000,
      "end_char": 648893
    },
    {
      "chunk_id": "pfizer_2023_chunk0811",
      "chunk_index": 811,
      "text": "clared from time to time by our Board of Directors, out of funds legally available therefor.\nUpon liquidation, dissolution or winding up of our affairs, the holders of common stock will be entitled to participate equally and ratably, in proportion to the number of shares held, in\nour net assets available for distribution to holders of common stock. The shares of common stock currently outstanding are fully paid and nonassessable. The common stock is\ntraded on the New York Stock Exchange under the trading symbol “PFE.”\nPreferred Stock\nUnder the Certificate of Incorporation, we are authorized to issue up to 27 million shares of preferred stock, without par value. The preferred stock may be issued in one or more\nseries, and the Board of Directors of Pfizer is expressly authorized (i) to fix the descriptions, powers, preferences, rights, qualifications, limitations, and restrictions with respect to",
      "char_count": 907,
      "start_char": 648800,
      "end_char": 649708
    },
    {
      "chunk_id": "pfizer_2023_chunk0812",
      "chunk_index": 812,
      "text": "he descriptions, powers, preferences, rights, qualifications, limitations, and restrictions with respect to\nany series of preferred stock and (ii) to specify the number of shares of any series of preferred stock.\nAnti-takeover Effects of the Certificate of Incorporation, Bylaws and Delaware Law\nCertificate of Incorporation and Bylaws. Various provisions contained in the Certificate of Incorporation and the Bylaws could delay or discourage some transactions involving an\nactual or potential change in control of us or a change in our management and may limit the ability of our stockholders to remove current management or approve transactions that\nour stockholders may deem to be in their best interests. Among other things, these provisions:\n \nlimit the right of stockholders to call special meetings of stockholders to holders of at least 10% of the total number of shares of stock entitled to vote on the matter to be\nbrought before the proposed special meeting;",
      "char_count": 969,
      "start_char": 649600,
      "end_char": 650570
    },
    {
      "chunk_id": "pfizer_2023_chunk0813",
      "chunk_index": 813,
      "text": "tings of stockholders to holders of at least 10% of the total number of shares of stock entitled to vote on the matter to be\nbrought before the proposed special meeting;\nauthorize our Board of Directors to establish one or more series of preferred stock without stockholder approval;\nauthorize the Board of Directors to issue dividends in the form of stock purchase or similar rights, including rights that would have the effect of making an attempt to\nacquire us more costly;\ngrant to the Board of Directors, and not to the stockholders, the sole power to set the number of Directors;\nrequire that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be\neffected by any consent in writing; and\nsubject to the rights of the holders of any one or more series of preferred stock then outstanding, allow our Directors, and not our stockholders, to fill vacancies on our",
      "char_count": 966,
      "start_char": 650400,
      "end_char": 651367
    },
    {
      "chunk_id": "pfizer_2023_chunk0814",
      "chunk_index": 814,
      "text": "ct to the rights of the holders of any one or more series of preferred stock then outstanding, allow our Directors, and not our stockholders, to fill vacancies on our\nBoard of Directors, including vacancies resulting from the removal of one or more Directors or an increase in the number of Directors constituting the whole Board of\nDirectors.\nDelaware Law. We are a Delaware corporation and consequently are also subject to certain anti-takeover provisions of the DGCL. Subject to certain exceptions, Section 203 of the\nDGCL prevents a publicly-held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for three years following the date that the person\nbecame an interested stockholder, unless (a) the interested stockholder attained such status with the approval of the corporation’s board of directors, (b) upon consummation of the",
      "char_count": 879,
      "start_char": 651200,
      "end_char": 652080
    },
    {
      "chunk_id": "pfizer_2023_chunk0815",
      "chunk_index": 815,
      "text": "approval of the corporation’s board of directors, (b) upon consummation of the\ntransaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at\nthe time the transaction commenced, exclusive of shares owned by directors who are also officers and by certain employee stock plans or (c) at or subsequent to such time, the\nbusiness combination is approved by the board of directors and authorized by the affirmative vote at a\n\nstockholders’ meeting, and not by written consent, of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder. A “business combination”\nincludes, among other things, a merger or consolidation involving the corporation and the “interested stockholder” and the sale of more than 10% of the corporation’s assets.",
      "char_count": 890,
      "start_char": 652000,
      "end_char": 652892
    },
    {
      "chunk_id": "pfizer_2023_chunk0816",
      "chunk_index": 816,
      "text": "and the “interested stockholder” and the sale of more than 10% of the corporation’s assets. In\ngeneral, an “interested stockholder” is any entity or person beneficially owning 15% or more of the corporation’s outstanding voting stock, and any entity or person affiliated with or\ncontrolling or controlled by such entity or person. Section 203 of the DGCL makes it more difficult for an interested stockholder to effect various business combinations with a\ncorporation for a three-year period. This statute could prohibit or delay mergers or other takeover or change in control attempts not approved in advance by our Board of Directors,\nand, as a result, could discourage attempts to acquire us, which could depress the market price of our common stock.\nDESCRIPTION OF DEBT SECURITIES\nReference should be made to the indenture dated as of January 30, 2001, between Pfizer and The Bank of New York Mellon (formerly known as The Bank of New York), as",
      "char_count": 948,
      "start_char": 652800,
      "end_char": 653749
    },
    {
      "chunk_id": "pfizer_2023_chunk0817",
      "chunk_index": 817,
      "text": "d be made to the indenture dated as of January 30, 2001, between Pfizer and The Bank of New York Mellon (formerly known as The Bank of New York), as\nsuccessor to JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank), as trustee, which we refer to as the “base indenture,” as supplemented by the ninth\nsupplemental indenture, dated as of March 6, 2017, among Pfizer Inc., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying\nagent, which we refer to as the “ninth supplemental indenture.” When we refer to the “indenture,” we mean the base indenture, as supplemented by the ninth supplemental\nindenture. The following description is a summary of selected portions of the base indenture and the ninth supplemental indenture. It does not restate the base indenture or the ninth\nsupplemental indenture, and those documents, not this description, define the rights of a holder of the notes.\nPrincipal, Maturity and Interest",
      "char_count": 975,
      "start_char": 653600,
      "end_char": 654576
    },
    {
      "chunk_id": "pfizer_2023_chunk0818",
      "chunk_index": 818,
      "text": "the base indenture or the ninth\nsupplemental indenture, and those documents, not this description, define the rights of a holder of the notes.\nPrincipal, Maturity and Interest\nThe notes were limited to €750,000,000 aggregate principal amount. The notes will mature on March 6, 2027. We issued the notes in denominations of €100,000 and in integral\nmultiples of €1,000 in excess thereof.\nInterest on the notes accrues at the annual rate of 1.000%. Interest on the notes is payable on March 6 of each year. Interest on the notes is computed on the basis of the actual\nnumber of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes to, but\nexcluding, the next scheduled interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) (as defined in the rulebook of the International Capital\nMarket Association).",
      "char_count": 938,
      "start_char": 654400,
      "end_char": 655339
    },
    {
      "chunk_id": "pfizer_2023_chunk0819",
      "chunk_index": 819,
      "text": "is payment convention is referred to as ACTUAL/ACTUAL (ICMA) (as defined in the rulebook of the International Capital\nMarket Association).\nWe make each interest payment to the holders of record of the notes at the close of business on the 15th calendar day (whether or not a business day) preceding the relevant\ninterest payment date.\nThe Bank of New York Mellon, London Branch, acts as our paying agent with respect to the notes. Upon notice to the trustee, we may change any paying agent. Payments of\nprincipal, interest and premium, if any, will be made by us through the paying agent to Euroclear Bank S.A./N.V. (the “Euroclear Operator”), as operator of the Euroclear System\n(“Euroclear”) and/or Clearstream Banking, Société Anonyme, Luxembourg (“Clearstream”) as described under “—Book-Entry.”\nIssuance in Euros\nPrincipal, premium, if any, and interest payments and additional amounts, if any, in respect of the notes are payable in euros.",
      "char_count": 945,
      "start_char": 655200,
      "end_char": 656146
    },
    {
      "chunk_id": "pfizer_2023_chunk0820",
      "chunk_index": 820,
      "text": "Issuance in Euros\nPrincipal, premium, if any, and interest payments and additional amounts, if any, in respect of the notes are payable in euros.\nIf the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or the euro is no longer used by the then member states of the\nEuropean Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions within the international banking community, then all\npayments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount payable on any date in euros will\nbe converted to U.S. dollars on the basis of the most recently available market exchange rate for euros, as determined by us in our sole discretion. Any payment in respect of the\nnotes so made in U.S. dollars does not constitute an event of default under the indenture or the notes.",
      "char_count": 974,
      "start_char": 656000,
      "end_char": 656975
    },
    {
      "chunk_id": "pfizer_2023_chunk0821",
      "chunk_index": 821,
      "text": "determined by us in our sole discretion. Any payment in respect of the\nnotes so made in U.S. dollars does not constitute an event of default under the indenture or the notes. Neither the trustee nor the paying agent is responsible for obtaining exchange\nrates, effecting conversions or otherwise handling redenominations.\nPayment of Additional Amounts\nAll payments in respect of the notes are made by or on behalf of us without withholding or deduction for, or on account of, any present or future taxes, duties, assessments or\ngovernmental charges of whatever nature, imposed or levied by the United States or any taxing authority thereof or therein, unless such withholding or deduction is required by law.\nIf such withholding or deduction is required by law, we pay to a beneficial owner who is not a United States person such additional amounts on the notes as are necessary in order",
      "char_count": 887,
      "start_char": 656800,
      "end_char": 657688
    },
    {
      "chunk_id": "pfizer_2023_chunk0822",
      "chunk_index": 822,
      "text": "t a United States person such additional amounts on the notes as are necessary in order\nthat the net payment of the principal of, and premium or redemption price, if any, and interest on, such notes to such beneficial owner, after such withholding or deduction (including\nany withholding or deduction on such additional amounts), will not be less than the amount provided in such notes to be then due and payable; provided, however, that the foregoing\nobligation to pay additional amounts will not apply:\nto any tax, assessment or other governmental charge that would not have been imposed but for the beneficial owner, or a fiduciary, settlor, beneficiary, member or\nshareholder of the beneficial owner if the beneficial owner is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered",
      "char_count": 841,
      "start_char": 657600,
      "end_char": 658442
    },
    {
      "chunk_id": "pfizer_2023_chunk0823",
      "chunk_index": 823,
      "text": "ower over an estate or trust administered\nby a fiduciary holder, being considered as (i) having a current or former connection with the United States (other than a connection arising solely as a result of the\nownership of such notes, the receipt of any payment or the enforcement of any rights thereunder), including being or having been a citizen or resident of the United States,\nor being or having been engaged in a trade or business in the United States or having or having had a permanent establishment in the United States; (ii) being a controlled\nforeign corporation related to Pfizer directly, indirectly or constructively through stock ownership for U.S. federal income tax purposes; (iii) being an owner of a 10% or\ngreater interest in voting stock of Pfizer within the meaning of Section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) or any successor\nprovision; or (iv) being a",
      "char_count": 919,
      "start_char": 658400,
      "end_char": 659320
    },
    {
      "chunk_id": "pfizer_2023_chunk0824",
      "chunk_index": 824,
      "text": "71(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) or any successor\nprovision; or (iv) being a\n\nbank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business;\nto any holder that is not the sole beneficial owner of such notes, or a portion of such notes, or that is a fiduciary, partnership or limited liability company, but only to the\nextent that a beneficiary or settlor with respect to the fiduciary, a beneficial owner or a member of the partnership or limited liability company would not have been entitled\nto the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly from Pfizer its beneficial or distributive share of the\npayment;\nto any tax, assessment or other governmental charge imposed by reason of the holder’s or beneficial owner’s past or present status as a passive foreign investment",
      "char_count": 961,
      "start_char": 659200,
      "end_char": 660162
    },
    {
      "chunk_id": "pfizer_2023_chunk0825",
      "chunk_index": 825,
      "text": "o any tax, assessment or other governmental charge imposed by reason of the holder’s or beneficial owner’s past or present status as a passive foreign investment\ncompany, a controlled foreign corporation, a foreign tax exempt organization or a personal holding company with respect to the United States or as a corporation that\naccumulates earnings to avoid U.S. federal income tax;\nto any tax, assessment or other governmental charge that would not have been imposed but for the failure of the holder or beneficial owner of the applicable notes to\ncomply with any applicable certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United\nStates of the holder or beneficial owner of such notes, if compliance is timely requested by Pfizer and required by statute, by regulation of the United States or any taxing",
      "char_count": 895,
      "start_char": 660000,
      "end_char": 660896
    },
    {
      "chunk_id": "pfizer_2023_chunk0826",
      "chunk_index": 826,
      "text": "y requested by Pfizer and required by statute, by regulation of the United States or any taxing\nauthority therein or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other\ngovernmental charge;\nto any tax, assessment or other governmental charge that is imposed otherwise than by withholding or deducting from the payment;\nto any estate, inheritance, gift, sales, transfer, wealth, capital gains or personal property tax or similar tax, assessment or other governmental charge;\nto any tax, assessment or other governmental charge required to be withheld by any paying agent from any payment of principal of or interest on any such note, if such\npayment can be made without such withholding by at least one other paying agent in a Member State of the European Union;",
      "char_count": 848,
      "start_char": 660800,
      "end_char": 661649
    },
    {
      "chunk_id": "pfizer_2023_chunk0827",
      "chunk_index": 827,
      "text": "g agent in a Member State of the European Union;\nto any tax, assessment or other governmental charge that is imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation\nthat becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later;\nto any tax, assessment or other governmental charge that would not have been imposed but for the presentation by the holder of any note, where presentation is required,\nfor payment on a date more than 30 days after the date on which payment became due and payable or the date on which payment thereof is duly provided for, whichever\noccurs later, except to the extent that the holder or beneficial owner thereof would have been entitled to additional amounts had the note been presented for payment on\nthe last day of such 30 day period;",
      "char_count": 880,
      "start_char": 661600,
      "end_char": 662481
    },
    {
      "chunk_id": "pfizer_2023_chunk0828",
      "chunk_index": 828,
      "text": "s had the note been presented for payment on\nthe last day of such 30 day period;\nto any withholding or deduction that is imposed on a payment pursuant to Sections 1471 through 1474 of the Code and related Treasury regulations and pronouncements\nor any successor provisions thereto (that are substantively comparable and not materially more onerous to comply with) and any regulations or official law, agreement or\ninterpretations thereof in any jurisdiction implementing an intergovernmental approach thereto; or\nin the case of any combination of the above listed items.\nExcept as specifically provided under this heading “—Payment of Additional Amounts,” we are not required to make any payment for any tax, duty, assessment or governmental\ncharge of whatever nature imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.",
      "char_count": 890,
      "start_char": 662400,
      "end_char": 663291
    },
    {
      "chunk_id": "pfizer_2023_chunk0829",
      "chunk_index": 829,
      "text": "olitical subdivision or taxing authority of or in any government or political subdivision.\nAs used under this heading “—Payment of Additional Amounts” and under the heading “—Optional Redemption of Notes; Redemption for Tax Reasons; No Sinking Fund,” the term\n“United States” means the United States of America, any state thereof, and the District of Columbia, and the term “United States person” means (i) any individual who is a citizen or\nresident of the United States for U.S. federal income tax purposes, (ii) a corporation, partnership or other entity created or organized in or under the laws of the United States, any\nstate thereof or the District of Columbia (other than a partnership that is not treated as a United States person for U.S. federal income tax purposes), (iii) any estate the income of\nwhich is subject to U.S. federal income taxation regardless of its source, or (iv) any trust if a U.S.",
      "char_count": 912,
      "start_char": 663200,
      "end_char": 664113
    },
    {
      "chunk_id": "pfizer_2023_chunk0830",
      "chunk_index": 830,
      "text": "income of\nwhich is subject to U.S. federal income taxation regardless of its source, or (iv) any trust if a U.S. court can exercise primary supervision over the administration of the trust and one\nor more United States persons can control all substantial trust decisions, or if a valid election is in place to treat the trust as a United States person.\nRanking\nThe notes are unsecured general obligations of Pfizer and rank equally with all other unsecured and unsubordinated indebtedness of Pfizer from time to time outstanding.\n\nListing\nThe notes are listed on the NYSE. We have no obligation to maintain such listing, and we may delist the notes at any time.\nCovenants\nThe indenture contains a provision that restricts our ability to consolidate with or merge into any other person or convey or transfer our properties and assets as an entirety or\nsubstantially as an entirety to any other person.",
      "char_count": 900,
      "start_char": 664000,
      "end_char": 664901
    },
    {
      "chunk_id": "pfizer_2023_chunk0831",
      "chunk_index": 831,
      "text": "ansfer our properties and assets as an entirety or\nsubstantially as an entirety to any other person. The indenture does not restrict our ability to convey or transfer our properties and assets other than as an entirety or substantially as\nan entirety to any other person. See “Article VIII - Consolidation, Merger, Conveyance or Transfer” in the base indenture. The indenture contains no other restrictive covenants,\nincluding those that would afford holders of the notes protection in the event of a highly-leveraged transaction involving Pfizer or any of its affiliates or other events involving us that\nmay adversely affect our creditworthiness or the value of the notes. The indenture also does not contain any covenants relating to total indebtedness, interest coverage, stock\nrepurchases, recapitalizations, dividends and distributions to shareholders, current ratios or acquisitions and divestitures.",
      "char_count": 907,
      "start_char": 664800,
      "end_char": 665708
    },
    {
      "chunk_id": "pfizer_2023_chunk0832",
      "chunk_index": 832,
      "text": "italizations, dividends and distributions to shareholders, current ratios or acquisitions and divestitures. The notes do not have the benefit of covenants that relate\nto subsidiary guarantees, liens and sale leaseback transactions that apply to other of our existing unsecured and unsubordinated notes.\nPfizer may, without the consent of the holders of notes of any series, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the\nnotes of any series (except for the issue date and the public offering price). Any additional notes having such similar terms, together with the notes of the applicable series, will\nconstitute a single series of debt securities under the indenture. No additional notes of any series may be issued if an event of default has occurred with respect to the notes of that\nseries.",
      "char_count": 855,
      "start_char": 665600,
      "end_char": 666456
    },
    {
      "chunk_id": "pfizer_2023_chunk0833",
      "chunk_index": 833,
      "text": "has occurred with respect to the notes of that\nseries. Pfizer will not issue any additional notes intended to form a single series with the notes of any series, unless such further notes will be fungible with all notes of the same\nseries for U.S. federal income tax purposes.\nOptional Redemption of Notes; Redemption for Tax Reasons; No Sinking Fund\nAt our option, we may redeem the notes (together, the redemption notes), in whole, at any time, or in part, from time to time, prior to December 6, 2026 (three months prior to the\nmaturity date). The redemption price will be equal to the greater of the following amounts:\n100% of the principal amount of the redemption notes being redeemed on the redemption date; and\nthe sum of the present values of the remaining scheduled payments of principal and interest on the redemption notes being redeemed on that redemption date (not",
      "char_count": 877,
      "start_char": 666400,
      "end_char": 667279
    },
    {
      "chunk_id": "pfizer_2023_chunk0834",
      "chunk_index": 834,
      "text": "d interest on the redemption notes being redeemed on that redemption date (not\nincluding the amount, if any, of accrued and unpaid interest to, but excluding, the redemption date) discounted to the redemption date on an annual basis at a rate equal to\nthe sum of the Comparable Government Bond Rate plus 15 basis points;\nplus, in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the redemption date.\nAt any time on or after December 6, 2026 (three months prior to the maturity date), we may redeem the redemption notes, in whole or in part, at a redemption price equal to 100% of\nthe principal amount of the redemption notes to be redeemed, plus in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the\nredemption date.\nNotwithstanding the foregoing, installments of interest on the applicable redemption notes that are due and payable on interest payment dates falling on or prior to a redemption date",
      "char_count": 997,
      "start_char": 667200,
      "end_char": 668198
    },
    {
      "chunk_id": "pfizer_2023_chunk0835",
      "chunk_index": 835,
      "text": "demption date.\nNotwithstanding the foregoing, installments of interest on the applicable redemption notes that are due and payable on interest payment dates falling on or prior to a redemption date\nwill be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the applicable redemption notes and the\nindenture. The redemption prices for the redemption notes will be calculated on the basis of a 365-day year or a 366-day year, as applicable, and the actual number of days elapsed.\nWe will mail notice of any redemption at least 10 days, but not more than 60 days, before the redemption date to each registered holder of the redemption notes to be redeemed.\nOnce notice of redemption is mailed, the redemption notes called for redemption will become due and payable on the redemption date at the applicable redemption price, plus",
      "char_count": 906,
      "start_char": 668000,
      "end_char": 668907
    },
    {
      "chunk_id": "pfizer_2023_chunk0836",
      "chunk_index": 836,
      "text": "for redemption will become due and payable on the redemption date at the applicable redemption price, plus\naccrued and unpaid interest applicable to such redemption notes to, but excluding, the redemption date.\n“Comparable Government Bond” means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an Independent Investment Banker, a German\ngovernment bond whose maturity is closest to the maturity of the redemption notes to be redeemed, or if such independent investment bank in its discretion determines that such\nsimilar bond is not in issue, such other German government bond as such Independent Investment Banker may, with the advice of three brokers of, and/or market makers in,\nGerman government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.",
      "char_count": 840,
      "start_char": 668800,
      "end_char": 669641
    },
    {
      "chunk_id": "pfizer_2023_chunk0837",
      "chunk_index": 837,
      "text": "ing the Comparable Government Bond Rate.\n“Comparable Government Bond Rate” means the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross\nredemption yield on the fixed rate notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal\nto the gross redemption yield on such business day of the Comparable Government Bond on the basis of the middle market price of the Comparable Government Bond prevailing at\n11:00 a.m. (London time) on such business day as determined by an Independent Investment Banker.\n“Independent Investment Banker” means one of the Reference Treasury Dealers appointed by us to act as the “Independent Investment Banker.”\n“Reference Treasury Dealer” means each of Barclays Bank PLC, BNP Paribas, Goldman, Sachs & Co. and J.P.",
      "char_count": 900,
      "start_char": 669600,
      "end_char": 670501
    },
    {
      "chunk_id": "pfizer_2023_chunk0838",
      "chunk_index": 838,
      "text": "ference Treasury Dealer” means each of Barclays Bank PLC, BNP Paribas, Goldman, Sachs & Co. and J.P. Morgan Securities plc (or their respective affiliates that are Primary\nTreasury Dealers), and their respective successors; provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and/or market maker in, German\ngovernment bonds (a “Primary Treasury Dealer”), we will substitute therefor another Primary Treasury Dealer.\n\nOn and after the redemption date, interest will cease to accrue on the redemption notes or any portion of the redemption notes called for redemption (unless we default in the\npayment of the redemption price and accrued and unpaid interest). On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the\nredemption price of and accrued and unpaid interest on the redemption notes to be redeemed on that date.",
      "char_count": 914,
      "start_char": 670400,
      "end_char": 671315
    },
    {
      "chunk_id": "pfizer_2023_chunk0839",
      "chunk_index": 839,
      "text": "o pay the\nredemption price of and accrued and unpaid interest on the redemption notes to be redeemed on that date. If fewer than all of the redemption notes are to be redeemed, the\nredemption notes to be redeemed shall be selected by Euroclear and/or Clearstream, in the case of redemption notes represented by a global security, or by the trustee by a method\nthe trustee deems to be fair and appropriate, in the case of redemption notes that are not represented by a global security.\nThe notes are not entitled to the benefit of a sinking fund.\nRedemption for Tax Reasons\nIf, as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United States (or any taxing authority thereof or therein),\nor any change in, or amendments to, an official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or",
      "char_count": 939,
      "start_char": 671200,
      "end_char": 672140
    },
    {
      "chunk_id": "pfizer_2023_chunk0840",
      "chunk_index": 840,
      "text": "ficial position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or\nbecomes effective on or after February 28, 2017, we become or, based upon a written opinion of independent tax counsel of recognized standing selected by us, will become\nobligated to pay additional amounts as described herein under the heading “—Payment of Additional Amounts” with respect to any series of the notes, then we may at our option,\nhaving given not less than 10 nor more than 60 days prior notice to holders, redeem, in whole, but not in part, the applicable series of notes at a redemption price equal to 100% of\nthe principal amount, together with accrued and unpaid interest (including any additional amounts) on such notes to, but excluding, the redemption date.\nBook-Entry\nGlobal Clearance and Settlement",
      "char_count": 862,
      "start_char": 672000,
      "end_char": 672863
    },
    {
      "chunk_id": "pfizer_2023_chunk0841",
      "chunk_index": 841,
      "text": "he redemption date.\nBook-Entry\nGlobal Clearance and Settlement\nThe notes were issued in the form of one or more global notes in fully registered form, without coupons, and are deposited with, or on behalf of, a common depositary, and registered\nin the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. Except as described herein, certificates will not be\nissued in exchange for beneficial interests in the global notes representing the notes.\nExcept as set forth below, the global notes representing the notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees.\nBeneficial interests in the global notes representing the notes are represented, and transfers of such beneficial interests are effected, through accounts of financial institutions acting\non behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream.",
      "char_count": 971,
      "start_char": 672800,
      "end_char": 673772
    },
    {
      "chunk_id": "pfizer_2023_chunk0842",
      "chunk_index": 842,
      "text": "al interests are effected, through accounts of financial institutions acting\non behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests are in denominations of €100,000 and integral multiples of\n€1,000 in excess thereof. Investors may hold the notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are\nparticipants in such systems.\nFor so long as any series of the notes is represented by a global note deposited with, and registered in the name of a nominee for, a common depositary for Euroclear and/or\nClearstream, each person (other than Euroclear or Clearstream) who is for the time being shown in the records of Euroclear or of Clearstream as the holder of a particular nominal\namount of the notes (in which regard any certificate or other document issued by Euroclear or Clearstream as to the nominal amount of the notes standing to the account of any",
      "char_count": 999,
      "start_char": 673600,
      "end_char": 674600
    },
    {
      "chunk_id": "pfizer_2023_chunk0843",
      "chunk_index": 843,
      "text": "of a particular nominal\namount of the notes (in which regard any certificate or other document issued by Euroclear or Clearstream as to the nominal amount of the notes standing to the account of any\nperson shall be conclusive and binding for all purposes save in the case of manifest error) shall upon their receipt of a certificate or other document be treated by Pfizer and the\ntrustee as the holder of such nominal amount of the notes and the registered holder of the global note representing such notes shall be deemed not to be the holder for all purposes\nother than with respect to the payment of principal or interest on such nominal amount of the notes, for which purpose the registered holder of the relevant global note shall be\ntreated by Pfizer and the trustee as the holder of such nominal amount of notes in accordance with and subject to the terms of the global note representing the notes, and the",
      "char_count": 913,
      "start_char": 674400,
      "end_char": 675315
    },
    {
      "chunk_id": "pfizer_2023_chunk0844",
      "chunk_index": 844,
      "text": "nal amount of notes in accordance with and subject to the terms of the global note representing the notes, and the\nexpressions “noteholder” and “holder of notes” and related expressions shall be construed accordingly.\nThe information in this section concerning Euroclear and Clearstream Banking and their book-entry systems and procedures has been obtained from sources that we believe to be\nreliable. We are not responsible for the accuracy or completeness of this information.\nWe have been advised by Clearstream and Euroclear, respectively, as follows:\nClearstream has advised that:\n \nIt is incorporated under the laws of Luxembourg and licensed as a bank and professional depositary. Clearstream holds securities for its participating organizations and\nfacilitates the clearance and settlement of securities transactions among its participants through electronic book-entry changes in accounts of its participants, thereby\neliminating the need for physical movement of certificates.",
      "char_count": 986,
      "start_char": 675200,
      "end_char": 676187
    },
    {
      "chunk_id": "pfizer_2023_chunk0845",
      "chunk_index": 845,
      "text": "securities transactions among its participants through electronic book-entry changes in accounts of its participants, thereby\neliminating the need for physical movement of certificates.\nClearstream provides to its participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and\nsecurities lending and borrowing. Clearstream interfaces with domestic markets in several countries.\nClearstream has established an electronic bridge with the Euroclear Operator to facilitate the settlement of trades between the nominees of Clearstream and Euroclear.\n\nAs a registered bank in Luxembourg, Clearstream is subject to regulation by the Luxembourg Commission for the Supervision of the Financial Sector.\nClearstream customers are recognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing",
      "char_count": 938,
      "start_char": 676000,
      "end_char": 676940
    },
    {
      "chunk_id": "pfizer_2023_chunk0846",
      "chunk_index": 846,
      "text": "ecognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing\ncorporations and certain other organizations and may include the underwriters. Indirect access to Clearstream is also available to others, such as banks, brokers, dealers\nand trust companies that clear through, or maintain a custodial relationship with, a Clearstream participant, either directly or indirectly.\nDistributions with respect to the notes held beneficially through Clearstream will be credited to cash accounts of Clearstream participants in accordance with its rules and\nprocedures.\nEuroclear has advised that:\nIt was created in 1968 to hold securities for its participants and to clear and settle transactions between Euroclear participants through simultaneous electronic book-entry",
      "char_count": 838,
      "start_char": 676800,
      "end_char": 677639
    },
    {
      "chunk_id": "pfizer_2023_chunk0847",
      "chunk_index": 847,
      "text": "ugh simultaneous electronic book-entry\ndelivery against payment, thereby eliminating the need for physical movement of certificates and any risk from lack of simultaneous transfers of securities and cash.\nEuroclear includes various other services, including securities lending and borrowing and interfaces with domestic markets in several countries.\nEuroclear is operated by the Euroclear Operator. All operations are conducted by the Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear\ncash accounts are accounts with the Euroclear Operator.\nSecurities clearance accounts and cash accounts with the Euroclear Operator are governed by the Terms and Conditions Governing Use of Euroclear and the related\noperating procedures of Euroclear, and applicable Belgian law (collectively, the “Terms and Conditions”).",
      "char_count": 838,
      "start_char": 677600,
      "end_char": 678439
    },
    {
      "chunk_id": "pfizer_2023_chunk0848",
      "chunk_index": 848,
      "text": "ectively, the “Terms and Conditions”). The Terms and Conditions govern transfers of securities and cash\nwithin Euroclear, withdrawals of securities and cash from Euroclear, and receipts of payments with respect to securities in Euroclear. All securities in Euroclear are held on\na fungible basis without attribution of specific certificates to specific securities clearance accounts. The Euroclear Operator acts under the Terms and Conditions only on\nbehalf of Euroclear participants, and has no records of or relationship with persons holding through Euroclear participants.\nEuroclear participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries and may include the\nunderwriters. Indirect access to Euroclear is also available to other firms that clear through or maintain a custodial relationship with a Euroclear participant, either directly\nor indirectly.",
      "char_count": 931,
      "start_char": 678400,
      "end_char": 679332
    },
    {
      "chunk_id": "pfizer_2023_chunk0849",
      "chunk_index": 849,
      "text": "to other firms that clear through or maintain a custodial relationship with a Euroclear participant, either directly\nor indirectly.\nDistributions with respect to the notes held beneficially through Euroclear will be credited to the cash accounts of Euroclear participants in accordance with the Terms and\nConditions.\nEuroclear and Clearstream Arrangements\nSo long as Euroclear or Clearstream or their nominee or their common depositary is the registered holder of the global notes representing the notes, Euroclear, Clearstream or such\nnominee, as the case may be, will be considered the sole owner or holder of the notes represented by such global notes for all purposes under the indenture and the notes.\nPayments of principal, interest and additional amounts, if any, in respect of the global notes representing the notes are made to Euroclear, Clearstream, such nominee or such\ncommon depositary, as the case may be, as registered holder thereof.",
      "char_count": 950,
      "start_char": 679200,
      "end_char": 680151
    },
    {
      "chunk_id": "pfizer_2023_chunk0850",
      "chunk_index": 850,
      "text": "s representing the notes are made to Euroclear, Clearstream, such nominee or such\ncommon depositary, as the case may be, as registered holder thereof. Neither Pfizer nor the trustee, or any affiliate of any of the above or any person by whom any of the above is\ncontrolled (as such term is defined in the Securities Act) has any responsibility or liability for any records relating to or payments made on account of beneficial ownership interests in\nthe global notes representing the notes or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests.\nDistributions of principal, premium, if any, and interest with respect to the global notes representing the notes are credited in euros to the extent received by Euroclear or\nClearstream from the paying agent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant system’s rules and procedures.",
      "char_count": 926,
      "start_char": 680000,
      "end_char": 680927
    },
    {
      "chunk_id": "pfizer_2023_chunk0851",
      "chunk_index": 851,
      "text": "gent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant system’s rules and procedures.\nBecause Euroclear and Clearstream can only act on behalf of participants, who in turn act on behalf of indirect participants, the ability of a person having an interest in the global\nnotes representing the notes to pledge such interest to persons or entities which do not participate in the relevant clearing system, or otherwise take actions in respect of such\ninterest, may be affected by the lack of a physical certificate in respect of such interest.\nSecondary Market Trading\nBecause the purchaser determines the place of delivery, it is important to establish at the time of trading of any notes where both the purchaser’s and seller’s accounts are located to\nensure that settlement can be made on the desired value date.",
      "char_count": 853,
      "start_char": 680800,
      "end_char": 681654
    },
    {
      "chunk_id": "pfizer_2023_chunk0852",
      "chunk_index": 852,
      "text": "hat settlement can be made on the desired value date.\nWe understand that secondary market trading between Clearstream and/or Euroclear participants occurs in the ordinary way following the applicable rules and operating procedures\nof Clearstream and Euroclear. Secondary market trading is settled using procedures applicable to conventional eurobonds in global registered form.\n\nThe holder of the notes should be aware that investors are only able to make and receive deliveries, payments and other communications involving the notes through Clearstream\nand Euroclear on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for\nbusiness in the United States.\nIn addition, because of time-zone differences, there may be problems with completing transactions involving Clearstream and Euroclear on the same business day as in the United\nStates. U.S.",
      "char_count": 944,
      "start_char": 681600,
      "end_char": 682545
    },
    {
      "chunk_id": "pfizer_2023_chunk0853",
      "chunk_index": 853,
      "text": "s, there may be problems with completing transactions involving Clearstream and Euroclear on the same business day as in the United\nStates. U.S. investors who wish to transfer their interests in the notes, or to make or receive a payment or delivery of the notes, on a particular day, may find that the transactions are\nnot performed until the next business day in Luxembourg or Brussels, depending on whether Clearstream or Euroclear is used.\nClearstream or Euroclear credits payments to the cash accounts of Clearstream customers or Euroclear participants, as applicable, in accordance with the relevant system’s rules\nand procedures, to the extent received by its depositary. Clearstream or the Euroclear Operator, as the case may be, takes any other action permitted to be taken by a holder under\nthe indenture on behalf of a Clearstream customer or Euroclear participant only in accordance with its relevant rules and procedures.",
      "char_count": 934,
      "start_char": 682400,
      "end_char": 683335
    },
    {
      "chunk_id": "pfizer_2023_chunk0854",
      "chunk_index": 854,
      "text": "the indenture on behalf of a Clearstream customer or Euroclear participant only in accordance with its relevant rules and procedures.\nClearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of the notes among participants of Clearstream and Euroclear. However, they are\nunder no obligation to perform or continue to perform those procedures, and they may discontinue those procedures at any time.\nExchange of Global Notes for Certificated Notes\nSubject to certain conditions, the notes represented by the global notes are exchangeable for certificated notes in definitive form of like tenor in minimum denominations of €100,000\nprincipal amount and multiples of €1,000 in excess thereof if:\nthe common depositary notifies us that it is no longer willing or able to act as a depositary for such global notes or ceases to be a clearing agency registered under the\nExchange Act and we fail to appoint a successor common depositary within 90 days;",
      "char_count": 986,
      "start_char": 683200,
      "end_char": 684188
    },
    {
      "chunk_id": "pfizer_2023_chunk0855",
      "chunk_index": 855,
      "text": "able to act as a depositary for such global notes or ceases to be a clearing agency registered under the\nExchange Act and we fail to appoint a successor common depositary within 90 days;\nan event of default has occurred and is continuing and the common depositary requests the issuance of certificated notes; or\nwe determine not to have the notes represented by a global note.\nIn all cases, certificated notes delivered in exchange for any global note or beneficial interest therein will be registered in the names, and issued in any approved denominations,\nrequested by or on behalf of the common depositary (in accordance with its customary procedures).\nPayments (including principal, premium and interest) and transfers with respect to the notes in certificated form may be executed at the office or agency maintained for such purpose",
      "char_count": 837,
      "start_char": 684000,
      "end_char": 684839
    },
    {
      "chunk_id": "pfizer_2023_chunk0856",
      "chunk_index": 856,
      "text": "or agency maintained for such purpose\nin London (initially the corporate trust office of the paying agent) or, at our option, by check mailed to the holders thereof at the respective addresses set forth in the register of\nholders of the notes (maintained by the registrar), provided that all payments (including principal, premium and interest) on the notes in certificated form, for which the holders\nthereof have given wire transfer instructions, are required to be made by wire transfer of immediately available funds to the accounts specified by the holders thereof. No service\ncharge is made for any registration of transfer, but payment of a sum sufficient to cover any tax or governmental charge payable in connection with such registration may be\nrequired.\nModification of Indenture\nUnder the indenture, the rights of the holders of the notes may be modified through a supplemental indenture if the holders of a majority in aggregate principal amount of the",
      "char_count": 965,
      "start_char": 684800,
      "end_char": 685767
    },
    {
      "chunk_id": "pfizer_2023_chunk0857",
      "chunk_index": 857,
      "text": "e indenture, the rights of the holders of the notes may be modified through a supplemental indenture if the holders of a majority in aggregate principal amount of the\noutstanding notes of all series affected by the modification (voting as one class) consent to it. No modification of the maturity date or principal or interest payment terms, no\nmodification of the currency for payment, no impairment of the right to sue for the enforcement of payment at the maturity of the debt security, no modification of any conversion\nrights, no modification reducing the percentage required for any such supplemental indenture or the percentage required for the waiver of certain defaults, and no modification of the\nforegoing provisions or any other provisions relating to the waiver of past defaults or the waiver of certain covenants, is effective against any holder without its consent.\nEvents of Default",
      "char_count": 898,
      "start_char": 685600,
      "end_char": 686499
    },
    {
      "chunk_id": "pfizer_2023_chunk0858",
      "chunk_index": 858,
      "text": "aiver of certain covenants, is effective against any holder without its consent.\nEvents of Default\nEach of the following will constitute an Event of Default under the indenture with respect to the notes of the applicable series:\nwe fail to make the principal or any premium payment on any note when due;\nwe fail to make any sinking fund payment for 60 days after payment was due by the terms of any note;\nwe fail to pay interest on any note for 60 days after payment was due;\nwe fail to perform any other covenant in the indenture and this failure continues for 90 days after we receive written notice of it; or\nwe, or a court, take certain actions relating to the bankruptcy, insolvency or reorganization of our company.\nA default under our other indebtedness will not be a default under the indenture for the notes, and a default under one series of the notes will not necessarily be a default under\nanother series.",
      "char_count": 917,
      "start_char": 686400,
      "end_char": 687318
    },
    {
      "chunk_id": "pfizer_2023_chunk0859",
      "chunk_index": 859,
      "text": "re for the notes, and a default under one series of the notes will not necessarily be a default under\nanother series. The trustee may withhold notice to the holders of notes of the applicable series of any default\n\n(except for defaults that involve our failure to pay principal or interest) if it considers such withholding of notice to be in the best interests of the holders.\nIf an Event of Default with respect to outstanding notes of any series occurs and is continuing, then the trustee or the holders of at least 33% in principal amount of outstanding notes\nof that series may declare, in a written notice, the principal amount (or, if any of the notes of that series are original issue discount securities, such portion of the principal amount of\nsuch notes) plus accrued and unpaid interest on all notes of that series to be immediately due and payable.",
      "char_count": 861,
      "start_char": 687200,
      "end_char": 688062
    },
    {
      "chunk_id": "pfizer_2023_chunk0860",
      "chunk_index": 860,
      "text": "n all notes of that series to be immediately due and payable. At any time after a declaration of acceleration with respect to notes of\nany series has been made, the holders of a majority in principal amount of the outstanding notes may rescind and annul the acceleration if:\nthe holders act before the trustee has obtained a judgment or decree for payment of the money due;\nwe have paid or deposited with the trustee a sum sufficient to pay overdue interest and overdue principal other than the accelerated interest and principal; and\nwe have cured or the holders have waived all Events of Default, other than the non-payment of accelerated principal and interest with respect to notes of that series, as\nprovided in the indenture.\nIf a default in the performance or breach of the indenture shall have occurred and be continuing, the holders of not less than a majority in principal amount of the outstanding notes",
      "char_count": 914,
      "start_char": 688000,
      "end_char": 688915
    },
    {
      "chunk_id": "pfizer_2023_chunk0861",
      "chunk_index": 861,
      "text": "e occurred and be continuing, the holders of not less than a majority in principal amount of the outstanding notes\nof all series affected thereby, by notice to the trustee, may waive any past Event of Default or its consequences under the indenture. However, an Event of Default cannot be waived\nwith respect to any series of notes in the following two circumstances: \na failure to pay the principal of, and premium, if any, or interest on any security or in the payment of any sinking fund installment; or\na covenant or provision that cannot be modified or amended without the consent of each holder of outstanding notes of that series.\nOther than its duties in case of a default, the trustee is not obligated to exercise any of its rights or powers under the indenture at the request, order or direction of any holders,\nunless the holders offer the trustee reasonable indemnity.",
      "char_count": 880,
      "start_char": 688800,
      "end_char": 689681
    },
    {
      "chunk_id": "pfizer_2023_chunk0862",
      "chunk_index": 862,
      "text": "ction of any holders,\nunless the holders offer the trustee reasonable indemnity. Holders of a majority in principal amount outstanding of any series of notes may, subject to certain limitations, direct the\ntime, method and place of conducting any proceeding or any remedy available to the trustee, or exercising any power conferred upon the trustee, for such applicable series of notes.\nWe are required to deliver an annual officers’ certificate to the trustee, stating whether we are in default in the performance and observance of any of the terms, provisions and\nconditions of the indenture, and, if we are in default, specifying all such defaults and the nature and status thereof.\nDefeasance\nWhen we use the term defeasance, we mean discharge from some or all of our obligations under the indenture.",
      "char_count": 804,
      "start_char": 689600,
      "end_char": 690405
    },
    {
      "chunk_id": "pfizer_2023_chunk0863",
      "chunk_index": 863,
      "text": "ure. Subject to certain additional conditions, if we irrevocably deposit with\nthe trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums due to the stated maturity date or a redemption date of the notes\nof a particular series, then at our option:\nwe will be discharged from our obligations with respect to the notes of such series; or\nwe will no longer be under any obligation to comply with certain restrictive covenants under the indenture, and certain events of default will no longer apply to us.\nTo exercise our defeasance option, we must deliver to the trustee an officer’s certificate and an opinion of counsel, each stating that all conditions precedent related to the\ndefeasance have been complied with.\n\nEXHIBIT 10.12\nAmendment No. 4\nPfizer Consolidated Supplemental Pension Plan for United States and\nPuerto Rico Employees\n(Amended and Restated December 31, 2016)\n* * *\n(New material underlined once; deletions crossed out)",
      "char_count": 991,
      "start_char": 690400,
      "end_char": 691392
    },
    {
      "chunk_id": "pfizer_2023_chunk0864",
      "chunk_index": 864,
      "text": "Pfizer Consolidated Supplemental Pension Plan for United States and\nPuerto Rico Employees\n(Amended and Restated December 31, 2016)\n* * *\n(New material underlined once; deletions crossed out)\nArticle 5 of Part A: Administrative and General Sections Applicable To All Participants, is amended to add new Section 5.3 to the end thereof to read as follows:\n5.3 Annuity Contracts.\n Notwithstanding any other provision in this Plan, assets from any Rabbi Trust may be used to purchase from one or more insurance companies one or more group\nannuity contracts for the benefit of certain Members meeting criteria designated by the Retirement Committee or the Investment SubCommittee of the Plan Assets\nCommittee, and each of such Committees’ Members is, authorized and empowered to take or cause to be taken any and all actions deemed necessary, advisable or",
      "char_count": 849,
      "start_char": 691200,
      "end_char": 692051
    },
    {
      "chunk_id": "pfizer_2023_chunk0865",
      "chunk_index": 865,
      "text": "any and all actions deemed necessary, advisable or\nappropriate to provide for the purchase of annuities for certain Members and the transfer of the administration of any current or future group annuity contracts.\nArticle 5 of Part B: Provisions Applicable To The Pfizer Sub-Plan, is amended to add new Section 5.10 to the end thereof to read as follows:\n5.10 In-Service Active Benefit Transfers\n(1)\nAn eligible Participant (as defined herein) may make a one-time election (“Active Benefit Election”) for an in-service transfer of the full lump\nsum value of his NonGrandfathered Benefit under this Part B of the Plan to the PSSP in accordance with the following:\n(2)\nA Participant shall be eligible to elect an Active Benefit Transfer if he: (i) has either attained age 65 or has a sum of his age and his years of\nCreditable Service (whether partial or complete) that equals or exceeds 90 (“Rule of 90”) before August 1, 2023; (ii) has a NonGrandfathered Benefit under",
      "char_count": 967,
      "start_char": 692000,
      "end_char": 692968
    },
    {
      "chunk_id": "pfizer_2023_chunk0866",
      "chunk_index": 866,
      "text": "his years of\nCreditable Service (whether partial or complete) that equals or exceeds 90 (“Rule of 90”) before August 1, 2023; (ii) has a NonGrandfathered Benefit under\nthis Part B of the Plan; and (iii) does not have an annuity election on file for payment of his NonGrandfathered benefit under Part B of the Plan as of June 15,\n2023.\n(3)\nThe Active Benefit Transfer amount shall be determined in accordance with the actuarial assumptions used to determine lump sum\ndistributions payable as of the August 1, 2023 benefit determination date, under the provisions of this Part B of the Plan. No interest adjustment will be added\nto the lump sum distribution due to the time that elapses between the August 1, 2023 benefit determination date and the transfer date (which will occur as\nsoon as administratively possible following the effective date of the Active Benefit Election).\n(4)",
      "char_count": 881,
      "start_char": 692800,
      "end_char": 693682
    },
    {
      "chunk_id": "pfizer_2023_chunk0867",
      "chunk_index": 867,
      "text": "tively possible following the effective date of the Active Benefit Election).\n(4)\nThe Active Benefit Transfer, including future investment returns thereon, shall thereafter be subject to the terms of the PSSP, except that it\nshall be distributed from the PSSP at the same time and in the same form that such amount would have been distributed from this Part B of the Plan had the\ntransfer not been elected, without regard to any additional distributions payable to such Participant from the PSSP.\n(5)\nAn Active Benefit Election must be made by July 20, 2023, and shall become effective on August 1, 2023. Notwithstanding the foregoing, in\nthe event that the Company’s Senior Vice President of Total Rewards, Vice President of Global Benefits, or Director of U.S. Retirement Plan Benefits\ndetermines, in such person’s sole discretion, that data processing errors result in a failure to identify eligible Members or prevent eligible Members from",
      "char_count": 943,
      "start_char": 693600,
      "end_char": 694544
    },
    {
      "chunk_id": "pfizer_2023_chunk0868",
      "chunk_index": 868,
      "text": "in such person’s sole discretion, that data processing errors result in a failure to identify eligible Members or prevent eligible Members from\nreceiving notice or electing at the same time as the other eligible Members, then such person, in their sole discretion, may extend the deadline.\nArticle 5 of Part E: Provisions Applicable To The Wyeth Sub-Plan, is amended to add new Section 5.8 to the end thereof to read as follows:\n\n5.8 In-Service Active Benefit Transfers\n(i)\nAn eligible Participant (as defined herein) may make a one-time election (“Active Benefit Election”) for an in-service transfer of the full lump sum value\nof his NonGrandfathered Benefit under this Part E of the Plan to the PSSP in accordance with the following:\n(ii) A Participant shall be eligible to elect an Active Benefit Election if he: (1) has attained age 65 before August 1, 2023; (2) has a NonGrandfathered Benefit",
      "char_count": 898,
      "start_char": 694400,
      "end_char": 695299
    },
    {
      "chunk_id": "pfizer_2023_chunk0869",
      "chunk_index": 869,
      "text": "Election if he: (1) has attained age 65 before August 1, 2023; (2) has a NonGrandfathered Benefit\nunder this Part E of the Plan; and (3) does not have an annuity election on file for payment of his NonGrandfathered benefit under Part E of the Plan as of June 15, 2023.\n(ii)\nThe Active Benefit Transfer amount shall be determined in accordance with the actuarial assumptions used to determine lump sum distributions\npayable as the August 1, 2023 benefit determination date under the provisions of Part E of the Plan. No interest adjustment will be added to the lump sum distribution due\nto the time that elapses between the August 1, 2023 benefit determination date and the transfer date (which will occur as soon as administratively possible following the\neffective date of the Active Benefit Election).\n(iii)\nThe Active Benefit Transfer, including future investment returns thereon, shall thereafter be subject to the terms of the PSSP, except that it shall be",
      "char_count": 961,
      "start_char": 695200,
      "end_char": 696163
    },
    {
      "chunk_id": "pfizer_2023_chunk0870",
      "chunk_index": 870,
      "text": "on).\n(iii)\nThe Active Benefit Transfer, including future investment returns thereon, shall thereafter be subject to the terms of the PSSP, except that it shall be\ndistributed from the PSSP at the same time and in the same form that such amount would have been distributed from this Part E of the Plan had the transfer not been\nelected, without regard to any additional distributions payable to such Participant from the PSSP.\n(iv)\nAn Active Benefit Election must be made by July 20, 2023, and shall become effective on August 1, 2023. Notwithstanding the foregoing, in the event\nthat the Company’s Senior Vice President of Total Rewards, Vice President of Global Benefits, or Director of U.S. Retirement Plan Benefits determines, in such person’s\nsole discretion, that data processing errors results in a failure to identify eligible Participants or prevent eligible Participants from receiving notice or electing at the same",
      "char_count": 925,
      "start_char": 696000,
      "end_char": 696926
    },
    {
      "chunk_id": "pfizer_2023_chunk0871",
      "chunk_index": 871,
      "text": "in a failure to identify eligible Participants or prevent eligible Participants from receiving notice or electing at the same\ntime as the other eligible Participants, then such person, in their sole discretion, may extend the deadline.\n\nEXHIBIT 10.29\n\nas Amended and Restated, effective January 1, 2008 with clarifications adopted January 1, 2012\nArticle 1. Purpose\n1.1 Pfizer Inc., a Delaware corporation (the “Company”), established, effective as of December 1, 1997, a deferred compensation plan for key employees as described herein,\nwhich shall be known as the “Pfizer Deferred Compensation Plan” (the “Plan”). The Plan is hereby amended and restated as of January 1, 2008 to continue to permit eligible\nEmployees to defer receipt of certain compensation pursuant to the terms and provisions set forth below.",
      "char_count": 813,
      "start_char": 696800,
      "end_char": 697614
    },
    {
      "chunk_id": "pfizer_2023_chunk0872",
      "chunk_index": 872,
      "text": "forth below. The Plan is intended (1) to comply with Section 409A (as defined below)\n(except with respect to amounts covered by Appendix A), and (2) to be “a plan which is unfunded and is maintained by an employer primarily for the purpose of providing deferred\ncompensation for a select group of management or highly compensated employees” within the meaning of sections 201(2), 301(a)(3) and 401(a)(1) of ERISA. Notwithstanding any\nother provision of this Plan, this Plan shall be interpreted, operated and administered in a manner consistent with these intentions. In order to clarify certain provisions applicable to\nmandatorily deferred awards with respect to certain employees subject to Section 162(m) of the Code, the Plan is hereby restated to incorporate such applicable provisions as\npreviously adopted by the Company.\n1.2 Purpose.",
      "char_count": 842,
      "start_char": 697600,
      "end_char": 698444
    },
    {
      "chunk_id": "pfizer_2023_chunk0873",
      "chunk_index": 873,
      "text": "iously adopted by the Company.\n1.2 Purpose. The purpose of the Plan is to provide certain employees of the Company with the opportunity to voluntarily defer a portion of their compensation, subject to the\nterms of the Plan. By adopting the Plan, the Company desires to enhance its ability to attract and retain key employees.\nArticle 2. Definitions\nWhenever used herein, the following terms when capitalized shall have the meaning set forth below:\n“Account” means a bookkeeping account established by the Company for each Participant electing to defer eligible Compensation under the Plan.\n“Affiliate” means any corporation or other entity that is treated as a single employer with the Company under section 414 of the Code.\n“Award” means the Annual Incentive Plan Award or the Global Performance Plan Award based on an assessment of performance, payable by the Company to a\nParticipant for the Participant’s services during a given calendar year of the Company under the Pfizer Inc.",
      "char_count": 983,
      "start_char": 698400,
      "end_char": 699384
    },
    {
      "chunk_id": "pfizer_2023_chunk0874",
      "chunk_index": 874,
      "text": "n Award based on an assessment of performance, payable by the Company to a\nParticipant for the Participant’s services during a given calendar year of the Company under the Pfizer Inc. Executive Annual Incentive Plan, Pfizer Inc. Annual Incentive Plan or\nthe Pfizer Inc. Global Performance Plan, as may be in effect from time to time or the Short-Term Shift Award payable by the Company pursuant to the Company’s Executive Longterm Incentive Program. Awards shall be deemed earned only upon formal announcement thereof by the Company.\n“Board” or “Board of Directors” means the Board of Directors of the Company.\n“Change in Control” shall mean the occurrence of any of the following events:\n(i) at any time during a two-year period, at least a majority of the Company’s Board of Directors shall cease to consist of “Continuing Directors” (meaning directors of the",
      "char_count": 861,
      "start_char": 699200,
      "end_char": 700062
    },
    {
      "chunk_id": "pfizer_2023_chunk0875",
      "chunk_index": 875,
      "text": "o consist of “Continuing Directors” (meaning directors of the\nCompany who either were directors at the beginning of such two-year period or who subsequently became directors and whose election, or nomination for\nelection by the Company’s stockholders, was approved by a majority of the then Continuing Directors); or\n(ii) any “person” or “group” (as determined for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934), except any majority-owned subsidiary of the\nCompany or any employee benefit plan of the Company or any trust or investment manager thereunder, shall have acquired “beneficial ownership” (as\ndetermined for purposes of U.S. Securities and Exchange Commission (“SEC”) Regulation 13d-3) of shares of Common Stock of the Company having 15% or\nmore of the voting power of all outstanding shares of capital stock of the Company, unless such acquisition is approved by a majority of the directors of the\nCompany in office immediately preceding such acquisition; or",
      "char_count": 991,
      "start_char": 700000,
      "end_char": 700992
    },
    {
      "chunk_id": "pfizer_2023_chunk0876",
      "chunk_index": 876,
      "text": "all outstanding shares of capital stock of the Company, unless such acquisition is approved by a majority of the directors of the\nCompany in office immediately preceding such acquisition; or\n(iii) a merger or consolidation occurs to which the Company is a party, whether or not the Company is the surviving corporation, in which outstanding shares of Common\nStock of the Company are converted into shares of another company (other than a conversion into shares of voting common stock of the successor corporation or\na holding company thereof representing 80% of the voting power or all capital stock thereof outstanding immediately after the merger or consolidation) or other\nsecurities (of either the Company or another company) or cash or other property; or\n(iv) the sale of all, or substantially all, of the Company’s assets occurs; or\n(v) the stockholders of the Company approve a plan of complete liquidation of the Company.\n“Code” means the Internal Revenue Code of 1986, as amended.",
      "char_count": 989,
      "start_char": 700800,
      "end_char": 701791
    },
    {
      "chunk_id": "pfizer_2023_chunk0877",
      "chunk_index": 877,
      "text": "all, of the Company’s assets occurs; or\n(v) the stockholders of the Company approve a plan of complete liquidation of the Company.\n“Code” means the Internal Revenue Code of 1986, as amended.\n“Committee” means the Compensation Committee of the Board or the Executive Leadership Team, as appropriate, and any successor thereto or properly authorized\ndelegate thereof.\n“Company” means Pfizer Inc., a Delaware corporation (including any and all subsidiaries), and any successor thereto.\n\n“Compensation” means the gross Salary, Awards, Long-Term Incentive Awards, and other payments which may be eligible for deferral under the Plan, which are payable\nto a Participant with respect to services performed while working during a specified period, not including compensation earned for services outside of the U.S. (unless on\ntemporary assignment of 30 days or less) and remaining on a U.S.",
      "char_count": 882,
      "start_char": 701600,
      "end_char": 702483
    },
    {
      "chunk_id": "pfizer_2023_chunk0878",
      "chunk_index": 878,
      "text": "e U.S. (unless on\ntemporary assignment of 30 days or less) and remaining on a U.S. payroll.\n“Deferral Election Form” means a written form provided by the Committee pursuant to which an eligible Employee may elect to defer amounts under the Plan.\n“Disability” means when a Participant (1) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment\nwhich can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, (2) is, by reason of any medically determinable physical or\nmental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits\nfor a period of not less than three months under an accident and health plan that covers Employees.\n“Employee” means a salaried employee of the Company who has been selected for participation under Section 4.1.",
      "char_count": 980,
      "start_char": 702400,
      "end_char": 703381
    },
    {
      "chunk_id": "pfizer_2023_chunk0879",
      "chunk_index": 879,
      "text": "three months under an accident and health plan that covers Employees.\n“Employee” means a salaried employee of the Company who has been selected for participation under Section 4.1.\n“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.\n“Federal Long-term Rate” means the 30-year constant maturity U.S. Treasury Rate from the Federal Reserve Bank for the previous month.\n“Grandfathered Benefits” means Plan benefits that were earned and vested as of December 31, 2004 within the meaning of Section 409A. Grandfathered Benefits are\nsubject to the distribution rules set forth in Appendix A.\n“Key Employee” means an Employee treated as a “specified employee” as of his or her Separation from Service under Code Section 409A(a)(2)(B)(i), Key Employees\nshall be determined in accordance with Section 409A using an identification date of February 28 in any plan year and the listing of Key Employees as of any such identification",
      "char_count": 947,
      "start_char": 703200,
      "end_char": 704148
    },
    {
      "chunk_id": "pfizer_2023_chunk0880",
      "chunk_index": 880,
      "text": "dance with Section 409A using an identification date of February 28 in any plan year and the listing of Key Employees as of any such identification\ndate shall be effective for the 12-month period beginning on the March 1 effective date following the identification date. Notwithstanding the foregoing, the Committee may, under\nthe alternative permissible methods allowable under Section 409A, adopt an alternative identification and effective date for purposes of determining which employees are Key\nEmployees.\n“Long-Term Incentive Award Payouts” means payouts of any Performance-Contingent Share Awards, Performance Share Awards, or Restricted Stock Units in cash or\nshares of Company stock or cash.\n“Participant” means an eligible Employee who has elected to participate in the Plan and make deferrals under Article IV, or an Employee with 162(m) Restricted Stock\nUnits.",
      "char_count": 872,
      "start_char": 704000,
      "end_char": 704873
    },
    {
      "chunk_id": "pfizer_2023_chunk0881",
      "chunk_index": 881,
      "text": "als under Article IV, or an Employee with 162(m) Restricted Stock\nUnits.\n“Salary” means all regular, basic wages, before reduction for amounts deferred pursuant to the Plan or any other plan of the Company, payable in cash to a Participant for\nservices to be rendered during the calendar year, exclusive of any Awards, Long-Term Incentive Award Payouts, other special fees, awards, or incentive compensation, allowance,\nor amounts designated by the Company as payment toward or reimbursement of expenses.\n“Section 409A” means Section 409A of the Code and the regulations and other guidance issued thereunder by the U.S. Treasury or Internal Revenue Service.\n“Separation from Service” means a “separation from service” within the meaning of Section 409A.\n“Unforeseeable Emergency” means a severe financial hardship to a Participant resulting from an illness or accident of the Participant, the Participant’s spouse, or a",
      "char_count": 919,
      "start_char": 704800,
      "end_char": 705720
    },
    {
      "chunk_id": "pfizer_2023_chunk0882",
      "chunk_index": 882,
      "text": "cial hardship to a Participant resulting from an illness or accident of the Participant, the Participant’s spouse, or a\ndependent (as defined in Code section 152(a)) of the Participant, loss of the Participant’s property due to casualty, or other similar extraordinary and unforeseeable circumstances\narising as a result of events beyond the control of the Participant.\n“162(m) Restricted Stock Units” means Restricted Stock Units held by an Employee subject to Section 162(m) of the Code which are mandatorily deferred into the Plan\npursuant to the Company’s tax policy in order to preserve the deduction. Effective February 1, 2012, any Employee who is grade 36 or above shall be assumed to be subject to\nSection 162(m) of the Code and his or her Restricted Stock Units will be mandatorily deferred into the Plan upon vesting.\nArticle 3. Administration\n3.1 Authority of the Committee. The Plan shall initially be administered by the Committee.",
      "char_count": 945,
      "start_char": 705600,
      "end_char": 706546
    },
    {
      "chunk_id": "pfizer_2023_chunk0883",
      "chunk_index": 883,
      "text": "into the Plan upon vesting.\nArticle 3. Administration\n3.1 Authority of the Committee. The Plan shall initially be administered by the Committee. Subject to the terms of this Plan, the Committee may appoint a successor\ncommittee to administer the Plan. The Committee has delegated the administrative duties under the Plan to the Senior Vice President, Total Rewards, or his or her successor.\nSubject to the provisions herein, the Committee shall have the exclusive discretion to select Employees for participation in the Plan; to determine the terms and conditions of each\nEmployee’s participation in the Plan; to make, in its sole discretion, all determinations arising in the administration, construction or interpretation of the Plan including the right to\nconstrue disputed or doubtful Plan terms and provisions, and any such determination shall be conclusive and binding on all persons, except as otherwise provided by law; to",
      "char_count": 930,
      "start_char": 706400,
      "end_char": 707332
    },
    {
      "chunk_id": "pfizer_2023_chunk0884",
      "chunk_index": 884,
      "text": "and provisions, and any such determination shall be conclusive and binding on all persons, except as otherwise provided by law; to\nconstrue and interpret any agreement or instrument entered into under the Plan; to establish, amend, or waive rules and regulations for the Plan’s administration; to amend (subject\nto the provisions of Article 9 herein) the terms and conditions of the Plan and any agreement entered\n\ninto under the Plan; and to make other determinations which may be necessary or advisable for the administration of the Plan. Subject to the terms of the Plan, the Committee may\ndelegate any or all of its authority granted under the Plan to one or more executives of the Company. The Committee has delegated review authority to the Senior Vice President,\nTotal Rewards.\n3.2 Claims Procedure. If a request for benefits by a Participant or beneficiary is wholly or partially denied, the Committee will provide such claimant written notice setting forth\nthe denial.",
      "char_count": 977,
      "start_char": 707200,
      "end_char": 708179
    },
    {
      "chunk_id": "pfizer_2023_chunk0885",
      "chunk_index": 885,
      "text": "cedure. If a request for benefits by a Participant or beneficiary is wholly or partially denied, the Committee will provide such claimant written notice setting forth\nthe denial. The Committee has delegated such claims review authority to the executive compensation staff. A review procedure is available upon written notice of the denial of the\nclaim, and includes the right to examine pertinent documents and submit issues and comments in writing to the Committee. The decision on review will be made within 90 days after\nreceipt of the request for review, unless circumstances warrant an extension of time not to exceed an additional 90 days and shall be in writing. If a decision on review is not made\nwithin such period, the Participant’s claim shall be deemed denied.\n3.3 Decisions Binding. All determinations and decisions of the Committee as to any disputed question arising under the Plan shall be final, conclusive and binding on all\nparties.\nArticle 4.",
      "char_count": 963,
      "start_char": 708000,
      "end_char": 708964
    },
    {
      "chunk_id": "pfizer_2023_chunk0886",
      "chunk_index": 886,
      "text": "determinations and decisions of the Committee as to any disputed question arising under the Plan shall be final, conclusive and binding on all\nparties.\nArticle 4. Eligibility and Participation\n4.1 Eligibility. Employees eligible to participate in the Plan include solely those executives selected by the Committee in its sole discretion who comprise a select group of\n“management or highly compensated employees,” such that the Plan will qualify for treatment as a “Top hat” plan within the meaning of Sections 201, 301 and 401 of ERISA.\nIn the event a Participant no longer meets the requirements for participation in the Plan, such Participant shall become an inactive Participant, retaining all the rights described\nunder the Plan, except the right to make any further deferrals, until such time as the Participant again becomes an active Participant.\n4.2 Participation.",
      "char_count": 873,
      "start_char": 708800,
      "end_char": 709675
    },
    {
      "chunk_id": "pfizer_2023_chunk0887",
      "chunk_index": 887,
      "text": "as the Participant again becomes an active Participant.\n4.2 Participation. Participation in the Plan shall be determined annually by the Committee based upon the criteria set forth in Section 4.1 herein. Subject to Section 4.3,\nEmployees who are chosen to participate in the Plan with respect to any given year shall be so notified in writing in advance of any required time to properly elect deferral for such\nyear.\n4.3 Partial Year Eligibility. In the event that an Employee first becomes eligible to participate in the Plan or another account balance plan required to be aggregated with this\nPlan under Section 409A during a calendar year, in the sole discretion of the Committee, such Employee may be notified as soon as practicable in writing by the Company and\nprovided with a “Deferral Election Form,” (or such other form approved by the Committee from time to time in accordance with Section 409A for the purpose of making elections to",
      "char_count": 943,
      "start_char": 709600,
      "end_char": 710544
    },
    {
      "chunk_id": "pfizer_2023_chunk0888",
      "chunk_index": 888,
      "text": "n Form,” (or such other form approved by the Committee from time to time in accordance with Section 409A for the purpose of making elections to\ndefer Compensation under the Plan) which must be completed by the Employee as set forth in Section 5.2 herein.\n4.4 No Right to Participate. No Employee shall have the right to be selected as a Participant, or, having been so selected for any given year, to be selected again as a\nParticipant for any other year.\nArticle 5. Deferral Opportunity and Distributions\n5.1 Amount Which May Be Deferred. A Participant may elect to defer up to one hundred percent (100%) of eligible components of Compensation, including but not limited to\nSalary, Awards and Long-Term Incentive Award Payouts, in any given year; provided, that the Committee shall have sole discretion to designate which components of Compensation",
      "char_count": 849,
      "start_char": 710400,
      "end_char": 711250
    },
    {
      "chunk_id": "pfizer_2023_chunk0889",
      "chunk_index": 889,
      "text": "ion to designate which components of Compensation\nare eligible for deferral elections under the Plan in any such year, and such Compensation shall not include any stock, stock option, stock appreciation right or other equity-based\ncompensation which is not treated as deferred compensation pursuant to Treas. Reg. §1.409A-1(a)(5) or other applicable authority. The minimum amount of any single eligible\ncomponent of Compensation (other than Performance Share Awards) which may be deferred in any given year is ten percent (10%) of each such component; provided that the\nminimum amount of Performance Share Awards that can be deferred in any year is twenty five percent (25%). In addition, an election to defer Compensation in any given year must\nbe expressed by each Participant in increments of ten percent (10%) of the applicable component of Compensation, except that Performance Share Awards must be deferred in\n25% increments.",
      "char_count": 931,
      "start_char": 711200,
      "end_char": 712132
    },
    {
      "chunk_id": "pfizer_2023_chunk0890",
      "chunk_index": 890,
      "text": "percent (10%) of the applicable component of Compensation, except that Performance Share Awards must be deferred in\n25% increments. Any equity-based compensation which is deferred into the Plan, including 162(m) Restricted Stock Units, shall (i) be deferred into the Plan in the form of Company\ncommon stock, (2) effective with respect to equity-based Compensation, including 162(m) Restricted Stock Units, deferred on or after December 31, 2007, shall remain “notionally”\ninvested in the Company common stock (and shall accrue dividend equivalents, as applicable), and(3) upon distribution, shall be payable in only Company common stock.\n5.2 Deferral Election. In order to elect to defer Compensation earned during a year, an eligible Employee shall file an irrevocable Deferral Election Form with the Committee\nbefore the beginning of such year.",
      "char_count": 847,
      "start_char": 712000,
      "end_char": 712848
    },
    {
      "chunk_id": "pfizer_2023_chunk0891",
      "chunk_index": 891,
      "text": "he Committee\nbefore the beginning of such year. Notwithstanding the foregoing, (1) if the Committee determines that any component of Compensation qualifies as “performance-based\ncompensation” under Section 409A, an eligible Employee may elect to defer a portion of such Compensation by filing a Deferral Election Form at such later time up until the date six\nmonths before the end of the performance period as permitted by the Committee, and (2) in the first year in which an Employee becomes eligible to participate in this Plan or any\nother account balance plan required to be aggregated with this Plan under Section 409A, a deferral election may be made with respect to services to be performed subsequent to\nthe election and within the same year only if such election is made within 30 days after the date the Employee first becomes eligible to participate in this or any other account\nbalance plan required to be aggregated with this Plan under Section 409A.",
      "char_count": 963,
      "start_char": 712800,
      "end_char": 713764
    },
    {
      "chunk_id": "pfizer_2023_chunk0892",
      "chunk_index": 892,
      "text": "the date the Employee first becomes eligible to participate in this or any other account\nbalance plan required to be aggregated with this Plan under Section 409A.\nParticipants shall make the following irrevocable elections on each “Deferral Election Form”:\n(a) The amount to be deferred with respect to each eligible component of Compensation for the specified year;\n(b) The length of the deferral period with respect to each eligible component of Compensation or the date or event upon which the Compensation is to be paid in the\nfuture, pursuant to the terms of Section 5.3 and 5.4 herein;\n\n(c) The form or method for payment of the Compensation; and\n(d) Prior to 2011, the form or method for payment of the Compensation to a beneficiary in the event of the death of the Participant as designated in Section 6.4.\n5.3 Length of Deferral.",
      "char_count": 838,
      "start_char": 713600,
      "end_char": 714440
    },
    {
      "chunk_id": "pfizer_2023_chunk0893",
      "chunk_index": 893,
      "text": "in Section 6.4.\n5.3 Length of Deferral. Subject to the remaining Sections of this Article 5, the deferral period elected by each Participant with respect to deferrals of Compensation for any\ngiven year will begin upon deferral and end as selected by the Participant on a Deferral Election Form from among the following choices as specified by the Committee from time to\ntime:\n(a) upon the Participant’s Separation from Service;\n(b) upon on a specific date identified by the Participant; or\n(c) the earlier of (a) or (b).\nIf a Participant elected to defer Compensation but fails to select a length of deferral, the Participant shall be deemed to have elected (a), to be payable on January 31 of the\nyear following (a). Notwithstanding anything in this Section 5.3 to the contrary, a specified date for a deferral period must be at least one (1) year following the end of the calendar",
      "char_count": 882,
      "start_char": 714400,
      "end_char": 715283
    },
    {
      "chunk_id": "pfizer_2023_chunk0894",
      "chunk_index": 894,
      "text": "a deferral period must be at least one (1) year following the end of the calendar\nyear in which the Compensation is earned and no later than five (5) years following the Participant’s retirement unless a specific date is designated.\nWith respect to 162(m) Restricted Stock Units, the deferral period will begin upon the vesting date and end upon the earlier of (i) when the Participant is no longer subject to\nSection 162(m) of the Code, or (ii) the January 31 following the Participant’s termination of employment (but paid no earlier than the first day following the sixth month anniversary\nof such termination of employment).\n5.4. Form or Method for Payment of the Compensation. A Participant shall elect on a Deferral Election Form to have the portion of his or her Account related to amounts\ndeferred under the Deferral Election Form (and earnings thereon) distributed in a lump sum or in annual installments over a period of no less than 2, and no more than 15, years with",
      "char_count": 978,
      "start_char": 715200,
      "end_char": 716180
    },
    {
      "chunk_id": "pfizer_2023_chunk0895",
      "chunk_index": 895,
      "text": "ferred under the Deferral Election Form (and earnings thereon) distributed in a lump sum or in annual installments over a period of no less than 2, and no more than 15, years with\npayments commencing upon the Participant’s Separation from Service or specified date as elected by the Participant on the Deferral Election Form. If the Participant fails to elect the\nform and method of payment on the Deferral Election Form, the form and method shall be a single lump sum.\n5.5 Cancellation of Election for Disability or Distribution for Unforeseeable Emergency. If a Participant incurs a Disability or obtains a distribution under Section 5.3 on\naccount of an Unforeseeable Emergency during a year, his or her deferral election for such year shall be cancelled.\n5.6 Distribution upon Separation from Service or upon a Specified Date.",
      "char_count": 830,
      "start_char": 716000,
      "end_char": 716831
    },
    {
      "chunk_id": "pfizer_2023_chunk0896",
      "chunk_index": 896,
      "text": "vice or upon a Specified Date. If a Participant has elected on a Deferral Election Form to have the portion of his or her Account\nrelated to amounts deferred under the Deferral Election Form (and earnings thereon) paid to the Participant upon a Separation from Service, upon a specified date, or upon the\nearlier of the specified date or Separation from Service, then the Distribution shall commence upon such Separation from Service or the specified date, as applicable, and be made\nin the manner specified in Section 5.4.\n5.7 Delay for Key Employees. Notwithstanding the foregoing, distributions may not be made to a Key Employee upon a Separation from Service before the date which is 6\nmonths after the date of the Key Employee’s Separation from Service (or, if earlier, the date of death of the Key Employee).",
      "char_count": 814,
      "start_char": 716800,
      "end_char": 717615
    },
    {
      "chunk_id": "pfizer_2023_chunk0897",
      "chunk_index": 897,
      "text": "Key Employee). Any payments that would otherwise be made during this\nperiod of delay shall be accumulated and paid as of the date that is six months after the Participant’s Separation from Service (or, if earlier, the first day of the month after the\nParticipant’s death).\n5.8 Distribution upon Disability. Notwithstanding the election made by a Participant on a Deferral Election Form under Sections 5.2, 5.3 and 5.4, if a Participant incurs a\nDisability while in payment status, but before full distribution of his or her Account balance, any remaining Account balance shall continue to be distributed in accordance with the\nParticipant’s election made on the Deferral Election Form under Sections 5.2, 5.3 and 5.4 hereof. If a Participant incurs a Disability prior to commencing receipt of any portion of his\nor her Account balance, the Participant’s Account balance shall be distributed in accordance with the Participant’s election made on the Deferral Election Form under Sections 5.2,",
      "char_count": 991,
      "start_char": 717600,
      "end_char": 718592
    },
    {
      "chunk_id": "pfizer_2023_chunk0898",
      "chunk_index": 898,
      "text": "tion of his\nor her Account balance, the Participant’s Account balance shall be distributed in accordance with the Participant’s election made on the Deferral Election Form under Sections 5.2,\n5.3 and 5.4 hereof.\n5.9 Distributions upon Death. Distributions of the portion of a Participant’s Account remaining in the Participant’s Account at the Participant’s death (and earnings thereon)\nshall be made in a lump sum. Nothing contained herein shall be deemed to affect, modify, alter or otherwise amend elections made pursuant to Deferral Election Forms that became\neffective prior to 2011 (each, a “Pre-Existing Election”), which shall continue to be honored with respect to the portion of his or her Account attributable to such Pre-Existing Election\nand remaining in the Account at the Participant’s death.\n5.10 Withdrawals for Unforeseeable Emergency.",
      "char_count": 853,
      "start_char": 718400,
      "end_char": 719254
    },
    {
      "chunk_id": "pfizer_2023_chunk0899",
      "chunk_index": 899,
      "text": "death.\n5.10 Withdrawals for Unforeseeable Emergency. Notwithstanding the election made by a Participant on a Deferral Election Form under Sections 5.2, 5.3 and 5.4, upon the\noccurrence of an Unforeseeable Emergency, a Participant may withdraw all or any portion of his or her Account balance provided that the amounts distributed with respect to an\nUnforeseeable Emergency may not exceed the amounts necessary to satisfy such Unforeseeable Emergency plus amounts necessary to pay taxes reasonably anticipated as a\nresult of the distribution, after taking into account the extent to which such hardship is or may be relieved through reimbursement or compensation by insurance or otherwise or by\nliquidation of the Participant’s assets (to the extent the liquidation of such assets would not itself cause severe financial hardship) or by cessation of deferrals under the Plan.",
      "char_count": 874,
      "start_char": 719200,
      "end_char": 720076
    },
    {
      "chunk_id": "pfizer_2023_chunk0900",
      "chunk_index": 900,
      "text": "use severe financial hardship) or by cessation of deferrals under the Plan.\n“Unforeseeable Emergency” means for this purpose a severe financial hardship to a Participant resulting from an illness or accident of the Participant, the Participant’s spouse, or a\ndependent (as defined in Code section 152(a)) of the Participant, loss of the Participant’s property due to casualty, or other similar extraordinary and unforeseeable circumstances\narising as a result of events beyond the control of the Participant.\n5.11 Change in Control. Notwithstanding any provision in the Plan to the contrary or the election made by a Participant on a Deferral Election Form under Sections 5.2, 5.3 and\n5.4, the provisions set forth in this section shall apply. A “Change in Control Event” means an event described in Code section 409A(a)(2)(A)(v) or otherwise under Section 409A.",
      "char_count": 862,
      "start_char": 720000,
      "end_char": 720863
    },
    {
      "chunk_id": "pfizer_2023_chunk0901",
      "chunk_index": 901,
      "text": "Code section 409A(a)(2)(A)(v) or otherwise under Section 409A.\n\n(a) As to any amounts deferred in respect of Compensation earned in any year commencing prior to January 1, 2017, the following rules shall apply:\n(1) in the event of a Change in Control that occurs on or prior to the first anniversary of the effective date of this amendment, notwithstanding any provision in the Plan to the\ncontrary or the election made by a Participant on a Deferral Election Form under Sections 5.2, 5.3 and 5.4, a Participant’s Account balance under the Plan shall be distributed in an\nimmediate lump sum payment upon the occurrence of a Change in Control that is a “Change in Control Event.” A “Change in Control Event” means an event described in Code\nsection 409A(a)(2)(A)(v) or otherwise under Section 409A.\n(2) in the event of a Change in Control which is not described in (1) above, notwithstanding any provision in the Plan to the contrary or the election made by a Participant on",
      "char_count": 973,
      "start_char": 720800,
      "end_char": 721774
    },
    {
      "chunk_id": "pfizer_2023_chunk0902",
      "chunk_index": 902,
      "text": ") in the event of a Change in Control which is not described in (1) above, notwithstanding any provision in the Plan to the contrary or the election made by a Participant on\na Deferral Election Form under Sections 5.2, 5.3 and 5.4, a Participant’s Account balance under the Plan shall be distributed in an immediate lump sum payment upon the tenth\nanniversary of the occurrence of a Change in Control that is a “Change in Control Event.” A “Change in Control Event” means an event described in Code section 409A(a)(2)(A)(v) or\notherwise under Section 409A.\n(b) As to any amounts deferred in respect of Compensation earned in any year commencing on or after January 1, 2017, such amounts shall not be subject to the\nautomatic distribution rule set forth in Section 5.11(a) above.\n5.12 Timing of Payments.",
      "char_count": 803,
      "start_char": 721600,
      "end_char": 722404
    },
    {
      "chunk_id": "pfizer_2023_chunk0903",
      "chunk_index": 903,
      "text": "ts. For purposes of Section 5.6 and 5.8, payment will be deemed to be made upon a Separation from Service or Disability, as applicable if payment is\nmade upon the date on which the event occurs or upon a date that is within 90 days of such event and the Participant does not have any control over when the payment is actually\npaid. For purposes of a payment on a specified date under Section 5.6, a payment will be deemed to be made upon a specified date if payment is made on such date, later in the\ncalendar year containing such specified date, or, if later, the 15 day of the 3 month following such specified date. The Participant will have no control over when the payment is\nactually paid. For purposes of Section 5.9, payment will be deemed to be made upon the Participant’s death if the payment is made to the Participant’s beneficiary in accordance",
      "char_count": 856,
      "start_char": 722400,
      "end_char": 723257
    },
    {
      "chunk_id": "pfizer_2023_chunk0904",
      "chunk_index": 904,
      "text": "t is made to the Participant’s beneficiary in accordance\nwith Section 6.4 by December 31 of the first year following the year in which the date of death occurs regardless of whether the payment recipient designates the taxable year of\npayment.\n5.13 Changes in Time or Form of Distribution. Notwithstanding the election made by a Participant on a Deferral Election Form under Sections 5.2, 5.3 and 5.4, a Participant\nmay make one or more subsequent elections to change the time or form of a distribution for a deferred amount, provided that such an election shall be effective only if the following\nconditions are satisfied:\n(a)\nThe election may not take effect until at least twelve (12) months after the date on which the election is made;\n(b)\nIn the case of an election to change the time or form of a distribution under Sections 5.6, a distribution may not be made earlier than at least five (5) years from the date the\ndistribution would have otherwise been made; and\n(c)",
      "char_count": 975,
      "start_char": 723200,
      "end_char": 724176
    },
    {
      "chunk_id": "pfizer_2023_chunk0905",
      "chunk_index": 905,
      "text": "f a distribution under Sections 5.6, a distribution may not be made earlier than at least five (5) years from the date the\ndistribution would have otherwise been made; and\n(c)\nIn the case of an election to change the time or form of a distribution under Section 5.6, the election must be made at least twelve (12) months before the date the distribution is\nscheduled to be paid.\n5.14 Effect of Taxation. If a portion of the Participant’s Account balance is includible in income under Section 409A, such portion shall be distributed immediately to the\nParticipant.\n5.15 Permitted Delays. Notwithstanding the foregoing, any payment to a Participant under the Plan may be delayed upon the Committee’s reasonable anticipation that the\nmaking of the payment would violate Federal securities laws or other applicable law; provided, that (i) the Company treats any such delays to similarly situated Participants on a",
      "char_count": 909,
      "start_char": 724000,
      "end_char": 724910
    },
    {
      "chunk_id": "pfizer_2023_chunk0906",
      "chunk_index": 906,
      "text": "applicable law; provided, that (i) the Company treats any such delays to similarly situated Participants on a\nreasonably consistent basis, (ii) no election may be provided to a Participant with respect to the timing of such delayed payment, and (iii) any payment delayed pursuant to this\nSection 5.15 shall otherwise be paid in accordance with Section 409A.\n5.16\nPre-2005 Deferrals. Notwithstanding the foregoing, Appendix A governs the distribution of amounts that were earned and vested (within the meaning of Section 409A and\nregulations thereunder) under the Plan prior to 2005 (and earnings thereon) and are exempt from the requirements of Section 409A.\n5.17\nRehires. If a Participant ceases to be eligible to participate and subsequently again becomes eligible to participate, he or she may, in the sole discretion of the Committee,",
      "char_count": 838,
      "start_char": 724800,
      "end_char": 725639
    },
    {
      "chunk_id": "pfizer_2023_chunk0907",
      "chunk_index": 907,
      "text": "the sole discretion of the Committee,\nmake an election in accordance with Sections 5.2, 5.3 and 5.4 on a Deferral Election Form that shall apply with respect to any amounts credited to his or her Account under the Plan\nafter the date of his or her re-eligibility (provided the Employee becomes so eligible in a different calendar year than the year in which he or she ceased to be eligible), and if no such\npayment election is made, the portion of the Account accrued with respect to the new eligibility period shall be paid in accordance with the election on the Deferral Election Form for\nthose amounts deferred prior to the Participant ceasing to be eligible to participate.\nArticle 6. Deferred Compensation Accounts\n6.1 Participants’ Accounts. The Company shall establish and maintain an individual bookkeeping Account for deferrals made by each Participant under Article 5 herein.",
      "char_count": 885,
      "start_char": 725600,
      "end_char": 726487
    },
    {
      "chunk_id": "pfizer_2023_chunk0908",
      "chunk_index": 908,
      "text": "ual bookkeeping Account for deferrals made by each Participant under Article 5 herein. Each\nAccount shall be credited as of the date the amount deferred otherwise would have become due and payable to the Participant.\n6.2 Interest or Dividends on Deferred Amounts. Compensation deferred under Article 5 shall accrue, in the sole discretion of the Committee, either (i) interest on a basis to be\nspecified by the Committee, at a rate equal to the return choice(s) selected by the Participant from among the alternatives specified by the Committee from time to time, or (2)\ndividends or dividend equivalents as determined by the Committee. Interest or dividends, as applicable, credited on deferred amounts (less the amount of any debits for any losses)\nshall be credited to the Participant’s Account and paid out to Participants at the same time and in the same manner as the underlying deferred amounts from such Account.",
      "char_count": 920,
      "start_char": 726400,
      "end_char": 727321
    },
    {
      "chunk_id": "pfizer_2023_chunk0909",
      "chunk_index": 909,
      "text": "d paid out to Participants at the same time and in the same manner as the underlying deferred amounts from such Account. Effective\nwith respect to equity-based Compensation, including 162(m) Restricted Stock\n\nUnits, deferred on or after December 31, 2007, such equity-based Compensation shall remain “notionally” invested in Company common stock and eligible to accrue dividend\nequivalents, and may not be diversified into any other alternative investment available under the Plan. Beginning August 8, 2014, such deferrals may be diversified to any other\ninvestment offered under the Plan.\n6.3 Charges against Accounts. There shall be charged against each Participant’s Account any payments made to the Participant or to his or her beneficiary.\n6.4 Designation of Beneficiary. Each Participant may designate a beneficiary or beneficiaries (who may be named contingently or successively) who, upon the Participant’s",
      "char_count": 914,
      "start_char": 727200,
      "end_char": 728115
    },
    {
      "chunk_id": "pfizer_2023_chunk0910",
      "chunk_index": 910,
      "text": "signate a beneficiary or beneficiaries (who may be named contingently or successively) who, upon the Participant’s\ndeath, will receive the amounts that otherwise would have been paid to the Participant under the Plan. All designations shall be signed by the Participant and shall be in such form as\nprescribed by the Committee. Each designation shall be effective as of the date received from the Participant by the Global Long-Term Incentive Compensation group of the\nCompany or its designee.\nParticipants may change their beneficiary designations on a form prescribed by the Committee. The payment of amounts deferred under the Plan shall be in accordance with the\nlast unrevoked written designation of beneficiary that has been signed by the Participant and delivered by the Participant to the Global Long-Term Incentive Compensation group or\nits designee prior to the Participant’s death.",
      "char_count": 892,
      "start_char": 728000,
      "end_char": 728893
    },
    {
      "chunk_id": "pfizer_2023_chunk0911",
      "chunk_index": 911,
      "text": "bal Long-Term Incentive Compensation group or\nits designee prior to the Participant’s death.\nIn the event that all the beneficiaries named by a Participant pursuant to this Section 6.4 predecease the Participant, the deferred amounts that would have been paid to the\nParticipant or the Participant’s beneficiaries shall be paid to the Participant’s estate in a lump sum.\nIn the event a Participant does not designate a beneficiary, or for any reason such designation is ineffective, in whole or in part, the amounts that otherwise would have been\npaid to the Participant or the Participant’s beneficiaries under the Plan shall be paid to the Participant’s estate in a lump sum.\nIn the event the beneficiary of a Participant should die prior to the final payment of the deferred amounts, the amounts that otherwise would have been paid to such beneficiary\nunder the Plan shall be paid to the beneficiary’s estate in a lump sum.\nArticle 7. Rights of Participants\n7.1 Contractual Obligation.",
      "char_count": 988,
      "start_char": 728800,
      "end_char": 729789
    },
    {
      "chunk_id": "pfizer_2023_chunk0912",
      "chunk_index": 912,
      "text": "hat otherwise would have been paid to such beneficiary\nunder the Plan shall be paid to the beneficiary’s estate in a lump sum.\nArticle 7. Rights of Participants\n7.1 Contractual Obligation. The Plan shall create a contractual obligation on the part of the Company to make payments from the Participant’s accounts when due. Payment of\naccount balances shall be made out of the general funds of the Company.\n7.2 Unsecured Interest. No Participant or party claiming an interest in deferred amounts or contributions through a Participant shall have any interest whatsoever in any\nspecific asset of the Company. To the extent that any party acquires a right to receive payments under the Plan, such right shall be equivalent to that of an unsecured general\ncreditor of the Company.\n7.3 Employment. Nothing in the Plan shall interfere with nor limit in any way the right of the Company to terminate any Participant’s employment at any time, nor confer upon",
      "char_count": 949,
      "start_char": 729600,
      "end_char": 730550
    },
    {
      "chunk_id": "pfizer_2023_chunk0913",
      "chunk_index": 913,
      "text": "in the Plan shall interfere with nor limit in any way the right of the Company to terminate any Participant’s employment at any time, nor confer upon\nany Participant any right to continue in the employ of the Company.\nArticle 8. Withholding of Taxes\nThe Company shall withhold from an employee’s regular compensation from the Company an amount sufficient to satisfy foreign, Federal, state, and local income or other\nwithholding tax requirements with regard to amounts deferred under the Plan. However, the Company reserves the right to institute alternative methods for satisfying the applicable\nincome and withholding tax requirements.\nArticle 9. Amendment and Termination\n9.1 Amendment or Termination. The Company reserves the right to amend or terminate the Plan when, in the sole discretion of the Company, such amendment or termination\nis advisable, pursuant to a resolution or other action taken by the Committee.",
      "char_count": 920,
      "start_char": 730400,
      "end_char": 731321
    },
    {
      "chunk_id": "pfizer_2023_chunk0914",
      "chunk_index": 914,
      "text": "he Company, such amendment or termination\nis advisable, pursuant to a resolution or other action taken by the Committee. The Plan may also be amended to the extent such amendment is required under applicable law or is\nrequired to avoid having amounts deferred under the Plan included in the income of Participants or beneficiaries for federal income tax purposes prior to distribution.\nNotwithstanding the foregoing, no amendment of the Plan shall apply to amounts that were earned and vested (within the meaning of Section 409A) under the Plan prior to 2005,\nunless the amendment specifically provides that it applies to such amounts. The purpose of this restriction is to prevent a Plan amendment from resulting in an inadvertent “material\nmodification” to amounts that are Grandfathered Benefits.\n9.2 Effect of Amendment or Termination.",
      "char_count": 839,
      "start_char": 731200,
      "end_char": 732040
    },
    {
      "chunk_id": "pfizer_2023_chunk0915",
      "chunk_index": 915,
      "text": "9.2 Effect of Amendment or Termination. Except as provided in the next sentence, no amendment or termination of the Plan shall adversely affect the rights of any Participant\nto amounts credited to his or her Account as of the effective date of such amendment or termination, without such Participant’s consent. Upon termination of the Plan, distribution of\nbalances in Accounts shall be made to Participants and beneficiaries in the manner and at the time described in Article V, unless the Company determines in its sole discretion that\nall such amounts shall be distributed upon termination in accordance with the requirements under Section 409A. Upon termination of the Plan, no further deferrals of eligible\nCompensation shall be permitted; however, earnings, gains and losses shall continue to be credited to Account balances in accordance with the Plan until the Account balances are\nfully distributed.",
      "char_count": 908,
      "start_char": 732000,
      "end_char": 732909
    },
    {
      "chunk_id": "pfizer_2023_chunk0916",
      "chunk_index": 916,
      "text": "e credited to Account balances in accordance with the Plan until the Account balances are\nfully distributed.\n\nArticle 10. Miscellaneous\n10.1 Notice. Any notice or filing required or permitted to be given to the Company under the Plan shall be sufficient if in writing and hand delivered or sent by registered or\ncertified mail to the Global Long-Term Incentive Compensation group of the Company. Notice to the Global Long-Term Incentive Compensation group, if mailed, shall be addressed\nto the principal executive offices of the Company. Notices shall be deemed given as of the date of delivery, or if delivery is made by mail, as of the date shown on the postmark on\nthe receipt for registration or certification.\n10.2 Nontransferability. Participants’ rights to deferred amounts and interest earned thereon under the Plan may not be sold, transferred, assigned, or otherwise alienated or\nhypothecated other than by will or by will or by the laws of descent and distribution.",
      "char_count": 976,
      "start_char": 732800,
      "end_char": 733777
    },
    {
      "chunk_id": "pfizer_2023_chunk0917",
      "chunk_index": 917,
      "text": "thereon under the Plan may not be sold, transferred, assigned, or otherwise alienated or\nhypothecated other than by will or by will or by the laws of descent and distribution. In no event shall the Company make any payment under the Plan to any assignee or creditor of a\nParticipant.\n10.3 Severability. In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan,\nand the Plan shall be construed and enforced as if the illegal or invalid provision had not been included.\n10.4 Gender and Number. Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine; the plural shall include the\nsingular, and the singular shall include the plural.\n10.5 Costs of the Plan. All costs of implementing and administering the Plan shall be borne by the Company.\n10.6 Applicable Law.",
      "char_count": 924,
      "start_char": 733600,
      "end_char": 734526
    },
    {
      "chunk_id": "pfizer_2023_chunk0918",
      "chunk_index": 918,
      "text": "5 Costs of the Plan. All costs of implementing and administering the Plan shall be borne by the Company.\n10.6 Applicable Law. The plan shall be construed and enforced in accordance with the laws of the State of New York. Notwithstanding anything herein to the contrary, the terms\nof the Plan are intended to, and shall be interpreted and applied so as to, comply in all respects with Section 409A. Any provision of this Plan governing the timing or form of\npayment of benefits hereunder may be modified by the Committee if, and to the extent deemed necessary or advisable, to comply with Section 409A. Nothing in this Section 10.6\nshall be construed as an admission that any of the benefits payable under this Plan constitutes “deferred compensation” subject to the provisions of Section 409A.\n10.7 Successors.",
      "char_count": 810,
      "start_char": 734400,
      "end_char": 735211
    },
    {
      "chunk_id": "pfizer_2023_chunk0919",
      "chunk_index": 919,
      "text": "uccessors. All obligation of the Company under the Plan shall be binding on any successor to the Company, whether the existence of such successor is the result of a\ndirect or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.\n\nAPPENDIX A\nGRANDFATHERED BENEFITS\nDistribution of amounts that were earned and vested (within the meaning of Section 409A) under the Plan prior to 2005 (and earnings thereon) and are exempt from the\nrequirements of Section 409A shall be made in accordance with the Plan terms as in effect on December 31, 2004 as set forth in this Appendix A.\nNotwithstanding the foregoing, with respect to any Participant employed by Zoetis Inc. On and following the date Zoetis Inc. is no longer a wholly owned subsidiary of the\nCompany due to a tax-free distribution to the Company’s stock holders of all or a portion of its equity interest in Zoetis, such Participant shall be deemed to have incurred a",
      "char_count": 995,
      "start_char": 735200,
      "end_char": 736196
    },
    {
      "chunk_id": "pfizer_2023_chunk0920",
      "chunk_index": 920,
      "text": "d subsidiary of the\nCompany due to a tax-free distribution to the Company’s stock holders of all or a portion of its equity interest in Zoetis, such Participant shall be deemed to have incurred a\ntermination of employment only upon his or “Separation from Service” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended for purpose of the\ndistribution of his or her Grandfathered Benefits.\n\nArticle 1. Purpose\n1.1 Pfizer Inc, a Delaware corporation (the “Company”), hereby establishes, effective as of December 1, 1997, a deferred compensation plan for key employees as described\nherein, which shall be known as the “Pfizer Deferred Compensation Plan” (the “Plan”).\n1.2 Purpose. The purpose of the Plan is to provide certain key employees of the Company with the opportunity to voluntarily defer a portion of their compensation, subject to the\nterms of the Plan.",
      "char_count": 891,
      "start_char": 736000,
      "end_char": 736892
    },
    {
      "chunk_id": "pfizer_2023_chunk0921",
      "chunk_index": 921,
      "text": "ity to voluntarily defer a portion of their compensation, subject to the\nterms of the Plan. By adopting the Plan, the Company desires to enhance its ability to attract and retain key employees.\nArticle 2. Definitions\nWhenever used herein, the following terms when capitalized shall have the meaning set forth below:\n“Award” means the Annual Incentive Award based on an assessment of performance, payable by the Company to a Participant for the Participant’s services during a given\ncalendar year of the Company. Awards shall be deemed earned only upon formal announcement thereof by the Company.\n“Board” or “Board of Directors” means the Board of Directors of the Company\n“Change in Control” shall mean the occurrence of any of the following events:\nat any time during a two-year period, at least a majority of the Company’s Board of Directors shall cease to consist of “Continuing Directors” (meaning directors of the",
      "char_count": 918,
      "start_char": 736800,
      "end_char": 737719
    },
    {
      "chunk_id": "pfizer_2023_chunk0922",
      "chunk_index": 922,
      "text": "ajority of the Company’s Board of Directors shall cease to consist of “Continuing Directors” (meaning directors of the\nCompany who either were directors at the beginning of such two-year period or who subsequently became directors and whose election, or nomination for election by the\nCompany’s stockholders, was approved by a majority of the then Continuing Directors); or\nany “person” or “group” (as determined for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934), except any majority-owned subsidiary of the Company or\nany employee benefit plan of the Company or any trust or investment manager thereunder, shall have acquired “beneficial ownership” (as determined for purposes of U.S.\nSecurities and Exchange Commission (“SEC”) Regulation 13d-3) of shares of Common Stock of the Company having 15% or more of the voting power of all outstanding",
      "char_count": 868,
      "start_char": 737600,
      "end_char": 738469
    },
    {
      "chunk_id": "pfizer_2023_chunk0923",
      "chunk_index": 923,
      "text": "he Company having 15% or more of the voting power of all outstanding\nshares of capital stock of the Company, unless such acquisition is approved by a majority of the directors of the Company in office immediately preceding such acquisition;\niii\na merger or consolidation occurs to which the Company is a party, whether or not the Company is the surviving corporation, in which outstanding shares of Common Stock\nof the Company are converted into shares of another company (other than a conversion into shares of voting common stock of the successor corporation or a holding\ncompany thereof representing 80% of the voting power or all capital stock thereof outstanding immediately after the merger or consolidation) or other securities (of either\nthe Company or another company) or cash or other property; or\nthe sale of all, or substantially all, of the Company’s assets occurs; or\nthe stockholders of the Company approve a plan of complete liquidation of the Company.",
      "char_count": 968,
      "start_char": 738400,
      "end_char": 739369
    },
    {
      "chunk_id": "pfizer_2023_chunk0924",
      "chunk_index": 924,
      "text": "rty; or\nthe sale of all, or substantially all, of the Company’s assets occurs; or\nthe stockholders of the Company approve a plan of complete liquidation of the Company.\n“Code” means the Internal Revenue Code of 1986, as amended.\n“Committee” means the Executive Compensation Committee of the Board or the Employee Compensation and Management Development Committee, as appropriate, and any\nsuccessor thereto.\n“Company” means Pfizer Inc., a Delaware corporation (including any and all subsidiaries), and any successor thereto.\n“Compensation” means the gross Salary, Award, Long-Term Incentive Awards, and other payments which may be eligible for deferral under the Plan, which are payable to a\nParticipant with respect to services performed during a specified period.\n\n“Disability” means a disability which would qualify the Participant for Long-Term Disability benefits under the Pfizer Long Term Disability Plan and, as such plan may be\namended from time to time.",
      "char_count": 962,
      "start_char": 739200,
      "end_char": 740163
    },
    {
      "chunk_id": "pfizer_2023_chunk0925",
      "chunk_index": 925,
      "text": "ich would qualify the Participant for Long-Term Disability benefits under the Pfizer Long Term Disability Plan and, as such plan may be\namended from time to time.\n“Employee” means a salaried employee of the Company.\n“ERISA” means the Employee Retirement Income Security Act of 1974.\n“Federal Long-term Rate” means the 30-year constant maturity U.S. Treasury Rate from the Federal Reserve Bank for the previous month.\n“Long-Term Incentive Awards” means Performance-Contingent Share Awards or earnings from stock option exercises.\n“Participant” means an Employee who has elected to participate in the Plan.\n“Salary” means all regular, basic wages, before reduction for amounts deferred pursuant to the Plan or any other plan of the Company, payable in cash to a Participant for\nservices to be rendered during the calendar year, exclusive of any Bonus, Long-Term Awards, other special fees, awards, or incentive compensation, allowance, or amounts",
      "char_count": 944,
      "start_char": 740000,
      "end_char": 740945
    },
    {
      "chunk_id": "pfizer_2023_chunk0926",
      "chunk_index": 926,
      "text": "during the calendar year, exclusive of any Bonus, Long-Term Awards, other special fees, awards, or incentive compensation, allowance, or amounts\ndesignated by the Company as payment toward or reimbursement of expenses.\nArticle 3. Administration\n3.1 Authority of the Committee. The Plan shall initially be administered by the Committee. Subject to the terms of this Plan, the Committee may appoint a successor\ncommittee to administer the Plan.\nSubject to the provisions herein, the Committee shall have the exclusive discretion to select Employees for participation in the Plan; to determine the terms and conditions of each\nEmployee’s participation in the Plan; to make, in its sole discretion, all determinations arising in the administration, construction or interpretation of the Plan including the right to\nconstrue disputed or doubtful Plan terms and provisions, and any such determination shall be conclusive and binding on all persons, except as otherwise provided by law; to",
      "char_count": 982,
      "start_char": 740800,
      "end_char": 741783
    },
    {
      "chunk_id": "pfizer_2023_chunk0927",
      "chunk_index": 927,
      "text": "e right to\nconstrue disputed or doubtful Plan terms and provisions, and any such determination shall be conclusive and binding on all persons, except as otherwise provided by law; to\nconstrue and interpret any agreement or instrument entered into under the Plan; to establish, amend, or waive rules and regulations for the Plan’s administration; to amend (subject\nto the provisions of Article 9 herein) the terms and conditions of the Plan and any agreement entered into under the Plan; and to make other determinations which may be necessary\nor advisable for the administration of the Plan. Subject to the terms of the Plan, the Committee may delegate any or all of its authority granted under the Plan to one or more\nexecutives of the Company.\n3.2 Claims Procedure. If a request for benefits by a Participant or beneficiary is wholly or partially denied, the Committee will provide such claimant written notice setting forth\nthe denial.",
      "char_count": 938,
      "start_char": 741600,
      "end_char": 742539
    },
    {
      "chunk_id": "pfizer_2023_chunk0928",
      "chunk_index": 928,
      "text": "articipant or beneficiary is wholly or partially denied, the Committee will provide such claimant written notice setting forth\nthe denial. A review procedure is available upon written notice of the denial of the claim, and includes the right to examine pertinent documents and submit issues and comments in\nwriting to the Committee. The decision on review will be made within 90 days after receipt of the request for review, unless circumstances warrant an extension of time not to exceed\nan additional 90 days and shall be in writing. If a decision on review is not made within such period, the Participant’s claim shall be deemed denied.\n3.3 Decisions Binding. All determinations and decisions of the Committee as to any disputed question arising under the Plan shall be final, conclusive and binding on all\nparties.\nArticle 4. Eligibility and Participation\n4.1 Eligibility.",
      "char_count": 876,
      "start_char": 742400,
      "end_char": 743277
    },
    {
      "chunk_id": "pfizer_2023_chunk0929",
      "chunk_index": 929,
      "text": "ng on all\nparties.\nArticle 4. Eligibility and Participation\n4.1 Eligibility. Employees eligible to participate in the Plan include key policy and decision makers of the Company, as selected by the Committee in its sole discretion. It is the\nintent of the Company to extend eligibility only to those executives who comprise a select group of “management or highly compensated employees,” such that the Plan will qualify\nfor treatment as a “Top hat” plan within the meaning of Sections 201, 301 and 401 of ERISA.\nIn the event a Participant no longer meets the requirements for participation in the Plan, such Participant shall become an inactive Participant, retaining all the rights described\nunder the Plan, except the right to make any further deferrals, until such time as the Participant again becomes an active Participant.\n4.2 Participation. Participation in the Plan shall be determined annually by the Committee based upon the criteria set forth in Section 4.1 herein.",
      "char_count": 975,
      "start_char": 743200,
      "end_char": 744176
    },
    {
      "chunk_id": "pfizer_2023_chunk0930",
      "chunk_index": 930,
      "text": "omes an active Participant.\n4.2 Participation. Participation in the Plan shall be determined annually by the Committee based upon the criteria set forth in Section 4.1 herein. Employees who are chosen to\nparticipate in the Plan in any given year shall be so notified in writing.\n4.3 Partial Year Eligibility. In the event than an Employee first becomes eligible to participate in the Plan during any given year, such Employee shall as soon as practicable be\nso notified in writing by the Company and provided with an “Election to Defer Form,” which must be completed by the Employee as set forth in Section 5.2 herein; provided, however,\nthat such Employee may make an election to defer with respect to only that portion of his or her Compensation for such year which is to be paid after the date of filing of the deferral\nelection.\n4.4 No Right to Participate.",
      "char_count": 861,
      "start_char": 744000,
      "end_char": 744862
    },
    {
      "chunk_id": "pfizer_2023_chunk0931",
      "chunk_index": 931,
      "text": "filing of the deferral\nelection.\n4.4 No Right to Participate. No Employee shall have the right to be selected as a Participant, or, having been so selected for any given year, to be selected again as a\nParticipant for any other year.\n\nArticle 5. Deferral Opportunity\n5.1 Amount Which May Be Deferred. A Participant may elect to defer up to one hundred percent (100%) of eligible components of Compensation, including but not limited to\nSalary, Award and Long-Term Awards, in any given year; provided, that the Committee shall have sole discretion to designate which components of Compensation are eligible for\ndeferral elections under the Plan in any such year. The minimum amount of any single eligible component of Compensation which may be deferred in any given year is ten percent\n(10%) of each such component.",
      "char_count": 814,
      "start_char": 744800,
      "end_char": 745615
    },
    {
      "chunk_id": "pfizer_2023_chunk0932",
      "chunk_index": 932,
      "text": "uch component. In addition, an election to defer Compensation in any given year must be expressed by each Participant in increments of ten percent (10%) of the\napplicable component of Compensation.\n5.2 Deferral Election. Participants shall make their elections to defer Compensation under the Plan for a given calendar year not later than (a) thirty (30) days prior to the\nbeginning of such calendar year or (b) if Participants are notified after the beginning of the calendar year of their selection to participate in the plan for such calendar year or a partial\ncalendar year, within thirty (30) days of receipt of such notice. All deferral elections shall be irrevocable; shall relate solely to amounts earned after the filing of a deferral election with\nthe Committee; and shall be made on an “Election to Defer Form,” as described herein.\nParticipants shall make the following irrevocable elections on each “Election to Defer Form”.",
      "char_count": 937,
      "start_char": 745600,
      "end_char": 746538
    },
    {
      "chunk_id": "pfizer_2023_chunk0933",
      "chunk_index": 933,
      "text": "ection to Defer Form,” as described herein.\nParticipants shall make the following irrevocable elections on each “Election to Defer Form”.\n(a) The amount to be deferred with respect to each eligible component of Compensation for the specified year;\n(b) The length of the deferral period with respect to each eligible component of Compensation, pursuant to the terms of Section 5.3 herein;\n5.3 Length of Deferral. The deferral periods elected by each Participant with respect to deferrals of Compensation for any given year shall be selected from among the choices\nspecified by the Committee. The Committee shall specify one or more deferral periods which are at least one (1) year following the end of the calendar year in which the\nCompensation is earned, and no greater than five (5) years following retirement.\n5.4 Payment of Deferred Amounts.",
      "char_count": 845,
      "start_char": 746400,
      "end_char": 747246
    },
    {
      "chunk_id": "pfizer_2023_chunk0934",
      "chunk_index": 934,
      "text": "retirement.\n5.4 Payment of Deferred Amounts. Subject to the provisions of Section 5.5 and Section 9 of the Plan, Participants shall receive payment of deferred amounts, together with\ninterest earned thereon, at the end of the deferred period in a single lump-sum cash payment, unless otherwise elected. If alternative methods for receiving payments are approved\nby the Committee, election of the method of payment shall be made by the Participant within the same time periods as required in Section 5.2 of the Plan.\n(a) Lump-Sum Payment. A lump sum payment shall be made in cash within sixty (60) days of the end of the deferral period by the Participant, as described in Sections\n5.2 and 5.3 herein.\n(b) Installment Payments. If approved by the Committee, Participants may elect payout in annual installments, with a minimum number of installments of two (2), and a\nmaximum of fifteen (15).",
      "char_count": 891,
      "start_char": 747200,
      "end_char": 748093
    },
    {
      "chunk_id": "pfizer_2023_chunk0935",
      "chunk_index": 935,
      "text": "stallments, with a minimum number of installments of two (2), and a\nmaximum of fifteen (15). The initial payment shall be made in cash within sixty (60) days after the commencement date selected by the Participant pursuant to Sections\n5.2 and 5.3 herein. The remaining installment payments shall be made in cash each year thereafter, until the Participant’s entire deferred compensation account has been\npaid. Interest shall accrue on the deferred amounts in the Participant’s deferred compensation account immediately prior each such payment, multiplied by a fraction, the\nnumerator of which is one (1), and the denominator of which is the number of installment payments remaining.\n \n(c) Alternative Payment Schedule. If approved by the Committee, a Participant may elect an alternate payment schedule.\n5.5 Change in Control.",
      "char_count": 826,
      "start_char": 748000,
      "end_char": 748827
    },
    {
      "chunk_id": "pfizer_2023_chunk0936",
      "chunk_index": 936,
      "text": "le.\n5.5 Change in Control. Notwithstanding any provision contained in the Plan, in the event of a Change in Control, all participants shall be entitled to an immediate lump sum\npayment of their deferred amounts, together with interest earned thereon.\nArticle 6. Deferred Compensation Accounts\n6.1 Participants’ Accounts. The Company shall establish and maintain an individual bookkeeping account for deferrals made by each Participant under Article 5 herein. Each\naccount shall be credited as of the date the amount deferred otherwise would have become due and payable to the Participant.\n6.2 Interest on Deferred Amounts. Compensation deferred under Article 5 shall accrue interest on a basis to be specified by the Committee, at a rate equal to the return\nchoice(s) selected by the Participant from among the alternatives specified by the Committee from time to time.",
      "char_count": 869,
      "start_char": 748800,
      "end_char": 749670
    },
    {
      "chunk_id": "pfizer_2023_chunk0937",
      "chunk_index": 937,
      "text": "among the alternatives specified by the Committee from time to time. Interest credited on deferred amounts (less the amount of any debits\nfor any losses) shall be paid out to Participants at the same time and in the same manner as the underlying deferred amounts.\n6.3 Charges Against Accounts. There shall be charged against each Participant’s deferred compensation account any payments made to the Participant or to his or her\nbeneficiary.\n6.4 Designation of Beneficiary. Each Participant may designate a beneficiary or beneficiaries (who may be named contingently or successively) who, upon the Participant’s\ndeath, will receive the amounts that otherwise would have been paid to the Participant under the Plan. All designations shall be signed by the Participant and shall be in such form as\nprescribed by the Committee.",
      "char_count": 823,
      "start_char": 749600,
      "end_char": 750425
    },
    {
      "chunk_id": "pfizer_2023_chunk0938",
      "chunk_index": 938,
      "text": "cribed by the Committee. Each designation shall be effective as of the date received from the Participant by the Senior Vice President - Employee Resources of the Company.\nParticipants may change their beneficiary designations on a form prescribed by the Committee. The payment of amounts deferred under the Plan shall be in accordance with the\nlast unrevoked written designation of beneficiary that has been signed by the Participant and delivered by the Participant to the Senior Vice President - Employee Resources prior to\nthe Participant’s death.\n\nIn the event that all the beneficiaries named by a Participant pursuant to this Section 6.4 predecease the Participant, the deferred amounts that would have been paid to the\nParticipant or the Participant’s beneficiaries shall be paid to the Participant’s estate.\nIn the event a Participant does not designate a beneficiary, or for any reason such designation is ineffective, in whole or in part, the amounts that otherwise would have been paid",
      "char_count": 997,
      "start_char": 750400,
      "end_char": 751398
    },
    {
      "chunk_id": "pfizer_2023_chunk0939",
      "chunk_index": 939,
      "text": "cipant’s estate.\nIn the event a Participant does not designate a beneficiary, or for any reason such designation is ineffective, in whole or in part, the amounts that otherwise would have been paid\nto the Participant or the Participant’s beneficiaries under the Plan shall be paid to the Participant’s estate.\nArticle 7. Rights of Participants\n7.1 Contractual Obligation. The Plan shall create a contractual obligation on the part of the Company to make payments from the Participant’s accounts when due. Payment of\naccount balances shall be made out of the general funds of the Company.\n7.2 Unsecured Interest. No Participant, or party claiming an interest in deferred amounts or contributions through a Participant, shall have any interest whatsoever in any\nspecific asset of the Company. To the extent that any party acquires a right to receive payments under the Plan, such right shall be equivalent to that of an unsecured general\ncreditor of the Company.\n7.3 Employment.",
      "char_count": 976,
      "start_char": 751200,
      "end_char": 752177
    },
    {
      "chunk_id": "pfizer_2023_chunk0940",
      "chunk_index": 940,
      "text": "tent that any party acquires a right to receive payments under the Plan, such right shall be equivalent to that of an unsecured general\ncreditor of the Company.\n7.3 Employment. Nothing in the Plan shall interfere with nor limit in any way the right of the Company to terminate any Participant’s employment at any time, nor confer upon\nany Participant any right to continue in the employ of the Company.\nArticle 8. Withholding of Taxes\nThe Company shall withhold from an employee’s regular compensation from the Company an amount sufficient to satisfy foreign, Federal, state, and local income or other\nwithholding tax requirements with regard to amounts deferred under the Plan. However, the Company reserves the right to institute alternative methods for satisfying the applicable\nincome and withholding tax requirements.\nArticle 9. Amendment and Termination\nThe Company hereby reserves the right to amend, modify or terminate the Plan at any time by action of the Committee.",
      "char_count": 976,
      "start_char": 752000,
      "end_char": 752977
    },
    {
      "chunk_id": "pfizer_2023_chunk0941",
      "chunk_index": 941,
      "text": "ding tax requirements.\nArticle 9. Amendment and Termination\nThe Company hereby reserves the right to amend, modify or terminate the Plan at any time by action of the Committee. Except as described below in this Article 9, no such\namendment, modification or termination shall in any material manner adversely effect any Participant’s rights to deferred amounts, contributions or interest earned thereon, without\nthe consent of the Participant.\nThe Plan is intended to be an unfunded plan maintained primarily to provide deferred compensation benefits for a select group of “management or highly compensated\nemployees” within the meaning of Sections 201, 301 and 401 of ERISA, and therefore to be exempt from the provisions of Parts 2, 3 and 4 of Title I of ERISA. Accordingly, the\nCommittee may terminate the Plan and commence termination payout for all or certain Participants, or remove certain employees as Participants, if it is determined by the United",
      "char_count": 956,
      "start_char": 752800,
      "end_char": 753757
    },
    {
      "chunk_id": "pfizer_2023_chunk0942",
      "chunk_index": 942,
      "text": "ate the Plan and commence termination payout for all or certain Participants, or remove certain employees as Participants, if it is determined by the United\nStates Department of Labor or a court of competent jurisdiction that the Plan constitutes an employee pension benefit plan within the meaning of Section 3(2) of ERISA which is not\nso exempt. If payout is commenced pursuant to the operation of this Article 9, the payment of such amounts shall be made in a lump sum regardless of the manner selected by each\nParticipant under Section 5.4 herein as applicable.\nArticle 10. Miscellaneous\n10.1 Notice. Any notice or filing required or permitted to be given to the Company under the Plan shall be sufficient if in writing and hand delivered, or sent by registered or\ncertified mail to the Senior Vice President - Employee Resources of the Company. Notice to the Senior Vice President - Employee Resources, if mailed, shall be addressed to the\nprincipal executive offices of the Company.",
      "char_count": 988,
      "start_char": 753600,
      "end_char": 754589
    },
    {
      "chunk_id": "pfizer_2023_chunk0943",
      "chunk_index": 943,
      "text": "ce President - Employee Resources of the Company. Notice to the Senior Vice President - Employee Resources, if mailed, shall be addressed to the\nprincipal executive offices of the Company. Notices shall be deemed given as of the date of delivery, or if delivery is made by mail, as of the date shown on the postmark on the\nreceipt for registration or certification.\n10.2 Nontransferability. Participants’ rights to deferred amounts and interest earned thereon under the Plan may not be sold, transferred, assigned, or otherwise alienated or\nhypothecated other than by will or by the laws of descent and distribution. In no event shall the Company make any payment under the Plan to any assignee or creditor of a\nParticipant.\n10.3 Severability. In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and",
      "char_count": 914,
      "start_char": 754400,
      "end_char": 755315
    },
    {
      "chunk_id": "pfizer_2023_chunk0944",
      "chunk_index": 944,
      "text": "egal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and\nthe Plan shall be construed and enforced as if the illegal or invalid provision had not been included.\n10.4 Gender and Number. Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine; the plural shall include the singular,\nand the singular shall include the plural.\n10.5 Costs of the Plan. All costs of implementing and administering the Plan shall be borne by the Company.\n10.6 Applicable Law. The plan shall be construed and enforced in accordance with the laws of the State of New York.\n10.7 Successors. All obligation of the Company under the Plan shall be binding on any successor to the Company, whether the existence of such successor is the result of a\ndirect or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.",
      "char_count": 971,
      "start_char": 755200,
      "end_char": 756172
    },
    {
      "chunk_id": "pfizer_2023_chunk0945",
      "chunk_index": 945,
      "text": "ch successor is the result of a\ndirect or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.\n\nEXHIBIT 21\nThe following is a list of subsidiaries of the Company as of December 31, 2023 omitting some subsidiaries which, considered in the aggregate,\nwould not constitute a significant subsidiary.\nCompany Name\nWhere Incorporated\n or Organized\n356 Royalty Inc.\nDelaware\nAgouron Pharmaceuticals, LLC\nCalifornia\nAH Robins LLC\nDelaware\nAHP Manufacturing B.V.\nNetherlands\nAlpharma Pharmaceuticals LLC\nDelaware\nAmerican Food Industries LLC\nDelaware\nAmplyx Pharmaceuticals, Inc.\nDelaware\nAnacor Pharmaceuticals, LLC\nDelaware\nArena Pharmaceuticals Canada Holdings, L.P.\nCanada\nArena Pharmaceuticals Development GmbH\nSwitzerland\nArena Pharmaceuticals Development, LLC\nDelaware\nArena Pharmaceuticals, Inc.\nDelaware\nArena Pharmaceuticals, LLC\nDelaware\nArixa Pharmaceuticals, Inc.\nDelaware\nArray BioPharma Inc.\nDelaware",
      "char_count": 983,
      "start_char": 756000,
      "end_char": 756984
    },
    {
      "chunk_id": "pfizer_2023_chunk0946",
      "chunk_index": 946,
      "text": "a Pharmaceuticals Development, LLC\nDelaware\nArena Pharmaceuticals, Inc.\nDelaware\nArena Pharmaceuticals, LLC\nDelaware\nArixa Pharmaceuticals, Inc.\nDelaware\nArray BioPharma Inc.\nDelaware\nBamboo Therapeutics, Inc.\nDelaware\nBiohaven Pharmaceutical Holding Company Limited\nBritish Virgin Islands\nBiohaven Pharmaceutical Ireland Designated Activity Company\nIreland\nBlue Whale Re Ltd.\nVermont\nBulldog (BVI) NewCo Limited\nBritish Virgin Islands\nC.P. Pharmaceuticals International C.V.\nNetherlands\nCICL Corporation\nDelaware\nCOC I Corporation\nDelaware\nColey Pharmaceutical Group, Inc.\nDelaware\nCyanamid de Argentina, S.A.\nDelaware\nDistribuidora Mercantil Centro Americana, S.A.\nDelaware\nEast Coast Ventures, Inc.\nDelaware\nEncysive Pharmaceuticals Inc.\nDelaware\nFoldRx Pharmaceuticals, LLC\nDelaware\nFort Dodge Manufatura Ltda.\nBrazil\nG. D. Searle & Co. Limited\nUnited Kingdom\nG. D.",
      "char_count": 869,
      "start_char": 756800,
      "end_char": 757670
    },
    {
      "chunk_id": "pfizer_2023_chunk0947",
      "chunk_index": 947,
      "text": "nufatura Ltda.\nBrazil\nG. D. Searle & Co. Limited\nUnited Kingdom\nG. D. Searle International Capital LLC\nDelaware\nGenetics Institute, LLC\nDelaware\nGenTrac, Inc.\nWisconsin\nGI Europe, Inc.\nDelaware\nGI Japan, Inc.\nDelaware\nGlobal Blood Therapeutics, Inc.\nDelaware\nHospira Adelaide Pty Ltd\nAustralia\nHospira Australia Pty Ltd\nAustralia\nHospira Benelux BVBA\nBelgium\nHospira Holdings (S.A.) Pty Ltd\nAustralia\nHospira Philippines, Inc.\nPhilippines\nHospira Pte. Ltd.\nSingapore\nHospira Puerto Rico, LLC\nDelaware\nHospira UK Limited\nUnited Kingdom\nHospira Worldwide, LLC\nDelaware\n\nHospira Zagreb d.o.o.\nCroatia\nHospira, Inc.\nDelaware\nIgnite Immunotherapy, Inc.\nDelaware\nInnoPharma, Inc.\nDelaware\nInternational Affiliated Corporation LLC\nDelaware\nJohn Wyeth & Brother Limited\nUnited Kingdom\nKing Pharmaceuticals Holdings LLC\nDelaware\nKing Pharmaceuticals LLC\nDelaware\nKing Pharmaceuticals Research and Development, LLC\nDelaware\nLaboratoires Pfizer, S.A.\nMorocco\nLaboratorios Pfizer Ltda.\nBrazil",
      "char_count": 980,
      "start_char": 757600,
      "end_char": 758581
    },
    {
      "chunk_id": "pfizer_2023_chunk0948",
      "chunk_index": 948,
      "text": "ldings LLC\nDelaware\nKing Pharmaceuticals LLC\nDelaware\nKing Pharmaceuticals Research and Development, LLC\nDelaware\nLaboratoires Pfizer, S.A.\nMorocco\nLaboratorios Pfizer Ltda.\nBrazil\nLaboratórios Pfizer, Lda.\nPortugal\nLaboratorios Wyeth LLC\nPennsylvania\nMayne Pharma IP Holdings (Euro) Pty Ltd\nAustralia\nMedivation Field Solutions LLC\nDelaware\nMedivation LLC\nDelaware\nMedivation Neurology LLC\nDelaware\nMedivation Prostate Therapeutics LLC\nDelaware\nMedivation Services LLC\nDelaware\nMedivation Technologies LLC\nDelaware\nMonarch Pharmaceuticals, LLC\nTennessee\nMPP Trustee Limited\nUnited Kingdom\nMTG Divestitures LLC\nDelaware\nNeusentis Limited\nUnited Kingdom\nPAH USA IN8 LLC\nDelaware\nParke, Davis & Company LLC\nMichigan\nParkedale Pharmaceuticals, Inc.\nMichigan\nPBG Puerto Rico LLC\nPuerto Rico\nP-D Co., LLC\nDelaware\nPeak Enterprises LLC\nDelaware\nPF Argentum Acquisition ULC\nCanada\nPF Argentum US Corporation\nDelaware\nPF Czech Republic Holdings B.V.\nNetherlands\nPF Finland Holdings B.V.\nNetherlands",
      "char_count": 990,
      "start_char": 758400,
      "end_char": 759391
    },
    {
      "chunk_id": "pfizer_2023_chunk0949",
      "chunk_index": 949,
      "text": "Delaware\nPeak Enterprises LLC\nDelaware\nPF Argentum Acquisition ULC\nCanada\nPF Argentum US Corporation\nDelaware\nPF Czech Republic Holdings B.V.\nNetherlands\nPF Finland Holdings B.V.\nNetherlands\nPF OFG South Korea 1 B.V.\nNetherlands\nPF OFG South Korea 2 B.V.\nNetherlands\nPF PR Holdings C.V.\nNetherlands\nPF PRISM C.V.\nNetherlands\nPF PRISM Holdings B.V.\nNetherlands\nPF PRISM IMB B.V.\nNetherlands\nPF Prism S.á.r.l.\nLuxembourg\nPfizer\nFrance\n\nPeople's Republic of China\n\nPeople's Republic of China\nPfizer (Malaysia) Sdn Bhd\nMalaysia\nPfizer (North Carolina) LLC\nDelaware\n\nAustralia\n\nThailand\n\nVietnam\n\nPeople's Republic of China\nPfizer AB\nSweden\nPfizer AG\nSwitzerland\n\nPfizer Anti-Infectives AB\nSweden\nPfizer ApS\nDenmark\nPfizer AS\nNorway\n\nSingapore\nPfizer Australia Holdings B.V.\nNetherlands\n\nAustralia\n\nAustralia\n\nAustralia\nPfizer B.V.\nNetherlands\nPfizer Biopharma Egypt LLC\nEgypt\nPfizer Biopharmaceuticals Egypt LLC\nEgypt\nPfizer Bolivia S.A.\nBolivia\n\nBrazil",
      "char_count": 949,
      "start_char": 759200,
      "end_char": 760150
    },
    {
      "chunk_id": "pfizer_2023_chunk0950",
      "chunk_index": 950,
      "text": "lia\n\nAustralia\nPfizer B.V.\nNetherlands\nPfizer Biopharma Egypt LLC\nEgypt\nPfizer Biopharmaceuticals Egypt LLC\nEgypt\nPfizer Bolivia S.A.\nBolivia\n\nBrazil\n\nPeople's Republic of China\nPfizer Canada ULC / Pfizer Canada SRI\nCanada\nPfizer Chile S.A.\nChile\n\nEcuador\n\nPennsylvania\nPfizer Consumer Healthcare\nUnited Kingdom\n\nIreland\n\nAustria\n\nHong Kong\n\nPanama\nPfizer Croatia d.o.o.\nCroatia\nPfizer Deutschland GmbH\nGermany\nPfizer Development LLC\nDelaware\n\nUnited Kingdom\nPfizer East India B.V.\nNetherlands\nPfizer Eastern Investments B.V.\nNetherlands\nPfizer Europe MA EEIG\nBelgium\nPfizer Export B.V.\nNetherlands\nPfizer Export Company\nIreland\nPfizer France International Investments\nFrance\nPfizer Free Zone Panama, S. de R.L.\nPanama\nPfizer Global Holdings B.V.\nNetherlands\n\nJapan\nPfizer Global Trading\nIreland\nPfizer Gulf FZ-LLC\nUnited Arab Emirates\n\nNew York\nPfizer Health AB\nSweden\n\nDelaware",
      "char_count": 879,
      "start_char": 760000,
      "end_char": 760880
    },
    {
      "chunk_id": "pfizer_2023_chunk0951",
      "chunk_index": 951,
      "text": "er Gulf FZ-LLC\nUnited Arab Emirates\n\nNew York\nPfizer Health AB\nSweden\n\nDelaware\n\nIndia\nPfizer Healthcare Ireland\nIreland\nPfizer Hellas, A.E.\nGreece\nPfizer Himalaya Holdings Coöperatief U.A.\nNetherlands\nPfizer Holding France\nFrance\n\nSingapore\n\nDelaware\nPfizer Holdings International LLC\nDelaware\nPfizer Holdings International Luxembourg (PHIL) SARL\nLuxembourg\nPfizer Holdings Singapore LLC\nDelaware\nPfizer Innovations LLC\nRussia\n\nPfizer International LLC\nNew York\nPfizer International Operations\nFrance\n\nIreland\n\nPeople's Republic of China\nPfizer Investment Enterprises Holdings LLC\nDelaware\n\nSingapore\n\nSingapore\n\nDelaware\n\nIreland\nPfizer Ireland PFE Holding 1 LLC\nDelaware\nPfizer Ireland PFE Holding 2 LLC\nDelaware\nPfizer Ireland Pharmaceuticals\nIreland\n\nIreland\n\nIreland\nPfizer Italia S.r.l.\nItaly\n\nJapan\n\nSouth Africa\n\nKenya\n\nIreland\n\nUnited Kingdom\n\nUnited Kingdom\n\nIndia",
      "char_count": 875,
      "start_char": 760800,
      "end_char": 761676
    },
    {
      "chunk_id": "pfizer_2023_chunk0952",
      "chunk_index": 952,
      "text": "Japan\n\nSouth Africa\n\nKenya\n\nIreland\n\nUnited Kingdom\n\nUnited Kingdom\n\nIndia\n\nTaiwan\nPfizer Luxco Holdings SARL\nLuxembourg\nPfizer Luxembourg Global Holdings S.à r.l.\nLuxembourg\nPfizer Luxembourg SARL\nLuxembourg\nPfizer Manufacturing Austria G.m.b.H.\nAustria\nPfizer Manufacturing Belgium N.V.\nBelgium\nPfizer Manufacturing Deutschland GmbH\nGermany\nPfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG\nGermany\nPfizer Manufacturing Holdings LLC\nDelaware\n\nIreland\nPfizer Manufacturing LLC\nDelaware\nPfizer Manufacturing Services\nIreland\n\nDelaware\n\nBrazil\nPfizer Mexico Holding B.V.\nNetherlands\n\nNew Zealand\nPfizer North America Services LLC\nDelaware\nPfizer OTC B.V.\nNetherlands\nPfizer Overseas LLC\nDelaware\nPfizer Oy\nFinland\n\nPakistan\nPfizer PFE AsiaPac Holding B.V.\nNetherlands\nPfizer PFE Australia Holding B.V.\nNetherlands\n\nAustralia",
      "char_count": 832,
      "start_char": 761600,
      "end_char": 762434
    },
    {
      "chunk_id": "pfizer_2023_chunk0953",
      "chunk_index": 953,
      "text": "lding B.V.\nNetherlands\n\nAustralia\n\nEcuador\nPfizer PFE Eastern Investments B.V.\nNetherlands\nPfizer PFE Global Holdings B.V.\nNetherlands\nPfizer PFE İlaçları Anonim Şirketi\nTurkey\nPfizer PFE Pharmaceuticals Israel Holding LLC\nDelaware\n\nIsrael\n\nPfizer PFE Service Company Holding B.V.\nNetherlands\nPfizer PFE Spain B.V.\nNetherlands\nPfizer Pharm Algerie\nAlgeria\nPfizer Pharma GmbH\nGermany\n\nPeople's Republic of China\n\nHungary\nPfizer Pharmaceuticals Global B.V.\nNetherlands\n\nIsrael\n\nRepublic of Korea\n\nPeople's Republic of China\nPfizer Pharmaceuticals Tunisie Sarl\nTunisia\n\nDelaware\nPfizer Polska Sp. z.o.o.\nPoland\n\nSingapore\nPfizer Production LLC\nDelaware\n\nConnecticut\n\nIndia\nPfizer R&D Holding B.V.\nNetherlands\nPfizer R&D Japan G.K.\nJapan\n\nUnited Kingdom\n\nDelaware\nPfizer Romania SRL\nRomania\nPfizer S.A.\nPeru\nPfizer S.A.S.\nColombia\nPfizer S.G.P.S. Lda.\nPortugal\nPfizer S.r.l.\nItaly\nPfizer S.R.L.\nArgentina\nPfizer SA (Belgium)\nBelgium",
      "char_count": 928,
      "start_char": 762400,
      "end_char": 763329
    },
    {
      "chunk_id": "pfizer_2023_chunk0954",
      "chunk_index": 954,
      "text": "eru\nPfizer S.A.S.\nColombia\nPfizer S.G.P.S. Lda.\nPortugal\nPfizer S.r.l.\nItaly\nPfizer S.R.L.\nArgentina\nPfizer SA (Belgium)\nBelgium\n\nSaudi Arabia\nPfizer Saudi Trading LLC\nSaudi Arabia\nPfizer Service Company BV\nBelgium\n\nIreland\nPfizer Services LLC\nDelaware\n\nIreland\nPfizer Shareholdings Intermediate SARL\nLuxembourg\nPfizer Singapore Development LP\nSingapore\n\nSingapore\n\nNigeria\n\nUnited Kingdom\nPfizer SRB d.o.o.\nSerbia\nPfizer Strategic Investment Holdings LLC\nDelaware\nPfizer Trading Polska sp.z.o.o.\nPoland\nPfizer Transactions LLC\nDelaware\nPfizer Tunisie SA\nTunisia\nPfizer Venezuela, S.A.\nVenezuela\nPfizer Ventures (US) LLC\nDelaware\nPfizer Ventures LLC\nDelaware\n\nIreland\nPfizer Zona Franca, S.A.\nCosta Rica\n\nPhilippines\nPfizer, S.A.\nCosta Rica\n\nPfizer, S.A. de C.V.\nMexico\nPfizer, S.L.U.\nSpain\nPfizer, spol.",
      "char_count": 804,
      "start_char": 763200,
      "end_char": 764005
    },
    {
      "chunk_id": "pfizer_2023_chunk0955",
      "chunk_index": 955,
      "text": "pol. s r.o.\nCzech Republic\nPharmacia & Upjohn Company LLC\nDelaware\nPharmacia & Upjohn LLC\nDelaware\nPharmacia Brasil Ltda.\nBrazil\nPharmacia Hepar LLC\nDelaware\nPharmacia Inter-American LLC\nPennsylvania\nPharmacia International B.V.\nNetherlands\nPharmacia Limited\nUnited Kingdom\nPharmacia LLC\nDelaware\nPHIVCO Corp.\nDelaware\nPHIVCO Holdco S.à r.l.\nLuxembourg\nPHIVCO Luxembourg S.à r.l.\nLuxembourg\nPIMB OFG Spain Holding, S.L.\nSpain\nPRISM Holdings B.V.\nNetherlands\nPT. Pfizer Indonesia\nIndonesia\nPurepac Pharmaceutical Holdings LLC\nDelaware\nRenrall LLC\nWyoming\nResApp Health Limited\nAustralia\nReViral Limited\nUnited Kingdom\nRinat Neuroscience Corp.\nDelaware\nSeagen Austria GmbH\nAustria\nSeagen B.V.\nNetherlands\nSeagen Canada Inc.\nCanada\nSeagen Denmark ApS\nDenmark\nSeagen France SAS\nFrance\nSeagen Germany GmbH\nGermany\nSeagen Inc.\nDelaware\nSeagen International GmbH\nSwitzerland\nSeaGen International Holdings, LLC\nDelaware\nSeagen Italy S.r.l.\nItaly\nSeagen Spain, S.L.U.\nSpain\nSeagen Sweden AB\nSweden",
      "char_count": 988,
      "start_char": 764000,
      "end_char": 764989
    },
    {
      "chunk_id": "pfizer_2023_chunk0956",
      "chunk_index": 956,
      "text": "Germany\nSeagen Inc.\nDelaware\nSeagen International GmbH\nSwitzerland\nSeaGen International Holdings, LLC\nDelaware\nSeagen Italy S.r.l.\nItaly\nSeagen Spain, S.L.U.\nSpain\nSeagen Sweden AB\nSweden\nSeagen U.K. Ltd.\nUnited Kingdom\nSeagen U.S. Inc.\nDelaware\nSeaGen US Holdings, LLC\nDelaware\nServicios P&U, S. de R.L. de C.V.\nMexico\nShiley LLC\nCalifornia\nSinergis Farma-Produtos Farmaceuticos, Lda.\nPortugal\nSolinor LLC\nDelaware\nSugen LLC\nDelaware\nTabor LLC\nDelaware\nThe Pfizer Incubator LLC\nDelaware\nTrillium Therapeutics ULC\nCanada\nVicuron Holdings LLC\nDelaware\nWarner Lambert del Uruguay S.A.\nUruguay\nWarner-Lambert Company GmbH\nSwitzerland\nWarner-Lambert Company LLC\nDelaware\nW-L LLC\nDelaware\nWyeth (Asia) Limited\nDelaware\nWyeth Ayerst Inc.\nDelaware\n\nWyeth Farma, S.A.\nSpain\nWyeth Holdings LLC\nMaine\nWyeth Lederle S.r.l.\nItaly\nWyeth LLC\nDelaware\nWyeth Pakistan Limited\nPakistan\nWyeth Pharmaceuticals LLC\nDelaware\nWyeth Subsidiary Illinois Corporation\nIllinois\nWyeth-Ayerst (Asia) LLC\nDelaware",
      "char_count": 983,
      "start_char": 764800,
      "end_char": 765785
    },
    {
      "chunk_id": "pfizer_2023_chunk0957",
      "chunk_index": 957,
      "text": "derle S.r.l.\nItaly\nWyeth LLC\nDelaware\nWyeth Pakistan Limited\nPakistan\nWyeth Pharmaceuticals LLC\nDelaware\nWyeth Subsidiary Illinois Corporation\nIllinois\nWyeth-Ayerst (Asia) LLC\nDelaware\nWyeth-Ayerst International LLC\nDelaware\nWyeth-Ayerst Promotions Limited\nDelaware\n\nEXHIBIT 22\nSubsidiary Issuers of Guaranteed Securities\nAs of December 31, 2023, Pfizer Inc. (Parent Guarantor) was the unconditional and irrevocable guarantor of the following\nunsecured registered notes issued by wholly-owned subsidiaries of Parent Guarantor:\nName of Subsidiary Issuer\nState of Formation of Issuer\nDescription of Registered Notes\nWyeth LLC\nDelaware\n6.45% Notes due 2024\nPharmacia LLC\nDelaware\n6.75% Debentures due 2027\nPharmacia LLC\nDelaware\n6.60% Debentures due 2028\nWyeth LLC\nDelaware\n6.50% Notes due 2034\nWyeth LLC\nDelaware\n6.00% Notes due 2036\nWyeth LLC\nDelaware\n5.95% Notes due 2037\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n4.650% Notes due 2025\nPfizer Investment Enterprises Pte.\nLtd.",
      "char_count": 995,
      "start_char": 765600,
      "end_char": 766596
    },
    {
      "chunk_id": "pfizer_2023_chunk0958",
      "chunk_index": 958,
      "text": "C\nDelaware\n6.00% Notes due 2036\nWyeth LLC\nDelaware\n5.95% Notes due 2037\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n4.650% Notes due 2025\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n4.450% Notes due 2026\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n4.450% Notes due 2028\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n4.650% Notes due 2030\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n4.750% Notes due 2033\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n5.110% Notes due 2043\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n5.300% Notes due 2053\nPfizer Investment Enterprises Pte.\nLtd.\nRepublic of Singapore\n5.340% Notes due 2063\n \n\nEXHIBIT 23\nConsent of Independent Registered Public Accounting Firm\nWe consent to the incorporation by reference in the registration statements listed below of our reports dated February 22, 2024, with respect to the consolidated financial",
      "char_count": 986,
      "start_char": 766400,
      "end_char": 767387
    },
    {
      "chunk_id": "pfizer_2023_chunk0959",
      "chunk_index": 959,
      "text": "ccounting Firm\nWe consent to the incorporation by reference in the registration statements listed below of our reports dated February 22, 2024, with respect to the consolidated financial\nstatements of Pfizer Inc. and Subsidiary Companies and the effectiveness of internal control over financial reporting.\n-Form S-8 dated October 27, 1983 (File No. 2-87473),\n-Form S-8 dated March 22, 1990 (File No. 33-34139),\n-Form S-8 dated January 24, 1991 (File No. 33-38708),\n-Form S-8 dated November 18, 1991 (File No. 33-44053),\n-Form S-8 dated May 27, 1993 (File No. 33-49631),\n-Form S-8 dated May 19, 1994 (File No. 33-53713),\n-Form S-8 dated October 5, 1994 (File No. 33-55771),\n-Form S-8 dated December 20, 1994 (File No. 33-56979),\n-Form S-8 dated March 29, 1996 (File No. 333-02061),\n-Form S-8 dated September 25, 1997 (File No. 333-36371),\n-Form S-8 dated June 19, 2000 (File No. 333-39606),\n-Form S-8 dated April 27, 2001 (File No. 333-59660),\n-Form S-8 dated April 16, 2003 (File No.",
      "char_count": 983,
      "start_char": 767200,
      "end_char": 768184
    },
    {
      "chunk_id": "pfizer_2023_chunk0960",
      "chunk_index": 960,
      "text": "tember 25, 1997 (File No. 333-36371),\n-Form S-8 dated June 19, 2000 (File No. 333-39606),\n-Form S-8 dated April 27, 2001 (File No. 333-59660),\n-Form S-8 dated April 16, 2003 (File No. 333-104582),\n-Form S-8 dated November 18, 2003 (File No. 333-110571),\n-Form S-8 dated December 18, 2003 (File No. 333-111333),\n-Form S-8 dated April 26, 2004 (File No. 333-114852),\n-Form S-8 dated March 1, 2007 (File No. 333-140987),\n-Form S-4 dated March 27, 2009 (File No. 333-158237),\n-Form S-8 dated October 16, 2009 (File No. 333-162519),\n-Form S-8 dated October 16, 2009 (File No. 333-162520),\n-Form S-8 dated October 16, 2009 (File No. 333-162521),\n-Form S-8 dated March 1, 2010 (File No. 333-165121),\n-Form S-8 dated March 2, 2015 (File No. 333-202437),\n-Form S-4 dated September 3, 2015 (File No. 333-206758),\n-Form S-8 dated August 8, 2019 (File No. 333-233166),\n-Form S-8 dated August 8, 2019 (File No. 333-202437),\n-Form S-3 ASR dated February 26, 2021 (File No.",
      "char_count": 958,
      "start_char": 768000,
      "end_char": 768959
    },
    {
      "chunk_id": "pfizer_2023_chunk0961",
      "chunk_index": 961,
      "text": "),\n-Form S-8 dated August 8, 2019 (File No. 333-233166),\n-Form S-8 dated August 8, 2019 (File No. 333-202437),\n-Form S-3 ASR dated February 26, 2021 (File No. 333-253605), and\n-Form S-8 dated February 24, 2023 (File No. 333-270024).\n/s/ KPMG LLP\nNew York, New York February 22, 2024\n\nEXHIBIT 31.1\nCertification by the Chief Executive Officer Pursuant to\nSection 302 of the Sarbanes-Oxley Act of 2002\nI, Albert Bourla, certify that:\nI have reviewed this Annual Report on Form 10-K of Pfizer Inc.;\nBased on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the\nstatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;\nBased on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the",
      "char_count": 944,
      "start_char": 768800,
      "end_char": 769745
    },
    {
      "chunk_id": "pfizer_2023_chunk0962",
      "chunk_index": 962,
      "text": "on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the\nfinancial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;\nThe registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in\nExchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the\nregistrant and have:\n(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to\nensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,\nparticularly during the period in which this report is being prepared;",
      "char_count": 969,
      "start_char": 769600,
      "end_char": 770571
    },
    {
      "chunk_id": "pfizer_2023_chunk0963",
      "chunk_index": 963,
      "text": "rant, including its consolidated subsidiaries, is made known to us by others within those entities,\nparticularly during the period in which this report is being prepared;\n(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our\nsupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes\nin accordance with generally accepted accounting principles;\n(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the\neffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and\n(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent",
      "char_count": 966,
      "start_char": 770400,
      "end_char": 771367
    },
    {
      "chunk_id": "pfizer_2023_chunk0964",
      "chunk_index": 964,
      "text": "valuation; and\n(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent\nfiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the\nregistrant's internal control over financial reporting; and\nThe registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the\nregistrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):\n(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably\nlikely to adversely affect the registrant's ability to record, process, summarize and report financial information; and",
      "char_count": 952,
      "start_char": 771200,
      "end_char": 772153
    },
    {
      "chunk_id": "pfizer_2023_chunk0965",
      "chunk_index": 965,
      "text": "l reporting which are reasonably\nlikely to adversely affect the registrant's ability to record, process, summarize and report financial information; and\n(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control\nover financial reporting.\nDate: February 22, 2024\n/s/ ALBERT BOURLA\nAlbert Bourla\nChairman and Chief Executive Officer\n\nEXHIBIT 31.2\nCertification by the Chief Financial Officer Pursuant to\nSection 302 of the Sarbanes-Oxley Act of 2002\nI, David M. Denton, certify that:\nI have reviewed this Annual Report on Form 10-K of Pfizer Inc.;\nBased on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the\nstatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;",
      "char_count": 934,
      "start_char": 772000,
      "end_char": 772935
    },
    {
      "chunk_id": "pfizer_2023_chunk0966",
      "chunk_index": 966,
      "text": "in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;\nBased on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the\nfinancial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;\nThe registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in\nExchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the\nregistrant and have:\n(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to",
      "char_count": 884,
      "start_char": 772800,
      "end_char": 773685
    },
    {
      "chunk_id": "pfizer_2023_chunk0967",
      "chunk_index": 967,
      "text": "sed such disclosure controls and procedures to be designed under our supervision, to\nensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,\nparticularly during the period in which this report is being prepared;\n(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our\nsupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes\nin accordance with generally accepted accounting principles;\n(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the\neffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and",
      "char_count": 954,
      "start_char": 773600,
      "end_char": 774555
    },
    {
      "chunk_id": "pfizer_2023_chunk0968",
      "chunk_index": 968,
      "text": "usions about the\neffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and\n(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent\nfiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the\nregistrant's internal control over financial reporting; and\nThe registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the\nregistrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):\n(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably",
      "char_count": 972,
      "start_char": 774400,
      "end_char": 775373
    },
    {
      "chunk_id": "pfizer_2023_chunk0969",
      "chunk_index": 969,
      "text": "equivalent functions):\n(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably\nlikely to adversely affect the registrant's ability to record, process, summarize and report financial information; and\n(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control\nover financial reporting.\nDate: February 22, 2024\n/s/ DAVID M. DENTON\nDavid M. Denton\nChief Financial Officer, Executive Vice President\n\nEXHIBIT 32.1\nCertification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to\nSection 906 of the Sarbanes-Oxley Act of 2002\n Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc.",
      "char_count": 892,
      "start_char": 775200,
      "end_char": 776093
    },
    {
      "chunk_id": "pfizer_2023_chunk0970",
      "chunk_index": 970,
      "text": "eby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the\nyear ended December 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and\nthat the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.\n/s/ ALBERT BOURLA\nAlbert Bourla\nChairman and Chief Executive Officer\nFebruary 22, 2024\n This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent\nrequired by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).\nSuch certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except",
      "char_count": 971,
      "start_char": 776000,
      "end_char": 776972
    },
    {
      "chunk_id": "pfizer_2023_chunk0971",
      "chunk_index": 971,
      "text": "ange Act”).\nSuch certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except\nto the extent that the Company specifically incorporates it by reference.\n\nEXHIBIT 32.2\nCertification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to\nSection 906 of the Sarbanes-Oxley Act of 2002\n Pursuant to 18 U.S.C. Section 1350, I, David M. Denton, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for\nthe year ended December 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934,\nand that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.\n/s/DAVID M. DENTON\nDavid M.",
      "char_count": 911,
      "start_char": 776800,
      "end_char": 777712
    },
    {
      "chunk_id": "pfizer_2023_chunk0972",
      "chunk_index": 972,
      "text": "material respects, the financial condition and results of operations of Pfizer Inc.\n/s/DAVID M. DENTON\nDavid M. Denton\nChief Financial Officer, Executive Vice President\nFebruary 22, 2024\n This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent\nrequired by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).\nSuch certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except\nto the extent that the Company specifically incorporates it by reference.\n\nEXHIBIT 97\n\nRECOUPMENT POLICY\nAs required by Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time, and the related rules or regulations",
      "char_count": 932,
      "start_char": 777600,
      "end_char": 778533
    },
    {
      "chunk_id": "pfizer_2023_chunk0973",
      "chunk_index": 973,
      "text": "d-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time, and the related rules or regulations\npromulgated by the SEC and the NYSE, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) adopts this Recoupment Policy (this “Policy”) to be applied to the\nExecutive Officers of the Company, effective as of the Effective Date (as defined below), pursuant to the recommendation and approval of the Compensation Committee (the\n“Committee”) and the Committee’s recommendation that the Board so approve.\nDefinitions\nFor purposes of this Policy, the following definitions shall apply:\n“Company Group” means the Company and each of its Subsidiaries, as applicable.\n“Covered Compensation” means any Incentive-Based Compensation granted, vested or paid to a person who served as an Executive Officer at any time during the",
      "char_count": 863,
      "start_char": 778400,
      "end_char": 779264
    },
    {
      "chunk_id": "pfizer_2023_chunk0974",
      "chunk_index": 974,
      "text": "erson who served as an Executive Officer at any time during the\nperformance period for the Incentive-Based Compensation and that was Received (i) on or after the Effective Date, (ii) after the person became an Executive Officer\nand (iii) at a time that the Company had a class of securities listed on a national securities exchange or a national securities association.\n“Effective Date” means the date on which the new NYSE listing standard 303A.14 becomes effective, related to recovery of Erroneously Awarded Incentive-Based\nExecutive Compensation.\n“Erroneously Awarded Compensation” means the amount of Covered Compensation granted, vested or paid to a person during the fiscal period when the applicable\nFinancial Reporting Measure relating to such Covered Compensation was attained that exceeds the amount of Covered Compensation that otherwise would have",
      "char_count": 860,
      "start_char": 779200,
      "end_char": 780061
    },
    {
      "chunk_id": "pfizer_2023_chunk0975",
      "chunk_index": 975,
      "text": "the amount of Covered Compensation that otherwise would have\nbeen granted, vested or paid to the person had such amount been determined based on the applicable Restatement, computed without regard to any taxes paid (i.e.,\non a pre-tax basis). For Covered Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not\nsubject to mathematical recalculation directly from the information in a Restatement, the Committee will determine the amount of such Covered Compensation that\nconstitutes Erroneously Awarded Compensation, if any, based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return\nupon which the Covered Compensation was granted, vested or paid and the Committee shall maintain documentation of such determination and provide such\ndocumentation to the NYSE.\n“Exchange Act” means the Securities Exchange Act of 1934.",
      "char_count": 937,
      "start_char": 780000,
      "end_char": 780938
    },
    {
      "chunk_id": "pfizer_2023_chunk0976",
      "chunk_index": 976,
      "text": "documentation of such determination and provide such\ndocumentation to the NYSE.\n“Exchange Act” means the Securities Exchange Act of 1934.\n“Executive Officer” means each “officer” of the Company as defined under Rule 16a-1(f) under Section 16 of the Exchange Act, which shall be deemed to include any\nindividuals identified by the Company as executive officers pursuant to Item 401(b) of Regulation S-K under the Exchange Act. Both current and former Executive\nOfficers are subject to the Policy in accordance with its terms.\n“Financial Reporting Measure” means (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the\nCompany’s financial statements, and any measures derived wholly or in part from such measures and may consist of GAAP or non-GAAP financial measures (as\ndefined under Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Exchange Act), (ii) stock price or (iii) total shareholder return.",
      "char_count": 983,
      "start_char": 780800,
      "end_char": 781784
    },
    {
      "chunk_id": "pfizer_2023_chunk0977",
      "chunk_index": 977,
      "text": "n-GAAP financial measures (as\ndefined under Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Exchange Act), (ii) stock price or (iii) total shareholder return. Financial\nReporting Measures may or may not be filed with the SEC and may be presented outside the Company’s financial statements, such as in Managements’ Discussion\nand Analysis of Financial Conditions and Result of Operations or in the performance graph required under Item 201(e) of Regulation S-K under the Exchange Act.\n“Incentive-Based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting\nMeasure. In addition, for purposes of this Policy, Incentive-Based Compensation is deemed “Received” in the Company’s fiscal period during which the Financial",
      "char_count": 824,
      "start_char": 781600,
      "end_char": 782425
    },
    {
      "chunk_id": "pfizer_2023_chunk0978",
      "chunk_index": 978,
      "text": "ring which the Financial\nReporting Measure specified in or otherwise relating to the Incentive-Based Compensation award is attained, even if the grant, vesting or payment of the IncentiveBased Compensation occurs after the end of that period.\n“Home Country” means the Company’s jurisdiction of incorporation.\n“Lookback Period” means the three completed fiscal years (plus any transition period of less than nine months that is within or immediately following the three\ncompleted fiscal years and that results from a change in the Company’s fiscal year) immediately preceding the date on which the Company is required to prepare a\nRestatement for a given reporting period, with such date being the earlier of: (i) the date the Board, a committee of the Board, or the officer or officers of the Company\nauthorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an",
      "char_count": 955,
      "start_char": 782400,
      "end_char": 783356
    },
    {
      "chunk_id": "pfizer_2023_chunk0979",
      "chunk_index": 979,
      "text": "authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an\nRestatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Restatement.\n \n\nRecovery of any Erroneously Awarded Compensation under the Policy is not dependent on if or when the Restatement is actually filed.\n“NYSE” means the New York Stock Exchange.\n“Restatement” means a required accounting restatement of any Company financial statement due to the material noncompliance of the Company with any financial\nreporting requirement under the securities laws, including (i) to correct an error in previously issued financial statements that is material to the previously issued\nfinancial statements (commonly referred to as a “Big R” restatement) or (ii) to correct an error in previously issued financial statements that is not material to the",
      "char_count": 950,
      "start_char": 783200,
      "end_char": 784152
    },
    {
      "chunk_id": "pfizer_2023_chunk0980",
      "chunk_index": 980,
      "text": "ments (commonly referred to as a “Big R” restatement) or (ii) to correct an error in previously issued financial statements that is not material to the\npreviously issued financial statements but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the\ncurrent period (commonly referred to as a “little r” restatement). Changes to the Company’s financial statements that do not represent error corrections under the\nthen-current relevant accounting standards will not constitute Restatements. Recovery of any Erroneously Awarded Compensation under the Policy is not dependent\non fraud or misconduct by any person in connection with the Restatement.\n“SEC” means the United States Securities and Exchange Commission.\n“Subsidiary” means any domestic or foreign corporation, partnership, association, joint stock company, joint venture, trust or unincorporated organization “affiliated”",
      "char_count": 946,
      "start_char": 784000,
      "end_char": 784947
    },
    {
      "chunk_id": "pfizer_2023_chunk0981",
      "chunk_index": 981,
      "text": "y domestic or foreign corporation, partnership, association, joint stock company, joint venture, trust or unincorporated organization “affiliated”\nwith the Company, that is, directly or indirectly, through one or more intermediaries, “controlling”, “controlled by” or “under common control with”, the Company.\n“Control” for this purpose means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such person,\nwhether through the ownership of voting securities, contract or otherwise.\nRecoupment of Erroneously Awarded Compensation\nIn the event of a Restatement, any Erroneously Awarded Compensation Received during the Lookback Period prior to the Restatement (a) that is then-outstanding but has not\nyet been paid shall be automatically and immediately forfeited; and (b) that has been paid to any person, shall be subject to reasonably prompt repayment to the Company Group in\naccordance with Section 3 of this Policy.",
      "char_count": 983,
      "start_char": 784800,
      "end_char": 785784
    },
    {
      "chunk_id": "pfizer_2023_chunk0982",
      "chunk_index": 982,
      "text": "and immediately forfeited; and (b) that has been paid to any person, shall be subject to reasonably prompt repayment to the Company Group in\naccordance with Section 3 of this Policy. The Committee must pursue (and shall not have the discretion to waive) the forfeiture and/or repayment of such Erroneously Awarded\nCompensation in accordance with Section 3 of this Policy, except as provided below.\nNotwithstanding the foregoing, the Committee (or, if the Committee is not a committee of the Board responsible for the Company’s executive compensation decisions and\ncomposed entirely of independent directors, a majority of the independent directors serving on the Board) may determine not to pursue the forfeiture and/or recovery of Erroneously\nAwarded Compensation from any person if the Committee determines that such forfeiture and/or recovery would be impracticable due to any of the following circumstances: (i) the",
      "char_count": 919,
      "start_char": 785600,
      "end_char": 786521
    },
    {
      "chunk_id": "pfizer_2023_chunk0983",
      "chunk_index": 983,
      "text": "etermines that such forfeiture and/or recovery would be impracticable due to any of the following circumstances: (i) the\ndirect expense paid to a third party (for example, reasonable legal expenses and consulting fees) to assist in enforcing the Policy would exceed the amount to be recovered\n(following reasonable attempts by the Company Group to recover such Erroneously Awarded Compensation, the documentation of such attempts, and the provision of such\ndocumentation to the NYSE) (ii) pursuing such recovery would violate the Company’s Home Country laws adopted prior to November 28, 2022 (provided that the Company obtains\nan opinion of Home Country counsel acceptable to the NYSE that recovery would result in such a violation and provides such opinion to the NYSE), or (iii) recovery would likely\ncause any otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)\n(13) or 26 U.S.C.",
      "char_count": 999,
      "start_char": 786400,
      "end_char": 787400
    },
    {
      "chunk_id": "pfizer_2023_chunk0984",
      "chunk_index": 984,
      "text": "ely\ncause any otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)\n(13) or 26 U.S.C. 411(a) and regulations thereunder.\nMeans of Repayment\nIn the event that the Committee determines that any person shall repay any Erroneously Awarded Compensation, the Committee shall provide written notice to such person by\nemail or certified mail to the physical address on file with the Company Group for such person, and the person shall satisfy such repayment in a manner and on such terms as\nrequired by the Committee, and the Company Group shall be entitled to set off the repayment amount against any amount owed to the person by the Company Group, to require the\nforfeiture of any award granted by the Company Group to the person, or to take any and all necessary actions to reasonably promptly recoup the repayment amount from the",
      "char_count": 939,
      "start_char": 787200,
      "end_char": 788140
    },
    {
      "chunk_id": "pfizer_2023_chunk0985",
      "chunk_index": 985,
      "text": "ed by the Company Group to the person, or to take any and all necessary actions to reasonably promptly recoup the repayment amount from the\nperson, in each case, to the fullest extent permitted under applicable law, including without limitation, Section 409A of the Internal Revenue Code and the regulations and guidance\nthereunder. If the Committee does not specify a repayment timing in the written notice described above, the applicable person shall be required to repay the Erroneously Awarded\nCompensation to the Company Group by wire, cash or cashier’s check no later than thirty (30) days after receipt of such notice.\nNo Indemnification\nNo person shall be indemnified, insured or reimbursed by the Company Group in respect of any loss of compensation by such person in accordance with this Policy, nor shall\nany person receive any advancement of expenses for disputes related to any loss of compensation by such person in accordance with this Policy, and no person shall be paid or",
      "char_count": 989,
      "start_char": 788000,
      "end_char": 788990
    },
    {
      "chunk_id": "pfizer_2023_chunk0986",
      "chunk_index": 986,
      "text": "licy, nor shall\nany person receive any advancement of expenses for disputes related to any loss of compensation by such person in accordance with this Policy, and no person shall be paid or\nreimbursed by the Company Group for any premiums paid by such person for any third-party insurance policy covering potential recovery obligations under this Policy. For this\npurpose, “indemnification” includes any modification to current compensation arrangements or other means that would amount to de facto indemnification (for example, providing the\nperson a new cash award which would be cancelled to effect the recovery of any Erroneously Awarded Compensation). In no event shall the Company Group be required to award\nany person an additional payment if any Restatement would result in a higher incentive compensation payment.",
      "char_count": 822,
      "start_char": 788800,
      "end_char": 789623
    },
    {
      "chunk_id": "pfizer_2023_chunk0987",
      "chunk_index": 987,
      "text": "compensation payment.\n\nMiscellaneous\nThe Board has the authority to amend this Policy as provided by Section 6 below. This Policy generally will be administered and interpreted by the Committee, provided that the\nBoard may, from time to time, exercise discretion to administer and interpret this Policy, in which case, all references herein to “Committee” shall be deemed to refer to the Board.\nAny determination by the Committee with respect to this Policy shall be final, conclusive and binding on all interested parties. Any discretionary determinations of the Committee\nunder this Policy, if any, need not be uniform with respect to all persons, and may be made selectively amongst persons, whether or not such persons are similarly situated.\nThis Policy is intended to satisfy the requirements of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time,",
      "char_count": 919,
      "start_char": 789600,
      "end_char": 790521
    },
    {
      "chunk_id": "pfizer_2023_chunk0988",
      "chunk_index": 988,
      "text": "of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time,\nand any related rules or regulations promulgated by the SEC or the NYSE, including any additional or new requirements that become effective after the Effective Date which upon\neffectiveness shall be deemed to automatically amend this Policy to the extent necessary to comply with such additional or new requirements.\nThe provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under\nany applicable law, such provision will be applied to the maximum extent permitted and shall automatically be deemed amended in a manner consistent with its objectives to the\nextent necessary to conform to applicable law. The invalidity or unenforceability of any provision of this Policy shall not affect the validity or enforceability of any other provision of this\nPolicy.",
      "char_count": 998,
      "start_char": 790400,
      "end_char": 791399
    },
    {
      "chunk_id": "pfizer_2023_chunk0989",
      "chunk_index": 989,
      "text": "tent necessary to conform to applicable law. The invalidity or unenforceability of any provision of this Policy shall not affect the validity or enforceability of any other provision of this\nPolicy. Recoupment of Erroneously Awarded Compensation under this Policy is not dependent upon the Company Group satisfying any conditions in this Policy, including any\nrequirements to provide applicable documentation to the NYSE.\nThe rights of the Company Group under this Policy to seek forfeiture or reimbursement are separate from and in addition to, and not in lieu of, any rights of recoupment, or\nremedies or rights other than recoupment, that may be available to the Company Group pursuant to the terms of any law, government regulation or stock exchange listing\nrequirement or any other policy, code of conduct, charter, employee handbook, employment agreement, equity award agreement (including without limitation, the Executive LongTerm Incentive Award Grant Agreements issued under the Pfizer Inc.",
      "char_count": 1000,
      "start_char": 791200,
      "end_char": 792200
    },
    {
      "chunk_id": "pfizer_2023_chunk0990",
      "chunk_index": 990,
      "text": "of conduct, charter, employee handbook, employment agreement, equity award agreement (including without limitation, the Executive LongTerm Incentive Award Grant Agreements issued under the Pfizer Inc. 2014 Stock Plan, the Pfizer Inc. 2019 Stock Plan and any successor plan, and the related Executive Points of\nInterest documents), the Company Group’s Global Performance Plan, or other plan or agreement of the Company Group (each an “Other Recoupment Policy”). To the extent that\nErroneously Awarded Compensation is also subject to recoupment pursuant to any Other Recoupment Policy, the Company Group shall not recover compensation, or obtain\npayment, reimbursement or restitution, in an amount that exceeds the greater of the maximum amount recoupable under this Policy or any Other Recoupment Policy.\nAmendment and Termination",
      "char_count": 829,
      "start_char": 792000,
      "end_char": 792830
    },
    {
      "chunk_id": "pfizer_2023_chunk0991",
      "chunk_index": 991,
      "text": "cy.\nAmendment and Termination\nTo the extent permitted by, and in a manner consistent with applicable law, including SEC and NYSE rules, the Board may terminate, suspend or amend this Policy at any time\nin its discretion.\nSuccessors\nThis Policy shall be binding and enforceable against all persons and their respective beneficiaries, heirs, executors, administrators or other legal representatives with respect to\nany Covered Compensation granted, vested or paid to or administered by such persons or entities.\n\nRECOUPMENT POLICY\nACKNOWLEDGMENT, CONSENT AND AGREEMENT\nI acknowledge that I have received and reviewed a copy of the Pfizer Inc. Recoupment Policy (as may be amended from time to time, the “Policy”) and I have been given an\nopportunity to ask questions about the Policy and review it with my counsel.",
      "char_count": 812,
      "start_char": 792800,
      "end_char": 793613
    },
    {
      "chunk_id": "pfizer_2023_chunk0992",
      "chunk_index": 992,
      "text": "my counsel. I knowingly, voluntarily and irrevocably consent to and agree to be bound by and subject to the Policy’s\nterms and conditions, including that I will return any Erroneously Awarded Compensation that is required to be repaid in accordance with the Policy. I further acknowledge,\nunderstand and agree that (i) the compensation that I receive, have received or may become entitled to receive from the Company Group is subject to the Policy, and the Policy may\naffect such compensation; and (ii) I have no right to indemnification, insurance payments or other reimbursement by or from the Company Group for any compensation that is\nsubject to recoupment and/or forfeiture under the Policy. Capitalized terms not defined herein have the meanings set forth in the Policy.\nSigned: _________________________________________\nPrint Name: _________________________________________\nDate: _________________________________________",
      "char_count": 928,
      "start_char": 793600,
      "end_char": 794529
    },
    {
      "chunk_id": "pfizer_2023_chunk0993",
      "chunk_index": 993,
      "text": "___________________________\nPrint Name: _________________________________________\nDate: _________________________________________",
      "char_count": 129,
      "start_char": 794400,
      "end_char": 794529
    }
  ]
}